WO2001075067A9 - Novel nucleic acids and polypeptides - Google Patents

Abstract

The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

Description

NOVEL NUCLEIC ACIDS AND POLYPEPTIDES

1. TECHNICAL FIELD

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with uses for these polynucleotides and proteins, for example in therapeutic, diagnostic and research methods.

2. BACKGROUND

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs, chemokines, and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization-based cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity, for example, by virtue of their secreted nature in the case of leader sequence cloning, by virtue of their cell or tissue source in the case of PCR-based techniques, or by virtue of structural similarity to other genes of known biological activity.

Identified polynucleotide and polypeptide sequences have numerous applications in, for example, diagnostics, forensics, gene mapping; identification of mutations responsible for genetic disorders or other traits, to assess biodiversity, and to produce many other types of data and products dependent on DNA and amino acid sequences.

3. SUMMARY OF THE INVENTION

The compositions of the present invention include novel isolated polypeptides, novel isolated polynucleotides encoding such polypeptides, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially naturally occurring variants such as allelic variants, antisense polynucleotide molecules, and antibodies that specifically recognize one or more epitopes present on such polypeptides, as well as hybridomas producing such antibodies.

The compositions of the present invention additionally include vectors, including expression vectors, containing the polynucleotides of the invention, cells genetically engineered to contain such polynucleotidesand cells genetically engineered to express such polynucleotides. The present invention relates to a collection or library of at least one novel nucleic acid sequence assembled from expressed sequence tags (ESTs) isolated mainly by sequencing by hybridization (SBH), and in some cases, sequences obtained from one or more public databases. The invention relates also to the proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. These nucleic acid sequences are designated as SEQ ID NO: 1 -30368. The polypeptides sequences are designated SEQ ID NO: 30369-60736. The nucleic acids and polypeptides are provided in the Sequence Listing. In the nucleic acids provided in the Sequence Listing, A is adenosine; C is cytosine; G is guanine; T is thymine; and N is any of the four bases. In the amino acids provided in the Sequence Listing, * corresponds to the stop codon.

The nucleic acid sequences of the present invention also include, nucleic acid sequences that hybridize to the complement of SEQ ID NO: 1-30368 under stringent hybridization conditions; nucleic acid sequences which are allelic variants or species homologues of any of the nucleic acid sequences recited above, or nucleic acid sequences that encode a peptide comprising a specific domain or truncation of the peptides encoded by SEQ ID NO: 1-30368. A polynucleotide comprising a nucleotide sequence having at least 90% identity to an identifying sequence of SEQ ID NO: 1-30368 or a degenerate variant or fragment thereof. The identifying sequence can be 100 base pairs in length.

The nucleic acid sequences of the present invention also include the sequence information from the nucleic acid sequences of SEQ ID NO: 1 -30368. The sequence information can be a segment of any one of SEQ ID NO: 1 -30368 that uniquely identifies or represents the sequence information of SEQ ID NO: 1-30368.

A collection as used in this application can be a collection of only one polynucleotide. The collection of sequence information or identifying information of each sequence can be provided on a nucleic acid array. In one embodiment, segments of sequence information is provided on a nucleic acid array to detect the polynucleotide that contains the segment. The array can be designed to detect full-match or mismatch to the polynucleotide that contains the segment. The collection can also be provided in a computer-readable format.

This invention also includes the reverse or direct complement of any of the nucleic acid sequences recited above; cloning or expression vectors containing the nucleic acid sequences; and host cells or organisms transformed with these expression vectors. Nucleic acid sequences (or their reverse or direct complements) according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology, such as use as hybridization probes, use as primers for PCR, use in an array, use in computer-readable media, use in sequencing full-length genes, use for chromosome and gene mapping, use in the recombinant production of protein, and use in the generation of anti-sense DNA or RNA, their chemical analogs and the like.

In a preferred embodiment, the nucleic acid sequences of SEQ ID NO: 1 -30368 or novel segments or parts of the nucleic acids of the invention are used as primers in expression assays that are well known in the art. In a particularly preferred embodiment, the nucleic acid sequences of SEQ ID NO: 1 -30368 or novel segments or parts of the nucleic acids provided herein are used in diagnostics for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., Science 258:52-59 (1992), as expressed sequence tags for physical mapping of the human genome. The isolated polynucleotides of the invention include, but are not limited to, a polynucleotide comprising any one of the nucleotide sequences set forth in SEQ ID NO: 1-30368; a polynucleotide comprising any of the full length protein coding sequences of SEQ ID NO: 1 -30368; and a polynucleotide comprising any of the nucleotide sequences of the mature protein coding sequences of SEQ ID NO: 1-30368. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent hybridization conditions to (a) the complement of any one of the nucleotide sequences set forth in SEQ ID NO: 1 -30368; (b) a nucleotide sequence encoding any one of the amino acid sequences set forth in the Sequence Listing (e.g., SEQ ID NO: 30369-60736); (c) a polynucleotide which is an allelic variant of any polynucleotides recited above; (d) a polynucleotide which encodes a species homolog (e.g. orthologs) of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of any of the polypeptides comprising an amino acid sequence set forth in the Sequence Listing.

The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising any of the amino acid sequences set forth in the Sequence Listing; or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides with biological activity that are encoded by (a) any of the polynucleotides having a nucleotide sequence set forth in SEQ ID NO: 1-30368; or (b) polynucleotides that hybridize to the complement of the polynucleotides of (a) under stringent hybridization conditions. Biologically or immunologically active variants of any of the polypeptide sequences in the Sequence Listing, and "substantial equivalents" thereof (e.g. , with at least about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% amino acid sequence identity) that preferably retain biological activity are also contemplated. The polypeptides of the invention may be wholly or partially chemically synthesized but are preferably produced by recombinant means using the genetically engineered cells (e.g. host cells) of the invention. The invention also provides compositions comprising a polypeptide of the invention.

Polypeptide compositions of the invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.

The invention also provides host cells transformed or transfected with a polynucleotide of the invention.

The invention also relates to methods for producing a polypeptide of the invention comprising growing a culture of the host cells of the invention in a suitable culture medium under conditions permitting expression of the desired polypeptide, and purifying the polypeptide from the culture or from the host cells. Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.

Polynucleotides according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use as oligomers, or primers, for PCR, use for chromosome and gene mapping, use in the recombinant production of protein, and use in generation of anti-sense DNA or RNA, their chemical analogs and the like. For example, when the expression of an mRNA is largely restricted to a particular cell or tissue type, polynucleotides of the invention can be used as hybridization probes to detect the presence of the particular cell or tissue mRNA in a sample using, e.g., in situ hybridization.

In other exemplary embodiments, the polynucleotides are used in diagnostics as expressed sequence tags for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., Science 258:52-59 (1992), as expressed sequence tags for physical mapping of the human genome.

The polypeptides according to the invention can be used in a variety of conventional procedures and methods that are currently applied to other proteins. For example, a polypeptide of the invention can be used to generate an antibody that specifically binds the polypeptide. Such antibodies, particularly monoclonal antibodies, are useful for detecting or quantitating the polypeptide in tissue. The polypeptides of the invention can also be used as molecular weight markers, and as a food supplement.

Methods are also provided for preventing, treating, or ameliorating a medical condition which comprises the step of administering to a mammalian subject a therapeutically effective amount of a composition comprising a polypeptide of the present invention and a pharmaceutically acceptable carrier.

In particular, the polypeptides and polynucleotides of the invention can be utilized, for example, in methods for the prevention and/or treatment of disorders involving aberrant protein expression or biological activity. The present invention further relates to methods for detecting the presence of the polynucleotides or polypeptides of the invention in a sample. Such methods can, for example, be utilized as part of prognostic and diagnostic evaluation of disorders as recited herein and for the identification of subjects exhibiting a predisposition to such conditions. The invention provides a method for detecting the polynucleotides of the invention in a sample, comprising contacting the sample with a compound that binds to and forms a complex with the polynucleotide of interest for a period sufficient to form the complex and under conditions sufficient to form a complex and detecting the complex such that if a complex is detected, the polynucleotide of interest is detected. The invention also provides a method for detecting the polypeptides of the invention in a sample comprising contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex and detecting the formation of the complex such that if a complex is formed, the polypeptide is detected.

The invention also provides kits comprising polynucleotide probes and/or monoclonal antibodies, and optionally quantitative standards, for carrying out methods of the invention. Furthermore, the invention provides methods for evaluating the efficacy of drugs, and monitoring the progress of patients, involved in clinical trials for the treatment of disorders as recited above.

The invention also provides methods for the identification of compounds that modulate (t.e., increase or decrease) the expression or activity of the polynucleotides and/or polypeptides of the invention. Such methods can be utilized, for example, for the identification of compounds that can ameliorate symptoms of disorders as recited herein. Such methods can include, but are not limited to, assays for identifying compounds and other substances that interact with (e.g., bind to) the polypeptides of the invention. The invention provides a method for identifying a compound that binds to the polypeptides of the invention comprising contacting the compound with a polypeptide of the invention in a cell for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and detecting the complex by detecting the reporter gene sequence expression such that if expression of the reporter gene is detected the compound that binds to a polypeptide of the invention is identified.

The methods of the invention also provides methods for treatment which involve the administration of the polynucleotides or polypeptides of the invention to individuals exhibiting symptoms or tendencies. In addition, the invention encompasses methods for treating diseases or disorders as recited herein comprising administering compounds and other substances that modulate the overall activity of the target gene products. Compounds and other substances can effect such modulation either on the level of target gene/protein expression or target protein activity.

The polypeptides of the present invention and the polynucleotides encoding them are also useful for the same functions known to one of skill in the art as the polypeptides and polynucleotides to which they have homology (set forth in the sequence listing). If no homology is set forth for a sequence, then the polypeptides and polynucleotides of the present invention are useful for a variety of applications, as described herein, including use in arrays for detection.

4. DETAILED DESCRIPTION OF THE INVENTION

4.1 DEFINITIONS

It must be noted that as used herein and in the appended claims, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise. The term "active" refers to those forms of the polypeptide which retain the biologic and/or immunologic activities of any naturally occurring polypeptide. According to the invention, the terms "biologically active" or "biological activity" refer to a protein or peptide having structural, regulatory or biochemical functions of a naturally occurring molecule. Likewise "immunologically active" or "immunological activity" refers to the capability of the natural, recombinant or synthetic polypeptide to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "activated cells" as used in this application are those cells which are engaged in extracellular or intracellular membrane trafficking, including the export of secretory or enzymatic molecules as part of a normal or disease process. The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence 5'-AGT-3' binds to the complementary sequence 3'-TCA-5'. Complementarity between two single-stranded molecules may be "partial" such that only some of the nucleic acids bind or it may be "complete" such that total complementarity exists between the single stranded molecules. The degree of complementarity between the nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands.

The term "embryonic stem cells (ES)" refers to a cell that can give rise to many differentiated cell types in an embryo or an adult, including the germ cells. The term "germ line stem cells (GSCs)" refers to stem cells derived from primordial stem cells that provide a steady and continuous source of germ cells for the production of gametes. The term "primordial germ cells (PGCs)" refers to a small population of cells set aside from other cell lineages particularly from the yolk sac, mesenteries, or gonadal ridges during embryogenesis that have the potential to differentiate into germ cells and other cells. PGCs are the source from which GSCs and ES cells are derived The PGCs, the GSCs and the ES cells are capable of self-renewal. Thus these cells not only populate the germ line and give rise to a plurality of terminally differentiated cells that comprise the adult specialized organs, but are able to regenerate themselves.

The term "expression modulating fragment," EMF, means a series of nucleotides which modulates the expression of an operably linked ORF or another EMF.

As used herein, a sequence is said to "modulate the expression of an operably linked sequence" when the expression of the sequence is altered by the presence of the EMF. EMFs include, but are not limited to, promoters, and promoter modulating sequences (inducible elements). One class of EMFs are nucleic acid fragments which induce the expression of an operably linked ORF in response to a specific regulatory factor or physiological event. The terms "nucleotide sequence" or "nucleic acid" or "polynucleotide" or "oligonucleotide" are used interchangeably and refer to a heteropolymer of nucleotides or the sequence of these nucleotides. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA) or to any DNA-like or RNA-like material. In the sequences herein A is adenine, C is cytosine, T is thymine, G is guanine and N is A, C, G or T (U). It is contemplated that where the polynucleotide is RNA, the T (thymine) in the sequences provided herein is substituted with U (uracil). Generally, nucleic acid segments provided by this invention may be assembled from fragments of the genome and short oligonucleotide linkers, or from a series of oligonucleotides, or from individual nucleotides, to provide a synthetic nucleic acid which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon, or a eukaryotic gene.

The terms "oligonucleotide fragment" or a "polynucleotide fragment", "portion," or "segment" or "probe" or "primer" are used interchangeably and refer to a sequence of nucleotide residues which are at least about 5 nucleotides, more preferably at least about 7 nucleotides, more preferably at least about 9 nucleotides, more preferably at least about 1 1 nucleotides and most preferably at least about 17 nucleotides. The fragment is preferably less than about 500 nucleotides, preferably less than about 200 nucleotides, more preferably less than about 100 nucleotides, more preferably less than about 50 nucleotides and most preferably less than 30 nucleotides. Preferably the probe is from about 6 nucleotides to about 200 nucleotides, preferably from about 15 to about 50 nucleotides, more preferably from about 17 to 30 nucleotides and most preferably from about 20 to 25 nucleotides. Preferably the fragments can be used in polymerase chain reaction (PCR), various hybridization procedures or microarray procedures to identify or amplify identical or related parts of mRNA or DNA molecules. A fragment or segment may uniquely identify each polynucleotide sequence of the present invention. Preferably the fragment comprises a sequence substantially similar to any one of SEQ ID NO: 1-30368.

Probes may, for example, be used to determine whether specific mRNA molecules are present in a cell or tissue or to isolate similar nucleic acid sequences from chromosomal DNA as described by Walsh et al. (Walsh, P.S. et al., 1992, PCR Methods Appl 1 :241-250). They may be labeled by nick translation, Klenow fill-in reaction, PCR, or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in

Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY; or Ausubel, F.M. et al., 1989, Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, both of which are incorporated herein by reference in their entirety. The nucleic acid sequences of the present invention also include the sequence information from the nucleic acid sequences of SEQ ID NO: 1-30368. The sequence information can be a segment of any one of SEQ ID NO: 1-30368 that uniquely identifies or represents the sequence information of that sequence of SEQ ID NO: 1-30368. One such segment can be a twenty-mer nucleic acid sequence because the probability that a twenty-mer is fully matched in the human genome is 1 in 300. In the human genome, there are three billion base pairs in one set of chromosomes. Because 4 possible twenty-mers exist, there are 300 times more twenty-mers than there are base pairs in a set of human chromosomes. Using the same analysis, the probability for a seventeen-mer to be fully matched in the human genome is approximately 1 in 5. When these segments are used in arrays for expression studies, fifteen-mer segments can be used. The probability that the fifteen-mer is fully matched in the expressed sequences is also approximately one in five because expressed sequences comprise less than approximately 5% of the entire genome sequence.

Similarly, when using sequence information for detecting a single mismatch, a segment can be a twenty-five mer. The probability that the twenty-five mer would appear in a human genome with a single mismatch is calculated by multiplying the probability for a full match (1 ÷4^2~) times the increased probability for mismatch at each nucleotide position (3 x 25). The probability that an eighteen mer with a single mismatch can be detected in an array for expression studies is approximately one in five. The probability that a twenty-mer with a single mismatch can be detected in a human genome is approximately one in five. The term "open reading frame," ORF, means a series of nucleotide triplets coding for amino acids without any termination codons and is a sequence translatable into protein.

The terms "operably linked" or "operably associated" refer to functionally related nucleic acid sequences. For example, a promoter is operably associated or operably linked with a coding sequence if the promoter controls the transcription of the coding sequence. While operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements e.g. repressor genes are not contiguously linked to the coding sequence but still control transcription/translation of the coding sequence.

The term "pluripotent" refers to the capability of a cell to differentiate into a number of differentiated cell types that are present in an adult organism. A pluripotent cell is restricted in its differentiation capability in comparison to a totipotent cell.

The terms "polypeptide" or "peptide" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide or protein sequence or fragment thereof and to naturally occurring or synthetic molecules. A polypeptide "fragment," "portion," or "segment" is a stretch of amino acid residues of at least about 5 amino acids, preferably at least about 7 amino acids, more preferably at least about 9 amino acids and most preferably at least about 17 or more amino acids. The peptide preferably is not greater than about 200 amino acids, more preferably less than 150 amino acids and most preferably less than 100 amino acids. Preferably the peptide is from about 5 to about 200 amino acids. To be active, any polypeptide must have sufficient length to display biological and/or immunological activity.

The term "naturally occurring polypeptide" refers to polypeptides produced by cells that have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including, but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. The term "translated protein coding portion" means a sequence which encodes for the full length protein which may include any leader sequence or any processing sequence.

The term "mature protein coding sequence" means a sequence which encodes a peptide or protein without a signal or leader sequence. The "mature protein portion" means that portion of the protein which does not include a signal or leader sequence. The peptide may have been produced by processing in the cell which removes any leader/signal sequence. The mature protein portion may or may not include an initial methionine residue. The methionine residue may be removed from the protein during processing in the cell. The peptide may be produced synthetically or the protein may have been produced using a polynucleotide only encoding for the mature protein coding sequence. The term "derivative" refers to polypeptides chemically modified by such techniques as ubiquitination, labeling (e.g., with radionuclides or various enzymes), covalent polymer attachment such as pegylation (derivatization with polyethylene glycol) and insertion or substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins.

The term "variant"(or "analog") refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using, e g., recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, may be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology (conserved regions) or by replacing amino acids with consensus sequence.

Alternatively, recombinant variants encoding these same or similar polypeptides may be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence may be reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of any part of the polypeptide, to change characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate.

Preferably, amino acid "substitutions" are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, i.e., conservative amino acid replacements. "Conservative" amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. "Insertions" or "deletions" are preferably in the range of about 1 to 20 amino acids, more preferably 1 to 10 amino acids. The variation allowed may be experimentally determined by systematically making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity. Alternatively, where alteration of function is desired, insertions, deletions or non-conservative alterations can be engineered to produce altered polypeptides. Such alterations can, for example, alter one or more of the biological functions or biochemical characteristics of the polypeptides of the invention. For example, such alterations may change polypeptide characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate. Further, such alterations can be selected so as to generate polypeptides that are better suited for expression, scale up and the like in the host cells chosen for expression. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges.

The terms "purified" or "substantially purified" as used herein denotes that the indicated nucleic acid or polypeptide is present in the substantial absence of other biological macromolecules, e.g., polynucleotides, proteins, and the like. In one embodiment, the polynucleotide or polypeptide is purified such that it constitutes at least 95% by weight, more preferably at least 99% by weight, of the indicated biological macromolecules present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000 daltons, can be present). The term "isolated" as used herein refers to a nucleic acid or polypeptide separated from at least one other component (e.g., nucleic acid or polypeptide) present with the nucleic acid or polypeptide in its natural source. In one embodiment, the nucleic acid or polypeptide is found in the presence of (if anything) only a solvent, buffer, ion, or other component normally present in a solution of the same. The terms "isolated" and "purified" do not encompass nucleic acids or polypeptides present in their natural source.

The term "recombinant," when used herein to refer to a polypeptide or protein, means that a polypeptide or protein is derived from recombinant (e.g., microbial, insect, or mammalian) expression systems. "Microbial" refers to recombinant polypeptides or proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a polypeptide or protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Polypeptides or proteins expressed in most bacterial cultures, e.g., E. coli, will be free of glycosylation modifications; polypeptides or proteins expressed in yeast will have a glycosylation pattern in general different from those expressed in mammalian cells. The term "recombinant expression vehicle or vector" refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a DNA (RNA) sequence. An expression vehicle can comprise a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an amino terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

The term "recombinant expression system" means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit extrachromosomally. Recombinant expression systems as defined herein will express heterologous polypeptides or proteins upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed. This term also means host cells which have stably integrated a recombinant genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers. Recombinant expression systems as defined herein will express polypeptides or proteins endogenous to the cell upon induction of the regulatory elements linked to the endogenous DNA segment or gene to be expressed. The cells can be prokaryotic or eukaryotic.

The term "secreted" includes a protein that is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence when it is expressed in a suitable host cell. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins that are transported across the membrane of the endoplasmic reticulum. "Secreted" proteins are also intended to include proteins containing non-typical signal sequences (e.g. Interleukin-1 Beta, see Krasney, P.A. and Young, P.R. (1992) Cytokine 4(2):134 -143) and factors released from damaged cells (e.g. Interleukin-1 Receptor Antagonist, see Arend, W.P. et. al. (1998) Annu. Rev. Immunol. 16:27-55)

Where desired, an expression vector may be designed to contain a "signal or leader sequence" which will direct the polypeptide through the membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques. The term "stringent" is used to refer to conditions that are commonly understood in the art as stringent. Stringent conditions can include highly stringent conditions (i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1 X SSC/0.1% SDS at 68°C), and moderately stringent conditions (i.e., washing in 0.2X SSC/0.1% SDS at 42°C). Other exemplary hybridization conditions are described herein in the examples. In instances of hybridization of deoxyoligonucleotides, additional exemplary stringent hybridization conditions include washing in 6X SSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligonucleotides), 48°C (for 17-base oligos), 55°C (for 20-base oligonucleotides), and 60°C (for 23-base oligonucleotides). As used herein, "substantially equivalent" can refer both to nucleotide and amino acid sequences, for example a mutant sequence, that varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences. Typically, such a substantially equivalent sequence varies from one of those listed herein by no more than about 35% (i.e., the number of individual residue substitutions, additions, and/or deletions in a substantially equivalent sequence, as compared to the corresponding reference sequence, divided by the total number of residues in the substantially equivalent sequence is about 0.35 or less). Such a sequence is said to have 65% sequence identity to the listed sequence. In one embodiment, a substantially equivalent, e.g., mutant, sequence of the invention varies from a listed sequence by no more than 30% (70% sequence identity); in a variation of this embodiment, by no more than 25% (75% sequence identity); and in a further variation of this embodiment, by no more than 20% (80% sequence identity) and in a further variation of this embodiment, by no more than 10% (90% sequence identity) and in a further variation of this embodiment, by no more that 5% (95% sequence identity). Substantially equivalent, e.g., mutant, amino acid sequences according to the invention preferably have at least 80% sequence identity with a listed amino acid sequence, more preferably at least 85% sequence identity, more preferably at least 90% sequence identity, more preferably at least 95% identity, more preferably at least 98% identity, and most preferably at least 99% identity. Substantially equivalent nucleotide sequences of the invention can have lower percent sequence identities, taking into account, for example, the redundancy or degeneracy of the genetic code. Preferably, nucleotide sequence has at least about 65% identity, more preferably at least about 75% identity, more preferably at least about 80% sequence identity, more preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% identity, more preferably at least about 98% sequence identity, and most preferably at least about 99% sequence identity. For the purposes of the present invention, sequences having substantially equivalent biological activity and substantially equivalent expression characteristics are considered substantially equivalent. For the purposes of determining equivalence, truncation of the mature sequence (e.g., via a mutation which creates a spurious stop codon) should be disregarded. Sequence identity may be determined, e.g., using the Jotun Hein method (Hein, J. (1990) Methods Enzymol. 183:626-645). Identity between sequences can also be determined by other methods known in the art, e.g. by varying hybridization conditions.

The term "totipotent" refers to the capability of a cell to differentiate into all of the cell types of an adult organism. The term "transformation" means introducing DNA into a suitable host cell so that the

DNA is replicable, either as an extrachromosomal element, or by chromosomal integration. The term "transfection" refers to the taking up of an expression vector by a suitable host cell, whether or not any coding sequences are in fact expressed. The term "infection" refers to the introduction of nucleic acids into a suitable host cell by use of a virus or viral vector. As used herein, an "uptake modulating fragment," UMF, means a series of nucleotides which mediate the uptake of a linked DNA fragment into a cell. UMFs can be readily identified using known UMFs as a target sequence or target motif with the computer-based systems described below. The presence and activity of a UMF can be confirmed by attaching the suspected UMF to a marker sequence. The resulting nucleic acid molecule is then incubated with an appropriate host under appropriate conditions and the uptake of the marker sequence is determined. As described above, a UMF will increase the frequency of uptake of a linked marker sequence.

Each of the above terms is meant to encompass all that is described for each, unless the context dictates otherwise.

4.2 NUCLEIC ACIDS OF THE INVENTION

Nucleotide sequences of the invention are set forth in the Sequence Listing. The isolated polynucleotides of the invention include a polynucleotide comprising the nucleotide sequences of SEQ ID NO: 1-30368; a polynucleotide encoding any one of the peptide sequences of SEQ ID NO: 30369-60736; and a polynucleotide comprising the nucleotide sequence encoding the mature protein coding sequence of the polypeptides of any one of SEQ ID NO: 30369-60736. The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent conditions to (a) the complement of any of the nucleotides sequences of SEQ ID NO: 1-30368; (b) nucleotide sequences encoding any one of the amino acid sequences set forth in the Sequence Listing; (c) a polynucleotide which is an allelic variant of any polynucleotide recited above; (d) a polynucleotide which encodes a species homolog of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of the polypeptides of SEQ ID NO: 30369-60736. Domains of interest may depend on the nature of the encoded polypeptide; e.g., domains in receptor-like polypeptides include ligand-binding, extracellular, transmembrane, or cytoplasmic domains, or combinations thereof; domains in immunoglobulin-like proteins include the variable immunoglobulin-like domains; domains in enzyme-like polypeptides include catalytic and substrate binding domains; and domains in ligand polypeptides include receptor-binding domains. The polynucleotides of the invention include naturally occurring or wholly or partially synthetic DNA, e.g., cDNA and genomic DNA, and RNA, e.g., mRNA. The polynucleotides may include all of the coding region of the cDNA or may represent a portion of the coding region of the cDNA.

The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. Further 5' and 3' sequence can be obtained using methods known in the art. For example, full length cDNA or genomic DNA that corresponds to any of the polynucleotides of SEQ ID NO: 1-30368 can be obtained by screening appropriate cDNA or genomic DNA libraries under suitable hybridization conditions using any of the polynucleotides of SEQ ID NO: 1-30368 or a portion thereof as a probe. Alternatively, the polynucleotides of SEQ ID NO: 1-30368 may be used as the basis for suitable primer(s) that allow identification and/or amplification of genes in appropriate genomic DNA or cDNA libraries. The nucleic acid sequences of the invention can be assembled from ESTs and sequences

(including cDNA and genomic sequences) obtained from one or more public databases, such as dbEST, gbpri, and UniGene. The EST sequences can provide identifying sequence information, representative fragment or segment information, or novel segment information for the full-length gene. The polynucleotides of the invention also provide polynucleotides including nucleotide sequences that are substantially equivalent to the polynucleotides recited above. Polynucleotides according to the invention can have, e.g., at least about 65%, at least about 70%, at least about 75%, at least about 80%, 81%, 82%, 83%, 84%, more typically at least about 85%, 86%, 87%, 88%, 89%, more typically at least about 90%, 91%, 92%, 93%, 94%, and even more typically at least about 95%, 96%, 97%, 98%, 99%, sequence identity to a polynucleotide recited above.

Included within the scope of the nucleic acid sequences of the invention are nucleic acid sequence fragments that hybridize under stringent conditions to any of the nucleotide sequences of SEQ ID NO: 1-30368, or complements thereof, which fragment is greater than about 5 nucleotides, preferably 7 nucleotides, more preferably greater than 9 nucleotides and most preferably greater than 17 nucleotides. Fragments of, e.g. 15, 17, or 20 nucleotides or more that are selective for (i.e. specifically hybridize to any one of the polynucleotides of the invention) are contemplated. Probes capable of specifically hybridizing to a polynucleotide can differentiate polynucleotide sequences of the invention from other polynucleotide sequences in the same family of genes or can differentiate human genes from genes of other species, and are preferably based on unique nucleotide sequences.

The sequences falling within the scope of the present invention are not limited to these specific sequences, but also include allelic and species variations thereof. Allelic and species variations can be routinely determined by comparing the sequence provided in SEQ ID NO: 1 - 30368, a representative fragment thereof, or a nucleotide sequence at least 90% identical, preferably 95% identical, to SEQ ID NO: 1 -30368 with a sequence from another isolate of the same species. Furthermore, to accommodate codon variability, the invention includes nucleic acid molecules coding for the same amino acid sequences as do the specific ORFs disclosed herein. In other words, in the coding region of an ORF, substitution of one codon for another codon that encodes the same amino acid is expressly contemplated. The nearest neighbor or homology result for the nucleic acids of the present invention, including SEQ ID NO: 1 -30368 can be obtained by searching a database using an algorithm or a program. Preferably, a BLAST which stands for Basic Local Alignment Search Tool is used to search for local sequence alignments (Altshul, S.F. J Mol. Evol. 36 290-300 (1993) and Altschul S.F. et al. J. Mol. Biol. 21 :403-410(1990)). Alternatively a FASTA version 3 search against Genpept, using Fastxy algorithm.

Species homologs (or orthologs) of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotides.

The nucleic acid sequences of the invention are further directed to sequences which encode variants of the described nucleic acids. These amino acid sequence variants may be prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant polynucleotide. There are two variables in the construction of amino acid sequence variants: the location of the mutation and the nature of the mutation. Nucleic acids encoding the amino acid sequence variants are preferably constructed by mutating the polynucleotide to encode an amino acid sequence that does not occur in nature. These nucleic acid alterations can be made at sites that differ in the nucleic acids from different species

(variable positions) or in highly conserved regions (constant regions). Sites at such locations will typically be modified in series, e.g., by substituting first with conservative choices (e.g., hydrophobic amino acid to a different hydrophobic amino acid) and then with more distant choices (e.g., hydrophobic amino acid to a charged amino acid), and then deletions or insertions may be made at the target site. Amino acid sequence deletions generally range from about 1 to 30 residues, preferably about 1 to 10 residues, and are typically contiguous. Amino acid insertions include amino- and/or carboxyl-terminal fusions ranging in length from one to one hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions may range generally from about 1 to 10 amino residues, preferably from 1 to 5 residues. Examples of terminal insertions include the heterologous signal sequences necessary for secretion or for intracellular targeting in different host cells and sequences such as FLAG or poly-histidine sequences useful for purifying the expressed protein. In a preferred method, polynucleotides encoding the novel amino acid sequences are changed via site-directed mutagenesis. This method uses oligonucleotide sequences to alter a polynucleotide to encode the desired amino acid variant, as well as sufficient adjacent nucleotides on both sides of the changed amino acid to form a stable duplex on either side of the site of being changed. In general, the techniques of site-directed mutagenesis are well known to those of skill in the art and this technique is exemplified by publications such as, Edelman et al., DNA 2: 183 (1983). A versatile and efficient method for producing site-specific changes in a polynucleotide sequence was published by Zoller and Smith, Nucleic Acids Res. 10:6487-6500 (1982). PCR may also be used to create amino acid sequence variants of the novel nucleic acids. When small amounts of template DNA are used as starting material, primer(s) that differs slightly in sequence from the corresponding region in the template DNA can generate the desired amino acid variant. PCR amplification results in a population of product DNA fragments that differ from the polynucleotide template encoding the polypeptide at the position specified by the primer. The product DNA fragments replace the corresponding region in the plasmid and this gives a polynucleotide encoding the desired amino acid variant.

A further technique for generating amino acid variants is the cassette mutagenesis technique described in Wells et al., Gene 34:315 (1985); and other mutagenesis techniques well known in the art, such as, for example, the techniques in Sambrook et al., supra, and Current Protocols in Molecular Biology, Ausubel et al. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used in the practice of the invention for the cloning and expression of these novel nucleic acids. Such DNA sequences include those which are capable of hybridizing to the appropriate novel nucleic acid sequence under stringent conditions.

Polynucleotides encoding preferred polypeptide truncations of the invention can be used to generate polynucleotides encoding chimeric or fusion proteins comprising one or more domains of the invention and heterologous protein sequences.

The polynucleotides of the invention additionally include the complement of any of the polynucleotides recited above. The polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic) or RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions that can routinely isolate polynucleotides of the desired sequence identities.

In accordance with the invention, polynucleotide sequences comprising the mature protein coding sequences corresponding to any one of SEQ ID NO: 1-30368, or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of that nucleic acid, or a functional equivalent thereof, in appropriate host cells. Also included are the cDNA inserts of any of the clones identified herein.

A polynucleotide according to the invention can be joined to any of a variety of other nucleotide sequences by well-established recombinant DNA techniques (see Sambrook J et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to polynucleotides include an assortment of vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.

The present invention further provides recombinant constructs comprising a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-30368 or a fragment thereof or any other polynucleotides of the invention. In one embodiment, the recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-30368 or a fragment thereof is inserted, in a forward or reverse orientation. In the case of a vector comprising one of the ORFs of the present invention, the vector may further comprise regulatory sequences, including for example, a promoter, operably linked to the ORF. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present invention. The following vectors are provided by way of example. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLneo, pSV2cat, pOG44, PXTI, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).

The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lad, lacZ, T3, T7, gpt, lambda PR, and trc. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene ofE coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an amino terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimuήum and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM 1 (Promega Biotech, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced or derepressed by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Polynucleotides of the invention can also be used to induce immune responses. For example, as described in Fan et al., Nat. Biotech. 17:870-872 (1999), incorporated herein by reference, nucleic acid sequences encoding a polypeptide may be used to generate antibodies against the encoded polypeptide following topical administration of naked plasmid DΝA or following injection, and preferably intramuscular injection of the DΝA. The nucleic acid sequences are preferably inserted in a recombinant expression vector and may be in the form of naked DΝA.

4.3 ANTISENSE

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1-30368, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, e.g. , complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a protein of any of SEQ ID NO: 30369-60736 or antisense nucleic acids complementary to a nucleic acid sequence of SEQ

ID NO: 1-30368 are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence of the invention. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence of the invention. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions). Given the coding strand sequences encoding a nucleic acid disclosed herein (e.g., SEQ

ID NO: 1-30368), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of a mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of a mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of a mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl- 2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection). The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a protein according to the invention to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g. , by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an -a n omeric nucleic acid molecule. An -a nomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual -uni ts, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids Res 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al.

(1987) Nucleic Acids Res 15: 6131-6148) or a chimeric RNA -DNA analogue (Inoue et al. (1987) FEBS Lett 215: 321-330).

4.4 RIBOZYMES AND PNA MOIETIES In still another embodiment, an antisense nucleic acid of the invention is a ribozyme.

Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as a mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave a mRNA transcripts to thereby inhibit translation of a mRNA. A ribozyme having specificity for a nucleic acid of the invention can be designed based upon the nucleotide sequence of a DNA disclosed herein (i.e., SEQ ID NO: 1 -

30368). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an mRNA of SEQ ID NO: 1-30368 (see, e.g., Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742). Alternatively, polynucleotides of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g. , Bartel et al., (1993) Science 261 :141 1-1418.

Alternatively, gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in target cells. See generally, Helene. (1991) Anticancer Drug Des. 6: 569-84; Helene. et al. (1992) Ann. N Y. Acad. Sci. 660:27-36; and Maher (1992) Bioassays 14: 807-15.

In various embodiments, the nucleic acids of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) Bioorg Med Chem 4: 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) above; Perry-O'Keefe et al. (1996) PNAS 93: 14670-675.

PNAs of the invention can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of the invention can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., SI nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup et al. (1996), above; Perry-O'Keefe (1996), above).

In another embodiment, PNAs of the invention can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn et al. (1996) Nucl Acids Res 24: 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag et al. (1989) Nucl Acid Res 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn et al. (1996) above). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen et al. (1975) Bioorg Med Chem Lett 5: 11 19-11124. In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, e.g. , Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.

4.5 HOSTS

The present invention further provides host cells genetically engineered to contain the polynucleotides of the invention. For example, such host cells may contain nucleic acids of the invention introduced into the host cell using known transformation, transfection or infection methods. The present invention still further provides host cells genetically engineered to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell.

Knowledge of nucleic acid sequences allows for modification of cells to permit, or increase, expression of endogenous polypeptide. Cells can be modified (e.g., by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the polypeptide at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the encoding sequences. See, for example, PCT International Publication No. WO94/12650, PCT International Publication No. WO92/20808, and PCT International

Publication No. WO91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the coding sequence, amplification of the marker DNA by standard selection methods results in co- amplification of the desired protein coding sequences in the cells.

The host cell can be a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, or electroporation (Davis, L. et al., Basic Methods in Molecular Biology (1986)). The host cells containing one of the polynucleotides of the invention, can be used in conventional manners to produce the gene product encoded by the isolated fragment (in the case of an ORF) or can be used to produce a heterologous protein under the control of the EMF. Any host/vector system can be used to express one or more of the ORFs of the present invention. These include, but are not limited to, eukaryotic hosts such as HeLa cells, Cv-1 cell, COS cells, 293 cells, and Sf9 cells, as well as prokaryotic host such as E. coli and B. subtilis. The most preferred cells are those which do not normally express the particular polypeptide or protein or which expresses the polypeptide or protein at low natural level. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., in Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, New York (1989), the disclosure of which is hereby incorporated by reference.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell 23:175 (1981). Other cell lines capable of expressing a compatible vector are, for example, the C127, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5 ' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements. Recombinant polypeptides and proteins produced in bacterial culture are usually isolated by initial extraction from cell pellets, followed by one or more salting-out, aqueous ion exchange or size exclusion chromatography steps. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or insects or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods. In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene's existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequence include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.

The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the host cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.

The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Patent No. 5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwin et al.; International Application No. PCT/US92/09627 (WO93/09222) by Selden et al.; and International Application No.

PCT/US90/06436 (WO91/06667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety.

4.6 POLYPEPTIDES OF THE INVENTION The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising: the amino acid sequences set forth as any one of SEQ ID NO: 30369-60736 or an amino acid sequence encoded by any one of the nucleotide sequences SEQ ID NO: 1-30368 or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides preferably with biological or immunological activity that are encoded by: (a) a polynucleotide having any one of the nucleotide sequences set forth in SEQ ID NO: 1-30368 or (b) polynucleotides encoding any one of the amino acid sequences set forth as SEQ ID NO:

30369-60736 or (c) polynucleotides that hybridize to the complement of the polynucleotides of either (a) or (b) under stringent hybridization conditions. The invention also provides biologically active or immunologically active variants of any of the amino acid sequences set forth as SEQ ID NO: 30369-60736 or the corresponding full length or mature protein; and

"substantial equivalents" thereof (e.g., with at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, 86%, 87%, 88%, 89%, at least about 90%, 91%, 92%, 93%, 94%, typically at least about 95%, 96%, 97%, more typically at least about 98%, or most typically at least about 99% amino acid identity) that retain biological activity. Polypeptides encoded by allelic variants may have a similar, increased, or decreased activity compared to polypeptides comprising SEQ ID NO: 30369-60736.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.

The present invention also provides both full-length and mature forms (for example, without a signal sequence or precursor sequence) of the disclosed proteins. The protein coding sequence is identified in the sequence listing by translation of the disclosed nucleotide sequences. The mature form of such protein may be obtained by expression of a full-length polynucleotide in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein is also determinable from the amino acid sequence of the full-length form. Where proteins of the present invention are membrane bound, soluble forms of the proteins are also provided. In such forms, part or all of the regions causing the proteins to be membrane bound are deleted so that the proteins are fully secreted from the cell in which they are expressed.

Protein compositions of the present invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier. The present invention further provides isolated polypeptides encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By "degenerate variant" is intended nucleotide fragments which differ from a nucleic acid fragment of the present invention (e.g., an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins. A variety of methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention. At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizers. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. This technique is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The polypeptides and proteins of the present invention can alternatively be purified from cells which have been altered to express the desired polypeptide or protein. As used herein, a cell is said to be altered to express a desired polypeptide or protein when the cell, through genetic manipulation, is made to produce a polypeptide or protein which it normally does not produce or which the cell normally produces at a lower level. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic sequences into eukaryotic or prokaryotic cells in order to generate a cell which produces one of the polypeptides or proteins of the present invention.

The invention also relates to methods for producing a polypeptide comprising growing a culture of host cells of the invention in a suitable culture medium, and purifying the protein from the cells or the culture in which the cells are grown. For example, the methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the encoded polypeptide. The polypeptide can be. recovered from the culture, conveniently from the culture medium, or from a lysate prepared from the host cells and further purified. Preferred embodiments include those in which the protein produced by such process is a full length or mature form of the protein.

In an alternative method, the polypeptide or protein is purified from bacterial cells which naturally produce the polypeptide or protein. One skilled in the art can readily follow known methods for isolating polypeptides and proteins in order to obtain one of the isolated polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography, and immuno-affinity chromatography. See, e.g., Scopes, Protein Purification: Principles and Practice, Springer-Verlag (1994); Sambrook, et al., in Molecular Cloning: A Laboratory Manual; Ausubel et al., Current Protocols in Molecular Biology. Polypeptide fragments that retain biological/immunological activity include fragments comprising greater than about 100 amino acids, or greater than about 200 amino acids, and fragments that encode specific protein domains.

The purified polypeptides can be used in in vitro binding assays which are well known in the art to identify molecules which bind to the polypeptides. These molecules include but are not limited to, for e.g., small molecules, molecules from combinatorial libraries, antibodies or other proteins. The molecules identified in the binding assay are then tested for antagonist or agonist activity in in vivo tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.

In addition, the peptides of the invention or molecules capable of binding to the peptides may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for SEQ ID NO: 30369-60736. The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequence can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein. Regions of the protein that are important for the protein function can be determined by various methods known in the art including the alanine-scanning method which involved systematic substitution of single or strings of amino acids with alanine, followed by testing the resulting alanine-containing variant for biological activity. This type of analysis determines the importance of the substituted amino acid(s) in biological activity. Regions of the protein that are important for protein function may be determined by the eMATRIX program.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and are useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein.

Such modifications are encompassed by the present invention.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif, U.S.A. (the MaxBat™ kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl™ or Cibacrom blue 3GA Sepharose™; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography. Alternatively, the protein of the invention may also be expressed in a form that will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX), or as a His-tag. Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("FLAG®") is commercially available from Kodak (New Haven, Conn.).

Finally, one or more reverse-phase high performance liquid chromatography (RP- HPLC) steps employing hydrophobic RP-HPLC media, e.g. , silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein." The polypeptides of the invention include analogs (variants). This embraces fragments, as well as peptides in which one or more amino acids has been deleted, inserted, or substituted. Also, analogs of the polypeptides of the invention embrace fusions of the polypeptides or modifications of the polypeptides of the invention, wherein the polypeptide or analog is fused to another moiety or moieties, e.g. , targeting moiety or another therapeutic agent. Such analogs may exhibit improved properties such as activity and/or stability. Examples of moieties which may be fused to the polypeptide or an analog include, for example, targeting moieties which provide for the delivery of polypeptide to pancreatic cells, e.g., antibodies to pancreatic cells, antibodies to immune cells such as T-cells, monocytes, dendritic cells, granulocytes, etc., as well as receptor and ligands expressed on pancreatic or immune cells. Other moieties which may be fused to the polypeptide include therapeutic agents which are used for treatment, for example, immunosuppressive drugs such as cyclosporin, SK506, azathioprine, CD3 antibodies and steroids. Also, polypeptides may be fused to immune modulators, and other cytokines such as alpha or beta interferon.

4.6.1 DETERMINING POLYPEPTIDE AND POLYNUCLEOTIDE IDENTITY AND SIMILARITY

Preferred identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in computer programs including, but are not limited to, the GCG program package, including GAP

(Devereux, J., et al., Nucleic Acids Research 12(1):387 (1984); Genetics Computer Group, University of Wisconsin, Madison, WI), BLASTP, BLASTN, BLASTX, FASTA (Altschul, S.F. et al., J. Molec. Biol. 215:403-410 (1990), PSI-BLAST (Altschul S.F. et al., Nucleic Acids Res. vol. 25, pp. 3389-3402, herein incorporated by reference), eMatrix software (Wu et al., J. Comp. Biol., Vol. 6, pp. 219-235 (1999), herein incorporated by reference), eMotif software (Nevill- Manning et al, ISMB-97, Vol. 4, pp. 202-209, herein incorporated by reference), pFam software (Sonnhammer et al., Nucleic Acids Res., Vol. 26(1), pp. 320-322 (1998), herein incorporated by reference) and the Kyte-Doolittle hydrophobocity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). The BLAST programs are publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul, S., et al. NCB NLM NIH Bethesda, MD 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990).

4.7 CHIMERIC AND FUSION PROTEINS

The invention also provides chimeric or fusion proteins. As used herein, a "chimeric protein" or "fusion protein" comprises a polypeptide of the invention operatively linked to another polypeptide. Within a fusion protein the polypeptide according to the invention can correspond to all or a portion of a protein according to the invention. In one embodiment, a fusion protein comprises at least one biologically active portion of a protein according to the invention. In another embodiment, a fusion protein comprises at least two biologically active portions of a protein according to the invention. Within the fusion protein, the term "operatively linked" is intended to indicate that the polypeptide according to the invention and the other polypeptide are fused in-frame to each other. The polypeptide can be fused to the N-terminus or C-terminus.

For example, in one embodiment a fusion protein comprises a polypeptide according to the invention operably linked to the extracellular domain of a second protein.

In another embodiment, the fusion protein is a GST-fusion protein in which the polypeptide sequences of the invention are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences.

In another embodiment, the fusion protein is an immunoglobulin fusion protein in which the polypeptide sequences according to the invention comprises one or more domains are fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand and a protein of the invention on the surface of a cell, to thereby suppress signal transduction in vivo. The immunoglobulin fusion proteins can be used to affect the bioavailability of a cognate ligand. Inhibition of the ligand/protein interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, e,g., cancer as well as modulating (e.g., promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies in a subject, to purify ligands, and in screening assays to identify molecules that inhibit the interaction of a polypeptide of the invention with a ligand. A chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the protein of the invention.

4.8 GENE THERAPY

Mutations in the polynucleotides of the invention gene may result in loss of normal function of the encoded protein. The invention thus provides gene therapy to restore normal activity of the polypeptides of the invention; or to treat disease states involving polypeptides of the invention. Delivery of a functional gene encoding polypeptides of the invention to appropriate cells is effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, Nature, supplement to vol. 392, no. 6679, pp.25-20 (1998). For additional reviews of gene therapy technology see Friedmann, Science, 244: 1275-1281 (1989); Verma, Scientific American: 68-84 (1990); and Miller, Nature, 357: 455-460 (1992). Introduction of any one of the nucleotides of the present invention or a gene encoding the polypeptides of the present invention can also be accomplished with extrachromosomal substrates (transient expression) or artificial chromosomes (stable expression). Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes. Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of polypeptides of the invention will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of polypeptides of the invention.

Other methods inhibiting expression of a protein include the introduction of antisense molecules to the nucleic acids of the present invention, their complements, or their translated RNA sequences, by methods known in the art. Further, the polypeptides of the present invention can be inhibited by using targeted deletion methods, or the insertion of a negative regulatory element such as a silencer, which is tissue specific.

The present invention still further provides cells genetically engineered in vivo to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell. These methods can be used to increase or decrease the expression of the polynucleotides of the present invention.

Knowledge of DNA sequences provided by the invention allows for modification of cells to permit, increase, or decrease, expression of endogenous polypeptide. Cells can be modified (e.g. , by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the protein at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the desired protein encoding sequences. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955. It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g. , ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the desired protein coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells. In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene's existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequences include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.

The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new sequences are

i_> added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.

The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Patent No. 5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwinet al.; International Application No. PCT/US92/09627 (WO93/09222)by Selden et al.; and International Application No. PCT/US90/06436 ( WO91 /06667) by Skoultchi et al . , each of which is incorporated by reference herein in its entirety.

4.9 TRANSGENIC ANIMALS

In preferred methods to determine biological functions of the polypeptides of the invention in vivo, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as "knockout" animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Patent No. 5,557,032, incorporated herein by reference.

Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Patent No 5,489,743 and PCT Publication No. WO94/28122, incorporated herein by reference.

Transgenic animals can be prepared wherein all or part of a promoter of the polynucleotides of the invention is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.

The polynucleotides of the present invention also make possible the development, through, e.g., homologous recombination or knock out strategies, of animals that fail to express polypeptides of the invention or that express a variant polypeptide. Such animals are useful as models for studying the in vivo activities of polypeptide as well as for studying modulators of the polypeptides of the invention.

In preferred methods to determine biological functions of the polypeptides of the invention in vivo, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as "knockout" animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Patent No. 5,557,032, incorporated herein by reference.

Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Patent No 5,489,743 and PCT Publication No. WO94/28122, incorporated herein by reference.

Transgenic animals can be prepared wherein all or part of the polynucleotides of the invention promoter is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.

4.10 USES AND BIOLOGICAL ACTIVITY The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified herein. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA). The mechanism underlying the particular condition or pathology will dictate whether the polypeptides of the invention, the polynucleotides of the invention or modulators (activators or inhibitors) thereof would be beneficial to the subject in need of treatment. Thus, "therapeutic compositions of the invention" include compositions comprising isolated polynucleotides (including recombinant DNA molecules, cloned genes and degenerate variants thereof) or polypeptides of the invention (including full length protein, mature protein and truncations or domains thereof), or compounds and other substances that modulate the overall activity of the target gene products, either at the level of target gene/protein expression or target protein activity. Such modulators include polypeptides, analogs, (variants), including fragments and fusion proteins, antibodies and other binding proteins; chemical compounds that directly or indirectly activate or inhibit the polypeptides of the invention (identified, e.g., via drug screening assays as described herein); antisense polynucleotides and polynucleotides suitable for triple helix formation; and in particular antibodies or other binding partners that specifically recognize one or more epitopes of the polypeptides of the invention.

The polypeptides of the present invention may likewise be involved in cellular activation or in one of the other physiological pathways described herein.

4.10.1 RESEARCH USES AND UTILITIES

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction. The polypeptides provided by the present invention can similarly be used in assays to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding polypeptide is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

4.10.2 NUTRITIONAL USES

Polynucleotides and polypeptides of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the polypeptide or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the polypeptide or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

4.10.3 CYTOKINE AND CELL PROLIFERATION/DIFFERENTIATION ACTIVITY A polypeptide of the present invention may exhibit activity relating to cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of therapeutic compositions of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DAI, 123, Tl 165, HT2, CTLL2, TF-1, Mo7e, CMK, HUVEC, and Caco. Therapeutic compositions of the invention can be used in the following: Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol.

145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., I. Immunol. 149:3778-3783, 1992; Bowman et al., I. Immunol. 152:1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human interleukin-γ, Schreiber, R. D. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-121 1, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6~Nordan, R. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991 ; Smith et al., Proc. Natl. Aced. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 1 1-Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991 ; Measurement of mouse and human Interleukin 9— Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse

Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11 :405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

4.10.4 STEM CELL GROWTH FACTOR ACTIVITY

A polypeptide of the present invention may exhibit stem cell growth factor activity and be involved in the proliferation, differentiation and survival of pluripotent and totipotent stem cells including primordial germ cells, embryonic stem cells, hematopoietic stem cells and/or germ line stem cells. Administration of the polypeptide of the invention to stem cells in vivo or ex vivo is expected to maintain and expand cell populations in a totipotential or pluripotential state which would be useful for re-engineering damaged or diseased tissues, transplantation, manufacture of bio-pharmaceuticals and the development of bio-sensors. The ability to produce large quantities of human cells has important working applications for the production of human proteins which currently must be obtained from non-human sources or donors, implantation of cells to treat diseases such as Parkinson's, Alzheimer's and other neurodegenerative diseases; tissues for grafting such as bone marrow, skin, cartilage, tendons, bone, muscle (including cardiac muscle), blood vessels, cornea, neural cells, gastrointestinal cells and others; and organs for transplantation such as kidney, liver, pancreas (including islet cells), heart and lung.

It is contemplated that multiple different exogenous growth factors and/or cytokines may be administered in combination with the polypeptide of the invention to achieve the desired effect, including any of the growth factors listed herein, other stem cell maintenance factors, and specifically including stem cell factor (SCF), leukemia inhibitory factor (LIF), Flt-3 ligand (Flt- 3L), any of the interleukins, recombinant soluble IL-6 receptor fused to IL-6, macrophage inflammatory protein 1 -alpha (MIP-1 -alpha), G-CSF, GM-CSF, thrombopoietin (TPO), platelet factor 4 (PF-4), platelet-derived growth factor (PDGF), neural growth factors and basic fibroblast growth factor (bFGF).

Since totipotent stem cells can give rise to virtually any mature cell type, expansion of these cells in culture will facilitate the production of large quantities of mature cells. Techniques for culturing stem cells are known in the art and administration of polypeptides of the invention, optionally with other growth factors and/or cytokines, is expected to enhance the survival and proliferation of the stem cell populations. This can be accomplished by direct administration of the polypeptide of the invention to the culture medium. Alternatively, stroma cells transfected with a polynucleotide that encodes for the polypeptide of the invention can be used as a feeder layer for the stem cell populations in culture or in vivo. Stromal support cells for feeder layers may include embryonic bone marrow fibroblasts, bone marrow stromal cells, fetal liver cells, or cultured embryonic fibroblasts (see U.S. Patent No. 5,690,926).

Stem cells themselves can be transfected with a polynucleotide of the invention to induce autocrine expression of the polypeptide of the invention. This will allow for generation of undifferentiated totipotential/pluripotential stem cell lines that are useful as is or that can then be differentiated into the desired mature cell types. These stable cell lines can also serve as a source of undifferentiated totipotential/pluripotential mRNA to create cDNA libraries and templates for polymerase chain reaction experiments. These studies would allow for the isolation and identification of differentially expressed genes in stem cell populations that regulate stem cell proliferation and/or maintenance.

Expansion and maintenance of totipotent stem cell populations will be useful in the treatment of many pathological conditions. For example, polypeptides of the present invention may be used to manipulate stem cells in culture to give rise to neuroepithelial cells that can be used to augment or replace cells damaged by illness, autoimmune disease, accidental damage or genetic disorders. The polypeptide of the invention may be useful for inducing the proliferation of neural cells and for the regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders which involve degeneration, death or trauma to neural cells or nerve tissue. In addition, the expanded stem cell populations can also be genetically altered for gene therapy purposes and to decrease host rejection of replacement tissues after grafting or implantation. Expression of the polypeptide of the invention and its effect on stem cells can also be manipulated to achieve controlled differentiation of the stem cells into more differentiated cell types. A broadly applicable method of obtaining pure populations of a specific differentiated cell type from undifferentiated stem cell populations involves the use of a cell-type specific promoter driving a selectable marker. The selectable marker allows only cells of the desired type to survive. For example, stem cells can be induced to differentiate into cardiomyocytes (Wobus et al., Differentiation, 48: 173-182, (1991); Klug et al., J. Clin. Invest., 98(1): 216-224, (1998)) or skeletal muscle cells (Browder, L. W. In: Principles of Tissue Engineering eds. Lanza et al., Academic Press (1997)). Alternatively, directed differentiation of stem cells can be accomplished by culturing the stem cells in the presence of a differentiation factor such as retinoic acid and an antagonist of the polypeptide of the invention which would inhibit the effects of endogenous stem cell factor activity and allow differentiation to proceed.

In vitro cultures of stem cells can be used to determine if the polypeptide of the invention exhibits stem cell growth factor activity. Stem cells are isolated from any one of various cell sources (including hematopoietic stem cells and embryonic stem cells) and cultured on a feeder layer, as described by Thompson et al. Proc. Natl. Acad. Sci, U.S.A., 92: 7844-7848 (1995), in the presence of the polypeptide of the invention alone or in combination with other growth factors or cytokines. The ability of the polypeptide of the invention to induce stem cells proliferation is determined by colony formation on semi-solid support e.g. as described by Bernstein et al., Blood, 77: 2316-2321 (1991).

4.10.5 HEMATOPOIESIS REGULATING ACTIVITY

A polypeptide of the present invention may be involved in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell disorders. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

Therapeutic compositions of the invention can be used in the following: Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81 :2903-2915, 1993. Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M. G. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H. J. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

4.10.6 TISSUE GROWTH ACTIVITY

A polypeptide of the present invention also may be involved in bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as in wound healing and tissue repair and replacement, and in healing of burns, incisions and ulcers. A polypeptide of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Compositions of a polypeptide, antibody, binding partner, or other modulator of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A polypeptide of this invention may also be involved in attracting bone-forming cells, stimulating growth of bone-forming cells, or inducing differentiation of progenitors of bone-forming cells. Treatment of osteoporosis, osteoarthritis, bone degenerative disorders, or periodontal disease, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes may also be possible using the composition of the invention. Another category of tissue regeneration activity that may involve the polypeptide of the present invention is tendon/ligament formation. Induction of tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament- forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The compositions of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a composition may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions that may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a composition of the invention.

Compositions of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

Compositions of the present invention may also be involved in the generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring may allow normal tissue to regenerate. A polypeptide of the present invention may also exhibit angiogenic activity. A composition of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A composition of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

Therapeutic compositions of the invention can be used in the following: Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, H. I. and Rovee, D. T., eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71 :382-84 (1978).

4.10.7 IMMUNE STIMULATING OR SUPPRESSING ACTIVITY A polypeptide of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A polynucleotide of the invention can encode a polypeptide exhibiting such activities. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SOD)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, proteins of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer. Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein (or antagonists thereof, including antibodies) of the present invention may also to be useful in the treatment of allergic reactions and conditions (e.g., anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens- Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis and contact allergies), such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein (or antagonists thereof) of the present invention. The therapeutic effects of the polypeptides or antagonists thereof on allergic reactions can be evaluated by in vivo animals models such as the cumulative contact enhancement test (Lastbom et al., Toxicology 125: 59-66, 1998), skin prick test (Hoffmann et al., Allergy 54: 446-54, 1999), guinea pig skin sensitization test (Vohr et al., Arch. Toxocol. 73: 501-9), and murine local lymph node assay (Kimber et al., J. Toxicol. Environ. Health 53: 563-79). Using the proteins of the invention it may also be possible to modulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a therapeutic composition of the invention may prevent cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, a lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens. The efficacy of particular therapeutic compositions in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:1 1102-11 105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of therapeutic compositions of the invention on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self-tissue and which promote the production of cytokines and autoanti bodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block stimulation of T cells can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or

NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (e.g., a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response may be useful in cases of viral infection, including systemic viral diseases such as influenza, the common cold, and encephalitis. Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.

A polypeptide of the present invention may provide the necessary stimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient mounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I alpha chain protein and β microglobulin protein or an MHC class II alpha chain protein and an MHC class II beta chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and WileyTnterscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981 ; Herrmann et al., J. Immunol. 128: 1968-1974, 1982; Handa et al., J.

Immunol. 135:1564-1572, 1985; Takai et al., I. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bowman et al., J. Virology 61 :1992-1998; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994. Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Thl and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine

173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al.. Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991 ; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1 :639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:1 11-1 17, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al.,

Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

4.10.8 ACTIVIN/INHIBIN ACTIVITY A polypeptide of the present invention may also exhibit activin- or inhibin-related activities. A polynucleotide of the invention may encode a polypeptide exhibiting such characteristics. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a polypeptide of the present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the polypeptide of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A polypeptide of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as, but not limited to, cows, sheep and pigs. The activity of a polypeptide of the invention may, among other means, be measured by the following methods.

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91 :562-572, 1972; Ling et al., Nature 321 :779-782, 1986; Vale et al., Nature 321 :776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

4.10.9 CHEMOTACTIC/CHEMOKINETIC ACTIVITY

A polypeptide of the present invention may be involved in chemotactic or chemokinetic activity for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Chemotactic and chemokinetic receptor activation can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic compositions (e.g. proteins, antibodies, binding partners, or modulators of the invention) provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis. Therapeutic compositions of the invention can be used in the following: Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Marguiles, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines

6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:1762-1768, 1994.

4.10.10 HEMOSTATIC AND THROMBOLYTIC ACTIVITY

A polypeptide of the invention may also be involved in hemostatis or thrombolysis or thrombosis. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Compositions may be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A composition of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

Therapeutic compositions of the invention can be used in the following: Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

4.10.11 CANCER DIAGNOSIS AND THERAPY Polypeptides of the invention may be involved in cancer cell generation, proliferation or metastasis. Detection of the presence or amount of polynucleotides or polypeptides of the invention may be useful for the diagnosis and/or prognosis of one or more types of cancer. For example, the presence or increased expression of a polynucleotide/polypeptide of the invention may indicate a hereditary risk of cancer, a precancerous condition, or an ongoing malignancy. Conversely, a defect in the gene or absence of the polypeptide may be associated with a cancer condition. Identification of single nucleotide polymorphisms associated with cancer or a predisposition to cancer may also be useful for diagnosis or prognosis.

Cancer treatments promote tumor regression by inhibiting tumor cell proliferation, inhibiting angiogenesis (growth of new blood vessels that is necessary to support tumor growth) and/or prohibiting metastasis by reducing tumor cell motility or invasiveness. Therapeutic compositions of the invention may be effective in adult and pediatric oncology including in solid phase tumors/malignancies, locally advanced tumors, human soft tissue sarcomas, metastatic cancer, including lymphatic metastases, blood cell malignancies including multiple myeloma, acute and chronic leukemias, and lymphomas, head and neck cancers including mouth cancer, larynx cancer and thyroid cancer, lung cancers including small cell carcinoma and non-small cell cancers, breast cancers including small cell carcinoma and ductal carcinoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer and polyps associated with colorectal neoplasia, pancreatic cancers, liver cancer, urologic cancers including bladder cancer and prostate cancer, malignancies of the female genital tract including ovarian carcinoma, uterine (including endometrial) cancers, and solid tumor in the ovarian follicle, kidney cancers including renal cell carcinoma, brain cancers including intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in the central nervous system, bone cancers including osteomas, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, hemangiopericytoma and Karposi's sarcoma.

Polypeptides, polynucleotides, or modulators of polypeptides of the invention (including inhibitors and stimulators of the biological activity of the polypeptide of the invention) may be administered to treat cancer. Therapeutic compositions can be administered in therapeutically effective dosages alone or in combination with adjuvant cancer therapy such as surgery, chemotherapy, radiotherapy, thermotherapy, and laser therapy, and may provide a beneficial effect, e.g. reducing tumor size, slowing rate of tumor growth, inhibiting metastasis, or otherwise improving overall clinical condition, without necessarily eradicating the cancer.

The composition can also be administered in therapeutically effective amounts as a portion of an anti-cancer cocktail. An anti-cancer cocktail is a mixture of the polypeptide or modulator of the invention with one or more anti-cancer drugs in addition to a pharmaceutically acceptable carrier for delivery. The use of anti-cancer cocktails as a cancer treatment is routine. Anti-cancer drugs that are well known in the art and can be used as a treatment in combination with the polypeptide or modulator of the invention include: Actinomycin D, Aminoglutethimide, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine,

Chlorambucil, Cisplatin (cis-DDP), Cyclophosphamide, Cytarabine HCl (Cytosine arabinoside), Dacarbazine, Dactinomycin, Daunorubicin HCl, Doxorubicin HCl, Estramustine phosphate sodium, Etoposide (VI 6-213), Floxuridine, 5-Fluorouracil (5-Fu), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosfamide, Interferon Alpha-2a, Interferon Alpha-2b, Leuprolide acetate (LHRH-releasing factor analog), Lomustine, Mechlorethamine HCl (nitrogen mustard), Melphalan, Mercaptopurine, Mesna, Methotrexate (MTX), Mitomycin, Mitoxantrone HCl, Octreotide, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thioguanine, Thiotepa, Vinblastine sulfate, Vincristine sulfate, Amsacrine, Azacitidine, Hexamethylmelamine, Interleukin-2, Mitoguazone, Pentostatin, Semustine, Teniposide, and Vindesine sulfate. In addition, therapeutic compositions of the invention may be used for prophylactic treatment of cancer. There are hereditary conditions and/or environmental situations (e.g. exposure to carcinogens) known in the art that predispose an individual to developing cancers. Under these circumstances, it may be beneficial to treat these individuals with therapeutically effective doses of the polypeptide of the invention to reduce the risk of developing cancers. In vitro models can be used to determine the effective doses of the polypeptide of the invention as a potential cancer treatment. These in vitro models include proliferation assays of cultured tumor cells, growth of cultured tumor cells in soft agar (see Freshney, (1987) Culture of Animal Cells: A Manual of Basic Technique, Wily-Liss, New York, NY Ch 18 and Ch 21), tumor systems in nude mice as described in Giovanella et al., J. Natl. Can. Inst., 52: 921-30 (1974), mobility and invasive potential of tumor cells in Boyden Chamber assays as described in Pilkington et al., Anticancer Res., 17: 4107-9 (1997), and angiogenesis assays such as induction of vascularization of the chick chorioallantoic membrane or induction of vascular endothelial cell migration as described in Ribatta et al., Intl. J. Dev. Biol., 40: 1189-97 (1999) and Li et al., Clin. Exp. Metastasis, 17:423-9 (1999), respectively. Suitable tumor cells lines are available, e.g. from American Type Tissue Culture Collection catalogs.

4.10.12 RECEPTOR/LIGAND ACTIVITY

A polypeptide of the present invention may also demonstrate activity as receptor, receptor ligand or inhibitor or agonist of receptor/ligand interactions. A polynucleotide of the invention can encode a polypeptide exhibiting such characteristics. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions. The activity of a polypeptide of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley- Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1- 7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

By way of example, the polypeptides of the invention may be used as a receptor for a ligand(s) thereby transmitting the biological activity of that ligand(s). Ligands may be identified through binding assays, affinity chromatography, dihybrid screening assays, BIAcore assays, gel overlay assays, or other methods known in the art.

Studies characterizing drugs or proteins as agonist or antagonist or partial agonists or a partial antagonist require the use of other proteins as competing ligands. The polypeptides of the present invention or ligand(s) thereof may be labeled by being coupled to radioisotopes, colorimetric molecules or toxin molecules by conventional methods. ("Guide to Protein Purification" Murray P. Deutscher (ed) Methods in Enzymology Vol. 182 (1990) Academic Press, Inc. San Diego). Examples of radioisotopes include, but are not limited to, tritium and carbon- 14. Examples of colorimetric molecules include, but are not limited to, fluorescent molecules such as fluorescamine, or rhodamine or other colorimetric molecules. Examples of toxins include, but are not limited, to ricin.

4.10.13 DRUG SCREENING

This invention is particularly useful for screening chemical compounds by using the novel polypeptides or binding fragments thereof in any of a variety of drug screening techniques. The polypeptides or fragments employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or a fragment thereof. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between polypeptides of the invention or fragments and the agent being tested or examine the diminution in complex formation between the novel polypeptides and an appropriate cell line, which are well known in the art. Sources for test compounds that may be screened for ability to bind to or modulate (i.e., increase or decrease) the activity of polypeptides of the invention include (1) inorganic and organic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of either random or mimetic peptides, oligonucleotides or organic molecules. Chemical libraries may be readily synthesized or purchased from a number of commercial sources, and may include structural analogs of known compounds or compounds that are identified as "hits" or "leads" via natural product screening.

The sources of natural product libraries are microorganisms (including bacteria and fungi), animals, plants or other vegetation, or marine organisms, and libraries of mixtures for screening may be created by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of the organisms themselves. Natural product libraries include polyketides, non-ribosomal peptides, and (non-naturally occurring) variants thereof. For a review, see Science 282:63-68 (1998).

Combinatorial libraries are composed of large numbers of peptides, oligonucleotides or organic compounds and can be readily prepared by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, Curr. Opin. Biotechnol. 8:701-707 (1997). For reviews and examples of peptidomimetic libraries, see Al-Obeidi et al., Mol. Biotechnol, 9(3):205-23 (1998); Hruby et al., Curr Opin Chem Biol,

1(1):1 14-19 (1997); Dorner et al., Bioorg Med Chem, 4(5):709-15 (1996) (alkylated dipeptides). Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit" (or "lead") to optimize the capacity of the "hit" to bind a polypeptide of the invention. The molecules identified in the binding assay are then tested for antagonist or agonist activity in in vivo tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.

The binding molecules thus identified may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells such as radioisotopes. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for a polypeptide of the invention. Alternatively, the binding molecules may be complexed with imaging agents for targeting and imaging purposes.

4.10.14 ASSAY FOR RECEPTOR ACTIVITY The invention also provides methods to detect specific binding of a polypeptide e.g. a ligand or a receptor. The art provides numerous assays particularly useful for identifying previously unknown binding partners for receptor polypeptides of the invention. For example, expression cloning using mammalian or bacterial cells, or dihybrid screening assays can be used to identify polynucleotides encoding binding partners. As another example, affinity chromatography with the appropriate immobilized polypeptide of the invention can be used to isolate polypeptides that recognize and bind polypeptides of the invention. There are a number of different libraries used for the identification of compounds, and in particular small molecules, that modulate (i.e., increase or decrease) biological activity of a polypeptide of the invention. Ligands for receptor polypeptides of the invention can also be identified by adding exogenous ligands, or cocktails of ligands to two cells populations that are genetically identical except for the expression of the receptor of the invention: one cell population expresses the receptor of the invention whereas the other does not. The responses of the two cell populations to the addition of ligands(s) are then compared. Alternatively, an expression library can be co-expressed with the polypeptide of the invention in cells and assayed for an autocrine response to identify potential ligand(s). As still another example, BIAcore assays, gel overlay assays, or other methods known in the art can be used to identify binding partner polypeptides, including, (1) organic and inorganic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules.

The role of downstream intracellular signaling molecules in the signaling cascade of the polypeptide of the invention can be determined. For example, a chimeric protein in which the cytoplasmic domain of the polypeptide of the invention is fused to the extracellular portion of a protein, whose ligand has been identified, is produced in a host cell. The cell is then incubated with the ligand specific for the extracellular portion of the chimeric protein, thereby activating the chimeric receptor. Known downstream proteins involved in intracellular signaling can then be assayed for expected modifications i.e. phosphorylation. Other methods known to those in the art can also be used to identify signaling molecules involved in receptor activity.

4.10.15 ANTI-INFLAMMATORY ACTIVITY Compositions of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Compositions with such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation intimation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Compositions of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material. Compositions of this invention may be utilized to prevent or treat conditions such as, but not limited to, sepsis, acute pancreatitis, endotoxin shock, cytokine induced shock, rheumatoid arthritis, chronic inflammatory arthritis, pancreatic cell damage from diabetes mellitus type 1, graft versus host disease, inflammatory bowel disease, inflamation associated with pulmonary disease, other autoimmune disease or inflammatory disease, an antiproliferative agent such as for acute or chronic mylegenous leukemia or in the prevention of premature labor secondary to intrauterine infections.

4.10.16 LEUKEMIAS

Leukemias and related disorders may be treated or prevented by administration of a therapeutic that promotes or inhibits function of the polynucleotides and/or polypeptides of the invention. Such leukemias and related disorders include but are not limited to acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia).

4.10.17 NERVOUS SYSTEM DISORDERS Nervous system disorders, involving cell types which can be tested for efficacy of intervention with compounds that modulate the activity of the polynucleotides and/or polypeptides of the invention, and which can be treated upon thus observing an indication of therapeutic utility, include but are not limited to nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention include but are not limited to the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (i) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries;

(ii) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia;

(iii) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (iv) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis;

(v) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration;

(vi) neurological lesions associated with systemic diseases including but not limited to diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis;

(vii) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and

(viii) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including but not limited to multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

Therapeutics which are useful according to the invention for treatment of a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, therapeutics which elicit any of the following effects may be useful according to the invention: (i) increased survival time of neurons in culture; (ii) increased sprouting of neurons in culture or in vivo;

(iii) increased production of a neuron-associated molecule in culture or in vivo, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (iv) decreased symptoms of neuron dysfunction in vivo. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may be measured by the method set forth in Arakawa et al. (1990, J. Neurosci. 10:3507-3515); increased sprouting of neurons may be detected by methods set forth in Pestronk et al. (1980, Exp. Neurol. 70:65-82) or Brown et al. (1981, Ann. Rev. Neurosci. 4:17-42); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron disorders that may be treated according to the invention include but are not limited to disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including but not limited to progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

4.10.18 OTHER ACTIVITIES

A polypeptide of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape

(such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, co-factors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

4.10.19 IDENTIFICATION OF POLYMORPHISMS

The demonstration of polymorphisms makes possible the identification of such polymorphisms in human subjects and the pharmacogenetic use of this information for diagnosis and treatment. Such polymorphisms may be associated with, e.g., differential predisposition or susceptibility to various disease states (such as disorders involving inflammation or immune response) or a differential response to drug administration, and this genetic information can be used to tailor preventive or therapeutic treatment appropriately. For example, the existence of a polymorphism associated with a predisposition to inflammation or autoimmune disease makes possible the diagnosis of this condition in humans by identifying the presence of the polymorphism.

Polymorphisms can be identified in a variety of ways known in the art which all generally involve obtaining a sample from a patient, analyzing DNA from the sample, optionally involving isolation or amplification of the DNA, and identifying the presence of the polymorphism in the DNA. For example, PCR may be used to amplify an appropriate fragment of genomic DNA which may then be sequenced. Alternatively, the DNA may be subjected to allele-specific oligonucleotide hybridization (in which appropriate oligonucleotides are hybridized to the DNA under conditions permitting detection of a single base mismatch) or to a single nucleotide extension assay (in which an oligonucleotide that hybridizes immediately adjacent to the position of the polymorphism is extended with one or more labeled nucleotides). In addition, traditional restriction fragment length polymorphism analysis (using restriction enzymes that provide differential digestion of the genomic DNA depending on the presence or absence of the polymorphism) may be performed. Arrays with nucleotide sequences of the present invention can be used to detect polymorphisms. The array can comprise modified nucleotide sequences of the present invention in order to detect the nucleotide sequences of the present invention. In the alternative, any one of the nucleotide sequences of the present invention can be placed on the array to detect changes from those sequences.

Alternatively a polymorphism resulting in a change in the amino acid sequence could also be detected by detecting a corresponding change in amino acid sequence of the protein, e.g., by an antibody specific to the variant sequence.

4.10.20 ARTHRITIS AND INFLAMMATION

The immunosuppressive effects of the compositions of the invention against rheumatoid arthritis are determined in an experimental animal model system. The experimental model system is adjuvant induced arthritis in rats, and the protocol is described by J. Holoshitz, et at., 1983, Science, 219:56, or by B. Waksman et al., 1963, Int. Arch. Allergy Appl. Immunol., 23:129. Induction of the disease can be caused by a single injection, generally intradermally, of a suspension of killed Mycobacterium tuberculosis in complete Freund's adjuvant (CFA). The route of injection can vary, but rats may be injected at the base of the tail with an adjuvant mixture. The polypeptide is administered in phosphate buffered solution (PBS) at a dose of about 1-5 mg/kg. The control consists of administering PBS only.

The procedure for testing the effects of the test compound would consist of intradermally injecting killed Mycobacterium tuberculosis in CFA followed by immediately administering the test compound and subsequent treatment every other day until day 24. At 14, 15, 18, 20, 22, and 24 days after injection of Mycobacterium CFA, an overall arthritis score may be obtained as described by J. Holoskitz above. An analysis of the data would reveal that the test compound would have a dramatic affect on the swelling of the joints as measured by a decrease of the arthritis score.

4.11 THERAPEUTIC METHODS

The compositions (including polypeptide fragments, analogs, variants and antibodies or other binding partners or modulators including antisense polynucleotides) of the invention have numerous applications in a variety of therapeutic methods. Examples of therapeutic applications include, but are not limited to, those exemplified herein. 4.11.1 EXAMPLE

One embodiment of the invention is the administration of an effective amount of the polypeptides or other composition of the invention to individuals affected by a disease or disorder that can be modulated by regulating the peptides of the invention. While the mode of administration is not particularly important, parenteral administration is preferred. An exemplary mode of administration is to deliver an intravenous bolus. The dosage of the polypeptides or other composition of the invention will normally be determined by the prescribing physician. It is to be expected that the dosage will vary according to the age, weight, condition and response of the individual patient. Typically, the amount of polypeptide administered per dose will be in the range of about 0.01 μg/kg to 100 mg/kg of body weight, with the preferred dose being about 0.1 μg/kg to 10 mg/kg of patient body weight. For parenteral administration, polypeptides of the invention will be formulated in an injectable form combined with a pharmaceutically acceptable parenteral vehicle. Such vehicles are well known in the art and examples include water, saline, Ringer's solution, dextrose solution, and solutions consisting of small amounts of the human serum albumin. The vehicle may contain minor amounts of additives that maintain the isotonicity and stability of the polypeptide or other active ingredient. The preparation of such solutions is within the skill of the art.

4.12 PHARMACEUTICAL FORMULATIONS AND ROUTES OF ADMINISTRATION

A protein or other composition of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources and including antibodies and other binding partners of the polypeptides of the invention) may be administered to a patient in need, by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s) at doses to treat or ameliorate a variety of disorders. Such a composition may optionally contain (in addition to protein or other active ingredient and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1 , TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the disease or disorder in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF-α and TGF-β), insulin-like growth factor (IGF), as well as cytokines described herein.

The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or other active ingredient or complement its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein or other active ingredient of the invention, or to minimize side effects. Conversely, protein or other active ingredient of the present invention may be included in formulations of the particular clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti- inflammatory agent to minimize side effects of the clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent (such as IL-lRa, IL-1 Hyl, IL-1 Hy2, anti-TNF, corticosteroids, immunosuppressive agents). A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

As an alternative to being included in a pharmaceutical composition of the invention including a first protein, a second protein or a therapeutic agent may be concurrently administered with the first protein (e.g., at the same time, or at differing times provided that therapeutic concentrations of the combination of agents is achieved at the treatment site).

Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms, e.g., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, a therapeutically effective dose refers to that ingredient alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein or other active ingredient of the present invention is administered to a mammal having a condition to be treated. Protein or other active ingredient of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co- administered with one or more cytokines, lymphokines or other hematopoietic factors, protein or other active ingredient of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein or other active ingredient of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

4.12.1 ROUTES OF ADMINISTRATION Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. Administration of protein or other active ingredient of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a arthritic joints or in fibrotic tissue, often in a depot or sustained release formulation. In order to prevent the scarring process frequently occurring as complication of glaucoma surgery, the compounds may be administered topically, for example, as eye drops. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a specific antibody, targeting, for example, arthritic or fibrotic tissue. The liposomes will be targeted to and taken up selectively by the afflicted tissue.

The polypeptides of the invention are administered by any route that delivers an effective dosage to the desired site of action. The determination of a suitable route of administration and an effective dosage for a particular indication is within the level of skill in the art. Preferably for wound treatment, one administers the therapeutic compound directly to the site. Suitable dosage ranges for the polypeptides of the invention can be extrapolated from these dosages or from similar studies in appropriate animal models. Dosages can then be adjusted as necessary by the clinician to provide maximal therapeutic benefit.

4.12.2 COMPOSITIONS/FORMULATIONS Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. These pharmaceutical compositions may be manufactured in a manner that is itself known, e.g. , by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of protein or other active ingredient of the present invention is administered orally, protein or other active ingredient of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein or other active ingredient of the present invention, and preferably from about 25 to 90% protein or other active ingredient of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein or other active ingredient of the present invention, and preferably from about 1 to 50% protein or other active ingredient of the present invention.

When a therapeutically effective amount of protein or other active ingredient of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein or other active ingredient of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein or other active ingredient solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein or other active ingredient of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained from a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner. For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

A pharmaceutical carrier for the hydrophobic compounds of the invention is a co-solvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1 :1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various types of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein or other active ingredient stabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Many of the active ingredients of the invention may be provided as salts with pharmaceutically compatible counter ions. Such pharmaceutically acceptable base addition salts are those salts which retain the biological effectiveness and properties of the free acids and which are obtained by reaction with inorganic or organic bases such as sodium hydroxide, magnesium hydroxide, ammonia, trialkylamine, dialkylamine, monoalkylamine, dibasic amino acids, sodium acetate, potassium benzoate, triethanol amine and the like.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) or other active ingredient(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B-lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithins, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent Nos. 4,235,871; 4,501,728; 4,837,028; and 4,737,323, all of which are incorporated herein by reference. The amount of protein or other active ingredient of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein or other active ingredient of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein or other active ingredient of the present invention and observe the patient's response. Larger doses of protein or other active ingredient of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μg to about 100 mg (preferably about 0.1 μg to about 10 mg, more preferably about 0.1 μg to about 1 mg) of protein or other active ingredient of the present invention per kg body weight. For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein or other active ingredient of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing or other active ingredient-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above- mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalcium phosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix. A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses

(including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt % based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells. In further compositions, proteins or other active ingredients of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- and TGF-β), and insulin-like growth factor (IGF). The therapeutic compositions are also presently valuable for veterinary applications.

Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins or other active ingredients of the present invention. The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling. Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA). Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.

4.12.3 EFFECTIVE DOSAGE

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from appropriate in vitro assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that can be used to more accurately determine useful doses in humans. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC_JO as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the protein's biological activity).

Such information can be used to more accurately determine useful doses in humans.

A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD ₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD₅₀ and ED₅₀. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. See, e.g., Fingl et al., 1975, in "The

Pharmacological Basis of Therapeutics", Ch. 1 p.l. Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the desired effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

An exemplary dosage regimen for polypeptides or other compositions of the invention will be in the range of about 0.01 μg/kg to 100 mg/kg of body weight daily, with the preferred dose being about 0.1 μg/kg to 25 mg/kg of patient body weight daily, varying in adults and children. Dosing may be once daily, or equivalent doses may be delivered at longer or shorter intervals.

The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's age and weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. 4.12.4 PACKAGING

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

4.13 ANTIBODIES Also included in the invention are antibodies to proteins, or fragments of proteins of the invention. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen-binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_ab, F_at,' and F_{(a ')2} fragments, and an F_ab expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgGi, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, (for example the amino acid sequence shown in SEQ ID NO: 30369), and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region on the surface of the protein of the invention that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human related protein sequence will indicate which regions of a related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

5.13.1 Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

5.13.2 Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen- binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it. Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature. 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro. The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice. Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal. The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

5.13.2 Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen- binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321 :522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science. 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

5.13.3 Human Antibodies Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison ( Nature 368. 812-13 (1994)); Fishwild et al,( Nature Biotechnology F4, 845-51 (1996)); Neuberger (Nature Biotechnology H, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker. A method for producing an antibody of interest, such as a human antibody, is disclosed in

U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

5.13.4 F_«b Fragments and Single Chain Antibodies

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_ab expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F_ab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_(ab')₂ fragment produced by pepsin digestion of an antibody molecule; (ii) an F_ab fragment generated by reducing the disulfide bridges of an F(_ab')2 fragment; (iii) an F_ab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

5.13.5 Bispecific Antibodies Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit. Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture often different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al, 1991 EMBO J., 10:3655-3659.

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121 :210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers. Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g.

F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets. Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5): 1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (Vn) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994). Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991). Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD 16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

5.13.6 Heteroconjugate Antibodies Heteroconjugate antibodies are also within the scope of the present invention.

Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4- mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

5.13.7 Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191- 1 195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and

ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).

5.13.8 Immunoconjugates The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ²¹²Bi, ^{13 l}I, ¹³¹In, ⁹⁰Y, and ^l86Re.

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1 ,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon- 14-labeled l-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX- DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

4.14 COMPUTER READABLE SEQUENCES In one application of this embodiment, a nucleotide sequence of the present invention can be recorded on computer readable media. As used herein, "computer readable media" refers to any medium which can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. A skilled artisan can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising computer readable medium having recorded thereon a nucleotide sequence of the present invention. As used herein, "recorded" refers to a process for storing information on computer readable medium. A skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising the nucleotide sequence information of the present invention.

A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. A skilled artisan can readily adapt any number of data processor structuring formats (e.g. text file or database) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present invention.

By providing any of the nucleotide sequences SEQ ID NO: 1-30368 or a representative fragment thereof; or a nucleotide sequence at least 95% identical to any of the nucleotide sequences of SEQ ID NO: 1-30368 in computer readable form, a skilled artisan can routinely access the sequence information for a variety of purposes. Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium. The examples which follow demonstrate how software which implements the BLAST (Altschul et al., J. Mol. Biol. 215:403-410 (1990)) and BLAZE (Brutlag et al., Comp.

Chem. 17:203-207 (1993)) search algorithms on a Sybase system is used to identify open reading frames (ORFs) within a nucleic acid sequence. Such ORFs may be protein encoding fragments and may be useful in producing commercially important proteins such as enzymes used in fermentation reactions and in the production of commercially useful metabolites. As used herein, "a computer-based system" refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware means of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based systems are suitable for use in the present invention. As stated above, the computer-based systems of the present invention comprise a data storage means having stored therein a nucleotide sequence of the present invention and the necessary hardware means and software means for supporting and implementing a search means. As used herein, "data storage means" refers to memory which can store nucleotide sequence information of the present invention, or a memory access means which can access manufactures having recorded thereon the nucleotide sequence information of the present invention.

As used herein, "search means" refers to one or more programs which are implemented on the computer-based system to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of a known sequence which match a particular target sequence or target motif. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. Examples of such software includes, but is not limited to, Smith- Waterman, MacPattern (EMBL), BLASTN and BLASTA (NPOLYPEPTIDEIA). A skilled artisan can readily recognize that any one of the available algorithms or implementing software packages for conducting homology searches can be adapted for use in the present computer-based systems. As used herein, a "target sequence" can be any nucleic acid or amino acid sequence of six or more nucleotides or two or more amino acids. A skilled artisan can readily recognize that the longer a target sequence is, the less likely a target sequence will be present as a random occurrence in the database. The most preferred sequence length of a target sequence is from about 10 to 300 amino acids, more preferably from about 30 to 100 nucleotide residues. However, it is well recognized that searches for commercially important fragments, such as sequence fragments involved in gene expression and protein processing, may be of shorter length.

As used herein, "a target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration which is formed upon the folding of the target motif. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences).

4.15 TRIPLE HELIX FORMATION In addition, the fragments of the present invention, as broadly described, can be used to control gene expression through triple helix formation or antisense DNA or RNA, both of which methods are based on the binding of a polynucleotide sequence to DNA or RNA. Polynucleotides suitable for use in these methods are preferably 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 15241 :456 (1988); and Dervan et al., Science 251 :1360 (1991)) or to the mRNA itself (antisense - Olmno, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide.

4.16 DIAGNOSTIC ASSAYS AND KITS The present invention further provides methods to identify the presence or expression of one of the ORFs of the present invention, or homolog thereof, in a test sample, using a nucleic acid probe or antibodies of the present invention, optionally conjugated or otherwise associated with a suitable label.

In general, methods for detecting a polynucleotide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polynucleotide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polynucleotide of the invention is detected in the sample. Such methods can also comprise contacting a sample under stringent hybridization conditions with nucleic acid primers that anneal to a polynucleotide of the invention under such conditions, and amplifying annealed polynucleotides, so that if a polynucleotide is amplified, a polynucleotide of the invention is detected in the sample.

In general, methods for detecting a polypeptide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polypeptide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polypeptide of the invention is detected in the sample. In detail, such methods comprise incubating a test sample with one or more of the antibodies or one or more of the nucleic acid probes of the present invention and assaying for binding of the nucleic acid probes or antibodies to components within the test sample.

Conditions for incubating a nucleic acid probe or antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid probe or antibody used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes or antibodies of the present invention. Examples of such assays can be found in Chard, T., An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G.R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of immunoassay s: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985). The test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as sputum, blood, serum, plasma, or urine. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention. Specifically, the invention provides a compartment kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the probes or antibodies of the present invention; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound probe or antibody.

In detail, a compartment kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the antibodies used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound antibody or probe. Types of detection reagents include labeled nucleic acid probes, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. One skilled in the art will readily recognize that the disclosed probes and antibodies of the present invention can be readily incorporated into one of the established kit formats which are well known in the art.

4.17 MEDICAL IMAGING

The novel polypeptides and binding partners of the invention are useful in medical imaging of sites expressing the molecules of the invention (e.g., where the polypeptide of the invention is involved in the immune response, for imaging sites of inflammation or infection). See, e.g., Kunkel et al., U.S. Pat. NO. 5,413,778. Such methods involve chemical attachment of a labeling or imaging agent, administration of the labeled polypeptide to a subject in a pharmaceutically acceptable carrier, and imaging the labeled polypeptide in vivo at the target site.

4.18 SCREENING ASSAYS

Using the isolated proteins and polynucleotides of the invention, the present invention further provides methods of obtaining and identifying agents which bind to a polypeptide encoded by an ORF corresponding to any of the nucleotide sequences set forth in SEQ ID NO: 1-30368, or bind to a specific domain of the polypeptide encoded by the nucleic acid. In detail, said method comprises the steps of:

(a) contacting an agent with an isolated protein encoded by an ORF of the present invention, or nucleic acid of the invention; and

(b) determining whether the agent binds to said protein or said nucleic acid. In general, therefore, such methods for identifying compounds that bind to a polynucleotide of the invention can comprise contacting a compound with a polynucleotide of the invention for a time sufficient to form a polynucleotide/compound complex, and detecting the complex, so that if a polynucleotide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified. Likewise, in general, therefore, such methods for identifying compounds that bind to a polypeptide of the invention can comprise contacting a compound with a polypeptide of the invention for a time sufficient to form a polypeptide/compound complex, and detecting the complex, so that if a polypeptide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified. Methods for identifying compounds that bind to a polypeptide of the invention can also comprise contacting a compound with a polypeptide of the invention in a cell for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a receptor gene sequence in the cell, and detecting the complex by detecting reporter gene sequence expression, so that if a polypeptide/compound complex is detected, a compound that binds a polypeptide of the invention is identified.

Compounds identified via such methods can include compounds which modulate the activity of a polypeptide of the invention (that is, increase or decrease its activity, relative to activity observed in the absence of the compound). Alternatively, compounds identified via such methods can include compounds which modulate the expression of a polynucleotide of the invention (that is, increase or decrease expression relative to expression levels observed in the absence of the compound). Compounds, such as compounds identified via the methods of the invention, can be tested using standard assays well known to those of skill in the art for their ability to modulate activity/expression. The agents screened in the above assay can be, but are not limited to, peptides, carbohydrates, vitamin derivatives, or other pharmaceutical agents. The agents can be selected and screened at random or rationally selected or designed using protein modeling techniques.

For random screening, agents such as peptides, carbohydrates, pharmaceutical agents and the like are selected at random and are assayed for their ability to bind to the protein encoded by the ORF of the present invention. Alternatively, agents may be rationally selected or designed. As used herein, an agent is said to be "rationally selected or designed" when the agent is chosen based on the configuration of the particular protein. For example, one skilled in the art can readily adapt currently available procedures to generate peptides, pharmaceutical agents and the like, capable of binding to a specific peptide sequence, in order to generate rationally designed antipeptide peptides, for example see Hurby et al., Application of Synthetic Peptides: Antisense Peptides," In Synthetic Peptides, A User's Guide, W.H. Freeman, NY (1992), pp. 289-307, and Kaspczak et al., Biochemistry 28:9230-8 (1989), or pharmaceutical agents, or the like.

In addition to the foregoing, one class of agents of the present invention, as broadly described, can be used to control gene expression through binding to one of the ORFs or EMFs of the present invention. As described above, such agents can be randomly screened or rationally designed/selected. Targeting the ORF or EMF allows a skilled artisan to design sequence specific or element specific agents, modulating the expression of either a single ORF or multiple ORFs which rely on the same EMF for expression control. One class of DNA binding agents are agents which contain base residues which hybridize or form a triple helix formation by binding to DNA or RNA. Such agents can be based on the classic phosphodiester, ribonucleic acid backbone, or can be a variety of sulfhydryl or polymeric derivatives which have base attachment capacity.

Agents suitable for use in these methods preferably contain 20 to 40 bases and are designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241 :456 (1988); and Dervan et al., Science 251 :1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560

(1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca

Raton, FL (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems.

Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide and other DNA binding agents.

Agents that bind to a protein encoded by one of the ORFs of the present invention can be used as a diagnostic agent. Agents which bind to a protein encoded by one of the ORFs of the present invention can be formulated using known techniques to generate a pharmaceutical composition.

4.19 USE OF NUCLEIC ACIDS AS PROBES

Another aspect of the subject invention is to provide for polypeptide-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences. The hybridization probes of the subject invention may be derived from any of the nucleotide sequences SEQ ID NO: 1-30368. Because the corresponding gene is only expressed in a limited number of tissues, a hybridization probe derived from of any of the nucleotide sequences SEQ ID NO: 1-30368 can be used as an indicator of the presence of RNA of cell type of such a tissue in a sample.

Any suitable hybridization technique can be employed, such as, for example, in situ hybridization. PCR as described in US Patents Nos. 4,683,195 and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide sequences. Such probes used in PCR may be of recombinant origin, may be chemically synthesized, or a mixture of both. The probe will comprise a discrete nucleotide sequence for the detection of identical sequences or a degenerate pool of possible sequences for identification of closely related genomic sequences. Other means for producing specific hybridization probes for nucleic acids include the cloning of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides. The nucleotide sequences may be used to construct hybridization probes for mapping their respective genomic sequences. The nucleotide sequence provided herein may be mapped to a chromosome or specific regions of a chromosome using well known genetic and/or chromosomal mapping techniques. These techniques include in situ hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent in situ hybridization of chromosome spreads has been described, among other places, in Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York NY. Fluorescent in situ hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of Science (265 : 1981 f). Correlation between the location of a nucleic acid on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals.

4.20 PREPARATION OF SUPPORT BOUND OLIGONUCLEOTIDES

Oligonucleotides, i.e., small nucleic acid segments, may be readily prepared by, for example, directly synthesizing the oligonucleotide by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer.

Support bound oligonucleotides may be prepared by any of the methods known to those of skill in the art using any suitable support such as glass, polystyrene or Teflon. One strategy is to precisely spot oligonucleotides synthesized by standard synthesizers. Immobilization can be achieved using passive adsorption (Inouye & Hondo, (1990) J. Clin. Microbiol.28(6) 1469-72); using UV light (Nagata et al, 1985; Dahlen et al., 1987; Morrissey & Collins, (1989) Mol. Cell Probes 3(2) 189-207) or by covalent binding of base modified DNA (Keller etal, 1988; 1989); all references being specifically incorporated herein.

Another strategy that may be employed is the use of the strong biotin-streptavidin interaction as a linker. For example, Broude et al. (1994) Proc. Natl. Acad. Sci. USA 91 (8) 3072-6, describe the use of biotinylated probes, although these are duplex probes, that are immobilized on streptavidin-coated magnetic beads. Streptavidin-coated beads may be purchased from Dynal, Oslo. Of course, this same linking chemistry is applicable to coating any surface with streptavidin. Biotinylated probes may be purchased from various sources, such as, e.g., Operon Technologies (Alameda, CA). Nunc Laboratories (Naperville, IL) is also selling suitable material that could be used. Nunc

Laboratories have developed a method by which DNA can be covalently bound to the microwell surface termed Covalink NH. CovaLink NH is a polystyrene surface grafted with secondary amino groups (>NH) that serve as bridge-heads for further covalent coupling. CovaLink Modules may be purchased from Nunc Laboratories. DNA molecules may be bound to CovaLink exclusively at the 5'-end by a phosphoramidatebond, allowing immobilization of more than 1 pmol of DNA (Rasmussenet α/., (1991) Anal. Biochem. 198(1) 138-42).

The use of CovaLink NH strips for covalent binding of DNA molecules at the 5'-end has been described (Rasmussen et al., (1991). In this technology, a phosphoramidatebond is employed (Chu et al., (1983) Nucleic Acids Res. 11(8) 6513-29). This is beneficial as immobilization using only a single covalent bond is preferred. The phosphoramidatebond joins the DNA to the CovaLink NH secondary amino groups that are positioned at the end of spacer arms covalently grafted onto the polystyrene surface through a 2 nm long spacer arm. To link an oligonucleotide to CovaLink NH via an phosphoramidatebond, the oligonucleotide terminus must have a 5'-end phosphate group. It is, perhaps, even possible for biotin to be covalently bound to CovaLink and then streptavidin used to bind the probes.

More specifically, the linkage method includes dissolving DNA in water (7.5 ng/ul) and denaturing for 10 min. at 95°C and cooling on ice for 10 min. Ice-cold 0.1 M 1 -methylimidazole, pH 7.0 ( 1 -Melm ), is then added to a final concentration of 10 mM 1 -Melm₇. A ss DNA solution is then dispensed into CovaLink NH strips (75 ul/well) standing on ice.

Carbodiimide 0.2 M 1 -ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), dissolved in 10 mM 1 -Melm₇, is made fresh and 25 ul added per well. The strips are incubated for 5 hours at 50°C. After incubation the strips are washed using, e.g., Nunc-Immuno Wash; first the wells are washed 3 times, then they are soaked with washing solution for 5 min., and finally they are washed 3 times (where in the washing solution is 0.4 N NaOH, 0.25% SDS heated to 50°C).

It is contemplated that a further suitable method for use with the present invention is that described in PCT Patent Application WO 90/03382 (Southern & Maskos), incorporated herein by reference. This method of preparing an oligonucleotide bound to a support involves attaching a nucleoside 3'-reagent through the phosphate group by a covalent phosphodiester link to aliphatic hydroxyl groups carried by the support. The oligonucleotide is then synthesized on the supported nucleoside and protecting groups removed from the synthetic oligonucleotide chain under standard conditions that do not cleave the oligonucleotide from the support. Suitable reagents include nucleoside phosphoramidite and nucleoside hydrogen phosphorate.

An on-chip strategy for the preparation of DNA probe for the preparation of DNA probe arrays may be employed. For example, addressable laser-activated photodeprotection may be employed in the chemical synthesis of oligonucleotides directly on a glass surface, as described by

Fodor et al. (1991) Science 251 (4995) 767-73, incorporated herein by reference. Probes may also be immobilized on nylon supports as described by Van Ness et al. ( 1991 ) Nucleic Acids Res. 19(12) 3345-50; or linked to Teflon using the method of Duncan & Cavalier (1988) Anal. Biochem. 169( 1 ) 104-8; all references being specifically incorporated herein.

To link an oligonucleotide to a nylon support, as described by Van Ness et al. ( 1991 ), requires activation of the nylon surface via alkylation and selective activation of the 5'-amine of oligonucleotides with cyanuric chloride.

One particular way to prepare support bound oligonucleotides is to utilize the light-generated synthesis described by Pease et al, (1994) PNAS USA 91(1 1) 5022-6, incorporated herein by reference). These authors used current photolithographic techniques to generate arrays of immobilized oligonucleotide probes (DNA chips). These methods, in which light is used to direct the synthesis of oligonucleotide probes in high-density, miniaturized arrays, utilize photolabile 5'-protected N-acyl-deoxynucleosidephosphoramidites, surface linker chemistry and versatile combinatorial synthesis strategies. A matrix of 256 spatially defined oligonucleotide probes may be generated in this manner.

4.21 PREPARATION OF NUCLEIC ACID FRAGMENTS

The nucleic acids may be obtained from any appropriate source, such as cDNAs, genomic

DNA, chromosomal DNA, mi crodissected chromosome bands, cosmid or YAC inserts, and RNA, including mRNA without any amplification steps. For example, Sambrook et al. ( 1989) describes three protocols for the isolation of high molecular weight DNA from mammalian cells (p.

9.14-9.23).

DNA fragments may be prepared as clones in Ml 3, plasmid or lambda vectors and/or prepared directly from genomic DNA or cDNA by PCR or other amplification methods. Samples may be prepared or dispensed in multiwell plates. About 100- 1000 ng of DNA samples may be prepared in 2-500 ml of final volume.

The nucleic acids would then be fragmented by any of the methods known to those of skill in the art including, for example, using restriction enzymes as described at 9.24-9.28 of Sambrook et al. (1989), shearing by ultrasound and NaOH treatment. Low pressure shearing is also appropriate, as described by Schriefer et al. (1990) Nucleic

Acids Res. 18(24) 7455-6, incorporated herein by reference). In this method, DNA samples are passed through a small French pressure cell at a variety of low to intermediate pressures. A lever device allows controlled application of low to intermediate pressures to the cell. The results of these studies indicate that low-pressure shearing is a useful alternative to sonic and enzymatic DNA fragmentation methods.

One particularly suitable way for fragmenting DNA is contemplated to be that using the two base recognition endonuclease, Cv/JI, described by Fitzgerald et al. (1992) Nucleic Acids Res. 20(14) 3753-62. These authors described an approach for the rapid fragmentation and fractionation of DNA into particular sizes that they contemplated to be suitable for shotgun cloning and sequencing.

The restriction endonuclease Cv/JI normally cleaves the recognition sequence PuGCPy between the G and C to leave blunt ends. Atypical reaction conditions, which alter the specificity of this enzyme (Cv/JI* *), yield a quasi-random distribution of DNA fragments form the small molecule pUC 19 (2688 base pairs). Fitzgerald et al. (1992) quantitatively evaluated the randomness of this fragmentation strategy, using a Cv/JI* * digest of pUC 19 that was size fractionated by a rapid gel filtration method and directly ligated, without end repair, to a lac Z minus M 13 cloning vector. Sequence analysis of 76 clones showed that Cv/JI* * restricts pyGCPy and PuGCPu, in addition to PuGCPy sites, and that new sequence data is accumulated at a rate consistent with random fragmentation.

As reported in the literature, advantages of this approach compared to sonication and agarose gel fractionation include: smaller amounts of DNA are required (0.2-0.5 ug instead of 2-5 ug); and fewer steps are involved (no preligation, end repair, chemical extraction, or agarose gel electrophoresis and elution are needed.

Irrespective of the manner in which the nucleic acid fragments are obtained or prepared, it is important to denature the DNA to give single stranded pieces available for hybridization. This is achieved by incubating the DNA solution for 2-5 minutes at 80-90°C. The solution is then cooled quickly to 2°C to prevent renaturation of the DNA fragments before they are contacted with the chip. Phosphate groups must also be removed from genomic DNA by methods known in the art.

4.22 PREPARATION OF DNA ARRAYS

Arrays may be prepared by spotting DNA samples on a support such as a nylon membrane. Spotting may be performed by using arrays of metal pins (the positions of which correspond to an array of wells in a microtiter plate) to repeated by transfer of about 20 nl of a DNA solution to a nylon membrane. By offset printing, a density of dots higher than the density of the wells is achieved. One to 25 dots may be accommodated in 1 mm , depending on the type of label used. By avoiding spotting in some preselected number of rows and columns, separate subsets (subarrays) may be formed. Samples in one subarray may be the same genomic segment of DNA (or the same gene) from different individuals, or may be different, overlapped genomic clones. Each of the subarrays may represent replica spotting of the same samples. In one example, a selected gene segment may be amplified from 64 patients. For each patient, the amplified gene segment may be in one 96-well plate (all 96 wells containing the same sample). A plate for each of the 64 patients is prepared. By using a 96-pin device, all samples may be spotted on one 8 x 12 cm membrane. Subarrays may contain 64 samples, one from each patient. Where the 96 subarrays are identical, the dot span may be 1 mm and there may be a 1 mm space between subarrays.

Another approach is to use membranes or plates (available from NUNC, Naperville, Illinois) which may be partitioned by physical spacers e.g. a plastic grid molded over the membrane, the grid being similar to the sort of membrane applied to the bottom of multiwell plates, or hydrophobic strips. A fixed physical spacer is not preferred for imaging by exposure to flat phosphor-storage screens or x-ray films.

The present invention is illustrated in the following examples. Upon consideration of the present disclosure, one of skill in the art will appreciate that many other embodiments and variations may be made in the scope of the present invention. Accordingly, it is intended that the broader aspects of the present invention not be limited to the disclosure of the following examples. The present invention is not to be limited in scope by the exemplified embodiments wliich are intended as illustrations of single aspects of the invention, and compositions and methods which are functionally equivalent are within the scope of the invention. Indeed, numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the present preferred embodiments. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.

All references cited within the body of the instant specification are hereby incorporated by reference in their entirety.

5.0 EXAMPLES

5.1 EXAMPLE 1

Novel Nucleic Acid Sequences Obtained From Various Libraries

A plurality of novel nucleic acids were obtained from cDNA libraries prepared from various human tissues and in some cases isolated from a genomic library derived from human chromosome using standard PCR, SBH sequence signature analysis and Sanger sequencing techniques. The inserts of the library were amplified with PCR using primers specific for the vector sequences which flank the inserts. Clones from cDNA libraries were spotted on nylon membrane filters and screened with oligonucleotide probes (e.g. , 7-mers) to obtain signature sequences. The clones were clustered into groups of similar or identical sequences. Representative clones were selected for sequencing. In some cases, the 5' sequence of the amplified inserts was then deduced using a typical

Sanger sequencing protocol. PCR products were purified and subjected to fluorescent dye terminator cycle sequencing. Single pass gel sequencing was done using a 377 Applied Biosystems (ABI) sequencer to obtain the novel nucleic acid sequences. In some cases RACE (Rapid Amplification of cDNA Ends) was performed to further extend the sequence in the 5' direction.

5.2 EXAMPLE 2

Novel Contigs

The novel contigs of the invention were assembled from sequences that were obtained from a cDNA library by methods described in Example 1 above, and in some cases sequences obtained from one or more public databases. The sequences for the resulting nucleic acid contigs are designated as SEQ ID NO: 1 -30368 and are provided in the attached Sequence Listing. The contigs were assembled using an EST sequence as a seed. Then a recursive algorithm was used to extend the seed EST into an extended assemblage, by pulling additional sequences from different databases (i.e., Hyseq's database containing EST sequences, dbEST version 115, gb pri 115, and UniGene version 103, and exons from public domain genomic sequences predicted by GenScan) that belong to this assemblage. The algorithm terminated when there was no additional sequences from the above databases that would extend the assemblage. Further, the inclusion of component sequences into the assemblage was based on a BLASTN hit to the extending assemblage with BLAST score greater than 300 and percent identity greater than 95%.

The novel predicted polypeptides (including proteins) encoded by the novel polynucleotides (SEQ ID NO: 1 -30368) of the present invention are incorporated in the attached Sequence Listing. A subset the predicted polypeptide sequences contain an unknown amino acid, a stop codon, a possible nucleotide deletion or a possible nucleotide insertion. These sequences have been shown in their entirety with the special characters in Table 2. Table 2 also shows the corresponding start and stop nucleotide locations to each of SEQ ID NO: 1 -30368. Table 2 also indicates the method by which the polypeptide was predicted. Method A refers to a polypeptide obtained by using a software program called FASTY (available from http://fasta.bioch.virginia,edu which selects a polypeptide based on a comparison of the translated novel polynucleotide to known polynucleotides (W.R. Pearson, Methods in Enzymology, 183:63-98 (1990), herein incorporated by reference). Method B refers to a polypeptide obtained by using a software program called GenScan for human/vertebrate sequences (available from Stanford University, Office of Technology Licensing) that predicts the polypeptide based on a probabilistic model of gene structure/compositional properties (C. Burge and S. Karlin, J. Mol. Biol., 268:78-94 (1997), incorporated herein by reference). Method C refers to a polypeptide obtained by using a Hyseq proprietary software program that translates the novel polynucleotide and its complementary strand into six possible amino acid sequences (forward and reverse frames) and chooses the polypeptide with the longest open reading frame. The nearest neighbor results for SEQ ID NO: 1 -30368 were obtained by a BLASTP version 2.0al 19MP-WashU search against Genpept release 121 and Geneseq release 200103 (Derwent), using BLAST algorithm. The nearest neighbor result showed the closest homologue for SEQ ID NO: 1-30368. The nearest neighbor results for SEQ ID NO: 1-30368 are incorporated in the attached Sequence Listing. Using eMatrix software package (Stanford University, Stanford, CA) (Wu et al., J.

Comp. Biol., Vol. 6 pp. 219-235 (1999) herein incorporated by reference), all the sequences were examined to determine whether they had identifiable signature regions. The attached Sequence Listing provodes the results obtained by eMatrix analysis for each polypeptide as follows: the signature region found in the indicated polypeptide sequences, the description of the signature, the eMatrix p-value(s) and the position(s) of the signature within the polypeptide sequence.

Using the pFam software program (Sonnhammer et al., Nucleic Acids Res., Vol. 26(1) pp. 320-322 (1998) herein incorporated by reference) all the polypeptide sequences were examined for domains with homology to certain peptide domains. The attached Sequence Listing provides the results obtained by PFAM analysis for each peptide, namely: the name of the domain found, the description, the p-value and the pFam score for the identified domain within the sequence.

Tables 1 and 2 follow. Table 1 shows the various tissue sources of SEQ ID NO: 1-30368. Table 2 shows the start and stop nucleotides for the translated amino acid sequence for which each assemblage encodes. Table 2 also provides a correlation between the amino acid sequences set forth in the Sequence Listing, the nucleotide sequences set forth in the Sequence Listing and the SEQ ID NO: in USSN 09/540,217

Table 1

Tissue RNA Library SEQ ID NOS: origin Source Name adult brain GIBCO AB3001 39-41 192197-200315-316540-542576-580608-622 63510041185-11871273-1279143114741721-1722 20362136-213724572471-247425132599-26032988- 29893105-310632123276-32773306-330833523365 3374-337634333448-34503555-355836933949-3953 4067-40724160-41624558-45604581-45824612-4614 4837-48405483-54845603-5606570058025980-5984 6135-61366403-64046452-64537209-72127447-7449 7452-74607536-75417554-75557622-76237630-7636 7660-76657701-770377717778-77837798-78017921- 792379948010-80128025-80268145-81518227-8229 84158497-84998936-89388986-89919002-90049013- 90179337-93389366-93689375-93769391-93929395- 93969431-943694439475-94769517-95189522-9525 9586-95899603-96049851-98529854-98559874-9895 9905-99089947-99529969-99809986-999210025- 1002610033-1003710167-101721027710480-10482 10488-1048910498-1050310520-1052210537-10538 10592-1059410628-1063011226-1122711339-11344 11406-1140711431-1143211731-1173412150-12151 1223912241-1224412555-1255912615-1261812785- 1278712978-1298112984-1298512997-1299913567- 1356813592-1359513606-1360813873-1387513999- 1400414360-1436914650-1465114684-1468515013- 150181509615174-1518115209-1521015250-15251 1525715323-1532415548-1555215568-1557215576- 1557715588-1558915699-1570015881-1588316438- 1643916473-1647816496-1649716609-1661116686- 1669316700-1670116727-1672916836-1684216934- 1693716949-1695317455-1745617857-1786117958- 1796318029-1803018136-1813818423-1842518516- 1851818535-1853718624-1862618668-1867218719- 1872218750-1875618790-1879318802-1880418836- 1883818899-1890318919-1892118943-1894518947- 1895018964-1896918989-1899019013-1901719045- 1904819057-1906519142-1914719154-1915519224 19316-1931719345-1934919355-193601936219370 19385-1938919415-1941719422-1943119442-19444 1950319560-195621956619604-196071969319709- 1971019727-1973219736-197421977219804-19808 19921-1992919933-1993819943-1994619969-19981 20015-2001720029-2004320087-2009420099-20102 20111-2011220122-2012720161-2016420167-20171 20180-2018120189-2019420198-2019920215-20218 20281-202822028920321-2032420349-2035420361 20393-2040020415-2041720437-2044020524-20535 20542-2054520554-2055820607-2061220614-20615 20646-2065220698-2070720718-2072520727-20732 20789-2079120806-2081220844-2084920888-20889 2092620938-2094220999-2100421027-2103121062- 2106621072-2107521137-2114021145-2114821153- Tissue RNA Library SEQ ID NOS: origin Source Name

2115421272- -2127421277-21283 21410-2141421434- 2143921485--2149121495-2150021647-2165521729- 2173321929--2193521958-2196121973-2197421978 22000-2200622026-2202922040--2204122087-22088 22101-2210722141-221432216022250-2225222284- 222892230922314-2231722336-2234222347-22348 22358-223592237222405-224082249522534-22539 22634-2264322653-2265422661--2266222665-22667 22671-2267422700-2270122794--2279622805-22809 22887-2289122899-2290022948-2295022952-22953 22982-2298622991-2299423059--230602307123141 232492325123329-2333723412-2341423489-23490 23492-2349323508-2350923543--235442370423834- 2383523890-•238922395924014-2401825289-25290 25319-2532125374-2537525966-2596826205-26206 26258-262592630326316-26321263272633726373- 2637426596-■2660126788-267892684326850-26852 2689727067-•2707027100-2710227150-2715127247- ^'2725127304-■2730527439-2744027493-2749527636- 2763927750-■2775427814-2781827861-2786427890- 2789227989-2799028099-2810028311-2831328424 28426-2842829278-2928329409-•294162944429718- 2972130141-30142 adult brain GIBCO ABD003 3051-52144-145170-171180-181202-203255-256302 315-316319-323326-327395406-407412-413464-465 540-542549553-554576-578626-637652-653656697- 699716-717721-725785-786825847-855952967969- 9711001-100410471067-10711092-10941097-1098 1123-11271169-11791259-12621269-127913071431 1453-14541471-147714831490-14921602-16031644- 16451667-1668184018601887-1889193119671986- 198720582275-22762383-23882455-245724692471- 247425132540-25412577-258425912599-26032663- 26652692-269427102814-281529262937-29382975- 297730013006-300830903151-31543205-32073366 343334513472-34733531-35343555-355835903624 36353671-367236853705-37063735-37363949-3953 4053-40544080-40824124-41264406-44074489-4493 4517-45224562-45734623-46394785-47894845-4851 4857-48614874-48894897-48984971-49745092-5094 5267-52685291-52945335-53365480-54825608-5609 5700576258025808-58125919-59215956-59575980- 59845986-59886011-60216140-61436293-62966400 6403-64046406-64106651 -66536662-66646791-6794 6877-68786932-69387214-72157245-72487447-7449 7536-75417611-76127624-76297640-76427668-7670 7695-76967757-775977717778-77867789-77937798- 780178907898-790079767986-79877995-79988002 8017-80198049-805680698117-81218152-81568162 8174-81778182-81838242-824682508301-83068343- 83448351-83608363-83668368-83708409-84148497- 84998512-85138543-85508607-86098612-86168754- 87598762-87668768-87708777-87798917-89189013- 90179031-90359038-90459063-90679072-90749306- 93139321-93239375-93769391 -93929406-94079437- Tissue RNA Library SEQ ID NOS: origin Source Name

94409444-94459454-94559517- 951895319561-9562 9603-96049729-97319733-97389757-97589763-9767 98269828-98329851-98529854-98559864-98669874- 98979923-99249947-99539956-99579969-998010011 10015-1001610033-1004010167-1017210265-10272 102771030610449-1045010470--1047310498-10503 10537-1054210592-1059410607-1060810612-10614 10624-1062610628-1063010638-1063910870-10875 10881-1088310886-1088910891 -1089310895-10898 10904-1090510913-1091410980-1098511035-11037 11066-110681108111123-1112411274-1127511295- 1129911339-1135011419-1142211465-1146611582- 1158311586-1160211607-116081167911693-11695 11731-1173411749-1175011775--1177611780-11782 11803-1180411835-118361184011842-1185511901- 1190511937-1193812042-1204412121-1212612131- 1213212150-1215112186-1218912194-1219612206- 1220812283-122841236112555-■1255912573-12574 12581-1258212615-126181263712653-1265412673- 126751272312760-1276212785--1278712796-12798 12805-1280613077-1307913083-1308613576-13579 13592-1359513603-1361213638-13641 1366413865- 1386613885-1388713903-1390513994-1399714008- 1402014023-1402614044-1404514130-1413114141- 1414214187-1419514264-1426514268-1426914299- 1430114313-143171434614360- 143691460414607- 1460914640-1464214650-1465114684-1468514789- 1479115019-1502415093-1509515182-1518315218- 1521915257-1525915290-1529115406-1540715486- 1548915532-1553515543-1554615553-1555615576- 1557715588-1558915631-1563215699-1570015988- 1599016006-1601516044-1604616075-1607916086- 1608816107-161091617216397-1639816422-16429 16451-1645216470-1647816498-•1650016609-16611 16636-16637166421665216698-1670516836-16842 16934-1693917010-1701417284-■1728517330-17332 1796318015-1801618029-1803018136-1813818400- 1840218419-1842018423-1842518492-1849418516- 185181852718533-185371861718625-1862618633- 1863718671-1867218689-1869218717-1872218750- 1875618759-18761 18771-1877218778-1879318796 18802-1880418811-1881318822- 1882418856-18880 18882-1888818899-1890318919- 18921 18934-18939 18941 18947-18951 18955-1895918975-1897718989- 1899018993-1899619005-1900919013-1901819045- 1904819057-1905819062-1906519074-1908019102- 1910519142-1914719154-191551915919209-19210 19213-1922019251-192521925719260-1926219266- 1926719306-1930919316-1931719355-1936019362- 193641937019373-1937419380-1938419387-19389 19395-1940019415-1941719422- 1943419442-19444 19446-1944819461 1948719526-195291953619560- 195621956619604-196071962619656-1965719667- 19668196931969819709-1971019727-1974219759- 1976319800-1980819813-1981519921-1992919933- Tissue RNA Library SEQ ID NOS: origin Source Name

1994619953-1995719962-1996319972-1998120029- 2004320072-2007920099-2010220106-2011220114- 201202013020146-2014820151-2015420161-20164 20167-2017120180-2019420198-2020720222-20225 20235-2024020257-2026220265-202782028920316 20321-2032420328-2033020345-203542036020393- 2040020415-2042020425-2043120441-2044620469- 2047420476-2047920485-2049020502-2050320505- 2051020514-2052020542-2054520548-2055720559- 205622056820607-2061220614-2061920644-20645 20649-206712068120683-2068520689-2069220698- 2070720712-2071320718-207252075320758-20767 20789-2079720806-2081220824-208492086320897- 2090020927-2092820938-2094220952-2095420999- 2100421027-2104521062-2106621069-2107521105- 2111121141-2114221153-2115421171-2117421197- 2119821202-2120721225-2122621229-2123521237- 2124721256-2126221272-2127421277-2128021297- 2129821301-2130321351-2135221434-2143921446- 2145021467-2146921485-2149121647-2165521712- 2171721729-2173321881-2188521899-2190221905- 2191021917-219212192421929-2193821948-21950 21955-2195721971-2197221978-2198222000-22015 22020-2202922042-2204622080-2208822090-22094 22101-2210722117-2211922141-221512216022169- 2217022187-2219222208-222262223022251-22252 22261-2226422277-2228922300-223022231822329- 2233222343-2235022358-2235922365-2237122373 22381-2238822399-2240422409-2241022434-22435 22440-22448224952255922571-2258122607-22609 22644-2265122653-2265422661-2266222665-22667 22671-2267422703-2270622760-2276222794-22796 22823-2282922857-2285822870-2287422881-22893 22923-2292422948-229542297322982-2298623007- 2302123047-230522307023080-2308323112-23116 23212-2321523229-2323323237-232392324923251 23329-2333723343-2334423382-233902339923412- 2342123486-2348723489-2349023492-2349323495- 2349623508-235092370423718-2372123726-23730 23761-2376323771-237802380023802-2380923816- 2381923827-2383323836-2383723843-2384423878- 2388023890-2389223941-239562395924005-24011 24014-2401824021-2402424772-2477425085-25090 25279-2529025307-2530825319-2532225373-25375 25403-2540725598-2560326196-2619926209-26213 26217-2621826221-2622326237-2623926258-26259 2626626304263272633726347-2634826350-26352 26359-2636526373-2637426376-263772639526423 26469-2647026596-2660126665-2666626681-26683 26691-266942673626755-2675626788-2678926844- 2684526876-2687927044-2704727053-2705727067- 2707027100-271022710527133-2713427193-27200 2720627209-272132721827254-2726027269-27270 27281-2728227299-2730127304-273052733427340- 2734227493-2749527501-2750327544-2754527574- Tissue RNA Library SEQ ID NOS: origin Source Name

27577 27600- -27606 27700-27701 27814-27815 27823- 2782427861- -2786427890-27892 27940-27942 27970 28040-28041 28099--2810028142- -2814528186 28263- 2826828286 28311-2831328324- 2834528361- 28362 2842429301- •2930329328-29337 29339-29340 29343- 2934529409- 2941629594-29604 29718-29721 29940- 2994929960- 2996130141-30142 30150-30156 30218- 3022030233- ^■3023530240-30242 adult brain Clontech ABR001 15227-230329-330414-418716-717934-9351136- 11391436-14371472-14731505-15061593-15942058 2132-21372139-21422378-238124072550-25522577- 25842587-25883094-30963221-322233773414-3417 3526-352938613949-39534340-43414515-45164574- 45764857-48614986-49875092-5094565457005864- 586659926140-61436540-65416570-65716814-6831 7668-76707802-780479948008-80098017-80198111 8129-8131816081628242-82468368-83698453-8454 8512-85138762-87668982-898393399391-93929510- 9516953196669682-9683982810167-1017210312 10520-1052210913-1091410959-109621106411071- 1107511345-1135011805-1180811835-1183611900 11937-1193812050-1205612194-1219712796-12798 13925-139261460414714-1471714785-1478615182- 1518315400-1540315462-1546315545-1554615563- 1556416123-1612816174-1617616570-1657316601 166231664216851-168531692416934-1693717963 18015-1801618046-1804818500-1850118516-18518 1853518655-1865818671-1867218762-1876618955- 189591901819045-1904819207-192081925719350 19380-1938419447-1944919484-1948619526-19529 19659-19661 19670-1967119706-1971019764-19767 19804-1980819924-1992519962-1996319965-19967 2012020189-2019420231-2023420271-2027320412- 2041320441-2044620456-2046820485-2049420521- 2052320676-2068020710-2071120718-2072520733- 2073420747-2075120824-2082620836-2084320926 21060-2106121069-2107521105-2111121153-21154 21353-2135421410-2141421454-2145721554-21556 21647-216552192421929-2193522003-2201522040- 2204122045-2204622077-2208322108-2211622165- 2216822246-2224922284-2228922373-2237422411- 2243222625-2262822637-2264322671-2267423080- 2308323112-231192314123201-2320223358-23360 23412-2341823526-235312376123793-2379723802- 2380523878-2388024014-2401824105-2411324116 25403-2540726232-2623326270-2627226285-26290 26685-2668627012-2701427028-2702927098-27099 27377-2737827493-2749527544-275452762327640- 2764127729-2773927840-278442797028361-28362 2842429427-2943830233-30235 adult brain Clontech ABR006 21360-361510-511546-547579-580792-795969-971 1165-11681228-1231 1252-12561453-14541472-1473 1681-16871975-19772044-20452214-22192231-2232 2270-227123062396-240024582826-28272951-2955 31583274-32753313-33143326-33313483-34843686 Tissue RNA Library SEQ ID NOS: origin Source Name

3856-38573939-39414080-40824091-409541734441- 44434484-44854765-47734785-47894795-48094988 499253645930-59315971-59726155-61596450-6451 7353-736773747580-75977701-77037784-77867972- 797580208101-810481068152-815681628184-8185 8342837084898758-87598936-89388978-89819009- 90179029-90309063-90679069-90789306-93119339 9479-94859517-951898289874-98959909-991210033- 1003710254-1026110498-1050310523-1053210624- 1063910923-1092610936-1093711328-1133111708- 1171012573-1257412743-1275012785-1278713556- 1355913660-1367513847-1384914054-1405614170- 1417214347-14348143901460414666-1466814996 150971525715283-1528615336-1534015397-15398 15576-1557715886-1588715896-1590516022-16023 1623716461-1646416496-164971662316643-16648 1665216752-1675317238-1724117369-1737017937- 1793917956-1795718029-1803018044-1804518049- 1806418393-1839418411-1841818423-1842518527 18536-1853718719-1872218762-1876618778-18780 18829-1883418899-1890318934-1893519001-19004 1915919207-1920819211-1921219221-1922219273 1935019484-1948619670-196711969819727-19732 19736-1974219800-1980819814-1981519855-19856 1993919943-1994619951-1995219972-1998020069- 2007120087-2009420099-2010220122-2012720157- 2018120200-2020720274-202782031620321-20324 2041420441-2044620456-2046820491-2049420524- 2053520542-205452054720554-2055720607-20612 20676-2068020718-2072520747-2075120897-20900 21005-2100821069-2107121088-2109621145-21148 21157-2116921171-2117421176-2118021213-21215 21241-2124721263-2126621272-2127421277-21280 21343-2135021377-2139721463-2146521554-21556 21911-2191221929-2193521955-2195721973-21974 2197822007-220152201922045-2204622070-22076 22080-2208822090-2209122108-2211422120-22127 22135-2213822144-2215122158-2215922246-22249 22284-2228922347-2234822375-2238222389-22432 22625-2262822653-2265422671-2267422833-22834 22881-2288622916-2292223007-230212307123080- 2308323223-2322523229-2323323358-2336023379- 2338123412-2341423434-234382348623506-23507 23543-2354423555-2356523771-2378023827-23833 23841-2384423941-2395624035-2404025213-25219 25279-252902531525383-2541526235-2623626280 26310-263142633726361-2636526409-2641026425- 26427266032668726860-2686227067-2707027100- 271022710527193-2720027209-2721327441-27443 27562-2756327589-2759227821-2782227825-27838 28146-28147282962846429328-2933129343-29345 29409-2941629439-2944529940-299493020530221- 30223 adult brain Clontech ABR008 3032-3342-44101 167180-181 197-200233-234307- 308319-327329-330332414-420540-545549576-580 Tissue RNA Library SEQ ID NOS: origin Source Name

612652656667-668694-695706-711716-717763845- 848852-855864-867895-898900910912927949-950 953-954981-9851001-100510291044-10461097-1098 11071123-11271131-11331158-1161 1169-11791185- 118711941196-11981203-12041210-12111232-1237 1273-1279130413071409-14101432-143514701483 1508-1510151215141566-15751577-15891591-1594 15961599-16101618-16191622-162616291632-1636 1640-1641 1643-164816751678-16871692-16931705- 17141717-17191721-17231828183818511853-1854 1885-18861905-19071923-19271931 1956-19591961- 19621967-198819902144-21502194-22032206-2219 2231-22322270-22742284-229823062379-23802383- 2415245724752570-25902592-260326072663-2665 2675-2678270827102724-27262730-27322781-2782 28062808-28112826-28272871-28762886-28872889- 289129202923-29242934-29352948-29492951 -2955 2983-29862988-298930013016-3017303930903098- 31003105-310631303147-31693182-31873192-3193 3195-32123214-32153219-32293237-32413244-3246 3250-32723276-3277329033093313-33143322-3323 3326-333133773414-34203426-34333477-34783507 3512-35143518-35203526-352935483555-35583593 3595-359936043618-36193635-36363657-36603671- 36723683-36843687-3691369337043735-37363752- 37533780-381738623866-38673873-387539113949- 39534053-40544062-408540904121-412641314141- 41434151-415541744209-42114484-44854515-4516 45344536-45394541-454245464574-45784593-4594 4660-466247004720-47254751-47584762-47734777- 47794785-47894795-48094819-48234825-48264854- 48564874-48894946-49484950-49564958-49634970 4984-49875100-510851225124-51265131-51325146 5154-51795190-51915246-52525272-52755331-5332 5485-54865525-55265532-55335557-55605567-5568 56555695-56985744-57475803-58045856-58585885- 58865899-59025973-59755977-59786005-60066010- 60216026-60426154-61616166-61686184-61856209- 62116219-62226235-62376297-629863416350-6351 636763786406-64106439-64406450-64516542-6543 6549-65776582-6584662266246640-66446662-6664 6669-66706773-67786832-68506884-68856898-6899 6943-69587187-71917198-72037206-72087213-7215 7236-72377249-72667275-72787350-73527364-7365 75517561-75627580-76007615-76177630-76367668- 76737681-76877693-769676987734-77367745-7746 7763-77717787-77887798-78017805-78087815-7818 7898-79017904-79127917-79187921-79237947-7948 7978-79837986-79877993-799480028006-80078010- 80168043-80458047-80488059-806880978107-8108 8112-81168132-81448152-81568160-81778184-8185 8187-82008204-82108227-82328253-825782698297- 830783428347-83488351-83608363-83648391-8399 8409-84158420-84218430-84528457-84588461-8477 8484-850585098512-85138543-85508554-85558588- Tissue RNA Library SEQ ID NOS: origin Source Name

85978612-86168688-869087098724-87378758-8759 8771-87768914-89458998-90019009-902090369049- 90679069-90719075-90789317-93189337-93399375- 937693829427-94289431-94339437-94409456-9458 9479-94819510-95189529-95319552-95549563-9566 95859590-95929594-96029617-9626966796729732 9745-97549786-97909792-97959808-98129828-9832 9857-98619867-98689874-98959899-99049909-9912 9925-99539965-99809984-99929997-1000910033- 1003710164-1017210265-1026710320-1032310326- 1032810454-1046610470-1048210498-1050510513- 1051510520-1052210543-1054910595-1059910603- 1060610609-1061110615-1063010640-1064410780- 10782108341087610881-1088310895-1089810906 10930-1093310936-109371094010965-1096610972 10976-1097810980-1098511024-1102711042-11044 11064-11070110801116011204-1120711212-11216 11228-1122911317-1132111345-1135011397-11398 11476-1147811711-1171211743-1174411757-11760 11805-11809118401184211878-1187911890-11891 11901-1190511910-11911119161193411937-11938 11947-1195011971-1197312011-1201312050-12057 12102-1211012112-1211512117-1211812144-12146 12190-1219112194-1219612202-1221012215-12217 1222512241-1225312255-1225812374-1237712398- 1240112403-1240512408-1240912412-1241912436 12545-1254612571-1257412593-1259712610-12612 12625-126311263712641-1264512648-1265412659- 1266212668-126691272312785-127871286912898- 1289913100-1310613499-1352813531-1353913545- 1355913571-1357313576-1358013584-1358813632- 1363313638-1364113645-1365113668-1367213757- 1375913850-1385313885-138871389813918-13919 1393013994-1399713999-1400314044-1404514058- 1405914061-1406314092-1409414105-1410614170- 1417214192-1419514199-14201 14209-1421514227 14236-1423814261-1426314283-1429114307-14317 14344-1434514360-1436914389-1439214452-14455 14570-145741460414607-1460914650-1465114681- 1468214684-1470414709-1471914789-1479114822- 1483814846-1484714871-1487414991-1499214994- 1499614998-1500215009-1502415093-1509515151- 1515715187-1518915212-1521515218-1521915222- 1522415243-1524815250-1525115257-1525915283- 1528615288-1528915292-1529315300-1530115329- 1534015343-1534415347-1535915381-1538515397- 1539815404-1540715443-1545315460-1546115464- 1546515468-1547215476-154781548515491-15525 15543-1554415563-1556415567-1557715591-15592 15606-1560715623-1562815661-1566315688-15694 15699-1570015705-1570815766-1577115780-15788 15855-1587915890-1589515902-1590315961-15963 15981-1598215988-1599016030-1604316053-16058 16060-16061 16096-1609716118-1612016123-16128 16130-161321613516138-1613916167-1617216174- Tissue RNA Library SEQ ID NOS: origin Source Name

1617616200-16201 1621816224-1622516233-16235 1623716290-1629516342-1634416350-1635116359 16422-1642916451-1645216456-1646016470-16472 16479-16481 16496-1649716501-1650416553-16556 16574-1657716614-166151662316628-1663116635 16643-1665516710-1671216714-1672316730-16733 16738-16739167421674516747-1674816752-16753 16765-1676716812-1682116836-1684216854-16858 16860-1687016878-1689816903-1690916911-16912 16925-1693216946-1694816967-1697416996-16999 17018-1702317067-1706917074-170791711517117- 1713217137-1714217145-1714617149-1716717202- 172031724217244-1724817263-1726717284-17306 17330-1733217359-1736017366-173701739617457- 1746217489-1749017571-1757417857-1786117922- 1792617930-1793117933-1793917949-1795017953- 1795517958-1796217995-1800418020-1802218029- 1803018038-1804218055-1806018097-1813418136- 1813818269-182701840318421-1842218500-18501 18516-1851818533-1853518621-1862418651-18658 1866118668-1867218717-1872618745-1874918759- 1876018762-1876618787-1879318806-1880718829- 1883418846-1885318857-1888018894-1889618904- 1890718915-1893318947-1895018964-1896918993- 1899519001-190091901219029-1903519045-19048 1905519057-1906519068-1907019074-1908019091- 1909219096-1910119142-1914719159-1916119211- 192201922419254-192551925719266-1926719274 19295-1929619306-1930719310-1931219316-19317 19331-1934019345-1935419375-1937919385-19389 19395-1940219422-1943119446-1944819458-19461 19464-1948619510-1952419526-1953719539-19554 19560-1956219564-1956619598-1960119617-19619 1962719659-1966819670-1967819683-1968719698- 1969919706-1971019727-1973519743-1974819757- 19771 19773-1980819813-1981519819-1982219855- 1985619921-1992319926-1992919938-1993919943- 199461995019953-1995719962-1996319965-19967 19972-19981 19995-2001720026-2002720053-20079 20087-2009420099-2010520111-2011220120-20154 20157-2018120189-2019420198-2022120231-20241 20244-2025220257-2026220265-2027020274-20278 20281-2028220286-2028720289-202962029920328- 2033020336-2033820345-2035420357-2035920401- 2040520414-2041720425-2043120437-2047120475- 2047920491-2049620505-2051020514-2053620542- 205452054720554-2056820575-2057820607-20612 20614-2061520625-2062820631-2063620642-20643 20646-2068720689-2069220708-2073420739-20757 2076720789-2079720801-2081220822-2082320827- 2084920853-20854208632086520879-2088020890- 2090120927-209322094320948-2094920952-20954 20977-2098420999-2100821016-2102021032-21045 21062-2106821076-2108721101-2111121122-21127 21133-2113521153-2115421157-2116921171-21174 Tissue RNA Library SEQ ID NOS: origin Source Name

21176-2119321225-2122621237-2124721253-21271 21277-2128021284-2129421297-2129821326-21334 21343-2135421377-2139721410-2141421434-21439 21454-2146121480-2148221485-2150021532-21533 21554-2155621568-2157221647-2165521712-21724 21877-2189421905-2195021955-2196621971-21972 21979-2198721989-2200222007-2201822020-22029 22040-2204122045-2204922056-2205922074-22083 22087-2212722135-2213822144-2215622158-22159 22161-2217522195-2219822208-2221122218-22224 22243-2224522261-2227022277-222992230922312- 2231322329-2233222343-2234622349-2235122358- 2235922365-2237122381-2238222389-2239222394- 2239822434-224352249522531-2253322545-22559 22561-2256822571-2258122599-2260222607-22609 22625-2265222671-2267422700-227012270722712- 2271522730-2273122743-227482276722805-22816 22823-2282722833-2283422843-2284522854-22856 22881-2288622916-229242293922941-2294722952- 22953229712297722980-2298623007-2302823047- 2305223064-2306723071-2307323080-2308323085- 2308623098-2310123125-2313623206-2320923223- 2322523229-2323323237-232392324523329-23339 23353-2335423356-2336023373-2337423379-23381 23392-2339523400-2340123415-234192342223425- 2343023434-2344723473-2348623489-2349023492- 2349823506-235072351423543-2354423549-23565 23587-2359823682-236862370423718-2372123731- 237362374223762-2376323768-2380523810-23819 23827-2383523839-2384223845-238482388223941- 239562395923999-2400124005-2401124014-24018 24021-2402424029-2403324035-2404024130-24144 24495-2449825085-2509025114-2512625258-25297 25306-2530825314-2531825322-2533025334-25337 25359-2536325376-2537725382-2540125403-25407 25410-2541325849-2585226029-2603126196-26199 26217-2621826258-2625926265262802628426294- 2630226310-263142632726332-2633726354-26355 26359-263652636926373-2637426378-2638526395 26406-2640726409-264112642326425-2642726429 26448-2645226465-2646626469-2654626604-26606 26657-2665926667-2666826678-2668026705-26707 26732267372674226748-26754268312684226844- 2684526860-2686226873-268752687926888-26890 27012-2701427028-270292709127100-2710227122- 2712827147-2714927193-272002721827247-27251 27261-2726527269-2727027304-2731427411-27431 27435-274402745527463-2746627476-2747727498- 2750027504-2750727520-2752127544-2754527548- 2755427557-2756427574-2757727602-2760627624- 2763427649-2765427662-2768927702-2770627729- 2773927750-2775627784-2778827790-2779627799- 2780227809-2781327816-2782027830-2783827840- 2784727853-2785627865-2786827890-2789227938- 2793928001-280042801828050-280862809228095-

Tissue RNA Library SEQ ID NOS: origin Source Name

14098-1409914117-1412214141-1414214166-14168

1422714264-1426514360-143691460414714-14717

14981-1498315019-15024151121525715292-15297

15329-15331 15381-1538515397-1539815408-15414

15543-1554415869-1587015884-1588515896-15900

16121-1612816168-1617116174-1617616233-16235

16408-1640916498-1650016570-1657316609-16613

16624-1662516702-1670316716-1672316738-16739

16851-1685317268-1727417292-172961745417956-

1796218536-185371862418717-1872218730-18732

18750-187561879618842-1884518897-1889818925-

1893318964-1896918989-189901901219074-19080

1914819207-1920819213-19220192241925319260-

192621927419306-1931219316-1931719351-19354

19363-1936419407-1941119432-194341944119511

19522-1952419526-1952919574-1957819663-19666

19700-1970519709-1971019736-1974219800-19803

19814-1981519921-1992319933-199371993919950

19972-1998120099-2010220104-2010520137-20148

20151-2015420157-2016420167-2017120200-20207

20229-202302024120257-2026220271-2027820281-

202822028920305-2030720437-2044020447-20451

20497-2049820514-2052020524-2053520537-20541

20559-2056220575-20578-20625-2062820649-20652

2068120683-2068520698-2070720712-2071320806-

2081220824-208432086520868-2087120879-20880

20890-2090020927-2092820957-209622102621101-

2111121123-2112721153-2115421171-2117421197-

2119821229-2123221241-2124721263-2126621284-

2129621377-2139721454-2145721495-2150021729-

2173321788-2179921899-2190221911-2191221917-

219212192421936-2193821958-2196622007-22015

2201922030-2203422037-2203922045-2204622080-

2208822092-220942209722101-2210722135-22138

22165-2216822200-2220322243-2224522261-22264

22277-2228922303-2230922381-2238222405-22408

22553-2255822566-2256822607-2261722661-22662

22730-2273122823-2282722907-2290822941-22947

22952-2295323059-2306023080-2308323085-23090

23212-2321523229-232332325123321-2332723399

23412-2341423425-2342723473-2347423483-23485

23692-2369323762-2376323845-238482388223890-

2390223999-2400124005-240112405624481-24490

25085-2509025319-2532225331-2533525366-25369

25374-2537525403-2540726140-2614326189-26194

26205-2620626258-26259263272633726349-26352

26354-26355263572639426406-2640726469-26470

26476-2647726604-266062673726860-2686227100-

27102272182722527261-2726527304-2730527497

27510-2751127544-2754527555-2755627562-27563

2758827602-2760627649-2765427726-2772827805-

2780627819-2782028099-2810028189-2819028199-

2820328468-2848428511-2851328580-2859528910-

2891329288-292892936329718-2972130085-30087

30135-3014030224-3023230236-30239 Tissue RNA Library SEQ ID NOS: origin Source Name cultured Stratagen ADP001 180-181221333-335373-374395398-399461-463534- preadi- e 535576-578619-620716-7171097-10981235-1237 pocytes 1240-1241 1453-145414741705-17141912-19132015- 2018205825132599-26032724-27262814-28152923- 29242975-29773374-33763414-341734333481-3482 3518-352036243789-37943916-39253949-39534515- 45164555-45564562-45684581-45824785-47894854- 48625190-51915572-55735580-55865768-57725802 5899-59025980-59846403-640468517209-72127447- 74497534-75357604-76057615-76177630-76367695- 76967745-77467757-775977717806-780878218113- 81148137-81418347-83488351-83608368-83698466- 84768497-84998607-86098612-86168723-87328762- 87668995-89969007-90089013-90179040-90429267- 92689287-92909306-93119482-94859522-95259531 9735-9742982610253-102611027710490-10493 10516-1051810899-1090010907-109101113511339- 1134411399-1140211416-1141811431-1143211465- 1146611561-1156211568-1157111711-1171211731- 1173411739-1174011780-1178211835-1183611873- 1187512150-1215112171-1217212194-1219612361 12432-1243312470-1247112545-1254612601-12602 1264012642-1264412755-1275912939-1294312997- 1299913077-1307913556-1355913592-1359513629- 1363113638-1364113873-1387513885-1388714058- 1405914261-1426314274-1427614283-1428814694- 147011478414818-148201507015100-1510915182- 151831525715302-1530315326-1532815439-15442 15545-1554615588-1558915600-1560115658-15660 15869-158701619016345-163491654516558-16562 166421665216836-1684216851-168531724217286- 1729117330-1733217335-1733917454-1746417958- 1796218015-1801618029-1803018061 18069-18072 18230-1823918500-1850118625-1862618644-18650 18655-1865818673-1867718771-1877218778-18780 187891879618894-1889618925-1893318964-18969 1897518989-1899019045-1904819096-1910119207- 192081922319251-1925219266-192671927319316- 1931719351-1935419362-193641937019372-19374 19387-1938919395-1940019407-1941119422-19434 19442-1944419515-1952119564-1956619670-19671 19736-1974219804-1980819813-1981519819-19822 19921-1992319933-1993819953-1995719972-19980 20099-201032013020161-2016420189-2019420226- 2022820231-2023420257-2027020286-2028720289 20328-203302036020415-2041720432-2044020447- 2045120456-2046820537-2054520554-2055720563- 2056720625-2062820631-2063420676-2068020686- 2068720733-2073420747-207512076720824-20826 20836-2084320858-208622086520927-2092820957- 20962209912101521062-2106621076-2108721122 21157-2116921181-2119321211-2121521225-21226 21272-2127421277-2128021297-2130321463-21465 21780-2178721911-2191221958-219612197822003- 2200622020-2202522040-2204122048-2204922062-

II Tissue RNA Library SEQ ID NOS: origin Source Name

22073 22080-22083 22092-22094 22120-2212722141-

2214322169-2217022208-2221122225-2222622250

22265-2227022277-2228922314-2231722323-22328

22349-2235022358-2235922362--2236422661-22664

22669-2267022698-2270122726--2272722852-22853

22870-2287422969-2297022978--2297923046-23050

23066-230672307023098-2310123218-2321923229-

232332323623252--2325623358--2336023379-23385

23448-2345023508-235092370423726-2373023760-

23761237642377023798-2379923802-2380523845-

2384823890-239022395923990-^■2399223999-24001

24313-2431425085-2509025336--2533725340-25341

25374-2537525416-2541725680--2568625986-26016

26024-260282626626310-26314263272633726409-

2641026421-2642226607-266092668426705-26707

26755-2675626860-2686226873--2687827150-27151

27261 -2726527269-2727027729--2773927750-27756

27825--2782627861 -2786427890--2789227989-27990

28099-281002818628315-2831628365-2837028407-

284152842428426--2842828450-■284532846428617-

2862728787-2878929096-2910129304-2930829328-

2933129354-2935729508-2951829663-2967229926-

2993529960-2996130141-3014230218-30220 adrenal Clontech ADR002 48-4951-52329-330332546-547635652656694-695 gland 864-867901-904100510581158-11611273-12791453- 14541516-151915511608-16101651-16521654-1656 1661-16751705-1714191419902015-201820582306 2383-23882393-23952417-24222517-25182540-2541 2599-26032675-26782695-26982911-29122923-2926 2951-29552983-2986300030043107-31083322-3323 33653441-34423605-36073649-365336933781-3784 3871-38723939-39414053-40544156-41574165-4170 4413-44144515-451645424550-45514581-45825057- 50595109-51155285-52875376-53785480-54825538- 55405695-56985766-5767580259466011-60216081- 60826166-61686223-62256299-63006339-63406403- 64046454-645868526857-68587209-72127228-7237 7258-72637407-74147461-74647536-75417611-7612 7630-76367657-76597681-76877693-76947745-7746 7757-775977947806-78087823789079577984-7985 7990-799280208025-80268069-807080798145-8156 82338301-83098370-83748430-84338461-84648504- 85058539-85428607-860986888736-87378758-8759 8762-87668982-89839002-90049072-90749456-9458 94609472-94749526-95309535-95379617-96269675 9733-97389743-97449770-97719780-97819794-9795 98289851-98539923-992499459965-99689984-9985 10015-1001610263-1026410273-102741027710279- 1028010311 10320-1032310513-1051510531-10532 10543-1054910592-1059410603-106061062710640- 1064410780-1078210870-1087210881-1088310891- 108931090610913-1091411081 11297-1129911405- 1140711465-114661154611582-1158311612-11639 11669-11671 1180911901-1190711918-1192012194- 1219612202-1220512237-1223812256-1225712259- Tissue RNA Library SEQ ID NOS: origin Source Name

1226212455-1245912470-1247112486-1254012545- 12561 12590-1259212601-126021272312785-12787 1294312968-1296912997-1299913077-1307913581- 1358313592-1359513638-13641 136651367613931- 1393314170-1417214257-1426314304-1430514360- 1436914456-144581460414661-1466214684-14685 14789-1479115025-1506915098-1509915218-15219 15243-1524815250-1525115258-1525915290-15291 15329-1533115392-1539615406-1540715412-15414 15526-1552715536-1553715578-1558015688-15694 15906-1590715961-1596315988-1599016118-16120 16174-1617616226-1622716350-1635116365-16366 16461-1646416508-16511166001662316636-16637 16643-1664816749-1675316851-1685316894-16896 16911-1691216933-1693717042-1705717067-17069 17255-1725617264-1726717292-1729617372-17374 17441-174501745417569-1757017583-1758417958- 1796218005-1800618029-180301806518412-18418 18421-1842518500-1850118577-1857818587-18616 18619-1862018644-1865018691-1869218723-18726 18738-1875818762-18766187891879618836-18838 1885618899-189031891018934-189351897518983- 1898518989-1899019001-1900419062-1906519071- 1908019211-1921219228-192291925719271-19272 19350-1935419363-193641937019401-1940219407- 19411 19415-1941719422-19431 194871951419560- 1956519604-1960719620-1962219656-1965719659- 19661 19667-1966819683-19687196931969819700- 1970819727-1973219759-1976319800-1980819814- 1981519855-1985619915-1992019933-1993719943- 1994619965-1996719972-1998020029-2004320072- 2007320106-2011020146-2015020161-2016420167- 2017120189-2019720208-2021420219-2022120235- 202402024320250-2025220265-2027320305-20307 20321-2032420328-203302036120366-2036820401- 2040520415-2041720437-2044020485-2049020505- 2051020514-2052320547-2055320569-2057420607- 2061220676-2068020710-2071120727-2073220758- 2076620788-2079120819-2082120836-2084920855- 2085720866-208672092620938-2094220948-20949 20963-2097221005-2100821072-2108721141-21142 21157-2116921171-2117421208-2121021241-21247 21377-2139721410-2141421451-2145321480-21482 21485-2149421647-2165521881-2188521899-21902 21958-2196121973-2197421983-2198722007-22015 22026-2202922035-2203622070-2207322115-22119 22128-2213422141-2214322152-2215622169-22170 22187-2219222195-2219822204-2220722218-22224 22261-2227622284-2228922292-2229922303-22308 22312-223132231822358-2235922365-2237122373 22375-2237622409-2241022433-2243522455-22465 2249522561-2256822625-2262822671-2267422690 22696-2269722700-2270122737-2273922760-22762 22810-2281622823-2282722857-2285822887-22891 229542304623051 -230522307123252-2325623329- Tissue RNA Library SEQ ID NOS: origin Source Name

2333723356-2335723439-23447 2348823499-23505 235992370423731 -2373623827-■2383323845-23848 23871-2387523878-238802388223890-2390224014- 2401824021-240242405624130-.2414424194-24196 24446-2444825085-2509025289-2529025293-25297 25323-2532525705-2571526024--2602826033-26049 26237-262392625226258-2625926361-2636526383- 2638526428-264292643126469-2647026479-26545 26559-2656026563-2656626596-2660126665-26666 26676-266772674626748-2675426804-2680526853- 2685427158-2716327209-2721327379-2738027383 27401-2741027441-2744527520--2752127544-27545 27600-2760127649-276542769727812-2781327825- 2782627890-278922792928050-2805928095-28096 2842428446-2844828458-2846029328-2933129343- 2934529940-2994929954-2995530135-3014030150- 3015630189-30194 adult heart GIBCO AHR001 3042-4451-52124-125156180-181192197-200202- 203221227-230260294-301315-316324-325329-330 332-335373-374395-397408-411414-421425-427505 515-517529576-578605-606660685-688716-722738- 740825845-846849-851891895-898901-904914919- 931934-9361001-10031005102810471071 1092-1094 1097-10981158-11611185-11871235-12371240-1241 1243-12451249-12621280-12821302-130313061312- 13131418-14191424-142914311453-14541467-1470 14741476-147714831488-14891569-15701608-1610 161816261667-16681692-16931792-179418281866- 18721905-19071912-19131925-192719431961-1962 1986-19871990-199220362222-22262272-22762341- 23432393-23952404-24062440-24442471-24742565- 25662570-25742599-260326252675-26782692-2694 2706286128642867-286829122923-292429262975- 29772988-2989299330013006-300830903126-3127 3151-31543161-31633205-32073223-322532283276- 32773281-32873326-33313374-33773392-33963433 3435-34423452-345435073531-35343620-36213661- 366336933729-37303770-37723789-37943834-3835 39303939-39413949-39534067-40724091-40964124- 41264141-41434338-43414354-43554420-44214469- 44704515-451645254531-45334555-45564562-4573 45794581-45824600-46014623-464346514663-4665 4675-46804698-46994785-47894825-48264833-4836 4857-48614971-49744989-49915057-50595074-5081 5084-5085513852465253-52665335-53365362-5363 5474-54775519-55215530-55315557-55605567-5568 5580-558357005743-57475754-575758025805-5807 5827-58285875-58795919-59215939-59415965-5966 5973-59755977-59785980-598460846135-61366166- 61686209-621162846389-639264006403-64046450- 64516523-65266551-656766226674-66756773-6778 7209-72127236-72407256-72637283-728474817536- 75417557-75597580-75977611-76127615-76177620- 76217630-76367671-76737678-76897695-76967701- 77037726-77277729-77417745-77467757-77597778- Tissue RNA Library SEQ ID NOS: origin Source Name

77837787-77947798-78017806-78087815-78187822 78907906-79127921-79257972-79757977-79837994 7999-80018008-80098013-801680208069-80708077- 80798084-80858090-80938098-81008107-81088112- 81148117-81218137-81418145-81518187-82008247- 824882508297-830083108342-83608368-83698409- 84148434-84528466-84768497-84998512-85138539- 85428612-861686888698-87008751-87538758-8759 8762-87668768-87798919-89338978-89819013-9017 9031-90369040-90459049-90679196-92009306-9311 9321-93239331-93339391-93929395-93969427-9428 94439472-94769478-94819487-94889491-94939506- 95099517-95189529-95319535-95379581-95849593 9603-96049617-962696599726-97279729-97319735- 97449794-97959799-98009803-980798269828-9832 9851-98529857-98619874-98959916-99209923-9924 9969-99809984-99859997-100091001210017-10019 10025-1002610033-1004010161-1016310167-10172 1026210268-10274102771030610326-1032810451- 1045310470-1047310484-1048910491-1049310498- 105031051910537-1053810551-1055410592-10594 10600-1060610612-1061410628-1063010870-10875 10877-1087810881-108831089410901-1090210913- 1091410931-1093310976-109781102111066-11068 11123-1112411202-1120711291-1129911308-11310 11314-113151132111326-1132711345-1135011372- 1139611468-1147411476-114781149511515-11517 11538-115401154611565-1156711579-1158111609 11644-1164811658-1165911711-1171211714-11720 11731-1173411745-1174811780-1178211803-11804 1180911835-1183711901-1190511921-1193011941- 119441195111977-1197812023-1204112050-12056 12117-1211812131-1213212135-121371214012150- 121511217312192-1219612202-1220812256-12258 1236112374-12401 12455-1245912470-1247112475- 1247612555-1255912573-1257412590-1259612637 12642-1264412655-1265812668-126691272312725- 1272712755-1275912785-1278712796-1279812805- 1280612872-1288112970-1297212978-1298112997- 1299913077-1307913545-1354813563-1356413567- 1356813576-1357913592-1359713652-1365913674- 1367513873-138751389813916-1391913954-13956 14023-1402614036-1403714044-1404514048-14053 14058-140601412914137-1413814166-1416814192- 1419514209-1421514236-1423814264-1426514283- 1428814304-1430514355-1435614360-1436914498- 14501 1460414640-1464414650-14651 14684-14685 14702-1470414709-1471714846-1484714991-14992 15013-1502415172-1517315182-1518315190-15191 15218-1521915243-1525115253-1525515257-15259 15283-1528615290-1529115298-1529915323-15324 15336-15340153441539915412-1541415530-15531 15568-1557215576-1557715588-1558915614-15616 15631-1563215699-1570015766-15771 15855-15857 15863-1587015881-1588515925-15931 15988-15990

15 Tissue RNA Library SEQ ID NOS: origin Source Name

16075-1607916110-161121613716141-1614316226- 1622716350-16351 16365-1636616403-1640716465- 1646616473-1648116496-1649716508-1651116520- 1652916536-165391660016602-1661116619-16621 16623-1662516636-16637166421665216700-16701 16704-1670516716-1672316836-1684216875-16877 16894-1689616911-1691216934-1693916949-16953 17036-17041 17105-1710617116-1711817124-17126 17131-17132172321724217292-1729617330-17332 17335-1733917451-1745617571-1757417857-17861 17958-1796218001-1800318015-1801618029-18030 18136-1813818400-1840218405-1840618421-18425 18490-18491 18495-1850118533-1853718583-18584 18625-1862618629-1863218644-1865818668-18670 18673-1867718689-1869318717-1872618729-18732 18745-1874918759-1876118771-1878318789-18793 1879618802-1880418806-1880718811-1881318822- 1883418839-1884518856-1888018882-1888818897- 1890318915-1892118923-1893918941-1894218944- 1895018955-1895918964-1896918975-1897718993- 1899519005-1900919013-1901819029-1903919049- 190531905519057-1905819062-190831909019096- 19101191341915319207-1921019213-1922019226- 1922719251-1925219254-1925519260-1926219266- 1926719295-1929619306-1930719316-1931719345- 193641937019373-1937419380-1940019407-19411 19415-1941719422-1943419438-1944419454-19455 19462-1946319467-194861950319526-1952919536 19560-1956219564-195661958619604-1960719656- 1965719663-1966819672-19673196881969319727- 1974819759-1976719772-1980819814-1981519819- 1982219921-1992919933-1993919943-1994619965- 1996719972-1998020029-2004320048-2006320069- 2007120087-2009420106-2011020114-2012020130 20133-2014820151-2015420161-2016420167-20171 20182-2019720208-2021420235-2024120244-20253 20257-2026220265-2027020274-2027820281-20282 202892029920305-203072031620321-2032420336- 2034120345-2035420393-204052041120414-20417 20425-2043120437-2047420476-2047920485-20494 20505-2050920514-2053520554-2055720559-20578 20614-2061920625-2063020646-2064820676-20681 20683-2068520698-2070720710-2071320718-20725 20727-2073420747-20751207672078820792-20797 20806-2081220836-2084920863208652087120879- 2088020897-209002092620929-2093220938-20942 20948-209492095120963-2097220977-2098820999- 2100421015-2102021027-2104521060-2106621072- 2107521101-2110421123-2112721137-2114221145- 2115121157-2116921171-2117421181-2119321202- 2120721227-2122821233-2123521237-2126621277- 2129421301-2130321351-2135221377-2139721408- 2140921434-2143921446-2145321463-2146521467- 2146921480-2148221485-2149121529-2153021587- 2165521881-2188521892-2189421925-2193521955-

16 Tissue RNA Library SEQ ID NOS: origin Source Name

2196821971-2197421978-2198721995-2199922003- 2201522019-2202522030-2203422040-2204422047 22050-2205522060-2206122070-2207622098-22107 22120-2212722135-2213822141-2214322152-22156 2216022165-2217522187-2219222195-2219822208- 2221122218-2222622246-2224922251-2225222261- 2227622284-2228922300-2230222310-2231822323- 2232822343-2235022352-2235622358-2235922365 2237322383-2238822409-224102249522553-22559 22571-2258122607-2260922625-2262822634-22636 22644-2265122653-2265422665-226672269022700- 2270122730-2273122760-2276222768-2277022805- 2281622821-2282222843-2284522857-2285822881- 2289122899-229002291122923-2292422941-22950 22952-2295422969-22970229732297722980-22989 22991-229942299823046-2305523059-2306023063- 2306723070-2307123094-2311123138-2314023201- 2320223206-2320923212-2321523220-2322123229- 2323323235-2323623251-2325623279-2328123356- 2336023373-2337723379-233852339923415-23421 2343323473-2347423486-2348723489-2349023492- 2349323495-2349623506-2351323519-2352023543- 2354423555-235652359923673-236742369123704 23726-2373623760-2376323771-2378023798-23799 23802-2380523827-2383323836-2383723849-23852 23878-2388023890-238922395923990-2399224014- 2401824021-240252405625213-2521925279-25290 25307-253082531325331-2533525340-2534325347- 2535425383-2540125403-2540725534-2553626024- 2602826195-2619926205-2620826237-2623926248- 2625226258-2626126266-2626726273-2628026285- 2629026305-2630626327-263282633726361-26365 2636926373-2637426389-26393263952641126423 26460-2646326469-2647026479-2654526563-26566 2660326665-2666626681-2668326698-2669926737 26748-2675426788-2678926804-268052683226843- 2684526850-2685726860-2686226876-2687926882- 2688426980-269842698827037-2703827040-27043 2705227067-2707027080-270902709227129-27132 27150-2715127154-2715527173-2717427193-27200 27209-2721327229-2723227247-2725127269-27270 27275-2727627283-2728727304-273052734327348- 2735327379-273802743827501-2750727510-27511 27544-2754527551-2755427560-2756427600-27601 27636-2763927649-2765427662-2767227700-27701 27729-2773927750-2775427807-2780827821-27822 27861-2786427896-279272798627989-2799028001- 2800328012-2801728095-2809628099-2810028108- 2812128142-2814528160281862828628290-28292 28311-2831328315-2831628324-2834528361-28362 28421-2842428426-2842829265-2926729278-29283 29328-2933729339-2934029343-2934529354-29357 29508-2951829594-2960429718-2972129919-29922 29940-2995329960-2996130141-3014230150-30156 30184-3019930218-3022030233-3023530243-30252 Tissue RNA Library SEQ ID NOS: origin Source Name

30361-30368 adult GIBCO AKD001 163042-4448-49156164167170-171180-181 197-200 kidney 202-203255-256260282-284302-318329-330332-335 339358-359373-375395398-399412-413419-420422- 429458461-467470-471505515-517524-525530-531 619-620635661664694-695706-707716-722779-782 785-786832-836847-848852-855880-882913934-935 938981-9851001-1003100510281044-104510471071 1092-10941097-10981123-11271169-11791203-1204 1240-12411280-12821295-12971302-130313071312- 13131346-13471414-14171431 1449-14501452-1454 1456-14601467-147014831488-148914991569-1570 1578-1585162016261705-17141721-17221792-1794 1912-19131915-19161918-19191925-19271947-1948 1980-19821986-198719902015-20182031-20322058 2231-22322275-227622992383-23882404-24062423- 24242471-24742570-25742599-26032649-26502695- 269828022808-28112820-28212871-28762883-2887 2923-292429262934-293529672975-29772988-2989 30013006-3008302030393078-3079309031123151- 31543205-320732283255-325932713274-32773326- 3331335233653374-33773418-3422343334663507 3515-35173525360636243671-3672368636933708 3729-37303768-37693789-379438093827-38283840- 38523949-39534091-40954124-41264213-42144220 43364342-43464413-44144424-44304441-44434469- 44704515-45164531-453345424555-45564562-4568 4581-45824612-46144640-46434785-47894857-4861 4868-48694971-49745092-50945109-511551925269- 52715311-53255335-534153705512-55215532-5533 5538-55605569-55735641-56495695-569857005802- 58075820-58225827-58285854-58555899-59025919- 59215930-59365939-59415943-59455956-59575973- 59755977-59785980-59846040-60426135-61366170 6209-62116235-62376300637663786403-64056450- 64536503-65106533-65356542-65436585-65926624 68837209-72127214-72197258-72667275-72767299- 73017447-74497576-75777604-760576097611-7612 7615-76217630-76367640-76427657-76597671-7687 7693-76967701-77037726-77287737-77437745-7746 7778-77867789-78047806-78087812-781878217891- 78957898-79007906-79127921-79257972-79757978- 79837990-799480028010-80128059-806380708074- 807680798107-81088113-81148132-81368145-8156 8163-81738187-82008216-82188227-822982348247- 824882508253-82578263-82658297-830083108342 8349-83648368-83698404-84068409-84158420-8421 8449-84528461-84648487-84888497-84998502-8505 8507-85088512-85158537-85508554-85558601-8603 8607-86098612-86168688-86908751-87538758-8759 8768-87708919-89338986-89949002-90049029-9036 9043-90459072-90749084-90859267-92689306-9311 9321-93239337-93389343-93469366-93719391-9392 9395-93969415-94199443-94449456-945894609472- 947694789482-94889506-95189522-95259531 -9534

11! Tissue RNA Library SEQ DD NOS: origin Source Name

9581-958395859594-96029617-962696599664-9665 96769682-968396889729-97319757-97679770-9771 9786-97909794-97959799-980098269828-98349848- 98529854-98559857-98619874-98959902-99089921- 99249927-99289954-99559965-99889997-10009 1001210025-1002610033-1003710161-1017210265- 1027710279-102801030610326-1032810449-10453 10480-1048210484-1048710498-1050310506-10507 10513-1051910531-1053210543-1054910588-10601 10603-1060610612-1062310638-1064410820-10821 10870-1087610881-1088310907-1091010913-10914 10931-10933109381101011024-1102511069-11070 11123-111241115811217-1121911230-1124911289- 1129011295-1129611300-113071131711326-11327 11339-1135011406-1140711423-1142611431-11432 11476-1147811493-1149511544-115461155311582- 1158311586-1160211607-1160911612-1163911644- 1164811658-1166111711-1171211715-1171611718- 1172011731-1173411739-1174011745-1174811775- 1177611803-1180811835-11836118401184211937- 1193812040-1204112127-121301214012149-12151 12175-1217612186-1218912202-1220812256-12262 12374-1237712470-124711247712486-1251812545- 1254612555-1256112565-1256812601-1260212615- 126181263712642-1264412653-1265812666-12667 12676-1267812714-1271512720-1272312725-12727 12755-1276212774-1277512782-1278712872-12881 12963-1296412997-1299913077-1307913556-13562 13592-1359513603-1361213638-1364113668-13672 13873-138751389813918-13921 1393013934-13936 13954-1395613999-1400414023-1402614044-14045 14058-1405914166-1416814170-141721418614192- 1419514236-1423814264-1426714314-1431714344- 1434514355-1435614459-144621460414607-14609 1462614640-1464214650-1465114661-1466214681- 1468214684-1468514705-1470614714-1471714723- 147241478414789-147911480915013-1501815093- 1509615182-1518315187-1519115218-1521915243- 1524815250-1525115257-1525915290-1529115336- 1534015412-1541415457-1545915530-1553115545- 1554615576-1557715588-1558915623-1562615699- 1570015867-1586815880-1588515890-1589515988- 1599016006-1601516044-1604616053-1605816115- 1611716121-1612216130-1613216141-1614316152- 1615316168-1617116174-1617616233-1623516238 1631516360-1636116364-1636616368-1637216408- 1640916434-1643716461-1646416470-1647816527- 165291654516558-1656216583-1658516602-16611 1662316636-166371664216652-1665516668-16674 16683-1669316700-1670316716-1672316800-16801 16823-1682616828-1683116836-1684216851-16853 16878-16881 16894-1689616913-1691516934-16939 17010-1701417026-1702817036-170371711417131- 1713217145-1714617153-1715417156-1715917238- 17241 17244-1724817251-1725417297-1730617330- Tissue RNA Library SEQ ID NOS: origin Source Name

1733217335-1733917356-1735817404-1740817454 17922-1792317951-1795217958-1796318008-18009 18015-1801618029-1803018069-1807218400-18402 18411-1841818421-1842518500-1850118516-18518 1852718533-1853418536-1853718577-1857818585- 1861718624-1862618629-1863718644-1865018655- 18661 18668-1868118689-1869318717-1872618730- 1873218738-1875618759-1876918771-1877218778- 1878318787-187931879618802-1880418806-18807 18811-1881318822-1883418836-188381885418856- 1888018882-1888818894-1889618899-1890318919- 1892118923-1893918947-1895018964-1896918975 18989-18990189961900019005-1900919012-19018 19025-1902819045-190481905419057-1905819062- 1906519071-1908519096-1910119106-1911819134 19138-1914019142-191471915319163-1920119207- 1922019226-1922719253-192551925719260-19262 1927319306-1930919316-1931719345-1935419361- 1936419368-1937019372-1937419385-1940219407- 1941119415-1941719422-1943419441-1944419458- 1946119494-194961950319512-1951319515-19521 19526-1953119560-1956219566-1957819580-19582 1958619617-196191962719656-1965719667-19668 19674-19678196931969819706-1971019727-19732 19736-19751 19759-197631977219800-1980819813- 1981519915-1991819921-1992919933-1994619953- 1995719962-1996319965-1996719972-1998120015- 2001720026-2002720029-2004320048-2005220069- 2007120074-2007920087-2010220106-2011220114- 2012020122-201272013020133-2015020161-20164 20167-2019420198-2020720215-2021820229-20241 20244-2025320257-2026220265-2027020274-20278 20289-2029620299-2030420317-2032420328-20330 20343-2034820366-2036820401-2040520415-20420 20425-2045520469-2047120482-204902050120510- 2053520537-2054520548-2055720559-2057820614- 2061920625-2063020635-2063620642-2066520681 2068820698-2070720710-2072620733-2073820747- 2075320758-2076720788-2079720806-2081220816- 2081820824-2084920855-208672087120879-20884 20897-2090020922-2092820933-2093520938-20943 20952-2095420963-2097220977-2098420999-21008 21021-2102321060-2106621069-2110021123-21127 21137-2114221145-2115121171-2117421176-21180 21194-2119821208-2121021233-2123521237-21240 21248-2125221256-2126621272-2129421297-21298 21326-2133421351-2135521377-213972140521428- 2145321458-2146121463-2146521467-2146921480- 2148221485-2149121495-2150021529-2153021532- 2153321554-2155621587-2165521729-2173321744- 2174721877-2188521892-2189421911 -2191221915- 219212192421929-219352193921948-2195021955- 2196821973-2197421978-2198822000-2201522019- 2202522030-2203422042-220442204722056-22076 22080-2208622101-2210722115-2211622135-22138 Tissue RNA Library SEQ ID NOS: origin Source Name

22141 •2214322160 22165-2217022187- ^■2219222195-

2219822208-2221122218-2222622231-^■2223522243-

2225022253-2225522261-2226422271-^■2228922300-

2230222312-2231822323-2232822333-•2233522343-

2235022358-2235922365-223712237322377-22380

22383-■2239222399-2240822434-2243522440-22448

22455--224652249522531-2253322551- 2255822560

22571-•2258122599-2260222607-2260922622-22628

22634-■2264322653--2265422661-2266722671-22674

2269022700-2270122726-2272722730--2273122760-

2276222768-2277022775-2277622781--2278222794-

2279622805-2281622821-2282222828--2282922838-

2284922852-2285322857-2285822899--2290022925-

2293822948-2295022952-2295322955--2295722973-

2297722991-2299422999-2302123026--2302823046-

2305223059-2306023063-2306723070--2307123098-

2310123117-2311923138-2314123201--2320223206-

2320923212-2321523218-232222323623240-23244

23247232492325123261-2326223328-■2333723343-

2334423356-2336023373-2337423382--2339023396-

2339923415-2342123425-2342723433--2343723439-

2345023470-2347423486-2348723489--2349023492-

2349323495-2349623508-2351323543--2354423555-

2356523718-2371923726-2373623761--2376323771-

2378023793-2379923802-2380923816--2381923827-

2383323839-2384223845-2385223871--2387523890-

2390223911-239402395923999-2400124014-24018

24021-240242405624120-241292466524772-24774

2528925290253062531425319-2532125331-25335

25342-2534325370--2537525383-2540125410-25413

25416-2541725534--2553625966-2596826024-26028

26196-2619926205--2620626237-262432625226261

2626626270-2627226305-2630926316-•2632126327

2633726341-263442635826361-2636526373-26374

26389-26393264112642326448-2645126460-26463

26469-2647026559--2656026596-2660126678-26680

26698-266992673726755-26756268062682826831

26842--2684326846--2684926853-2685726860-26862

26873--2687926980--2698427012-2701427028-27029

2703527044-2704727050-270572709127142-27146

27156--2715727173--2717427184-2718727193-27205

2721827247-2725127269-2727027275-■2727627283-

2728727299-2730527323-2732527331-^■2733327441-

2744427446-2744927498-2750727510-2751127544-

2754527562-2756327570-2757127574-2757727588

27593--2759427600--2761527636-2763927649-27654

27662-•2767227698--2770127726-2774327750-27756

27814--2781827821--2782227825-2782627861-27868

27896--2792827943--2794727989-2799028008-28011

28050--2805928097-■2810028105-2812228142-28145

2818628204-2820928263-2826828272-2827628286

28290-•2829228311 ■2831328361-283642842428426-

2842828446-2844829265-2926729278-2928329328-

2933129339-2934029354-29357293712937529432-

2943529451-2945229746-2976129940-2995529958- Tissue RNA Library SEQ ID NOS: origin Source Name

2996130085-3008730141-3014230150-3015630195- 3019930218-3022030224-3023230361-30368 adult Invitroge AKT002 136-138255-256333-335414-418543-545553-554576- kidney n 578665-666716-717847-848913919-922981-9851034 1071 1086-10871097-10981123-11271158-11611298 1312-13131346-13471461-14631569-15701692-1693 1980-19822015-20182209-22102255-22562471-2474 2540-25412675-26783006-300832713276-32773374- 33773435-34403452-345335073789-37943834-3835 3840-38543949-39534122-41234160-41624486-4487 4515-45164562-45684660-46624785-47894795-4809 4971-49745149-51505331-5332551057005932-5936 5980-59846140-61436166-61686235-62376335-6336 6403-64046533-65356570-65716656-66617008-7010 7209-72127216-72197536-75417611-76127643-7647 7657-76597742-77437784-77867795-77977815-7818 7924-79257972-79757978-79838008-80128017-8019 80468059-806380798142-81518187-82008211-8213 8216-8218831083428368-83698512-85138526-8535 8543-85508554-85558936-89388982-898390369072- 90749337-93389369-93719391-93929456-94589475- 94769487-948895589563-956695859594-96029617- 96269735-97429759-97629828-98329851-98529916- 992099469989-999210015-100191027710449-10457 10520-1053010588-1059410600-1060110603-10606 10886-108891101011217-1121911300-1130111476- 1147811544-1154511603-1160611658-1165911715- 1171611731-1173411772-1177411835-1183611842 11873-1187511937-1193812121-1212612131-12132 121401214912186-1218912374-1237712545-12546 12560-1256112578-1258012593-125961259812637 12723-1272712796-1279812968-1296912984-12985 12997-1299913585-1358813592-1359513627-13631 13638-136411366513925-1392613954-1395614023- 1402614299-143011460414684-1468514721-14724 1478415243-152481525715326-1532815545-15546 15576-1557715588-1559015593-1560115623-15626 15863-1586616075-1607916096-1609716345-16349 16392-16394165451664216833-1683516934-16937 17026-1702817238-1724117251-1726117335-17339 17454-174561841118423-184251852718533-18534 18585-1858618625-1862618633-1863718671-18672 18717-1871818730-1873218759-1876118771-18776 18778-1878018790-187931879618802-1880418822- 1882418839-1884118906-1890718919-1892118934- 1893518944-1894519045-1905319057-1906119134 19207-1920819254-1925519283-1929419351-19354 19362-1936419368-1937019390-1940219407-19411 19461 19494-194961950319560-1956219567-19578 19656-1965719667-1966819727-1973519814-19815 19924-199251993819953- 1995720015-2001720026- 2002720029-2004320087-2009420099-2010220122- 201272013020146-2014820161-2016620182-20194 20200-202072024120257-2026220265-2027020279- 2028020290-2029620328-2033020412-2041320421-

Tissue RNA Library SEQ ID NOS: origin Source Name

2714627193-272002721827247-2725127269-27270 27493-2749527504-2750727544-2754527600-27601 27700-2770127755-2775627821-2782227825-27826 27861-2786427989-2799028008-2801128142-28145 2828628416-2841729278-2928329328-2933129343- 2934529352-2935329960-2996130141-3014230224- 3023230361-30368 lymph Clontech ALN001 167170-171180-181302332395425-427505635670- node 671849-851919-922973-987998-1000102810471086- 10871232-12341259-12621273-127913071456-1460 14991569-15701667-16681705-17141879-18801943 2063-20652126-21292272-22742404-240624092471- 247425333151-31543322-332333773461-34633512- 3514373738223834-38353879-388042554555-4556 4562-45685335-53365572-557355805650-56515802 5805-58075910-59116403-64046832-68507216-7219 7447-74497643-76477654-765576977744-77467757- 77597763-777078907972-79757978-79858010-8012 83428698-87009043-90459306-93119475-94769487- 948895319615-96169780-97819916-992010273- 102741030611123-1112411295-1129611339-11344 11431-1143211476-1147811538-1154011607-11608 1169611780-1178211835-118361214012150-12151 12374-1237712545-1254612615-1261812642-12644 1272312760-1276212782-1278412796-1279812872- 12881 13077-1308213592-135951390614304-14305 14546-1454915182-1518315190-1519115290-15291 15545-1554615548-1555015576-1557715699-15700 16044-1604616110-1611216284-1628916370-16374 16536-165381654516609-1661116628-1663116636- 16637166421665216954-1696117046-1705717131- 1713217330-1733217454-1745617958-1796218015- 1801618029-1803018405-184061841118533-18534 18579-18581 1861718719-1872618750-1875818771- 1877218778-18780187891880518811-1881318822- 1882418836-1883818846-1885318899-1890318975 189961901819062-190651909019122-1913119138- 1914019154-1915519211-192121927419283-19294 1937019380-1938419390-1939419401-1940219415- 1941719442-194441950319526-195291968819693 19706-1970819743-1975119813-1981519915-19918 19921-1992319948-1994919972-1998020048-20052 20066-2006820106-2011020161-2016420172-20179 20182-2018820235-2024020257-2026220437-20440 2055820563-205672076720924-2092520938-20942 21027-2103121233-2123521277-2128021377-21402 21480-2148221495-2150021529-2153021587-21646 21978-2198222115-2211622141-221432216022277- 2228322312-2231322336-2234222358-2235922373 22455-2246522644-22651226682269022700-22701 22732-2273522737-2273922823-2282722838-22842 230462307023074-2307623098-2310123237-23239 23379-233812343323448-2345023473-2347423486 23492-2349323495-2349623508-2350923526-23531 2376123802-2380523999-2400124014-2401824772- Tissue RNA Library SEQ ID NOS: origin Source Name

24774 25085- 25090 25319- ■2532125383- •2540126024- 2602826237-■26239262662633826341-2634426373- 2637426479-■26545 26755-2675626855-•2685727113 27147-■2714927158-2716327177-2717827203-27206 2721827245-2724627269-2727027283-•2728727304- 2730527510-2751127562-2756327600-^■2760127636- 2763927814-2781527825-2782627861-■2786427989- 2799028142-2814528157-281592844929328-29331 29339-■2934029451 •2945229940-2994930141-30142 30150-■30156 young GIBCO ALV001 10-14165-166170-171202-203218-219324-325332 liver 461-463534-535582-584674-676847-848900-904 1035-10371058-10601123-11271346-13471431 1470 14781527-15281705-17141778-17791908-19091967 1980-19822015-20182284-22982570-25742599-2603 3255-32593276-32773374-337635073512-35143518- 35204091-40954160-41624273-42744343-43464370- 43714515-45164562-45684600-46014640-46434857- 48615152-51535335-533653705512-55165519-5521 5572-55735899-59025997-60006011-602164006572- 65746585-65926791-67947209-72127214-72157258- 72637426-74427536-75417630-76367648-76537671- 76737681-76877701-77037742-77437778-77837798- 78057815-78187930-79327947-79487995-79978017- 801980798113-81148145-81518157-81598187-8200 8242-8246825083428349-83508377-83798434-8452 8461-84648497-84998502-85038512-85138543-8550 8554-85558607-86098689-86908758-87598762-8766 9317-93189391-93929395-939694609475-94769478 9522-9525953195589561-95629585-95899617-9626 9719-97229829-98329848-98509854-98559874-9895 9902-99049929-99359965-99689984-998510167- 1017210265-102671027710484-1048710520-10522 10588-1059110907-1091210936-109371096611314- 1131511406-1140711431-1143211468-1147211495 11741-H74211803-118041184011890-1189112140 1217312177-12181126371272312829-1283012948- 1296213077-1307913638-1364113865-1386613873- 1387513999-1400314054-1405614692-1469314784 14789-14791 15011-1501215019-150241509615182- 1518315218-1521915243-1524815250-1525115290- 15291 15381-1538515406-1540715412-1541415530- 1553115548-1555015576-1557715588-1558915591- 1559215863-1586616168-1617116177-1618116365- 1636616484-164861654516550-165521660116636- 1663716642-166481665216702-1670316710-16712 16752-1675316851-1685316878-1688116894-16896 16913-1691516934-1693717026-1702817284-17285 17330-1733217857-178611795518001-1800318029- 1803018069-1807218207-1821018421-1842218500- 18501 1852718536-1853718642-1864318668-18677 18719-1872218730-1873218745-1875818761 18773- 18777187891879618829-1883418857-1888018906- 1890718925-189331894218955-1895918976-18977 19029-1903519221-1922219224-1922519228-19229 Tissue RNA Library SEQ ID NOS: origin Source Name

19274-1927919306 1930719316-1931719345-19349 1937019387-1938919395-1940219422-1943119512- 1951319567-195731958619598-1960119617-19619 19663-19666196701967319706-1970819727-19732 19736-1974819759-1976319814-1981519819-19822 19919-1992019943-1994620029-2004320087-20094 20133-2014820151 -2015420161-2016420189-20194 20208-20218202412025320265-2027320286-20287 2029920349-203542041120425-2042620432-20446 20469-204712054720554-2055720559-2056220575- 2057820614-2061920635-2063620646-2065220666- 2067120676-206802068820712-2071320718-20725 2075320758-2076620792-2079720819-2082120827- 2084320868-2087020897-2090020938-2094220999- 2100421027-2103121062-2106621076-2109621170- 2117421202-2121021241-2124721256-2126221277- 2128321297-2129821326-2133421359-2136021434- 2143921447-2145021463-2146521470-2147621516- 2152821647-2165521877-2188021925-2192821962- 2196621973-2197421978-2198222000-2200222007- 2201522020-2202522030-2203422040-2204422084- 2208622101-221072216022165-2216822187-22192 22261-2227022284--2228922303-2230922333-22335 22343-2234622351223652249522534-2253922571- 2258122607-2260922655-2265722661-2266422675- 2267722680-226842269022794-2279622805-22816 22948-229502297122991-2299423057-2305823212- 2321523229-2323323379-2338123415-2341923433 23473-2347423483--2348523492-2349323508-23511 23519-2352023543--2354423673-2368623700-23701 2376123771-237802380023878-2388023893-23902 24014-2401824021--2402424481-2449025085-25090 2530625319-2532125347-2535425374-2537525416- 2541726024-2602826196-2619926205-2620626221- 2622326237-26239262602632726347-2634826373- 263742642326469-2647026788-267892684326853- 2685426860-2686526873-268752687926882-26884 27044-270472705227173-2717427180-2718827193- 2720027269-2727027340-2734227498-2750327544- 2754527649-2765427729-2773927750-2775427809- 2781127814-2781527989-2799028099-2810028186 282862842429328-2933129343-2934529940-29949 adult liver Invitroge ALV002 77170-171255-256318398-399553-554619-620716- n 717901-904912969-9711001-10031080-10811097- 10981120-11211123-11271136-11391205-12061273- 127913071432-14351438-1439149915201678-1680 1688-168916911705-171418381923-19242015-2018 2086-20872570-257426902871-287332033374-3377 3468-34713512-35143555-35583686-36913840-3852 3925-39303934-39353949-39534151-41554441-4443 4531-45334543-45454555-45564863-48644874-4889 4979-49815080-50815285-52875808-58125973-5975 5980-59846135-61366488-64896638-66396791 -6794 7275-72767279-728273747461-74647615-76177648- 76537671-76737681-768777717787-77887795-7797 Tissue RNA Library SEQ ID NOS: origin Source Name

7972-79758017-80198084-808580948107-81088113- 81148187-82008227-82328242-824683108323-8325 83428347-83488434-84488507-85088512-85138576- 85828733-87379072-90749264-92659306-93119317- 93189454-94559475-94769529-95319594-96029617- 96269757-97679794-979598289899-99019927-9928 99539956-99579969-99809984-998510015-10016 10262-1026710451-1045310498-105031055010595- 1059910603-1060610624-1062610835-1083910870- 1087210881-1088310913-1091411046-1104711212- 1121911544-1154511563-1156411574-1157611612- 1163911651-1165511669-1167111757-1175811835- 1183611901-1190511921-1193012150-1215112190- 1219112206-1220812486-1251812673-1267812707- 1271112725-1272712829-1283012944-1296212965- 1297213505-1351113531-1353513576-1357913603- 1360513632-1363313638-1364113668-1367213937- 1393814048-1405314061-1406314137-1413814264- 1426914283-142881460414650-146511468314720 14789-1479114981-1498315182-1518315243-15248 15412-1541415576-1557715588-1558915614-15616 15661-1566315688-1569415863-1586615988-15996 16365-1636616536-165381654516570-1657316602- 1660816642-16648166521679817026-1702817112 17131-1713217238-1724117335-173391745417487- 1748817791-1779918015-180161802318136-18138 18421-1842218642-1865018655-1865818750-18756 18773-187761879618806-1880718829-1883418839- 1884518904-1890518919-1892118925-1893319062- 1906519096-1910119207-1920819213-1922019271- 1927219274-1927919308-1930919316-1931719351- 1935419368-1937019385-1938619390-1939419422- 1943119442-1944419458-194601950319514-19521 195661958619617-1961919663-1966619670-19671 19709-1971019733-1973519757-197631977219915- 199181993919943-1994619953-1995720128-20130 20133-2013620146-2014820157-2016020200-20207 20231-202342024120263-2026420271-2027320286- 202872028920363-2036820406-2040720432-20446 20469-2047120485-2049020514-2052020524-20535 20559-2056820635-2063620646-2064820712-20717 20727-2073420747-2075120758-2076620789-20791 20816-2081820822-2082320836-2084320855-20857 2087120897-209002094320948-2094920999-21008 21027-2103121088-2109621105-2111121133-21135 21171-2117421194-2119621208-2121021248-21252 21281-2128321297-2129821326-2133421377-21397 21410-2141421447-2145321467-2147621485-21491 21718-2172421788-2179921911-2191221917-21921 22007-2201522030-220342204722074-2207622117- 221192216022265-2227622284-2228922303-22309 22323-2232822333-2233522343-223462235122357 2249522534-2253922551-225522255922571-22581 22607-2260922625-2262822632-2263322644-22651 22661-2266222680-2268422730-2273122833-22834 Tissue RNA Library SEQ ID NOS: origin Source Name

23125 -2313623279 -2328123415 -2341923475-23479

23492-2349323515--2351823543--2354423673-23674

23682-23686236902376123771-•2378023793-23797

23839-2384023845--2384823878-2388023890-23902

23999-2400124005--2401825085 -2509025279-25288

25319-2532125323--2532525340--2534125347-25354

25374-2537525416--2541726024--2602826196-26199

26248 -2625126273-•262792633826347-2634826350-

2635226610-266142723927384-273852743827446-

2745127498-2750027544-2754527600-2760127636-

2763927649-2765427861-278642798327995-27997

2800428050-2805928087-2809128099-2810028142-

2814728272-2827628416-2842428426-2842828882-

2888729332-2933729354-2935729427-2943129938-

2993929950-2995330085-30087 adult liver Clontech ALV003 53708434-844893829475-947611123-1112413638- 1364118829-188341914819221-1922219275-19279 19667-1966819921-1992323419263272684327269- 2727030141-30142 adult Invitroge AOV001 3-410-14163048-4951-52144-145156170-171177- ovary n 178180-181192195-200221227-230251-252255-256 273-280307-308315-316324-325329-330332360-361 367373-374395400404-407412-413419-420425-427 464-467470-471515-517524-525528534-535540-547 549573-575582-584635637669677680-684689-699 716-722785-786832-836845-848852-855860-863868- 875878-882901-904913919-922934-935964969-971 981-9851001-10041040-104110471072-10731092- 10941097-10981101-11061108-11391158-11611199- 120012461259-12651273-12791291-13061308-1313 13591371-13751388-14011408-14191422-14231430- 14371440-144814511453-14541467-147014741478 14831499-15021618162016261667-16681678-1687 1705-17141721-17221778-1779184018511866-1872 1899-19001912-19131915-19161925-192719671986- 19872015-201820302033-2034203620722197-2198 2202-22032222-22262234-22352272-227622992306 2404-24062428-24312469-2474251325162525-2528 2540-25412570-25742585-25862656-26582663-2665 2774-27752814-281528462852-28532871-28732888- 291029162918-29192923-292429262934-29352948- 29492951-29552975-29772988-29893006-30083023- 30253037-30383094-30963105-31063126-31273151- 31543182-31873195-31973205-32073255-32593268- 32693271-32723276-327932903306-33083310-3311 3322-33233326-33313336-333733453374-33763433- 343434543464-34663468-34713477-347835073512- 35203526-35293531-35343550-35603565-35883624 3675-36763686-369136933731-37323768-37693789- 38093834-38353840-385238603939-39413949-3953 4067-40764122-41264134-41364151-41624220-4238 4413-44154441-444344504483-44854512-45164531- 453345424555-45564562-45764581-45824600-4601 4608-46144623-46394683-468447004780-47814785- 47894795-48094819-48234857-48614868-48694950- Tissue RNA Library SEQ ID NOS: origin Source Name

49514958-49594971-49744980-49814984-49855057- 50595080-50825092-50945109-51155149-51505192 5253-52665269-52715285-52875335-533653645371 5384-53865480-54825495-54965499-55015517-5521 5525-55265557-55605572-55735581-55835591-5592 5652-56545695-569857005703-57045710-57115744- 57475765580258245827-584658495854-58585898- 59225939-59415943-59485953-59545973-59755980- 59845986-59896135-61366140-61436163-61686235- 62376282-62836335-633663866403-64056452-6453 6461-64836523-65266533-65356551-656766236657- 66616791-67946853-68546932-69387056-70577187- 71907192-71937209-72127216-72197245-72487256- 72717283-72987360-73617421-74237426-74427534- 75417554-75557576-75777580-75977604-76057608 7611-76127615-76177620-76217624-76297643-7647 7654-76567660-76657671-76737678-76897693-7703 7726-77277742-77437745-77517778-77867789-7797 7802-78057815-78187821-78227824-78257890-7901 7904-79127917-79187924-79257953-795579577968- 797179767978-79857988-799480028008-80128017- 80208025-80268041-80428049-805680698074-8076 80798084-80858090-80938132-81368142-81568162 8178-81858187-82008216-82188227-823282348247- 82488253-82578263-82658297-83008313-83148339- 83448347-83608363-83648368-83698383-83898404- 840684158420-84258430-84338449-84528461-8464 8487-84888497-84998504-850585098512-85138537- 85508601-86038607-86098612-86168736-87378751- 87668768-87708917-89338936-89458982-89838986- 89919002-90069013-90209022-90259031-90459063- 90679072-90749306-931193169331-93339337-9338 9343-934693829391-93929408-94149443-94459456- 94599472-94769479-94859506-95319546-95499559- 95669570-95789581-95839590-95929594-96049609- 961096139615-9626965996769714-97189726-9727 9729-97319733-97449782-97839794-97959815-9820 9828-98349848-98529854-98559857-98619899-9904 9916-99209923-99249927-99359947-99529956-9957 9960-99619965-99689981-99929997-1000910015- 1001910025-1002610038-1004010164-1016610173- 101741025310263-10277103061031110449-10453 10480-1048210488-1048910491-1049310498-10503 10508-1051210531-1053210537-1053810588-10594 10600-1060810612-1062310627-1063310638-10644 10820-10821 10873-1087510877-1087810881-10883 10899-1090310913-1091410927-1092810931-10933 10936-1093710963-109641096610980-1098511042- 1104411066-110681113511147-1115611212-11219 11292-1130311318-1132011339-1135011372-11396 11406-1140711419-1142611429-1143411460-11466 11473-1147411476-1147811489-1149411496-11498 11538-1154011544-1154611561-1156211586-11606 11609-1164811656-1165711669-11671 1169611715- 1171611731-1173411739-1174011745-1174811753- Tissue RNA Library SEQ ID NOS: origin Source Name

1176311766- -1176811777-11782 11791 11803-11804 1180911835 -118361184211856- 1185711886-11891 11901-1190511941-1194412023-1202612040-12041 12121-1212612131-1213212135-1213712150-12151 12186-1219112202-1220812215-1221712226-12228 12245-1225312256-1225712259-122621236112374- 1237712432-•1243312446-1245012455-1245912470- 1247112478-■1248212486-1254212545-1254612555- 125611256412573-1257412581- 1258212619-12624 1263712642-■126441264612655- 126581266512673- 1267512701-•1270512707-12711 12714-1272312755- 1276212785-•1278712796-1279812803-1280612824- 1282712829- 1283012872-1288112968-1296912977- 1298112997- 1299913068-1307013077-1307913425- 134951351213552-1355913571- 1357313576-13579 13585-1358813592-1359713603-1361213627-13633 13638-13651 13752-1375313865 ■1386613876-13881 13885-1388713908-1391013927 •1392913937-13938 13954-139561400414008-1402014044-1404514054- 1405614058- 1405914098-140991410414123-14124 14130-1413114137-1414014173 ■14181 14192-14195 14199-142011420614216-142261425714261-14265 14283-14291 14304-143051434614355-1435614546- 145491460414607-1460914628- 1463514650-14651 14666-1466814681-1468214684- 146891470714784 14789-1479114866-1487014991-■1499215011-15012 15075-1508415091-1509615182 ■1518315187-15189 15218-1521915233-1523615243-■1524815250-15251 1525715283- 1529115302-1532215329-1534015392- 1539615406- 1541415454-1545615460-1546115496- 1552515536- 1553715545-1554615563-1556415568- 1557215576- 1557715581-1558415588-1558915600- 1560115631- 1563215686-1568715699-1570015863- 15868158781588015888-1589515925-1593115988- 1599016041-160461605916075-1607916086-16088 16096-1609716107-1610916115-■1611716141-16143 16145-1614616152-1615516168-16171 16174-16176 16237162391637716408-1640916422-16431 16443- 1644516470-1647216479-1648816494-1650016508- 165111654516576-165981660016602-1660816623 16636-1665516663-16667167021670516714-16723 16752-1675316787-16788168001680316828-16831 16836-1684216851-16853168601687016894-16896 16934-169371694216949-1695316996-1699717018- 1702017038-1704117074-1707717119-1712217131- 1713217145- 1714617153-1715417242-1724317264- 1727417286- 1729617330-1733217335-1733917394- 1739517454-1745617791-1779917958-1796318015- 1801618024- 1803018038-1804218046-1804818097- 1813418136-1813818374-1837518400-1840218405- 1840618412-1841818421-1842518495-18501 18516- 185181852718536-1853718583- 1858618629-18637 18644-1865018655-186581866218668-1867718680- 1868118691- 1869318717-187261872918745-18761 18771-1877618784-1879318797- 1880418806-18807

13! Tissue RNA Library SEQ ID NOS: origin Source Name

18836-1884118846-1885418856-1888018882-18888 18894-1889618899-1890518908-1891018915-18918 18923-1893918943-1895018955-1895918964-18969 18975-1897718989-1899018993-1899619001-19004 1901219018-1902419029-1903919045-1904819055 19057-1906519071-1908319096-191181913419142- 1914719207-192101922419226-1922719251-19257 19260-192621926419266-1926719273-1927419283- 1929619306-1930919316-1931719341-1934219345- 1936019362-1936419368-1937019372-1937419380- 1938419387-1940219415-1943419438-1944419461 19484-1948619488-194931950319515-1952119530- 1953119560-1956219564-1956519567-1957819586- 1958719617-19622196251962719656-1965719659- 1966119663-1966819670-1967819683-1968719689- 1969319699-1970819727-1973519743-1974819759- 197671977219800-1981519855-1985619915-19929 19933-1993919943-1994619948-1995019965-19967 19969-1998120015-2001720029-2005220066-20073 20087-2010220106-201122012020122-2012720130 20133-2014820157-2016020167-2019720200-20214 20226-2023020235-2024020244-202492025320257- 2027020286-202892029920317-2032020328-20330 20345-203592036220366-2036820393-2040520412- 2041320415-2043120437-2045120456-2047520485- 2049420497-204982050120505-2052020524-20535 20537-2054520548-2057820607-2061220614-20619 20625-2063420644-2065220666-2067120676-20681 20683-2068520688-2069220698-2070720710-20711 20714-2072620752-2075320758-2076720788-20791 20801-2081520819-2084920853-2086320865-20870 2088120885-2090020922-2093220938-2094320948- 2094920957-2097220977-209882099120999-21004 21011-2101521021-2102321027-2103121060-21071 21076-2108721097-2111421122-2112721141-21142 21145-2115121153-2115421157-2116921171-21174 21197-2119821202-2120721221-2122221225-21226 21229-2123521237-2125221256-2126621272-21274 21277-2128021284-2129421297-2129821301-21303 2133421343-2135021353-2135421359-2136021377- 2139721410-2141421418-2142621428-2143921447- 2145321463-2146521467-2146921480-2148221485- 2149121495-2150021516-2153021554-2155621587- 2165521718-2172421729-2173321877-2188521892- 2189421911-2191221915-2192121924-2193921955- 2196821971-2197221975-2198721989-2199321995- 2202522047-2204922056-2207622080-2208322090- 2209422101-2210722115-2211922128-2213822141- 221432216022165-2216822171-2217722187-22192 22195-2219822204-2221122218-222262223022243- 2225222256-2226022265-2229922303-2230922312- 2233522343-2235622358-223712237322377-22380 22399-2241022433-2243522440-2244822455-22465 2249522534-2253922551-2255822560-2256522570- 2258122599-2260222607-2260922622-2262822632- Tissue RNA Library SEQ ID NOS: origin Source Name

2265122653-2265422661-2266722669-2267722690 22696-2269722700-2270122726-2272722730-22735 22741-2274222750-2276222768-2277022775-22776 22781-2278222794-2279622801-2281622821 -22822 22828-2282922846-2285322861-2286822870-22874 22881-2288622899-229062291122923-2292422955- 2295722962-2297022973-2297622978-2298622991- 229942299823007-2302123046-2305023059-23060 2306323070-230762308423098-2310423117-23119 23125-2313623138-2314123201-2320223206-23221 23229-2323323236-2323923242-232452324923251- 2325623261-2326323279-2328123321-2332723343- 2334423353-2335423356-2336023379-2339023392- 2339523399-2340123415-2341923428-2343223448- 2345023470-234792348623489-2349023492-23493 23495-2349823508-2351423543-235442354623599 23682-2368623692-236932370423718-2372123726- 2373623760-2376323765-2376723770-2378023793- 2379723806-2380923816-2381923827-2383323839- 2384023843-2384823867-2387023878-2388023882- 2390423906-2391023941-2395623990-2399223999- 2400124005-2401124014-2401824021-2402524029- 2403324035-240402405624092-2409724120-24125 24481-2449024772-2477424802-2481625085-25090 25114-2512625279-2529025319-2532125323-25325 25338-2534125355-2535825368-253692537325376- 2537725416-254172584826024-2602826196-26199 26205-2621326235-2624326258-262592626626280 26285-2629026292-2630226305-2630626316-26321 2632626328-263292633726349-2635226358-26365 26373-2637426376-2637726421-264242643126460- 2646326567-2658526596-2660626665-2666626678- 266802668426733-267352674626755-2675626788- 2678926804-2680526843-2684526860-2686226873- 2687926885-2688726980-2698426998-2701127044- 270472705227058-2705927067-2707027074-27077 2709127100-271022710527150-2715127154-27155 27173-2717427193-2720027207-2721527218-27221 27229-2723227247-2725127261-2726527269-27276 27283-2728727293-2730127304-2730527348-27353 27411-2741227414-2743127439-274442746827493- 2749527497-2750727510-2751127520-2752127544- 2754527557-2756327574-2758427589-2759227600- 2760627636-2763927649-2765627662-2767227698- 2770127719-2772027729-2773927807-2780827812- 2782227825-2782627840-2784427848-2785227861- 2786427890-2789227940-2794227989-2799027992- 2799728045-2804728050-2805928095-2809628099- 2810028105-2812228138-2814028142-2814528157- 281582818628199-2820328263-282682828628290- 2829228311-2831328315-2831628361-2836228424 28426-2842828468-2848428573-2857829050-29070 29265-2926729278-2928329301-2930329328-29331 29339-2934029343-2934529354-2935829378-29379 2940529409-2941629418-2941929432-2943529451-

I JJ

Tissue RNA Library SEQ ID NOS: origin Source Name

22284 -2228922303 -223082249522760 -2276222768- 2277022904-22906229712307123358-2336023473- 234742376123890- 2389223941-2395624495-24498 25085-250902530625374-2537525866-2587526175- 2618426359-2636026973-2697927053 •2705727074- 2707727269-2727027401-2741027439-2744027504- 2750727510-2751127544-2754527649•2765427662- 2767227825-2782628192-2819828365 •2837028728- 2873129278-292832936729409-2941629594-29604 adult GIBCO ASP001 170-171180-181197-200221326-327329-330358-359 spleen 373-374395404-405412-413425-427528534-535543- 545553-554656708-711785-786847-848934-935981- 9851001-100310051026-103110471086-10871101- 11031235-12371295-1297130714311453-14541499 15211569-15701692-16931705-17141721-17221879- 18801947-19482015-2018219423062383-23882420- 242125162599-260329262929-29302939-29433090 311231153274-32753326-33313374-33773418-3420 352536243681-36823810-38113949-39534206-4208 4386-43874417-44194441-44434515-45164555-4556 45614581-45824819-48245285-528753335335-5336 5525-55265534-55365557-55605572-557357765802 58465919-59215973-59756103-610464006403-6404 6523-65266791-67946898-68997209-72127216-7219 7447-74497580-759776087620-76217630-76367681- 76897745-77467757-77597778-77837921-79237984- 7985799480028041-80428077-80788101-81048113- 81148157-815981628187-82008247-82488363-8364 8449-84528507-85088512-85138543-85508607-8609 8612-86168689-86908936-89388986-89919007-9008 9013-90179038-90429063-90679072-907493059337- 93389427-94289470-94769487-94889519-95219526- 95289531-95349561-956295849723-97259735-9738 9782-97859794-97959815-9820982698289851-9852 9854-98559874-98959986-998810167-1017210277 1030610320-1032310523-1053210595-1059910615- 1062310627-1063010638-1063910873-1087510904- 1090510913-1091410980-1098511006-1100811198- 1119911397-1139811476-1147811561-1156211612- 1163911731-1173411745-1174811835-1183611878- 1187911886-118891193412023-1202612040-12041 12150-1215112186-1218912226-1222812256-12257 12361124511247712545-1254612565-1256812637 12642-1264412666-12667126991272312785-12787 12824-1282712872-1288112997-1299913077-13079 13865-138661389813927-1392913999-1400314094 14170-1417214209-1421514452-1445314546-14549 1460414650-1465114684-1468515182-1518315187- 1518915195-1519615222-1522415290-1529115326- 1532815486-1548915576-1557715588-1558915600- 1560115699-1570015867-1586816044-1604616110- 1611216174-1617616233-162351643316451-16452 16508-16511 16535-1653916542-1654516558-16562 1662316636-16637166421665216799-16801 16851- 1685316894-1689616934-1693717026-1702817058- Tissue RNA Library SEQ D3 NOS: origin Source Name

1706417105-171061711517238-17241 17330-17332 17335-1733917394-1739517454-1745617571-17574 17857-17861 17958-1796217998-1799918015-18016 18029-1803018419-1842018492-18501 18536-18537 18633-1863718691-1869218719-1872218750-18760 18767-1876918771-1877218778-187801878918796 18802-1880418811-1881318822-1882418836-18838 18842-1884518857-1888018882-1888818894-18896 1891018915-1891818923-1893318936-1893918960- 1896918975-1897719005-190091901819045-19048 19071-19083190901913419138-191471915119207- 1921019260-1926219266-1926719283-1929419306- 1930719316-1931719345-1935019362-1936419370 19373-1937419385-1938919395-1940219415-19417 19422-1943119438-1944419458-1946019462-19463 19488-1949319515-1952119526-195291953619566 1958619620-196241962719667-1966819672-19673 19679-196821969319706-1970819736-1975119772 1981319855-1985619915-1991819921-1992519933- 199391995020029-2004320106-2011220122-20127 2013020146-2014820161-201642024120244-20249 202532028920299-2030420328-2033020345-20354 203602041120418-2042420437-2044620472-20474 20485-2049420497-204982050120511-2051320548- 2055320569-2057820599-2060120614-2061920629- 2063420649-2065220666-206712068120714-20717 20727-20732207522076720788-2079120813-20815 20819-2082120836-2084320855-208632086520868- 2087020882-2088420890-2090020927-2092820938- 2094220999-210082112221176-2118021194-21196 21202-2120721256-2126221272-2127421277-21280 21284-2129421301-213032133421398-2140221447- 2145021480-2148221492-2150021647-2165521881- 2188521892-218942192421955-2195721967-21968 21978-2198722003-220152204722117-2212722141- 221432216022187-2219222253-2225522261-22276 22284-2228922312-2231322343-2234822358-22359 2237322405-224082249522534-2253922571-22581 22607-2260922634-226362269022700-2270122703- 2270622750-2276222781-2278222794-2280022810- 2281622821-2282222838-22842229112297323046 23051-2305223059-2306023064-2306523070-23071 23074-2307623123-2312423138-2314023201-23202 23212-2321523229-232332325123261-2326223356- 2336023386-2339023400-2340123415-2341823434- 2343723448-234502348623495-2349623508-23511 23543-2354423555-2356523760-2376123843-23844 23903-2390423906-2391024002-240042405624126- 2412925085-250902531325331-2533525340-25341 25370-2537525410-2541325416-2541726024-26028 26033-2604926196-2619926237-262392626626327 26341-2634426389-2639326421-2642226469-26470 266022684326858-2686226880-2688127025-27027 270912713527139-2714627193-2720027209-27213 2721827229-2723227247-2725127254-2726027269- Tissue RNA Library SEQ ID NOS: origin Source Name

27270 27299- 27301 27379-27380 2749627510- 27511 27544-•2754527562-■2756327572--2757327633- -27634 27636 •2763927649■2765627698--2769927750- ^■27756 27830-•2783827861-■2786427890--2789227989- ^■27990 28099-•2810028138 •2814028142--2814528286 28290- 2829228311-283132842428426-2842829278- 29283 29339-•2934029343-•2934529364--2936629409- ^■29417 29508-•2951829718--2972129938-■2993929960- •29961 30141-■3014230206--3021730243-■3025030361- •30368 testis GIBCO ATS001 51-52156221332395425-427468-469477-482524- 525635656913969-9711001-100510471123-1127 1273-127914511667-166818121912-191319442072 2202-22032212-22132540-25412599-26032874-2876 2988-298930043195-31973281-32823374-33763479- 34803531-35343555-35583679-36804091-40954124- 41264343-43464435-44364515-45164562-45684581- 458246514785-47894865-48674984-49855335-5336 5572-55735581-55865656-56575766-576757735802 5919-59215943-59455973-59755980-59846140-6143 6235-62376403-64046762-67646791-679468527209- 72127216-72197283-72847447-74497534-75357604- 760576087611-76127618-76197654-76557671-7673 7745-77467763-77707787-77887806-780879948069 8137-81418145-81598187-82008242-82488368-8369 8383-83898409-84158507-85088539-85508607-8609 8738-87408762-87669007-90089040-90429337-9338 94449449-94509475-94769482-94859510-95259617- 96269829-98329851-98529874-989510025-10026 10038-1004010167-10172102771030610449-10453 10488-1048910531-1053410607-1060810615-10623 10628-1063010638-1063910873-108751093811011- 1101211123-1112411339-1134411372-1139611431- 1143211476-1147811541-1154611568-1157111582- 1158311674-1167811697-1169811711-1171211731- 1173411739-117401180911835-1183612150-12151 12202-1220512226-1222812374-1237712398-12401 1263712676-126781272312785-1278712984-12985 12997-1299913107-1311713603-1360513609-13612 13627-1362813865-1386613873-1387513954-13956 14048-1405614098-1410014105-1410614268-14269 14640-1464214650-1465115190-151911520615250- 1525115258-1525915290-15291 15300-1530115460- 154611546515545-1554615548-1555015576-15577 15588-1558915988-1599016168-1617116365-16366 16473-1647816609-1661116636-166371664216804- 1680716851-1685316913-1691516938-1693916949- 1695317024-1702817156-171591723217238-17242 17286-17291 17330-1733217455-174561758017958- 1796218015-1801618029-1803018412-1841818527 18644-1865018668-1867018673-18681 18691-18692 18729-1873218738-1874918761 18771-1877218778- 1878018784-18786187891879618802-1880418839- 18841 18846-1885318894-1889618899-1890318947- 1895018955-1895918964-1896918978-1898219013- 1901719029-1903519045-1904819059-1906119106- Tissue RNA Library SEQ ID NOS: origin Source Name

1911819132 1913419253 1926419345- 1934919351- 19354193621937019380- 1938419407- 1941119422- 1943419526--1952919604--196071962519656-19657 19667-196681969319699--19705197091971019733- 197481981319921-199231993919943- 1994619972- 1998120029--2004320064--2006520087-2009420106- 2011220146--2015020161-•2016420172- 2017920253 20288-2028920401-2040720412-2041320415-20417 20437-2044020485-204902051020514- 2052020547 20575-2057820616-2061920625-2063020683-20685 20698-2070720718-2072520747-2075120758-20767 20824-2083520929-2093220938-2094220948-20949 20999-2100821021-2102321072-210752112221157- 2116921171--2117421202--2120721237--2124721256- 2126621275--2127621377--2139721408--2140921485- 2149121529--2153021647--2165521718--2172421973- 219742197822000-2200222016-2201822020-22025 22030-2203422040-2204122060-2206122070-22073 22090-2209122141-221432216022187--2219222212- 222172225022265-2227022277-2228322310-22311 22314-2231722323-2233522343-2234822358-22361 22366-223712237322399-■224042249522534-22539 2254422561--2256522571-2258122599-•2260222644- 2265122661--2266222730-■227312274922833-22834 22850-2285122857-2285822861-2286822974-22976 2299523047-■230552307123201-232022325123343- 2334423379-•2338523425-2342723489--2349023508- 2350923720-^■2372123731-2373623762--2376323771- 2378023793-■2379923816-2381923839--2384023882 23893-2390223990-2399224014-2401824029-24033 24772-2477425319-2532125368-253692537325416- 2541726024-■2602826196-2619926237-■2623926266 26285-2629026305-26306263272673726748-26754 2684326860-•2686226876-2687826980-■2698427052 2709727114-•2712627147-2714927173-^■2717427193- 2720027261-^■2726527269-272722729427304-27305 27570-2757127600-2760127636-2763927726-27739 27861-2786427890-2789227943-2794727989-27990 28095-2809628142-281452828628308-•2831328424 29278-2928329328-2933729339-2934029409-29416 29718-2972130141-3014230150-3015630218-30220

Genomic Research BAC001 3338-33394122-41234175-41764180-41904911-4914 DNA from Genetics 5021-50235030-50355045-50465154-51797065-7066 BAC (CITB 7370-73747426-74428802-88068836-88388855-8859 63118 BAC 8877-88919087-90999152-91929194-91959213-9215

Library) 9217-92259239-925792599269-92769291-92939301- 93049312-931310443-1044410684-1068910691-10703 10723-1072410726-1072710835-1083910842-10867 10879-1088012218-1222013130-131321314513176- 1317813324-1332513422-1342313677-1368013683- 1368513693-1369413708-137181382313854-13860 14663-1466515718-1572515815-158171582715910- 1591615934-1595015978-1598015991-1600016024- 160271623217637-17641 1767317688-1769617738- 1773917748-1775117763-17781 17783-1778617842- Tissue RNA Library SEQ ID NOS: origin Source Name

1784717862-17863 17876-17879 17881-1788517888- 178901792118024--1802818066--1808218090-18096 1813518139-18156182261824218247-1825318255- 1825818275-1827718286-1828818293-1829518354 18365-1837018382-1839221304-2132521501-21515 21549-215532156321752-2177221863-2187622436- 2243922449-2245422525-2253022596-2259822605- 2260623532-2353923820-2382624187-2419324255- 2425924269-2427324333-2434024370-2437424402- 2442524449-2446224610-2462324686-2469324727- 2475424757-247702479424820-■2483724855-24862 24919-2492324928--249482495124964-2497424993- 2499925041-2504825093-2509525112-2512625158- 2517725254-2525625366-2536725418-2544025447- 2546025471-2549425496-2551425537-2554125583- 2559325598-25603256212562325651-2565625660- 2567225676-2567925687-2570225741-2578225821- 2584225853-2587525903-2590525944-2594625956 25969-2601626054-2605826077-2608626090-26099 26105-2611126114-2611526136-2613826150-26152 26165-2617126629-2665326691 -2669426700-26703 27677-2768827714-2771727943 -2794728352-28357 28504-2850728514-2851728531 -2854728565-28570 28596-2860628673 -2867828709-2871928732-28742 2874828754-2876028775-2878128809-2882128831- 2883628841-2884728901-2890928914-2892628933- 2893528944-289582901229031-•2903829071-29075 29096-2910129104--2910729154■2915629179-29186 2920329225-2923129446-2946629468-2948729492- 2951829529-2954329547-2956329569-2957729583- 2960529608-2961029627-2962929631-2963729645- 2965429660-2967229686-2970329708-2971029763- 2987529880-2988429991-2999430011-3001330038- 300473006130118-3013430165-3017730179-30182 30201-3020430236--3023930254-■3025530260-30270 30275-3027830352

Genomic Research BAC002 40074037-40424177-41904193-41994905-49075030 DNA from Genetics 5036-50465326-53307036-70377043-70557089-7091 BAC (CITB 7094-70997175-717773747392-73957407-74147421- 39316 BAC 74427444-74468466-84768710-87158802-88068839-

Library) 88418855-88598866-88689150-91519182-91939201- 92089213-92299231-92349258-92599277-92869291- 929693009312-931310324-1032510330-1033110349- 1035010443-1044410704-1071810723-1072410726- 1075010755-1076910773-1077710835-1083910842- 1086710879-1088011890-118911317613184-13188 13324-133251370113706-1373613751 13815-13818 1382313825-1383113854-138601496214981-14983 15110-1511415718-1572515838-15841 15847-15854 15910-15911 15939-1594315951-1596015964-15982 15991-1600016016-1601816024-1602717275-17277 17409-1743017637-1764117688-1769617699-17700 17748-17751 17771-1777617783-1778617805-17806 17813-1781717819-1782417828-1782917837-17841 17843-1784717871-1787317876-1787917888-17890 Tissue RNA Library SEQ ID NOS: origin Source Name

18010-18012 18024-1802818075 1808018090-18092 18139-1814418155-1815618161 1816818175-18190 18204-1820618211-1822318226-1825318255-18268 18275-1828418300-183221835418361-1837018382- 183921840421501-2151521563--2156721576-21646 21656-2165921718-217242172821752-2177222498- 2253322540--2254322603-2260622610-2261722658- 2266022698--226992270223029--2304523364-23370 23702-2370323820-2382624183-241932422724246- 2426824282-2428924300-2430324308-2431224319- 2432424345 -2435724375-2438324402-2443524449- 2446224610 ■2462324666-2468024686-2469324726- 2475424757 ■2477024794-2480124820-2483724846- 2486224871 •248882492424939-^■249482495124975- 2497725029^■2504825052-2506025078-2508425091- 2509225096■2510025112-2512625158-2517725193- 2521225228 ■2523825247-2524825359-2536325380- 2538125436•2544025450-2547025476-2548225496- 2550525515 •2552125537-2556125572-2559325598- 2560325633 •2565625660-2567225676-2568925703- 2584225847 •2589625901-2596525969-2601826077- 2607926105 •2611526121-2612626136-2613826172- 2617426185 ■2619426629-2665326691-2669726700- 2670327714-•2771728352-2835728489-2849028504- 2850728514-•2852128525-2853028533-2853928565- 2857128617-■2862728646-2865028679-2868028688- 2869428709-■2871928754-2876028768-2878128800- 2882128875-■2888128910-2891328917-2892628933- 2893528943-■2895828964-2897229013-2901929031- 2903829071-■2907529087-2908829096-2910129128- 2914129179-•2918629234-2924129290-2929529327 29446-294502946629468-2947229478-2948029488- 294912949929501-2951829544-2954629551-29574 29590-2960429606-2961029614-■2963729642-29678 29685-2971729722-2974529762-•2984129870-29875 29877-2992229926-2993729964-•2996829986-29990 29995-3000130006-3000730011-■3001930038-30058 3006130085-3009330098-3010030109-3013430145- 3014930165-3017730271-3027830283-3029530321 30343-3034730352

Genomic Research BAC003 1578-1585405242054899-49034908-49105031-5032 DNA from Genetics 504253346796-68007061-70647067-708770917094- BAC (CITB 709973747392-73957426-74427467-74768839-8841 39316 BAC 885988628899-89029145-91499152-918192599269-

Library) 930410443-1044410759-1076410819-1086811076- 1107713130-13132131831375113815-1383215112 15120-1512315718-1572515847-1585415944-15945 15966-1596815991-1601816021 1760917653-17667 17683-1768417734-1773617771-1777617783-17786 17791-1779917805-178061782717837-1784117843- 1784717862-1786818010-1801218075-1808018152- 1815418175-1818318211-1821418216-1821818230- 1823918255-1825818275-1837021304-2132521501- 215152172821788-2179922498-2252222525-22530 22582-2259822603-2260622610-226172270223029- Tissue RNA Library SEQ ID NOS: origin Source Name

2304523702-2370323993-23998 2422724231-24245 24255-2426824300-2430724333 -2434424370-24374 24397-2440124436-2443824481 -2449024495-24498 24615-2462324727-2473524749-2477024794-24801 24889-2489924928-2493824964-2497724989-24992 24995-2499925027-2502825041 -2504825052-25060 25093-2509525101-2511125147-2517025359-25363 25418-2543525450-254602547525542-2555025633- 2565025660-2566525676-2567925690-2570425737- 2579525821-2583525883-2589625912-2594325957- 2596525969-2601626050-2605826068-2608926100- 2612626133-2619426629-2665326700-2670428504- 2850728514-2851728531-2853928663-2866528673- 2867828688-2869428699-2870728728-2874228748 28754-2876028775-2878128815-■2882128944-28958 28964-289722901229096-2910129128-2914129420- 2942529446-2945029462-2946529468-2947229501- 2950729535-2954329564-2956829583-2958629590- 2959329606-2961029614-2962029642-2964329645- 2965429673-2968429686-2970329736-2973929746- 2976129763-298362987929892-2989529923-29935 29964-2997429980-3001930022-^■3006430084-30100 30109-3013430179-3018230236-■3023930256-30259 30334-3034030360 adult Invitroge BLD001 221329-330716-717796-7971123-11272570-2574 bladder n 2674-26863006-300833773461-346335603649-3653 37074213-42144266-42725134-51355480-54825919- 59215943-5945615464607534-75357924-79258010- 801282968430-843384659475-9476953195849726- 97279729-97319763-97679851-98529956-995710254- 10261 10881-1088310904-1090510980-1098511345- 1135011731-1173412371-1237312432-1243412829- 1283012978-1298113601-136021376015290-15291 15617-1561815623-1562616568-165691664217010- 1701417286-1729117330-1733217455-1745618405- 1840618730-18732187771878918802-1880418806- 1880718923-1892419225193621937019387-19389 19395-1940219407-1941119415-1941719422-19431 19706-1970819757-1976319926-1992919962-19963 19972-1998120066-2006820099-2011020122-20127 201302028920300-2030420333-203352036020366- 2036820495-204962050120505-2051020524-20535 20537-2054120625-2062820631-2063420676-20680 20747-2075120868-2087021021-2102321171-21174 2123621284-2129421351-2135221428-2143321447- 2145321495-2150021554-2155621955-2195721962- 2196622003-220062204722050-2205522080-22083 22161-2216422366-2237122553-2255822678-22679 22728-2272922857-2285822881-2288623007-23021 23252-2325623321-2332723682-2368623839-23840 23878-2388023999-2400124021-2402425085-25090 25323-2532525331-253332537326024-2602826341- 2634426460-2646326860-2686226880-2688127807- 2781127861-2786427890-2789228099-2810028286 28352-283572842428426-2842829718-2972130195- Tissue RNA Library SEQ ID NOS: origin Source Name

30199 bone Clontech BMD001 3035-3848-4955-7387-95105130-143156164-167 marrow 170-171173-181184197-200227-230240-250255-256 273-278301329-330332368-371419-420425-427483 504-506515-517546-549585-588607635656716-720 738-740792-795798-803832-836870-871891912919- 922934-935937-940942-944969-971981-9851001- 1003100510281044-104510471049-10501065-1066 1092-10941097-10981158-11611163-11641240-1241 13071314-131913211388-14011414-141714311467- 14691474148314991667-16681681-16871692-1693 1705-17141721-1722177718401853-18541862-1863 1879-1880190919141945-19461980-19821986-1987 19902015-2018203020362062-206720722086-2087 2102-21132222-22262272-22742404-240624312471- 24742550-25522554-255525762595-259626672773 28062828-28452871-28732886-28872923-29242926 2951-29552983-29862988-2989299330013006-3008 3037-30383144-31463151-31543205-320732283326- 33313355-335634333461-346334743508-35103515- 351735473555-355836353649-3653367636863693 3776-37773834-38353939-39413949-395540644151- 41554160-41624239-424042564422-442344504509- 45114515-45164555-45564562-45684726-47274751- 47554857-48614967-49685091-509451925279-5283 5335-5336539053935480-54865499-55015519-5521 5525-55265557-55605572-55735584-55865591-5592 5744-57475758-576158025805-58075907-59095919- 59215980-59846011-602160846095-60986403-6404 6442-64446452-64536773-67746791-679468526877- 68786884-68857187-71907209-72127216-72197245- 72487258-72637407-74147447-74497536-75417554- 75557561-75627580-75977604-76057615-76177622- 76237630-76367640-76477657-76597678-76877693- 76947701-770377297734-77367742-77437745-7751 7757-77597776-778377947806-78087815-78187924- 7925797779888059-80638077-80788098-81048132- 81518182-81838219-82208230-823282348247-8248 82508253-82578263-82658301-83068349-83508361- 83628368-83698383-83898416-84198449-84528466- 84768497-849985098539-85428576-85828607-8609 8698-87008736-87378741-87508777-87798917-8918 8986-89919002-90049040-90469100-91449196-9200 9306-93119321-93239329-93309336-93389340-9346 9355-93579362-93659375-93769429-94309456-9459 9475-94769487-948895319561-95629577-95789590- 95929603-96049617-96269743-97449759-97629780- 97839794-979598269828-98329835-98409854-9855 9857-98619902-99049923-99249929-993599539969- 99809984-99859989-99929997-1000910017-10019 10025-1003110033-1004010164-1016610175-10252 10273-1027410277-102781030610451-1045710480- 1048210513-1051510531-1053210537-1053810543- 1054910588-1059410607-1060810628-1063010638- 1064410890-1089310936-1093810954-1095610980- Tissue RNA Library SEQ ID NOS: origin Source Name

10985 11029-11031 11123-11124 111351114311157-

1119711295-11296 11300-11301 11308-1131011314-

113151131711339- 1134411399- 1140211431-11432

1143411467-11474 11476-114781149511505-11506

11531-1153211538 -1154011544-1154611561-11562

11586-1160211607 -11609116491165011669-11671

11711 •1171211731 1173411745 1174811766-11768

11780-1178211809 11835-11836118401184211974-

1197612006-12010 12046-1205612117-1211812131-

121321214012150- 1215112171- 1217212186-12189

12192-1219312202 -1220512229-122301223912241-

122441225812360- 1236112374- 1237712446-12450

12455-■1245912519 1254012543 ■1254612555-12559

12565-■1256812573 1257412590 •1259212615-12618

12642 -1264412655 -1265812666 ■1266712701-12705

1272312725-12727 12755-1276212785-1278712796-

1279812872-12881 12984-1298512997-1300413068-

1307013077-13079 13120-1312313556-1355913592-

1359513598-13600 13603-1360513609-1361213627-

1362813632-13633 13638-1364113873-1387513896-

1389813903-13906 13922-1392413931-1393313937-

1393813954-13956 14030-1403114048-1405314058-

1405914061-14064 14192-1419514228-1423514261-

1426314304-14305 14318-1434314347-1435114355-

1435614386-14387 14546-1454914552-1455514557

1460414607-14609 14650-14651146831478415003-

1500915013-15024 15151-1515715182-1518615195-

1519615218-15219 15222-1522415250-1525115257

15277 ■1527815290- •15291153261532815356-15357

15406 ^■1540715412- -15414155301553115563-15564

155881558915600- •1560115623 1562615699-15700

158691587015906- ■15907159881599016044-16046

160591606116075- ■16079161101611216160-16162

161681617116219- •16220162691628316290-16295

162971630016304- 163051630916403-1640716434-

1643916451-16452 16467-1646916517-1651916530-

1653116535-16538 16542-1654416576-1657716583-

1658516609-16611 16619-1662116636-1663716642

16649- 1665716672- 1667416704- 1670516714-16715

16828- 16831 16851- 1685316860- 1687016934-16939

17070- 1707117094- •171001711617120-1712217145-

1714617292-17296 17330-1733217335-1733917385

17454- 1745617489- 1749017924-1792617940-17942

17958- 1796218015- 1801618029-1803018055-18060

18069- 1807218157- 1816018371-1837218376-18377

18405- 1840618411- 1841818492-1849418500-18501

18516- 1851818520- 1852718536-1853718562-18581

18583- 1861718625- 1862818644-186501866118668-

1867018673-18677 18691-1869318717-1872618734-

1873718750-18758 18762-1876618777-1878018787-

187891879618802- 1880418806- 1880718825-18828

18836- 8841 18854 18856-1888018882-1888818899-

1890318908-18910 18915-18921 18934-1893518941

18955 1895918964- 1896918975 1897718983-18985

1900019019-19024 19029-1903519062-1906519071- Tissue RNA Library SEQ ID NOS: origin Source Name

1908519106-19118 19134-1913719153-1915819211- 19212192531925719260-1926219266-1926719283- 1929419316-1931719345-1934919351-1935419362 1937019380-1938419387-1940219413-1941719422- 1943119442-19445194611950319514-1952119560- 195621956619604- 196071962719672-1968719693 19698-1969919733 1974219749-19751 19759-19763 19768-19771 198101981819915-1991819921-19929 19938-1993919943-1994619953-1995719965-19968 19972-1998020029-2006320072-2007320087-20094 20099-2010220104-201122012020122-2012720146- 2014820161-2016420182-2018820208-2021420222- 2022520235-2024020244-202492025320257-20262 20265-20270202892029920308-2031520328-20330 20345-2035420393-2040020411-2044020456-20468 20472-2047420476-2047920482-2049420497-20498 2051020524-2053620542-2054520568-2057820599- 2060620614-2061920621-2062420629-2063420644- 2064520649-2065220676-2068020683-2068520688 20698-2070720714-2072520727-207342075220767- 2078720806-2081220822-2082320836-2084920855- 2086220865-2086720881-2088420897-2090020922- 2092520938-2094220948-2094920952-2095420963- 2097620985-2098821005-2100821058-2105921062- 2106621072-2107521112-2111421141-2114221145- 2114821176-2118021202-2120721225-2122621233- 2123521237-2127421277-2128021284-2129621343- 2135221377-2139721408-2140921434-2144521447- 2145021463-2146921485-2149121495-2150021516- 2153021532-2153321554-2155621587-2165521729- 2173321744-2174721892-2189421915-2191621955- 2196121967-2196821973-2197421978-2198222007- 2201522040-2204122060-2206122092-2209422141- 2214322160-2216422187-2219222195-2219822208- 2222422251-2225522261-2227622284-2228922292- 2230222310-2232222336-2234822358-2235922365- 223712237322377-•2238022383-2238822399-22404 22409-2241022440--2244822455-2246522531-22539 22571-2258122618--2262122634-2265122663-22664 22669-2267022675--226792269022696-2269722700- 2270122703-2270722728-227292273622749-22762 22768-2277022794--2279622805-2280922835-22845 22850-2285122857--2285822881-2288622909-22910 22925-229262295122955-2295722969-2297022974- 2297622990-2299423007-2302123046-2305023053- 2305523057-2305823063-2306723070-2307123074- 2307623098-2310123138-2314023206-2320923218- 2322223229-232332325123261-2326223343-23344 23379-2339023400--234082343323439-2345023470- 234742348623489-2349023492-2349323495-23496 23506-2351123514--2351823526-2353123543-23544 2359923675-2368123705-2370823718-2372123726- 237302376123771-2378023798-2379923802-23805 23827-23835238432384423871-2387523890-23892 24014-240182411624126-2414424495-2449825085-

Tissue RNA Library SEQ ID NOS: origin Source Name

12050-120561214012202-1220512245-1225312258 12309-12311 1236212374-1237712560-1256112615- 126181263712676-1267812701-1270512782-12787 12796-1279812871-1288112894-1289712997-12999 1352813592-1359513627-1362813885-1388713925- 1392614137-1413814261-1426314546-1454914604 1462614714-147171478414809-1481314822-14838 15151-1515715182-1518315290-1529115329-15331 15336-1534015356-1535715412-1541415631-15642 15652-1565615855-158571587815906-1590716053- 1605816403-1640716422-1642916443-1644516473- 164781660016636-166371664216652-1665516894- 1689617046-1705717105-1710617120-1712217397 17399-1740017940-1794218136-1813818286-18288 1840318405-1840618500-185011852718579-18581 18757-1875818767-1876918771-1877218777-18780 18802-1880418899-1890318934-1893918964-18969 1901819059-1906519074-1908019106-1911819156- 1915819211-1921219221-1922219228-1922919254- 1925519260-1926219283-1929419351-1935419362 1937019373-1937419380-1938419390-1939419401- 1940219418-1943119442-1944419461 19512-19513 19515-1952119672-1967319679-196821969319698- 1969919733-1973519743-1975119800-1980319813 19819-1982219919-1992319938-1994219958-19963 19972-1998020015-2001720029-2004320074-20079 20087-200942012020146-2014820167-2017120195- 2019720208-2021420222-20225202412025320257- 2026220265-2027020290-2029620425-2042620432- 2044620476-2047920485-2049420497-2049820502- 2050320524-2053620563-2056720599-2060620620 20631-2063420653-2066520727-207322078820816- 2081820853-2085420858-2086220897-2090020938- 2094220948-2094920952-2095420977-2098421058- 2105921122-2112721141-2114221145-2114821157- 2116921197-2119821202-2120721216-2123221236- 2124721277-2128021284-2129421398-2140221408- 2140921463-2146521480-2148221485-2149421647- 2165521729-2173321744-2174721892-2189821917- 2192121948-2195421978-2198722026-2202922070- 220732208922092-2209422120-2212722141-22143 22171-2217522208-2222422292-2229922310-22311 22319-2232222336-2234622358-2235922440-22448 22644-2265122663-2266422678-226792269022838- 2284222846-2284922899-2290023047-2305023064- 2306523070-2307123074-2307623085-2308623252- 2325623382-2338523415-234182343323473-23474 23510-2351123543-2354423555-2356523720-23721 2376123793-2379723802-2380523827-2383323903- 2390425307-2531025323-2532525410-2541326024- 2602826196-26199262662628026285-2629026310- 2631426341-2634426373-263742659526744-26745 26832268432687926888-2689027100-2710227127- 2712827142-2714627193-272002720627209-27213 27216-272182729427476-2747727498-2750027544- Tissue RNA Library SEQ ID NOS: origin Source Name

2754527562-2756327636-2763927649-2765627814- 2781527848-2785227861-2786428050-2805928358- 283602842428426-2842829117-291232924629271- 2928329309-2931429339-2934029354-2935729367 29378-293792944530150-30156 bone Clontech BMD004 65610485335-53368768-87709956-995712872-12881 marrow 15290-15291 18673-1867718719-1872219156-19158 2197822669-2267023046253732684327193-27200 2721827790-2779627989-2799028199-2820328286 bone Clontech BMD007 373-37441744362-43658320-83229531 15908-15909 marrow 16044-160461665217160-1716718771-1877219749- 1975119814-1981520698-2070722310-2231123070 25370-253722626627702-27706

Adult Invitroge CLN001 170-171398-399700-701723-72510041235-12371273- colon n 12791608-16101667-16681961-196224392471-2474 2599-26032687-27063306-330836063735-37363789- 37943949-39534213-42144221-42384515-45164666 7216-72197258-72637536-75417742-774380468074- 80788297-83008323-832583428420-84218430-8433 8497-84998512-85138917-89189343-93469391-9392 9475-94769506-9509953196889735-9738982810148- 1016010263-102641031110506-1050710531-10532 10904-109051146711473-1147411544-1154511612- 1163912006-1201012150-12151124351272312725- 1272712872-128811294313540-1354213581-13583 14137-1413814277-1428014546-145491460414784 15093-150951525715406-1540715530-1553115855- 1585716345-1634916558-1656216570-1657316602- 166081699517105-1710617335-1733917394-17395 17958-1796218269-1827018412-1841818495-18499 18719-1872218778-187801879618925-1893319045- 190481913419283-1929419316-1931719368-19369 19390-194021956619683-1968719736-1974219759- 1976319926-1992919933-1993719972-1998020103 20106-2012020161-2016420189-2019420200-20207 20231-2023420300-2030420321-2032420328-20330 20336-2033820393-2040020480-2048120485-20490 2050120524-2053520676-2068020806-2081220819- 208232086520890-2089620963-2097221208-21210 21225-2122621256-2126221284-212942133421377- 2139721428-2143321447-2145021516-2152821877- 2188021955-2195722003-2201522026-2203422204- 222112225022343-2234622358-2235922405-22408 22551-2255222700-2270122810-2281822838-22842 22952-2295323053-230552307023074-2307623212- 2321523358-2336023415-2341823827-2383324005- 2401126307-26309263272633726341-2634426359- 2636526373-2637426421-2642226858-2685927100- 2710227156-2715727304-2730527640-2764127812- 278152818628255-282612826928468-2848430141- 30142

Mixture of Various CTL016 373-374847-8484581-45827465-74667745-77469267- 16 tissues Vendors* 926813638-13641 14344-1434515277-1527815356- 1535718825-1882819049-1905319306-1930719370 mR As* 19706-1970820263-2026420345-2034820425-20426 Tissue RNA Library SEQ ID NOS: origin Source Name

20712-20713 20792-20797 22343-22346 22881-22886 26409-26410 27989-27990

Mixture of Various CTL021 1667-16684206-42084562-4568 5335-533653705919- 16 tissues Vendors* 59217256-72578434-84489984-998510588-10591 10870-10872109651214912714--1271515126-15129 mRNAs* 15530-1553115543-1554415576-155771665216894- 1689618371-1837218516-1851819049-1905319211- 1921219283-1929419401-1940219422-1943119706- 1970819736-1974219749-19751 198132028921155- 2115621208-2121022101-221072230922358-22359 2237322632-226332269023074--2307627544-27545 27593-2759427989-2799029332-2933730135-30140 adult BioChain CVX001 3048-4951-52144-145156180-181201221255-256 cervix 301329-330332395419-420425-427515-517524-525 530-531543-547551-552694-695716-720738-740832- 836901-904934-9351001-100310471185-11871259- 12651273-12791302-13031424-142914311453-1454 1456-1460147414831499-15021563-156415961667- 16681705-171418001866-18721887-18891899-1900 2015-2018203620622220-22272275-227623072375 2404-240624312471-247425162540-25412599-2603 2626-26422644-26512653-26582661-26732692-2694 271028022921-29302951-29552988-298930013090 3205-32073245-32463268-32693290-33033421-3422 3455-345634663507-35103512-35203526-35293531- 35343555-35583661-36703705-37063763-37653817 3949-39534122-41234160-41624221-42384469-4470 4599-46014663-46654692-46944762-47634785-4789 4795-48094819-482349575084-50855092-50945109- 51155124-512651335335-533653645483-54845581- 558356545766-57675932-59365973-59755980-5984 5997-60006011-602162846371-63766403-64046484 6486-64896624-662667796877-68816932-69386980 7192-71937209-72127216-72197279-72827294-7295 7350-73527534-75507576-75777601-760376097640- 76427671-76737678-76897693-76947701-77037728 7742-77437747-775177717778-77837787-77887794- 780178907924-79257976798880208025-80268070 8084-80858115-81218132-81418145-81568184-8186 8258-82628270-82768313-831483428347-83608368- 83708383-838984158422-84258430-84338466-8476 8504-85068543-855086888751-87538758-87598869 8917-89338982-89838986-899190219029-90359037 9072-90749196-920093059321-93239337-93389391- 93929427-942894449456-94589487-94889506-9509 9522-95259531-95349617-96269684-968797099729- 97319763-97679794-97959815-9820982698289854- 98569899-99019916-99209923-99249958-99619969- 99809989-99929997-1000910017-1001910038-10040 10175-1019610273-10274102771030610451-10453 10484-1048910498-1050310508-1051510523-10532 10539-1054210588-1059410873-1087510877-10878 10886-1088910901-109021097911013-1101711028- 11031 11147-1115611217-1121911252-1127311300- 113031131711345-1135011423-1142611431-11432 Tissue RNA Library SEQ D3 NOS: origin Source Name

11468-1147211476-1147811505-1150611538-11540 11544-1154611553-1155411584-115851160911715- 1171611731-1173411749-1175011761-1176311777- 1177811803-1180411835-118361184211873-11875 11886-1188911921-1193012011-1201312042-12044 12121-1212612206-1220812215-1222512280-12282 12371-1237712420-1242912470-1247112519-12540 12555-125591256412593-125961259812601-12602 12606-126091264012668-1266912682-1268312707- 1271112720-1272312760-1276212785-1278712805- 1280612829-1283012832-12834129051294312978- 1298112984-1298513077-1307913560-1356213584 13592-1359513606-1360813645-1365113761-13795 13954-1395614023-1402614058-1405914192-14195 14261-1426314304-1430514546-1454914575-14604 14628-1463514645-1464814684-1468514702-14704 1478414789-14791 14866-1487015025-1506915182- 1518315190-1519115243-1524815292-1529315326- 1532815406-1540715486-1549015545-1554615588- 1558915699-1570015855-1585715863-1586815880- 1588315961-1596315988-1599016110-1611216141- 1614316145-1614616226-1622716299-1630016484- 1648616494-1649516508-1651116542-1654416579- 1658216609-1661116636-1663716643-1664816652 16686-1669316828-1683116851-1685316899-16900 16934-1693716993-1699417038-1704117046-17057 17268-1727417330-1733217335-1733917366-17368 17441-1745017454-1745617525-1752717924-17926 17958-179631800718015-1801618029-1803018069- 1807218136-1813818400-1840218412-1842018423- 1842518533-1853418587-1861618644-1865018680- 1868118691-1869218750-1875618759-1876018767- 1876918771-187761878918802-1880418806-18807 18811-1881318825-1883418836-1883818842-18845 1885418857-1888018894-1889618899-1890318910 18915-1891818923-1893318936-189391894118944- 1894518947-1895018960-189691897518989-18990 19029-1903519045-1904819059-1906519068-19080 19084-190851909019096-1910119106-1911819142- 1914719154-191551915919209-192101922519273- 1927419306-19307193621937019373-1937919387- 1939419401-1940219415-1941719422-1943419441- 1944419454-1945519458-19461 19484-1948619488- 1949319515-1952119526-1953119580-1958219604- 1960719656-1965719667-1966819683-1968719693- 1969819727-1973519749-19751 1975619759-19767 19804-1981519921-1992519933-1993919953-19957 19962-1996319965-1996719969-1997119981 19995- 2001720029-2004320048-2005220064-2006520069- 2007320080-2009820106-20112201202013020151- 2015420161-2016420167-2017920182-2018820200- 2021420231-2024120243-202492025320257-20264 20279-202802028820299-2030720328-2033020345- 2035420393-204072041120415-2042020427-20431 20441-2044620452-2045520469-2047920514-20520 Tissue RNA Library SEQ ID NOS: origin Source Name

20524-2054520559-2056220569-2057820621-20624 20649-2066520676-2068120683-206852068820698- 2070720718-207342075320758-2076620792-20812 20819-2082120836-2084320858-208622087120897- 2090020922-2092620929-2093220938-2094320948- 2094920963-2098420992-2099420999-2100421021- 210232102621062-2106621069-2108721101-21104 21122-2112721141-2114221145-2115121171-21174 21194-2119621213-2121521227-2123221263-21280 21284-2129421297-2129821351-2135221410-21414 21428-214332144621463-2146521467-2146921480- 2148221485-2150021647-2165521891-2189421917- 2192121925-219282193921955-2195721967-21968 21971-2197822000-2200222007-2201522020-22025 22030-2203422040-2204122050-2205522074-22076 22090-2209122135-2213822152-221562216022165- 2216822176-2218422187-2219222195-2219822208- 2221122218-2222422261-2228922292-2230222310- 223112231822333-2234222347-2235022357-22359 22365-223712237322405-224102249522534-22539 22553-225602256922607-2260922622-2262422634- 2264322653-226542269022700-2270122737-22739 22741-2274222750-2275922768-2277022794-22796 22810-2281622833-2283422843-2284522854-22856 22904-2290622952-2295322955-2295722969-22970 22978-2297922991-2299423007-230212304623053- 2305523059-2306023064-230672307123080-23083 23117-2311923125-231362314123206-2320923212- 2321523242-2324423251-2325623329-2333723356- 2335723364-2337023382-2338523402-2341123415- 2341823428-2343023486-2348723489-2349023492- 2349323515-2351823532-2353923543-2354423555- 2356523600-2362423675-236812370423726-23730 237612377023806-2380923820-2383323836-23837 23839-2384223867-2387523878-2388023990-23992 24021-2402424035-2404024042-2404324126-24144 24147-2415825085-2509025334-2533725347-25358 25376-2537725383-2540126024-2602826209-26213 26225-26231262522626626270-2627226285-26290 26294-2630226316-263212632726341-2634426358 264312645326460-2646426469-2647026596-26601 26676-26677266872674226748-2675426788-26789 26819-2682626842-2684326853-2685426873-26875 26980-269842698827012-2701427040-2704327052 27067-2707027100-2710227173-2717427177-27178 27193-2720027269-2727027348-2735327478-27479 27510-2751127520-2752127544-2754527557-27559 27600-2760127635-2764127662-2767227729-27739 27755-2775627781-2778827790-2780427861-27864 27890-2789227940-279472797027981-2798227989- 2799028008-2801128045-2804728095-2809628099- 2810028108-2812128157-281582816028199-28203 28255-282612828628311-2831328573-2857828768- 2877429117-2912329278-2928329321 -2932629354- 2935729409-2941629938-2994929960-2996330141- Tissue RNA Library SEQ ID NOS: origin Source Name

3014230150-3015630184-3019930218-3022030233- 3023530240-3024230361-30368 diaphragm BioChain DIA002 5581-55837978-79838187-82008349-83509072-9074 9366-936811123-1112411745-117481654619800- 1980319972-199802013020437-2044020554-20557 20614-2061520676-2068022212-2221723252-23256 25340-253412537326876-26878 endothelia Stratagen EDT001 19-2084124-125156158-159164170-171180-181192 I cells 197-200227-230251-252255-256260301307-308315- 316319-323329-330358-359373-374395414-418425- 427461-465505515-519524-525534-535553-554557- 559576-578619-620635656706-707712716-722832- 836845-848880-885891913919-922981-9851004- 10051044-104510471074-10871092-10981101-1103 1123-11271158-11611203-12041235-12371240-1241 1259-12661268-128913071310-131113341414-1417 14311453-14541467-1469148314991569-15731618 16201667-16681678-16801705-17141721-17221778- 17791792-17941910-19131925-192719671971-1974 19771986-19872015-2018202220722202-22032272- 227623062404-240624092432-24352471-24742570- 25742597-260326252724-27262886-28872903-2904 2923-292429262934-29352939-29432975-29772983- 298630013006-30083078-307930903107-31083115 3226-322832413255-325932663276-32773304-3309 3336-333733653374-33773421-342234333448-3450 3455-34563464-34653477-34783504-35073518-3520 35253555-355836063624368636933781-37843789- 37943834-38353949-39534067-40724080-40824084- 40854122-41234160-41624213-42144244-42474343- 434644504469-44824486-44884526-452745424555- 45564562-45734581-45824600-46014612-46144651 4785-47894857-48614966-49684971-49745089-5090 5092-509451925335-53365384-53865572-55735580- 55835594-5602565857005714-57165802-58125820- 582358805885-58975907-59095939-59415980-5984 5986-59886140-61436166-61686186-618963016342- 63436403-64056551-65676585-65926627-66286657- 66616669-66706791-67946832-685068526932-6938 7056-70577209-72127216-72197285-729573747415- 74207447-74497536-75417557-75597580-75977601- 760576097615-76177620-76217630-76367643-7647 7654-76557657-76657671-76737681-76877693-7696 7701-770377297742-77437745-77517784-77867794- 7797782178907906-79127921-79257946-79487972- 79757978-79837990-7992799480028010-80128017- 80198043-804480708090-80938117-81218152-8159 8163-81738182-81838187-82008211-82138216-8220 8227-822982348247-82488253-825783428347-8360 8363-83648368-837084158449-84528497-84998504- 85058507-85098512-85138539-85428554-85558584- 85878607-86098688-86908754-87578760-87618777- 87798936-89388986-89919002-90049013-90209038- 90459072-90749084-90859196-92009260-92639306- 931193169321-93239331-93339337-933893829391- Tissue RNA Library SEQ ID NOS: origin Source Name

93929445-94489454-94559475-94769478-94819487- 94909522-95259531-95349546-954995589561-9566 9586-95899617-962696599664-966596729682-9683 9729-97319735-97429757-97589763-97679794-9795 9815-982098269828-98349851-98529854-98559896- 98979902-99049923-99249927-992899539960-9964 9993-999610033-1004010167-1019610273-10274 1027710281-103041030610326-1032810451-10453 10480-1048210508-1051510537-1053810595-10599 10603-1060810612-106231062710638-1063910881- 1088310901-1090210913-1091810936-1093810963- 1096511035-1103711123-11124111351114311217- 1121911295-1130511314-1131511339-1135011359- 1136911372-1139611405-1140711431-1143211434 11465-1146611468-1147411476-1147811495-11498 11538-115401154611579-11606116091169611711- 1171211715-1171611731-1173411737-1175011780- 1178411786-1178811803-1180411835-1183611840 1184211873-1187511901-1190511941-1194411947- 1195012002-1200512050-1205612112-1211412121- 1213712150-121511217312190-1219112237-12238 12256-1225712259-1226212285-123021236112374- 1237712398-1240112446-1245012470-1247112477 12486-1254012545-1254612555-1255912590-12592 12615-12618126371264012642-1264412666-12667 1267012707-1271112714-127151272312755-12762 12796-1279812805-1280612829-1283012978-12981 12997-1299913077-1307913576-1357913581-13583 13592-1359713603-1360813629-1363113645-13651 13796-1379713873-1387513918-1391913999-14003 14044-1404514054-1405614058-1405914130-14131 14141-1414214170-1417214175-14181 14192-14195 1420614216-1422614236-1423814261-1426314299- 143011434614498-145011460414607-1460914681- 1468214684-1468514714-147171478414802-14808 14866-1487015013-1502415071-1507415093-15095 15165-1517015172-1517315182-1518315190-15191 1522015222-1522415233-1523615243-1524815250- 15251 1525715277-1527815283-1528615290-15291 15298-1530315323-1532415336-1534015356-15357 15406-1540715412-1541415457-1545915530-15535 15545-1554615548-1555015563-1556415576-15577 1558515588-1558915614-1561615699-1570015855- 1585715869-1587015880-1588315890-1589515988- 1599016044-160461605916075-160791608216096- 1609916103-1610416110-1611216141-1614316168- 1617116174-16176162371623916371-1637216388- 1639116422-1642916461-1646616479-1648116501- 1650416508-1651116536-165391654516563-16573 16576-1657716583-1658516600-16601 16609-16611 16619-16621 16628-1663716642-166481665216675- 1668216702-1670516771-1677216804-1680716833- 1684216851-1685316873-1687416894-1689616934- 1693717070-17071 1711417120-1712217131-17132 1724217284-17291 17297-1730617330-1733217335- Tissue RNA Library SEQ ID NOS: origin Source Name

173391739817454-1745617571-1757417937-17938 17958-1796217964-1796818015-1801618029-18030 18055-1806018136-1813818376-1837718407-18418 18421-1842518427-1842918492-1849418500-18501 18516-185181852718533-1853418536-1853918617 18624-1863718644-1865018655-1865818671-18677 18691-1869318717-1872618730-1873218745-18756 18759-1876118771-1878018784-1878918796-18807 18811-1881318822-1882818855-1888018882-18888 18894-1889618899-1890718919-1892118925-18939 189411894618964-1896918975-1897718989-18990 189961901219025-1903519045-190481905519057- 1906519071-19083190901913419138-1914019163- 1920119207-1921019213-192201922419251-19252 19254-1925719260-1926319266-192671927319295- 1929619306-1930719316-1931719345-1934919351- 1936019362-1936419368-1937019373-1937419380- 1938919401-1940219415-1941719422-1943419441- 1944419458-1946319484-194861950319514-19521 19530-19531 1953619560-1956219566-1957319586 19598-196011962519656-1965719659-1966119667- 1966819670-19671196881969319698-1969919727- 1974819759-197631977219800-1980319810-19815 19819-1982219855-1985619915-1991819921-19929 19933-1994619953-1996119965-1996719972-19981 20015-2001720026-2002720029-2004720066-20068 20072-2007920087-2009420099-2010220106-20110 20114-2012020122-201272013020133-2013620146- 2015420161-2016420167-2017920182-2019420200- 2021820222-2022520235-2024120250-2025220257- 2026220265-2027020274-2027820281-2028220289 20328-2033020345-203542036020393-2040020406- 204072041420418-2042620432-2045120456-20474 20476-2047920482-204942050120505-2051020521- 2053520542-2054520548-2055720563-2056720575- 2057820614-2061920625-2063420644-2064820653- 2067120688-2069220698-2070720710-2071120718- 2073220752-2075320758-207672078820806-20821 20824-2084320853-2086320879-2088020897-20900 20924-2092520927-2092820948-2094920955-20962 20973-2098821005-210082101521026-2103121060- 2106621069-2107121076-2108721101-2110421122- 2112721137-2114021145-2115121171-2117421176- 2118021197-2119821202-2120721225-2122621233- 2123521241-2124721256-2127421277-2128021284- 2129821301-2130321351-2135421359-2136021377- 2139721434-2145021467-2146921480-2148221495- 2150021516-2153021647-2165521718-2172421729- 2173321877-2188021892-2189421911-2191221915- 21921219242193921951 -2196621978-2198722000- 2200622019-2202522040-220442204722060-22076 22080-2208322092-2209422117-2211922128-22138 22141-2214322160-2216422169-2217022187-22192 22195-2219822200-2220322208-2221122225-22226 22251-2225222265-2228922292-222992230922314- Tissue RNA Library SEQ ID NOS: origin Source Name

2231722319-2233222336-2234222349-2235022358- 2235922365-223712237322377-2238022383-22388 22434-2243522455-224652249522531-2253922553- 2255822571-2258122607-2260922622-2262422634- 2263622644-2265122653-2265422663-2266722678- 226792269022700-2270122703-2270622726-22727 22730-2273122750-2276222768-2277022781-22782 22794-2279622810-2281622821-2282222852-22856 22870-2287422904-2290622909-2291122925-22938 22948-2295322955-2296122974-2297622978-22979 22991-2299423007-2302123046-2305223057-23060 23063-2306723070-230712308423098-2310123112- 2311623120-2313623138-2314123201-2320223218- 2322223237-2324123251-2325623258-2326323279- 232812333823343-2334423358-2336023379-23390 23415-2341823448-2345023470-2347223475-23479 23486-2348723489-2349023492-2349323499-23505 23508-2351123526-2353123555-2356523673-23674 23700-237012370423718-2371923726-2373623760- 2376123765-2376723771-2378023793-2379923806- 2380923827-2383323839-238482388223890-23892 23941-239562395923990-2399223999-2400124014- 240182402524029-2403324035-240402405624120- 2412924772-2477425085-2509025213-2521925293- 2529725307-2530825319-2532125334-2533525338- 2534125355-2535825370-2537525416-2541725534- 2553626024-2602826196-2619926205-2620626237- 2623926248-262522626626273-2627926285-26290 26316-2632126327263292633726339-2634026361- 2636526373-2637426409-2641126460-2646326469- 2647026559-2656026596-2660126678-2668026719- 26726267422674626748-2675626804-2680626843 26853-2685726860-2686226876-2687926980-26984 2703527040-270432705227067-2707027074-27077 27122-2712627133-2713427150-2715127173-27174 27193-2720227206-272132721827240-2725127254- 2726527269-2727027273-2727427281-2728727304- 2730527372-2737527439-2744027493-2749527501- 2750727510-2751127520-2752127544-2754527548- 2754927574-2758427586-2758727600-2760627636- 2764127649-2765427662-2767227698-2770627726- 2773927755-2775627814-2781827861-2786427890- 2789227896-2792727948-2796927989-2799028045- 2804728050-2805928095-2809628099-2810028105- 2810728138-2814028142-281562818628263-28268 2828628290-2829228311-2831328315-2831628361- 283622842428426-2842828468-2848428573-28578 28732-2874229117-2912329278-2928329304-29314 29317-2932029328-2933729339-293402935829406- 2941629418-2941929432-2943529614-2962029718- 2972129950-2995329960-2996130141-3014230150- 301563020530221-3022330361-30368

Genomic Genomic EPM001 880-882 1 142- 1 152 3281 -3282 4007-4052 4177 4180- clones DNA 4190 4899-4907 491 1 -4917 4921 -4922 4928 4945 4997- from the from 5023 5031-5035 5037 5042-5046 5202-5239 5241 5361 Tissue RNA Library SEQ ID NOS: origin Source Name short arm Genetic 6796-6800701970267028-70297031-70357041-7055 of Research 7058-70917094-709971737175-71777371-73727374 chromoso 7392-73957407-74147421-74257444-74457469-7472 me 8 74758466-84768710-87158800-88138820-88418850- 88538855-88598862-88688877-89029047-90489081- 90859088-90999145-91499152-918191939205-9208 9213-92299231 -92349239-92599269-92769291-9299 9314-93159962-996410320-1032510329-1033110334- 1034210443-1044410679-1068310723-1072410726- , 10741 10748-1075010755-1075710759-1076510775- 1077710822-1083010834-1086710879-1088011058- 1106211416-1141811890-1189112218-1222013000- 1300413127-1312813130-1313613142-1317413176- 1319013307-1331113316-1331813324-1333713425- 134951367713681-1368213695-1369813706-13707 13712-1372113723-1372713730-1375113815-13821 138231383113854-1386014876-1487714962-14977 15120-1512315593-1559915705-157081571015718- 15741 15773-1577415780-1578815815-1581715826 15828-1583115836-1583715842-1584515915-15916 15939-1594315946-1595615964-1597615978-15980 15991-1599616001-1601816047-1605216258-16268 1723217366-173681757917593-1759817602-17609 17637-1766717673-1768417688-1770017703-17707 17722-1772417734-1778917791-1779917805-17806 17818-1782417828-1782917836-1784917857-17861 17864-1786817871-1787317876-1787917881-17885 17888-1789417902-1790417909-1791618008-18012 18024-1802818066-1806818075-1808918139-18151 18155-1815618161-1816218166-1816818186-18187 18197-1820318207-1821418216-182181822618230- 1823918242-1824518247-1825318255-1826318275- 1827718286-1828818291-1829418308-1832918335- 1834918353-1835918365-1837018380-1839218398 21304-2132521501-2151521534-2155321557-21563 21568-2164621656-2171121718-217242172821738- 2174321748-2175121788-2179921863-2187622523- 2253322582-2258822596-2260222605-2260622610- 2261722658-2266022817-2281823029-2304523532- 2353923993-2399824183-2419624199-2422524227- 2426824274-2431224319-2432424333-2438724397- 2447024473-2449024607-2463124646-2466524681- 2470224722-2477024775-2481624820-2486224869- 2492324925-2495124964-2497724985-2506025093- 2511125114-2514625158-2517025178-2521225220- 2522425228-2524625249-2525325359-2536325366- 2536725450-2547025475-2549425506-2551425539- 2556125572-2559325598-2560325633-2565625660- 2567925690-2580025807-2584725853-2587525878- 2588025883-2589625906-2595125957-2596525969- 2601826050-2605326077-2608626090-2612026127- 2612926133-2614326157-2618426189-2619426219- 2622026237-2623926629-2665526691-2669427677- 2768827714-2771727809-2781128352-2835728489- 2851028514-2854828556-2857228579-2862728635- Tissue RNA Library SEQ ID NOS: origin Source Name

28719 28732-28799 28809-28824 28831-2883628841-

2889628901-2895828964-2897229012-2903829047-

2904929071-2908129087-2910129104-2910729116

29128-^■2914129147-■2915129154--2915629159-29168

29179- 2918629221-■2924129290--292952932729368-

2936929420-2942529446-29450294612946629468-

2947229486-2948729492-2949829501-2954629551-

2956829583-2960429606-2961029614-2962929631-

2963729645-2965429660-2967829686-2970329708-

2971429722-2973929741-2974229746-2983629842-

298712987629879-2991129919-2993529964-29968

29980- 2998129986-2999429998-^■3000130022-30031

30036-•3006430084-•3010030109--3013430167-30177

30179- 3018230236-•3023930253-■3027830281-30295

30297- 3030030310-•3031730321-■3032730330-30337

30342- 3034730352-30360

Genomic Genomic EPM003 1604-16074008-40364049-40514180-41904923-4928 clones DNA 52425326-53307067-708770937175-71777426-7442 from the from 74758807-88138822-88358839-88468850-88538855- short arm Genetic 885888628870-887388768892-88989088-90999152- of Research 91819205-92089226-92299239-925792599294-9296 chromoso 9301-93041034310347-1035010443-1044410726- me 8 1072710759-1076410775-1077710842-1086713000- 1300413307-133081334113422-1342313425-13495 13730-1373513737-137501382314981-1498315110- 1511115120-1512315718-1572515815-1581715827- 1583315939-1594315966-1596815991-1599616016- 1601817606-17608177011783617857-1787417876- 1788717891-1789418097-1813418145-1815118155- 181561818418255-1826318291-1829218335-18340 1835421549-2155321573-2158621660-2171121728 21788-2179921863-2187622525-2253022596-22598 22605-2260622658-2266024187-241932422724358- 2436924436-2443824473-2448024607-2460924722- 2472624749-2477124795-2481624869-2487024908- 249232496325017-2504825052-2506025078-25084 25091-2510025114-2513925147-2517025187-25192 25247-2524825359-2536325461-2547025489-25494 25515-2552125539-2555025572-255932562325633- 2565025676-2567925728-2573225741-2578225883- 2588925901-2590225906-2591125957-2595925969- 2601626059-2606726136-2613826150-2615226157- 2616426629-2665327943-2794728522-2852428533- 285392857128607-2861428646-2865028709-28719 2874828754-2876028768-2878128809-2881428822- 2882428882-2888728914-2891628933-2893529012 29031-2903829071-2908229087-2909529104-29107 29116-2914129154-291582932729446-2945029492- 2949429590-2960529614-296202963029645-29654 29663-2967829686-2970329741-2974229763-29836 29842-298692987929902-2991129964-2996830002- 3000330048-3005230084-3009330118-3013430145- 3014930167-3017730179-3018230201-3020430236- 3023930254-3025530275-3028130343-30347

Genomic Genomic EPM004 3281-32824924-492849454997-50205043-50445243- Tissue RNA Library SEQ ID NOS: origin Source Name clones DNA 52457061-70647067-708771677170-71777426-7442 from the from 7474-74758466-84768807-88138822-88388877-8902 short arm Genetic 9047-90489152-91819217-92259231-92339269-9286 of Research 9291-92939314-931510443-1044410446-1044810679- chromoso 1068310775-1077710842-1086713000-1300413145 me 8 13177-131781318913309-1331113328-1333013424- 1349513497-1349813719-1372113730-1373613815- 138181382313854-138601583415836-1583715842- 1584615946-1595015966-1596816006-1601817232 17585-1758617650-1765217674-1767617748-17751 17763-1777017850-1785117888-1792118075-18080 18097-1813418139-1814418161-1816218264-18268 18275-1827718286-1828818300-1830718323-18333 18353-1835418361-183701840419093-1909521549- 215532156321573-2158621661-217112172821780- 2187622523-2253022586-2258822605-2260623820- 2382623993-2399824187-2419324260-2426824333- 2434024358-2436924426-2443524449-2447024473- 2448024610-2461424681-2469324703-2471524757- 2477024775-2477924794-2480124827-2483724846- 248542495125005-2502625052-2506025096-25100 25112-2511325158-2523825247-2525625450-25460 25471-2547425515-2552125539-2554125551-25561 25673-2567925690-2570225716-2571825737-25782 25796-2580025807-2582025836-2584725853-25865 25901-2590225986-2601626077-2608626090-26099 26116-261202621626273-2627926629-2665327677- 2768828531-2853228540-2854728558-2856428617- 2862728695-2869828709-2872728768-2878128809- 2882128831-2883628841-2884728872-2887428901- 2890928933-289352894329031-2903829159-29170 29179-291972920329221-2923329290-2929529420- 2942529481-2948529488-2949129508-2951829529- 2953429551-2956329587-2958929631-2963729763- 2983629842-2986929872-2987529885-2989129936- 2993729980-2998129991-2999430059-3006030084- 3008730109-3011730179-3018230201-3020430271- 30274 esophagus BioChain ESO002 4581-45824810-48115335-53368466-84769475-9476 15588-155891665218781-1878319943-1994621277- 212802684327100-271023020530233-30235 fetal brain Clontech FBR001 202-203847-8481097-10981259-12621721-17222404- 24062951-29555276-527858027902-79038377-8379 9196-9200944398289969-998010273-1027410326- 103281087610976-1097811024-1102511476-11478 11731-1173411803-1180412127-1212812150-12151 13107-1311713581-135831460417366-1736817455- 1745618627-1862818964-189691901819211-19212 1936219387-1938919401-1940220328-2033020345- 2034820554-2055721256-2126621377-2139721434- 214392197822141-2214322200-2220322637-22643 22899-22900232222370923893-2390225416-25417 26307-2630926329268312711327245-2724627386- 2738927976-279822818630141-30142 fetal brain Clontech FBR004 1667-166819902114-2115238948185980-59847542- Tissue RNA Library SEQ ID NOS: origin Source Name

75507699-77007757-77597986- 79878274-82768307 8588-85979049-90629862-986310480-1048211018 11308-1131012581-1258215397-1539819074-19080 19306-1930719800-1980320087-2009420104-20105 2024120415-2041720491-2049420563-2056720607- 2061220698-207072086520897- 2090021105-21111 2193922087-2208822144-2215122625-2262823007- 2302123526-235312371025347-2535425534-25536 2632926347-2634826383-263852684328148-28156 2842429954-29955 fetal brain Clontech FBR006 3-4168192197-200240-250324-325329-330362373- 374464-465532-535553-554576-578613-614713-715 847-848912927934-935949-9501044-10451071 1097- 10981203-12041235-12371273-127913041411-1413 1488-14891569-15701591-15921678-16871705-1714 1923-192419772023-2029214522282231-22532259- 2264235623752396-24002404-240624312437-2439 24752525-25282599-26032656-26582663-26652707- 27162720-27322734-27452770-27722808-28112871- 28732889-28912931-29352951-2955300130393080- 30813105-31063205-320732133261-326333773477- 347835073512-35143555-355835963671-36733683 3687-3691369337083711-37123729-37303781-3784 38093939-39413949-39534055-406140654091-4100 4122-41264137-41394209-421045424562-45684574- 4576466746734683-46844720-47254765-47734795- 48094845-48514854-48564870-487149484964-4965 49705136-5137513952465251-52525291-52945392 5532-55335557-55605567-55685594-56025744-5747 6011-602161376155-61616209-62116217-62226378- 63886393-63956406-64106452-64536488-64906513- 65156542-65436669-66706674-66756775-67787194- 71977220-72277236-72377264-72667350-73527364- 73657426-74427452-74607482-75177557-75597580- 75977604-76057630-76367657-76597695-76967745- 77467778-77837787-77887898-7900794679577986- 798779938013-801680798137-81418152-81568162- 81738187-82008204-82058211-82138230-82338247- 82498263-82658301-83108313-83148320-83228335- 83368347-83488351-83608371-83748383-83898420- 84218426-84288457-84588461-84658497-84998506 8512-85138588-85978607-860986888733-87358758- 87598762-87668919-89338936-89458974-89778982- 89838998-90049029-90309043-904590689306-9311 9380-93819510-95189529-953195859603-96049729- 97319763-97679799-98009808-98129829-98329929- 99359958-99599969-99809989-99929997-10009 10015-1001610033-1003710449-1045310477-10478 1048310513-1051810523-1053010537-1053810603- 1060810638-1063910780-1078210901-1090210931- 10933109651102611081 11123-111241131711345- 1135011465-1147211476-11478115771167211711- 1171211731-1173411739-1174011803-1180411934 12102-1211012117-1211812131-1213212202-12208 12215-1221712226-1222812333-1233412374-12377 Tissue RNA Library SEQ ID NOS: origin Source Name

12403-1240512437-1243812441-1244512451-12453 12486-12518125981272312894-1289713503-13512 13529-1353513585-1358813796-1379713838-13844 1389813994-1399714023-1402614044-1404514061- 1406314127-1412814137-1413814173-1417414209- 1421514236-1423814261-1426314349-1435114391 14410-1441214605-146091462614681-1468214684- 1468914694-1470114709-1471314988-1499314999- 15001 15019-1502415253-1525515257-1525915300- 1530115358-1535915381-1538515397-1539815406- 1540715454-1546115491-155251556715855-15857 15861-1586615890-1589515902-1590316022-16023 16060-1606116110-1611216115-1611716123-16128 16130-1613216219-1622016365-1636616434-16437 16465-1646616470-1647216496-1649716553-16556 16570-16573165991662316628-1663116636-16637 16643-16651 16714-1672316836-1684216860-16870 16903-1690916938-1694116962-1696516996-16999 17002-1700917018-1702317026-1702817067-17069 17105-171061711517120-1712217264-1726717286- 1730617359-1736017372-1737417571-1757417685- 1769617857-1786117927-1792917949-1795217958- 1796218001-1800418038-1804218136-1813818411 18427-1842918500-1850118516-1851818536-18537 18625-1862618644-1865018655-1866018691-18692 18719-1872618730-1873218771-187721878918806- 1880718829-1883418857-1888018882-1888818925- 1893318944-1894518947-1895018955-1895918964- 1896919005-1900919029-1903519045-1904819055 19071-1907319081-1908319096-1910119138-19140 19159-1916119211-1921219266-192671927419295- 192961935019362-1936419375-1937919385-19389 19422-1943119442-1944419447-1944819526-19529 19548-1955319566-1957319598-1960219659-19661 19670-19671 1969319706-1970819733-1973519814- 1981819933-1993919948-1995019953-1996319972- 1998020029-2004320069-2007120095-2010220120- 2019420198-2022120235-2024020244-2025220265- 2027020274-2027820321-203242041420437-20440 20447-2045120456-2047120476-2047920505-20509 2054720559-2056820607-2061220621-2062420631- 2063420646-2064820676-2068120686-2068720698- 2070720718-2072520727-2073420747-2075120754- 2075720801-2080520827-208432086520929-20932 20952-2095420957-2096221062-2106621112-21114 21141-2114221157-2116921176-2118021197-21198 21213-2121521229-2123221253-2125521263-21266 21326-2133321353-2135421377-2139721410-21414 21454-2145721480-2148221495-2150021554-21556 21647-2165521712-2171721729-2173321744-21747 21881-218852189121899-2190421911-2191221915- 2192421951-2197421978-2198221995-2200222007- 2201822020-2202922035-2203622045-2204622056- 2205922062-2206922074-2207622080-2208322092- 2209422108-2211422128-2213422141-2214322152-

Tissue RNA Library SEQ ID NOS: origin Source Name

81368152-81598182-81838187-82008227-82328253- 82578335-83368347-834883708404-84068487-8488 8497-84998502-85038607-86098689-86908762-8766 8917-89189013-901790369454-94589475-94769506- 950995319535-95379586-95929594-96029617-9626 9664-96659682-96839729-97319735-97389743-9754 9757-97589784-9785982698289851-98529854-9855 9896-98979909-99129927-99289956-99579969-9980 10017-100191030610451-1045310477-1047810520- 1052210603-1060610638-1063910780-1078210881- 1088310899-1090210913-1091410919-1092211135 1114311212-1121611228-1122911306-1130711345- 1135011538-1154011603-1160611680-1169611711- 1171311731-1173411739-1174011761-1176311772- 1177411803-1180411843-1185511873-1187512040- 1204112150-1215112194-1219612206-1220812430- 1243112455-124591263712755-1275912803-12804 12898-1289912997-1299913552-1355513585-13588 13592-1359513796-1379713918-1391913999-14003 14046-1404714123-1412814137-141381460414709- 147131478414822-1483815019-1502415182-15183 15233-1523615257-1525915290-1529115298-15299 15326-1532815486-1548915496-1552515576-15577 15588-1558915623-1562615867-1586816115-16117 16174-1617616371-1637216387-1639116576-16577 16614-166181662316643-166481679916851-16853 16894-1689617026-1702817038-1704117120-17122 17131-17132172421745417958-1796218001-18003 18136-1813818412-1841818427-184291862418655- 1865818750-187561878918806-1880718842-18845 18894-1889618904-1890518919-1892118947-18950 18964-1896918976-1897718989-1899018993-18996 19062-1906519068-1907019207-1920819266-19267 19308-1930919316-1934219345-193501936219380- 1938919407-1941119422-1943419441 19458-19460 1956619659-1966119667-1966819670-1967119699- 1970519709-1971019759-1976319810-1981319933- 19937199391995019962-1996319965-1996719972- 1998020099-2010220122-201272013020137-20145 20161-2016420167-2017120198-2020720215-20218 20231-202342024120363-2036520415-2041720452- 2045520469-2047120497-2049820514-2052020524- 2053520537-2054120575-2057820607-2061220625- 2062820631-2063420646-206482068120816-20818 20836-208432086520927-2092821005-2100821076- 2108721101-2110421137-2114021153-2115421171- 2117421229-2123221253-2125521284-2129421351- 2135221410-2141421447-2145021454-2145721467- 2146921485-2149121495-2150021532-2153321712- 2172421729-2173321877-2188021903-2190421924 21936-219382197821983-2198722000-2200222007- 2201522026-2202922042-2204622101-2210722135- 2213822152-2215622165-2216822200-2220322218- 2222622243-2224522284-2228922292-2229922309 22349-2235022358-2235922381-2238222394-22398

Tissue RNA Library SEQ ID NOS: origin Source Name

21027- ■2103121275 -2127621516 •2152821967- •21968 21983 •2198722007-220152202 •2202522056- ^■22059 22333-•223352237322622-2262422637-22643 22669- 2267022700-2270122728-2272922887-22891 23059- 230602306323229-•2323323470-2347223903- 23904 25334-■2533525370-2537227269--2727027304- •27305 27386-■2738927570-2757128008--2801128234- ■28254 28311-^■2831329409-2941630085 ^■3008730150- ■30156 fetal lung Invitroge FLG003 255-256412-413461-463534-535619-620785-786981- n 9851273-127913371678-16801792-17942207-2208 2341-23432471-24742774-27752779-27922874-2876 2923-29242936-29383326-333137084531-45334685- 46904795-48095337-53416235-62376530-65316932- 69387258-72637536-75417660-76657745-77467901 8017-80198074-80768113-81148152-81568318-8322 8349-83508422-84258434-84528457-84588502-8503 86888736-87379022-90259100-91449306-93119472- 947495849733-97349759-97629794-979598289833- 98439857-98619864-98669909-99129923-99249958- 995910015-100161027710523-1053011345-11350 11423-1142611431-114321157711610-1161111901- 1190512050-1205612455-1246412565-1256812581- 125821259812760-1276212978-1298113585-13588 13931-1393314236-1423814261-142631460414624- 1462515412-1541415558-1556015588-1558915902- 1590316145-1614616345-1634916636-1663716642 16851-1685317024-1702517046-170571745417934- 1793618015-1801618405-1840618655-1865818796 18899-189031891018915-1891819138-1914019159 19308-1930919375-1937919401-1940219623-19624 19800-1980319943-199461998120053-2006320103- 2010520222-2022520231-2025320263-2026420289 20340-2034120401-2040520412-2041320415-20417 20456-204682050120537-2054120607-2061220646- 2064820698-207072072620733-2073420827-20835 2086320957-2096220977-209842101521076-21087 21097-2110021157-2117421248-2125221277-21280 21284-2129421403-2140421428-2143321492-21494 21911-2191221939-2194622000-2200222007-22015 22056-2205922062-2206922120-2212722158-22160 22200-2220322265-2227622336-2234622358-22364 22561-2256822571-2258122708-2270922843-22845 2297723007-2302123098-2310123252-2325623506- 2350723532-2353923599-2362823827-2383324021- 2402424120-2412525373-2537525410-2541326237- 2623926294-263022632726350-263522635726359- 2636026383-2638526479-2654526607-2660926698- 266992674226860-2686226876-268792722527441- 2744327544-2754527790-2779627812-2781327845- 278522797028099-2810028133-2813728142-28145 28426-2842828768-2877429117-2912329950-29953 30195-30199 fetal lung Clontech FLG004 1569-15706005-60066403-640419074-1908019706- 1970820676-2068021157-2116923098-2310123543- 2354426383-26385 Tissue RNA Library SEQ ID NOS: origin Source Name fetal liver- Columbi FLS001 1-6810-1621-232530-3335-3848-5474-7981-120 spleen a 122-123126-129156158-159164167170-171177-178

Universit 180-181 185-192195-205215-224226-235237-239251- y 253255-256260273-284286-291307-309319-325328 331-332373-374395398-399404-405412-420461-465 505515-517524-525528546-547551-556576-578582- 584619-620626-630652685-688694-695697-699708- 711716-722729738-748754-757763771-772777-778 785-786796-797832-836847-848852-855864-867880- 882891-898900-911913919-922934-935969-971979- 9851001-10031005102810471067-10711080-1081 1092-10941097-10981109-11101114-11151123-1127 11291140-11411158-11611163-11641169-11791240- 1241 1259-12621273-12791295-12971302-13031307 1310-131313681372-13731388-14011424-14291432- 14371440-14471453-14541467-1469147814831544- 1546155116181658-16601667-166816751678-1687 1705-17141721-17221725-17261732-17371747-1749 177317771792-179418401879-18801912-19131915- 19161921-19241961-196219771986-19872015-2018 2030-20342058-20602063-20662114-21152201-2203 2222-22262272-22762284-229923062354-23552362- 23632383-23882393-23952404-2406243124392457 2471-24742517-25182540-25412561-25622570-2574 2599-26032649-265026662687-26882695-26982706 274528062808-28112814-28152871-28732889-2891 2918-29192923-292429262934-2935296729732975- 29772983-29863002-30033006-30083026-30283078- 307930903101-31043107-31083118-31193144-3146 3151-31543182-31873195-31973205-320732643276- 327732903304-3308334533523366-33693374-3377 3414-341734333435-34453464-34653468-34713477- 34783512-35203525-35293565-358836763686-3691 369337083789-37943820-38213834-38353840-3852 3879-38803939-39413949-39534084-40854091-4095 4101-41164141-41464151-41554160-416242114220- 42384244-424742554261-42654273-42754343-4346 4386-43904441-44434469-44824486-44874489-4493 4512-45164531-4533454245464555-45564562-4573 4581-45824623-46394660-466246664668-46724712- 47134720-47274738-47504780-47814785-47894795- 480948414857-48614897-48984967-49684980-4981 4984-49854989-49915057-5059506650825109-5115 51395151-51795190-51915269-52715279-52835335- 534153605362-53665368-537553815387-53895480- 54845487-548854905493-54965512-55185530-5531 5557-55605567-55685572-557355805591-55925658 5703-57045717-57185768-57725802-58045827-5828 58465907-59095919-59215939-59415943-59455967- 59695973-59755980-59845997-60006011-60216084 6135-61366166-61686226-62346291-62966335-6336 63776403-64046439-64406445-64496455-64586461- 64836488-64896503-65106523-65266533-65356540- 65436551-65676585-65926669-66726674-66756709- 67136745-67466773-67786791-679468526896-6899 Tissue RNA Library SEQ ID NOS: origin Source Name

6959-69607001-7007701172037209-72127216-7219 7245-72487256-72637267-72687275-72767296-7298 7368-73697447-74497534-75417551-75597572-7577 7604-760576087613-76177620-76217630-76367648- 76537660-76657671-76737681-76877693-76967698- 77037726-77277742-77437745-77517763-77757778- 77887794-77977802-78057815-78217891-78957898- 79017904-79157921-79257940-79457947-79487957 7972-79757978-798579887990-7992799479988002 8010-80128069-80738077-80798084-80858087-8093 8113-81148117-81218132-81418145-81568163-8173 8187-82008203-82058211-82138227-82298242-8248 8253-82578297-830683108313-83148337-83428347- 83508365-83668368-8369839084158422-84258434- 84488461-84648466-84768487-84898500-85018507- 85088512-85138537-85508554-85558588-86008607- 86098612-86168688-86908698-87008724-87328754- 87668768-87708777-87798917-89338939-89458978- 898389979002-90049007-90089013-90209028-9036 9038-90469049-90679072-90789196-92009264-9265 9267-92689306-931193169321-93239326-93289337- 93389340-93429353-93579362-93639366-93689375- 937693829391-93929395-93969420-94239427-9428 94449446-94489454-945894609472-947694789486 9510-95189522-95259531-953795589561-95629585- 95929603-96049609-96109617-96269664-96659667 96769682-96839726-97279729-97319735-97449757- 97679780-97839794-97959813-982098269828-9832 9841-98429851-98529854-98559857-98619896-9897 9899-99089913-99209923-99249929-993599539956- 99619969-998810011-1001210017-1001910025-10026 10033-1003710045-1012610164-1017210263-10274 10277-10278103061031210320-1032310449-10457 10470-1047610488-104901049410498-1050310508- 1051210519-1053210543-1055010588-1059410600- 1060110603-1060810612-1061410628-1063010638- 1064410873-1087510881-1088310886-1088910891- 1089310895-1089810901-1090210904-1090510907- 1091010913-1091410931-1093310963-1096410966 1097210976-1097810980-109851103811042-11044 11066-1106811071-1107511078-1112111123-11125 11128-1114211208-1120911212-1121911222-11229 11250-1127511281-1128211289-1129011295-11301 11306-1131011314-1131511339-1135311359-11369 11399-1140711423-1142611431-1143211460-11464 11468-1147211476-1147811493-1149511501-11506 11513-1151411538-1154511561-1156211565-11567 11574-1157611582-1158311586-116061160911612- 1163911644-1165011658-116591167211700-11707 11711-1171211731-1173411739-1174011745-11750 11761-1176311766-1176811775-1177611780-11782 11803-1180811811-1183211835-118361184211873- 1187511890-11891 11921-1193011939-1194011947- 1195012011-1201312027-1203912050-1205612121- 121261214012150-12151 12186-1218912192-12196 Tissue RNA Library SEQ ID NOS: origin Source Name

12202-12208 12226-1222812241 1225312256-12258 12280-1228412331-1233212371 123971242912436- 1243812446-1245012455-1245912470-1247112486- 1254012545-1254612562-1256312565-1256812590- 1259212601-1260212619-1262212637-1263812640 12642-1264412666-1266712673-1267812701-12705 1272312725- 1272712755-1275912792-1279312796- 1279912803-1280412824-1282712894-1289712963- 1296412968- 1296912978-12981 12984-1298512997- 1299913071-1307413077-1307913107-1311713512 13556-1355913567-1356813576-1357913581-13583 13592-1359513598-1360013609-1361613632-13633 13638-1364113652-1365913668-1367213761-13795 13838-138421386113867-1386813873-1387513898- 138991390713925-1392613954- 1395613999-14004 14023-1402614036-1403714044-.1404514048-14056 1410314127-1412814143-1416414170-1418114192- 1419514209-1421514236-142381425714261-14263 14268-1426914347-1434814389--1439014463-14497 14546-145491460414607-1460914628-1463514650- 14651 14661-1466514676-1467814681-1468214684- 1468914694-1470114709-14717147841479214818- 1482014866-1487015011-1506915093-1509615118- 1511915132-1515715174-1518315190-1519115197- 1520015222-1522415233-1523615243-1524815257- 1525915277-1527815283-1528615290-1529115298- 1530315321-1532215326-1532815336-1534015358- 1535915381-1538815406-1541415457-1545915530- 1553515545-1554615551-1555215558-1556015563- 1556415576-1557715588-1558915614-1562015629- 1563215661-1566315699-1570015855-1585715867- 158701587815880-1588515890-1589515969-15974 15988-1599016022-1602316041- 1604616053-16058 16060-160611606716115-1611716141-1614316163- 1616416168-1617116174-1617616200-1620116206- 1620816216-1621716233-16237162391625016255- 1626816279-1628016284-1629516304-1630516310- 1631416345-1634916365-1636616371-1637216399- 1640216418-1642916434-1643716440-1644816461- 1646416470-1647216479-1648116484-1648616489- 1649316508-1651116517-1651916536-1653816545 16550-1655216558-1656216579- 1658516601-16611 16619-16621 1662316636-1663716642-1664816652- 1665516686-1669316702-1670516714-1671516727- 1672916802- 1680316836-1684216851-1685316860- 1687016873-1687416894-168961691016913-16915 16918-1691916934-1693916949- 1695316967-16970 17026-1702817038-1704117067- 1706917078-17079 1711417120-1712217233-1723417237-1724217268- 1727417286-1729117330-1733217335-1735817366- 1736817441-1745017454-1745617463-1746417538- 1756517571-1757417581-1758217855-1786117934- 179361795517958-1796217995-1799718001-18003 18015-1801618018-1802318029-1803018038-18042 18046-1804818097-1813418136-1813818371-18372 Tissue RNA Library SEQ DD NOS: origin Source Name

18374 1837518400 -1840218405 - 18418 18421 -18425

18427 1842918495185191852718535- 18537 18577-

18578 18587-1861718621-1863718642-18660 18662

18668 1867718691 1869318717 ^■ 18726 18730-18732

18738 18756187591876118771 ^•18780 18784-18786

18789 -18793187961880718811 ^■ 18813 18822-18834

18836 -1885518857 -1888018882 ^■18888 18897-18905

18910 18915-1892118923-1893918941 18944-18945

18947 -18950189551897318975 ^■ 1 8977 18986-18988

18993 1899619005 -190091901219018 19029- 19035

19045 190481905519057-1905819062- 19065 19071-

19085 19096-19101191321913419138- 19140 19142-

19148 19153-191551915919202- 19210 19213-19220

19224 -1922719251 -1925719260 -19262 19266-19267

19271 -1927219274 -1927919283 19296 19306-19309

19316 -193171934319350-1936419368-19370 19372

19375 -1938419387 -19402194071941 1 19413-19417

19422 -1943119438 -1944419454.19455 19461 19467-

19487 1950319512- 1952119526- 19529 19536 19548-

19553 19560-19562 19564-1957819583- 19586 19604-

19607 19609-19615 19617-1961919625 19627 19659-

19661 19663-19668 19670-1971019727-19748 19757-

19763 1977219800- 1981219814- -19822 19855-19856

19915 -1992919933 -199461995019953-19957 19962-

19963 19965-19967 19972-1998019995-20017 20026-

20047 20072-20080 20087-2009420099-20103 20106-

20112 20114-20120 20122-2013220146-20148 20151-

20154 20157-20181 20189-2021420226-20230 20235-

20241 20244-20253 20257-2027820281 -20282 20286-

20296 2029920321- 2032420328- -20330 20345-20354

20366- -2036820393 -204072041120415-20440 20447-

20451 20456-20474 20476-2047920482-20494 20497-

20498 20502-20503 20505-205092051 1 -20520 20524-

20535 20537-20541 20547-2055720559-20567 20569-

20578 20602-20612 20614-2063420639-20640 20644-

20648 20653-20671 20676-2068120683-20685 20688-

20692 20698-20707 20710-2072520727-20734 20747-

20752 20758-20766 20788-2079720806-20812 20816-

20849 20853-20857 208632086520871 20879-20880

20885 ■2088720897 -2090020924 -20932 20938-20943

20948 ^■2094920951 -2095420957 -20976 20985-20988

20999 ^■2100821027 -2105621058 -21 1 1 1 21 122-21 127

21137 ■2114021145 -2114821155 -21 169 21 171-21 174

21176 ^■2118021199 ■2121021213 -21215 21225-21228

21233 ^■2123521237 -2125221256 -21262 21267-21274

21277 •2129621334 21340-21342 21351-21352 21359-

21360 21377-21397 21405 21410- 21414 21434-21453

21463- -2146521467- -21476 21480 •21482 21485-21491

21495- 2150021516- -2153021532 ■21533 21554-21556

21587- ■2165521712- -21724 21744 •21747 21773-21775

21877- 2188021892- -21894 21899 •21902 21905-21912

21917- ^■2192121925- -21935 21939 21948-21968 21971-

21987 21995-22015 22019-22036 22040-22044 22047-

22079 22090-22094 22097 22101 - 22107 221 15-221 19

22128- 2213822141- -22143 22152 •22156 22160 22165- Tissue RNA Library SEQ ID NOS: origin Source Name

2216822171-2218622193-2219422204-2221122218- 2222622231-2223522246-2225022261-2228922292- 2232822336-2235122358-2235922362-2237322377- 2238022383-2239222399-2243222434-2243522440- 2244822455-224652249522531-2253922551-22560 22570-2258122599-2260222607-2260922618-22624 22632-2265122653-2265722661-2266722669-22670 22680-226842269022696-2269722700-2271522725- 2272722730-2273122760-2276422767-2277022781- 2278222794-2279622805-2281622821-2282722833- 2283422843-2284922852-2285622870-2287422887- 2289122904-2290622909-2291022916-2292422927- 2293822948-2295022969-2297722980-2298122991- 229942299823022-2302523046-2305523059-23060 23063-2306723070-2307123074-2307623088-23090 23094-2310123112-2311923138-2314123201-23202 23206-2320923212-2321523218-232212322623229- 2323323235-2323623242-23244232472325123261- 2328123356-233602337823382-2339023392-23398 23402-2340823415-2342123433-2343723470-23474 23486-2348723489-2349023492-2349323495-23496 23508-2351123515-2351823543-2354423547-23548 23555-2356523599-2362423673-2368123700-23701 23704-2370923725-2373023760-2376323771-23780 23793-2379923802-2380923816-2381923827-23835 23839-238482388223890-2390223906-2391023959 23999-2401124014-2401824021-2402524035-24040 24056-2409124105-2411324120-2412924194-24196 24749-2475424772-2477425085-2509025279-25288 25306-2530825319-2532125323-2532525331-25337 25340-2534125347-2535425359-2536325370-25375 25383-2540125403-2540725410-2541325534-25536 25598-2560325966-2596826024-2602826033-26049 26196-2619926205-2621326221-2624526248-26251 26253-26257262612626626273-2628026285-26290 26310-2631426316-26321263272633726347-26348 26350-2635226358-2636526373-2637426383-26385 2639826409-26411264232643126455-2646326469- 2647026559-2656026563-2656626596-2660226660- 2666126676-2668026691-2669426705-2672626731- 2673526737-2673926741-2675626782-2678526796- 2679826802-2680626813268272683526843-26845 26853-2685426860-2686226873-2687926888-26890 26980-2698727028-2702927044-2704727100-27102 2710527122-2712627133-2713427142-2714927173- 2717427177-2717827193-2720027209-2721327218 27240-2724627269-2727027275-2727627281-27282 27299-2730127304-2730527348-2735327386-27391 27414-2743127438-2744327458-274592749727501- 2750727510-2751127520-2752127544-2754527551- 2755427557-2755927586-2758727600-2760627636- 2763927649-2765427662-2767227698-2769927707- 2770827729-2774327750-2775627799-2780227812- 2782027825-2782627861-2786427896-2792727943- 2794727988-2799027992-2799728050-2809128095- Tissue RNA Library SEQ ID NOS: origin Source Name

28096 28099- -2810028105- ■2810728142- -2815628192- 281982823228234-282542828628308-2831328361- 28370284242844928533-2853928573- 2857829250- 2925229278-•2928329296-■2930029304--2931429327- 2933729339-■2934029343-•2934529354-■2935729367 29371-■2937929409-2941629508-2951829529-29534 29718-■2972129950-2995529960-2996130085-30087 30135 •3014230150-3015630195-301993020530218- 3023230236- 3024230361-30368 fetal liver- Columbi FLS002 1-25-621-2326-273035-3848-497477-7887-94108- spleen a 112129150-151164170-171180-181 188-192197-200

Universit 205218-220227-230235237-239251-252273-278304 y 309319-323328-330332362395414-420425-427505 515-519528532-533543-547582-584619-620674-675 685-688694-699708-711716-717742754-757763777- 778785-786825832-836847-848852-855892895-898 901-906910-912969-971979-98510051067-10701080- 10811092-10941109-11101163-11641185-11871202 1210-1211 1235-12371240-12411259-12621273-1279 1299-13001302-13031312-13131432-14351440-1447 1453-14541467-14691476-14781544-15461557-1558 161816251667-166816751678-16871705-17141725- 17261757-1758183818401866-18721879-18801912- 19131915-19161918-19191961-196219671986-1987 1991-19922015-201820362058206620722122-2124 2195-21962202-220522212275-2276227922992308- 232123482354-23552383-23882393-240024312457- 245825142517-25202529-25422544-25742663-2665 26912695-27002717-271927452808-281128192871- 28762908-29092913-291429172929-29302948-2949 2975-29772988-29893006-30103078-307930903112 31143126-31283130-31313165-31693182-31873226- 32273306-33093326-3331335233773392-33963418- 342034333461-34633468-34713508-35103526-3529 3555-35583562-35643661-36633676-36783687-3691 3693-36943699-37033869-387739343949-39533970- 40064077-40794101-410341314141-41464151-4155 4206-42084220-42384343-43464362-43654386-4387 4417-44194441-444944834489-44934515-45164526- 4527454645524562-45684623-46394658-46624666 4668-46724720-47254751-47554795-48094813-4815 4842-48514872-48984958-49594967-496849704980- 49814984-49854989-499150825087-50885109-5115 5129-51305152-515351925200-52015253-52665269- 52715279-52835288-52905311-53255368-53695381 5480-54825557-55605567-55685580-55835656-5658 5703-57045803-58045829-584658795912-59185932- 59365939-59415943-59455973-59755980-59845992 60846114-61256155-615961706172-61746186-6189 6223-62256346-6366638664006403-64046461-6484 6488-64896516-65196542-65436570-65716657-6661 6709-67116714-67476762-67646791-679468516877- 68996932-69846998-70147094-70997216-72197245- 72487256-72637267-72687275-72787296-72987364- 73657479-74807554-75557557-75597580-75977604- Tissue RNA Library SEQ ID NOS: origin Source Name

76057615-76177630-76367640-76427654-76557657- 76597671-76737678-76877693-76947701-77037726- 77277742-77437745-77517757-77597763-77707794- 779778057815-782079017924-79257947-79487972- 79757978-79837990-7992799880028008-80128017- 80198069-807080798084-80858090-80938098-8100 8107-81088117-81218129-81318137-81518157-8159 8163-81738178-818182038242-82468253-82628266- 82688297-83008308-83098313-83198339-83428347- 83508368-83698383-83898422-84258430-84488457- 84588461-84648487-84898497-84998504-85058509 8516-85188537-85388554-85558576-85828588-8597 8601-86098612-86178688-86908698-87008733-8735 8738-87408751-87668768-87998917-89338936-8945 89979002-90049013-90209031-90369038-90469049- 90629072-90749084-90859306-93119327-93289337- 93389343-93529362-93639366-936893829391-9392 9395-93969427-94289446-94489454-94599464-9469 9482-94869506-95189526-95289531-95379550-9551 95589561-95629577-95789594-96029609-96129617- 96269682-96839726-97289739-97429757-97699786- 97909794-97959813-98209828-98329835-98409848- 98509857-98619864-98669899-99089913-99209923- 99249927-99289942-99449953-99559958-99599969- 99809993-999610015-1001610033-1003710129-10145 10161-1016310173-1017410263-1026410273-10276 10278-1031110326-1032810449-1045310474-10476 10488-1048910491-1049310498-1050310508-10515 10531-1053210550-1055410588-1059910603-10611 10615-1062310628-1063010640-1064410783-10785 10873-1087510877-1087810881-1088310886-10889 10891-1089310904-1090510907-1091010913-10918 10923-1092610957-1095810965-1096610973-10975 11022-1102311029-110311103811040-1104111066- 110681108111123-1112411130-111321113511208- 1120911212-1121911226-1122711230-1124911281- 1128211308-1131011318-1132011339-1134411406- 1140711460-1146411473-1147411476-1147811505- 1150611574-1157611586-1160611649-1165011669- 1167111711-1171211715-1171611731-1173411739- 1174011761-1176311780-1178211811-1183211840 11901-1190511912-119141191611941-1194411947- 1195012011-1201312023-1203912050-1205612121- 1212612133-1213412150-1215112186-1219112194- 1219612206-1220812221-1222412245-1225312256- 1225712309-12311 12331-12332123621236812374- 12401 12403-12411 12446-1245012455-1245912468- 12471 12486-1251812547-1255412590-1259612637 1264012642-1264412666-1266712714-1271512720- 1272212725-1272712785-1278712794-1281212814- 1282212824-1282712829-1283012832-1283412872- 1288112894-1289712944-1294712963-1296412977- 12981 12984-1298512997-1300613062-1306313066- 13124135121351613545-1354813576-1357913585- 1358813596-1359713606-136121361713632-13633 Tissue RNA Library SEQ ID NOS: origin Source Name

13761 -1379713810 13873-13875 13930-1393313937- 139381400414023-1402614044-.1404514048-14056 1406114063141271412814137--1413814170-14172 14175- 14181142091421514261--1426314304-14305

14347-1434814355--14356143891439114550-14551

145601460414661--1466214681- 1468214692-14693

147141471714789-147911479314810-1481314841-

1487514999-1500115013-150701509015093-15096

151181511915182-1518315187-1518915197-15200

15209-1521015212-1521515221 -1522415243-15248

15250-1525115258-1525915283 -1528615290-15291

15321 -1532215358-1535915392•1539615406-15407

15460-1546115491 -1549515545 •1554615551-15552

15561 •1556215568-1557215606•1560715631-15632

15679-1568515688-1570015861 •1586615869-15870

15878-1588015988-1599016022^■1602316041-16043

1606716075-1607916115-1611716121-1612216137

16141 •1614316168--1617116174-■161791620216206-

1621716233-1623716279-1628016290-1629516365-

1636616434-1643716443-1644516465-1646616470-

1647216496-1649716508-1651116517-1651916542-

1654516558-1656216579-1658216601 16609-16611

16632 •1663416643--166481665216656-1665716666-

1666716702-1670516771-1677216781-1678216836-

1684216860-1687016894-168961690016918-16919

16962 •1696617067--170691711417120-1712217131-

171321723717268-■1727417284-1728517297-17306

17335-^•1733917359--1736017365- 1737117399-17400

17436-^■174501745417497-1749817525-1752717534-

1757017575-1757817580-1758417891-1789417956-

1796218001-1800318008-1801218020-1802218038-

1804218069-1807218097-1813418136-1813818207-

1821018371-1837218378-1837918407-1841018412-

1841818421-1842518492-1849418500-1851818536-

1853718583-1858418624-1862618629-1863718644-

1865018655-1865818668-1867718680-1868118693

18717- 1871818723--1872618730-1873218738-18744

18750- 1875618759-•1876618771-1877218778-18780

18787- 1879318802--1880418822-1883418836-18853

18856- 1888018904-•189051891018915-1891818925-

1893518941 18944-1894518947-1895018955-18959

18964- 18973189751899619001- 1900419011-19012

1901819029-1903919045-1904819054-1905519062-

1906519068-1908319096-19118191321913419138-

19140191481915319202-1920619209-1921019213-

192201922519228-1922919251-192521925719266-

1926719271-1927219275-1927919298-1930019302-

1930319306-1930719355-1936419368-1937019380-

1938919401-1940219413-1941419432-1943419442-

1944419458-1946019484-19486195031953619560-

1956219564-195781958619598-1960119604-19608

19617-19622196251962719656-1965719659-19661

19667-1966819672196881969319733-1974819757-

1976319800-1980819813-1981519921-1992919933-

1993819940-1994619948-1994919958-1996319965- Tissue RNA Library SEQ ID NOS: origin Source Name

1996719972-1998119995-2001420018-2004720053- 2006320069-2007320087-2009420099-2010220106- 2011220114-2012020122-2012720133-2013620149- 2015020167-2017920189-2019420198-2021420231- 202412025320257-2027820281-202822028820317- 2032020340-2034120345-2035420366-2036820411- 2041320415-2043620447-2045120469-2047920482- 2049420497-2049820501-2050320505-2052020524- 2053520547-2055320563-2056720575-2057820602- 2061220614-2061920621-2062420631-2063420639- 2064020646-2065220666-2067120689-2069220698- 2070720712-2071720727-2073420747-2075120758- 2078820792-2079720801-2081220819-2082320827- 2083520844-2084920853-2086320865-2086720871 20888-2088920897-2090020922-2092620929-20932 2094320952-2095420957-2096220973-2098820999- 2100421016-2102521027-2103121046-2107121076- 2115121157-2116921171-2117421194-2119621202- 2120721229-2123221241-2125221256-2126221267- 2127421277-2129421297-2129821301-2130321334 21340-2134221351-2135221377-2140221405-21427 21434-2145721462-2146621470-2147621480-21500 21532-2153321554-2155621712-2172421744-21747 21877-2188521892-2189421905-2191021917-21921 21929-219352193921951-2195421967-2196821971- 2197721983-2198721989-2199321995-2200222007- 2201522019-2203622040-2204122047-2205522060- 2206122070-2207322077-2207922090-2209422101- 2210722115-2211622135-2213822141-2214322160- 2216822171-2218422187-2219222195-2219822208- 2221122218-2222622246-2225022256-2226022265- 2227622284-2228922300-2230222310-2234222351 22357-2235922377-2238022389-2239222399-22408 22411-2243222440-224482249522534-2253922551- 2255922561-2256522570-2258122599-2260222607- 2260922618-2262822632-2263322644-2265122653- 2265422661-2266222665-2266722669-2267422680- 226842269022696-2269722700-2270122703-22707 22760-2276422767-2277422801-2280422810-22816 22823-2282722846-2284922852-2285322870-22874 22904-2290622925-2293822948-2295022962-22970 22973-2297622982-2298623007-2302123046-23050 23053-2305523059-230602306323080-2308323112- 231192314123212-2321523229-2323323237-23239 232452324723251-232562326323279-2328123343- 2334423358-2336023375-2338523392-2339523402- 2341123428-2343023439-2344723475-2347923487 23492-2349323515-2352323545-2354823555-23565 23587-235932359923673-236862369023692-23693 237042372523760-2376123770-2378023793-23797 23802-2380923827-2383523839-2384023843-23848 238652388123883-2388923941-239562395923990- 2399224002-2400424014-2401824029-2404124044- 2404524056-2411624120-2412924145-2416224194- 2419624749-2475425085-2509025279-2528825300- Tissue RNA Library SEQ ID NOS: origin Source Name

2530425314 25319-2532125323- -2532525342-25343 25347-2535425359-2536325370-2537225374-25375 2538225403--2540725522-2553125534-2553625966- 2596826033--2604926196-2619926205-2620626209- 2621326221-•2622326240-2624326248-2625126261 2626626270--2627926285-2629026347-2634826354- 2635526359-•2636526373-2637426378-2638126409- 2641026414264232643126446-2644726469-26470 26559-2656026586-2660226617--2662826657-26661 26665-2666626684-2668626705--2670726719-26726 267412674626748-2675426796-•2679826806-26812 26876-2687826980-2698427012--2701427037-27038 27044-2704727067-2707327100--2710227114-27120 27129-2713227142-2714927154--2715527180-27187 27203-272052721827229-2723227240-2724427269- 2727027283-•2728727299-2730127304-2730527340- 2734227372-■2737527379-2738027401-2741027414- 274312743827441-2744327456-2745927487-27488 27493-2749527510-2751127520--2752127548-27549 27557-2755927586-2758727600-•2760127633-27634 27640-2764127674-2767627740--2775627758-27768 27812-2781327819-2782027890--278922792827995- 2799728040-2804128045-2804728050-2805928097- 2810028105-2810728133-2814028234-2825428278- 2827928290-2829528305-2831628347-2834928365- 2837028440-2846028463-2848829117-2912329265- 2926729278-2928329304-2931429321-2932629328- 2933129339-2934029354-2935729367-2940429409- 2941629427-2943129594-2960429718-2972129872- 2987529938-2995329962-2996330085-3008730195- 3019930221-3023230240-3025030325-3032730361- 30368 fetal liver- Columbi FLS003 674-6756773-677480708434-844811226-1122715588- spleen a 155891665216851-1685317958-1796218642-18643

Universit 18773-1877618802-1880419275-1927919375-19379 y 20189-2019420263-2026420602-2060621256-21262 22265-2227023890-2389224772-2477427193-27200 28424 fetal liver Invitroge FLV001 3-410-14112170-171255-256713-715847-848969- n 971981-9851001-10031097-10981123-11271142-1164 1273-1279147016251918-192720582272-22742414 2471-247424762663-26652871-28732939-29432948- 294930013021-302231643255-32593374-33773485- 34863512-35213555-3558362437083735-37363768- 37693818-38193949-39534562-45684600-46014623- 46395480-54825803-58045856-58585899-59026011- 60216166-61686551-65676932-69387216-72197421- 74237534-75357678-76807745-77467902-79037924- 7925795780708090-80938101-81048113-81168132- 81368157-81598230-82328253-82578274-82768416- 84198434-84488512-85138588-85978689-86908771- 87768936-893893059391-93929475-94769581-9584 9735-97389743-97449768-976998289833-98349909- 99129969-99809984-998510326-1032810474-10476 10480-1048210498-1050310592-1059410603-10606 Tissue RNA Library SEQ ID NOS: origin Source Name

10870-1087210881-1088310907-1091010913-10914 10936-1093711022-1102311123-1112411345-11350 11423-1142611658-1165911669-116721167911757- 1175811873-1187512050-120561214012190-12191 12455-1245912470-124711263712676-1267812723 1294312948-1296212978-12981 12997-1299913629- 13631 13638-13641 14044-140451411614460-14462 1460414640-1464214818-1482015011-1501215019- 1502415126-1512915277-1527815329-1533115576- 1557715661-1566315855-1585715886-1588716174- 1617616290-1629516403-1640716422-1642916496- 164971654516576-1657716599-1660816851-16853 17026-1702817150-1715217268-172741745417924- 1792617958-1796218001-1800318010-1801218395- 1839718516-1851818536-1853718585-1858618644- 1865018655-1865818771-187721878918829-18834 18846-1885318897-1889818919-189211897518996 1901219096-19101 19251-192521927419295-19303 19308-1930919345-193491937219390-1940219422- 1943119441-19444195141956319617-1961919625 19679-196821969819700-1970519727-1973219772 19814-1981519819-1982219926-1992919933-19937 19943-1994619948-1995019965-1996719972-19980 20133-2014520161-2016420167-2017120189-20194 20215-2021820257-2026420271-2027820281-20282 2028920321-2032420336-2033820340-2034120366- 2036820393-2040020432-2045120456-2046820514- 2052020563-2056720575-2057820607-2061220620 20625-2062820683-2068520836-2084320868-20870 20927-209322094320948-2094920952-2095421058- 2105921101-2111121157-2116921197-2119821208- 2121021248-2125221326-2133321351-2135221470- 2147621480-2148221495-2150021899-2190221917- 2192121925-2192821958-2196621983-2198722000- 22015220192204722074-2207622092-2209422101- 2210722161-2216422169-2217022204-2220722218- 2222622256-2226022277-222832231822343-22348 2249522551-2255222571-2258122625-2262822680- 2268422708-2270922760-2276222810-2281622823- 2282722852-2285323047-2305023080-2308323201- 232022341923433-2343723473-234742348723599 23673-2367423731-237362376123793-2379723845- 2384823876-238772388223890-2389223903-23904 23941-2395623999-2400124005-240112405624772- 2477425293-252972531525322-2532525331 -25333 25336-2533725374-2537525676-2567925966-25968 26024-2602826033-2604926196-2619926205-26206 262662632726347-2634826350-2635226359-26360 26383-2638526409-264112684326853-2685426860- 268622721827222-2722427304-2730527372-27375 27439-2744327510-2751127518-2752127544-27545 27636-2763927649-2765427814-2781528087-28091 28105-281072818628234-2825428365-2837028424 28426-2842828533-2853929409-2941729508-29518 29718-2972129960-299613006130085-3008730224- Tissue RNA Library SEQ ID NOS: origin Source Name

30232 fetal liver Clontech FLV002 3461-3463 6331-6334 7757-7759 10638- 10639 14098- 14099 14261-14263 20180-20181 23007-23021 23555- 23565 27317-27322 28277 fetal liver Clontech FLV004 218-219 1436-1437 5370 7216-7219 8247-8248 8512- 8513 8936-8938 9854-9855 10640-10644 1 1842 12121- 12126 12824-12827 16226-16227 16470-16472 16652 17924-17926 18500-18501 18516-18518 18527 18723- 18726 18778-18780 18964-18969 1921 1 -19212 19370 19401-19402 19422-19431 19461 19583-19585 19736- 19742 19919-19920 19924-19925 19943-1994620208- 20214 20437-20440 20792-20797 20948-20949 21277- 21280 21470-21476 22265-22270 22690 22730-22731 22846-22849 22881-22886 23047-23050 23356-23357 25319-25321 25323-25325 25966-25968 26843 27504- 27507 29343-29345 fetal Invitroge FMS001 158-159180-181251-252551-552697-699716-717832- muscle n 836847-8481123-11271371 1717-17192254-2258 2440-24442793-27992923-292430393107-31083377 35073555-35583686-36913773-37744127-41284343- 43464388-43904536-45384561-456846914795-4809 5372-53755965-59666403-64046669-66707209-7212 7620-76217681-76877695-76967745-77467815-7818 7891-78957921-792579467990-79928090-80938132- 813681628253-825783108313-83148345-83488598- 86008612-86168768-877088699306-93119321-9323 9343-93469366-93689479-94819491-94939517-9521 98289848-985098989927-99281030610320-10323 10451-1045310491-1049310638-1063910895-10898 10936-1093711217-1121911297-112991131711345- 1135011372-1139611731-1173411835-1183611840 12121-1212612129-1213012455-124591246512467 12569-125701272312743-1275012978-1298113581- 1358313592-1359513638-1364113885-1388713925- 1392614137-1413814270-142731460414640-14642 148751500915151-1515715243-1524815600-15601 15623-1562615863-158661613716147-1615116174- 1617616352-1635316576-1657716619-1662116836- 168421711417330-1733217335-1733917455-17456 17958-1796218008-1800918029-1803018400-18402 18412-1841818421-1842218500-1850118671-18672 18781-187831878918802-188041885618923-18924 1894219135-191371927319306-1930719355-19360 19362-193641937019380-1938419390-1940019422- 19431195031958619667-1966819679-1968219700- 1970519800-1980319813-198151993920029-20043 20151-2015420161-2016420200-2021420231-20234 20263-2027320281-202822028920328-2033020361 20401-2040520437-2044020491-2049420514-20520 2068120727-207322087120897-2090020952-20954 20957-2096220977-2098421005-210082101521123- 2112721157-2116921171-2117421208-2121021223- 2122421229-2123221284-2129421301-2130321351- 2135221377-2139721408-2140921958-2196121983- 2198722020-2202922080-2208322092-2209422160 Tissue RNA Library SEQ ID NOS: origin Source Name

22165 -22168 22212- -22217 22277 ^■22283 22329-22335

22347 -22348 22405- •22408 22553 ^■22558 22607-22609

22637 -22643 22669- -22670 22700 ^■22701 22730-22731

22810 -22816 22881- •22891 22980 •22981 22991 -22994

23007 -23021 23084 23206-23209 23222 23229-23233

23329 -23337 23382- •23385 23510 -2351 1 23599 23827-

23833 23941 -23956 24014-24018 24446-24448 25085-

25090 25315 25319- 25321 25340- 25341 25403-25407

26024 ■26028 26258- -26260 26285 •26290 26307-26309

26421 •26422 26435 26559-26560 26737 26842 26879

27052 27091 27100- 27102 27304- 27305 27455 27520-

27521 27544-27545 27574-27577 27600-27601 27647

27698 -27699 27729- ■27739 27755- •27756 27825-27826

27853- •27857 27971 27989-27990 28008-2801 1 28142-

28145 2831 1-28313 28424 28426- 28428 29278-29283

29332- •29337 29956- ^■29957 30141 - ■30142 30189-30194

30236 ^■30239 fetal Invitroge FMS002 534-53533774562-45684581-45826403-64047236- muscle 72379018-902012194-1219613638-1364116545 16851-1685318044-1804518655-1865818802-18804 1915319254-192551937019422-1943120263-20264 2028920437-2044020625-2062822020-2202522212- 2221722284-2228922362-2236422399-2240422531- 2253322669-226702269022887-2289125342-25343 26860-2686227602-27606 fetal skin Invitroge FSK001 35-38170-171192227-230315-316329-330373-374 n 425-427464-465551-552579-580605-606635685-688 713-715718-720785-786832-836969-971981-985 1001-100410311053-10571097-10981123-11271169- 11791203-120413071414-14171431 14511578-1585 1600-16011611-161616751705-17141729-17311778- 177918601885-18861912-19131915-19162136-2137 23072383-23882540-25412599-26032675-26782706 28002802-28122814-28152826-28272923-29242944 29462951-29553094-30963276-32793322-33233336- 3337335233773477-347835073526-35293531-3534 3555-355836863715-37163773-37743834-38353855- 38573860-38643873-38753926-39273939-39413949- 39534003-40064124-41264129-41314141-41434206- 42084213-42144343-43464358-43614441-44434489- 44934550-45514562-45684581-45824623-46394668- 46724686-46894705-47074795-480948184824-4831 4857-48614897-48984971-49744980-49815061-5062 50655480-54825581-558358025919-59215980-5984 6166-61686219-62226331-633463996403-64046623 66506657-66706692-66976877-68787209-72127216- 72197258-72637296-72987447-74497536-75417580- 759776087615-76177620-76217660-76657681-7689 7695-76967701-77037745-77517757-77597778-7788 7806-780878217824-78257904-79057924-79257972- 79757978-79837990-799279948077-80788080-8081 8090-80938113-81168129-81418152-815981628187- 82008216-82188242-82468253-82628274-82768310 8313-83148326-83278347-83608368-83698375-8376 84158434-84528487-84888502-850385368539-8542 Tissue RNA Library SEQ ID NOS: origin Source Name

8554-85558576-85828607-860986888724-87328768- 87708939-89458978-89819026-90289031-90369038- 90399043-90459079-90809264-92659305-93119321- 93239340-93429375-93769456-94599472-94769506- 95099517-951895319535-95379561-95629590-9592 9594-96029689-97079735-97389759-97629780-9781 98289846-98529854-98559857-98619867-98689874- 98959902-99049916-99209923-99249954-99559965- 998010020-1002410032-1003710161-1016310167- 1017210254-1026110480-1048210495-1050310513- 1051810523-1053010612-1062310628-1063010876 1090610936-109371096511035-110371115811250- 11251 11306-1131011345-1135011372-1139611431- 1143211465-1146611473-1147411496-1149811609 11612-1163911669-11671 11731-1173411745-11748 11757-1175811780-1178211803-1180411835-11836 1184011901-1190512011-1201312112-1211412140 1217312175-1217612280-1228212374-1237712422- 1242712460-124621246512468-1247112555-12559 12651-1265212666-126671267012676-1267812714- 1271512720-1272212728-1276612782-1278412803- 1280412823-128271294312978-1298112997-12999 13077-1307913100-1310613503-1351113596-13597 13603-1360513609-1361213629-1363113638-13641 13652-1365913834-1383713865-138661393013999- 1400414058-140591411714236-142381425714346 14355-143561460414626-1463514640-1464214725- 1472914784-1478814991-149921499615071-15074 15126-1512915182-1518315250-15251 1525715277- 1527815300-1530115341-1534215358-1535915404- 1540515408-1541415576-1557715588-1558915606- 1560715617-1561815623-1562615863-1586615925- 1593115988-1599016030-1604016044-1604616059 16121-1612216168-1617116174-1617616200-16201 16345-1634916365-163661637016388-1639116422- 1642916470-1647216593-16598166001662316636- 166371665216716-1672316851-1685316934-16937 17010-1701417026-1702917070-1707117104-17111 17156-171591723717244-1725017263-1727417278- 1732617335-1733917454-1745617571-1757417958- 1796218001-1800318015-1801618029-1803718136- 1813818393-1839418423-184251853518583-18584 18587-1861618624-1862618644-1865018655-18658 18671-1867218719-1872618730-1873218745-18749 18771-1877218787-1878918797-1880418811-18813 18829-1883418846-1885318894-1889618899-18903 18908-1890918915-1891818947-1895018955-18959 18976-1897719001-190041904019045-1905319062- 1906519074-1908019135-1913719142-1914719224 19228-1922919251-1925219258-1926219266-19267 19306-1930719316-1931719341-1934219350-19354 1936219368-1937019375-1938419395-1940019407- 19411 19422-1943419441 19458-1946019464-19466 19484-194861950219515-19521 19548-1955319564- 1956519574-1957819604-1960719617-1961919659- Tissue RNA Library SEQ ID NOS: origin Source Name

19661 19663-1966619670-19671 19683-1968819693 19700-1970519727-1974219764-1976719813-19815 19921-1992919933-1993719943-1994619972-19981 20029-2004320087-200942012020130-2014520161- 2016420180-2018120189-2019420198-2021420229- 202412025320257-2027020279-2028220286-20288 20290-202962029920328-2033020401-2040720414 20427-2043120447-2045120456-2046820476-20479 20485-204902050120505-2050920524-2053520537- 2054520548-2055320559-2056720629-2063020639- 2064020644-2064820666-2067120676-2068120683- 2068520689-2069220698-2070720710-2071120714- 2072520727-2073420747-20751207532076720789- 2079120806-2081220844-2084920868-2087020882- 2088420890-209002092620929-2095420957-20984 20989-2099021005-2100821026-2103121076-21087 21097-211002112221149-2115121157-2116921197- 2119821208-2121021213-2121521225-2122621241- 2125221263-2126621277-2128021284-2129421334 21351-2135221410-2141421428-2143321440-21445 21447-2145321463-2146521480-2148221495-21500 21529-2153021554-2155621718-2172421729-21733 21881-2188521911-2191221917-2192121929-21938 21958-2196621973-219742197821983-2198722020- 2202922062-2207322077-2208322092-2209422101- 2210722141-2214322160-2216822176-2217722195- 2219822208-2221122218-2222622246-2224922261- 2227022277-2228922292-2229922303-2231122347- 2235022358-2235922362-223712237322375-22380 2239322433-224352249522534-225392256022566- 2256822571-2258122599-2260222607-2260922622- 2262822637-2264322661-2266422669-2267022690 22700-2270122737-2273922801-2280422828-22829 22852-2285322870-2287422881-2289122904-22908 22916-2292222941-2294722952-2295322969-22970 2297323007-2302123047-2305023059-2306023071 2308423088-2309023201-2320223212-2321523218- 2321923229-2323323252-232562326323356-23357 23364-2337023373-2337423379-2338123386-23390 23392-2339523409-2341123415-234192343323470- 234722351423526-2353123543-2354423673-23689 2370423726-2373023771-2378023806-2380923845- 2384823865-238662388223893-2390223911-23940 23990-2399223999-240012402524035-2404024056 24092-2409724481-2449025085-2509025306-25308 2531325319-2532125331-2533325340-2534125461- 2547025598-2560326024-2602826196-2619926207- 2620826261262662628026316-263212632726337 26350-263522641426558-2656126676-2667726691- 2669426829-268302684326893-2689526980-26984 2705227067-270702709127100-2710227269-27270 27275-2727627283-2728727411-2741227480-27481 2749727520-2753927544-2754527600-2760127636- 2763927649-2765427677-2768827726-2772827755- 2775627812-2781527848-2785227858-2786827885-

Tissue RNA Library SEQ ID NOS: origin Source Name

90359040-90429267-92689329-93309343-93469366- 93689391-939294439472-94749486-94889506-9509 9529-95309532-95349561-95629590-95929594-9602 9609-96109726-97279780-97819799-980098269828 9844-98459848-98529854-98559916-99209923-9924 9929-99359939-99409953-99551001210015-10019 10025-1002610038-1004110254-1026110277-10278 1030610498-1050310513-1051810531-1053210543- 1054910592-1059410609-1062310638-1063910873- 1087510931-109331093810963-109641096611006- 1100811116-1112111123-111241113511302-11303 11345-1135011359-1136911431-1143211467-11472 11561-115621160911658-1165911715-1171611731- 1173411803-1180411835-118361184211873-11875 11878-1187911901-1190511935-1193611947-11950 12127-1212812133-121341214012202-1220512221- 1222412259-1226212398-1240112430-1243112637 12666-126671272312774-1277812780-1278712791 12796-1279812824-1282712978-1298113068-13070 13077-1307913083-1308613505-1351113560-13562 13571-1357313592-1359513838-1384213865-13866 1400414058-1405914118-1412414130-1413114141- 1414214166-1416814170-1417214192-1419514236- 1423814261-1426314270-1427314304-1430514498- 14501 1460414607-1460914640-1464214684-14685 1470814726-147291478414789-147911487515096 15182-1518315218-1521915243-152481525715290- 1529115412-1541415496-1552515530-1553115548- 1555015576-1557715612-1561815699-1570015855- 158571588015988-1599016044-1604616121-16122 16174-1617616451-1645216484-1648616494-16497 16583-165851662316636-16637166421665216683- 1668516724-1672516752-1675316758-1676016851- 1685316938-169391697417026-1702817038-17041 17074-1707717120-1712217153-1715417233-17234 17286-1729117327-1733917454-1745617538-17565 17958-1796218015-1801618044-1804518069-18072 18097-181341841118421-1842518427-1842918492- 1849918516-1851818535-1853718644-1865018655- 1865818668-1867018691-1869218719-1872218750- 1875618759-1876018767-1876918771-1877218787- 187891879618802-1880418806-1880718842-18845 1885618899-1890318923-1892418941 18955-18959 18964-189691897519029-190351905519062-19065 19074-1908319096-1910119138-1914019209-19210 19226-1922719251-1925319316-1931719341-19342 1935019355-19360193621937019373-1937419387- 1938919407-1941119415-1941719422-1943119438- 1944019442-1944419461 19487194971950319515- 19521 19526-1953119560-195621956619574-19578 19580-1958619598-1960119604-196071962719667- 1966819670-196711969319698-1970519733-19735 19743-1974819764-19771 19804-198081981319921- 1992519933-1993719943-1994619953-1995719965- 1996719969-19971 19981 19995-2001420029-20043 Tissue RNA Library SEQ ID NOS: origin Source Name

20048-2005220074-2007920087-2009420106-20110 20114-2012020122-201272013020149-2015020161- 2016620172-2017920182-2019420198-2019920208- 202142024120263-202702028920298-2030420316 20328-2033020345-2035420401-2040520427-20451 20485-2049420497-2049820524-2053520548-20558 20563-2057820599-2060120616-2061920625-20628 20631-2063420649-206522068120698-2070720753 2076720788-2079720813-2081520836-2084320855- 2086320866-208702088120885-2088720927-20928 20963-2097220990-2104521076-2108721097-2llll 21145-2115121171-2117421208-2121521277-21283 21295-2129821377-2139721408-2141421434-21439 21446-2145321516-2152821554-2155621647-21655 21712-2171721905-2191021929-2193521951-21954 21962-2196621978-2198221989-2199322003-22006 22020-2202522050-2205522080-2208322101-22107 22120-2212722135-2213822141-2214322152-22156 2216022171-2217522185-2219222208-2221122261- 2227622343-2235022358-2235922362-2236422366- 223712237322399-2240422434-2243522455-22465 2249522534-2253922570-2258122599-2260222622- 2262822653-2265422663-2266422669-2267022690 22696-2269722700-2270122794-2279622843-22845 22852-2285322899-2290022909-2291022955-22957 22977-2298123046-2305023053-230552307123141 23206-2320923212-2321523220-2322223229-23233 232362324923251-2325623261-2326223353-23354 23364-2337023382-2339023399-2340123428-23430 2343323489-2349023508-235112354623682-23686 2370423723-2372423726-237302376023764-23767 23798-2379923806-2380923836-2383723839-23840 23867-2388023890-2390223941-239562395923990- 2399224021-2402424035-2404024092-2409724120- 2412925085-2509025289-252902530625319-25321 25340-2534125359-2536325368-2536925374-25375 25403-2540725416-2541725598-2560326196-26199 26207-26208262662628026285-262902632726337 26373-263742639426563-265662660326615-26616 26676-266772668726691-26694268062684326860- 2686226876-2687926980-2698427028-2702927050- 2705227067-2707027114-2712027203-2720527254- 2726027271-2727227501-2750327557-2755927562- 2756327586-2758727589-2759227633-2763427729- 2773927809-2781127859-2786427869-2787327890- 2789227989-2799028099-2810028105-2810728142- 2814528173-2817528272-282792828628311-28313 28361-283622842428573-2857829225-2923129278- 2928329321-2932629328-2933129339-2934029354- 2935729378-2937929960-2996130141-3014230150- 3015630195-30199 fetal brain GIBCO HFB001 16121 144-145148152156-163177-178192197-200 227-230255-256282-284307-308329-330332373-374 395398-399419-420425-427524-525532-535540-542 549557-561568-581635716-720750-752758-762785- Tissue RNA Library SEQ ID NOS: origin Source Name

786792-795825832-836845-851860-861901-904912- 913934-9351001-10051044-104510471067-1071 1097-10981101-11031112-11131123-11271165-1168 1205-12061228-12311235-123712461273-12821312- 13131411-141714231431 1453-14541467-14701499 1667-1668167517551792-17941961-19621980-1982 2015-20182083-20842136-21372202-22032275-2276 23482354-23552383-23882404-24062420-24212471- 24742550-255225762599-2603267927062724-2726 274528062871-28732903-290429262934-29352951- 29552975-29772983-29862988-29893205-32073276- 327732903322-33233336-333733523355-33563361- 336233643374-33773421-342234333441-34453468- 34713477-347835073512-35143555-35583612-3613 3729-37303781-378438603949-39534080-40824091- 40954124-41264151-41574206-421042484343-4346 4486-44874489-44934515-45164526-45274531 -4533 4562-45734581-45824612-461446514726-47274785- 47894825-48264975-49784980-49814984-49855065 5084-50855092-50945109-51155190-51915335-5336 5376-53785382-53835470-54775480-54825517-5521 5525-55265557-55605572-55735587-55925659-5698 5710-57115768-577258025808-58125899-59025907- 59095919-59215943-59455973-59755980-59845986- 59886029-60356088-60896166-616864006403-6404 6406-64106450-64536488-64896523-65266542-6543 6657-66616669-66706775-67787001-70077056-7057 7209-72127216-72197236-72377256-72577325-7340 7536-75417557-75597611-76127615-76217630-7636 7657-76597666-76737681-768976987701-77037726- 77277734-77367747-77517778-778377947798-7801 7806-78087824-782578907902-790379167921-7923 79577972-79757978-798379887990-799279948002 8017-801980708077-80798117-81218137-81568162 8187-82008219-82208242-824882508253-82578313- 83148349-83508368-83708409-84148466-84768497- 84998512-85138536-85508607-86098612-86168688- 86908736-87378754-87668919-89338982-89839007- 90089013-90209029-90309038-90429072-90749196- 92009306-931193169321-93239331-933393359337- 93399391-939294439459-94609482-94859487-9488 9506-95189522-952595319535-95379561-95629570- 95769617-96269664-96659682-968396889729-9731 9735-97429828-98329851-98529854-98559873-9895 98989902-99049923-99249927-99289956-99599969- 99809984-99859989-999210032-1004010167-10172 10263-1026410273-10274102771030610326-10328 10451-1045310470-1047310484-1048710498-10503 10508-1051210531-1053210588-1059110600-10601 10603-1060810615-1062310628-1063010638-10644 10881-1088310913-109141093810963-1096410980- 1098511066-1106811123-11124111351114311161- 1119711200-11201 11204-1120711297-1129911308- 113101131711326-1132711399-1140211431-11432 11460-1146411468-1147211476-1147811607-11608 Tissue RNA Library SEQ ID NOS: origin Source Name

11649-1165011674- 1167911696 11715-1171611731- 1173411739-1174011761-1176311766-1176811786- 1178811805-1180811835-118361184011843-11855 11937-1193812112- 1211412131 -1213212150-12151 12186-1218912192- 1219612225-1222812241-12244 1225812283-1228412374-1237712455-1245912468- 1246912486-1251812573-1257412590-1259212598 1263712642-1264412655-1265812666-1266712714- 127151272312725-1272712755- 1276412785-12787 12796-1279812829- 1283012832-1283412898-12899 12997-1299913077-1307913107-1311713576-13579 13585-1358813592-1359513606-1360813627-13628 13632-1363313638-1364113645 -1365113796-13797 13865-1386613873-1387513885 -138951389813918- 1391913954-1395613994-1399714023-1402614058- 140591409414127-1412814137- 1413814170-14172 14236-1423814261-1426314270-1427314283-14288 14314-1431714353-143541460414650-1465114684- 1468514714-1471714789-1479115013-1501815070 15093-1509515162-1516415182■1518315225-15230 15243-1524815250-1525115257-1525915290-15291 15323-1532415341-1534215358-1535915392-15396 15406-1540715412-1541415443 ^■1545215530-15531 15545-1554615563- 1556415576^■1557715588-15589 15600-1560115699-1570015780 ■1578815855-15857 15867-1587015884-158851596 ^■1596315988-15990 16059-1606116075-1607916096 ■1609916121-16128 16141-1614316152-1615316168 ^■1617116224-16225 16233-1623516281-162831629616371-1637216418- 16421 16449-1645316473-16481 16498-1650016521- 165261654516602-1661116632- 1663416636-16637 166421665216686-1669316702- 1670516716-16723 16804-1680716828-1683116836■1684216851-16853 16894-168961692416934-1693716954-1696117104 1711417120-1712217131-1713217145-1714617286- 17291 17330-1733217335-1733917454-1745617489- 1749017958-1796318001-1800318015-1801618029- 1803018055-1806018136-1813818393-1839418421- 1842518427-1842918492-1849418500-1850118516- 185181852718533-185371854018587-1861618625- 1862618644-1865418668-1867218691-1869218717- 1872618730-1873218738-1874418750-1875618761 18771-1877218778-1878018784- 1878918796-18804 18825-1883418842-1884518856- 1888018882-18888 18899-1890318919-1893518947- 1895018964-18969 18983-1898518989-189901899619001-1900919011 19018-1902419029-190351905519062-1906519074- 1908319096-19101 19138-1914019142-1914719153 19159-1916119163-19201 1925719260-1926219266- 1926719274193081930919316- 1931719345-19349 19351-19354193621937019380- 1938419395-19400 19407-19411 19415-1941719422- 1943419441-19444 19447-1944819464-1948319515- 1952419526-19531 19560-1956219564- 1956619583- 1958519604-19607 1962719659-19661 19663-1966819670-1967119674- Tissue RNA Library SEQ ID NOS: origin Source Name

19678 19683-19687 1969319700- 1971019727-19748

19759-197631977219800-1980819810-1981519819-

1982219921-1992919933-199371993919943-19946

1995019962-1996319972-1998120029-2005220069-

2007920087-2009420099-2010220106-2011020114-

2012020122-2012720133-2015420165-2016620172-

2019420200-2021820226-2022820235-2024120244-

202492025320257- 2026220265-2027020274-20278

2028920328-2033020345-2034820355-2035620393-

2040520415-2041720425-2043120437-2044020447-

2045120456-2047120485-204942050120505-20509

20524•2054520547 -2055820563-2056720569-20578

20607 •206122061 -2061920621-2062420629-20634

20639-2064020644 -2064520649-2067420676-20681

206982070720710--2071120718-2072520733-20734

20747-2075120753207672078820792-2079720806-

2081220819-2082120824-2084320853-2086220865

20868-2087120897-2090020926-2093220938-20942

20948-2094920955-2095620963-209842099120999-

2100421021-2102321060-2106121069-2107521097-

2110021137-2114021145-2114821153-2115421171-

2117421176-2118021197-2119821202-2120721213-

2121521229-2123221237-2124021248-2125221256-

2127421277-2128021284-2129421297-2129821301-

2130321326-2133321343-2135421377-2139721434-

2143921447-2145021454-2145721463-2146521477-

2147921485-2149121495-2150021516-2153021532-

2153321554-2155621587-2165521712-2171721729-

2173321877-2188521892-2189421911-2191221915-

2191621929-219352193921955--2195721967-21968

21971 -2197421978--219872199422000-2200222007-

2201522019-2202922037-2203922045-2204622056-

2206922074-2207622087-2208822090-2209422115-

2211622128-2213422141-2214322160-2216422169-

2217022187-2219222195-2219822208-2222622243-

2224522261-2226422271-2228922300-2230822312-

2231822323-2233222336-2235022358-2235922365-

2237122381-2238822399-2240422409-2241022434-

224352249522531-■2253922553-•2255822561-22565

2257022599-2260222607-2260922618-2262122625-

2262822634-2265122653-2265422663-2266722671-

226772269022696^■2269722700-•2270122726-22727

22730-2273122741 -2274822763 -2276422768-22770

22794■2279622810-2281622852-2285322859-22874

22899-2290022912-2292222927-2293822952-22961

22969-2297022973 -229762299 -2299423007-23021

23046 -2305523059-2306023070-2307123085-23086

23098 -2310123105 -2310823117-2311923125-23136

23203 •2320923220-2322123223 -2322523236-23239

23242 ■232452325123261-2326223279-2328123343-

2334423356-2335723382-2339023400-2340123415-

2341823420-2342123423-2343023434-2343723489-

2349023492-2349323508-2350923515-2351823555-

235652359923682-^■2368623700-237012370423718-

2372123731-2373623760-2376323768-2376923798-

Tissue RNA Library SEQ ID NOS: origin Source Name

50545190-51915335-533653615567-55685572-5573 57005702-57045744-57475762-57645829-58455907- 59095919-59215929-59375939-59415956-59575960- 59645973-59755986-59886038-60396137-61396170 6235-62376403-64046406-64106511-65196775-6778 68556861-68627056-705771917209-72127216-7219 7236-72407258-72637299-73017304-731673627452- 74607542-75507554-75557557-755976097611-7612 7620-76217630-76367648-76537668-76737678-7689 7695-769777297734-77437752-77597778-77837787- 778877947798-78017898-79007906-791279167972- 79757986-79877995-799780028017-80198041-8042 8064-80678077-80788087-80938095-80968122-8124 8152-815681628187-82008204-82058234-82418247- 824883108339-83418343-83448347-83508368-8370 8403-84068420-84218461-84648492-84968504-8505 8512-851385368539-85508607-86098612-86168688- 86908701-87058736-87378758-87598768-87768822- 88358917-89188939-89458982-89919013-90209031- 90359040-90469063-90679069-90719264-92659305 9337-93399427-94289431-94339456-94589464-9469 9472-94749479-94819506-95099522-952595319535- 95379561-95629594-96029611-96129617-96269664- 966596769719-97229726-97279729-97319745-9756 9801-98029828-98329854-98559864-98669874-9895 9899-99019927-99289946-99529969-99809997-10009 1001110017-1001910033-1003710161-1016310167- 1017210254-1026110268-1027210326-1032810449- 1045010470-1047310477-1047810480-1048210484- 1048710491-1049410498-1050310520-1052210531- 1053210588-1059110607-1060810615-1062310627- 1063010634-1064410780-1078210873-1087510899- 1090210913-1091410919-1092210936-1093710972 10976-1097810980-1098511022-110251113511198- 1119911222-1122411292-1129411300-1130111306- 1131011345-1135011468-1147211524-1152511531- 1153411541-115431160911656-1165711721-11729 11772-1177611805-11808118401184211901-11905 11937-1193811941-1194412040-1204412112-12114 12141-121461214912194-1219612206-1220812215- 1221712226-1222812280-1228212305-1231112437- 124401245312470-1247112480-1248212541-12542 12589-1259812623-126241263712673-1267512723 12755-1275912785-1278712832-1283413077-13079 13107-131171351313543-1355113556-1355913576- 135791358413592-1359513638-13641 13645-13651 13668-1367213752-1375313838-1384213918-13919 13954-1395613999-1400314023-1402614038-14041 14044-1404514054-1405614065-1408914098-14099 14123-1412414141-1414214170-1417214209-14215 14236-1423814283-1428814355-1435614360-14369 14456-1445814561-145681460414640-1464214650- 1465114709-1471714789-1479114841-1484315002 15013-1501815093-1509515158-15161 15182-15183 15233-1523615243-1524815250-15251 15253-15255 Tissue RNA Library SEQ ID NOS: origin Source Name

15257- -1525915277 1527815283 1528615326-15328

15358 -1535915397 1539815415 -1543715473-15475

15530 1553115543 1554615551 -155561556715588-

15589 15623-15626 15780-15788 15867-1586815871-

15877 15896-15900 15988-15990 160821610516133-

16134 16168-16171 1620216345- 163491635916365-

16366 16418-16431 16451-16452 16508-16511 16532-

16535 1654516570- 1657316623 16643-1664816653-

16655 1666216702- 1670316714- 1672316802-16803

16833 1684216851 1685316860 ■1687017074-17081

17153 -1715417238 1724217286 -1729117297-17306

17489 1749017924 -1792617958 -1796318010-18012

18029 -1803018395 -1839718407 -1841018412-18418

18423 1842518500 -1850118516 -185181852718535

18583 1858418644 -1865018655 -1866018668-18677

18691 -1869218719 1872218730 -1873218750-18756

18759 -1876118777 -1878018787 -1879618815-18821

18825 -1883418836 -1883818842 -1884518857-18880

18899 -1890518910 18919-18921 18923-1893518947-

18950 18964-18969 18976-18977 18989-1899018993-

18996 1899919049- -1905319055 19068-1907019074-

19080 19093-19101 19106-19118 191321914819153

19159 -1916119207 -1920819213 -1922019228-19229

19251 -1925219257 19266-19267 19308-1930919316-

19317 19345-19350 19363-19364 1937019387-19411

19422 -1943119447- -1944819454 -1945519461 19511

19526 1952919560 -1956219564 -1956519567-19578

19604 1960719620 -1962219626 -1962719659-19661

19663 1966819672 -1967819683 -1968719706-19710

19733 1974219759 -1976319800 -1980819810-19815

19855 1985619921 -1992319926 -1992919931-19937

19939 19943-19946 19965-19967 19972-1998120026-

20027 20029-20043 20069-20079 20099-2010220111-

20112 2012020122 2012720137 •2015420157-20164

20167 2017120180 2018120189 -2019420198-20207

20235 2024120274 2027820281 -2028220290-20296

20317 2032420328 2033020345 -2034820393-20407

20415 2041720421 2043120437 -2045520469-20481

20485 2049020511 2051320524 -2053520547-20553

20559 2056220568 2057420607 -2061220614-20619

20635 2063620646 2064820676 -2068020683-20685

20689 2069220698 2070720712 -2072520727-20732

20747 2075320767 20806-20812 20819-2082120824-

20843 20853-20854 20865-20870 20879-2088020882-

20887 20897-20900 2092620929- 2093220948-20949

20952- 2095420957 ■20972 20999 2100821069-21071

21097- 2110021105 ■21 1 1 1 21 123 2112721141-21142

21145- 2114821153 ■21 169 21 171 2117421197-21198

21208- 2121021213 -21215 21225- 2123221241-21274

21284- 2129421297 -21298 21301 2130321343-21354

21377- 2139721408 .21414 21434 2145021454-21457

21480- 2148221485 ■21491 21529 2153021532-21533

21554- 2155621587 21655 21718 2172421729-21733

21881- 2188521892 ■2189421899- 2190221911-21914

21922- 2192421929 2193521940- 2194621958-21961 Tissue RNA Library SEQ ID NOS: origin Source Name

21973-2197421978 21989-21999 22003-2202922035- 2203622045-2204922070-2207322084-2208822090- 2209422098-2210022108-2211622120-2213822144- 2215622161-2216822171-2217522187-2219222195- 2219822208-2221722225-2222622243-2224522250 22261-2226422277-2228922300-2230922312-22313 2231822336-2234222358-2235922381-2238822405- 2240822434-2243522531-2253922553-2255822561- 2256522570-2258122607-2260922625-2262822637- 2265122653-2265422671-226742269022700-22701 22760-2276422810-228162286922881-2288622892- 2289322916-2292422941-2294722955-2295722969- 2297022991-2299423022-2302523047-2305223064- 2306523085-2308623088-2309023112-2311623125- 2313623212-2321523223-2322523229-2323323242- 23245232512326323353-2335423373-2337423399 2341923425-2342723434-2343823495-2349623508- 2350923512-2351323543-2354423555-2356523704 23720-2372123771--2379723802-2380523816-23819 23839-2384023845--238482388123890-2390223941- 2395623999-2400124005-2401124014-2401824021- 2402424201-2422024481-244902479425085-25090 25279-25290253132532225340--2534125383-25401 25403-2540725410--2541325416--2541725666-25672 25966-2596826205--2620626209-2621326217-26218 26235-2623926258--262592628026285-2629026304- 2630626310-26321263272633726347-2634826361- 2636526373-2637426412-26413264232643626469- 2647026604-2660626705-2670726788-2678926804- 268052684326860-268622687927028-2702927036- 2703827067-2707027100-2710527201-2720227288- 2729127304-273052744427520-■2753927544-27545 27588-2759627602--2760627649--2765427709-27710 27814-2782027865-•2786827890--2789227987-27991 27995-2799728042--2804328045--2804728108-28121 28133-2813728142--281452818628199-2820328234- 282542828628311-2831328426-2842828458-28460 28549-2855529117--291232924429278-2928329288- 2928929296-2930829328-2933129339-2934029343- 2934529418-2941929427-2943129508-2951829718- 2972129954-2995530085-3008730135-3014030195- 301993020530218-3022030233-3023530240-30242 infant Columbi IB2003 144-145165-166360-361619-620763796-797852-855 brain a 900934-935955-956981-9851001-10031097-1098

Universit 1312-1313154716751692-16931792-17941931 1961- y 1962207224392675-267827102724-27262886-2887 2934-29352951-29552975-29772983-29863182-3187 3322-33233353-335433773681-36823781-37843936- 39384117-41184160-41644362-43654471-44824562- 45684720-472548184967-49685572-55735594-5602 5829-5845593760846403-64046775-677868556861- 68626877-68816959-69607542-75507615-76177630- 76367648-76537660-76657668-76707695-76967726- 77277784-77887806-78087906-79127924-79257972- 79757978-79837990-79928017-80198087-80898129- Tissue RNA Library SEQ ID NOS: origin Source Name

81368152-81568162-81738187-82008343-83448349- 83508368-83698383-83898404-840685098612-8616 86888733-87538939-89458992-89949013-90179069- 907193059594-96029617-96269664-96659726-9727 9801-980298289896-98979947-99529965-99809989- 999210033-1003710161-1016310268-1027210312 10326-1032810470-1047310477-1047810491-10493 10498-1050310592-1059410612-1062310628-10630 10638-106391097210980-1098511022-1102311135 11406-1140711419-1142211541-1154311835-11836 1184011941-1194412006-120101214912280-12282 1272312755-1275912785-1278712973-1297613552- 1355913609-1361213638-1364113865-1386613885- 1388714127-141281425714264-142651460414650- 1465114709-1471314817-1482115013-1502415209- 1521015243-152481525715326-1532815397-15398 15406-1540715863-1586815884-1588515890-15895 15988-1599016133-1613416434-164371654516570- 1657316804-1680717074-1707717297-1730617489- 1749017958-1796218015-1801618492-1849418516- 185181853518655-1865818673-1867718691-18692 18730-1873218750-1875618759-1876018778-18780 18790-1879318815-1882118839-1884518919-18921 18925-1893318947-189501899619045-1904819074- 1908019148191591925719316-1931719363-19364 19387-1938919395-1940019405-194061948719526- 195291953619564-1956519659-1966119706-19710 19800-1980319816-1981819921-1992519933-19937 1993919943-199461995019965-1996719972-19980 20087-2009420099-2010220111-2011220151-20154 20157-2016020189-2019420198-2020720235-20240 20274-2027820281-2028220290-2029620317-20324 20328-2033020349-2035420415-2041720425-20431 20437-2045120456-2047120514-2052020554-20557 20559-2056220607-2061220614-2061920625-20628 20635-2063620639-2064020644-2064520698-20707 20710-2071120718-2072520727-2073220768-20787 20806-2081220824-2082620836-208492087120926 20929-2093220999-2100821016-2102021069-21071 21123-2112721153-2115421171-2117421208-21210 21213-2121521225-2122621248-2125221256-21262 21272-2127421277-2128021284-2129421340-21354 21377-2139721447-2145021495-2150021529-21530 21647-2165521729-2173321877-2188521911-21912 21917-2192121929-2193521958-2196622007-22029 22070-2207322084-2208622101-2211422135-22138 22152-2215622161-2216422208-2221122218-22226 2223022246-2224922261 -2226422271-2228922381- 2238222394-2239822405-2240822434-2243522495 2257022644-2265122669-226742269022700-22701 22743-2274822760-2276222810-2281622861-22868 22881-228862297123047-2305023112-2311623201- 2320223212-2321523229-2323323237-2323923321- 2332723379-2338123412-2341823425-2342723434- 2343723526-2353123555-235652370423793-23797

Tissue RNA Library SEQ ID NOS: origin Source Name

86038698-87008760-87618982-898389979013-9017 9072-90749306-9311944394609475-94769487-9488 9506-95099531 -95349617-962696599757-97589826 9851-985298739981-998310273-102771030610498- 1050310520-105221090310980-1098511476-11478 11538-11540115461160911674-116781169611731- 1173411739-1174011766-1176811803-1180411835- 1183611912-1191412283-1228412486-1251812545- 1254612555-1255912615-126181263712642-12644 12760-1276212977-1298113592-1359513645-13659 14058-1405914270-1427314607-1460914663-14665 14684-1468514714-147171478415093-1509515290- 1529115302-1530315548-1555015568-1557515855- 1585716006-1601516168-16171 162371630116360- 163611637016576-1657716636-1663716851-16853 16873-1687416934-1693717330-1733217335-17339 17455-1745617491-1749218015-1801618029-18030 1806118097-1813418423-1842518492-1849418516- 1851818536-1853718682-1868818719-1872218750- 1875618759-1876018796-1880718811-1881318825- 1882818857-1888018882-1888818936-1893918941 18955-189591897518989-189901899619001-19009 19011-1901219057-1905819062-1906519081-19083 19096-19101 19213-1922019251-1925219254-19255 19266-192671927319316-1931719345-1934919362- 193641937019373-1937419385-1938919395-19400 19442-194451950319530-1953319598-1960119625 19709-19710197561981319819-1982219921-19925 1993919969-1997120044-2006320106-2011020130 20146-2014820180-20188202432025320257-20262 2028820300-2030420345-203482036020421-20424 20469-2047120485-2049020542-2054520563-20568 20575-2057820629-2063020698-2070920718-20725 20733-2073420747-2075120758-2076720788-20791 20836-208432086320879-2088020897-2090020929- 2093220938-2094220973-2097620985-2098821027- 2103121060-2106121101-2110421149-2115121197- 211982123621272-2128021351-2135221361-21374 21451-2145321744-2174721917-2192121951-21954 2197822003-2200622141-221432216022187-22192 22261-2226422271-2227622284-2228922314-22317 22343-2234622349-2235022358-2235922365-22371 223732249522534-2253922632-2263622644-22651 22663-2266422797-2280022843-2284522854-22856 22899-2290622955-2295722974-2297923046-23050 2306323066-23067230702314123218-2322223249 23358-2336023386-2339023409-234112348623515- 2351823700-237012370423726-2373023760-23763 23806-2380924126-2412925085-2509025096-25100 25334-2533525368-2537226024-2602826209-26213 26217-2621826248-2625126285-2629026596-26601 2673726748-267562684326876-2687926980-26984 2705227067-2707027203-2720527247-2725127283- 2728727379-2738027522-2753927636-2763927662- 2767227861-2786427896-2792728099-2810028108- Tissue RNA Library SEQ ID NOS: origin Source Name

2812128142-2814528315-2831628361-2836228424 28430-2843428573-2857829225-2923129250-29252 29278-2928329309-2931429328-2933729339-29340 2935829940-2995329960-2996129964-2996830141- 3014230150-3015630233-3023530361-30368 lung tumor Invitroge LGT002 35-3851-5287-94105136-138158-159167192197-200 n 216227-230255-256260329-330333-335360-361373- 374398-399406-407419-420425-427524-525528534- 535543-545549553-554560-561619-620631-633635 667-668694-695697-699706-707716-717777-778783- 790792-795847-848852-855901-904912-913919-922 964981-9851001-10051035-10371044-10451047 1097-10981123-11271158-11611203-12041235-1237 1263-12651273-1279128913041312-13131322-1344 1346-13471349-13541414-14171432-14351440-1447 1467-1469147414991569-15701667-16681678-1680 1692-16931705-17141721-17221792-17941879-1880 1912-19131925-19271941-19461949-19501956-1960 2015-20182058-20612259-2266230624312440-2444 2457-24592471-247425132570-25742599-26032663- 26652675-26782702-2705274527802871-28762934- 29352939-29442951-29552975-29773006-30083037- 3038309031123255-32593306-33083316-33213334- 33403374-3377343334663472-34733477-34783555- 35583561367636863729-37303789-379438173827- 382938323840-38523873-38753998-40024053-4054 4134-41364151-41554158-41624215-421642204273- 42744340-43414386-43874402-44034469-44704489- 44934531-453345424562-45684581-458246204623- 46434757-47584785-47894795-48114813-48154824 4845-48514857-48614891-48964967-49684980-4981 4984-49855109-51155127-51285152-515351925253- 52665335-534153645532-55335557-55605572-5573 5581-558356585695-56985703-57085717-57185731- 57425766-576758025805-58075827-58285919-5921 59285943-59455973-59755980-59845986-59886163- 61686223-62256330-63346403-64046406-64106533- 65356625-66266630-66376775-67786879-68816883 6932-69387209-72127216-72197256-72577285-7293 7296-72987302-730373747604-76057611-76127620- 76217624-76297640-76427671-76737678-76897701- 77037726-77287745-77517778-77867794-77977802- 78047806-78087815-78187902-79057924-79257972- 79757977-798579887993-799480028008-80098025- 80268041-804280468059-80638074-807680798084- 80858090-80938098-81058107-81088113-81148117- 81218129-81368142-814481628178-81818184-8185 8187-82008211-82138216-82188242-82468253-8257 8271-82738313-83148323-83258339-83428349-8360 8363-83648368-83698371-83748430-84338449-8454 8497-84998502-85038510-85188534-85358588-8597 8607-86098612-86168688-86908698-87008768-8779 9013-9017902890379063-90689072-90749196-9200 92669306-93119337-93389375-937693829391-9392 94449454-94609475-94769510-95189522-95259529- Tissue RNA Library SEQ ID NOS: origin Source Name

95319535-953795589563-956695849590-95929603- 96049609-96109617-9626967697289735-97429757- 97589763-976997919829-98329841-98429848-9850 9857-98619874-98959899-99019923-99249954-9955 9965-1001010161-1017210175-1019610263-10264 10273-102741027710279-102801030610326-10328 10451-1045710480-104821049010498-1050310506- 1050710516-1051810539-1054210592-1059410603- 1060810612-1061410638-1064410873-1087510877- 1087810895-1089810929-1093010936-1093810953 10976-1097810980-109851101011066-1106811123- 11124111351114311212-1121611252-1127311295- 1129611300-1130111306-1130711339-1134411359- 1136911405-1140711419-1142211431-1143211460- 1146611476-1147811493-1149411499-1150411538- 1154011584-1158511644-1164811651-1165511660- 1166111711-1171211731-117341176511769-11771 11835-118361184011873-1187511886-1188911937- 1193812040-1204112045-120561214012150-12151 12186-12191 12329-123321233512374-1237712398- 1240112468-124711247712486-1251812545-12546 12565-1256812571-1257212590-125921263712666- 1266712673-1268312698-1269912720-1272212755- 1276212785-1278712829-1283012832-1283412872- 128811294312965-1296712978-1298112997-12999 13077-1307913540-1354213563-1356413576-13579 13585-1358813592-1359513598-1360013603-13605 13627-1362813632-1363313638-1364113873-13875 13918-1391913925-1392613931-1393313998-14004 14044-1404514054-1405614058-1405914137-14138 14166-1417214209-1422614236-1423814299-14305 14355-143561439014498-14501 14546-1454914645- 1464814718-147201478414789-147911480914999- 1500115019-1506915093-1509615142-1515015182- 1518315187-1518915195-1519615233-1523615243- 1524815257-1525915290-15291 15321-1532815332- 1533515392-1539615406-1540715412-1541415454- 1545615496-1552515536-1553715545-1554615561- 1556215576-155771558615588-1558915600-15601 15623-1562615631-1563215855-1585715869-15870 1588015884-1588515961-1596315983-1598415988- 1599016041-1604616141-1614316145-1614616174- 1617616365-1636616403-1640716451-1645216470- 1647216479-1648116508-165111654516558-16562 16576-1657716602-166111662316636-1663716652- 1665516661 16672-1667416716-1672316730-16733 16802-1680316828-16831 16851-1685816894-16896 1691016934-169371694217058-170641710417114 1711917127-1713217145-1714617153-1715417235- 1723717330-1733217335-173391745417857-17861 17930-17931 17958-1796218015-1801618029-18030 18271-1827218376-1837718412-1841818423-18425 18495-18501 18516-185181852718579-1858118633- 1863718644-1865018655-1865818668-1867018673- 1867718680-1868118691-1869318717-1872618730- Tissue RNA Library SEQ ID NOS: origin Source Name

1873218745-1875818761 18773-187891879618802- 1880418806-1880718825-1882818839-1885318855 18857-1888018882-1888818894-1890518923-18935 18944-1894518964-1896918975-1897718993-18996 19005-190091901219045-1905319057-1906519074- 1908019084-190851913419138-1914019142-19148 19153192241927319283-1929419298-1930019302- 1930319306-1930719316-1931719350-1935419362- 193641937019380-1938419387-1940219415-19417 19422-1943419441-1944419454-1945519458-19460 19488-19493195031951419526-1952919532-19533 19560-1956219564-1957319598-19601 1960819617- 196191962719667-1966819670-196781969319727- 1975119759-197631977219814-1981519819-19822 19855-1985619921-1992519933-1993819943-19946 1995019953-1995719965-1996719972-1998020015- 2001720026-2002720029-2004320048-2005220069- 2007120087-2009420099-2010220111-2011220122- 2012720131-2013220137-2015020157-2016020165- 2016620172-2017920200-2021820235-2024020244- 202492025320271-2028020286-202872028920317- 2032020328-2033020336-2033820345-2034820361 20366-2037420393-204052041420418-2042020432- 2044620456-2047920485-2049020497-2049820501- 2050320510-2052320548-2055720559-2056720575- 2057820607-2061220614-2061920621-2062820646- 2065220676-2068120683-2068520698-2070720718- 2072520727-2073420747-207512075320758-20766 20789-2079120806-2081220816-2081820822-20854 20858-2087020885-2088720890-2090020922-20928 20938-2094320952-2095420957-2098820999-21008 21032-2104521060-2106621072-2107521112-21114 21122-2112721133-2113521149-2115121157-21169 21194-2119821225-2122621233-2123521241-21252 21256-2127121277-212942133421351-2135521359- 2136021377-2139721410-2141421428-2143321447- 2145021467-2146921480-2148221485-2149121516- 2152821647-2165521712-2172421744-2174721881- 2188521892-2189421905-2191221925-2193521955- 2195721962-219662197821995-220292204722056- 2205922062-2206922074-2207622084-2208622090- 2209122141-2214322160-2216822187-2219422208- 222112225022253-2225522261-2228922300-22308 22310-2231722323-2232822333-223502235722373 22405-2241022440-2244822455-224652249522531- 2253922607-2260922622-2262822634-2263622644- 2265122653-2265422661-2266222671-2267422690 22696-2269722700-2270122741-2274222760-22764 22794-2279622810-2281622838-2284922852-22853 22887-2289122923-2293822948-2295022952-22954 22977-2298622991-2299422999-2300623046-23050 23059-2306023070-2307123074-2307623098-23101 23125-2313623138-2314023206-2320923212-23215 23223-232282324723252-2325623261-2326323328 23343-2334423382-2339023402-234112341923433 Tissue RNA Library SEQ ID NOS: origin Source Name

23439-2345023473 -2347423486 -2348723489 23490 23492-2349323512 -2351323526-2353123543-23544 23555-2356523675 -23681236902370423726-23730 23760-2376323770 23806-2380923827-2383323838- 2384223871-23875 23878-2388023890-2389223941- 2395623990-23992 23999-2400124021-2402424029- 240332405624116 2466524772-2477425017-25026 25293-2529725306 25309-253102531525319--25321 25334-2533525340 -2534125355--2535825368--25369 25373-2537725383- -2540125410 -2541325966--25968 26024-2602826196 -2619926205-2620626235--26239 26248-2625226260 26270-2627926292-2629326305- 263062632726337 26341-2634426361-2636526421- 264222643126469- •2647026479-•265462655626559- 2656026596-26601 26607-2660926657-2665926681- 266832673726748- ■2675626776-■267812680626813 26843-2684526860- -2686226873 -268792703927067- 2707027074-27079 27100-2710227150-2715127173- 271742720627209- ■2721327216-•2721827269-■27270 27275-2727627280 27283-2728727304-2730527354- 2735727439-27444 27501-2750727544-2754527548- 2754927562-27563 27600-2760127636-2764127649- 2765427662-27672 27700-2770127714-2771727726- 2772827750-27756 27814-2781827845-2785227861- 2786427888-27889 27896-2792727989-2799027992- 2799428045-28047 28050-2805928095-2809628099- 2810028105-28121 28133-2813728142-2814728161 28169-2820328255- -2826128290-•2829228311--28313 28315-2831628424 28426-2842828573-2857829250- 2925229278-29283 29328-2933729339-2934029354- 2935829406-29417 29508-2951829529-2953429594- 2960429655-29659 29718-2972129938-2995330085- 3008730141-30142 30195-3019930224-3023230240- 3025030361-30368 lymphocyt ATCC LPC001 310-314332360-361373-374464-465506576-578792- es 795912934-9351123-11271273-127913341432-1435 14701667-16681705-17141721-17221971-19742015- 20182086-20872234-22352275-227623892396-2400 2570-25742599-26032923-29242988-298929933001 3006-30083078-30793110-311132443326-33313441- 34423508-35103781-3784386038783913-39153939- 39414137-41394151-415542034221-423842554343- 43464531-45334751-47554891-48964971-49745057- 5059508251805269-52715525-55265530-55335717- 57185943-59455980-59846081-60826769-67787368- 73697447-74497536-75417561-75627580-75977609 7630-76367671-76737678-76877693-76947726-7727 7734-77367742-77437778-778377947806-78087906- 79127924-792580028084-808582038211-82138247- 824983428349-83508368-83698383-83898453-8454 8512-85138537-85388607-86098688-86908736-8737 8758-87598762-87668768-87708914-891690379264- 92659408-94149427-942894609506-95099517-9518 9526-95319535-953796769735-97389763-97679815- 982098289851-98529909-99129916-99209962-9964 Tissue RNA Library SEQ ID NOS: origin Source Name

9986-998810033-1003710146-1016310167-10172 10197-102521030610311 10516-1051910533-10534 10551-1055410595-1059910870-1087210895-10898 10904-1090510913-1091410936-1093710980-10985 11042-1104411123-11124111351115911406-11407 11431-1143211468-1147211493-114941155411603- 1160611766-1176811878-1187912006-1201312050- 1205612150-1215112439-1244012470-1247112475- 1247612555-1255912565-1256812615-1261812637 12642-1264412673-126751272312805-1280612823- 1283012835-1286712872-1288112977-1298113576- 1357913598-1360013632-1363313638-1364113922- 1392413927-1392913954-1395614304-1430514346 1460414785-147861480014802-148081507015141 15151-1515715233-1523615250-152511530515326- 1532815408-15411 15460-1546115545-1554615623- 1563215869-1587015890-1589516174-1617616226- 1622716284-1628916614-1661516628-1663116649- 16651 16730-1673316851-1685317105-1710617153- 1715417380-173951739817677-1768117924-17926 18015-1801618412-1842018492-1849418516-18518 1852718659-1866018730-1873218745-1875618761 18773-187771879618802-1880418822-1882818842- 1884518897-1889818925-1893318964-1896918976- 1897719029-190351905519059-1906119081-19083 19154-1915519213-1922019251-1925219306-19307 19316-1931719351-193541937019415-1941719441 19484-1948619512-1951319548-1955319604-19607 19659-1966119663-1966619670-19671 1968819698 19706-1970819768-1977119813-1981519933-19939 19943-1994619953-1996319965-1996719969-19980 19995-2001420029-2004320048-2005220106-20110 20137-2014820161-2016420172-2017920182-20188 20208-2021420229-2023020265-202702028920299 20349-2035420366-2036820427-2043120441-20446 20485-2049420497-2050020524-2053520542-20545 20602-2060620614-2061520631-206342064120646- 2065220683-2068520698-2070720718-2072520727- 2073420792-2079720806-2081220824-2083520885- 2088720890-2090020927-2092820938-2094220952- 2095420963-2097220977-2098421027-2103121062- 2106821076-2108721097-2110021105-2111121145- 2115621170-2117521194-2120721211-2121221233- 2123521241-2124721277-2128021284-2129421301- 2130321458-2146121463-2146521480-2148221495- 2150021917-219212192421962-2196621973-21974 21983-2198722000-2200222007-220152201922077- 2207922092-2209422117-2211922161-2216822187- 2219422208-2221122218-2222422253-2225522284- 2228922314-2231722319-2232222336-2234622399- 2240822440-224482249522607-2260922634-22636 22661-2266222700-227012270722823-2282722835- 2283722861-2286822941-2294723022-2302523046 23064-230652307023125-2313623206-2320923212- 2321523242-2324423261-2326223264-2327823356- Tissue RNA Library SEQ ID NOS: origin Source Name

23357 23379-23381 23392-23395 23400-2340123494

23508-2350923555-2356523731--2373623762-23763

23841 -2384223845-2384823883-2389223906-23910

24014-240182405624772-2477425213-2521925293-

2529725309-2531025323-2532525331-2533325336-

2533725340-2534125347-2535425436-2544025598-

256032628026307-■2630926341--2634426373-26374

266032668426691-266942684326860-2686226873-

268752687926893-2689527074-•270772721827304-

2730527510-2751127544-27545275502756427640-

2764127767-2776827814-2781527819-2782027970

27989-2799028097--2809828133--281372828628315-

2834928365-283702842428426--2842828468-28484

28511- 2851329328-•2933129339--2934029343-29345

2937029427-2943129594-2960429718-2972129940-

2995330085-3008730130-3013430195-3019930205

30361 •30368 leukocyte GIBCO LUC001 10-1442-4451-52112156164167170-171177-178 180-181 197-200202-203206-211221227-230255-256 259282-284289-292319-327329-330332-335339343- 353357-363366-367372-374395398-399414-420425- 427464-465505-506509-519522-525527-528534-535 540-542546-547549576-578591-593626-630635656 667-668706-707758-759785-786792-795825847-848 852-855880-882901-904912-913919-922934-935945- 946981-9851001-1003100510281044-10451047 1065-10661101-11031109-11101123-11271153-1155 1169-11791203-12041235-123712461269-12821307 1312-131313341346-13471431-14351453-14541467- 147014741476-147814991569-15731667-16681705- 17141721-1722177017771792-179418601879-1880 1887-18891912-191319671980-19821986-19872015- 20182023-20342052-2054206220722086-20872202- 22032222-22262267-22692272-22762383-23882437 2460-24612471-24742540-25412599-26032656-2658 2780280628462874-287629052918-29192923-2924 2934-29352951-29552983-29862988-29892993-3010 3014-30193026-30333105-31083144-31463205-3207 324132443255-325932653274-327732903306-3308 3310-33113326-333133523355-335633653374-3378 3421-342234333477-34783507-35103512-35203550- 35583649-36533681-368236933729-37303741-3753 3760-37623768-37693781-37843834-38353840-3852 3873-38753949-39534091-40954119-41204137-4139 4141-41434160-41624200-42034209-421042554266- 42744367-43684386-43904486-44874489-44934531- 45334555-45564562-45764581-45824612-46144640- 464346664692-46944712-47134720-47274785-4789 4833-48364857-48614971-49744980-49815057-5059 50825092-50945119-512051925253-52665269-5271 5285-52875335-53365480-54845499-550155105522 5525-55365557-55605572-55735579-558057005766- 576758025805-5807582358465910-59215932-5936 59465973-59755980-59846103-61046106-61096135- 61366154-615961756331-63366388639564006403- Tissue RNA Library SEQ ID NOS: origin Source Name

64046450-64516516-65196523-65266533-65356542- 65436551-65676585-65926638-66396772-67746791- 67946879-68816898-68996932-69387209-72127216- 72197245-72487252-72557258-72637267-72687296- 72987355-73577447-744974817536-75417556-7559 7580-76057608-76097611-76127615-76177620-7621 7630-76367660-76657671-76897693-76947701-7703 77297737-77437745-77517757-775977717778-7786 7789-77977802-78047815-7818782278907898-7900 7904-79127921-792579577972-79757984-79857988 7990-79928010-80128049-80568059-80638098-8104 8113-81148132-81448157-81598178-81818184-8185 8187-82008211-82138247-82488253-82578271-8273 8297-830083428349-83508365-83668368-83708409- 84148416-84258430-84528461-84648487-84888502- 8503850685098512-85138537-85428607-86098612- 86168688-86908698-87008741-87508754-87578760- 87668917-89188986-89918998-90089018-90209031- 90369043-90459063-90679072-90749196-92009306- 93119321-93239337-93389380-93819406-94079445 9456-94589475-94769487-94889510-95189522-9534 9561-956295849617-962696599664-96659726-9727 9729-97319739-97449763-97679782-97839792-9793 9808-981298269828-98329851-98529854-98559857- 98619874-98959898-99089916-99209923-99249927- 99359956-99579965-99929997-1000910017-10019 10025-1002610161-1016310167-1017210268-10274 10277103061031110320-1032310326-1032810449- 1045710484-1048710498-1050310508-1051210520- 1052210531-1053210543-1054910551-1055410588- 1059410603-1060610615-1062310627-1063010638- 1064410873-1087510891-1089310895-1090010904- 1090610913-1091410938109531097211071-11075 1108111086-1111511123-111241113511208-11209 11226-1122711295-1129611302-1130311306-11311 11314-113151131711332-1133311339-1135011359- 1136911372-1139611406-1140711423-1142611431- 1143211467-1147411476-1147811544-1154611561- 1156211582-115831160911640-1165011660-11661 11669-1167111674-116781169611711-1171211731- 1173411739-1174011780-1178211803-1180411811- 1183211835-11836118401184211873-1187512023- 1202612040-1204112050-1205612121-1212612133- 121371214012150-1216912186-1219612202-12205 12258-1226212280-122821233612361-1236212374- 1237712398-1240112421 12446-1245012455-12459 12470-12471 12475-1247612519-1254012545-12559 12590-1259212601-1261412619-126221263712642- 126441264612653-1265812666-1266712701-12705 127231272912755-1275912785-1278712796-12798 12803-1280612824-1282712829-1283012835-12843 12872-12881 12978-1298112997-1299913077-13079 1351213556-1355913565-1356813571-1357313592- 1359513598-1360013603-1360513609-1361213638- 13641 13645-13651 13754-1375513796-1379713898 Tissue RNA Library SEQ ID NOS: origin Source Name

13918 1391913925 -1393013954- •1395613994-13997

1400414044-1404514054-1405614105-1410614137-

1413814173-1417414209-1421514228-1423514264-

1426514283-1428814304-143051434614355-14369

1454614549145571460414607-1460914650-14651

14666 -1466814681 -1468214684- 1468514714-14717

14784 14822-1483814871-1487415019-1502415182-

15183 15193-1520015243-1524815250-1525115257

15290 -152911530515321-1532415326-1532815336-

15340 15356-1535915406-1540715412-1541415454-

15456 15530-1553115545-1554715558-1556015568-

15572 15576-1557715588-1558915600-1560115623-

15626 15686-1568715699-1570015855-1585715861-

15862 15867-158681588015888-1588915988-15990

16044 -1604616053 ^■1605816060- 1606116075-16079

16082 16096-1609716110-1611216141-1614316163-

16164 16168-1617116206-1620816219-1622016226-

16227 16233-1623516284-1629516339-1634116350-

16353 1638016434- 1643916443-1644516451-16452

16456 -1646916473-^■1647816498-1650016508-16511

16536 -165381654516576-165771660016609-16611

16623 16636-1663716642-1664816652-1665516675-

16682 16686-1669316704-1670516752-1675316828-

16831 16833-1684216851-1685316860-1687016878-

16881 16894-1689616911-1691516934-1693716974

17024 -1702817046-•1705717082-1708417105-17106

17114 17117-1711817160-1716717264-1726717286-

17291 17330-1733217335-1733917454-1745617791-

17799 17857-1786117924-1792617930-1793117958-

17962 17969-1799418015-1801718029-1803018055-

18060 18097-1813418136-1813818371-1837218400-

18402 18407-1841018412-1841818421-1842218490-

18501 18516-185181852718533-1853418536-18537

18583 ■185861861718624-1862818633-1863718644-

18650 18661-1866218668-1867718680-1868118689-

18693 18717-1872618730-1873218745-1876918771-

18776 18778-1878018787-1878918796-1881318822-

18828 18839-1885318856-1888818893-1889618899-

18905 18908-1891018925-189391894618964-18969

18975- ■1897719001- 190091901819029-1903519045-

19053 1905519062-1906519068- 1907319081-19083

19090 19106-1911819138-1914019142-1914819153

19207- ^■1921019213- 1922019228- 1922919251-19252

19257 19266-192671927419283- 1929419306-19312

19316- ■1931719345- 1936019362- 193641937019372-

19374 19380-1940219407-1941119413-1941719422-

19434 19438-1944419454-1945519461-1946319502

19512- 1952119530- 1953119560- 1957319598-19601

19604- 1960719617- 196191962719656-1965719659-

19661 19667-1966819670-1967319679-1968719693

19698- 1969919706-1970819727- 1974819759-19763

19800- 1980819813-1982219915- 1991819921-19929

19933- 1994619948- 994919953- 1996319965-19980

20015- 2001720026-2002720029-2004320048-20063

20072- 20079200872009420099-2010220106-20112 Tissue RNA Library SEQ ID NOS: origin Source Name

20120 20122-20127 2013020137 2014820151-20154

20157-2016620172■2017920182-2019420200-20214

20231 -202342024120244-2024920257-2026220265-

2027020274-2027820281-2028220286-2028920299

20328-2033020345-203542036020366-2036820393-

20405204112041420418-2045120456-2046820472-

2047420476-2050320510-2052020524-2053520537-

2054120548-2055320559-2056820575-2057820599-

2060620614-2061920625-2062820631-2063420644-

2065220666-2067420676-2068020683-2068720698-

2070720718-2073420752-2075320758-2076720789-

2079720816-2082120824-2084920853-2086320866-

2087020879-2088420888-2088920897-2090020922-

2093220938-2094320948-2094920952-2095420957-

2097620999-2100821027-2103121060-2106621069-

2108721097-2110021122-2112721145-2115121153-

2116921171-2117421176-2118021194-2119821202-

2120721225-2122621233-2123521241-2125221256-

2126621272-2127421277-2128021284-2129421297-

2129821301-213032133421351--2135521359-21360

21377--2140221434--2143921447--2145021458-21461

21463--2146521467--2146921480--2148221485-21500

21529--2153021554--2155621587--2165521729-21733

21744--2174721881--2188521891 -2189421915-21921

2192421955-2196821973-219742197821983-21987

21995--2201522019--2202522042--2204422056-22076

2208922092-2209422115-2212722135-2213822141-

2214322158-2216422187-2219222195-2219822204-

2221122218-222262223022246-•2224922253-22264

22277--2230222310--2232822336--2234622358-22359

22365--2237322377--2238022383--2238822399-22410

22440--2244822455--224652249522531-2253322571-

2258122607-2260922634-2265122653-2265422661-

226642269022696-■2269722700-•2270122703-22707

22726--2272722732--2273522760--2276422794-22796

22805--2281622821--2282722833--2283722843-22849

22852--2285322875--2287622881--2289122904-22906

22925-■2293822952--2295722974--2297722982-22986

22991-^■2299423007--2302123046--2305023059-23060

23064-^■2306523070--2307123074--2307623098-23101

23125-•231362314123201-2320223206-2320923212-

2321523218-2322123236-2323923242-2324423249

2325123261-2326223321-2332723343-2334423379-

233902339923415-^■2341823425-:234272343323438-

2345023473-2347423486-2348723489-2349023492-

2349323495-2349623506-2351323515-2351823543-

2354423555-235652359923673-2367423682-23686

236902370423723 ^•2373023760- 2376123806-23809

23827-•2383323856■2386023878 ■2388023890-23892

23906-^■2391023941 ^■2395623999 ■2400124014-24018

24021-•2402524035 ■24040240562411624126-24129

25085-■2509025289■2529025316 •2532125323-25325

25336-■2533725340 ■2534125355-^■2535825370-25377

25416-^■2541725436■2544025598 •2560326019-26028

26196-2619926205 ■2621326237- 262432625226260

Tissue RNA Library SEQ ID NOS: origin Source Name

20559-2056220616-2061920631 -2063420676-20680 20801-2080520855-2086220938-2094220948-20949 20957-2096220977-2098421067■2107121123-21127 21145-2114821225-2122621241 -2124721277-21280 21351-2135221377-2139721467•2146921647-21655 21892-2189421915-2191622003 -2200622077-22079 22101-221072216022169-2217522187-2219222250 22253-2225522303-2230822343-^■2234622366-22371 22405-2240822534-2253922661-^■226622269022794- 2279622843-2284522881-2288622991-2299423070 23343-2334423402-234082341923439-2345023488 23495-2349623508-2351123856--238602388223906- 2391024014-2401826237-26239262662628426327 26361-2636526469-2647026796-■267982689627052 27074-2707727193-272002721827261-2726527492 27544-2754527551-2755427562-■2756327648-27654 27989-2799028142-2814528263-■282682842428573- 2857829278-2928329343-2934530150-30156 melanoma Clontech MEL004 10-143048-4951-52164366395576-578635697-699 from cell 716-717785-786798-803832-8369671044-10451071 line ATCC 1440-14471488-14891705-17141778-17791912-1913 #CRL 2275-2298230625492692-26942699-27002950-2956

1424 2967-29713078-30793151-31543226-32283255-3259 3336-33373738-37393856-38573949-39534515-4516 4600-46014623-46394819-48235109-51155335-5336 5569-557158025805-58075932-59365980-59846166- 616863776491-65106814-68316857-68587536-7541 7630-76367681-768777717778-778677947972-7975 7995-79978145-81518301-83068332-83338380-8390 8409-84148461-84648543-85508601-86038762-8766 8998-90019040-904290689337-93389340-93429360- 936194459529-953096599735-9738982698289862- 98689927-99289989-99921030610449-1045010488- 1048910508-1051210520-1052210615-1062310876 1115811419-1142211473-114741160911731-11734 11766-1176811780-1178211805-1180811910-11911 11921-1193012127-121281214012190-1219112206- 1220812547-1255412560-1256112581-1258212585- 1258812615-1261812824-1282712978-1298113077- 1307913589-1359113629-1363113638-13641 13954- 1395614137-1413814170-141721460414607-14609 14628-146351464914681-1468214694-1470115222- 1522415290-1529115329-15331 15358-1535915412- 1541415576-1557715699-1570015863-1586615881- 1588316075-1607916121-16122161351615616623 166421665216683-1668516704-1670516860-16870 17070-170731724217297-1730617330-1733217454 18015-1801618097-1813418405-1840618411 18533- 1853418583-1858418761 18777-187801878918825- 1882818857-1888018923-1892418947-1895018964- 189691897519045-190481905519062-1906519081- 1908319096-19101 19106-19118191481925319297 19316-1931719345-19350193621937019373-19374 19385-1938919422-1943119442-1944419515-19521 1969319709-1971019727-1973519768-19771 19804- Tissue RNA Library SEQ ID NOS: origin Source Name

1980819813 -1981519855-19856 19921-1992519969- 1998020029 -2004320087-2009420099-2010220106- 20110201202013020146-2014820172-2017920235- 2024120265-202702028920418--2043120511-20513 20537-2054120607-2061220625-2062820646-20648 2068820698--2070720733-2073420752-2075320788- 2079120816--2081820824-2082620836-2084320858- 2086220888-■2088920929-209322094320948-20949 20963-2097220977-2098421005--2100821024-21025 21062-2106621069-2107121076--2108721149-21151 21202-2120721275-212802144621554-2155621587- 2165521744--2174721881-2188521892-2189421903- 2190421922-•2192321951-219542197822016-22018 22042-2204422062-2207322087--2208822117-22119 22152-221562216022169-2217022178-2218422187- 2219222195-^■2219822225-2222622231-2223522261- 2226422271-■2227622300-223022231822343-22346 2237322434-^■224352249522607-•2260922632-22633 22637-2265122661-2266222700--227012270722760- 2276222948-•2295022974-2297623046-2305023053- 230552306323138-2314123206-2320923220-23222 23252-2325623261-2326223358-•2336023379-23385 23392-233952343323448-234502348623682-23686 23711-237192376123798-2379923827-2383323893- 2390225331-■2533325374-2537525583-2559326209- 2621326316-263212632726361-2636526469-26470 26596-2660126860-2686226980--269842703527193- 2720027245-•2724627254-2726027299-2730127439- 2744027586-2758727698-2769927814-2781527825- 2782627861-2786427896-2792727983-2798528040- 2804128099-2810028142-2814528204-2820928732- 2874229328-2933729339-293402935829427-29431 29746-2976130141-30142 mammary Invitroge MMG001 167170-171180-181255-256260319- -325358-359395 gland n 398-399406-407419-420425-427461 -465534-535582- 584604619-620706-707754-757776785-786826-827 832-837847-848852-855900-904912969-971981-985 1001-10041035-1037107110781082- 10851092-1094 1097-10981123-11271131-11331196--119812421273- 12791346-13471432-14351470147814831486-1492 1498-14991578-15851703-17191721--17261728-1731 1866-187219021925-19271939-19401961-19671980- 19822015-201820302055-20582284-22992306-2307 2382-23882410-24132471-24742540-■25412577-2584 2599-26032663-26652675-26782776-■27782820-2821 2874-28762886-28872889-28912903-•29042923-2924 2934-29352951-29553078-30793205-■32073261-3263 3276-327733123322-33233326-33313374-33773452- 34533459-34603477-34783483-34843507-35103512- 35143526-35293531-35343550-355836113649-3653 3686-36913729-37303768-37693781-37843789-3794 3834-38393873-38753949-39534091-40954129-4130 4141_41434160-41624206-42084404-44054515-4516 4526-45274531-45334562-45734600-46014623-4639 4644-46504686-46894785-47894795-48154857-4861 Tissue RNA Library SEQ ID NOS: origin Source Name

4980-4981505050735109-511551175147-51485291 - 52945335-534153715480-54825530-55315572-5573 5581-55835594-56025695-569857095717-57185803- 58045829-58455899-59025919-59215960-59645973- 59755980-59846085-60896140-61436166-61686184- 61856235-62376389-63926403-64046450-64516488- 64896638-663966456650-66556879-68817209-7212 7216-72197238-72407296-730173747421-74237534- 75357604-76057615-76177620-76217660-76657678- 76967745-77517787-77887795-78047815-78187821 7896-78977902-79157921-79257930-79327972-7975 7978-798579887990-79927994-799780028006-8007 8010-801280208071-80788084-80858090-80938106- 81108113-81148129-81368152-81598187-82008204- 82138227-82328247-82488253-826283108313-8314 8323-83258351-836483708383-83898404-84068434- 84488461-84648502-85058509-85158554-85558576- 85828607-86098689-86908760-87618771-87768869 8917-89338936-89388998-90019007-90089013-9017 90289040-90459072-90749196-92009264-92659305- 931193169337-93389340-93429366-936893829427- 94289456-94589472-94769506-95169522-95259529- 95319563-956695859594-96029617-962696599664- 966596769726-97279733-97389759-97679792-9795 9815-9820982698289833-98349841-98429857-9861 9864-98669874-98959899-99049909-99129916-9920 9927-99359965-99839989-999210011-1001610032 10161-1017210254-1026110263-1026410268-10272 10278103061031110326-1032810451-1045310480- 1048210491-1049310498-1050310519-1053010543- 1054910603-1060610612-1061410624-1062610638- 1063910820-1082110870-1087210881-1088310886- 1088910899-1090010913-1091810931-1093310936- 1093810957-1095810980-1098511006-1100811010 11022-1102311032-110341108111217-1121911345- 1135011372-1139611406-1140711423-1142611431- 1143211465-1146611505-1150611538-1154011544- 1154511582-1160811644-1164811660-1166111711- 1171211731-1173411761-1176311780-1178211803- 1180811835-118361184011843-1185911873-11875 11890-1189111901-1190511937-1195012050-12057 12131-121321214012150-1215112175-1217612190- 1219612202-1220812241-1224412309-1231112362 12378-1239712430-1243112470-12471 12480-12482 12637126401264612673-1267512701-1270612714- 1272312755-1275912829-1283012872-1288112943 12997-1299913505-1351113552-1355513565-13566 13592-1359513629-1363113638-136411366513752- 1375313896-1389713908-1391013918-1391913925- 1392613935-1393613999-1400414044-1405314058- 140591410414118-1412214175-1418114192-14195 14199-14201 1420514228-1423514274-1428014344- 1434614360-1436914452-1445314546-1455514604 1462614628-1463514640-1464214650-14651 14666- 146681468314714-1471714784-1478614789-14791 Tissue RNA Library SEQ ID NOS: origin Source Name

14981-1498315019-15024150701509615126-15129 15182-1518315187-1518915218-1521915222-15224 15232-1523615243-1524815257-1525915268-15270 15290-15291 15294-1529715326-1532815341-15342 15412-1541415460-1546115476-1547815491-15495 15568-1557215587-1558915661-1566315679-15685 15688-1569415855-1585715863-158681588015896- 159001590815991-1599616129-161321616716174- 1617616233-1623516359-1636116365-1636616388- 1639116395-1639616438-1643916470-1647216479- 1648116496-164971654516558-1656216602-16608 16619-16621 1662316642-1664816702-1670316707- 1670816710-1671216716-1672316761-1676716828- 1683116836-1684216851-1685816894-1689616934- 1693717026-1702817046-170571710417238-17243 17249-1725017284-1728517292-1730617330-17332 17335-1733917394-1739517454-1745617791-17799 17956-1796218029-1803718136-1813818269-18270 18371-1837218376-1837718412-1841818516-18518 18536-185371854018579-1858118585-1858618624 18644-1865818668-1867018673-1867718717-18718 18730-1873218750-1875818771-1877218778-18780 18787-187931879618806-1880718839-1885318856 18899-189031891018925-1893318947-1895018955- 18959189751899619005-1900919012-1901719019- 190241905519057-1906119081-1908319096-19101 1915119209-1922019251-1925219266-1926719274 19283-1929619302-1930319306-1931219316-19317 19345-1936019362-1937019375-1938419390-19402 19407-1941119415-1941719422-1943419441-19444 19458-1946019464-1946619484-1948719494-19496 19515-1952119526-195291953619567-1957319586 19598-1960119617-196191962719659-1966119663- 1966819670-1967319683-1968719700-1970519727- 1975119759-197671977219800-198031980919813- 1981819855-1985619926-1992919933-1994619950 19962-1996319965-1996719972-1998120044-20047 20066-2006820099-2010220120-2012120128-20130 20133-2015420157-2016420167-2017120189-20194 20200-2020720231-2024120244-2025220257-20262 20274-2028020286-2028720289-202962029920305- 2030720321-2032420328-203302033920349-20354 2036120363-2036820393-2040020406-2040720411- 2041320415-2041720432-2046820472-2047420485- 204902050120505-2050920514-2053520537-20541 2054620548-2055720559-2057420607-2061220620 20625-2062820631-2063420646-2067120676-20681 20686-2068720698-2070720727-207322075220758- 2076620768-2079120798-2080020806-2081220822- 208432086320868-2087120879-2088120885-20900 20927-209282094320948-2094920952-2095420957- 2096220977-2098420999-210082101521021-21023 21026-2104521060-2106621072-2107521122-21127 21133-2113521137-2114021155-2116921171-21174 21176-2118021197-2119821208-2121021213-21215 Tissue RNA Library SEQ ID NOS: origin Source Name

21223-212262123621248-2125221263-2126621272- 2127421284-2129421297-2129821301-2130321334 21353-2135421377-2139721408-2140921428-21433 21440-2144521447-2145321467-2146921480-21482 21485-2149121495-2150021554-2155621712-21717 21788-2179921877-2188021899-2190221911-21912 21917-2192121925-2192821936-2193821958-21966 21983-2198721995-2199922003-2203422040-22041 2204722062-2206922074-2207622080-2208622090- 2209422101-2210722115-2211622141-2214322152- 2215622160-2216822193-2219422204-2221122218- 2222622256-2228922303-223082231822323-22328 22333-2233522343-2235022357-2235922362-22365 22377-2238022405-2240822434-2243522440-22448 22455-224652249522531-2253922553-2255922571- 2258122607-2260922622-2262822644-2265122661- 2266422669-2267422700-2270122730-2273122741- 2274222760-2276222805-2281622821-2282722838- 2284222846-2284922852-2285322870-2287422881- 2288622907-2290822925-2292622940-2294722952- 2295322969-229712297322999-2302123046-23052 2306323066-230672307023072-2307623080-23086 23098-2310123201-2320223212-232152322223229- 2323323237-232392324723252-2325623258-23263 23279-23281233282334123356-2337023375-23377 23379-2338123386-2339023392-2339523409-23411 2341923433-2343823473-2347923508-2350923514 23543-2354423555-2356523673-236862369023709 23720-2372123726-2373623760-2376123771-23797 23802-2380523827-2383323839-2384223845-23848 23867-2387523878-238802388223890-2390223990- 2399223999-2400124005-2401124035-2404024056 24120-2412524402-2442524772-2477425017-25026 25085-2509025279-2528825293-2529725300-25304 2530625319-2532125323-2532525331-2533325336- 2533725340-2534125366-2536725373-2537725383- 2540125403-2540725416-2541725542-2555026024- 2602826140-2614326175-2618426195-2619926205- 262062626626285-2629026305-2630626324-26325 263272633726339-2634426350-2635226359-26360 26370-2637426395-2639626421-2642226455-26459 26469-2647026479-2654526684267372674226807- 268122682826860-2686226876-2688126985-26987 27040-2704327050-2705127074-270772709127100- 2710227129-2713227150-2715127156-2715727180- 2718327193-272002721827229-2723227269-27270 27354-2737527439-274432745527458-2746227510- 2751127520-2752127544-2754727586-2758727600- 2760627633-2763427636-2764127649-2765427662- 2767227719-2772027726-2773927755-2775627799- 2780227816-2781827848-2785227861-2786427890- 2789227896-279272797027981-2798227995-27997 28099-2810028105-2810728142-281452818628192- 2820328212-2822128233-282612828628365-28370 28416-284172842428426-2842828549-2855529278- Tissue RNA Library SEQ ID NOS: origin Source Name

2928329288-2928929328-2933729354-2935829364- 2936629409-2941729427-2943129508-2951829594- 2960429611-2961329718-2972129746-2976129960- 299613006130085-3008730141-3014230150-30156 30189-3019930221-3023230243-3025030325-30327 induced Stratagen NTD001 188-191289-291576-578617-618716-71710301034 neuron e 1097-109816462540-25412599-26032675-26782724- cells 27262871-287329733326-33313374-33763649-3653 3908-391039303949-39534165-41704486-44874515- 45164581-45824984-49855053-50545272-52755335- 53365777-577858025919-59215980-59846403-6404 6787-67906795-68007170-71727258-72637325-7343 73637368-73697557-75597688-76897693-76947701- 77037745-77467778-77837906-79127990-79928187- 820082508497-84998689-86908758-87598998-9001 9029-90309040-90429047-904890879321-93239559- 95609829-98329909-99129947-99529993-999610477- 104781049410531-1053210592-1059410615-10623 10842-1086710980-109851104511228-1122911314- 113151140511431-1143211541-115431154611609 11700-1170711739-1174011803-1180811886-11891 11941-1194412131-1213212241-1224412258-12262 12898-1289912902-1290512997-1299913592-13595 13609-1361213652-1365914304-1430515182-15183 15190-15191 15290-1529115588-1558915969-15974 16028-1602916180-161811654516619-1662116642 17292-1729617401-174321743517455-1745618029- 1803018097-1813418300-1830718400-1840218412- 1841818691-1869218771-1877218796-1880118839- 1884118846-1885318899-1890318989-1899019001- 190041901219074-1908019106-1911819207-19208 19256-1925719266-1926719306-1930719316-19317 1934319355-1936019387-1938919447-1944819458- 1946019488-194931956619598-1960119617-19619 19659-1966119736-1974219804-198081981319939 19972-1998020029-2004320099-2010220106-20110 20114-2011920122-2012720182-2018820208-20218 20485-2049020521-2052320607-206122068120698- 2070720827-2083520853-208542087121105-21111 21248-2127121275-2128021284-2129421463-21465 21495-2150021587-2164621929-2193522020-22025 22045-2204622070-2207322141-221432216022187- 2219222195-2219822243-2224522358-2235922365- 2237122381-223882243322653-2265422671-22674 2269022916-229222297723201-232022325123358- 2336023420-2342123700-2370123798-2379923806- 2380923890-2389224749-2475424928-2493824985- 2498825029-2504025279-2528825376-2537926024- 2602826205-2620626209-26213262662628026310- 263142632726361-2636526678-266802709127100- 2710227269-2727027446-2744927522-2753927544- 2754527729-2773927861-2786427896-2792727989- 2799028315-2831628361-2836429117-2912329328- 2933729343-2934529418-2941929426-2943129885- 2989130167-301773035230361-30368 Tissue RNA Library SEQ ID NOS: origin Source Name retinoid Stratagen NTR001 2599-260344504581-45825038-50395253-52665335- acid e 53367695-76967787-77888537-85388612-86169049- induced 90629563-956612755-1275912978-1298113638-13641 neuronal 15530-15531 15588-1558916110-161121654516652 cells 16836-1684217238-1724117335-173391779018673- 186771879618825-1882818936-189391897519152 19306-1930719363-193641937019387-1938919759- 1976319962-1996320328-2033020437-2044020554- 2055721208-2121021277-2128021467-2146921587- 2164621881-2188522020-2202522187-2219222265- 2227023261-2326223771-2378023843-2384425306 2537326205-2620626237-262392632726860-26862 27156-2715728142-2814528426-2842829328-29331 neuronal Stratagen NTU001 240-250373-374425-427576-578847-8481388-1401 cells e 1432-1435147014991778-177923062599-26032944 3040-30763107-31083326-33313421-34223477-3478 3483-34843789-37943912-39154055-40584171-4172 4206-42084515-45164562-45684581-45824785-4789 5186-51895253-52665272-52755279-52835525-5526 5943-59456135-61366403-64047264-72667346-7352 7784-77867815-781882038227-822984658497-8499 8716-87188998-90049007-90089038-90399049-9068 9472-94749479-94819535-95379594-96029735-9738 9929-99359969-998010161-1016310167-1019610516- 1051810615-1062310873-1087510915-1091811308- 1131011334-1133511775-117761184012150-12151 1225812590-1259212653-1265412716-1271912997- 1299913552-1355513638-13641 13847-1384914038- 1404114044-1404514137-1413814277-1428014640- 1464214814-1481515025-1506915100-1510915277- 1527815408-1541115530-1553115563-1556415576- 1557715588-1558915863-1587016141-1614316174- 1617616182-1618916545166421665216836-16842 16851-1685317284-1728517435-1744017451-17454 17958-1796218029-180301804318097-1813418500- 18501 18562-1857618671-1867218796-1880118825- 1882818857-1888018925-189331897518993-18995 19049-190531915319298-1930019306-1930719316- 1931719351-193541937019375-1937919395-19400 19415-1941719432-194341951119515-1952119526- 1952919564-195661962519659-1966119683-19687 19813-1981519855-198561993819940-1994219965- 1996719972- 1998020026-2002720099-2010220106- 2011020161-2016420200-20207202412028920336- 2033820406-2040720437-2044020485-2049020521- 2052320537-2054120602-2061220631-2063420639- 2064020646-2064820666-2067120792-2079720827- 208432087120897-2090020924-2092520927-20928 20938-2094220957-2096221032-2104521208-21210 21241 -2124721256-2126221272-2128321295-21296 21554-2155621587-2165521899-2190421936-21938 21951 -2195421958-2196622007-2201522040-22041 22047-2204922070-2207322152-2215622165-22168 22171 -2217522218-2222422243-2224522253-22255 22292-2229922312-2231322343-2234622372-22373

Tissue RNA Library SEQ ID NOS: origin Source Name

952195319561-95629617-96269680-96819763-9767 982810309-1031110470-1047310588-1059410628- 1063010820-1082110901-1090210941-1094310965 11496-114981154611780-117821180911835-11836 1184011951-1196912027-1203912171-1217312194- 121961225812615-126181264012997-1299913576- 1357913592-1359713609-1361213843-1384414058- 1405914092-1409314130-14131 14166-1416814389 1460414684-1468514821 15182-1518315190-15191 1543815454-154561547915699-1570015855-15857 15863-1586615890-1589515961-1596315988-15990 16053-1605816168-1617116392-163941664216773- 1678016851-1685316949-169531711417330-17332 1745417958-1796218015-1801618500-1850118516- 1851818533-1853418625-1862618655-1865818671- 1867218719-1872618762-187661879618802-18804 18857-1888018899-1890319059-1906519081-19083 1909019135-1913719154-19155192741937219415- 1941719442-1944419683-196871969319700-19705 1977219814-1981519921-1992519943-1994619972- 1998020048-200522013020161-2016420172-20179 20182-2018820265-202702028920305-2030720339 20357-2035920393-2040020537-205412055820575- 2057820625-2063020644-2064520698-2070720753 20758-2076720792-2079720806-2081220819-20821 2088120948-2094920957-2096221016-2102321069- 2107121101-2110421225-2122621237-2124021284- 212942142721495-2150021529-2153021647-21655 21892-2189421905-2191021973-219742197822026- 2202922040-2204122090-2209422212-2221722230 22284-222892231822336-2234222347-2234822358- 223642257022622-2262422634-2263622653-22654 22700-2270122768-2277022857-2285822899-22900 22955-229612297322991-229942306323070-23071 23098-2310123218-2321923252-2325623364-23370 23415-2341823473-2347423519-2352023700-23701 23704237612377023802-2380523827-2383324005- 2401124772-247742531325340-2534125374-25375 25416-2541726339-2634026657-2665926755-26756 26804-2680526850-2685426873-2687527100-27102 2721827463-2746627468-2747527655-2765627700- 2770127816-2781827825-2782627861-2786427989- 2799028108-2812128204-2820928426-2842829278- 2928329432-2943529960-2996130085-3008730150- 3015630184-3019430236-30242 rectum Invitroge REC001 180-181534-535540-5421681-16871705-17141721- n 17221745- 17462272-22742675-26782695-26982813- 28463326-33313555-35583687-36913717-37203834- 38353949-39534692-46954857-486152465337-5341 5572-55735802-58045919-59216209-62116400-6404 6406-64107209-72127426-744276097747-77517757- 77597778-77838074-80788323-83258329-83348453- 84548741-87508986-89919029-90309043-90459305 9375-93769391-93929456-94589531958598289921- 99229986-998810263-10264102771030610480-10482

21 I Tissue RNA Library SEQ ID NOS: origin Source Name

10491-1049310498-1050310523-1053010907-10910 10919-1092211006-1100811372-1139611399-11402 11660-1166111835-1183611886-118891214012150- 12151123621243512455-1245912472-1247312571- 1257212642-126441272312755-1275912788-12790 12824-1282712872-1288113576-1357913601-13602 13629-1363113638-1364114546-145491460414636- 146421509615233-1523615336-1534015623-15626 15855-1585716716-1672317010-1701417031-17035 17038-1704117956-1796218374-1837518395-18397 1862418651-1865418717-1872618757-1875818767- 18769187891879618944-18945191321922419257 19283-1929419306-1930719380-1938419390-19394 19401-1940219407-1941119422-1943419454-19455 19488-194961962519733-1973519743-1975119814- 1981519972-1998020122-201272013020137-20145 20189-2019720235-2024020274-2027820297-20298 20300-2030720321-2032420328-2033020441-20451 20456-2047120476-2048120524-2053520569-20574 20625-2062820758-2076620806-2081220827-20835 20858-208622087120882-2088420952-2095421005- 2100821021-2102321145-2114821171-2117421229- 2123221256-2126221297-2129821351-2135221428- 2143321440-2144521447-2145021467-2146921480- 2148221492-2149421877-2188021903-2190422003- 2201522020-2202922050-2205522062-2206922092- 2209422117-2211922200-2220722261-2226422277- 2228322292-2229922349-2235022455-2246522495 22571-2258122622-2262422663-2266422760-22762 22781-2278222838-2284222974-2297723074-23076 2308423229-2323323252-2325623392-2339523433 23543-2354423599-23624236902376123806-23809 23878-2388024021-240242405624092-2409724120- 24125246652530625347-2535825966-2596826347- 2634826359-2636026421-2642226448-2645126455- 2645926855-2685726879-268812709127129-27132 27193-2720027245-2724627269-2727027304-27305 27510-2751127544-2754527799-2780227814-27815 27869-2788627888-278922798328199-2820328232 28255-2826128511-2851329278-2928329309-29314 salivary Clontech SAL001 260307-308331551-552832-836969-971981-985 gland 1312-13131721-17221810-1811207223032306-2307 2599-260328472850-28603151-315436573723-3728 37373840-38523949-39534515-45164531-45334555- 45564581-45824857-48614971-49745269-52715525- 55265652-5653565857006337-63386411-64126442- 64496762-67647452-74607678-76877701-77037745- 77467778-7783780579888145-81518187-82008337- 83428383-83898554-85558986-89919018-90209038- 90399427-942895319535-95379782-978398289899- 99019923-99249997-100091030610531-1053210607- 10611 108761100911123-111241160911644-11648 11669-11671 11731-1173411835-1183612040-12041 12175-1217612202-1220512229-122301236212434 12468-124691247412565-1256812573-1257412642- Tissue RNA Library SEQ ID NOS: origin Source Name

1264412701-12705 1272312794- -1279512803-12804 12872-12881 12984 1298512997-1299913077-13079 13545-1354813592 -1359513638-13641 13937-13938 14132-1413614546 1454914552-145551460414650- 14651 14714-14717 15003-1500815294-1529715542 15545-15546155481555015614-1561615884-15885 16168-161711662316636-1663716653-1665516716- 1672316851-1685317058-1706617094-1710017255- 1725617330-1733217489-1749018010-1801218412- 184181852718624- 1862618673--1867718682-18688 18691-1869218717-1871818723-187261878918796 18829-1883418934-1893518964-189691897518993- 1899519096-191011913419209--1921019283-19294 19308-1930919350-1935419362-1936419380-19384 19401-194021969919706-1970819749-1975119759- 1976319855-1985619921-1992320111-2011220120 20146-2014820244-2024920288-2028920316-20320 20325-20335204142050120710-•2071120752-20753 20758-207662078820792-2079720813-2081520858- 2086320902-209212094320952--209542101521248- 2125221281-2129421403-2140421451-2145321529- 2153021532-2153321647-2165521955-2195721978 22026-2202922077-22079220972216022208-22211 2223022314-2231722323-2232822343-2234622358- 223592237322440-224482249522571-2258122690 22737-2273922838 -2284222923--2292422980-22981 22991-2299423059-2306023066--230672307023074- 2307623212-2321523235-2323623251-2325623524- 2352523726-237302376123878-•2388023911-23940 2405625085-250902530625323-■2532525340-25341 25370-2537325383--2540126024--2602826341-26344 26373-263742642326596-2660126844-2684527067- 2707027281-2728227304-2730527740-2774327814- 2781527861-2786427893-2789528105-2810728192- 2819828212-282162823328255-2826128311-28313 2842429278-2928329332-2933729940-2994930150- 3015630233-30235

Salivary Clontech SALs03 981-9858698-870011538-1154014546-1454920316 gland 27814-2781527989-2799028424 skin ATCC SFB001 1307 3374-3376 6285-6288 6791-6794 10306 12258 fibroblast 17026-17028 18029-18030 1901 1 19939 19972-19980 20182-20188 22141-22143 22160 22495 23415-23418 28424 30150-30156 skin ATCC SFB002 29265805-58076166-6168103061225817026-17028 fibroblast 17038-17041 17455-1745618029-1803019011 19548- 195531981321060-2106122141-221432216022373 2249522531-225332687927636-276392842430150- 30156 skin ATCC SFB003 5803-5804 6166-6168 12258 17335-17339 18029- 18030 fibroblast 18778-18780 19062-19065 19548-19553 20182-20188 22007-22015 23051-23052 23419 25340-25341 27269- 27270 27814-27815 28424 30150-30156 small Clontech SIN001 83 87-94 195-200 307-308 332 373-374 557-559 674-675 intestine 783-784 852-855 901 -904 1071 1240-1241 1470 1678- 1680 1755-1762 1764-1766 1769-1772 2030 2048 2089-

2 i : Tissue RNA Library SEQ ID NOS: origin Source Name

21002337-233824682599-26032871-28733006-3008 3151-31543461-34633487-35033661-366336754137- 41394531-4533454945524640-464346515279-5283 5744-57475980-59846095-60996103-61046155-6159 6186-61896235-623764846982-69847267-72687407- 74147576-75777681-76877778-77867798-78017906- 79127972-79758074-807681628211-82138247-8248 83708539-85428762-87668917-89189196-92009456- 94589475-947694789529-953098289905-99089925- 99269997-100091049010508-1051210592-10594 10624-106261093010936-10937109651102111505- 1150611538-1154011612-1163911772-1177411886- 1188911977-1197812027-1204112642-1264412814- 1282212872-12881 12978-1298112997-1299913087- 1308913592-1359513999-1400314090-1409114283- 1428814546-145511460414663-1466515182-15183 15258-1525915294-1529715326-1533115336-15340 15532-1553515869-1587015961-1596316096-16097 16163-1616416601-166081662316702-1670316724- 1672516836-168421689916918-1691917268-17274 17366-1736817455-1745617489-1749017525-17527 17958-1796218020-1802218421-184221852718655- 1865818719-1872218757-187581876118842-18845 1915119283-1929619306-19307193501937019387- 1938919401-1940219422-1943119488-1949619617- 196191962719663-1966619733-1973519749-19751 19814-1981519924-1992519972-1998020026-20027 20111-2011220151-2015420165-2016620231-20234 20265-2027020343-2034420349-2035420425-20426 20432-2043620447-2045120469-2047120491-20494 20514-2053520548-2055320575-2057820646-20648 20666-2067120698-2070720714-2071720747-20751 20758-2076620768-207872092620938-2094220952- 2095421027-2103121069-2107121097-2110021176- 2118021377-2139721647-2165521744-2174721925- 2192821948-2195021967-2196821971-2197422077- 2207922117-2211922152-2215622200-2220322218- 2222422323-2232822343-223462236522399-22404 22700-2270122763-2276422838-2284222870-22874 22881-2288622969-22970229982304623074-23076 2323623252-2325623373-2337823386-2339023434- 2343723543-2354423806-2380923890-2389224056 25085-250902530625338-2533925383-2540125705- 2571526196-2619926237-262392625226361-26365 2687926893-2689527304-2730527476-2747727497 27600-2760127729-2773927853-2785627861-27864 27940-2794227989-2799028199-2820328468-28484 29309-293142942630141-30142 skeletal Clontech SKM001 170-171255-256912981-9851259-12621280-1282 muscle 1436-14371483268329722975-29773661-36633740 4091-40954338-43394388-43904515-45164562-4568 4708-47115525-55265581-55835591-55926671-6672 6773-67747681-76877784-77867806-78087815-7818 7902-79037972-79757990-79928216-82188351-8360 8502-85038512-85138554-85559100-91449327-9328

Tissue RNA Library SEQ ID NOS: origin Source Name

1220812237-1223912259-1226212337-1236112430- 12431 12477-1247912555-125591263713077-13079 13592-1359513796-1379714032-1403314048-14053 14228-1423814264-1426514289-1429714445-14447 1460414794-1479515133-1514015182-1518315290- 15291 15360-1538015543-1554415561-1556215867- 1586815884-1588516062-1606516115-1611716418- 1642116496-1649716579-1658216724-1672516783- 1678616851-1685317074-1707717330-1733217335- 1733917441-1745017454-1745617940-1794217963 1800418029-1803018044-1804518055-1806018219- 1822318371-1837218423-1842518490-1849118516- 185181852718673-1867718719-1872218761 18796- 1880118811-1881318894-1889618906-1890718964- 1896918976-1897718989-1899019057-1905819066 19068-1907019102-191051915119209-1921219256- 19257193621937019401-1940219438-1944019442- 1944419548-195531956619580-1958219590-19592 19604-1960719617-1961919667-1966819672-19673 1969319709-1971019727-1973219736-1974219764- 1976719810-1981219943-1994720029-2004320048- 2005220074-2007920087-2009420111-2011220122- 2012720137-2014520151-2015420161-2016420250- 2025220274-2027820281-2028220366-2036820401- 2040520415-2042020437-2044020452-2045520491- 204942050420514-2052020524-2053520563-20567 20569-2057420653-2066520676-2068020718-20725 20727-207342075320806-2081220827-2083520882- 2088420938-2094220999-2100421032-2104521122 21157-2116921253-2125521272-2127421343-21350 214272144621463-2146521485-2149121529-21530 21587-2164621729-2173321973-219742197822047 22074-2207622090-22091221572216022187-22192 22208-2221122218-2222622246-2224922261-22264 22284-2228922347-2234822381-2238222411-22432 22434-2243522571-2258122637-2265122661-22662 22700-227012274022768-2277022828-2282922833- 2283422854-2285622870-2287422952-2295322977 2304623064-2306523070-2307123080-2308323212- 232152323523251-2325623379-2338523412-23414 2348723489-2349023492-2349323515-2351823802- 2380523867-238702388223893-2390223941-23956 24005-2401125085-2509025289-2529025334-25335 25347-2535425368-2536925403-2540725966-25968 26024-2602826258-2625926294-2630226347-26348 2635726409-2641026448-2645126604-2660626843 26860-2686227048-270492710527147-2714927225 27269-2727027281-2728727570-2757127595-27596 27607-2761527729-2773927758-2775927861-27864 27890-2789228008-2801128142-2814528311-28313 2842428882-2888729343-2934529409-2941629940- 2995329958-2995929962-2996330233-30235 adult Clontech SPLcOl 188-191546-547667-668697-699792-795934-935981 spleen 98510471259-12621411-14131705-171417772052- 205420722599-26032649-26503326-333133773661-

Tissue RNA Library SEQ ID NOS: origin Source Name

23046 2307023112- 2311623201- 2320223358-23360 23492- ■2349323543 -235442359923798-2379923841- 2384223845-2384823871-2387523893-2390224126- 2412925340-2534125966-259682660227067-27070 27080-^■2709027269-2727027302-^•2730327480-27481 2765728204-2820929328-293312935829418-29419 29950■2995330141 -3014230195-^■30199 thalamus Clontech THA002 124-125398-399464-465901-9041044-10451295-1297 1334-1336151415471806-18071809-18121817-1818 1820-18231826-18311833-18351837-18391925-1927 220123392354-23572410-24132471-24742561-2562 2675-267828062983-29863182-31873322-33233618- 36213789-37943853-38543926-39274515-45224531- 45334562-45684845-48514950-49515557-55605899- 590259926040-60426166-61686176-61836282-6283 6406-6410700073627580-75977615-76177681-7689 7978-798380208132-81368152-815681628206-8210 8230-82328253-82578701-870587168724-87328771- 87768822-88359049-90629305-931193829535-9537 9590-959297089719-97229792-979398289981-9983 9986-998810167-1017210326-1032810488-10489 10780-1078211405-1140711460-1146411766-11768 11835-11836118401190011937-1193812202-12205 1263712671-1267212701-127051272312829-12830 12978-1298113500-1350213552-1355513796-13809 1422714264-1426514314-1431714505-1454514604 14793-1479515025-1506915093-1509515661-15663 16096-1609716118-1612016141-1614316787-16788 1692016943-1694517038-1704117156-1715917242 17454-1745617571-1757418015-1801618097-18134 18651-1865418691-186921879618842-1884518919- 1892118925-189331901819096-191011913419256 19260-1926219295-1929619306-1930719355-19360 1944619512-1951319594-1960319620-1962219659- 1966119674-1967819727-1973219800-1980319814- 1982219919-1992019943-1994619950-1995720106- 2011020133-2013620146-2014820161-2016420167- 2017120180-2018120215-2021820235-2024020317- 2032020406-2040720432-2043620456-2046820514- 2052020524-2053520676-2068020827-2084320853- 2085421101-211042112221153-2115421211-21212 21229-2123221284-2129421353-2135421447-21450 21463-2146521477-2147921492-2149421554-21556 21718-2172421881-218852192422003-2200622040- 220412204722080-2208322090-2209122120-22127 22161-2216422225-2222622243-2224522256-22260 22290-222992236522381-223822239322531-22533 2257022625-2262822661-226622269022870-22874 22952-2295322969-2297023007-230212307123223- 2322523229-232332334223412-2341423420-23421 23489-2349023726-2373023781-2379223843-23844 2388223999-2400124005-2401124021-2402424120- 2412924231 -2424024471 -2447225085-2509025342- 2534325374-2537526205-2620626359-2636026375 2639826460-2646326678-2668027012-2701427397 Tissue RNA Library SEQ ID NOS: origin Source Name

27482-2748527662-2767227750-277562778127819- 2782027890-2789228095-280962828628361-28370 28468-284842936329508-2951830189-30194 thymus Clontech THM001 112180-181216227-230302329-330332524-525546- 547576-578697-699796-797900934-9351065-1066 1210-12111259-12621346-13471431 149915481551 1667-166816751681-16871705-17141721-17221777 2072-20752083-20842122-21242202-22032383-2388 2570-2574263628062913-2920299331283151-3154 33773508-35103649-365536863789-37943949-3953 4067-40724137-41394160-41624469-44704489-4493 4640-46435057-50595092-509451925335-53365654 5808-581262896403-64046450-64516488-64897216- 72197275-72767640-76427681-76877745-77467778- 77837902-79038113-81148132-81368163-81738253- 82578297-83068313-8314836784658607-86098758- 87598768-87708917-89188982-89839029-90369038- 90399049-90629196-92009391-93929456-94589472- 947494869517-95219529-95309594-96029617-9626 9739-97429794-979598269828-98329851-98529857- 98619909-991210273-102741027710498-10503 10508-1051210520-1053010533-1053410537-10538 1090611011-1101211069-1107011081 1116011252- 1127311314-1131511345-1135011406-1140711476- 1147811496-1149811579-1158111607-1160811715- 1171611731-1173411739-117401184011901-11905 11947-1195012121-1212612202-1220512283-12284 1247712555-12561126371272312984-1298513083- 1308613107-1311713556-1356213581-1358313592- 1359513603-1360813796-1379713896-1389713999- 1400314175-141811460414640-1464214694-14701 14818-1482015182-1518315277-1527815321-15322 1534415392-1539615406-154071543815568-15572 15576-1557715588-1558915988-1599016053-16058 16121-161221623716434-1643716461-1646416496- 16497166231664216653-1665516851-1687016899 17074-1707717105-171061711417238-1724118008- 1801718029-1803018097-1813418421-1842218579- 1858118583-1858418629-1863218644-1865018655- 1865818691-1869218750-1875618759-1876118806- 1880718836-1883818842-1884518857-1888018899- 1890318947-1895019001-1900419068-1907019209- 1921019283-1929419310-1931219316-1931719345- 1935019362193701937219380-1938419415-19417 19441195661962719659-19661 19670-19671 19693 19706-1970819727-1973219736-1974219749-19751 19813-1981519921-1992319943-1994619962-19963 20029-2004320087-2009420111-2011220128-20129 20146-2015420161-2016420182-2018820208-20214 20244-2025320265-202702028920328-2033020360 2036220406-2040720412-2041320415-2041720425- 2042620437-2044020485-2049020495-2049820505- 2050920514-2052020524-2053520542-2054520563- 2056720621-2062420631-2063420646-2064820681 20698-20707207532076720853-208542088120897-

Tissue RNA Library SEQ ID NOS: origin Source Name

8059-80638113-81168132-81368206-821082508258- 82628301-83068351-83608422-84488453-84608465 8490-84918502-85038519-85258539-85428588-8597 86888758-87618771-87798790-87998917-89188998- 90019013-90209029-90309049-90679075-90789306- 9311931693539420-94239456-94589482-94859506- 950995319603-96049617-96269726-97279729-9731 9743-97449763-97699782-978398269848-98509857- 98619874-98959909-99249929-99359965-99809984- 99929997-1000910015-1001610161-1016310167- 1019610273-1027410281-103041030610326-10328 10454-1045710470-1047310498-1050310506-10507 10531-1053210588-1059110628-1063010638-10639 10931-1093310941-1094211024-110251108111161- 1119711212-1121611220-11221 11308-1131011314- 1131511339-1134411493-114941154611658-11659 11680-11691 11745-117481184011901-1190512050- 1205612117-1211812175-1218112192-1219312202- 1220512245-1225312312-1232812331-1233212362 12374-12377124341-2562-1256312590-1259212606- 1261212623-1263612638-12640127231272912785- 1278712796-1279812805-1280612824-1282712829- 1283012869-1287012872-1288112973-1297412997- 1299913505-13511 13517-1352313668-1367213796- 1379713854-1386013865-1386613954-1395614004 14044-140451410014127-1412814137-1413814187- 14191 1431314380-1438114552-145551455714607- 1460914661-1466914673-1468314787-1478814822- 1483814999-1500115019-150241509615182-15183 1525715277-1527815300-1530115329-1534015358- 1535915392-1539615439-1544215454-1545615480- 1548415496-1552515545-1554615551-1556215576- 1557715600-1560115653-1565615661-1566315726- 15741 15861-158681587815881-1588315890-15895 15988-1599016053-1605816075-1607916158-16159 16163-161641623716352-1635316403-1640716418- 1642116470-1647216614-166151662316636-16637 1664216653-1665516771-1677216812-1681416836- 1684216873-1687416894-1689616911-1691216946- 1695317043-1705717074-1707717094-1710317105- 1710617112-1711617145-1714617297-1730617356- 1735817455-174641757917924-179261793917951- 179521800418015-1801718029-1803018062-18064 18097-1813418157-1816018376-1837918400-18402 18412-1841818421-1842218562-1857618629-18632 18644-1865018668-1867018673-1867718691-18692 18717-1871818750-1875818761 18767-1876918789- 1879318825-1882818842-1884518882-1888818899- 189031891018919-1892118955-1895918964-18969 19001-1900419059-1906519096-191011913419266- 1926719283-1929619306-1930719331-1934019350 19363-193641937019380-1938419387-1940219415- 1941719438-1944019464-194661948719515-19521 19526-19531 1956319567-1957319598-1960119604- 196071962519663-1966819670-196711969319699 Tissue RNA Library SEQ ID NOS: origin Source Name

19706-1970819733-1974819752-1975519759-19763 19804-1980819814-1981519823-1985419915-19918 19921-1992319926-1992919938-1993919948-19949 19953- 19961 19965-1998020029-2004320074-20079 20106-2011220122-2013020137-2014520167-20171 20208-2021420231-2023420244-2024920274-20278 20289-2029620345-2035420357-2035920401-20405 20441-2044620456-2046820472-2047420476-20479 20485-2049620502-2050320505-2051020514-20553 20558-2057420599-2060620616-2063620639-20641 20646-2065220676-2068020698-2070720718-20725 20727-207342075320789-2079120819-2082120824- 2084320853-2085420868-2087020879-2088020890- 2090020924-2092520938-2094220952-2095420957- 2096220977-2098821005-2100821016-2102021026- 2104521060-2106621072-2108721097-2110021105- 2111121123-2112721133-2113521176-2118021194- 2119821208-2121521233-2123521241-2124721277- 2128021295-2129621301-2130321359-2136021377- 2139721410-214142141721428-2143321440-21445 21447-2145021492-2150021516-2153021554-21556 21647-2165521729-2173321881-218852189121915- 2191621924-2192821948-2195021962-2196821975- 2197721989-2199322007-2201522020-2202922074- 2207922090-2209422101-2210722128-2213822152- 2215622161-2216422171 -2217722204-2220722212- 2222422253-2227622284-2229922310-2231122319- 2232222336-2234622349-2235022358-2236122365- 2237122377-2238022383-2238822440-2244822495 22561-2256522571-2258122607-2260922644-22651 22653-2265422663-2266422678-226792269022708- 2270922763-2276422801-2281622823-2282722835- 2283722854-228582291122925-2292622941-22947 2297123007-230212304623051-230522306323066- 2306723074-2307623085-2308623098-2310123109- 2311123125-2313623138-2314023206-2320923212- 2321523218-2321923252-2325623261 -2326223343- 233442334623356-2335723379-2338523392-23398 23415-2341823439-2345023470-234722348623492- 2349623521-2352323555-2356523675-2368123704 23718-2371923731-2374223760-2376723802-23805 23812-2381323834-2383523839-2384023845-23848 2386523867-2387023903-2390423990-2399224014- 2401824021-2402424035-2404024481-2449025289- 2529025323-2532525347-2535425383-2540125461- 2547026029-2603126116-2612026270-2627926294- 263022633726341-2634426373-2637426383-26385 26389-263932641526455-2645926467-2647026610- 2661226657-26659267322674226757-2677126796- 2679826855-268572687926882-2688427100-27102 27127-2713227173-271742721827247-2725127269- 2727027497-2750027520-2752127562-2756327586- 2758727600-276012762127649-2765427674-27676 27784-2778827807-2780827812-2781327865-27868 27938-2793927995-2799828001-2801128018-28039 Tissue RNA Library SEQ ID NOS: origin Source Name

28042-2804328045-2808628099-2810028142-28145 28192-2819828263-282682828628315-2831628360 28363-283642842428468-2848429250-2925229278- 2928329304-2930829328-2933729343-2934529354- 2935729432-2943529529-2953429655-2965930150- 3015630189-3019930361-30368 thyroid Clontech THR001 197-200221255-256259-260309324-325329-330333- gland 335395464-465524-525546-547635656684690-691 847-848852-859872-875891900-904913919-922929- 931957-958969-971981-9851034-103710471092- 10941109-11101123-11271235-123712421273-1279 130713371409-141014311453-14541467-14691488- 14891553-15551557-15591667-166816751705-1714 182818401850-18521856-18601862-18631865-1873 1879-18801885-18891912-19131925-19271945-1946 1964-19661969-19701990205820622130-21312222- 22262275-227623062354-23552360-23672383-2388 2393-23952471-24742480-25112513-25142540-2541 2597-26032663-26652679277928062826-28272871- 28732951-29552983-29862988-298930043006-3008 3107-310831313144-31463151-31543306-33083310- 33113316-33213366337734333441-34423448-3450 34663512-35143526-35293555-35583565-35883679- 368236933763-37653789-37943834-38353944-3955 4067-40724124-41264160-41624489-44934512-4516 4555-45564562-457346074612-4614465546664701- 47044712-47134720-47254785-47894795-48094868- 48714971-4974506550735109-5115511851925276- 52785285-52875335-53365519-552158025805-5807 582358465899-59065919-59215994-60006106-6109 6155-61596284-62886290-629663006341-63436386 6403-640464906533-65356542-65436551-65676859- 68766982-698472037209-72127216-72197350-7352 7450-74517482-75177536-75417554-755576087611- 76127615-76177630-76367671-76737678-76877701- 77037734-77367757-77597763-77707805-78087815- 781878227972-79757978-798379887990-79927994 80028049-80568059-8063807080798087-80898113- 81148137-815981618174-81778206-82138221-8229 823482498251-82658297-83008313-83148349-8362 8368-83698383-83898409-84148434-84528465-8476 8497-84998506-85088512-85138534-85358537-8550 8607-86098751-87538762-87678917-893389979037 9040-90459072-90749264-92659331-93339360-9361 9391-93929395-93969408-94149429-94309444-9448 94609472-94779486-94889522-95349561-95669617- 96269682-96839709-97139726-97279729-97319735- 97389757-97629770-97719782-97839794-97959828 9835-98409848-98529899-99049923-99249929-9935 9954-99559965-99689981-99839989-99929997-10009 10015-1001610025-1002610033-1003710164-10166 10275-1027610278103061031110326-1032810451- 1045310470-1047310490-1049310498-1050310520- 1052210533-1053410537-1053810543-1054910592- 1059410609-1061110615-106231062710881-10883 Tissue RNA Library SEQ ID NOS: origin Source Name

10895 -1089810903 10931-10933 1094510957-10958

1097110980-1098511035-1103711042-1104411071-

11075110811113511147-111561116011217-11219

11274-1127511295-1129611345 -1135011419-11422

11468-1147211476•114781154611607-1160811660-

1166111731-1173411766-1176811780-1178211811-

1183211835-118361184211901- 1190511921-11930

12011 •1201512017•1202212175 ■1217612186-12193

12206 ■122081222512241-1224412259-1226212366-

1239712470-1247112486-1251812545-1254612555-

1255912615-1261812637127231272912760-12762

12785 •1278712796■1279812803 •1280412829-12830

12968 •1296912975 ■1297612978 •1298112984-12992

12997■1299913087■1308913107 ■1311713425-13495

13531 ■1353513560■1356213592■1359513603-13605

13931 •1393313954■1395614023 •1402614058-14059

14130 •1413114170^■141721420614228-1423814261-

1426314298-1430514382-1438514505-1454514604

1462614644-1464814650-1465114666-1466814681-

146851478414789- 1479115182- 1518315257-15259

15290 •1529315306•1532015332 ■1533515345-15346

1535815359153861538815400-•1540315454-15456

15538 ■15541155451554615576-■1557715588-15589

1566115663156991570015789- 1581415869-15870

1588015902-1590315988-1599016044-1604616075-

1607916096-1609716121-1612216130-1613216168-

1617116200-1620116219-1622016269-1627016279-

1628016451-1645216461-1646416470-1647216484-

1648616496-16497165351655716570-1657316579-

165821662316632- 1663416636-166371665216686-

1669316727-1672916851-1685316875-1687716894-

1689616911-1691216921-1692316943-1694516954-

1696117038-1704117046-1705717094-1710017105-

1711117131-1713217237-172421727917284-17285

1733017332173351733917372-■1737417441-17450

1745417456174931749617610-■1763617924-17926

1795817962179981799918001-■1800318015-18016

1802918030183761837718421-■1842518492-18494

1850018501185331853418536-■1853718625-18626

186551866018671 1867218691-■1869218717-18718

1872318726187301873218738-■1874418767-18769

1877818780187871878918796-1880418806-18807

1882518828188351883818842-1884518857-18880

18894189031891018919-1892118925-1893518941

18946- 1895018960- 1897318976189771899619001-

1900919029-1903519045-190481905519057-19058

19062- 1906619074-19083190961910119106-19118

19138- 1914019142- 1914819154191551915919254-

192551925719266-192671927419283-1929419306-

1931219316-1931719345-19360193621937019380-

1940219405-1940619415-1941719422-1943419442-

1944419458-1946119484-1948619494-1949619515-

1952119548-1955319560-1956219564-1956619574-

195781959319604-1960819617- 1961919627-19655

19667-1966819683-19687196891969319727-19735 Tissue RNA Library SEQ ID NOS: origin Source Name

19743-19751 1975619759-1976319768-1977219804- 1980819814-1982219855-1985619921-1992919933- 1993719939-1994619948-1994919953-1995719962- 1996319965-1996719972-1998120015-2001720029- 2004320048-2006520074-2007920087-2009420099- 2010220106-201132012020122-2012720130-20132 20137-2014820167-2017920189-2019420208-20214 20235-2024020250-2025320265-2027020274-20278 20289-202962029920305-2030720316-2032020328- 2033020345-2035420391-2040020415-2041720425- 2043120437-2045120485-2049020497-2049820501 20510-2052020524-2053520537-2054520554-20567 20575-2057820614-2061920642-2064320676-20681 20686-2068820698-2071120726-2073220752-20753 20758-2076620789-2079720806-2081220819-20821 20824-2084920853-2085420858-208632086520881 20890-2090020922-2092320929-209352094320952- 2095620963-2097220977-209882099120999-21004 21027-2104521060-2106621069-2108721097-21114 2112221145-2115121202-2120721223-2122621233- 2123521248-2125221256-2127121277-2129421301- 2130321326-2133421340-2134221351-2135221377- 2139721408-2140921434-2143921447-2145021458- 2146121477-2148221495-2150021516-2153021587- 2165521913-2192121929-2193521967-2196821973- 219742197821989-2199321995-2201822020-22029 22042-2204422050-2205922074-2207622092-22094 2209722115-2211622141-2214322152-2215622160 22187-2219222195-2219822204-2222622246-22255 22271-2228922292-2229922314-2231822323-22328 22333-2233522343-2234822358-2235922365-22371 22383-2238822399-2240822434-2243522440-22448 2249522534-2253922553-225582256022571-22581 22599-2260222607-2260922622-2262822634-22643 22653-2265422661-2266222700-227012270722741- 2274222760-2276222768-2277022805-2281622823- 2282922833-2283422846-2284922854-2285822870- 2287422927-2293822948-2295022955-2295722969- 2297122991-2299423047-2305023059-2306023066- 2306723070-2307123074-2307623085-2308623098- 2310123117-2311923123-2312423218-2321923242- 23244232492325123261-2326223358-2336023382- 2338523392-2339523439-2344723470-2347223489- 2349323510-2351123514-2351823524-2352523532- 2353923543-2354423682-236862370423718-23719 2376123771-2378023793-2379723806-2380923827- 2383323843-2384423856-2386023871-2387723890- 2389223906-2391023941-2395623999-2400124005- 2401124014-2401824026-240282405624126-24129 24772-247742530625316-2531825323-2532525334- 2533525340-2534125370-2537525534-2553625966- 2596826024-260282619526209-2621326235-26236 26248-2625226294-2630226307-2630926316-26321 263272633726341-263442634926359-2636526373- 2637426383-2638526401-26402264052641126424 Tissue RNA Library SEQ ID NOS: origin Source Name

26440-26445 2645326596 -2660226615- •2661626732 2673726796--2679826843 •2684526850-^■2685226858- 2686226876--2687926891 -2689226980-•2698426988 27048-270492705227074 -27077270912710527122- 2712627147--2714927209 -2721327229-•2723227269- 2727027275--2727627414 ■2743127439-■2744327468 27486-274922749627498 ^■2750027510-^■2751127589- 2759227602--276062762227636-2763927649-27654 2765827662--2767227698 ■2769927726-■2773927744- 2774827767--2776827816 ■2781827840-•2784427848- 2785227861--2786427890•2789227896-2792727989- 2799028019-■2803828097■2810028142-2814728161 28192-2819828204-2820928290-2829228311-28313 28315-2831628361-2836228365-283702842028424 28435-284392846428468-2848429117-2912329278- 2928329309-•2931429332-2933729364-2936629378- 2937929940-2995330135-3014230150-3015630195- 3019930224-■3023230240-3024230361-30368 trachea Clontech TRC001 177-178180-181255-256395518-519546-547847-848 919-922934-9351312-1313143115611667-16681875- 18771879-18801884-18922015-20182370-23732516 29262951-295530013165-31693322-33233441-3442 35253622-362336763840-38523949-39534067-4072 4151-41554158-41594386-43874515-451650565253- 52665337-53415530-553158466002-600461136226- 62347618-76217745-774677947806-780879888041- 804283428449-84528510-85118543-85508576-8582 8919-89339049-90629264-926595319729-97319739- 97429786-979098289848-98501030610449-10450 10551-105541086910980-1098511123-1112411252- 1127311731-1173411906-119071236012374-12377 12432-1243312760-1276212872-1288113609-13612 13632-136331400414048-1405314058-1405914105- 1410614170-1417214207-1420814546-1454914604 15290-1529115491-1549515588-1558916434-16437 16636-1663716666-1666716727-167331707317455- 1745617958-179621852718633-1863718673-18677 1879618857-1888018882-1888818894-1889618975 19057-1905819074-1908019084-1908519138-19140 193621937019401-1940219422-1943119494-19496 19749-1975119764-1976719953-1995719962-19963 19972-1998120257-2026220265-2027020289-20296 20441-2045120472-2047420548-2055320631-20634 20698-2070720727-2073220792-2079720813-20815 20929-2093220952-2095420973-2097621060-21066 21097-2110021137-2114021171-2117421297-21298 21403-2140421410-2141621447-2145021973-21974 2197822135-2213822171-2217522358-2235922383- 2238822455-2246522551-2255222634-2263622760- 2276222828-2282922870-2287422955-2295722969- 2297022972230712322223261-2326223382-23385 23726-2373023762-2376323827-2383323871-23875 23890-2389224126-2412924772-247742530625347- 2535426270-2627226341-2634426469-2647026665- 2666626876-268792705227129-2713227557-27559 Tissue RNA Library SEQ ID NOS: origin Source Name

27600-2760127814-2781527819-2782028142-28145 282332936730141-30142 uterus Clontech UTR001 124-125188-191227-230251-252301329-331738-740 919-922102810471453-14541562-15641705-1714 1893-1901 1912-191323662374-237729262988-2989 30013205-32074557-45604712-47134971-49745903- 59065919-59216114-61366235-62376403-64046533- 65356625-66266932-69387678-7680772877717798- 78017921-792379468010-80128084-80858090-8093 8137-81418313-83148368-837084158420-84218689- 86909072-90749264-92659517-95219535-95379577- 95789828-98329848-98509929-9935995310033- 1003710268-1027210508-1051210537-1053810980- 1098511071-110751113511505-115061154611609 11731-1173411803-1180412023-1202612046-12049 12190-12191 12378-1239712432-1243312894-12897 13107-1311713592-1359713888-1389513954-13956 14058-1405914261-1426314445-144471460414650- 1465114988-1499215182-1518315187-1518915290- 152911539015576-1557715699-1570015855-15857 16145-1614616174-161761660016643-1664816716- 1672316851-1685317330-173321745417958-17962 18015-180161852718655-1865818673-1867718761 1878918825-1883418894-1889618899-1890318936- 1893919036-1903919074-19083193621937019375- 1937919387-1938919442-1944419560-1956219609- 196151969319727-1973219764-1976719816-19818 19926-1992919933-19937199501998120029-20043 2012020122-2012720146-2014820151-2015420289- 202962029820328-2033020366-2036820401-20405 20427-2043120469-2047120491-2049420554-20557 20602-2060620629-2063020649-2065220689-20692 2075320758-2076720801-2080520858-2086220864 20938-2094221005-2100821072-2107521213-21215 21281-2129421377-2139721911-2191221955-21957 21978-2198222019-2202522050-2205522090-22091 22187-2219222218-2222422251-2225222261-22264 22358-2235922362-223642237322405-2240822571- 2258122622-2262422644-2265122663-2266422887- 2289122955-2295722969-2297023047-2305023094- 230972314123425-2342723439-2344723543-23544 24029-2403324130-2414425085-2509025340-25341 25374-2537525416-2541726221-2622326270-26272 26285-262902632726607-2660926676-2667726755- 2675626853-2685426860-2686227173-2717427294 27348-2735327493-2749627602-2760627636-27639 27649-2765427729-2773927861-2786427896-27927 28105-2812128133-2813728311-283132842428426- 2842829339-2934029378-2937929962-2996330150- 30156

*The 16 tissue-mRNAs and their vendor source, are as follows: 1) Normal adult brain mRNA (Invitrogen),2) normal adult kidney mRNA (Invitrogen), 3) normal adult liver mRNA (Invitrogen), 4) normal fetal brain mRNA (Invitrogen), 5) normal fetal kidney mRNA (Invitrogen), 6) normal fetal liver mRNA (Invitrogen), 7) normal fetal skin mRNA (Invitrogen), 8) human adrenal gland mRNA (Clontech), 9) human bone marrow mRNA (Clontech), 10) human leukemia lymphablastic mRNA (Clontech), 1 1) human thymus mRNA (Clontech), 12) human lymph node mRNA (Clontech), 13) human spinal cord mRNA (Clontech), 14) human thyroid mRNA (Clontech), 15) human esophagus mRNA (BioChain), 16) human conceptional umbilical cord mRNA (BioChain).

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3400 33768 A 3437 2052 MVLVVVAVVVVVLVVAVIVV

VVVVVAAVVVGAVVVVVVVV

MVVVVVVVVVEEDNQHKTGA

INNNNTAKNPQQSPFHSPATST

GAEATQMRRNQKTNPHNMTK

QVSLTPPKITLAHQQWIQTKKK

YLIYLKKHSGVNKIPRNPTYEG

CEGPFQGELQTTAQQNKGGHK

QTEDHSMLMDRKNQYCENGH

TAQAVPNPYTLLSQIPEDAEWF

TVLDPKHAVFCIPVHPDSQFLF

AFEDPSNPMSQLIWTVLPQGFR

NSPHLFGQALAQDLSQFSYLDT

LVLRYMDDLLLATHSETLCHQ

ATQALLNFLATCGYKVSKPKA

QLCSQQVKYLGLKLSKGTRTLS

EERIQPILGYPHPKTLKQLTAFL

GITGFCQIWIPRYSKIARPLNTRI

KETQKANTHLVRWTPEAEVAF

QALKKALTHAPVLSLPVGQNFS

LYVTEKYTGIALGVLT/PGTSAQ

LAELIALTRAPELGEGKRVNIY

ANSIGREREFLTSKGTLVKHQE

AIKRLLLAVQKPKEVAVLHCW

GHQKGKEREIEENRQADIEARR

A ARQDPPLEM LTEGPL AFEL A

MATARAELSLAIHHCCLPPPPQ

TRC WLPSLRIRQG VCC I PDPAR

AITLTAWPKIPFLGIRKAKNPRS

EKTRLATILEAACCHFGSGPPPS

WELWEQGPPVTVQTHILRSHL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkπown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3450 5818 3487 2302 MTECLDRFIDS1AAVPRSTKSTV

QKCLPCLSDGEDKIPDLIAITWT

PRQGELLEKNVISETGTLLPTPC

LDTSTKETADKSTSGKTIHQSIK

TVLKDLSGSIDDLPTGTEATLSS

AVSASGSTSSQGDQSNPAQSPF

SPHASPHLSSIPGGPSPSPVGSPV

GSNQSRSGPISPASIPGQDPGYG

NS/DKSMGHEYSQR/SFLEDRFP

IAVWWPRPLRLKNCLSVLSYSS

PSEVTPHPKSESSGTS/SAAQDL

QGCSQDVGQPASSSGGSTREQS

TSSFIRIVAASSPSSCWKLQVLL

SG/AGGDYSPVLLIGGYSRVCLP

Q*SDASAATREP/GQNPVPIPP*

ASHQCHRKEGPPCRQQAGASQ

MLSRD*AKQLKPSSSHTLSKHK

TT/GTRKSLLFGIKKAYNFTNKY

YSELMTQTRPQSTPSIPSPLPLD

DAGLERSQGNVSASSFMVLGN

RERGEDTTGAGFGRSRNKEEVP

CTIYVGAESP/EMC*WMDHT*R

KEGKGGLVGVPCV/SREHLEEW

QYQLQR*ISLKTQQV*RRKSEV

LLGRS/SNTAQACSCWQLTCFM

AGTQRNPQMAQYGPQQTGPSM

SPHPSPGGQMHAGISSFQQSNSS

GTYGPQMSQYGPQDGGGDVSD

VVMAIDDDGSCHLLGSAVPGA

VLVTFNLLLIIVVTLQMTEPQFR

EYITGDPLESTCRHASLALAVV

LHQETAMTMITDSLAVVPHSG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3499 53867 A 3536 2502 MTELTGIQQPQIVLFEHKGHKL

VQGSSSDAGKVNRIYQHYEAS

DKFNYTTGLAWKTAPEQTGKT

VRKQQIKLNVKKMESRSKMQE

HSSSPPMEQSWRENDFDELREE

AFRRSNYSELQEEIQTKGQEVK

NFEKTLDEYITRITNTEKCLKEL

MELKAKARELREECRSLRSRCD

QLEERVSVMEDEMNEMKREG

KFREKRIKRNEQSLQEKWDYV

KTPNLRLIGVPESDGENGTKLE

NTLQDIIQENLPNLVRQANIQIQ

EIQRTPQRYSSRRATPRHIIVRFT

K VEM KEKMLRA AREKEIQTTIR

E Y YKH L Y ANKLENLEEMDKFL

DTYTLPRLNQEEVESLNRPITGS

EIVAIINSLPTKKSP/GPVGFTAE

FCQRKVEGILSISFCEASIILIPKL

GRDTTKKENFRPISLMTIDTKIF

NKILANQIQQHIKKLIHHDQVG

FIPGMQGWFNICKSINVIQHINR

TKDKNHMIISIDAEKAFDKIQQL

FMLKTLNKLGIDGTYFKIIRAIY

DKPTANIILNGQKLEAFPLKTGT

RQGCPLSPLLFNIVLEVLAGAIR

QEKEIKGVQLGKEEVKLSLFAD

DMIVYLENHIVSAQNLLKLISNF

SKVSGYKINVQKSLAFLYTNNR

QTESQIMSELPFTIASKRIKYLGI

QLTRDVKDLFKENYKPLLNEIK

EDTNKWKNIPCSWVGRINIVK

MAILSKVIYRFNAIPINLPITVFT

SEQ ID SEQ ID NO: Met SEQ ID NO- Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possιble nucleotide sequence 09/540,217 codon lor peptide ol peptide sequence deletion, \=possιble nucleotide insertion) sequence

3500 33868 3537 2197 MNNAKENFLGRFQDGRIGTAP

VYSPQHQRRRRRVISALPTEPPL

VIPRQTGFGVDLQQTPTDLQLR

VLTVRRKTTKQEGHSTKTPSVR

YHHQRPKEDKTTKMGRNQSRK

AENSKNESASSPPKECSSSPATE

QSWMENDFDKYTEVGFRQLVI

TNFSELKEDVQTHHKEAKNLE

KRLDEWLTRINSIENTLIDLMEL

KTMARELRDSCTSFSRQFDQVE

ERVSVIEDQMNEMKREEKFRE

KKMLEVLPRAIRQEKEIKGIQL

GKEEVKLSLFADNMTVYLENPI

ISAQNLPKLISNFSKVSGYKINV

QKSQ AFLYTNN RQTESQIMSEL

SFTIASKRIKYLGIQLKRDVKEL

FKNYKPLLKEIKEDTN K WKN IP

CSWVGRTNIVKMAILPKIIYRFN

A I PIKPPMTFFTELEKTTLKFI RN

QKRAHIAKTILSKKNKAGGIML

PDFKLYYKATVTKTAWYWYQ

NRDIDQWYRAEASEIMPHIYNY

L1FDKPEKNKQWGKDSLFNKW

CWENCLAICGKLKLDPFLTPYT

KINSRWIKDLNVRPKAIKILEEN

LGNTIQDTGMGKDFMSKTPKA

MATKAKIDKWDLIKLKSFCTA

KETTIRVNRQPTKWEKIFATYS

SDKGLISRIYNELKQ1YKKKTN

NSINKRAKDMNRHFSKEDIYAA

KRHMKKCSSSLAIREMQIKTTM

RYHLTPPEVEVVLETL/NH/RSW

3501 33869 3538 242 NLEEMDKYLDTYTLPRLNQEEF

ESLNRPITGSEIEAIINSLPTKKSS

GPDGFTAKFYQSIVLEVLARAI

RQEKEIKGIQLGKEEVKLSLFA

DDMIVYLENPIISAQNLLKLLSN

FSKVSGYKINVQKSQAVLYTN

NKQTESQIMSEPSFTIASKRIKY

LGIQRTRDVKDLFKENYKPLLN

KIKEDTNKWKNTPCSWIGRINI

MKMAIVPKVIYRFNAIPIKLPM

TFFTELEKTTLKFIWNQKRARIA

KSILSQKN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3587 53955 3624 2056 REALQGIQVRLKHLRTFG1IVPC

QSPCNTLLLPFPKPRTKDYSQV

QDLRLLHQATLTFHPTVPNPTT

LLGLLPAKDSGFTCLDPKDAFF

PIRLAPERQKLFAFQWEDPESG

VTTQYTWTGLPQGFKNSPTIFG

EAWARDLQKFPSRDLGCVLLQ

*VDDLLLGHPTAVGCAKGTDA

LHRHLEDCGCKVSKKKAQICR

QQALAATALRVQEANKLTLEQ

NLNIKASRAVVTLMNTKGHHW

LTNARLTQYQTWLCENPRITIE

VCNSLHPATLLPVSESPVEPRC

VEVLDTIDSSRPDLRGQPWASV

DWELYVDGSSFFNPQGERGAG

CAVITLDTVVEARSLSQATSAQ

KAELIAFIRALELS/EGRKGLSPG

RGKDK*WRKDGFGYRMGEYC

ATAARSCSCTGCARNHPSTSGV

TGKVVRPVFLHLAFVS\FAKTV

RQRCVTCRQHDARQGPAVLPGI

G A YG A APFEG LQ VDFTEMPKC

GGNKYVLVLVCTYSGWVEAYP

TLTEKAREVTRVLLRDLIPRFRP

PLRIGSDKGPAFLAALLQKTAK

MGTRSDTQLAHIGTVLRDIHVS

VCSDGPNLRTGLNVILGGVEW

QSTPGNLVRRQGETGLHLHIYH

WWQAVAIFPVYLGSSLHMKVG

GRSFEQEEDTEHIPVSYDREGQ

ECDTELKGQEGDELEAGSVVP

3588 33956 3625 491 964 R1QLCCRTRGTGAQKKRMKVS

SRCTPAPATRGTGAWQPQAQQ

APGVRATEAPRL*AHDEVSQPA

PAPPSTRHSPRR* PVAGKEHLE

AAVDKERHEVAQAVVTHVLEG

QLEDVAPAHAAQI/GSPPWAGK

RLRTNPAPRPCHPIQTLSRRLGP

QNHTLLH

3589 33957 3626 131 351 NVGLKGTAGER\GGSGPPS*PPA GRNSGPAGRRPPAARAPTPGSA AR*PAPPGPPRPPAGRGAAAAA GPAGGGA

3590 53958 3627 428 G EWEA PPLLRHTRPG PA/PAPPA

PSGASCAPCGGQTCRPRPLRQA

PPSPITTGHARIWLGQPRPRSSS

ATPPKELP*GPTE\PHTGELWVA

SGSCPSGTKLPEEGSGSNTYFSA

VSAGDTQSNIIWNGPPANSNRP

AAEGPDC

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3614 53982 3654 854 5009 VNSHSQLLQRE*NT*ESNLQGM

*RTSSRRTTNHCSMK*KRIQTN

GRTFHAHG*E/RVN1VKMAILP

KIQSDLTSHEISLEEMKKHNQG

KEAAQRVLSQIDVAQKKLQDV

SMKFRLFQKPANFEQRLQESK

MILDEVKMHLPALETKSVEQE

WQSQLNHCVNLYKSLSEVKS

EVEMVIKTGRQIVQKKQTENPK

ELDERVTALKLHYNELGAKVT

ERKQQLEKCLKLSRKMRKEMN

VLTEWLAATDMELTKRSAVEG

MPSN LDSEV A WGKATQKEI EK

QKVHLKSITEVGEALKTVLGKK

ETLVEDKLSLLNSNWIAVTSRA

EEWLNLLLEYQKHMETFDQNV

DHITKWIIQADTLLDESEKKKP

QQKEDVLKRLKAELNDIRPKV

DSTRDQAANLMANRGDHCRK

LVEPQISELNHRFAAISHRIKTG

KKPSWRRGVSNLGEMLVEVYL

KALMSEDLRKGINQDEFSPTIY

YFPITVFGSEGDLLLGKIRWIQG

AYCLMIGQDVFMDTRLRVSAC

FLKTKMKTVLWFDQNEDNEG

TVKELLQRGDNLQQRITDERKR

EEIKIKQQLLQTKHNALKDLRS

QRRKKALEISHQWYQYKRQAD

DLLKCLDDIEKKLASLPEPRDE

RKIKEIDRELQKKKEELNAVRR

QAEGLSEDGAAMAVEPTQIQLS

KRWREIESKFAQFRRLNFAQIV

3615 33983 5655 44 953 GVHNGVEELILVRRMQKSPGP

GEMESGSLEKEPLGTQTGPVPS

E/EYGIGLSQSI STKH PETSPKDS

RIRENDVTADGRTTEDHITADP

GTTEDSVTADPGTTEDNVTVDP

GTTEGSVTADPATTKDYVSADP

GTTKDSVTADPGTTENFVTADP

GTTKDSITADPRTTENFVTADP

GTTKHSITVDPGTTEDSVTADP

GTTKHSITADPGTTEDSVTADP

GTTEDETTKHGDTHLL*TTSVT

AVKPTRLLTPMGIILISLAATTV

TVVLFVGLGFIVKECFLPPLNPS

TRVIYHPHVMDYSTP

3616 33984 A !656 200 542 CSPPSTRPGPGP/SGTAWPGPRG TKRSSPSSSSSSPSTTSTTTSSSSS SSSSSSSSAPPRGFSSTRPSPLRR LLPPSSSSPSSSSSSPSTTSTTTSS SSSSSSASAGGRRAGTRG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3633 34001 A 3673 1270 MGDPSRRRTCRAMQAKYPLVF

KGCGVCWGSLDPRCRVASQV

WPIPKRLSRGWPFHNAVGRQV

SDWKSGQDFADFGTTHQTGFS

PAGANQRGPLAATLSGPGGEG

QSAVARLTGEKKNHPGAQYAN

RLSPRVGRFINAAGTTGFPTGK

RAVSATQLMILCLLPGYLCNGK

RKLSAIQGLLDNGSELSLFPENP

KRHCGLPVKVGAYGGQKTDRS

WRKTVDYCKLNQVVAPIVAAV

PDV/WSLLEQINTSPGTWYAAI

DLTNAFFSIPVHKAHQKQFAFS

WQGQQYTFTVLPQGRWEINMT

KIQGPSTSVKFLGVQWCGACQ

DIPSKVKDKLLHLVPPTTKKEA

QHLTGLFGFRRKYIPYLGVLLC

PIYQVTRKAASFQWRPEQEKAL

QQVQAAMQAALPLGPYDPAGP

MVLEIAVADTEAVWGH

3634 34002 3674 1978 LTIYAVNLSLILPQGDLWPFTRV

TVH*GKGNDQTFQELLDTGSEL

TLIPGYPKRHCCPPVKVRVYGG

QVINGVLAQV*LTVGPVGPRTH

PWISPVPECIIMLSSWQNPHIGF

LTGRARAIMVGKAKWKPLELT

LPRKIVNKKQYHILGGTVEISAT

IKDLKDTEAVTPTTSPFΝSPIWP

VQKTDGSWRMTVDYCKLΝQV

VTPIAAAVPDWSLLEQIΝTSPG

TWFEWSPK\KALQQVQAAVQA

ALPFGPYDPADPMVLEVSVAD

RDAIWSLWΝAAIGESQRRPLGF

WSKALLSSADΝYSPFERQLLAS

YWALVETERLTVGHQVTLRPE

LPIMΝWVLSDPSSHKVSGAQQ

RSIIKLKWYIHDWVRAGPEGTS

KLHEEVAQMPMVSTPATLPSLS

QPALMASGGVPYYQLTEEEKT

RAWFTDGSARYAGTTQKWTA

AALQPFSRTPLKDSCEGKSPHH

PVIAQWAHEQSGHGGRDGGYL

WAQQHGFPLTKADLAMATAE

CPICQQQRPTLSPRYGTIPQGDQ

PATWWQVDYMGPLPSWKGQR

FVLTGIDTYCGYGSAYSARΝAS

AKTTIHGLTECLFHCLG1PHSIA

SDRGTHFMDKEAPSASVLGLA

LALLAPQLADSLLEDPVIVKGT

DEAEYFQSVREEPDSGVKRKK

MLKSGKΝY

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3692 34060 3732 5695 MGKRSFERVLVDKCDSGRSCL

RKQHENECAFIQILDTQSLMIPG

QRGSFRLADSQHTDRVLCTLM

AEKWDRKALSYTRNSFRAQIRL

RKTRFQGKGCMICKKSRVLPY

QAAYVSQHGSACQPSSHLPSVG

SLSSTGDDEEEEEIVHMGNAIM

SFYSALIDLLGRCAPEMHLIQTG

KGEA1RIRSILRSLVPTEDLVGII

SIPLKLPSLNKDGSVSEPDMAA

NFCPDHKAPMVLFLDRVYGIK

DQTFLLHLLEVGF

3693 34061 3733 2523 MKQFLLYLDESNALGKKFIIQDI

DDTHVFVIAELVNVLQERCHTR

LGYTEFLVAWRVTFGLCVEAV

TLHLKYQILIRGLLEMMSFSDA

DILKQLPVTVPGLFPASLSPSSL

LGNSPPSWLRHNSESKVSAVSS

PSATKTLSTGIGKLDPGHKEMA

EESELLKNKMQAPPLSRCPESQ

KCQHQLRLHHWKPSVRHQVKR

RSPAVLRSAMPPADCPAVLEAT

TATHPEKGTALSKHLPSSDSMS

LKVDVE A LENSPGATYI WKGG

KVTRDSQPKEQGKGDLKKKKK

GKLPKNYDPKLTPDPERWLPM

QECSFYQGRKKGKKKDQMGK

GTQGATAGASSELDARKTVSSP

PTSPRPGSAATLSASTSNIIPPRH

QRPAGAPATKKKQQQKKKKG

GKGFPVLREITWKVDTLWFQ

ILEERLSVFHIQYDTSYPFSTVDI

EDHECAVWLLLRKSKSDDKTT

RLEAVREMSETHHWHDAEKAF

DKIQQPFMLKTLNKFGVDGTY

LKI I RAI YDKPTAN I ILNGQKLE

AFPLKTGTRQGCPLSPLLFNTV

LEVLARAIRQEKEIKGIQLGKEE

VKLSLFAGDIIVYIENSIVSAPKL

LKLISNFSKVSEYKINVQKSQAF

LYTNNRJ-ΠΈSQIMSKLPFTIATK

RIKYLGIQLTRDVKDLFKENYK

PLLNEIKEDTNEWKNIPCSWVG

RINIMKMAILPKVIYRFNAISIKL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3774 34142 3814 75 807 GIAGFVNIHLDSLSFLTGVPGVK

AERF\E*RMTAKHCALSLVGEPI

MYPEINRFLKLLHQCKISSFLVT

NAQFPAEIRNLEPVTQLYVRVD

ASTKDSLKKIDRPLFKDFWQRF

LDSVKALAVKYLQRIGSRTPM

DTKIYSYCPAVHPAEPTDMKS

WPSLFEVPTSLEYCPFYLQLVES

ADAEGTQKYRRLTAYYIPVYTE

PPLITKEPSCLWKQAEFGDLGK

HVWLVEQFSSTRVQEHGVGW

3775 34143 3815 35 2088 KVMNKRSQTQNGTRYMTPPPR

SSHTKQHLL\PTPPPRSSHTKQH

PLHDPITTKLTH RT/CTR YTTPSP

RSSDTEQHPL\PAPSPRSSDTEQ

HPL\PAPSSRSSDTEQHPLHDPT

TTKLTYRTAPATRPHHHEAHTQ

NSTRYTTPSPRSSDTEQHPLHGP

ITTKLTHRTAPATRPHHHEAHT

QNSTRYTAPPPRSSDTEQHPLH

GPTTTKLRHTTAPATRPHHHEA

HTQNSTRYTAPSPRSSDTEQHP

LHGPITTKLTHRTAPAT/PAPSP

RSSHTEQHPLPAPPPRSSDTEQ

HPLHGPTTTKLTHRTAPATRPH

HHEAHTQNSTRYTAPPPRSSDT

EQHPL\PAPPPRSSHTEQHPL\PA

PSPRSSHTEQHPL\PAPSPRSSHT

EQHPLHGPITTKL/STQNSTRYT

APSPRSSDTEQHPL\PTPSPRSSH

TEQHPL\PTPSPRSSHTEQHPLH

GPITMKLTHRTAPATRPHHHEA

HTQNSTRYTAPSPRSSHTEQHP

L\PAPSPRSSHTEQH PL\PAPSPRS

SHTEQHPLHGPITTKLTHRTAP

AP/PTPSPRSSDTEQHPLHGPITT

KLRHRTAPATRPHHHEVQEQA

KPIK*PPRPSPETTRAQPREPAV

TLLPSGALGQACPCDATAGPHG

TTLWPAVPPRWQQHLTRELLH

PVPRACP*QGQGQPFTAGPGRG

SHPYDPTGASPKGQSSIL

3776 34144 3816 83 84 RLTLPDRLGSPPDTH*AQHITRA VLPQGFTDSPH

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3819 34187 5859 852 DEEEWAREEEEEEEEEEMVPE

ESMASAGPEDFEQDGEEAALA

RGAPAVDSLGMEEEVDIETEPV

AHEKRPSMLDEPPLPVGVEEPA

DSREPPEEPGLSQEGAMLLSPEP

PAKGLAHPNGSQKV1FRVPLRV

IHGPKAVELQVFPGLHKQPTNQ

PK/TEPCDPHSWFKSCYHLLFIP

VGISRPP/HNPTITATIFASTASV

LW/PVLDTCMSSNSGYFKAVLE

SYSSKVLSVTQYGNPRATGSAG

LRGRPGS\PGSSGSRGPAWP*PQ

AAPRCPPSSGRPGPTSQSPS

3820 34188 A 5860 1997 AQGSWPGLFWAFLQLEVNCL

LESPIIQGKFHFRLER1SWEPQE

RKRLSFRKSEI*P*K*SLVKKL*E

RLKTRKQMQLAΝRLRRYGYSV

VES*FPΝLKVSSSVSTTPTTTYIP

MTHKAIFSSYFLWDGRSAFLTI

YKMMSSHPQEEEEEEEEEGGE

GEERKRRKKEEERGKRRKRRR

RMK*RRRRTRKRRKRRKMK*R

RRRRRRNM RKKRKEGKNMKK

KM/REEIKRQNALYEIEMRKKL

EKKREEMHESRRRFLAPLFSSP

TANCSTSLVPRLRLASLPAALPS

NRWRVTTPPAGVRGAWRHSH

FSRSRSIMDTSSEMLVRFGRRC

GRAKESTGRDWNSLKSSEEDR

KMWESLELPRDLLNAFDQNAD

SDMDNKMQAEMVSDGDEELS

GNWSKGDSCYVLAKRLASFYL

CPRDLWNFEKDDLGYLAEEISK

QQSIQEAQRSRRKKWFYGPGPG

SLCCVQPIDLVPCVPAAPAMAE

RGQCRAHAVASEGGSPKPWQL

PHGVEPVGAQKSRIEVWEPPPR

FQKMYGNAWMSRQKFAAEAG

PHGEPLLGQCRRELWGRSSHVE

SLMGHYLVELLSIGAMGIKVQR

PRCFFDIAINNQPGEKGTGKSTQ

KPLHYKSCLFHRVVKDFMVQG

GDFSEGNGRGGESIYGGFFEGP

AMGPNATNNFTKLAG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3859 34227 5899 2289 GELHGVAEQAEGDPREGSPGP

AEQASGTELREVPGPHWPLHPP

EAPVCQHYHRPMVQKGN*GSV

WGRGESLVQG/AHGQTSQRSV

QMTGGGAWTGQTSQRSVQMT

GGGGTPRGSRSSSPRTTYTPGTA

EDTEGEPAGAGEQAAGRPVRP

LHGHPGAGQEAAAGVRELPPA

EPAAHLHPQPALLIQQHPISHAR

SQHPRRPCCLPGPGLRAGGTAE

GLPCAFCSQRDERAEGRERDLE

GGGEAASGPGRQAQAPGQGGH

LGPPLTPAAPLPWWLEGHHRE

ATGRPRGG*GRPPGRGPTGRRK

ASRAQDISSGQNLPRGHPA*VA

SPRHEPPAHLQPAARDHCRGA\

PGSQACPADRGPANGTPPPLPA

RSSPPSP\GMSVASPWTASCGPP

GPPP* PMGPEALPEGGPALPPKP

PPVPA PSEPPQQPPG PCCSPQRP

PAPGPEGQRSRGLGGAHRTAG

AAQCPGGHAGPSPGGGTAPAP

GPAAAAG*GQGRQCQAKGPAH

TRGDAALPTSRLRL*GP*E*GD

QGSSGVAAGLSGGRHTQPAGPG

RAQRTEAAATQDCALDKPLDL

SEWGRARGQDTPKPAGQHGSL

SPAAAHTASPEPPTQSGPLTRSP

QALSNGTKGTRVPEQEEASTPM

PPDLDGHP\GPARLKC*DQSPTN

WM RQTPQA A\SG PELPGGG\PT

STTGEGPEC1CTQEHGQGPPRK

3860 34228 3900 3169 ASQLVLTLAYQANCVSVSYTD

LLGKPGGSYFTFLYVLNIRSRSR

LKKDYDDFRRQPDHDTFNREL

WTTDEGEGDLGKDSPKGEISKS

IDSTEPLDILEKDHFDSDDMKLS

EIDFPMARSKLLKKELPSKDLP

KTLLKTLKRQSKQTDYVDDST

KELSPRKKAKLSTNETTVENLE

SDVQIDCFSESKHTEPSFPESFA

SLDSVPVSTLQKGTKPIQALLA

KNIGNKVTLTNQLPPSTGRNAL

AVEKPVLSPPEAS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3866 34234 A 5906 4527 MGFCCRECRPRLLKGRPCIQHA

GPVAAFKVATPYSLYVCPEGQ

NVTLTCRLLGPVDKGHDVTFY

KTWYRSSRGEVQTCSERRPIRN

LTFQDLHLHHGGHQAANTSHD

LAQRHGLESASDHHGNFSITMR

NLTLLDSGLYCCLVVEIRHHHS

EHRVHGAMELQVQTGKDAPSN

CWYPSSSQDSESNHGNNFRIH

VSNGLLMRGPRPLDRERNSSHV

LIVEAYNHDLGPMRSSVRMRK

LRQSTALAQHWTGTALDR

5867 34235 3907 2180 MALTFPCRKFEWYGRRQPEVR

YSVPASHQLKATDADEGEFGR

VWYRILHGNHGNNFRIHVSNG

LLMRGPRPLDRERNSSHVLIVE

AYNHDLGPMRSSVRMRKLRQS

TAL\DSTGQAQHWTESRSGSPG

SPVAPTCSART*QTSAS\VHLCL

SGKSHHAWPP*TPFKLYYVH\E

YSAHIHKENLVLVIVYVEDIND

EAPVFTQQQYSRLGLRETAGIG

TSVIWQATDRDSGDGGLVNY

RILSGAEGKFEIDESTGLIITVNY

LDYETKTSYMMNVSATDQAPP

FNQGFCSVYITLLNELDEAVQF

SNASYEAAILENLALGTEIVRV

QAYSIDNLNQITYRFDAYTSTQ

AKALFKIDAITRILGTQMDTKM

NKTLLSPQRVLRLEVEMELIQD

ANQS ATRRCAEN YN RG V VEPL

RAQQSYLAGEAGRLHGRGGFP

VECEREEGIQQTECPGEVMPDR

GSDMEGVITVQGLVDREKGDF

YTLTWADDGGPKVDSTWSG

TRVYITVLDENDNSPRFDFTSDS

AVSIPEDCPVGQRVATVKAWD

PDAGSNGQVVFSLASGNIAGAF

EIVTTNDSIGEVFVARPLDREEL

DHYILQWASDRGTPPRKKDHI

LQVTILDINDNPPVIESPFGYNV

SVNENVGGGTAWQVRATDRD

IGINSVLSYY1TEGNKDMTFRM

DRISGEIATRPAPPDRERQSFYH

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno>vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3900 54268 5940 1566 IQTTIGEYYKHLYTNKLENLEE

MDKFLDTYTLPRLNQEEGESLK

RPMAGSEIEAIINSLPTKNSPGP

DRFTAEFYQRYKEELLISNFSK

VS/VIQNQWEKITSIPIHQ*QTNR

EPNHE*TPIHNCFKENKI\LGIQL

TRDVKDLFKENYKPLLSEIKED

TNKWKNIPCSWIGRTNIVKMAI

LPKDKTSKYIDVDENEGSHCGK

RKYKYGMEKALEILARAIRQEK

EIKGIQLGKEEVKLSLFADDMI

VHLENPIISAQNLLKLISNFSKV

SGHKINVQKSQTFLYTNNRQTE

SQIMSGLPFKIATKRIKYLGIQL

TRDVRDLFKENYKPLLNETKED

TNKWKKNILSSWIGRINIVKMA

ILPKVIYRFNAILINLPMTFFTEL

EKTTLKFIWNQKRACIAKTILSQ

RNKAGGITLRDFKPYYKATETK

TASEMKYYLENKIPFKVLHMV

YNVPTHPPFIGDLHPNTKWSL

PPNITSLIEPMNQGVISAFKDCY

LRKTFVQAVATPEGETEMTVM

QFWKDYNT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO. of peptide hod in USSN location of first codon tor last ammo acid *=Stop codon, /=possιblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possιble nucleotide msei tion) sequence

3901 34269 A 3941 2580 MVKGSIQQEELTILNRYAPNTG

APRSIKQVLSDLQRDLDSHTIIM

GDFNTPLSTLDRSTRQKVSKDI

QELNSVLHQADLIDIYRTLHPK

STECTFFSAPHRTYSKIDHIVGS

KALLSKYKRTEIITNCCSDHSAT

KLELRINKLTQN RSTT WKLNN L

LLN DY W VHNEM KAQIKMFFET

NENKDTAYQNLWDTFKAMCR

GKFIALNAHKRKQERSKIDTLT

SRLKELEKQEQTLHSKDSRRQE

INAEKAFDKIQQPFMLKTLNTL

DIDETYLKIIRAIYDKPTVNIILN

GQKLEVFPLKTGTRQGCRLSPL

LFNIMLEVLARAIRQEKEIKGIQ

LGKEEVKLSLFADDMIVYLENP

IISAQNLLKLISNFSKVSGYKIN

VQESQAFLYTNNRQTESQIMSE

LP\FTIASKRIKYLGIQLTRDVKD

LFKENYKPLLKEIKEDTNKWK

NIP\CSWVGRINIVKMAILPKVI

YRFNAISNKLPMTFFTELEKTTL

K\FI*KQKRACIAKSILSQKNKA

GGITLPDFKLY\YYKAIVTKTA

WYWYQNRDIDQWNRTEPSEIIP

HIYNHLIFDKPDKNKKWGNDS

LFNKRCWENWLAICRKLKLDP

FLTPYTKINS\RWIKDLHVRPKT

IKTLEENLGNTIQDIGMG KDFM

TKTPKAMATKS\KIDKWDLIKL

KSFCTAKETΠIRVNRQPTEWK

KI FTI YPSDKGLI SRI YKEPKQI Y

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

3908 34276 A 5949 2377 SLFHGKVCHFLHEPLPLVYLSL

CTGYQLFKPSL1SWLEEEEELST

LPRVLQEWKMCLKTKGPALW

QDNFCLKTLNGIQLARNQNGEE

LYDCKQCEDVFCKHPCLKTNM

STQNRGNTSECIQYAKDLLSLY

NKTSTIRKVSVFSKHGKSFRL\F

*MFRSRESVHKINPLK/CTDYGK

AFIYQSYLEAHRKTQSGEKLNE

WKQCGEAFTHSTSHAVNVETH

IIKNPYECKECGKDFRYPTHLN

NHMQTHIGIKPYKCKHCGKTFT

VPSGFLEHVRTHTGEKPYGCKE

CGKAFGTSAGLIEHIRCHAREK

TFKCDHCGKAFISYPSLFGHLR

VHNGEKPYEHKEYGKAFGTSS

GVIEDRRSNTGQKRFDCDQCG

KVFVSFSSLFAHLRTHTGEKPF

KCYKCGKPFTSSACLRIHMRTH

TEERLYQCKKCGKAFTKCSYLT

KHLRTH AGEKPYECM KCG KAF

TERSYLTKHLRRHSGEKPYECK

KCGKAFTERSDLTKHLRRHTG

DKPYEYKDCGKAFWSSSLVD

HLRTHTGYKPYKCNACEKAYS

RSCVLTQHLKTHAAEKTSECN

ACGNSFRNSMCFHDRLKTLTKI

KPYKCKDCGKAFTCHSDLTNH

VRIHTGEKPYKCKECGKAFRTS

SGRIQHLRTHMGEKPFECDQCG

KAFA\FSQLVLHI*KHTREKPCG

CEECGKTFAVSSSLTEHVKIHR

3909 34277 5950 455 GLLHERQAEARCSICLDYLRHP

MTTDCRHYI*SARIHQCW*ELQ

DISPCPVCLQHCPDKNLKRNFQ

LCHMTDIAKQLLTTARRKRKL

QGEEPVCRKSDVALFCEKDPEL

LCHQYRVSLDH*DH/SPMPIEQ

AAAKHRKQFESY1EPLEKQV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

4175 34543 A 4216 896 1626 NATTIRYEHQRVLKAAQYLHQ

QG1TRCNSSSTLTSAAPGRVDSP

PTSMIVAPALIIRFACFTASISEL

CVPPSEKESGVTLRIPITHLMRE

LTCRLIRDKSATVTGSHTLWA

RHCCYAAPGGCCLLANWLKPG

LFGPIGVLSRRGTSVILPIGGFY

QWNPMICPNGWPMQHG*RRG

LAQERPLEEWLPVCRDMLNAF

FLPDAETEAAMTLIEQQWQAII

AEG LG AQ YGDA VPLSLLRDEL

AQRLDQERISQRFLAGPVNICTL

MPMRSIPFKVVCLLGMNDGVY

PRQLAPLGFDLMSQKPKRGDRS

RRDDDRYLFLEALISAQQKLYI

SYIGRSIQDNSERFPSVLVQELI

DY1GQSHYLPGDEALNCDESEA

RVKAHLTCLHTRMPFDPQNYQ

PGERQSYAREWLPAASQAGKA

HSEFVQPLPFTLPETVPLKRYN

DSVRAPTCAESRAIFTSTRNNTL

QLFFNANFRRPWARGLATNVN

DRRASVDHQIRMFHRIYQRVM

RATI RKG I RRD VEDPH YSSD AG

TYLSPNSRQISNGNWQSHIGRSP

SLLLCRTWGLLFTGKLVETRFI

WPNRGVIPTGNERYIAHRRFLP

MEPDDMPQWRCPHATWLAEA

KMFDSLAKAGKYLGQAAKLMI

GMPDYDNYVEHMRVNHPDQT

PMTYEEFFRERQDARYGGKGG

4176 34544 4217 838 1575 CFFLSPSPPSSPPSPNRSQTTEEE

TKRQE/ERERKREEEEEKKGRR

KETKKRRNRQEGKQHRKEEKE

GEKQTKQRTETERETKRRRENE

QAKAHKGTRKRKEEQKKAKA

ARRRTHKRQNPSRGREGTHPK

QRQGKEE/VNRQNKEEAKQKR

EEAGRTRR/EDRGRKDDKKERR

QQQTEKKAKPKAEHGQERTDT

TTKKARQREGRPSERRRREREE/

MSKHDPQNRAEKTNEEKEEGR

QHER*TQKSSTGI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

4239 54607 4280 2661 MTMNFVADSHTGRNPLASAAG

AKTGLRPLPRPCGARVWNPPD

AGGGGVGSLKTSTPLGPLSAAN

SPVHQGSVPQTRARGGGTLFQE

WTSRTLAFRNSLSAFTEVTSG

TVSGRKGGRSTHLAGRRVSGG

EGSRKAAAAALAAVAAAPGPV

RRCSSQSCFSSSGSSHYSARTSP

VRVRPRRSLSSRSAAGNRAEAT

ESAMEKTLETVPLERKKREKEQ

FRKLFIGGLSFETTEESLRNYYE

QWGKLTDCVVMRDPASKRSRG

FGFVTFSSMAEVDAAMAARPH

SIDGRWEPKRAVAREESGKPG

AHVTVKKLFVGGIKEDTEEHHL

RDYFEEYGKIDTIEIITDRQSGK

KRGFGFVTFDDHDPVDKIVLQK

YHTΓNGHNAEVRKALSRQEMQ

EVQSSRSGRGDGYGSGRGFGD

GYNGYGGGPGGGNFGGSPGYG

GGRGGYGGGGPGYGNQGGGY

GGGYDNYGGGNYGSGNYNDF

GNYNQQPSNYGPMKSGNFGGS

RNMGGPYGGGIWKNTSITERK

KSRKLDLIQSKKGSRTKEAPQP

PVASLCMHLGHWSRLMVSPGA

QLTGKNSHGLSVSSVRKSNVGP

RRLCAAMKATGPDNAQSQVSP

PGHAPSAEDPTGSRTVSSPCTD

RPHPFLSRPKPPTQISLVLPLKT

DGALERMPQQL/HIASS/GAKVP

NPSTQTPPVLLAFFYPFNLPP*N

4240 54608 4281 908 MRKVKGKNRQSFKCLPPPSGA

LQAHGAAAPHGSLLTLHLHLV

PVSSAAMKATGPDNAQSQVSP

PGHAPSAEDPTGSRTVSSPCED

RPHPFLSWPTWISLALLLKTDG

ALERMPQQLPSLHPSQGTQSIH

PDPSSTSSFLLPFQPPTLKRAAFP

CPPSIVNPAVWDTSTPSVAEHH

TPIRITLKEPTQFLSQKQYPIPQA

ALVGLQPIISHLLASHLLRPTDS

PFNTPILPVKKPNGTYRLVQDL

RLINQAVLPLVQE/DYSVLLYLP

LNVTPGLPPATAFSYPPSPGPVA

RARLASRLHSHAA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

4343 3471 1 A 4384 495 EDTGTFRIY\ESAGAVKKARGF

LEFVEDFIQVSKNLIGKVIGKNG

KVIQEIVDKSDMVPVRIEGDSE

NKLPREDKDDRDSRHQRDSRR

CPGGRCRSVSGRRGRGGPRGG

KSSISSVPKDPDSNPYSVLDN/T

ESDQTADTDASKSHHSTNRHTR

SRRRRTDEDAVL

4344 54712 A 4385 550 TESERKDELSDWSLAGEDDRDS

RHQRDSRRRPGGRGRSVSGGR

GRGGPRGGKSSISSVLKDPDSN

PYSLLDNTESDQTADTDASESH

HSTNRRRRSRRRRTDEDAVLM

DGMT\ESDTASVNENGL\AKDV

IEEHGPSEKAINGPT\SASG\DDIS

KLQRTPGERKRLIP*KKENTQE

AAVLNGVS

4345 3471 4386 2063 MAELTVEVRGSNGAFYKGFIK

DVHEDSLTVVFENNWQPERQV

PFNEVRLPPPPDIKKEISEGDEV

E VYSRAN DQEPCG WWL AKVR

MMKGEFYVIEYAACDATYNEI

VTFERLRPVNQNKTVKKNTFFK

CTVDVPEDLREACANENAHKD

FKKAVGACRIFYHPETTQLMIL

SASEATVKRVNILSDMHLRSIR

TKLMLMSRNEEATKHLECTKQ

LAAAFHEEFVVREDLMGLAIGT

HGSNIQQARKVPGVTAIELDED

TGTFRIYGESADAVKKARGFLE

FVEDFIQVPRNLVGKVIGKNGK

VIQEIVDKSGWRVRIEGDNEN

KLPREDGMVPFVFVGTKESIGN

VQVLLEYHIAYLKEVEQLRME

RLQIDEQLRQIGMGFRPSSTRGP

EKEKGYATDESTVSSVQGSRSY

SGRGRGRRGPNYTSGYGTNSEL

SNPSETESERKDELSDWSLAGE

DDRDSRHQRDSRRRPGGRGRS

VSGGRGRGGPRGGKSSISSVQY

RSNIHNCSTLKRIFLASDMNIVL

KDPDSNPYSLLDNTESDQTADT

DASESHHSTNRRRRSRRRRTDE

DAVLMDGMTESDTASVNENGL

DDSEKKPQRRNRSRRRRFRGQ

AE\DRQPAIDFIYKEVEKVVSL

WQAKDVIEEHGPSEKAINGPTS

ASGDDISKLQRTPGEEKINTLKE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

4394 34762 A 4435 2571 MKAEIKMFFETNENKDTTYQN

LWNTFKAMCRGKFIALNAHKR

KQERSNTDTLTSQLKELKKQEQ

THSKPSRRQEITKIRAEMKEIET

QKTLQKIKESRTWFFEKINKIDR

LLARLTKKKREKNQIDAIKNDK

GDITTDPTEIQTTIREYYKHLYA

NKLENLEEMDKFLDTYTLPRLN

QEEVESLNRPITGSEIEAIINSLP

T/KKCPGPDGFTAEFYRRKRGM

LPNSFYEASIILIPKPGTDTTKKE

NFRPISLMNIDVKILNKILANRI

QQHIKKLIHHDQVGFIPGMQG

WFNIRKSINIIQHINRAKDKNH

MIISIDAEKAFDKIQQCFMLKTL

NKLGIDGTYLKIIRAIYDKPTAN

IILNGQKLEVFPLKTGTRQGCPL

SPLLFNIVLEVLARAIRQEKEIK

GIQLGNEEVKLSLFADDMIVYL

ENPIISAPNLLKLINNFSKGSAY

KIKVQKSQAFLYTNNRQTESQI

MSELPFTIASKRIKYLGIQLTRD

VKDLFKENYKPLLKEIKEDTNK

WKNIPCSWVGRINIMKMAILPK

VIYRFNAILIKLPMTFFTELEKST

LKFIWNQKRARIAKSILSQKNK

AGGITLPDFKLYYKATVTKTA

WYWYQNRDIDQWNGTEPSEIM

PHIYNYL1FDKPEKNKQWGKDS

LFNKWCWENWLAICRKLKLDP

FLTPYTKINSRWIKDLHVRPKTI

KTLENLGNTIQDIGMGKDFMSK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

4395 34763 4436 1965 MTLESEQTFVYAVTATQTGAK

EGTRMSKSNVAGQQGDSGEKA

LQKTYQKILREKESALEAKYQA

MERAATFEHDRDKVKRQFKIF

RETKENEIQDLLRAKRELESKL

QRLQAQGIQVFDPGESDSDDNC

TDVTAAGTQCEYWTGGALGSE

PSIGSMIQLQQSFRGPEFAHSSID

VEGPFANVNRDDWDIAVASLL

QVTPLFSHSLWSNTVRCYLIYT

DETQPEMDLFLKDYSPKLKRM

CETMGYFFHAVYFPIDVENQYL

TVRKWEIEKSSLVILFIHLTLPRI

KYLGIQLTRDVKDLFKENYKPL

LNEIKEDTNKWKNILCSWTGR

NNVMKMATLPKVIYRFNAIPIK

LPMTFFTELEKTTLKFIWNQKR

AHIAKTILSEKNKAGGIMLPDF

KLYFKATVTKAAWYWCQNRD

IDQWNRTEASEITPHIYNHLIFD

KPDKNKKWGKDSLFNKWCWE

NWLAICRKLKLDPFLTPYTKIN

SRW1KDLN VRPKTI KTLEENLG

NAIQDIGMGKDFMTKTPKAMA

TKAKIDKWDLIKLKSFCMAKET

PIGVNRQLTEWEKIFAIYPSDKG

LISRIYKELKQTYKKKTNNPIEK

LAKEMNRHLSKEDIYAANRHK

KKCSSSLVIREMQIKTT/MRYHL

TPVRMAIIKKSGNNRCWRGCG

4396 34764 4437 300 476 PDLSL WLPLTFFPSFQL W* I*QL

CVLELLFSRSIFVAFSVFPEFES

WPALLGWGSSPG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Ammo acid sequence ( λ=Unkno\vn,

NO: of peptide hod in USSN location of first codon for last ammo acid *=Stop codon, /=possιble nucleotide sequence 09/540,217 codon tor peptide of peptide sequence deletion, \=possιble nucleotide insertion) sequence

4407 34775 4448 1802 MSYPADDYESEAAYDPYAYPS

DYDMHTGDPKQDLAYERQYE

QQTYQVIPEVIKNFIQYFHKTVS

DLIDQKVYELQASRVSSDVIDQ

KVYEIQDIYENSWTKLTERFFK

NTPWPEAEAIAPQVGNDAVFLI

LYKELYYRHIYAKVSGGPSLEQ

RFESYYN YCNLFN Y I LNADGPA

PLELPNQWLWDIIDEFIYQFQSF

SQYRCKTAKKSEEEIDFLRSNP

K1WNVHSVLNVLHSLVDKSNIN

RQLEVYTSGGDPESVAGEYGR

HSLYKMLGYFSLVGLLRLHSLL

GDYYQAIKVLENIELNKKSMYS

RVPECQVTTYYYVGFAYLMMR

RYQDAIRVFANILLYIQRTKSM

FQRTTYKYEMINKQNEQMHAL

LAIALTMYPMRIDESIHLQLREK

YG\DKMLRMQKGDPQVYEELF

SYSCPKFL\SPWPNYDNVHPN

YHKE\PFLQ\QLKGVF**SSSQQ

AQLS/TPIRSFLKLYTYTMPWAK

LAGFPGPSQSQEF\RI PG FF VFKQ

QDERTSVWTQRVFSAPGW*NF

SQASEVDF\YI\DKDMI\HIADTK

VA\RRYG\DFFIRQI\HKF\EELNR

TLKEGWGQRPWMIFHTHFREP

GFECIIGQGSVFC

SEQ ID SEQ II) NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

4508 34876 A 4549 1602 NLSPILPQDLWPFTRVTVHWGK

GNDQTFQGLQDTGSELMLIPGD

PKRHCSPPVKVGSYGGQVINGV

LAQVRLTVGTVGPRTHPWISP

VPEC1IDIDILNSWQNPHIDSLTG

RVKAIMVGKAKWKPFEPLLPIK

IVNQKQYRIPGGIAEISATIKDL

KDAGWIPITLPFNSPFWPVKKT

DGSWRMKWYCKLNQWTPIT

AAVPDV/WSLLEQINTSPGTW

YAAIDLANAIFSIPVHKAHQKQ

FAFSWQGHQNTFTVFTILLHIH

KVGHAQQHSIIKWKWYIHDGA

RAGSEGTSKLNEEVPQMPMVT

TSAALPSLPRPAPMASWGVLY

DQLTEEEKTRAWFTDGSARYA

GTTQKWTAAALQPLSRTSLKG

SGEGKSSQWAELQAVHLWHF

SWKDKWPDVRLYIDSWAVAN

GLAGWSGTWKKHDWKIGDKEI

WGRGMWMDLSEWPKPVKIFG

SHVSAHQWVISAEEDFNNQVD

KMTCSVDITQPLSPATPVITQW

AHKQSGHGGRDGGYTWAQQH

GLPLTKTGLAMATAECPI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

4745 351 13 A 4786 832 ERHHPPPQAGPHPPRRRKERNT

HRQPTPQPHGA/WKISVPQTTN

KGISSSITSTQRNQPQATTVEKA

HNESTRTPEEPKGAVRGTR*KK

KKTSRDTPPQTP*EKSSSATRNK

AGGKDSDKRERKATEDQTTPS

KRRKLH PM AKKLKTLKKN *MN

G*LE*PMQRSP*RT*WS*KPRHE

NYVMNAQASVTDAINWKKGPP

PRPTTNDAKIVTRPTHPTCSHH

RPPRKPPRTHPTPTPTQNKISQ*

NGYTPPRGKRVREDRCKPPQAP

TSAPRAAKQRQS

4746 351 14 4787 1580 4673

4747 351 15 4788 462 MKLEHQEAQRRSGQGREKRR

WPEGKAGPGCEGAWILCPESQ

DDSKQEGDNNMIWSRNAVRS

VKAEFQGDNLENWESCSEAIIV

QGRDNGVPHKAHGLGTEEEGT

VLKISERQNWLDLVDFILLGGD

LFHENKPSRKTLHTCLELLRKY

CMGDRPVQFEILSDQSVNFGFR

KLTNRKDIHTKNPSVRHHHQRP

KVDETIKMGKTQSRKTRNSKN

QSTSPPPKERSSSPAIEQSWMEN

DFDELKEEGFRRSNYSELKEEV

RTNGKEVKNLEKKLDKWITRIT

NAEKSLKDLMELKTIAQELRDE

CTSLSNQCDQLEERVSVMEDQ

MNEMKREEKFREKRIKRNEQS

LQEI WDY VKRPN LCLIG VPESD

GENGTKLENTLQDIIQVNFPNL

ARQANIQIQEIQRMPQRYSLRR

ETPRHIIVRFTKVEMKEKMLRT

AREKGLECSGAGLAHCKLWLL

GPSDPPDCSSVSPVLRVHLVLPS

SLPHSVGTPFLGSVSIPPSVPRFP

DRVFHPYPYTHYCDNLKTCHT

SHGSVMAETAVINHKKRKNSP

RIVQSNDLTEAAYSLSRDQKRM

LYLFVDQIRKSDGTLQEHDGIC

EIHVAKYAEIFGLTSAEASKDIR

QALKSFAGKEWFYRPEEDAG

DEKGYESFPWFIKRAHSPSRGL

YSVHINPYLIPFFIGLQNRFTQFR

LSETKEITNPYAMRLYESLCQY SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λniino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

4748 55116 A 4789 1314 2221 KNRNYNKLSLRPQCNPTRTQD*

ETHSKPLNYMETEQPSPE*LLG

T*RNEGRHKAVL*NQ*EKRHNI

PESLGHI/AKQCVEGNL*H*MPT

RESRKDLKLTP*/PSQLKELEKQ

EQTHSKAGRRQE/TN*DQSRIEG

DRDTKNPSKNQ*IQELVF*KDQ

QN**TASKT/IQRRKERRIK*TQ*

KMLKEDITTDPTEIKTIIREYYK

HLYAHNLENLEEMDKFLDTYT

LPRLNQEEAESLNRPITNSEIET

VINSLKEKAQDQKDLQLNSTRA

LFTI AKA WNQPKCPSMTDE I K/I

NVEHIHHGILCSHQKE

4749 351 17 4790 2260 TKDKNHMIISIDGGKAFDKIQQ

PFMLKTLNKLGIDGTYLKRIRAI

FDKPTANIILNGQKLEAFPLKTG

TRQGCPLSPLLFNIVLEVLARVI

RQEKEI GIQFGKEEVKLSLFA

DDMTVYLENPIFSAQNLLKLIS

NFSNVSGYKINVQKSQAFLYTN

NSQIMSELPFTIATKRITYLGIQL

ARDVKDLFKENYKPLLNEIKED

TNKWKNIPCSQIGRILWPYCPR

QEDENFNSLLQNGDILNSSTEE

KFKAHDKKDFNLPEYDLNVEE

RLVLIEKSVDSTATADDTHKLD

HINMNLNKLITNDTFQPEIMERS

KTQDIVLGTSFLSINSKEETEHL

ENGNKYPNLESVNKVNGHSEE

TSQSPNRTEPHDSDCSVDLGISK

STEDLSPQKSGPVGSWKSHSIT

NMEIGGLKIYDILSDNGPQQPST

TVKITSAVDGKNIVRSKSATLL

YDQPLQVFTGSSSSSDLISGTKA

IFKFDSNHNPEEPN 11 RGPTSGPQ

SAPQAYGPPQYNIQYSSSAAVK

DTLWHSKQNPQIDHASFPPQLL

PRSESTENQSYAKHSANMNFSN

HNNVRANTAYHLHQRLGPARH

GEMWAISPNDRLIPAVTRSTIQR

QSSVSSTASVNLGDPGSTRRAQ

IPEGDYLSYREFHSAGRTPPMM

PGSQRPLSARTYSIDGPNASRPQ

SARPS1NEIPERTMSVSDFNYSR

TSPSKRPNARVGSEHSLLDPPG

4750 35118 4791 1516 1729 ILAPHSLLACRVSAERSAVSPM GFPLWVTQPFSLAALN/DFFLHF NFG/R QLCVLELLFSRSrWAF SEFP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Ammo acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possιble nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possιble nucleotide insertion) sequence

4888 S5256 4929 2502 MFFETNENKDTTYQNLWDTFK

AVCRGKFIALNTHKRKQERSKI

DTLTSQLKEPEKQEQTHSKASR

RQEITKIRAELKEIETQKTLQKIL

QKINESRSWFFEEINKIDRLLAR

LIKKKREKNQIDAIKNDKGDITT

DRTEIQTTIREYYKHLY ANKLE

NLEEMDKFLDTYNLPRLNQEE

VESL\HRLITGSEIEAIINSLPTKK

SPGPDGFTAKFYQRYKEELVPF

LLKLFQSIEKEGILPNSFYEANII

LIPKPGTDTTKKENFRPISLMNI

DVKILNKILANRIQQQIKKLIHH

DQVGFIPGMQGWFNIHKSINVI

QHINRTKDKNHMIISIDAEKAF

DKIQQPFMLKSLNKLVLEVLAR

AIRQEKEMKGIQLGKEEVKLSL

FADDMIVYLENPIISAQDLLKLI

SNFSKVSGYEINVQKSQASLYT

NNRQTESQIMSELPFTIASKRIK

YLG1QLTRDVKDLFKENYKPLL

NEIKEDTNKWKNIPCSWVGRIN

IVKMAILPKVIYRFNAILIKLPM

TFFTELEK\TTLKFIRNQKRACIA

KS1LSKKE\KAGGIMLPEFKL*Y

KATVTKTVWYWCQNRYIDQW

NRTEPSEIIPHIYNHLIFDKPDKN

KKWGKDSLFNKWCWEHWLAI

CRKLKLDPFLTPYTKINSRWIK

DLNVRPKTIKTLAGHLGNTIRDI

GLGKDFMTKTPKAMATKAKID

KWDLIKLKSFCTAKETAIRVNR

4889 35257 A 4930 4187 MGDFNTPLSTLDRSMRQKVNK

DSQELNSALHQADLTDICRTLH

PKSTEYTFFAAPHHTYSKIDHIV

GSKALFSKCKRTEIITNCLSDHS

A I KLELRIKKLTQNRSTTWKLN

NLLLNDYWVHNEMKAEIKMFF

ETN ENKDTTYQNL WDTFKAVY

RGKFIAFKAVCRGKFIALNAQN

RKQERSKIDTLTSQLKELEKQE

QTHSKASRRQEITKIRAELKEIE

TQKTLQKMSESRSWFFEKTNKI

DRPLARLIKKKR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

5088 35456 5129 2462 MRALWVLGLCCVLLTFGSVRA

DDEVDVDGTVEEDLGKSREGS

RTDDEWQREEEAIQLDGLNAS

QIRELREKSEKFAFQAEVNRM

MKLIIHSLL*NKGIFLERLISNSS

C\ALDRLSLISLTDENALSVNE*

LTVNMKCDKEKNLLHVQHTGV

GMT\REELVKN\LGTIAQIWDQ

ASFLNKMP*SHRKMGPVNLPEL

IGPVWVSGFLFPPSLVADKVIVT

SKHKQPIPQH I WG V WTPNGIFL

*LLDPRGKHS*DRGNRQFTLCP

* KEE ASDLP WNLDTI KNLRQKN

I HSFIKLFLIYVW\SSKTETV*G A

PWGEEEAAKEEKEESDDEAAW

EEEEEEKKPKTKKVEKTVWDW

ELMNDIKPIWQRPSKEVEEDEY

KAFYKSFSKESDDPMAYIHFTA

EGEVTFKSILFVPTSAPRGLFDE

YGSKKSDYIKLYVRRVFITDDF

HDMMPKYLNFVKGWDSDDL

PLNVSRETLQQHKLLKVIRKKL

VRKTLDMIKKIADDKYNDTFW

KEFGTNIKLGVIEDHSNRTRLA

KLLRFQSSHHPTDITSLDQYVE

RMKEKQDKIYFMAGSSRKEAE

SSPFVERLLKKGYEVIYLTEPVD

EYCIQALPEFDGKRFQNVAKEG

VKFDESEKTKESREAVEKEFEP

LLNWMKDKALKDKIEKAWSQ

RLTESPCALVASQYGWSGNME

RI M KAQA YQTGKDISTN Y YAS

5089 35457 5130 45 416 RWGLAMFPSLDNKSETLSQKK

KKKDLCPHISFEMDLTTADAR

WVQDAATRLLATTRCPPNSRG

SR**ISWRAGCCPGGWAGPHW

GHDGCL*PSCVSSS

5090 35458 5131 477 GRLPRHRGGEPGAAQPAGRQP

RGGAAATAAGAPRAGGGAAA

GNARRCREAAARDPHHGEGSG

PEPSQCEGAAHQRAGRAQGD*

GGSGATGEGGRRGHDSHNPLG

RVRGSTLPPS**N*VGL*VPSWP

QCGPAHPPGQHPALQEIHQRLP

LESGGHRW

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

5270 35638 531 1 2333 TGRGYCGDHESSFGAMEEPGA

TPQPYLGLLLEELRRWAALPE

GMRPDSNLYGFPWELVICAAV

VGFFAVLFFLWRSFRSVRSRLY

VGREKKLALMLSGLIEEKSKLL

EKFSLVQKEYEGYEVESSLKDA

SFEKEATEAQSLEATCEKLNRS

NSELEDEILCLEKELKEEKSKHS

EQDELMADISKRIQSLEDESKSL

KSQVAEAKMTFQIFQMNEERL

KIAIKDALNENSQLQESQKQLL

QEAEVWKEQVSELNKQKVTFE

DSKVHAEQVLNDKESHIKTLTE

RLLKMKDWAAMLGEDITDDD

NLELEMNSESENGAYLDNPPK

GALKKLIHAAKLNASLKTLEGE

RNQI YIQLSEVDKTKEELTEH I K

NLQTQQASLQSENTHFENENQ

KLQQKLKVMTELYQENEMKL

HRKLTVEENYRLEKEEKLSKV

DEKISHATEELETYRKRAKDLE

EELERTIHSYQGQIISHEKKAHD

NWLAARNAERNLNDLRKENA

HNRQKLTETELKFELLEKDPYA

LDVPNTAFGRGSRGPGNPLDH

QITNERGESSCDRLTDPHRAPS

DTGSLSPPWDQDRRMMFPPPG

QSYPDSALPPQRQDRFCSNSGR

LSGPAELRSFNMPSLDKMDGS

MPSEMESSRNDTKDDLGNLNV

PDSSFPVAKKEATGPGFVPPPLA

PVRGPLFPVDARGPFLRRGPPFP

SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

35838 5516 114 2695 GSACRDPDPDPLRLVGGGAAA

PPCSSVSPSAWRQSRPREYYEG

GRGLHAPDRETALGLG1ATSER

MLGICRGRRKFLAASLSLLCIPA

ITWIYLFSGSFEDGKPVSLSPLE

SQAHSPRYTASSQRERESLEVR

MREVEEENRALRRQLSLAQGR

APSHRRGNHSKTYSMEEGTGD

SENLRAGIVAGNSSECGQQPW

EKORRNPLHFHLIADSIAEQILA

TLFQTWMVPAVRVDFYNADEL

KSEVSWIPNKHYSGIYGLMKLV

LTKTLPANLERVIVLDTDITFAT

DIAELWAVFHKFKGQQVLGLV

ENQSDWYLGNLWKNHRPWPA

LGRGYNTGVILLLLDKLRKMK

WEQMWRLTAERELMGMLSTS

LADQDIFNAVIKQNPFLVYQLP

CFWNVQLSDHTRSEQCYRDVS

DLKVIHWNSPKKLRVKNKHVE

FFRNLYLTFLEYDGNLLRRELF

GCPSEADVNSENLQKQLSELDE

DDLCYEFRRERFTVHRTHLYFL

HYEYEPAADSTDVTLVAQLSM

DRLQMLEAICKHWEGPISLALY

LSDAEAQQFLRYAQGSEVLMS

RHNVGYHIVYKEGQFYPVNLL

RNVAMKHISTPYMFLSDIDFLP

MYGLYEYLRKSVIQLDLANTK

KAMIVPAFETLRYRLSFPKSKA

ELLSM LDMGTLFTFRYHV WTK

GHAPTNFAKWRTATTPYRVEW

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Uπkπo\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

5616 35984 A 5662 2142 MIILIDAEKAFDKIQQPFMLKTL

NKLG1DGTYLK1TRAIYDKPTA

NIILNGQKLEAFPLKTGTRQGCP

LSPLLFNIVLEVLAQAIRQEKEI

KGIQLGKEEVKLSLFADDMILY

LENPIVSAQKLLKLISNVSKVSG

YKINVQKSQAFLYTNNRQTESQ

IMSEFPFTIATKRIKYLGIQLTRD

VKDLFKKYKPLLNK1KEDTNK

WKNIACSWIGRINIMKMAFPR

WELNNENTWTQEGEHHTLGPV

VGWGKRGGIALVDIPNVNDKL

MVLEVLARAIRQKKEIKGIQLG

KEEVKLSLFADDMIVYLENSIV

SAQNLKLISNFSKVSGYKINVQ

KSQAFLYTNNRQTESQIMSEFP

FTIATKRIKYLGIQLTRDVKDLF

KENYKPLLKEIREDTNKWKNIP

CSRIGRINIMKMAILPKVIYRFN

DIPIKLPMTFFTELEKTTLKFIW

NQKRACIAKTILSKKNIAGGITL

PDFKLYYKATVTKTAWYWYQ

NRDIDQWNRTEASEVTSHIYNH

LIFYKPDKNKKWGNDSLFNKW

CWENWLAICRKLKLDPFLTPYT

KIHSRWIKDLNVRPKTIKTLEEN

LGNTIQDIGMGKDFMTKTPKA

MATKAKVDKWDVIKLKSFCTA

KETTIRVSRQPTEWEKIFAIYPS

DKGLISRIYKELKQIYRKK\TNN

PIKKWAKNMNRHFSKEDIYAA

NRQMKKCSSSLVIREMQIKTTM

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last A ino acid sequence ( X=Unknovvn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

5619 35987 5665 2460 MPHAGHARSPGHTLIKLAEWW

MSRWMEWNPGFPLSIDAKCHK

DLPRDIQFDSEKGVDFVLNYSK

ALNQEEVESLNRPITGSEIEAIIN

SLPTQKSSGPDGFTAEFYQRYK

EELVPFLLKLFQSIEKEGILPNSF

YEASIILIPKPGRYTHKKNNFRPI

SLMΝIDAKILΝKILAΝRIQQHIK

KLIHQDQVGIIPGMQSWFΝ1HK

SIΝVIQHIΝRTKDKΝHMI1SIDAE

KAFDKIQQPFMLKTLΝKL\GIK

YLRIQLTRDVKDLFKENYKSLL

NEIKEDTNKWKNIPCSWIGRMN

IIKMAI/LPKVIYRFNVIPIKLPMT

FFSELEKSTLKFIWNQKRARIAK

TILSQKN KAGGIMLPDFKL Y YK

ATVTKTAWYWYQNRDIDQWN

RTEPSEMTPHIYNHLIFDKPDKN

KQWGKDSLFNKWCWENWLAI

GRQLKLDPFLTPYTKINSRWIK

DLNVRPKTIKTLEENLGNTIQDI

SMGKDFMSKTPKAMATKAKM

DKWDLIKLKSFCTAKETTIRVN

RQPTEWEKNFAIYSSDKGLISRI

YKQLKQIYKKKTNNPIKKWAK

DMNRHFSKEDVYAANRHMKK

CSSSLAIREMQIKTIMIYHLTPV

TMAIIKKSGNNRCWRGCGEMG

TLLYCWWDCKLVQPLWKTLW

QFLRDLELGIPFDPAI PLLG I YPK

DYKSCCYKDTCTPKLARDDQI

HILKQHRRKELETRQKQYRAW

5620 35988 5666 689 1909 LIAYQPKKSRTRWIHNQILPERI

KYLGIQLTRDVKDFLKEKYKPL

LNEIKEDINKWKNIPCSWIGRIN

LVKMAIL/PQAICRKLKLDPFLT

TYTKINSRWIKDLHVRPKTTKT

LEENLGNTIQDIGMGKDFMSKT

PKAMATEAKIDKWDLIKRKSFC

AAKETTTRVNRQPTDWEKMFA

IYSSDKGLISRIYEELKQ1YKKK

TNNPINKWAKDMNRHFSKEDI

YAANRHMKKCSSSLAIREMQIK

TTVSPFAAQWVSQRYGKWQEA

HPSNNDGKGYRGKPRFQSLSD

VHGPQDQKKIIKESALPPTPTFI

NILMNAKTIENGQFPYLLNALK

QQQPHDAENLFTWGKENAAIV

SPCIEVSAALSQWKVPAWPQRS

GIPNR1LRSPIPGLGSWVAFLDL

VWVRGDPTALK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, V=possible nucleotide insertion) sequence

6261 56629 2052 MGDFNTPLSTLDRSMRQKVNK

DTQELNSALHQADLIDIYRTLH

PKSTEYTFFSAPHHTYSKIDHIV

GSKALLSKCKRTEI ITN YLSDHS

AIKLELRIKNLTQNRSTTWKLN

NLLLNDYWVHNEMKAEIKMFF

ETNENKDKTYQNLWDAFNAV

CRGKFVALNAHKRKQEGSKID

TLTSQLKELEKQEQTHSKASRR

QEITKVRAELKEIETQKTLQKIN

ESRS\ARLIKKKR£KNQI/DAIKN

DKRDITIDPTEIQTTIREYYKHL

Y ANKLENLEEM DKFLDTYTLP

RLNQEEVESLNRP1TGSEIVAIIN

SLPTKKSPGPEGFTAEFYQRYK

EELVPFLLKLFQSTEKEGILPNS

FYEASIILIPKPGRDTTKKENFRP

I SLMNI DAKILNKIL AKRIQQHI

QKLIHHDQVGFIPGMQGWFNIC

KSINVIQHINRTKDKNHMIISID

AEKVFDKIQQRFM LKTLNKL V

LEVLARAVRQEKKIKGIQLGKE

ELKLSLFADDMIVYLENPIVSA

QNLLKLISNFSKVSEYKINVQKS

QAFLYTNNRQTESQIMSELPFTI

ASKRIKYLGIQLTRDVKDLFKE

NYKPLLKEIKEDVNKWKNIPCS

WVGRINIVKMAILPKVIYRFNAI

PIKLPMTSFTELEKTTFKFIWNH

KGARIAKSILSQKNKAGGITLPD

FKLYYKATVTKTAWY

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

6307 56675 6357 2569 MRTKTQHTRISWDAFKAVCRG

KFIALNAHKRKQERSKIDTLTS

QLKELEKQEQTHSKASRRQEIT

KIRAELKEIETQKSLQKINESRS

WFFERTNNIDRPLARLIKKKREK

NQIDTIKNDKGDITTDPTEIQTTI

REYYKHLYANKLKNLEEMDKF

LDTYTLPRLNQEEVESLNRPITG

SEIVTIINSLPTKKSPGPDGFTAE

FYQRYKEELVPFLLKLFQSIEKE

GILPNSFYEASIILIPKPGRDTTK

KENFRPISLMNIDAKILNKILAN

RIQQHIKKLIHHDQVGFIPGMQ

GWFNIRKSINVIQHVNRAKDKN

HMIISIDAEKDFDKIQQPFMLKT

LNKLG I DGTYLKI I RAI YDKPTA

NIILNGQKLEAFPLKTGTRQGCP

LSPLLFNIWEVLASAIRQEKEI

KAQNLLKLISNFSKVSGYKINV

QKSQAFLYTNNRQTESQIMSEL

PFIIASKRIKYLGIQLTRDVKDLF

KENYKPLIKEIKEDTNKRKNIPC

SRVGRINIVKMAILPKVIYRFNA

IPIKLPMTFFTELEKTTLKFIWN

QKRAHIAKSILSQKNKAGGITLP

DFKLYYKATVTKTAWYSYQNR

DIDQWNRTEPSEITPHIYNYLIF

DKPEKNKQWGKDSLFNKWGW

ENWLAIWRKLKLDPFLTPYTKI

NSRWIKDLNVRPKTIKTLEENL

GITIQDIGMGKDFMSKTP/TSNG

NKRQN*QMGSNETKELLHSKR

6308 36676 6358 1702 2252 FLSLFFF1SLASSLSILLIHIMNSW

IPHSPIFTDLΝVESSRLCPLGDIM

M*IPLTWYLIVTCTHLSREITTV

PRGLARLWSFTRICPRTHCKPIP

AWLLRAGCPPSCWWDQDTHS

QLPSKRSSYTLFFCTVTEYPFLD

*WP*ΝHGTPC*TAPLWSMF/PCS

CWYPVTGPGVSCSPSCVQVFSL

FISHL*VRTCGVWFFVLAIVC*E

*WFPASSMSQAVLVTVAL*YSL

KSGSVMPPA\FSFGLGLTWRCR

LFFGSIRTLK*IFPIL*RKSLVA*

WGWH*IYKLRWAVWPFSRY*F

FLPMSM/VMFFHLFVSSFISLSS

GL*FSLKRSFMSLVSWIPKYFIL

FEAIVNGSSLM1WLSVCLLLLH

KNACDFCTLILYPETFLKLLISL

RRFWAETMGFSRYT1MSSANR

DNLTSSFPN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

6923 37291 6974 261 2667 TWCSGRYMVGCR/DWHLLLV7

KGLRKLTIVAEGEGGAGMSLG

ESGNKIKRDKEGHYIMVNGSIQ

QEELTILNIYAPNTGAPRFIKQV

LRDLQRDLDSHTIIMRDFNTPLS

ALERSTREKVNKDIQELNSALH

QADLVDIYRTLHPKSTEYTFFS

APHRTYSNIDHIVGSKALLSNC

KRTEIITKCLSDHSTIKLELRIKK

LTQNRSTTWKLNNLLLNDYWV

HNEMKAEIKMFFETIENKDTTY

QNLWDTFKAECRGKFIALNAH

KRKQERSKIDTLTSQLKELEKQ

EQTHSKASRRQEITKIRAELKET

ETQKTLQKINESRSWFFERXNKI

DRPLARLIKKKREKNLIDAIKN

DKGDITTDPTEIQTTIREYYKHL

YANKLENLEEMDKFLDTYTLP

RLNQEEVESLNRPITGSEIVAIIN

SLPTKKSPGPDGFTAEFYQRHT

VSILISYCQGGSLMSQVYWNQQ

EKPPSSSNAPPGLSVNKAQHRH

VCCRGEMLKRVQVHYVRAGES

DSASFHCVAQGPRAFGKPLILS

KENHLLTVTAIAKLNHKLCEIK

SMG VFINTEPL Y DSCLEQKHAL

FASPPATTHSTTMISKAKVIPML

SLTPGSFQTVESSLAPSAGKFQG

TETSSLKTLINLCCPKLPSPSPA

HLGGLPGGSQERPSRQYLYESA

RTTVLLGLGCPLKQIQLRSQHS

SPLEYLESLPKKDRKKREKIQIN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

6926 37294 6977 1921 MGESVQSLLTLAQKRSMMIQV

AVAPRTPTLLLKLYKEKASKTQ

LKKVNLWQDGQSLESIEVHD

HEPADTYKLLSLVKEPAEEIPR

VIQNVFGHRSKKENLKDSYGLR

QSSTMVATTWNNVSLMQHHSL

RRPNRHLTASYPHFHFQEIPVNF

FHSGRDSESFGWNQHIKKDKE

GHHIMVKGSIQQEELTMLNIYA

PNTGAPRFINQVLSDIERDLDSH

KI I MGDFNTPLSTLDRSTRQKV

NKDTQELNSALHQADLTDIYRT

LHPKSTEYTLFSAPHHTYSKIDH

IVGSKALLSKWKRTEIITNCLSD

PRAIKLELRIKKLTQNRSSIWKL

NNVLLNDYWVHNEMKAEIKIF

FETNENKDTSCQNLWDTFKAV

CRGKFIALNAHRRKQERSKIDT

LTSQLKELEKQERTHSKASRRQ

EITKIRAEMKEIETQKYTLQKINE

SRSWFFEKINKIDRPLARLIKKK

REKNQIDAIKNNKGDITTDPTEI

ETTIREYYKHLYTNKLENLEEM

DKFLDTYTLPRLNQEEVESLNR

PITGSEVVAIINSLPTKKSPGPDG

FTAEFHQRYKEKLISELLPMPN

HTALKKQTQDLSDCKAMFLYY

QSVSVQTAIINYHRLRGLNNRN

LFLTVLEYSSLRSGCEHSRVL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Uπkπo\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

6930 S7298 A 6981 2156 KSLKDLMELKIMAQELCDEWT

SLSSRCNQLEERVSVMEDEMN

EMKDKHRPKIKEWRKIYQANG

QQKKTRVANLVSDKTEFKPTKI

KRDKEGHYIMVKGSIQQEELTI

VNIYAPNTGAPRFIKKVLSDLQ

RALDSHTIIMGDFNTPLSTLDRS

TRQKVNKDIQELNSALHQADLI

DIYRTLHPKSTEYTFFSAPHYTY

PKIDHIVGSKALLSKCKRTEIIT

NCLS\DHSAIKLELKIKKLTQNL

STTWKLNNLLLKDYWVHKEM

KAEIKMFFETNKNKDTTYQNF

WDTFKAVCRGKFIALNAHKRK

QEGFKIDTLTLQLKELEKQEQT

HSKASRRINKIDRPLARLIKKKR

EKNQIDTIKNDKGDITTDPTEIQ

TTIREYYKHLYANKLENLEEM

DKFLDTYTLPRLNQEEVESLNR

PITGAEIVAIINSLPTKKSPGPDG

FTAKFYQRYKEELVPFLLKLFQ

SIEKEGILPNSFYEASIILIPKPGR

DITKKENFRPISLMNIDAEILNKI

LASQMQQHIKKLIYHNQVGFIH

GMQGWFNIHKSMNVIQHINRTK

DKNHTIISLDAEKAFDKIQQPF

MLKLKTLNKLGIDGMYLKIIRA

IYDKPTANIILHWQKLEAFPLKT

GTRQGCPLSPLLFNIVLEVLAR

AVRKEKEIKRTQIGREEIKLSLF

ADDMIVYLENPIVSAQNLLKLIS

NFTKVSGYKINVKKSQAFLYN

6931 37299 A 6982 3721 8717 MLPIKRHRL AN WI K\SQDP\SVC

CIEETλHLTCRDAHRHKIKGWR

KIYQANGKQNKTKQQKKQGLQ

ILVSDKRDFKPTKIKRDKEGHYI

M VKG PI QQVEELTILNI YAP\NTG

APRFIKQVLSDLQRDLDSHTLI\

MGD\FNTPLSTLDRSMRQKVNK

DTQELNSALHQADLIDIYRTLH

PKSTEYTFFSAP\HHTYSKIDHIL

GSKALLSKCKRTEIIT\NYLSD\H

SA\IKLKLRIKNLTQNHSTT\WK

LNNL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

7485 37853 7539 169 PPLLIPRQTGSGVDLQQTPTDLQ

LRVLTVRRKTNKQKGHPHQNSI

CTSPSSKTKDFKPTKIKRDKEG

HYIMVKGSIQQEELTILNIYTPN

TGAPRFIKQVLRDLQRDLDSHT

IIVGDFNTPLSTLDSSKRQKVDK

DIQELNSALYQADLTDIYRTLH

PKSTEYTFFSAPHHTYSKIDHIV

GSKALLSKCNRTEIITNCLSDHS

AIRLELRIKKLTENRSTTWKLN

NLLLKDYWVHNEMKAEIKMFF

ETNENKDTTYQNLWDTGKAAC

RGIFIAINAHKRNQKRSKMDTL

TSQLKELEKQEQRHSKASRRLN

QEEVESLNKPRTGSEIEAIINSLP

TKKSPGADGFTAEFYQRYKEE/

PGTIPSETIPINRKRGNTP*LIL*G

QHHPDTKA

7486 37854 7540 404 MDEFLNTYTLPRLNQEEVESLN

RPITGSEIVAIINSLPRKKSPGPD

GFTAEFYQRYKEELVPFLLKLF

QSIEKEGILPNSFYEASIILIPKPG

RDTTIKENFRPISLMNIDAKILN

KIILANRIQQH I KKLIHHDQ VGFI

PGMQGWFNIRKSINVIQHINRT

KDKNHMIISTDAEKAFDKIQQP

FMLKTLKKFGIDGTYLKIRIKYL

GIQLTRDVKDLFKENYKPLLNE

IKEDTKKWKNIPCSWVGRINIM

KMAILPKVIYRFNAIPIKLPMTF

LTELEKTTLKFIWNQKRARIAK

SILSQKNKAGGITLPDFKLYYK

ATVTKTAWYWYQKRDIHQWN

TTEPSEITPHI YN HLIFDKPEKNK

QWGKDSLFNKWCWENWLAIW

RKLKLDPFLTPYTKINSRWIKD

LNVRPKTIKTLEENLGITIQDIG

MGKDFMSKTPKAMATKAKIDK

WDLIKLKSFCTAKETTIRVNRQ

PTKWEKIFTTYSSDKGLISRIYN

ELKQIYKKKSDNPIKKWVKDM

NRHFSKEDIYAAKKHMKKCSP

SLAIREMQIKTTMRYHLTPPSLL

IPRQTGSGVDLQQTPTDLQLKV

LTVRRKTNKQKVHPHQNPICTS

PSSKTKELEKQEQTHSKASRRQ

EITKIRAELKEIETQKNLQKINES

RSWFLEKVNKIDRLLARLIKKK

REKDQIDAIKNDKGDITTDPTEI

QATIREHYKHLYANKLENLEE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

7527 57895 7581 2677 TKETCFIRGPKTPVPVTDWEGS

LPLVFNHCRDTSVIIHPRFKGVR

PRRDACLGPSPLAASPAFLGKG

QAELGPNSSSASAPPPYNLFIAS

PPHT WSG LQFRS VTSPPPPAQQF

TLKKVAGAKGIVKRLKTDTAR

SPWKTPRPSRTPSFRKAERTKG

LLKIHLTKLSHQLKKDWTILLP

LSLLRIQACPRNATRLATGQLG

YPFISQSYVLVNGFQTVEDLCE

AADLRVSVADLRVSVTALKVA

RLELFVPPGGLWSLASAVKLQ

TFAVLQLIKAKRWDWGTLEQG

AALIGEARDAQEPTEGVGGSG

MAGCRSRDLPRGKAAKARREI

ERSAGLTIKKERCI RNG YSKEK

MKLIWSHGLHVNDLQHKLTL

FTKETYTYLARDSEKQKQGYL

AGLEGAHANRVNQQISDNLW

KTGALPPPYRTKGEKLYFYMSR

QNCLFSVSGQLLQGFFPNGGQA

APNPYALLSQIPEEAEWFTVLD

LKDDFFCIP/VHPDSQFFFAFEDP

SNPTSQLTWTVLPQGFRVHLFG

QALAQDLSQFSYLDTLVLCGVL

KSPIIIVWELNQIDTIKNDKGDIT

TDPTEIQTTIREYYKHLYTNKLE

NLEEMDKFLNTYTLPRLNQEEV

ESLNRPITGAEIEAIINSLPTKKS

PGPDGFTAEFYQRVADVKLREE

KDENMLL VPLSDLL YQ V H APIP

QLPEVLAANSPTCHLDPPTITES

7528 37896 7582 459 MAVRYTDENVLRKGTREAGT

MMRLRGTTECCADFAAWDVT

HDALRATGGELPGAQVMLTTT

ECGRHVDFCDRAVWLPRMWG

YPLALPGEMRKLYTVRMAGRD

ILAKAGAIIHLNIGEGTPVRCPL

L/EGINPEVWKTEGQYRQAKNA

RPVQVKL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possi hie nucleotide insertion) sequence

7829 38197 7884 809 KPRLENYVKNAEASGADA1NW

KKGY/LVMEDEMNEMKREGKF

REKRIKRNEQSLQEIWDYVKRP

TLHLIDVPETLNAHKRKQERSK

TDTLTSQLKELEKQEQTHSKAS

RRQEITKIRAELKEIETEKTLQKI

N ESRS WFFERINK IDRPLARLIK

KKREKNQIDAIKNDKGDITSDP

TEIQTTIREYYKHLYANKLENL

EEMDKFLDTYTLPRLNQEEVES

LNRPITGSEIVAIINSLPTKKSPG

PDGSTAEFYQRYKEEL

7830 38198 7885 2142 MIILIDAEKAFDKIQQPFMLKTL

NKLGIDGTYLKITRAIYDKPTA

NIILNGQKLEAFPLKTGTRQGCP

LSPLLFNIVLEVLAQAIRQEKEI

KGIQLGKEEVKLSLFADDMILY

LENPIVSAQKLLKLISNVSKVSG

YKINVQKSQAFLYTNNRQTESQ

IMSEFPFTIATKRIKYLGIQLTRD

VKDLFKKYKPLLNKIKEDTNK

WKNIACSWIGRINIMKMAFPR

WELNNENTWTQEGEHHTLGPV

VGWGKRGGIALVDIPNVNDKL

MVLEVLARAIRQKKEIKGIQLG

KEEVKLSLFADDMIVYLENSIV

SAQNLKLISNFSKVSGYKINVQ

KSQAFLYTNNRQTESQIMSEFP

FTIATKRIKYLGIQLTRDVKDLF

KENYKPLLKEIREDTNKWKNIP

CSRIGRINIMKMAILPKVIYRFN

DIPIKLPMTFFTELEKTTLKFIW

NQKRACIAKTILSKKNIAGGITL

PDFKLYYKATVTKTAWYWYQ

NRDIDQWNRTEASEVTSHIYNH

LIFYKPDKNKKWGNDSLFNKW

CWENWLAICRKLKLDPFLTPYT

KIHSRWIKDLNVRPKTIKTLEEN

LGNTIQDIGMGKDFMTKTPKA

MATKAKVDKWDVIKLKSFCTA

KETTIRVSRQPTEWEKIFAIYPS

DKGLISRIYKELKQIYRKK\TNN

PIKKWAKNMNRHFSKEDIYAA

NRQM KKCSSSL V I REMQIKTTM

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

7844 38212 7899 1751 MIISIDAEKAFDKIQQPFMLKTL

NKLGIDGTYFKIIRANYDKPTA

NIILNGQKLEALPLKNGTRQGC

PLSPLLFNTVLEVLARAIRQEKE

IKGIQLGNVEVKLSLFADDMIV

YLENPIVSAQNLLKLISKFSKVS

GYKINVQKSQAFLYTNNRQTES

QIMSELPFTIASKRIKYLGIQLTR

DVKDLFKENYKPLLKEIKEDTN

KWKNIPCSWVGRLNIMKMAILP

KVIYRFNAIPIKLPMPFFTELEK

TTLKFIWNQKRARIAKSILSQK

NKAGGITPPDFKLYYKATVTKT

AWCWYQNRDIDQWNRTEPSEI

TPHIYNYLIFDKPEKDKQWGKD

SLFNKRCWENWLAICRKLKLD

PFLTPYTKINSRWIKDLKVRPKT

IKTLQENLGFTIQDIGMGKDFM

SKTPTAMGTKDKIDKWDLIKL

KSFCTAKETTIRVNRQPTKWEK

IFTTYSSDNGLISRIYNELKQIYK

KKTNNPI KQWAKDMNRHFSIE

DIYAAKKHMKKCSSSLAIREM

QIKTTMRYHLTPVRMAIIKKSG

NNRNHLDFKH I RI LGIC YL/D* KI

YQP*LHLVSRNRKPEKLSPKQA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

7845 18213 7900 2540 MGDFNTPLSTLDRSTRQKVNK

DTQELNSALHQPDLIDIYGTLHP

KSTEYTFFSAPHHTYSKIDHILG

SKALLSKCKRTEIITSYLSDHSAI

KLELRIQNLTQNHSTTWKLNNL

LLNDYWLHNEMKAEIKMFFET

NENKDTTYQNLWDAFKAVCR

GKFIALNAHKRKQERSKTNTLT

SINKIDRPLARLIKKKREKTQID

AIKNDKGDITTDPTEMQTTIRE

YYKHLYANKLENLEEMDKFLN

TYTLPRLNQEEVESLNRPITGAE

IVAIINSLPTKKSPGPDGFTAEFY

/HEL\LKENKIPRNPTY/RGCEGP

LQGELQTTAQ*NKRGYKQMEE

HSMLMDRKNQYRENGHTAQG

NLQIQCHPH K ATNDFLHRSGKN

YFKVHMEPKKSPHRQVNPKPK

EQSWRHHAI*LQTILQGYSNQN

SMVLVPKQRYRSMEKNRALRN

NAAYLQLSNL*QT*EKQAMGK

GFLI**MVLGKLASHM*KAETG

SLPYTLYKNQFKMD*RLKH*T*

NHKNPRRKPRHYHSGHRHGQG

LHV*NTKSNGNKSQN*QMGSN

^♦TKELLHSKRNYHQSEQATYKL

GENFCNLPI*PRANNQNLQ*TQ

TNLQEKNKQPHQKVGKGHEQT

LLKRRHLCSQKTHEKMLSITGH

QRNANQNHNEIPSHTS*NGNH*

KVRK*QVLNGLDDVQLFR*NK

QPCCSHKACLWSSYRRA*SLV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

7876 38244 7931 3146 MGDFNTPLSTLDRSSRQKVNK

DTQELNSTLHHADLIDIYRTLHP

KSTEYTFFSAPHHTYSKIDHW

GSKALLSKCKRTEIITNCLSDHS

AIKPELRIKKLTQNRSTTWKLN

NLLLNDYWVHNKMKAEIKMFF

ETNENKDTTYQNLWDTFKAVS

RGKFIALNAHKRKQKRCKIDTL

ASQLKEVEKQEQTHSKASRRQ

EITKIRAELKEIETQKTLQKINES

RSWFLERINKIDRPLARLIKKKR

EKNQIDVIKNDK

7877 38245 7932 2669 MHNTDGNRFLSHWGYRQALSI

SKPASASLHPSSKTKPLGTQSKT

WAKRNREHGKKERSSSPAME

QS WMEN DFDELREEGFRRSNY

SELREDIQTKGKEVENFEKNLE

ECITRITNTEKCLKELMELKTK

ARELREECRSLRSRCDQLEERR

KQERSKIDTLTSQLKELEKQEQ

THSKAGRRQEITKIRAELKEIET

QKTLQKINESRSWFFERINKIDR

PLARLIKKKREKNQIDTIK\NDK

GNITTDPTEIQTTIREHYKHLYA

NKLENLEGMDKFLDTYTLPRL

NQKEVESLNRPITGSEIVAIINSL

PTKKSPGPDGFTAEFYQRYKEE

LHINRAKDKNHMIISIDAEKAF

DKIQQPFMLKTLNKLVLEVLAR

AIRQEKEIKGIQLGKEEVKLSLF

ADDMIVYLENPIVSAQNLLKLL

SNFSKVSGYKINVQKSQAFLYT

NNRQTESQIMSELPFTIASKRIK

YLGIQLTRDVKHLFKENYKPLL

KEIKEDTNKWKNIPCSWVERIN

IVKMAILPKVIYRFNAIPIKLPM

TFFTELEKTTLKFIWNQKRARIA

KSILSQKNKAGGITLPDFKLYY

KATVTKTAWYSYQNRDIDQW

NRTEPSEILPRIYNYLIFDKPEKN

KQWGKDSLFNKWCWENWLAI

CRKLKLDPFLKPYTKIKSGWIK

DLNVRPKTIKTLEENLGITIQDI

GMGKDFMSKTPKAMATKAKID

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod n USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

7939 38307 7994 2367 HRVTVISGETGCGKTTQVTQFI

LDNYIERGKGSACRIVCTQPRRI

SAHSSCGKSSCRKGQNLVASGN

STGY\QIRLPESVAQGNRVLSYT

VPTRNHPSSGSQSDPYLSSVSHI

VLDEIHERNLQSDVLMTWKD

LLNFRSDLKVILMSATLNAEKF

SEYFGNCPMIHIPGFTFPWEYL

LEDVIEKIRYVPEQKEHRCQFK

RGFMQGHVNSQEKEEKEAIYK

ERWPDYVRELRRRYSASTVDVI

EMMEDDKVDLNLIVALIRYIVL

EEEDGAILVFLPGWDNISTLHD

LLMSQVMFKSDKFLIIPLHSLM

PTVNQTQVFKRTPPGVRKIVIA

TNIAETSITIDDWYVIDGGKIK

ETHFDTQNNISTMSAEWVSKA

NAKQRKGRAG\RVQPGSLLFICI

NGS*EASLLGWT1QLPEIFEE\PF

WEGTLFTK*RFLRLGEIAYFLSR

*MDPPSNEPVLLSIRHL\RSLNA

LDKQEELTPLGS\HLARLPVEPH

IGKMILF\GALFCCLDPVLTIAAS

LKFQ\SPFVIPLGKEKIADARRK

ELAKDTRSDHLTWNAFEGWE

EARRRGFRYEKD\FCWEYFLSS

NTLQMLHNMKGQFAEHLLGA

GFVSSRNPKDPESNINSDNEKII

KAVICAGLYPKVAKIRLNLGKK

RKMVKVYTKTDGLVAVHPKS

VNVEQTDFHYNWLIYHLKMR\

TSSIYLY\DCTEVSP\YCLLFFG\G

7940 38308 7995 25 312 WLIYVITDARMYRQRGRYYFL

VSSSLDKVLMISFLLGWRRSSR

RLRAFLVLHLRASPWAPRSFVR

PVSAFSVGMCHMKTRVFENTF

PFTLGHTVRYVGREI F/CRRVFT

RYRESIKISLPTYLTVCPRVKGN

VFSNTRVFMWHIPTLKADTGRT

KLLGAQGEARRCKTKKARKRR

EERLQPNKKEIIKTLSKEEETKK

7941 38309 7996 417 QQIRKLIKVGLIIHKPVIVHSQV

GCQKSTFS/RTRKGRHMGTG*R

KSTANFQMPEKVTWMRRMRIL

HWLFGRYHESKKTDHHMYHSL

YLKVQGNMFTNKQILMEHNHK

LKADKAHKKFLADQAEARSSK

TNKASKLREER

7942 58310 7997 124 KKRPELRDLLNQARKETL/ARK EDRSASSGAEGDVSSEREP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8246 38614 8301 2558 FEVLWSDSSITSVTKSSSEVTEFI

SKLCQLYPEENLEKLIPCLAGPD

AFYVERNHVDLDSGLRYLASLP

SHVLKNDHVRRFLSTSSPPQQL

QSPSPGNPSLSKVGTVMGVSGR

PVCGVAGIPSSQSGAQHHGQHP

AGSAAPLPHCSHAGSAGSALA

YRTQMDTSPAILMPSSLQTPQT

QEQNGILDWLRKLRLHKYYPV

FKQLSMEKFLSLTEEDLNKFES

LTMGAKKKLKTQLELEKEKSE

RRCLNPSAPPLVTSSGVARVPPT

SHVGPVQSGRGSHAAELRVEV

EQPHHQLPREGSSSEYSSSSSSP

MGVQAREESSDSAEENDRRVEI

HLESSDKEKPVMLLNHFTSSSA

RPTAQVLPVQNEASSNPSGHHP

LPPQMLSAASHITPIRMLNSVH

KPERGSADMKLLSSSVHSLLSL

EERNKGSGPRSSMKVDKSFGSA

MMDVLPASAPHQPVQVLSGLS

ESSSMSPTVSFGPRTKWHAST

LDRVLKTAQQPALWETSTAA

TGTPSTVLHAARPPIKLLLSSSV

PADSAISGQTSCPNNVQISVPPA

IINPRTALYTANTKVAFSAMSS

MPMGPLQGGFCANSNTASPSR

HPSTSFANMATΛMPSCPAPSSSP

ALSSVPESSFYSSSGGGGSTGNI

PASNPNHHHHHHHQQPPAPPQP

APPPPGCIVCTSCGCSGSCGSSG

LTVSYANYFQHPFSGPSVFTFPF

8247 38615 8302 266 YCGPL*SVWVARNPPGFAFVEF EDPRDAAGVV*ELDGRTLCGP\ PSWGHRP*DDYCRRGLPPRRRP PRRRNLSCSRSRSLYSPWTLSL

8248 38616 A 8303 37 535 ESWLVLGRRKAGRLIGACGFEP

PHFLTLDLEMHRDSCPL\DCKV

YVGNLGNNGNKTELERAFGYY

GPLRSVWVARNPPGFAFVEFED

PRDAADAVRELDGRTLIGC\RV

REE\LSNGEKKK/SRNRGPPPS\W

GRPPSENDNRKEESFPPR\RRSP

R\RRSFS\RSRSRSLF

SEQ ID SE ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of pept ide hod in USSN location of first codon for last amino acid *=Stop codon, /=possιble nucleotide seq nee 09/540,217 codon for peptide of peptide sequence deletion, \=possιble nucleotide insertion) sequence

8262 58630 8318 186 2123 CPAHCWQEAMLSAWRLVMSP

GG PCTQHPAPACHPS VLTTPRK

AGEPRP*WPPCPAWGPLADSSK

PHRWRPKPPASCRPLVRRPWGP

QRTLTPTLTSHWRASIR*SWNW

TPPSSCFPQGLGAPRLSWPRAPC

Q* ERRRNLKPWT* STSR* PPPDQ

GATMAPSTAPAPLSPRPSAPFA

WASSFPETSPERHEAAVRASSS

LGTRAGGTSALCPPQRVSP/HRP

PNSPSISIPCMGSKASSPHGLGSP

LVASPRLEKRLGGLAPQRGSRI

SVLSASPVSDVSYMFGRTPHSP

PLAKEHA\AAAPHPSPTPWWTY

PLC* STAAQN/RGSSPPQRTPGH

QNSVQPGAASPSNPCPATRSNS

QTLSDAPFTTCPEGPARDMQPT

MKFVMDTSKYWFKPNITREQG

CPGGAVSISDSRIVPAIELLRKE

EPGAFVIRDSSSYRGSFGLALK

VQEVPASAQSRPGEDSNDLIRH

FLIESSAKGVHLKGADEEPYFG

SLSAFVCQHSIMALALPCKLTIP

QRGCHTLYLSSVSVETLTGALA

VQKAISTTFERDILPTPTWHFK

VTEQGITLTDVQRKVFFRRHYP

LTTLRFCGMDPEQRKWQKYCK

PSWIFGFVAKSQTEPQENVCHL

FAEYDMVQPASQVIGLVTALL

QDAERM

8263 38631 8319 15 909 LHVSHPGHADARGGLLQPCAA

PPLWLCRIQCPPRWFQTPSQVF

YHAATEHGGKDVYPGQCLWE

GCEPFQRQRFSFITHLQAANCR/

EAQ/RSTPRAQKAIVNHPSAAL

MALRRGSRNLVFRDFTDEKEG

PITKHIRLTAALILKN IGKYSEC

GRSWPRASRYQQGHQDLFILRS

DLPSQVFIRDKLMERRNRRTGR

TEKARI WEVTDRTVRTWIG E A

VAAAAADGVTFSVPVTPHTFR

HSYAMHMLYAGIPLKVLQSLM

GHKSISSTEVYTKVFALDVAAR

HRVQFAMPESDAVAMLKQLS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

83 13 38681 8369 130 LDFQHHNYKAMRKLMKQVQE

QCPNITRIYSIGKSYQGLKLYV

MEMSDKPGEHE/LGYWHGEW

GEVGTGQGPRHEPAASPHVSPG

EPEVRYVAGMHGNEALGRELL

LLLMQFLCHEFLRGNPRVTRLL

SEMRIHLLPSMNPDGYEIAYHR

GSELVGWAEGRWNNQSIDLNH

NFADLNTPLWEAQDDGKVPHI

VPNHHLPLPTYYTLPNATVSILR

AAVEVLWGADPCLCLLPLLTCP

IQVAPETRAVIKWMKRIPFVLS

ANLHGGELVVSYPFDMTRTPW

AARELTPTPDDAVFRWLSTVY

AGSNLAMQDTSRRPCHSQDFS

VHGNIINGADWHTVPGSMNDF

SYLHTNCFE VTWELFCDM FPH

ENELPHEWENNTDA

8314 38682 8370 2229 MWGLLLALAAFAPAVGPALGA

PRNSVLGLAQPGTTKVPGSTPA

LHSSPAQPPAETANGTSEQHVR

IRVIKKKKVIMKKRKKLTLTRP

TPLVTAG PL VTPTPAGTLDPAE

KQETGCPPLGLESLRVSDSRLE

ASSSQSFGLGPHRGRLNIQSGLE

DGDLYDGAWCAEEQDADPWF

QVDAGHPTRFSGVITQGRNSV

WRYDWVTSYKVQFSNDSRTW

WGSRNHSSGMDAVFPANSDPE

TPVLNLLPEPQVARFIRLLPQT

WLQGGAPCLRAEILACPVSDPN

DLFLEAPASGSSDPLDFQHHNY

KAMRKLMKQVQEQCPNITRIY\

RIGKSYQGLKVYWEMSDKPG

EHELGEPEVRYVAGMHGNEAL

GRELLLLLMQFLCHEFLR\GNP

RVTRLLSEMRIFLLPSMNPDGY

EIALH\RSS*LVGLSEGRWNNQS

IDLNHNFADLNTPLWEAQDDG

KVPHIVPNHHLPLPTYYTLPNA

TVAPETRAVIKWMKRIPFVLSA

NLHGGELWSYPFDMTRTPWA

ARELTPTPDDAVFRWLSTVYA

GSNLAMQDTSRRPCHSQDFSVL

NGNIINGA\DWHTVPG\SMNDFS

YLHTNCFEVTVELSCDKFPPEE*

ICPKEWEVNNKDALLTYLEQVR

MGIAGVVRDKDTELGIADAVIA

VDGINHDVTTALGPGIIWRLA*

PPGD\YMVDLPSSEGYHSVTRN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8342 38710 8399 89 1685 KGPLLLSLPCRAGAMAETSVAT

GACGEAMAAAEGSSGPAGLTL

GRSFSNYRPFEPQAFGASSPS\W\

RLDGAFSGNERAEGCKVPQEG

RLLKLLAG\LTRP\DVRPP\LGRG

\LVGGQEEASQEAGLPAGAGPS

PTFPALGIGMDSCVIPLRHGGLS

LVQTTDFFYPLVEDPYMMGRIA

CANVLSDLYAMGITECDNMLM

LLSVSQSMSEEEREKVTPLMVK

GFRDAAEEGGTAVTVGQTVVN

PWDLLIGGVATCSIANQFEFAM

PDSAWGDVLWLTKPFRNPGL

LFNAHQWLG*FLERWD*S*RW

WFSREE\VEL\AYQEA\MFNMA

TLNQNCCRV*MHTFNAHAATD

IT\GFG\ILGHSQNL\AKQQRNEV

SFVIHNLPIIAKMAAVSKRASGT

VWGFFQGTSA\ETSGGITGFCLP

R\EQGGLAFCS\EIQILPKYGRGS

PKAWMVGIVEKGNRTAPDPLTS

PRVIEV\LPRG\ATAAVLAP\DSS

NALLLSLAREIERTEWWTLEP

LSTITDG SQELI VKKFPKKA ACI

WPAALSR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8343 3871 A 8400 30 2391 ARGRPLLAARSSRPCGPRLPFK

RAGPAPAAPHRGDQEARWFSG

AAPSRLPPAPRFSGPAAIFLSAQ

GPPSGAMQPTLLLSLLGAVGLA

AVNSMPVDNRNHNEGMVTRCI

I E VLSN ALSKSS APPITPECRQV

LKTSRKDVKDKETTENENTKFE

VRLLRDPADASEAHESSSRGEA

GAPGEEDIQGPTKADTEKWAE

GGGHSRERADEPQWSLYPSDS

QVSEEVKTRHSEKSQREDEEEE

EGENYQKGERGEDSSEEKHLEE

PGETQNAFLNERKQASAIKKEE

LVARSETHAAGHSQEKTHSRE

KSS/QFSAA*EAGSQENRPQESK

GQPRSQEKSEEGDEDATSEVDK

RRTRPRHHHGRSRPDRSS\QGG

SFPS\EEKGHPQ\EESEESNVSM

ASLGEKRDHHSTHYRASEEEPD

YGEEIKGYPGVQAPEDLEWER

YRGRGSEEYRAPRPQSEESWDE

EDKRNYPSLELDKMAHGYGEE

SEEERGLEPGKGRHHRGRGGEP

RAYFMSDTREEKRFLGEGHHR

VQENQMDKARRHPQGAWKEL

DRNYLNYGEEGAPG\KWQQQG

VLQDTK\ENRVEARFQDKQYSS

HHTAEKRKRLGELFNPYYDPL

QWKSSHLERRDNMIDNFLEGE

EENELTLNEKNFFPEYNYDWW

EKKPFSEDVNWGYEKRNLARV

PKLDLKRQYDRVAQLDQLLHY

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

8349 38717 8406 10 580 KQCALLTFICSLPMSFGFAPA1T

VTWN/PRHPLIRDMLRRIKEDE

DDKTVLDLAWLFETATLRSG

YLLPDTKAYGDRIERMLRLSLN

IDPDAKVEEEPEEEPEETAEDTT

EDTEQDEDEEMDVGTDEEEET

AKMS*ALLTFICSLPMSFGFAPA

ITVTWNHFVLCSKTGSQVFRS

ENWKVWAESSRGDHDDCLDL

CSVLCWGRTATGAFSCPAQLIF

AVSSSSSVPTSISSSSSCSVSSW

SSAVSSGSSSGSSSTFASGSMFK

LRRSILSILSPYALVSGKRYPDR

SVAVSNKTTARSKTVLSSSSSLI

RRSMSLISGCRD

8350 38718 8407 1967 MTMAAAAWARGAGARAATA

AALRGGCGTAARGRPCAGPAR

PLCTAPGTAPDMKRYLWERYR

EAKRSTEGTKKYTTSLNARHY

YTHFTEENEDEINSSSSYASQKK

TFEINPRHPLIRDMLRRIKEDED

DKTVLDLAWLFETATLRSGYL

LPDTKAYGDRIERMLRLSLNID

PDAKVEEEPEEEPEETAEDTTE

DTEPDEDEEMDVGTDEEEETG

KESDDPMAYIHFTAEGEVTFKS

ILFVPTSAPRGLFDEYGSKKSDY

IKL YVRRVF ITDDFHDM MPKYL

NFVKGWIRKKLVRKTLDMIK

KIADDKYNDTFWKEFGPTTKL\

GVIEDHSNRTΛRLAKLLRIQSSH

HPTDITSLDQYVEK\MKEKQDK

IYFMAGSS\RKEAESSPFVERLL\

KKGYEVIYLTEPVD\EYCIQALP

\EFD\GKRF\QNWQGKECKFHE

S* ENLRK* *CKSVEQRIS ALCLN

W\MKDKALKDKI*K/ALWVSSA

ALTESPVLLLVAQPVRDWSWP

TLGE/RSMKAQAYQTGQGHLL

QIYYAESERKHFEINPQTPRLIR

D\MLRRIKEDEDDKTV\LDLA\V

VLV*NRQRLGSGYLFTQTLKAY

GDW/RLERMLRLSLNI*PLMPK

VEEEPR/EEEPEETAEDTTΛEDTE

\QDED\EEMDVG\TDEKG RTSKG

8351 38719 8408 181 462 GMASASDSSKTGFRGKQWAG

AVGDSAKESQGQPPGAPPRRA

AGL/WRRHHCSF*AD*TTNAPG

GKNPRPGKGAGGEQGTAGDFT

CQMPRTQNTL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8394 38762 8451 2460 MEEKSKRRGVLWSLLILALKFG

DEPPLGSPNSCKYKLTTLKELG

WREVFSSLQFCLCTSVASQMLS

QYFEYTQPHPGDICHPETCALQ

KVFLTSSGQSSSTSSSSQQFVLQ

INAIQTILEKTPTHISTPTPTPTLA

NPTAVGLEEDREQDVGTSSRG

GAWDTRIKRELEKMSEKCGGQ

INGGDIAVFASRAGHGVCWHPP

CFVCTVCNELLVDLIYFYQDGK

IYCGRHHAECLKPRCAACDEIIF

ADECTEAEGRHWHMKHFCCFE

CETVLGGQRYIMKEGRPYCCH

CFESLYAEYCDTCAQHIGEAIF

GSQ/HWSFC/RCGHLCFGEWG*

PQLLWMLC*LELTKGPRDAIMS

SLHSWHLRKGVRRRRRKKEDK

SPEVLP*KS\SSGTLSH*R*RPH*

SLFLGSRVSL\PSGECRGPGPPYS

HSLRLYSQQALPTGRGPSSSQFP

FCQFYCCYKKSLLCDCLSKSPA

LEKAMRGIDQGQMTYDGQHW

HATETCFCCAHCKKSLLGRPFL

PKQGQIFCSRACSAGEDPNGSD

SSDSAFQNARAKESRRSAKIGK

NKGKTEEPMLNQHSQLQVSSN

RLSADVDPLSLQMDMLSLSSQT

PSLNRDPIWRSREEPYHYGNKM

EQNQTQSPLQLLSQCNIRTSYSP

GGQGAGAQPEMWGKHFSNPK

RSSSLAMTGHAGSFIKECREDY

YPGRLRSQESYSDMSSQSFSET

8395 38763 8452 942 NKNPKNHYPESYVSLKNDFTK

LTSRRHRGVEQALVQLCHVFV

CEHGHVIVTLSSGFIVYRTRAN

YSSSAQGVGIAAAALDAVLIRA

HQRTQGCHHELSALLAFEKGSE

KKEEEEGGQVSRSSSLKVQAQE

LSATEDKGHISPFFWEAVYHYA

SGECRGPGPPYSHSLRLYSQQA

LPTGRGPSSSQFPFCQFYCCYK

KSLLCDCLSKSPALEKAMRGID

QGQMTYDGQHWHATETCFCC

AHCKKSLLGRPFLPKQGQIFCS

RACSAGEDPNGSDSSDSAFQNA

RAKESRRSAKIGKNKGKTEEP\

C*TSTASCK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmiπo acid sequence ( X=Unkno n, NO: of peptide hod n USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8435 38803 8492 2563 MGDFNTPLSTVDRSMRQKVDK

DTQELNSALHQADLIDIYRTLH

PKSTEYTFFSAPHHTYSKIDNIIG

SKALLSKCKGTEIITNSLSDHSA

IKLELRIKKLTQNHSTTEKLNNL

LLNDYWVHNEMKAEIKMFSET

NENKDTTYQNLWDTFKAVCRG

KFIALNAHKRKQERSKIDTLTS

QLKELEKLNQEEVESLNRPITG

AEI VAIINSLPTKKSPGPDG FTA

KFYWRYKEELVPFLLKLFQSIE

KEGILPNSCYEASIILIPKPGRDT

TKKENFRPISLMNIDAKILNKIL

ANRIQQHIKKLIHHDQVGFIPG

MQGWFNICKSINVIQHINRTKD

KNHMIISIDAEKAFDKIQQPFML

KTLNKLAQNLLKLISN/SQQSLR

IQNQCTKITSILIHQ*QTNREPNH

E*TPIHNCFKENKIPRNPTYKGC

EGPLQGELQTTAQGNKRGYKQ

MEEHSMLMGRKNQYLENGHT

AQGNL*I/QMPSPSSY**LSSQN

WKKLL* SS YGTKK\GPHSQVN P

KPKEQSWRHHTT*LQTILQGYS

NQNSM VLAPKQR* RPMEQNRA

LRNNAAYLQLSDL*QT*QKQA

MGNGFPI**MVLGKLASHMEK

AETGSLPYTLYKN*FKMD*RLT

H*S*NHKNPRRKPRQYHSVHRH

GQGLHV*NTKSNGNKSQN*RM

GSN*TKELLHSERNYHQSEQAT

HKMGENFRNLLI*QRANIQNLQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8440 38808 A 8497 1614 3085 AGEGNKADKQLQQSLRIQNQC

TKITSILIHQQQTNREPNHESTPI

HNCFKENKIPRNPTYKGCEGPL

QGELQTTAQGNKRGYKQMEE

HSMLMGRKNQYHENGHTAQG

NLQI/QMPSPSSYQ*LSSQNWKK

LLSSSYGTKK\GLHHQVNPKPK

EQSWRHHAT*LQTILQGYSNQN

SMVLVPKQRYRSMEQNRALRN

NAAYLQLSDL*QT*EKQAMGK

GFPI * * M VLGKL ASHM* KAETG

SLPYTLYKNQFKMD*RFKR*T*

NHKNPRRKPRHYHSGHRHGQG

L/LCPKHQKQW/HTKAKIDKWD

LIKL/IELLHSKRNYHQSEQATY

KMGENFRNLLPQRANIQNLQ*

TQTNLQEKNKQPHQKVGEGHE

QTLLKRRHLCSQETHEKMLIIT

GHQRNANQNHNEIPSHTS*NGN

/QLKSQETTG AG EDVEK*EH F Y

TVGGTVN*FNHCGSQCGDSSGI

*N*KYHLTQPSHYWVYTQRTIN

HAAIKTHAHVCLLRHYSQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8443 3881 8500 3 2202 EGRNKDVI*NQREQRHNIPESL

GHIQSSV*REI*NTKCPQEKAGK

IQN*HPNITIKRTRKARANTFKS

*QKARNN*NQSRIEGNRDTKNP

SKN**IQTTIREYYKHLHANNLE

NLEEMDKFLDTYTLPRLNQEEV

ESLNRPITGSEIVAIINSLPTKKS

PGPDGFTAKFYQRYKEELRIKY

LGIQLTRDVKDLFKENYKPLLK

EIKEDTNKWKNIPCSWVGRINI

VKMAILPKVIYRFNGIPIKLPITF

FTELEKTTLKFIWNQKRARVAK

SILSQKNKAGGIMLPDFKLYYK

ATVTKTAWYWYQNRDIDQWN

RTEPSEIMPHIYNYLIFDKPEKN

KQWGKDSLFNKWCWENWLAI

CRKLKMDPFLTPYTKINSRWIK

DLNVRPKTIKTLEENLGNTIQDI

GMGKDFMSKTPKAMATKAKID

KWDLIKLKSFCTAKETTIGVNR

QPTKWEKIFATYSSDKGLIFRIY

NELKQIYKKKTNNPIKKWAKD

MNRQFSKEDIYAAKRHMKKCS

TSLAIREMQIKTTMRYHLTPVR

TAIIKKSGNNRCWRGCGEIGTL

LHCCWDCKLVQPLWKSVWRF

LRDLELEIPFDPAIPLLGIYPKDY

KSCCYKDTCTRMFTAALLTIAK

TWNQPKCPTMIDWIKKMWHIY

TMES YAA I NDEFMSF VGT WM

KLEIIILSKLSQGQKTKQRIFSLI

DGN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8444 38812 8501 437 2163 KQKCNISHLWNAVKVERIKYL

GIQLTRDVKDLFKENYKPLLKE

IKEDTNKWKNIPCSWVEES1P*K

WPYCPR*FTDSMPSPSSYQ*LSS

QNWKKLL*SSYGTKKEPASPSQ

S*AKRTKLEASHYLTSNYSTRL

Q*PPGKRGPPEVQGHNADENN

HTEDRQGNRRHEHSIDQLAVT

DVHSTTAEYTFLSTRGGFSKID

HMLGCKTNLNKYKEIEIIQSIFS

NHNEIKQEINSRRKTRKSTNLW

ELSSALLMNGSEKKTQVNLDNI

WKLMKAKMQHITLMECSESRK

NKIPRNPTYKGREGPLQGELQT

TAQGNKRGYKQMEEHPMLMG

G RINTVKM A ILPK VI YRFNAIPI

KLPMTFFTELEKTTLKFIWNQK

RARIAKSILSQKNKAGGLTLPD

FKLFYKATVTKTAWYWYQNR

DIDQWNRTEPSEIMPHIYNYVIF

DKPEKNKQWGKDSLFNKWCW

ENWLAICRKLKLDPFLTPYTKI

NSRWIKDLTVRPKTIKTLEENL

GITIQDIGMGKDFMSKTPKAMA

TKAKIDKWDLIKLKSFCTGKET

TIRVNRQPTKWKKIFATYSSDK

GLISRIYNELKQIYKKKTNNPIK

KWVKDMΝRHFSKEDIYAAKK

HMKKCSPSLAVREMQIKTTMR

YHLTPVRMAIIKKSGNNRCWR

GCGEIGTLLHCWWDCKLVQPL

WKSVWQFLRDLELEIPFDPAIPL

8445 38813 8502 2001 MPHIQVMLMQEMDSHSLGKLC

PYGFAEYSPTSSCFHGFVLSVC

GSSRDKATQRVDALVRQVIVN

GGIVLDQFAVHDRVALADLIDL

LVDLSAMMLCGVPTTGDPFVA

FALGHPDDFDHLILPKHLVDRY

LLLEPLLGPVQLLSHSASVHLD

LHQFCSDFSYGIQLTRDVKDLF

KENYKPLLKEIKEDTNKWKNIP

CS WVGRINIMKMAMλRPR* FI D

SMPSPSSYQ*LSSQNWKKLL*SS

YGTKKEPVSPSQALA

8446 38814 B 8503 152 3166

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last A ino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8454 38822 851 1 1990 EPHRIASPRFRQAFDSDGTDRTL

*FLSDIEEEELTRGDPEQRHVPL

RRKSEWKWAADRAAIDSRWN

WLQAHVSDLEYRIRQQTDIYK

QIRANKGLIGLGEVPPP\EHTTD

LFLPLSSEVKTDHGTDKLIESVS

QPLENHGAPIIG\HISESLSTKSC

G ALRP VNG VINTLQPVL ADH I P\

GDCSDAEEQLHKKQRLNLVSSS

SDGTCVAARTRPVLSCKKRRLV

RPNSIVPLSKKVHRNSTIRPGCD

VNPSCALCGSGSINTMPPEIHYE

APLLERLSQLDSCVHPVLAFPD

DVPTSLHFQSMLKSQWQNKPF

DKIKPPKKLSLKHRAPMPGSLP

DSARKDRHKLVSSFLTTAKLSH

HQTRPDRTHRQHLDDVGAVPM

VERVTAPKAERLLNPPPPVHDP

NHSKMRLRDHSSERSEVLKHH

TDMSSSSYLAATHHPPHSPLVR

QLSTSSDSPAPASSSSQVTASTS

QQPVRRRRGESSFDINNIVIPMS

VAATTRVEKLQYKEILTPSWRE

VDLQSLKGSPDEENEEPASPDV

SSSHSLSEYSHGQSPRSPISPELH

SAPLTPVARDTPRHLASEDTRC

STPELGLDEQSVQPWERRTFPL

AHSPQAECEDQLDAQERAARC

TRRTSGSKTGRETEAAPTSPPIV

PLKSRHLVAAATAQRPTHR

8455 38823 8512 19 739 ADDRDHLHIQTWCAKAPVFLQ

PGSSWLSTKGKKM/PETPASDE

PPLRQPAVRFEFLQHAPPDSLQP

LGSPGHS*GPSSDTGQPAAGRW

PRRQP*AAVQDLGPQTRGSASP

ESQTVLPAAPSAPGSARPHGSM

SASAPSPTASPQMSKPPCAAAC

LRGSGAGGGTVGPCLEPGGSAP

PRARLPRCAAGSARPGAAAGPP

PGAGTTRAVP

8456 38824 8513 343 MRMCLRLPTLMTKCTNWHVT

GHLCRPT/MREPTPEP/WTGDTT

TA*METRWPAEQPALAERRLFR

AAPRGAFAGIAAPSPAAPPQPG

SLGILPEPTPAQAWAARNQLRG

RIKERGS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8477 38845 8534 569 1278 GHTACEWYSQGRHPGPELSPFL

*GPG*NAGHVISMPAARPMEPC

LGTGGLDVLLHHLRPDLPPAAL

PG S A WPGEG ALPLPGQVSGRG

RSAACLQPGAWPGRGAAPVRR

RPRPAAAGSVREAELLESPHLA

AHRDC*LARKLNSGGYIPQAEY

GKHAGLPLPGARALSCGCRAR

APVPAALPHPLLDHQDPGPAGR

IYGTGAGTQTLDGSAPRTSRAL

GSTQMPEARPGLAGWGVAGV

WSRG* SR*TRGSAS/SPRPRRCA

LLALPGAAVSGDLRARNPRGSR

PPKAPSGRGGPLLPPHRSTPRR

8478 38846 8535 2494 YQRQSSSPEDPAETASPTYALIA

ACQSEIQLQTRQQPCDMAPGPL

DCDPVKGSSRKRMFLMNAPPV

VALQPKWEASVPPGSFRFPECF

SEADKGVESMSPTMHKELPAL

AACGLVADFDPVGEEETADFG

PLVLDSDSDDSVDRDIEEAIQEY

L/KGGGSRCKRELAHSS/APTAL

CSPKLVPGSGG/GGPGSQVGSS

KDQGSASPVSMSRADSFEQSIR

AEIEQFLNEKRQHETQKCDGSV

EKKPDTHENSAKSLSKSHQEPA

TKWHRQGLMGVQKEFAFCRP

P\RLAKTNVQPRSLRSKVTTTTT

QEKEGSTKPATP/TRPSEAVQN

KSGIKRSASTARRGKRVTSAVQ

APEASDSSSDDGIEEAIQLYQVQ

KTRKEADGDPPQRVQLQEERA

PAPPAHSTSSATKSALPETHRKT

PSKKKPVPTKTTDPGPGDLDAD

HSPKIPKETKAPPPTSPASRSKF

VEWSSCQADTSAELRAVLDIFK

TILP/APMEGSDGSLSASPLFYSP

NVPSRSDGDSSSVDSDDSIEQEI

WTFLALKVQSRSLLARGAAGQ

APERVEKQAPAGAEELPKSKRD

SCEGSRKKPPSVFGSRAERTKP

RPSCSSVDSDDSIELEIRKFLVE

KAKESGVPGQAQPCLWKPTLA

GEEGLRSPAKQEGLTSAIVAGIS

AALGPEHTWVPGATTPRTPSVA

PVLVPAVPTHWKKLAPACGGP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8652 39020 8709 1779 MGDFNTPLSTLDRSTRQKVNK

DTQELNSALHQADLIDIYRTLH

PKSTEYTFFSAPHHTYSNIDHIV

GSKALFSKCKRTEIITNCLSDHS

AIKLELRIKKLTQNHSTTWQLN

NLLLNDYWVNNEMKAEIKMFF

ETNENKDTTDQNLWDTFKAVC

RGKFMALNAHKRKQERSKMG

TLTSQLKELEKQEQTHSKASRR

QEITKIRAELKEIET/QKTLQKIN

ESRYTEIQTTIREYHKHLYANKL

ENLEEMDKFLDTYILPRLNQEE

VESLNRPVTGSEIEAIINSLPTKK

SPGPYGFTAEFYQRYKEELHIN

RTKDKNHMIISIDAEKAFDKIQ

QPFMLKTLNKLGIDGTYLKILR

AIYDKPTANIILNGQKLEAFHLK

TGTRQGCPLSPLLFNIVLEVLAR

AIRQEKEIKGIQLGKEEVKWSL

FADDMIVYLENPIVSTQNLFKLI

SNFSKVSGYKINVQKSQAFLYT

NNRQTESQIMSELPFTIASKRIK

YLGIQLTRDVKDLFKENYKPLL

NEIKEDTNKWKNIPCSRAGRINI

VKMAILPKVIYRFSAIPIKLPMT

FFTELEKTKVFIWNQKRAHIAKS

ILSQKHKAGGITLP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8653 39021 8710 2093 MEITTNCLSEHSAITLQLRIKKL

TQNCTTTWKLNYLLLNDYWV

NNEMKEEIKMFFETNENKDTT

YQNLWDVFKAVCRGKFIALSA

HKRKQERSKTDTLTSQLKELEK

QEQTHSKASRRQEITKIRAELKE

IETQKTLQEINDSRSSFSEKLNKI

DRPLARLIKKKREKTQIDAIKN

DKGEINTNPTEIQTTIREYYKYL

YANKVENLEEMDTFLDTYTLP

RLNQEEVESLNRPITGSEIEAIIN

SLPTKESPGPDGFTAEFY/HEGN

QERERNKGYSIRKRGSHIVPVC

R*HDCLFRKPHHLSSKSHEAVK

QLQQSLRIQNQWAKITSMPVH

Q*QTNREPNHE*TPIHNCYKEN

KIPRNPTYEGCEGPLQGELQTT

AQQNKRGQKEMEKHSMLMDR

KNHYHENGHTAHGNL*IQCHP

HQATNDFLHRIGKNYVNFHME

PKKSLHCQENPKQREQSWRHH

AT*LQTILQGYSNQNSMVLVPK

QIHRTMEQNRGLRNNTTHLQPS

DL*QI*QKQEMGKQFPI**MVL

GKLASYM*KAETGSLPYTLYK

N*FKMD*RLKC*T*NHKNPRRK

PRQYHSGHRHGQGLHD*NTRS

NGNKNQNRQMGSN*TKELLHG

KRNYHQSAQTTYRMGENFCNL

PI*QRANIQNLQRT*TNLQEKNK

QPHQKVGKGHEQTLLKRRHLC

SQQTHEKM L I ITGHQRN ANQN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8657 39025 8714 1842 VPPTTCGNYGSTIQDEIWMGTQ

NQTISVSEEMMFQAEEIASAQK

MWNQHHITPSKVDHIVGSKAL

FSKCKRTEIITNYLSDHSAIKLK

LRIKKLTQNRSTTWKLNNLLLN

DYWVHNEMKAEIKIFFETNEN

KDTTCQNLWDTFKAMCRGKFI

TLNAHKRKQQRCKIDTLTSQLK

ELEKQEQTHSKASRRQEITKIRA

ELKEIEAQKTLQKINESRSWIFE

KINKTDRLLARIIKKKREMNQI

DAIKNDKGDITTNPTEIQTTIRE

YCKHLYANKLENLEEMDKFLN

TYTLPRLNQEEIESLNRPITGSEI

EAIINSLPTKKSPGPDGFTAEFY

QRYKEEMIEKKAFDKSQQPFM

LKTLNKLGIDGTFLKIRRAIYDK

PTANIILNGQKLEAFPLKTGTRQ

GCPLSPLLFNIVLEVLAREIRQG

KEIKHIQLGKEEVKFSLFADDVI

AYLENPIVSAQNLLKLISNFSKV

SGYKINVQKLQAFLYTNNRQTE

SQIMSEFPFTIASKRIKYLGIQLT

RDVKDLFKENYKPLLNKIKEDT

NKWKNIPCSWIGRINIMKMAIL

H KVIDRFSA I PFKL/PKD/FFTEL

EKTTLKFIWNQKRPRISKTILSK

KNKAGGITLR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence- 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

8874 39242 8932 2466 MLRGVNVLADAVKVTLGPKG

RNVVLDKSFGAPTITKDGVSVA

REIELEDKFENMGAQMVKEVA

SKAN D A AG DGTTT AT VL AQ A 11

TEGLKAVAAGMNPMDLKRAS

RSRKGYGPARIRQELNQKGISR

EATEKAMRECDIDWCALARDQ

ATRKYGEPLPTVFSEKSRKLIA

GVKRAFTHQAVNAGFCTQPAV

SVIAGDFDRHGFNTRHFTFRLF

DDFSFETTRFCPAQIHTLKHARP

VLCFRTARPRLNIEVAVGAVIF

AREHTAELKLRQFFQGAPQKA

VISIPVVPQVTGVVIEVTDKKNT

LIKKGEVLFRLDPTRYQARVDR

LMADIVTAEHKQRALGAELDE

MAANTQQAKATRDKFAKEYQ

RYARGSQAKVNPFSERDIDVAR

QNYLAQEASVKSSAAEQKQIQS

QLDSLVLGEHSQIASLKAQLAE

AKYNLEQTIVRAPSDGYVTQVL

IRPGTYAASLPLRPVMVFIRSET

SLRTHCPGHADYVKNMITGAA

QMDGAILVVAATDGPMPQTRE

HILLGRQVGVPYHVFLNKCDM

VDDEELLELVEMEVRELLSQY

DFPGDDTPIVRGSALKALEGDA

EWEAKILEL/RWLPGFLYSGTR

ACD*QAVPAADRRR/SSPSPVV

VPLLPVV*NAVSSKLVKKLK\R

WYPRDSEVYLYWR*NVPPTAG

RRPC W*ERRCSAAWYQT* RNR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last ammo acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possιble nucleotide insertion) sequence

8995 59363 9054 1737 MKEKPAVEVRLDKWLWAARF

YKTRALAREMIEGGKVHYNGQ

RSKPSKIVELNATLTLRQGNDE

RTVIVKAITEQRRPASEAALLYE

ETAESVEKREKMALAQMIMPQ

HDQLHRYLFENFAVRGELVTV

SETLQQILENHDYPQPVKNVLA

ELLVATSLLTATLKFDGDITVQ

LQGDGPMNLAVINEΓNERAQNP

LLCAFRCVNTYGSYECKCPVG

YVLREDRRMCKAVFPYCQNES

SDVLWQFDSTSQIFLKGTPKTT

VRRGGEHNLKNPDECEDNPNIC

DGGQCAGIPGRNRCLCYDGFM

ASEDMKTCVDIDECSLPNICVF

GTCHNLPGLFRCECEIGYELDR

SGGNCTEDPDHSKSRSGRSQND

WGRRRKT/S*KRSAVYR*RQLY

IRRQP Y A ERPSLR* RQRP* IPCIR

SQHGNRKRMRRRRIFI/STKRTT

AAARTSSVKKARSFSRALKNA

MLS*RTAPSVS*S*IMITH*KK**

SR*SLQTR*LMKSSARVFSK*TA

NGTWSL/HSRGSKVTIDGINSND

IYMLGYVSNSLTGPYRPVDKTG

LGLEMGLDPNDVTLTYSHFRVP

EAEAAMWVSHAT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9010 39378 9069 1687 ICVPKSVPSFLWAGRGPHCLLP

CGSSSP*SGGLARA*GVFQGRA

GVARAPSHLSFHNSPCVWSLST

CCRAGSQDGPCPHAAGQGPGK

QTSSGTGASSSPWTSCL*KSLPK

\VCS*GLETTIGRGRVKPIKVTD

TAQ*CAASVTAPLLSS*LQDGG

STAKVTRCT/TAGGRAVYGTAE

G KAFPE A PELTCRS/ALAALGT

WPLPPLQVSCGLRNPSPDLPSV

VGSRASV*TKSGSSPAKVWPLA

EWFKSGSA\PVTGQEAWLLWA

SDSSSELSLCPRKHAAPPHSAEH

RQISQGLASSCWGAGGDKVVS

ASMVGSAPGQCPMSALMTGSA

SGQCPGHPCWSGTNADS*GRDP

HRASRLLALPTASYEQ*PQPHW

GSWTAHGQNGLGIFFQRVSWF

V*GQTMVSRPRISGLGQPVCLS

AASPQAAPLGSHDPTPAGR*GL

EPGGRQPSSS*IYVWEAPPGLW

VPPGPFLSH*SWRFGRTKAAPL

KEPRPGGRCPGDRPSPRAEAGL

PQTRKPALPAIGR/PKKACSLRR

PRVILEQSSQHLAAALSSWMQP

ALLETGGKAVFFTPGGL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

901 39379 A 9070 66 1956 PLLAIPAHSTFPARKPEEPPRPD'

LCPHIHCAAV*GEIRTVP/SKTV

RGVATRTRPRSASSLGTTTGLR

VSSVRRVQLSIKPGCSRVNENSS

NSPCSSSQPGTΛSVLPCPTVCRE

AGP/AGP*PPG*ALSLPAAGFTT

ATEWKQSQLSSGG*THSGEDM

GRATAAATEKAQEQCMLREKL

GTRQK AESG SRG AVAGLQHFCS

APRTAWQPRASRA/RAGVRAW

PCADPM*PPSHSPSFPKPFIPAA/

PGAQTLGAAGVEHVAGSARIPC

CRTGLE/PHPHSPRRTLERQARI

SGAGRRSSPNAATGARPRPAAG

SPVSARRAPRRRPA*SSPCSGPW

TAVSAPRSPGPRGGGRPPSPGR

RRPCCSVFSGGASPSSARVSSPS

GSCSASPPAAPAVPGASGAVVA

GPVVGSPREHGG*LRPPLPRLG

VPGLLAARTSGAEVIHEQAAAQ

GTAADTPGAPGLLLAPAAAGA

V/TRPGPPGASGCPRPAPRPPTP

ASRSGRPWPGGGRGRRGGRGA

GGEALQGAVVGGQVGGSGAL

A/ATARGSPAAGVSRWTAPRCR

HRRSDASASGTPARFPGAGRKG

RTLWQ*SWRSAPPPGLSELL*G

LPRPLPESGRSKAPLPSGSTPLPS

GRTPLPSGRSPSTRRSPS

9012 39380 9071 95 1423 GLENKRAKGTEAHTRACP*GK

STEQDTTWTNTGRNEQQGPRP

KGEQTQRKTERKPGRERQVQV

LSSPPGRWC*DVGPLGGLPSRA

KAEAALTAAQKAQGRRGSPGS

LPKSSPLPSAPGKR/TPPRGHLL

VPLPSPYYPALLSQHPPQGPPCG

ASAPPSALLQRAPPPGTRTL\QR

PPGPRVTCGTTP/MAAKAKSQS

NAPRGSLLKKSNSFYNIPLKQV

SCLITISKHSRNEVSVYQTSRPR

AAATDVPRTΛPSLSVGCSWSCT

RGHWPSSCCPTAPRGQGL*EHS

QGPGSRSKLPWPTGPCGGLTPS

CWSLAGSAGERVDLNQAAASR

PHCAARTMAGKTLSGGCGCVD

VGAASAHRSPRLRCTTSPTDGP

NTERGSRKTGWTPGPPGFWPCP

RPPTSNTTTPLGLMDSARPGKA

PAPFTDFRTPSGLLLPGWAVRA

RREEDGCG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9047 39415 9106 1249 MAVLIFLGCLLGGIAIGLPIAWA

LLLCGAALMFWLDMFDVQIMA

QTLVNGADSFSLLAIPFFVLAGE

IMNAGGLSKRIVDLPMKLVGH

KPGGLGYVGVLAAMIMASLSG

SAVADTAAVAALLVPMMRSA

NYPVNRAAGLIASGGIIAPIIPPSI

PFIIFGVSSGLSISKLFMAGIAPG

MMMGATLTLGKRARFTEDDTR

ERDAISVINHQRNAVLIRQRVK

LQQLFVIRVLAMRIFVYGSLRH

KQGNSHWMTNAQLLGDFSIDN

YQLYSLGHYPGAVPGNGTVHG

EVYRIDNATLAELDALRTRGGE

YARQLIQTPYGSAWMYVYQRP

VDGLKLIESGDWRVLRWLRVH

SIDVPDPIFGLTVTGDRTDRAG

KTSPAQAGCKLFLTNPLGIGVL

TTAEKKSLLKPEHQGLATEVM

CRMNIAGASFANIEGVKAMTD

VTGFGLLGH LSEMCQG AG VQA

RVDYEAIPKLPGVEEYIKLGAV

PGGTERNFASYGHLWLR*LAL

AP/LEVVEANGSL*CSGERGCL

YGQTTTIQLNFRPAFCPEHAIAG

QKVAILRLNMQIDIKRVSSRTH

GNHFTNFKFTVQHYRSCLT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknovvn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9066 59434 A 9125 2340 QFGIWLDSSSPEQTVPYLWSEE

TPATPIGQAIHRLLLIQAFRPDR

LLAMAHMFVSTNLGES\FMSIM

EQPLDLTHIVGTEVKPNTPVLM

CSVPGYDASGHVEDLAAEQNT

QITSIAIGSAEGFNQADKAINTA

VKSGRWVMLKNVHLAPGWLM

QLEKKLHSLQPHACFRLFLTME

INPK\VPV\NLLRAGRIFVFEP\PP

GWKANMLRTFSSIPVSRICKSP

NERARLYFLLAWFHAIIQERLR

YAPLGWSKKYEFGESDLRSAC

DTVDTWLDDTAKASGRQNISP

DKIPWSALKTLMAQSIYGGRV

DNEFDQRLLNTFLERLFTTRSF

DSEFKLACKVDGHKDIQMPDGI

RREEFVQWVELLPDTQTPSWL

GLPNNAERVLLTTQGVDMISK

MLKMQMLEDEDDLAYAETEK

KTRTDSTSDGRPAWMRTLHTT

ASNWLHLIPQTLSHLKRTVENI

KDPLFRFFEREVKMGAKLLQD

VRQDLADVVQVCEGKKKQTN

YLRTL1\NELVKGILP\RSWSHYT

VPAG\MTVIQWGVPISARRI\KQ

LQNISLAAASGGAKELKNIHVC

LGGLFVPEAYITATRQYVAQAN

SWSLEELCLEVNVTTSQGATLD

ACSFGVTGLKLQGATCNNNKL

SLSNAISTALSLTQLRWVKQTN

TEKKASVVTLPVYLNFTRADLI

FTVDFEIATKEDPRSFYERGGG

9067 39435 A 9126 6375 HKVAAPDVVVPTLDTVRHEAL

LYTWLAEHKPLVLCGPPGSGK

TMTLFSALRALPDMEVVGLNFS

SATTPELLLKTFDHYCEYRRTP

NGVVLAPVQLGKWLVLFCDEI

NLPDMDKYGTQRVISFIRQMVE

HGGFYRTSDQTWVKLERIQFV

GACNPPTDPGRKPLSHRFLRHV

PVVYVDYPGPASLTQIYGTFNR

AMLRLIPSLRTYAEPLTAAMVE

FYTMSQERFTQDTQPHYIYSPR

EMTRWVRGIFEALRPLE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9140 59508 A 9199 2491 MGDFNTPLSTLDRSTRQEVNK

DTQELNSALHQVDLIDIYRTLH

PKSTEYTFFSAPHYTYSKIDHIV

GSKALLSKCKRTEIITNCLSDHS

AIKLELRIKKLTQNHSTTWKLN

NLLLNDYWVNNEVKAEIKMFF

ETNENKDTTYQNLWDTFKAIN

KIDRPLARLIKKKREKNQIDAIK

NDK\WDITTDPTEIQTTIREYYK

HLYANKLENLEEMDKFLDTYT

LPRLNQEEVESLNRPITGSEIEAI

TNSLTΛTKKSPG PDGFTA KFYQR

YKEELVP\FLLKLFQLIEKEGILP

NSFYEASIILIPKPGRDTTΛKQKK

NFRPISLMNIDAKILNKILANRI

QQ\HIKKLIHHDQVGFIPG\MQG

LFNICKSINVIHHINRTKDKNYM

IIS/I*DAEKAFDKIQQPFMLKTL

NKLGIDGTYLKIIRAIYDKPTAD

11 LNGQKLE AFSLKTGTRQGCPL

SPLLFNIVLEVLARAVRQEKEIK

GIRLGKEEVKLSLLADDMIVYL

ENPIVSAPNLLKLISNFSKVSGY

KINVQKSQAFLYTNNRQTESQI

MSELPFTIASKRIKYLGIQLTRD

MKDLFKEΝYKPLLΝEIKEDTΝK

WKΝIPCSWVGRIΝIMKMAILPK

VIYRFNAIPIKLPMTFFTELEKTT

LKFIWNQKRARIAKSILSQKNK

AGGITLPDFKLYYKATVTKTA

WYWYQNRDIDQWNRTEPSEIT

PHIYNYLIFDKPEKMSIIDTGGW

9141 39509 9200 3083 MGKKQNRKTGNSKTQSASPPP

KERSSSPATEQSWMENDFDELR

EEGFRRSNYSELWEDIQTKGKE

VENFEKNLEECITRITNTEKCLK

ELMELKTKARELREECRSLRSR

CDQLEERVSAMEDEMNEMKRE

GKFREKRIKRNEQSLQEIWDYV

KRPNLRLIGVPESDVENGTKLE

NTLQDIIQENFPNLARQANVQI

QEIQRTPQRYSSRRATPRHIIVR

FTKVEMKEKMLRAAREKEIQT

TIREYYKHLYANKL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9273 39641 A 9333 1365 STETLSPLPATPGEVTLRHLDV

VSAEQQMFSGLVEKIQVTGSEG

ELGIYPGHAPLLTAIKPGMIRIV

KQHGHEEFIYLSGGILEVQPGN

VTVLADTAIRGQDLDEARAME

AKRKAEEHISSSHGDVDYAQAS

AELAKAI AQLR VIELTKKAM * H

RLEKHKSQSGNRLAFFCACDPS

9274 39642 9334 601 MLSAVGYQP/TLAEEMGVLQE

RIPSTKTGSITSVQAVYVPADDL

TDPSPATTFAHLDATVVLSRQI

ASLGIYPAVDPLDSTSRQLDPL

VVGQEHYDTARGGQFILARYQ

ELESLLVAILGMNDLSEEDKLVV

ARARKIQRFLSQPFFVAEVFTGS

PGKYVSLKDTIRGFKGIMEGEY

DHLPEQAFYMVGSIEEAVEKA

9275 39643 B 9335 681 1071

9276 39644 A 9336 203 2189 VASSARRGLPVHGPAPLQGPGN

SQDRL/ESGTNRCGLRGPLVKG

GKGGRFPSARL1QTVKKGGTPS

RDHA\IEPSGY\SVSAGVGE\RTR

KGSVFAHEMPDCNVIDKVSLV

YGQMTEPPGNCMRVALSGLTM

AEKFRDEGRDVLLFVDNIYRYA

LAG*ERFATVGR*ASN/AVGIQP

TLAEKMGVLQERITSTKTGSITS

VQAVYVPANDLTDPSPATTFA

HLDATVVLSRQIASLGIYPVAVD

PLDSTSRQLDPLVVGQEHYDTA

RGG*SI\LQRF\QELKDFMALP/G

LSDELSEEDKLVVARARKIQRF

LSQPFFVAEVFTGSPGKYVSLK

DTIRGFKGIMEGEYDHLPEQAF

YMGDMAMTYHLDVVSAEQQ

MFSGLVEKIQVTGSEGELGIYS

GHAPLLTAIKPGMIRIVKQHGH

EEFIYLSGGILEVQPGNVTVLAD

TAIRGQDLDEARAMEAKRASG

KVKPSIMQSLTPEKIAAILPLQF

FPQPADFTGPYVMLTSRRNNRA

LSRCDDQTLMPGLAIRGIRHRH

QQAGVRILLNNAIEHVVDGEK

VELTLQSGDTLQADVVIYG1GIS

ADEPLAREANLDTANGIVIDEA

CRTCDPAIFAGGDVP1TSSLINV

VDEIIHDILLTQPVATRYCIVKVI

FEAVMILRDSGGAPFCSNGMAT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9325 39693 9385 1852 SKQKPMNVGLSETQNGGMSQE

AVGNIKVTKSPQKSTVLTNGEA

AMQSSNSESKKKKKKKRKMV

NDAEPDTKKAKTENKGKSEEE

SAETTKETENNVEKPDNDEDES

EVPSLPLGLTGAFEDTSFASLCN

LVNENTLKAIKEMGFTNMTEIQ

HKSIRPLLEGRDLLAAAKTGSG

KTLAFLIPAVELIVKLRFMPRNG

TGVLILSPTRELAMQTFGVLKE

LMTHHVHTYGLIMGGSNRSAE

AQKLGNGINIIVATPGRLLDHM

QNTPGFM YKN LQCL VIDE ADRI

LDVGFEEELKQIIKLLPTRRQTM

LFSATQTRKVEDLARISLKKEPL

YVGVDDDKANATVDGLEQGY

VVCPSEKRFLLLFTFLKKNRKK

KLMVFFSSCMSVKYHYELLNYI

DLPVLAIHGKQKQNKRTTTFFQ

FCNADSGTLLCTDVAARGLDIP

EVDWIVQYDPPDDPKEYIHRVG

RT ARG\LNG RG H ALLI LRPEELG

FLRYLKQSKVPLSEFDFSWSKIS

DIQ\SQLEKLIEK\NYFLHKSA\Q

EAYKSYIRAYDSHSLKQIFNVN

NLNLPQVALSFGFKVPPFVDLN

VNSNEGKQKKRGGGGGFGYQ

KTKKVEKSKIFKHISKKSSDSRQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, --possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9358 39726 9418 1875 EPEKQQLYDIPASPKKAGLHPP

DSQASGQGVPLISVTTLRRGGY

STLPNPQKSEWIYDTPVSPGKA

SVRNTPLTSFAEESRPHALPSSS

STFYNPPSGRSRSLTPQLNNNVP

MQKKLSLPEIPSYGFLVPRGTFP

LDEDVSYKVPSSFLIPRVEQQN

TKPNIYDIPKATSSVSQAGKELE

KAKEVSENSAG\QIPHGSPDGQ/

RSPSPEPDRLSGSSSDSRASIVSS

CSTTSTDDSSSSSSEESAKELSL

DLDVA KETVM A LQHKVVSS VA

GLMLFVSRKWRFRDYLEANID

AIHRSTDHIEESVREFLDFARGV

HGTACNLTDSNLQNRIRDQMQ

TISNSYRILLETKESLDNRNWPL

EVLVTDSVQNSPDDLERFVMV

ARMLPEDIKRFAS1VIANGRLLF

KRNCEKEETVQLTPNAEFKCEK

YIQPPQRETESHQKSTPSTKQRE

DEHSSELLKKNRAN1CGQTLPN

LEEKDKPILEQRLDENKDLGTM

NPGPLIPQPSSQQTPERKPRLSE

HCRLYFGALFKAISAFHGSLSSS

QPAEIITQSKLVIMVGQKLVDT

LCMETQERDVRNEILRGSSHLC

SLLKDVALATKNAVLTYPSPAA

LGHLQAEAEKLEQHTRQFRGT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9363 59731 9423 504 1862 RMLEATSKMRKGVPSSIQ/SSQ

GNSYTLIPSAKSDNLSDSSHSEI

SSRSSIVSNCSVDSMSAALQDE

RCSSQALAVPESTGALEKTEHA

SGIGDHSQHGPGWTLLKPSLIK

CLAVSSSVSNEEISQEHIIIEAAD

SGSWEVGTSCSSSSHDNFQSLP

NPKSWDFLNSYRHTHLDDPIAE

VEPTDSEPYSCSKSCSRTCGQC

KGSLERKSWTSSSSLSDTYEPN

YGTVKRRVLESTPAESSEGLDP

KDATDPVYKTVTSSTEKGLIVY

CVTSPKKDDRYREPPPTPPGYL

GISLADLKEGPHTHLKPPDYSV

AVQRSKMMHNSLSRLPPASLSS

NLVACVPSKIVTQPQRHNLQPF

HPKLGDVTDADSEADATLGNK

CKLLYMSDVRNPVPAVKDVLV

QKYTSFNFFHPQEALDRRREEL

ALPEGASGEACLSTRSLKRSGV

QALAQQTHSRNFLPEKQPFSAQ

AAGILHGSINHNTRGPCLLEGT

KMMTGVLYRAYLLCIAYSRDLI

VDEQIMNGLRKAI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λniino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9516 59884 A 9576 131 1066 SHSSSAAAHPLGLLPIAAQSLA

VFIEPWSQASSRGQLQ/VSAPGI

WGIGVATQKVNLNQIPLGRDM

HSLVMRNDGALYHNNEEKNRL

PANSLPQEGDVVLCWSNNGHS

LCKEESLSPILPTSDGEERRRKR

KKRKRKKRKQKQQQQQEAAA

PAE A DAE ATA AE AA VEE AAAR

KEEEEEGEEGEGNGEEEEEKAA

AAARGDWSQQEKACKSSLQAI

LFGHAKLEPGRLPRPTQCRVEA

TVLVGTNSPLDNPLWSISWSLW

QKPVGTSQQQPLGLWTREFPLE

GHLLTRN ETFTEATPLIPEIGML

SQMMSEEHI

9517 39885 9577 2363 ELQRDIEKHSTGVASVLNLCEV

LLHDCDACATDAECDSIQQATR

NLDRRWRNICAMSMERRLKIE

ETWRLWQKFLDDYSRFEDWLK

SSERTAAFPSSSGVIYTVAKEEL

KKFEAFQRQVHECLTQLELINK

QYRRLARENRTDSACSLKQMV

HEGNQRWDNLQKRVTSILRRL

KHFIGQREEFETARDSILVWLTE

MDLQLTNIEHFSECDVQAKIKQ

LKAFQQEISLNHNKIEQIIAQGE

QLIEKSEPLDAAIIEEELDELRR

YCQEVFGRVERYHKKLIRLPLP

DDEHDLSDRELELEDSAALSDL

HWHDRSADSLLSPQPSSNLSLF

ASLQPLRSER\SGRDTPG\SVDSI

PLVEWDHDYDLSRDLESAMSRA

LPSEDEEGQDDKDFYLRGAVG

LSDVMIPESPEAYVKLTENAIK

NTSGDHSALESQIRQLGKALDD

SRFQIQQTENIIRSKTPTGPELDT

SYKGYMKLLGECSSSIDSVKRL

EHKLKEEEESLPGFVNLHSTET

QTAGVIDRWELLQAQALSKEL

RMKQNLQKWQQFNSDLNSIW

AWLGDTEEELEQLQRLELSTDI

QTIELQIKKLKELPESCWDHR\K

AIILSINLCSPEFTQADSKESRDL

QDRLSQMNGRWDRVCSLLEE

WRG LLQDA LMQCQGFHEMSH

GLLLMLENIDRRKNEIVPIDSNL

DAEILQDHHKQLMQIKHELLES

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Ammo acid sequence ( X=Unkno n, NO: of peptide hod in USSN location ot first codon for last ammo acid ^:Stop codon, /=possιb!e nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possιble nucleotide insertion) sequence

9677 40045 A 9737 1665 MAGACWLMAFQYWVLKLLVV

KSA/SWPRQSSLKWNWNFKGC

QDLETWGKKETRKFYGYRRNE

EAQKYSCRIPRKPD*WCHCWQ

W**WLMAFQYWVLKLLVVKS

AYGLVKALSNGIGISKVAKTW

KPGGKKRLENFMAIEEMKKHR

STHVGFPENLTNGATAGNGDD

GLIPPRKSRTPESQQFPDTENEE

YHRDFSKLCLGSAANGVVHVE

VKMCVYNGKGERQEEKMKGLI

SMNLVVEEEMKKHESNNVGLL

ENLTNGVTAGNGDNGLIPQRKS

RTPENQQFPDNESEEYHSLGDK

SKTSFQNSNNNNNKQQEQQQQ

NPTFSNTRKLTKLYKAPIPPSIIL

SGCPNINDSNWQEIEHGMQTA

GLPTRPLSHGLQQKGAAFRCLG

CKCSEPFTGSLILQKAKTNTQK

WQATYPKSQNEQLVPSVGKSY

RCSTPAQPMKTAVGHKPCKAT

GAELPKALGAQPLHPCALDVG

QGFKKGNFGAVGLNGLLGLEF

HGVSGVLLVGPGDGGLISEGVV

REDLMCGVWSAGTWSVGTAE

RCLEKPGALHVIEGPLDSWDGP

VMPNGPVKSRQSSCLDGPGRC

CSEILTGQSHGNKKPARASSKS

SQSINDRPLAVLTNQYQCEQLA

SERQPSSNSCSIRIDSA

9678 40046 9738 1 15 RRTARGPQQTSTDGLGTSPCRN

ASEHTADILELSTLIV*RRQ*ICL

CLDFLYY/LIPEGRCFCRACDLV

HNFVDTIILQQHRTLTSQGVDDF

LKAKATFKASDFIDALVLSKVA

SPRILIQGGRMGA*DQVSDQAS

VYGRCSSSGAEAAKRPKSAWL\

LLGYDSRASGLY*ILYNLTKHP

D/YRECCQP VMQES* S * RRTAR

GPQQTSTDGLGTSPCRNASEHT

ADILELSTLIV

9679 40047 9739 506 MVIVGLAAGVLLVGPGDGGLIS

EGVVREDLMCGVWSAGTWSV

GTAERCLEKPGALHVIEGPLDS

WDGPVMPNGPVKNHKGEQQE

VPSKHPQMALEICLCLDFLYY/L

I PEG RCFCRACDL VHNF\DTI ILQ

QHRTLTSQGVDDFLKAKATFK

ASDFIDALVLSKVASPGS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod n USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9831 40199 9892 121 2320 EM AFQKA VKGTI LVGGG ALAT

VLGLSQFAHYRRKQMNLAYVK

AADCISEPVNREPPSREAQLLTL

QNTSEFDILVIGGGATGSGCAL

DAVTRGLKTALVERDDFSSGTS

SRSTKLIHGGVRYLQKAIMKLD

IEQYRMVKEALHERANLLEIAP

HLSAPLPIMLPVYKWWQLPYY

WVGIKL\YDLVARKANCLKSSY

VLSKSRALEHFPMLQKDKLVG

AIVYYDGQHNDA\RMNLAIALT

AA\RYGAATANYMEVVSL\LKK

TDP\QTGK\VHVSGARCKGCPST

GQEFDVRAKCVINATGPFTDSV

RKMDDKDAAAIVCQPSAGVHIV

MPG Y YSPESMG LLDPATSDGR

VIFFLPWQKMTIAGTTDTPTDV

THHPIPSEEDINFILNEV\RNYLS

CDVEVRRGDVLAAWSGIRPLV

TDPKSADTQSISRNHVVDISESG

LITIAGGKWTTYRSMAEDTINA

AVKTHNLKAGPSRTVGLFLQG

GKDWSPTLYIRLVQDYGLESEV

AQHLAATYGDKAFEVAKMAS

VTGKRWPIVGVHLVSEFPYIEA

EVKYGIKEYACTAVDM1SRRTR

LAFLNVQAAEEALPRIVELMGR

ELNWDDYKKQEQLETARK\FL

YYEMGYKSRSEQLTDRSEISLL

PSDIDRYKKRFH KFDADQKGFI

TIVDVQRVLESINVQMDENTLH

EILNEVDLNKNGQVELNEFLQL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9832 40200 9893 2020 MLKPLMGGGAHRRAAAGARK

WDGTAIIASTSGLEVLWVTTSR

SKTVESVGLAKPGQHNDARMN

LAIALTAARYGAATANYMEVV

SLLKKTDPQTGKVRVSGARCK

DVLTGQEFDVRAKCVINATGPF

TDS VRKM DDKD AAAI\CQA\SA

GVHIVMPGYYSPESMGLLDPAT

SDGRVIFFLPWQKMTIAGTTDT

PTDVTHHPIPSEEDINFILNEVR

NYLSCDVEVRRGDVLAAWSGI

RPLVTDPKSADTQSISRNHVVDI

SESGLITIAGGKWTTYRSMAED

TIΝAAVKTHΝLKAGPSRTVGLF

LQGGKDWSPTLYIRLVQDYGL

ESE V AQH LAATYGDKAFE VAK

MASVTGKRV/WPIVGVRLVSDF

PYIEAEVKYGIKEYACTAVDMT

SRRTRLAFLΝLQAAEEALPRLL

ELMGRELΝWDDYKKQEQLET

ARKFLYYEMGYKSRSEQLTDR

SEISLLPSDIDRYKRRCHKFDAD

QRGFMTVVEVQRVLESIΝVQM

DEΝTLHEILΝEVDLΝKΝGQVEL

ΝEFLQLMSAIQKGRVSGSRLAI

LMKTAEEΝLDRRVPIPVDRSCG

GLYFCVRΝWWVLGLTDFKΝE

AADPSGVKLQTFTVSVTALKV

ARLELFVSPGGLVVLLGSGVKL

QIFAPΝMAMHΝKAAPPQIPDTR

RELAELVKRKQELAATLAKFG

9833 40201 9894 593 ISSAVEFETSQLSGLWTEQSAA

RSRGEΝIVCGPQGPRG/GPWVP

AEPTGSPVVSEEPLDLLPTLDLR

QEMPPPRVFKSFLSLLFQGLSVL

LSLAGDVLVSMYREVCSIRFLF

TVVSLL\ΝLFLSAFWLGLLYLVS

PLENEPKEMLTLSEYHERVRSQ

GQQLQQLQAELDKLHKEVSTV

RAANSERGAKLVFQRLNEGFV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod n USSN location of first codon for last amino acid Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9859 40227 A 9920 868 NSSPPFPFPRIVVGATLHSKETS

SYRLGSQPSHQVPTPSPRPRVFT

PQSSPAMPLAPSH PSPYQG PRT

QNISDYRAPGPQAIQPLPLSPGV

RPGPQDSWKEAPAPRGNLQRN

KLPETFMPPAPITGPS/IM/RPHP*

ATRDSSLTAPLSPV*VMLPQEF

QENS\PAGDKDNVFPSLGKPPSP

PCVQVMVDGPHSSR/PCAEGD

WVQVPGVLTAEKGRLLISPTLL

*WEQCDCESLGTSP*GSHEKDS

LPLWPFSLLLYQQLQHLPPEKM

ERKELPPEHQSLKSSFEALLQRC

9860 40228 9921 307 MKLKELERPAVQAWSPASQYP

LYLATGTSAQQLDSSFSTNGTL

EIFEVDFRDPSLDLKHRGVLSA

LSRFHKLVWGSFGSGLLESSGV

IVGGGDNGMLILYNVTHILSSG

KEPVIAQKQKHTGAVRALDLN

PFQPPEDIKALSWNRQAQHILSS

AHPSGKAVVWDLRKNEPIIKVS

DHSNRMHCSGLAWHPDIATQL

VLCSEDDRLPVIQLWDLRFASS

PLKVLESHSRGILSVSWSQADA

ELLLTSAKDSQILCRNLGSSEPC

PRLVFISQVTTESEFLMRSAELQ

EALGSGNLLNYCQNKSQQALL

QSEKMLWQFLKVTLEQDSRMK

FLKLLGYSKDELQKKVATWLK

SDVGLGESPQPKGNDLNSDRQ

QAFCSQASKHTTKEASASSAFF

DELVPQNMTPWEIPITKDIDGLL

SQALLLGELGPAVELCLKEERF

ADAIILAQAGGTDLLKQTQERY

LAKKKTKISSLLACVVQKNWK

DVVCTCSLKNWREALALLLTY

SGTEKFPELCDMLGTRMEQEGS

RALTSEARLCYVCSGSVERLVE

CWAKCHQALSPMALQDLMEK

VMVLNRSLEQLRGPHGVSPGP

ATTYRVTQYANLLAAQGSLAT

AMSFLPRDCA/PAARDIYAPSTN

YCSSYEPHP*ATRDSSLTAPCLQ

SASAPAT*EDGKEGAAPRASVL

EEQL*GASPTLLPVCN*LKDKK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9922 40290 9983 2023 MGGGSWAPTGLCPLQSLLAMS

PEKRKLAAQEGQFTEPRPEEPP

KEKLHTLEEFSYEFFRAPEKDM

VSMAVLPLARARGHLWAYSCE

PLRQPLLKRVHANVDLWDIAC

QIFVDILPHQPACTSAVVGVSV

YPQSVSAWSCPSTVLLDSHTUL

RYMGDYPSRQAWPTLELTDQIF

TLALQHPALQDEVYCQILKHLT

HNSDRHSEERGWQLLWLCTGL

FPPSKGLLPHAQKFIDTRRGKLL

APDCSRRIQKVLRTGPRKQPPH

HVEVEAAEQNVSRICHKIYFPN

DTSEMLEVVANTRVRDVCDSI

ATRLQLASWEGCSLFIKISDKVI

SQKEGDFFFDSLREVSDWVKK

NKPQKEGEEASVELGEGVAGW

VEGALAASVRPMPIHPSIRSRVS

LGCGNNQALGPGGAPVTLPYQ

VYFMRKLWLNISPGKDVNADT

ILHYHQELPKYLRGFHKCSRED

AIHLAGLIYKAQFNNDRSQLAS

VPKILRELVPENLTRLMSSEEW

KKSILLAYDKHKDKTVEEAKV

AFLKWICRWPTΛFGSAFF/EGEG

KPCPTPGPPTQAASAQPSPSRPS

VNQHTSWQTSEPSYPDVILIAIN

RHGVLLIHP\KTKDLLTTYPFTK

ISSWSSGSTYFHMALGSLGRGS

RLLSETΛSLGYKMDDLLTSYVQ

QLLSAMNKQRGSKAPALAST

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod n USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9923 40291 9984 428 2502 VSKEIVYNKLLPYAERLDAESD

LQLAQIKCNLGRAVQLQELWP

GGLFWTRKLS/TRAGPLALSSLE

LSPSGDPRVVTEPVKYSSRPPCH

FPTGLPGSLPSLYVLRICFSRSV

RVVVFPPGGPWVAQGPRPRGR

ETWGFTMLLRYIRLYGRKFSKE

DHVLFIKLLYELVSIPKLEISMM

QGFARLLINLLKYFPADATAEM

LEEWRPLMCPFDVTMQKAITY

FEIFLPTSLPPELHHKGFKLWFD

ELIGLWVSVQNLPQWEGQLVN

LFARLATDNIGYIDWDPYVPKG

GPSKLVQKHLAGLFNSITSFYH

PSNNGRWLNKLMKLLQRLPNS

VVRRLHRERYKKPSWLTPVPDS

HKLTDQDVTDFVQCIIQPVLLA

MFSKTGSLEAAQALQNLALMR

PELVIPPVLERTYPALETLTEPH

QLTATLSCVIGVARSLVSGGRW

FPEGPTHMLPLLMRALPGVDPN

DFSKCMITFQFIATFSTLVPLVD

CSSVLQERNDLTEVERELCSAT

AEFEDFVLQFMDRCFGLIESSTL

EQTREETETEKMTHLESLVELG

LSSTFSTILTQCSKEIFMVALQK

VFNFSTSHIFETRVAGRMVADM

CRA A VKD WGKPGDL WNLG IQ

WHVPSSEEVSFAFYLLDSFLQP

ELVKLQHCGDGKLEMSRDDIL

QSLTIVHNCLIGSGNLLPPLKGE

9924 40292 9985 5396 AESDLQLAQIKCNLGRAVQLQE

LWPGGLFWTRKLSTYIRLYGR

KFSKEDHVLFIKLLYELVSIPKL

EISMMQGFARLLINLLKKKELL

SRADLELP WRPL YDMVERI LYS

KTEHLGLNWFPNSVENILKTLV

KSCRPYFPADATAEMLEEWRP

LMCPFDVTMQKAITYFEIFLPTS

LPPELHHKGFKLWFDELIGLWV

SVQNLPQWEGQLVNLFARLAT

DNIGYIDWDPYVPKIFTRILRSL

NLPVGSSQVLVPR

9925 40293 9986 477 VREFPGRRFRGCCGALRPRYKR

LVDNIFPEDP\GYVCIAMEALDQ

LLMACHCQSINLFVESFLKMVA

KLLESEKSNLQILGTNSFVKFA

N IEEDTPS YHRSYDFFVSRFSEM

CHSSHDDLEIKTKIRMSGIKSLQ

G V VRKTVNDELQAN I WDPQH SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

9926 40294 A 9987 2371 AGGARLRPARGRPPRLLPPRPG

PCRPPP V PAPT VNERRAPPRAG

WERRSDAGLSRGARPAEMYGV

CGCCGALRPRYKRLVDNIFPED

PEDGLVKTNMEKLTFYALSAPE

KLDRIGAYLSERLIRDVGRHRY

GYVCIAMEALDQLLMACHCQS

INLFVESFLKMVAKLLESEKPN

LQILGTNSFVKFANIEEDTPSYH

RSYDFFVSRFSEMCHSSHDDLEI

KTKIRMSGIKGLQGVVRKTVN

DELQANIWDPQHMDKIVPSLLF

N LQH VEEAESRSPSPLQAPEKE

KESPAELAERCLRELLGRAAFG

NIKNAIKPVLIHLDNHSLWEPK

VFAIRCFKIIMYSIQPQHSHLVIQ

QLLGHLDANSRSAATVRAGIVE

VLSEAAVIAATGSVGPTVLEMF

NVTLLRQLRLSIDYALTGSYDGA

VSLGTKIIKEHEERMFQEAVIKT

VGSFASTLPTYQRSEVILFIMSK

VPRPSLHQAVDTGRTGENRNR

LTQIMLLKSLLQVSTGFQCNNM

MSALPSNFLDRLLSTALMEDAE

IRLFVLEILISFIDRHGNRHKFSTI

STLSDlSVLKLKVDKCSRQDTV

FMKKHSQQLYRffiYLSCKEETN

VQKHYEALYGLLALISIELANE

EVVVDLIRLVLAVQDVAQVNE

ENLPVYNRCALYALGAAYLNLI

SQLTTVPAFCQHIHEVIETRKKE

APYMLPEDVFVERPRLSQNLDG

9927 40295 9988 662 IPGSTISWSPAAARGLSVCRCCR

LHPASAMDLFGDLPEPERSPRP

AAGKEAQKGPLLFDDLPPASST

DSG/SSLQALPGSGGPLLFDDLP

PASSGDSGSLATSISQMVKTEG

KGAKRKTSEEEKNGSEELVEK

KVCKASSVIFGLKGYVAERKGE

REEMQDAHVILNDITEECRPPSS

LITRVSYFAVFDGHGGIRASKF

AAQNLHQNLIRKFPKGDVISVE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

10002 40370 10063 2480 RPITGAEIVAIINSLPTKKSPGLD

GFTAEFYQRYKEELVPFLLKLF

QSIEKEGILPNSFYEASIILIPKPG

RDTTKKENFRPISLMNIDAKILN

KILANRIQQHIKKLIHHDQVGFI

PGMQGWFNIRKSINVIQHINRT

KDKNHMIISIDAEKAFDKIQQ/R

LHAKNS/RIN*VLM/ETYFKIIRA

IYDKPIANIILNGQKLEAFPLKT

GTRQGCPLSPLLFNIVLEVLAR

AIRQEKEIKGIQLGKEEVKLSLF

ADDMIVYLENPIVSAQNLLKLIS

NFSKVSGYKINVQKSQAFLYTN

NRQTESQIMSELPFTIASKRIKY

LGIQLTRDVKDLFKENYKPLLK

EIKEDTNKWKNIPCSWVGRINI

VKMAILPKVIYRFNAIPIKLPMT

FFTELEKTTLKFIWNQKRAHIA

KSILSQKNKAGGITLPDFKLYY

KATITKTAWYWYQNRDIDQW

NRTEPSEITPHTYNCLIFDKPEK

NKKWGKDSLFNKWCWENWLA

ICRKLKLDPFLTPYTKINSRWIK

DLNVRPKTIKTLEENLGITIQNI

GMGKDFMSKTPKAMATKDKID

KWDLIKLKSFCTAKETTIRVNR

QPTKWEKIFATYSSDKGLISRIY

NELNQIYKKKTNNPIKKWAKD

MNRHFSKEDIYAAKKHMKKCS

SSLAIREMQIKTTMRYHLTPVR

MAIIKKSGNNRCWRGCGEIGTL

LHCWWDCKLVQPLWKSVWRF

10003 40371 10064 317 582 STVCCFLLRFIGGGFRHIPLSVD LWIHYIKILKETLDPGDPETNNT IRGYVEH*Y*NVFYDINNYSDV DNRAHES*AGSLTSIPLLKK

10004 40372 A 10065 41 434 GDLQPTAALWEPLSGLAKAGA

RSLSLQGGVGGEARARTRAAR

GACGPAAAPGGHGLGGHALGA

AGR/RLLALGRLGTCSLPCLSLP

PSPWAPVPPEPPR*VPPHAPGRP

VPSATQRLRSAGAQRRTGRQL

10005 40373 10066 67 459 LRDCKYTHRHCVSSSRFINTPIN

TLCLAQGL*VHQSTLCI*LLWV

GGLGGNFCVQYSVSN* SDGDV

ENLCPLRDCKCTNQHPVKTGH

FGSTNQQDVGWGQIKRIKAGLP

EPASGNSLGSPSTLWELCSLQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

10130 40498 10191 272 2722 ETSCPLVRVHYAEAITGRCTAP

EDEGSLGQKPPARRSNNRTEGA

WGKRQLM SSP/STEPRVCLTIEG

QEIDFLLDTGAAFSVLISCPGRL

SSTSVTIQGILGQPVTRYFSHLL

SCΝWETLLFSHAFLLMPERPTG

LLGRDILAKAGAIIYMNMGNKL

PICCPLLEEGINPEVWALEGQFG

RAKNAHPVQIRLKDPTTFPYQR

QY/PLRPEAHKGLQNIVKHLKA

QGLVRKCSSPCNTPILEVQRPRL

VQDLRLIN EAVISL YPVVPNPYT

LLSQIPEEAEWFTVLDLKDAFF

CVPLHSDSQFLFAFEDPTNHTS

QLTWMVLPQGFRDSPHLFGQA

LAKDLGHFSSPGTLVLQYVDDL

LLATS*EALCQQATLDLLNFLA

NQGYKVSMSKAQLCLQQVKY

LGLILAKGTRALSKE*IQPILAY

PRPKTLKQLREFLGITSFCRLWI

PGYSETARPLYTLIKDTQRANT

HLVEWESEAETAFKTLKQALV

QAPGLSLPTGQNFSLYVTERAG

IALGVLTQTRGTTPQPVAHLSK

ETDVVAKGWPHCLRVVAAVA

VLVSEAIKIIQGKDLIVWTTHEV

NGILGAKGSLWLSDNCLLRYQ

A LLLEGPVLQICTCMALNPATF

LPEDGEPIKHDCQQIIVQTYAAR

DDLLEVPLTNPDLNLYTDGSSF

VENGI/RKVSDVTILESKPLPPGT

SAQLAELVALTWALELGKGKR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last ammo acid *=Stop codon, /=possιble nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possιble nucleotide insertion) sequence

10218 40586 10279 1722 MIISIDAEKAFDKIQQRFMLKTL

NKLGIDGLYLKIIRAIYDKPTAN

IILNGQKLEALPLKTGTRQGCPL

SPLQFNIVLEVLARAIRQEKEIK

GIQLGKEEVKLSLLADDMIVYL

ENPIVSAQNLLKVISNFSKVSGY

KINVQKSQAFLYTNNRQTESQI

MSELPFTIASKRIKYLGIQLTRD

VKDLFKENYKPLLNEIKEDTKK

WKNIPCSWVGRINIVKMAILPK

VIYRFNAIPIKLPMTFFTELEKTT

LKFIWYQKRARITKSILSQRNK

AGDITLPDFKLYYKATVNKTA

WYWHQNRHIDQWNRTKPSEIT

LHIYNYLFFDNPDKNKKWGKD

SLFNKWCWENWLAICRKLKLD

PFLTPYTKINSRWIKDLNIRPKTI

KTLEENLGITIQDIGMGKYFMT

KTPKAMATKAKIDKWDLIKLK

SFCTGKETTIRVNRQPTKWEKIF

ATYSSDKGLISRIYNELKQIYKK

KTNNPIKKWAKDMNRHFSKED

IYAAKKHMKKCSPSLAIREMQI

KTTMRYHLTPT/RLIVIGIEECLR

GKEKLETLYYWNSDTDHQV*W

LGWP*WKSDHKKEQPSF

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

10219 40587 10280 2076 MDKFLNTYTIPRLNQEEVESLN

RSITGSEIEAIINNLPTKRSPGPD

G FTPEF YQRYKEEL VPFLLKLF

QSIVKEGFLPNSFYEGSIILITKS

GRDTTKKENLRPISLMNINAKIL

NKILANQIQQHIKKLIHHEQVDF

IPGMQGWFNIRKSINVIQHINRT

NDKNHMIISIDAEKAFDKIQQLF

MLKTLNKLGIDGTYLKIIRAIYD

KHTANIILNGQKLEAFPLKTGT

RQGCPLSPLLFNIVLEVLARAIS

QEKEIKGIQLGKEEVKLSLFAD

DMIVYLENPIVSAQNLLKLIGNF

SKVSGYKISVQKSQAFLYTNKR

QTESQIMSELPFTIVSKRIKYLGI

QLTRDVKDLFKENYKPLLNEIQ

DETNKWKN\CSWVGRINIVKM

VILP/KELEKTTLKFIWNQKRAR

IAKTILSQKNKAGGITLPDFELH

YKATVTKTACYLYQNRDIDQR

NRTEPSEIMPHIYNYLIFDKSDK

NKKWGKDSLFNKWCWENWLA

ICRKLKLDPFLPPYTKINSRWIK

DLNVRPKTIKTLEENLGNTIQDI

GMGKDFMSKTPKAMSTKAKID

KWDLIKLKSFCTAKETAIRVNR

EPTEWEKIFAIYSSDKGLISRIYN

EFKQIYKKKTNNPIKKWAKDM

NRHFSKEDIYAANRHMKKCSSS

LAIREMQIKTTQVGGSEEKSAS

ELGNKLIELDQSEEWRGKED

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno>vn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

10233 40601 10294 2605 M K AEIKMFFETN EN KDTTYQN

LWDAFKAVCRGKFIALNAYKR

KQERSKIDTLTSQLKELEKQEQ

SHSKAGRRQEITKIRAELKEIET

QKTLQKINESRSWFFERINKIDR

PLARLIKKKREKNQIDTIKNDK

GDITTNPTEIQTTIREYYKHLYA

NKLENLEEMDTFLDTYTLPRLN

QEEVGSLNTPITGSEIVAIINSLP

TKKSPGPDGFTAEFYQRYKEEL

PGRVPTKKENFRPISLMNIDAKI

LNKILANRIQQHIKKLIHHDQV

GFIPGMQGWFNIRKSINVIQHIN

RAKDKNHMIISIDAEKAFDKIQ

QPFMLKTLNKLGIDGTYFRIIRA

I YDKPTANIILNGQKLEAFPLKT

GTRQGCPLSPLLFNIVLEVLAR

AIRQEKEIKGIQLGKEEVKLSLF

ADDMIVYLENPIVSAQNLLKLIS

NFSKVSGYNFYVQKSQAFLYT

NNRQTESQIMSELPFTIASKRIK

YLGIQLTRDVKDLFKENYKPLL

KEIKEDTNKWKNIPCSWVGRIN

IVKMAILPKV1YRFNAIPIKLPM

TFFTELEKTTLKFIWNQKRARIA

KSILSQKNKAGGITLPDFKLYY

KATVTKTAWYWYQNRDIDQW

NRTEPSEIMPHIYNYLIFDKPEK

NKQWGKDSLFNKWCWENWLA

ICRKLKLDPFLTPYTKINSRWIK

DLN VRPKTIKTLEENLG ITIQDI

GVGKDFMSKTPKAMATKAKID

10234 40602 B 10295 111 2440

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last a ino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

10241 40609 10302 248 2623 RQWAGVVGRCSHLASWVSSNT

SETGAIRSSTEVDAPDDSMLLST

CDIDLTAARRAWLGCLPTKKSP

GPDGFTAEFYQRCKEELVPFLL

KLFQSI/EKEGILPNLFDEASIILI

PKRGRDTTKKENFRPISLMNID

AKILNKILANRNQQHIKKLIHH

DQVGFIPGMQGWFNICKSINVI

QHINRTKDKNHMIISIDAEKAF

DKIQQPFMLKTLNKLGIDGTYL

KIIRAIYDKPTANIILNGQKLEAF

PLKTGTRQGCPLSPLLFNIVLEV

LARAIRQEKEIKGIQLGKEEVKL

SLFADDMIVYLENPIVSAQNLL

KLISNFSKVSAYKINVQKSQAF

LYTNNRQTESQIMSVFPFTIASK

RIKYLGIQLARNAKDLFKENYK

PLLNEIKEDTKKWKNIPCSWVG

RINI VKM Al LPKVI YRFN A I PIKL

PMTFFTELEKTTLKFIWNQKRA

RIAKSILSQKNKAG\GIT\LPDFK

LYLQGLQ*PKTAWYWY\QNRD

IDQWNRTEPSEITPH1YNYLIFD

KPEKNKQWGKDSLFNKWCWE

NWLATCRKLKLDPFLTPYTKIN

SRWIKDLNVRPKTIKTLEENLGI

TIQDIGVGKDFMSKTPKAMAT

KAKIDKWDLIKLKSFCTAKETA

IRVNRQPTTWEKIFATYSSDKG

LISRI YNELKQI YKKK\TNN PIKK

WAKDMNRHFSKEDIYAANKH

MKKCSPSLAIREMQIKTTMRYH

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

10276 40644 10337 3 2431 GCLQELSVLFARGEPRGPCHNL

LHYMLALIGVPEVFWAFLFHCS

LGLEEEKLAPLIKGEEKIVWLRS

SFYFQHCLVDKSTLLPSSSVSLG

IFHEEKNSGEFPIFAKAVRLALV

PLRYVKLEDRDNWISVDSVTSE

IKLAKLPDFESRYVQNGTYTVK

IVAISEDYPRKTITGTVLINVEDI

NDNCPTLIEPVQTICHDAEYVN

VTAEDLDGHPNSGPFSFSVIDKP

PGMAEKWKIARQESTSVLLQQ

SEKKLGRSEIQFLISDNQGFSCP

EKQVLTLTVCECLHGS\GCREA

QHDSYVGLGPAAIALMILAFLL

LLLVPLLLLMCHCGKGAKGFTP

IPGTIEMLHPWNNEGAPPEDKV

VPSFLPWDQGGSLVGRNGVGG

MAKEATMKRKVSSASIVKGQH

EMSEMDGRWEEHRSLLSGRAT

QFTGATGAIVMTTETTITARATG

ASRDVAGAQAAAVALNEEFLK

NYFTDKAASYTEEDENHTAKD

CLLVYSQEETESLNASIGCCSFI

EGELDDRFLDDLGLKFKTLAEV

CLGQKIDINKEIEQRQKPATETS

MNTASHSLCEQTMVNSENTYS

SGSSFPVPKSLQEANAEKVTQEI

VTERSVSSRQAQKVATPLPDPM

ASRNVIATETSYVTGSTMPPTT

V I LG PSQPQSLI VTERV Y AP AST

L V DQP YANEGT V V VTERVIQPH

GGGSNPLEGTQHLQDVPYVME

10277 40645 10338 354 RPRLTSQDIKKPDC/DGEDAIGR

GFECDGLHLEKIVHFALHLEKN

VNQSLLELHKLATDKNDPHLC

DFIETHYLNEQVKAIKELGDHV

TN M HEMG APDSG V AEYLFDKH

TLGDSDNES

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno» n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

10622 40990 10684 7232 MPEPPTHSMGSCAAGASLTSTA

PCSTAPSPIDHLRAKECERTAQ

DWQAAPPAALVRDPLAALVRT

WRTFMSSSRIVNTPIGTLCLAQ

GFQWFSVLSQVHASTDQEIQE

MH DEQAΝPQΝ A VGTLD VGL I D

SVCASDSPDRPΝSFVIITAΝRVL

HCΝADTPEEMHHWITLLQRSK

GDTRVEGQEFIVRGWLHKEVK

ΝSPKMSSLKLKKRWFVLTHIPG

LLQEFREDALΝ WG PDEKIFKET

ELVΝDMDKIΝGRIERAE

10623 40991 10685 2146 IDSVCASDSPDRPΝSFVIITAΝR

VLHCΝADTPEEMHHWITLLQR

SKGDTRVEGQEFIVRGWLHKE

VKΝSPKMSSLKLKKRWFVLTH

ΝSLDYYKSSEKΝALKLGTLVL

ΝSLCSVVPPDEKIFKETGYWΝV

TVYGRKHCYRLYTKLLΝEATR

WSSAIQΝVTDTKAPIDTPTQQLI

QDIKENCLNSDVVEQIYKRNPIL

RYTHHPLHSPLLPLPYGDMNLN

LLKDKGYTTLQDEAIKIFNSLQ

QLESMSDPIPIIQGILQTGHDLRP

LRDELYCQLIKQTNKVPHPGSV

GNLYSWQILTCLSCTFLPSRGIL

KYLKFHLKRIREQFPGTEMEKY

ALFTYESLKKTKCREFVLSRDEI

EALIHRQDMTSTVYCHGGGSC

KITINSHTTΛAGEVVEKLIRGLA

MEDSRNMFALFEYNGHVDKAI

ESRTVVADVLAKFEKLAATSEV

GDLPWKFYFKLYCFLDTDNVP

KDSVEFAFMFEQAHEAVIHGH

HPAPEENLQVLAAHATSSIMQG

DYT\LHA\AIPP\LEEVYSLQRLK

ARISQSTKTFTPCERLEKRRTSF

LEGTLRRSF\RTGSVVRQKVEEE

QMLDMWIKEEVSSARASIIDK

WRKFQGMNQEQAMAKYMALI

KEWPGYGSTLFDVEVRTGCHV

LGWAGCWHLRTWITAKFMWR

EDKMEHFALSTSFFRAPKIVPLT

PPFSSQFLFSCVVNASVILGMN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

10764 41 132 10826 99 2052 NPADGRTGFTLCATGEALSSAT

IAAAERRQALQEGCDDILS/HG

DADMVSMAR/PFLADAELLSK

AQSGRA/DEINTCIGCNQACLD

Q/IFVGKVTSCLVNPRACH/ETK

MPILPAVQKKNLA/VVGAGPAG

LAFA\FNIAKQIPGKEEFYD/TL/

RYYRRM I EVTG VTLKL/NHTVT

ADQLQAFDETILAVG/IVPRTPPI

DGIDHP/KVLSYPDVLRDKAPV/

SN/KVAIIGCGGIGFDTAM/YLS

QPGESTSQNIAGFC/NEWGIDSS

LQQADCDAPAKASKPGQGLGK

TTGWI/HRTTL/LSRGVKMIPGV

S/YQKIDDDGLHVVINGANQGS

DMLRLQGELDSASRIGRRSAAP

KLGSLNDGRCFINCHILDRLPY

KGLVPACSWNGGSLDPLEGRP

DEPHVEVLGIPPAAMLDQAPRL

ASTLNGCLGVAGPYEDERTQE

GLPGPRDTAAEEVLGVQTGGA

GSRGRVRGPQPADLPSASGPGA

ACWSMSPPPDQPPCVLAHGFFR

RTPTSTQQRPAEQCFHSPAPLEL

PLSSTSSILSFAEYGNAMAWLY

RGKILPSGTPDDLKAQSANDGN

PDPTMEKAFIQLIHDGIRSIAMS

NPILSCRRYGRYQEWCLTIPAV

FISAPYVRRYVRFHEHQEGGGV

RQEATVREIPLAIAVIPNSRTPC

10765 41133 10827 525 DAMVSSWNRAAPNTIPTAAKA

GGNYLSSLLVGSEARRHGYQE

GIALDVNGYISEGAGENLFEVK

DGVLFTP/PGFTSSALPGITRDAI

IKL\AKE\LGIEVREQVLSR/EKS

LYLADEVF\MSGT\AGEITPR\RS

GNGYSGLAKGRCGPVTKRIQH

ALQGVYSWVTPGYFESVRCTA

10766 41 134 10828 573 REPAGENGPPVCDGAMLDLKA/

WGSECHQQLTGRDNQQIKRSIY

LLPERAKLAELRLLVIPGQVDY

LQHIEELAAFIKGLGDVPVRLN

AFHAHGVYGEAQSWASATPED

VEPLADALKVRGTCRPDKTRQ

ASHQALCANCRMRRERLIRPTV

RHKPVG M I RRDKRRIRH Y APT A

GCGVNALSGLRFGTDL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

10872 41240 10934 2358 VPMVVVPPVGAKGNTPATGTT

QGKKAEGTQNQSKKAEGAPNQ

GRKAEGTPNQGKKTEGTPNQG

KKAEGTPNQGKKA\EGTPNQG

KKAEGAHNQGKKVDTTPNQG

KKVEGAPTQGRKAEGAQNQA

KKVEGAQNQGKKAEGAQNQG

KKAEGAQNQGKKAEGAQNQG

KKAEGGQNQGKKTEEAQKQG

KKAEGAQIQGKKNEGAQTQGK

KAEGAQNQGKKNEGAQTQGK

KAEGAQTQGKKADGAQNQGK

KAEGAQNQGKKAEGAQNQGK

KAEGAQNQGKKADGAQNQGK

KAEGAQNQGKKAEGAQNQGT

KAEGAQNQGKKAEGAQNQGK

KAEGAQNQGKKAEGAQNQGK

KAEGAQNQGKKAEGAQNQGK

KAEGAQNQGKKAEGAQNQGK

KAEGAQNQGKKAEGAQNQGK

KAEGAQNQGKKAEGAQNQGK

KVEGAQNQGKKAEGAQNQGK

KAEGAQNQGKKAEGAQNQGQ

KGEGAQNQGKKTEGAQGKKA

ERSPNQGKK\GEGAPIQGKKAD

SVANQGTKVEGITNQGKKAEG

SPSEGKKAEGSPNQGKKADAA

ANQGKKTESAFVQGKNTDVAQ

SPEAPKQEAPAKKKSGSKKKGE

PGPPDADGPLYLPYKTLVSTVG

SMVFNEGEAQRLIEILSEKAGII

QDTWHKATQKGDPVAILKRQL

10873 41241 10935 967 1574 SLKCLIISLSPVHSYPGKRPEVSF

SPINSGQPPNYEMLKEEHEVAV

LGVAYNPAPPTSTVIHIRNETSV

PDHV/VLVPVQHSLHEP\CCLGF

IAFA YSVKSRH RKMVGDLTGA

Q/ALCLHRQVPEHLGPDFGHPH

DHSAHHHPSVDLPSLPSSFLLLF

LFLFLPA LQLLFLSFSLVFFFFFS

FFPLFQRLELWGWGEWDHHST

10874 41242 10936 370 RVATIVDIWEKSISGKKNSQNL FVNPCCLGFIAFAYSVKSRDRK MVGDLTGAQA/LCLHRQVPEH LSPDCGHPHDHSAHHHPGVDL PSLSIDQEASSRPGARALQDGA WASVFPSVQWEQQGW

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

11425 41793 A 1493 1955 FVSCQAPWSHPPAQLSPVGADA

MTLTLSVLICLGLSVGPRTCVQ

AGTLPKPTLWAEPASVIARGKP

VTLWCQGPLETEEYRLDKEGLP

WARKRQNPLEPGAKAKFHIPST

VYDSAGRYRCYYETPAGWSEP

SDPLELVATGFYAEPTLLALPSP

VVASGGNVTLQCDTLDGLLTF

VLVEEEQKLPRTLYSQKLPKGP

SQALFPVGPVTPSCRWRFRCYY

YYRKNPQVWSNPSDLLEILVPG

VSRKPSLLIPQGSVVARGGSLTL

QCRSDVGYDIFVLYKEGEHDL

VQGSGQQPQAGLSQANFTLGP

VSRSHGGQYRCYGAHNLSPRW

SAPSDPLDILIAGL1PDIPALSVQ

PGPKVASGENVTLLCQSWHQID

TFFLTKEGAAHPPLCLKSKYQS

YRHQAEFSMSPVTSAQGGTYR

CYSAIRSYPYLLSSPSYPQELVV

SGPSGDPSLSPTGSTPTPGPEDQ

PLTPTGLDPQSGLGRHLGVVTG

VSVAFVLLLFLLLFLLLRHRHQ

SKHRTSAHFYRPAGAAGPEPKD

QGLQKRASPVADIQEEILNAAV

KDTQPKDGVEMDARAAASEAP

\QDVTYAQLHSLTLRREATEPPP

S\QER£PPAEPSIYAPLAIHLAHG

GPRSHTQQKETQRLQKARELPP

VDTNEPQPAWDP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

13345 43713 13425 1307 1992 DKLNPVAHQKAYLAQSSQCHP

QNARLVQHTQIRILPISEPPSNRI

FACWGKPAWTACCN/FSQGQA

VKGNQLLPVSLVKRKTTLAPNT

QTASPRALADSLMQLARQVSR

LESGQDFADFGTTIKQDFRLLG

QTSVDRLLQLSQGQAVKGNQL

LPVSLVKRKTTLAPNTQTASPR

ALADSLMQLARQVSRLESGQD

FADFGTTIKQDFRLLGQTSVDR

LLQLSQGQAVKGNQLLPVSLV

KRKTTLAPNTQTASPRALADSL

MQLARQVSRLESGQDFADFGT

TI KQDFRLLGQTS VDRLLQLSQ

GQAVKGNQLLPVSLVKRKTTL

APNTQTASPRALADSLMQLAR

QVSRLESGQLKHKEVESPNRPI

TSSEIQVLIKSLPIKKSPGPDGFT

AEFYERYKEELVPFLLKLFQTIE

QERLLPNSFYEASIILTSKPSRD

ATKKDNFRPTSLMNIYAKILNK

IGQTESSSTSKSLFSTIKSVSSPE

CKAGSTYANQDFADFGTTIKQ

DFRLLGQTSVDRLLQLSQGQA

VKGNQLLPVSLVKRKTTLAPNT

QTASPRALADSLMQLARQVSR

LESGQETTPWSPFSDPVLAFDY

KVFMAFVYNVVRVSQRMVVA

GCISAFNDKLLNDLICFPVAPVS

SKQIFPSDVKVAEPDHSCVSSY

RIGSMAPNLTLSEMPRHNYFPA

GNSVDHDNEFEL

13346 43714 13426 560 844

13347 43715 B 13427 200 1519

13348 43716 13428 950 1230 CSWHDRFPDWKAGRILPISEPPS

NRIFACWGKPAWTACCN/FSQG

QAVKGNQLLPVSLVKRKTTLA

PNTQTASPRALADSLMQLARQ

VSRLESGQDFADFGTTIKQDFR

LLGQTSVDRLLQLSQGQAVKG

NQLLPVSLVKRKTTLAPNTQTA

SPRALADSLMQLARQVSRLESG

QDFADFGTTIKQDFRLLGQTSV

DRLLQLSQGQAVKGNQLLPVS

LVKRKTTLAPNTQTASPRALAD

SLMQLARQVSRLESGQDFADF

GTTIKQDFRLLGQTSVDRLLQL

SQGQAVKGNQLLPVSLVKRKT

TLAPNTQTASPRALADSLMQLA

RQVSRLESGQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

13950 44318 14032 2685 MGDFNTPLSTLDRSTRQKVNK

DTQELNSAPHQADLIDIYRTLH

PKSTEYTFFSAPHHTYSKTDHIL

GSKALLSECKRTEIITNYLSDDS

AIKLELRIKNLTQNRSTTWKLN

NLLLDDYWVHNEMKAEIKMFF

ETNENKDTTYQNLWDAFKAVC

RGKFVALNAHKRKQGRSKIDT

LTSQLKELEKQEQTHSKASRRQ

EITKIRAELKEIETQKTVQKINES

RSWFFERINKIDRQLARLIKKKR

EKNLIDAIKNDKGDITTDPTEIQ

TTIREYYKHLYANKLENLEEM

DKFLDTYTLPRLNQEEVESLNR

PITGSEIVAIINSLTTKKSPGPDG

FTAEFYQRAIRQEKEIKGIQLGK

EEVKLSLFADDMIVYLENPIVS

AQKLISNFSKVSGYKINVQKSQ

AFLYTNNRQTESQIMSELPFTIA

SKRIKYLGIQLTRDVKDLFKEN

YKPLLKEIKEDTNKWKNIPCSW

VGRINIVKMAILPKVIYRFNAIPI

KLPMTFFTELKKTTLΝFIWΝQK

\RAHIAKS/VLSQKΝKAGGITLP

DFKLYYKATVTKTAWYWYQN

RDTDQWNRTEPSEIMPRIYNYL

IFDKPEKNKQWGKDSLFNKWC

WKNWLAICRKLKLDPFLTPYT

KINSRWIKDLNIRPKTIKTLEEN

LGITIQDIGMGKDFMSKTPKAM

ATKAKIDKWDLIKLKSFCTAKE

TTNRVNRQPTKWEKIFATYSSD

13951 44319 14033 845 1616 ARAEVKLSLFADDMIVYLENPII

* ARAEVKLSLFADDMI VYLENP

IISAQNLLKLISKFSKVSRYKINV

QKSQAFLYTNNRQTESQIMSEL

PFTIATKRIKYLGIQLTRDVKDL

FKENYKPLLNEIKEDTNKWKNI

PCSWIGRINIVKMAILPKVIYRF

SAIPIKLPMTFFTELEKKNWLAI

CRKLKLDFFFIPYTKINSRWIKD

LNVRPKTMKTLEESLGNTIQDI

GIGKDFMTKTPKAMATKA/KKS

FCTAKETTIRVNRQPTEWEKIF

AIYPSDKGLIS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

13990 44358 14072 2156 MGKKQSRKTGNSKNQSASPPP

KERSSSPAMEQSWMENDFDDL

REEGFRQSNYSELKEEVRTHGK

EVKNLEKKLDEWLTRITNAEKS

LKDLMELKTTARELHDECTSLK

RVSVTEDQMNEMKREEKFREK

RIKRNEQSLQEIWDYVKRPNLH

LIGVPESDRENGTKLENTLQDII

QENFPNLVRQANIQIQEIQRTPQ

RYSSRRATPRHIIVRFTKVEMK

EKMLRAAREKGRVTHKGKPIR

LTADLLAETLQARREWGPIFNI

LKEKNFQPRISYPAKLSFIDRST

RQKVNKDTQELNSALHQADLI

DIYRTLHPKSTEYTFFSAPHHTY

SKIDHIVGSKALLSKCKRTEIIT

NCLSDHSAIKLELRIKKLTRNHS

TTWKLNNLLLNDYWVHNEMK

A EIKMFFETNENKDKTYQNL W

DTFKTVCRGKFIALNAHKRKQE

RSKIDTLTSQLKGLEKQEQTHS

KASRRQEITKIRAELKEIETQKT

LQKINESRSWFFEKINKIDRPLA

RLIKNKREENQIDAIKNDKGDIT

TDPTEIQTAISEYYKHLYANKL

ENLEEMDKFLDTYTLPRLNQEE

VESLNRPITGSEIEAIINSLPTKK

SPGPDG FM RRILPEGQGGAGTI

PSETVPINRKRGNPP*/PHFM/SA

SIMLIPKPGRDTTKKENFRPISL

MNIDAKI/RQ*NTGKPNPAAHQ

KAYPP*SSGLHPWDARLVQLTQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14026 44394 14108 146 2616 LAAVGMASHCFRQRRQSQSPA\

GLRGAGSAYSPA\EGARSSHGQ/

PPWRGRRRGPGDPVRGAARCR

RPRAAAQPARPAARPPARPRPA

P*AACCE/VPSAANSVAPSAAM

*SSAGRDGASSQRSRRPHAAPP

RSSALPANGK/PPSPVTRAARTC

GARSSNTGA*SAARPKHSAASS

RHPPPAA/MPLPARHA PGGTSG

RPLPTPQGSAPTSSASPRGPATP

PPAGPRAPPPSPRRAAAPRPPGR

QLSPAPGTPAAGGGGPPFPALR

*SGSVFGRQLVGDGERGRACG

ARGSAAVPALRTFVVSPSTVVA

GAACPLAVALPAPDPLPCSE*A

PLRSG*VPQPASLFCSQFRPQA

WQHP*LLRAPCPRLGAAVPCV

WCHSRALDSATPRWM*G*RLP

AVWL\PAFPSPPFNQAFVPPCQQ

NCSLQNRQTLSASAKIGTEEWD

IAIKIPENVEVTLELGNEQRLEE

FGGLRRRQEDEGKFGTPTDWL

NGCDQNADSNMDSEGQGEDG

GCSFGGAGLRGSGWGDQTRET

FLALKANLRWPFRSSAQSQTSQ

EGAAGARSGLKGGKKNPLKLP

KKQAKKMNKAFKQKQEKERK

KHKELKAKASWKGLRPQVEFK

NLAERRGEAAVPGCPVVAGHS

WRLLSLARGCAKRARQLLFPSE

KLLAALREGSTRGGGAASQPQ

RKLRVCMRVLDSSVEDFHMDG

14027 44395 14109 885 MIISIDTEKALDKILHPFILKTLN

KLGIDGTYLKIIRALYDKPTANI

IMNEQKLEAFPLKSNTKQGCPF

LPLLFNIVLEVLARAIKQEKEIK

SIQIGREEVKLSLFADDMIVYLE

NPIISAPNLLKLISNFSKVSGYKI

NVQKSQAFLYTSNRQTEIQMM

SELPFTIATKGIKYLGI\HPLTRD

VKDLFKENSKPLL/KELEKTTLN

FIWNQKRAHIAKTMLSKKNKA

GGVMLPDFKLYYKAAVTKTA

WLGDDQVFLIPRGHISDYHMG

KNLGQYPAFQDRGPCGFPQCIV

PLVYRD

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14116 44484 14198 560 MAALLLVGASWL/LLLLVGAS

WLLARVLAW/TYAFYDNCHRL

QCFQQ/PPKRNCF*GHLSLCGA/

TEEDMRLMEDL/VPLFRDVQL

WWLGSFYPVL/SLVHPTFTAPV

LQASGG*PGFTTTMGLSFKRAK

WQRLA/SEGS VRLEMFEHI SLM

TLDSLQKCIFSFDSHCQMVSPG

SCTTSRGPRIPGALPTGGARAPE

NGDPKEIE

141 17 44485 14199 175 2225 RWSSVSFASGMPSAPCCWGHP

QCPSAAQPTGPSWAGCRGLTM

PNGQASPAS*VPPGAFPFLCIKQ

PLWENLMTGVGKFSREAATLE

GPTLPTR/GVGPQCRQIADLPLE

RTEGWRGD\GNPVRGVRQKRK

QLVAGETAASLLPCQASGESCS

VP*QARGPPVLFLPQ\WGRRWA

KGCASRSCF*PDFRPSHAVPGA

REGAGLAAAPKRVARLSPAVPP

ACC\GLQGGSSSAAQAL*PQLS

GPRLPREK*GA/PCWRGGPRCC

PQNSAPETLEYVEPRGTGAPGT

THTGLPSPSQGCRGAEGW/WGL

PGLPGPRAGSSPQPRGRAWRPR

ARTPPPASWAAKGRGRPLAAG

GLARPRDPGPGSGVAPAGSLRP

HSSGRGWGRRRLRARPTGGNR

GSEWPR/RPPGYPGARPGAPSVP

RPQP/PAA*TRPLPVGCGARPFH

PVPATVWPHAGPP/SGMGRRRG

RYPRPASARPAGRCGAGSAEPG

RGTDKGGDGGEGKTKRGGG/L

GGG AG APKAAPG AAEPMGG R

GAGAGGGGA\R*GGGGGGGSG

TTGSGSSSRPRPPRTRAPPETDP

APRPRPGLVRAAGGGAASGSG

TGRGAEGCGVRAARGVPASLR

AALARGAQARVLVSGPAPGWA

EPRPAGGARGVGVWGPVLAGP

GRGPRGGAGRGPRALSRGCAA

*AWTPGRGAGQRGPGSGRGSG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14235 44603 14318 2340 MFVWRNVEGHSAAVFSWYSIP

FLTPPCSHTRPSNLPVTQWPPTR

ENNLPSWQPLLMSVHQAQSLS

ALRKEQDSSSEKDGRSPNKSDK

DHIRWPMSGAHDLQQAAPGPG

GAHQGHPNQDNRTVSQMLSER

WYTLGPNEMQKYNLAFQNVE

ARIRYVIVRGNEQGFFRMHHLR

GVSSLQLGRRRPGPGTYRLEW

DMITIDARYRCSGLRSPPDPDH

LKSVDLHRNEHFFLQKARWEIH

LVLQATPSQIQLLHVAFVLAKQ

PLRCRKQTLFLISWGTKEKNV

ASEGRNPVRPLRGHRWLPASPP

AAEHFAGGADRKSRLSRAPRSA

ATATPANEQRAVADVGQWAR

ARGGRVRAAGRSGSCALRRSR

CRRRRRRHRRHRYRGRAEPLA

PRRAASGQPGKLRARRGINCNA

SSIPMLQWRIKSISKHCQMAR

VAGEGSLPLSHAQLTHCVFGN

KQVQRTIAYLPPQQQGVQGFL

KNTMSNGYEDHMAEDCRGDIG

RTNLIVNYLPQNMTQDELRSLF

SSIGEVESAKLIRDKVAVGLLSL

CVPIRNVEIVASTSWWSLPLAP

YVPRGIRRSQPSTLMDDLSCRS

HQAAAPFTASVLLYISGRVKAH

TAAQGFNHIPEEGVSQEAGSG

WSQAWKDGWLTNVFMFSCTG

HSLGYGFVNYVTAKDAERAIN

TLNGLR PPVKNH*GRPLQLGFL

14236 44604 14319 701 1050 LIVHFCLQVGCGVGNTVFPILQ

TN/NTNSEYDPSRCFAFVHDLC

DEEKSYPVPKSSLDIIILIFVLSAI

VPDKMQKAINRLSRLLKPGGM

MLLRDYGRYDMAQLRFKKGIL

KVLNPNH

14237 44605 14320 701 1519 LIVHFCLQVGCGVGNTVFPILQ

TNNDPGLFVYCCDFSSTAIELV

QTNSEYDPSRCFAFVHDLCDEE

KSYPVPKGSLDIIILIFVLSAIVP

DKMQKAINRLSRLLKPGGMVL

LRD YG RYDM AQLRFKKGQCLS

GNFYVRGDGTRVYLCHTRCNW

TRFSPTAGLEKPQKPWDRRLQ

VNRGKTTDNVPGLDSVQILQAP

SVQHQLRGYLLPTRCKPVWS

GLFLKKKIVALGW/RCL*SQPL

RRLRRGGSIE/HQQSNLGKIVRD

PVSESNDKIKRI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14269 44637 14352 2380 MMWSVLLQPVVLAAVERQGE

ALEFLIGVPESDGENGTKLENT

LQDIIQEDFPNLARQAHVQIQEI

QRTPQRYSLRRATPRHIIVRFTK

VEMKEKMLRAAREKGRVTLK

GKPIRLTADLSAETLQARRDRG

PIFNILKEKNFQPRISYPAKLSFT

SEGEIKYFTDKQMLRDFVTTRP

ALKELLKEALNMERNNRNFFG

VTFAFFVGGQSLGKALQETSIPF

LREEDLEKTSILETGNGDWEAT

RGLPEECAGMRERDCQQNEKY

QVPQFDQSTIKNIESAKGLDVW

DSWPLQNADGTVAEYNGYHV

VFALAGSPKDADDTSIYMFYQ

KVGDNSIDSWKNAGRVFKDSD

KFDANDPILKDQTQEWSGSATF

TSDGKIRLFYTDYSGKHYGKQS

LTTAQVNVSKSDDTLKINGVED

HKTIFDGDGKTYQNVQQFIDEG

NYTSGDNHTLRDPHYVEDKGH

KYLGLIPTYDISSNIYLISKSCLW

QANFRLNSALAQSPAITNFQFR

GHSLKTLDLLTMKNLDSKVNII

PVIAKADTVSKTELHKFKIKFM

SELVSNGVQIYQFPTDDDTIAK

VNAAMNGQLPFAWGSMDEIK

VGNKMVKARQYPWGWQVEN

ENHCDFVKLREMFICTNMEDL

REQTHTRUYELYRVRLQLEEMG

FTDWAPKNKPASVQETYEAKR

HEFHGERQRKEEEMKQMFVQR

14270 44638 14353 105 328

14271 44639 14354 107 676 IRPDSLPSASPAQDFYAASSNTF

PA/DRWSALTKIYEDQTSHNIPL

SQ/TLIQSKALTLFNSVKAEKDE

EAAEEKFEVTRWHIRGLIDGV

VEADIVEALQEFGLISYVMVMS

KKRQALVEFEDVLEACNAVNY

TADNQIHIAGHPAFVNYSTSQKI

SRPGNSDDPEREQCASLYHPEP

HLFDHHGCSLHYR

14272 44640 14355 221 648 LD WLRRV VG I PSLRWTC ATL V

GTRRAARNRCVNVWECGGLKE

ITY*SVEGLCRA/EKPKPLALLE

ETCKLPERQVVNAKEKFLEEMK

SATPVNT*MIRKRNCIITDMEK

V*AVWIEDQTSHNLPLSQSLIES

RALTLFNYVMA

14273 44641 14356 122 317

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14304 44672 14390 723 PVLRGGIQEFAYIKALYERKFL

VPKPIDYNRHAVDMELINGYPL

C*IHHVEDPASVYDEAMELIVE

LANHGLIHGDFNEFNLILDESD

H ITMIDFPQMDSTSH PN AE WYF

DRDVKCIIDFFMKRFSYESELFP

TFKDIRREDTLDVEVSASGYTK

EMQADDELLHPLGPDDKNIETK

EGSEFSFSDGEVAEKAEVYGSE

NESERNCLEESEGCY\SDHLETL

NK*RKTVYQKRVLMHGVLK

14305 44673 14391 1889 MGSKVKEVEDDSQMSDLVRG

MNAFSKTGSGGVEQGRTGQGG

TNGHIKKAKARDRDRRFKKTP

QRKVGNDNLQLPLRWTEQHAE

THIMNFCSKNYNRNIPGKPRESI

DTLNEAACRGRLSKTARKLWS

EAQDQRSFQATEMQAFLFSAK

RIAAEKKTIIRRRDLCSIWGKLL

PRPGSQSVPAQIPENLQEQEERA

KWLLNGRSKFFPQTTSTLGKVT

SNKTGVKEPELESRQPNLLKVE

MGMKNHEIVPGSLIASIASLKH

GGCNKVLRELVKHKLIAWERT

KTVQGYRLTNAGYDYLALKTL

SSRQWESVG\NQMGVGK\ESYT

YIVANEEGQQFALKLHRLGRTS

FRNLKNKRDYHKHRHNVSWL

YLSRLSAMKEFAYMKFRTLEIR

D YFYWVKINVLTG PCSPKRGSS

GEFVPCLLQLLLGFGDCWHSFG

LWHITPVSVSMLTLLPSLLLVK

QKKPTLDSRMGQFDFWELQL

YLCVLEREVIREYPPDGQIFGRY

FDRDVKCIKDFFMKRFSYESEL

FPTFKDIRREDTLDVEVSASGY

TKEMQADDELLHPLGPDDKNIE

TKEGSEFSFSDGEVPEKAEVYG

SENESERNCLEESEGCYλSDHLE

TLNK*RKTVYQKRVLMHGVLK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14435 44803 14521 2616 TTYQNLWDAFKAVCRGKFIAL

NVHKRKQERSKIDTLTSQLKEL

EKQEQTHSKASRRQEITKIRAEL

KEIETQKTLQKINESRSWFFERI

NKIDRPLARLIKKKREKNQIDAI

KNDKGDITTNPTEIQTTIREYYK

HLYANKLENLEEMHKFLDTYT

LPRLNQEEVESLNRPITGAEIVA

IINSLPTKKSPGPDGFTGEFYQR

YKEELVPFL/LKLFQSIEKEG M

NIDAKILNKILANRIQQHIKKLI

HHDQVGFIPGRQGWFNICKSIN

VIQHINRAKDKNHMIISIDAEKA

FDKIQQLFMLKTLNKLGIDGTY

FKIIRAIYDKPTANIILNGKKLEA

FPLKTGTRQGCPLSPLLFNIVLE

VLARAIRQEKEIKGIQLGKEEV

KLSLFADDM I V YLEΝPI VSAQΝ

LLKLISNFSKVSGYKINVQKSQ

AFLYTNNRQTESQIMSELPFTIA

SKRIKYLGIQLTRDVKDLFKEN

YKPLLKEIKEDANKWKNIPCSW

VGRINIVKMAILPKVIYRFNAIPI

KLPMTFFTELEKTTLKFIWNQK

RAHITKAILSQKNKARGITLPDF

KLYYKATVTKTAWYWYQNRD

IDQWNRTQPSEITPHIYNYLIFD

KPDKNKQWGKGSLFNKWCWE

NWLAICRKLKLDPFLTPYTKIN

SRWIKDLNVRPKTTKTLEENLG

ITIQDIGMGMDFMSKTPKAMAT

KDKIDKWDLIKLKSFCTAKETT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possib!e nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14635 45003 A 14721 696 1791 VWIALKSENITCELLLFKMQTQ

CQVLVYLFPIFQPSFLGKRCPIS

TDPQNLTDVSIFLLLEVSGDPEL

QPSPCWAVPCPCAWVTVLGNL

LIILAISPDSHLHTPMYFFLSNLS

LA\DIGFTSTTVPK\MIVDI\QSHS

RVISYAGCLTQMSLFAIFGGME

E\DMLLS VMA YD WFV A ICHPL

YHSAIMNLCSVGFLVLLSFFFFV

LSLSDSQLHΝLIALQMTCFKDV

EIPΝFFWEPSQLSHLACCDTFTΝ

ΝIIMYFPTAIFGFLPISGTLFSYY

KIVSSILRVSSSGGKYKAFSTCG

SHLSWC*FYGRGVGGYLSSDD

VSSSPRKGAVASVMYTWTPM

LΝPFIYSLRΝRDIKSVLRRPTEH

CLISKK

14636 45004 14722 1971 MTRKVTLLLRTWRGGCGRLA

MGMEATPQGSLHPLFQEHWIR

AEDFGVLSPMHPΝSVQGVDDM

IRLGDLΝEAGMVHΝLLIRYQQ

HKIYVSLPSPVSTGEPLTGAΝLL

DREKKMMHRGHCPIALTEGVS

GPDΝPEGRARAKAKAKARAEL

PLPGAEGTDHLLPSQTYTGSILV

AVNPFQVLPLYTLEQVQLYYSR

HMGELPPHVFAIAΝNCYFSMK

RΝKRDQCCIISPQΝRVGAQTDT

VLKVFQHLLISLICKTTLQACCI

PSHPYLSSAPGPPPLTTQCRSYS

DSLLGPQLFGDVCYΝCSHVIEG

DGEALCSLPHPTCSPGAWVLQL

VSPLΝKAWCVSCFSCSTCΝSKL

TLKΝKFVEFDMKPVCKRCYEK

FPLELKKRLKKLSELTSRKAQP

KATDLΝSAEGPLAQLGAVGA/V

TGITHEPHIPQVEΝGSQQLDDV

PALGV\EΝWRIFMAERMEAQG

GQRLLLSTMHEEYEFVSPSSVAI

AELVALFLEGLKERSIFAMALQ

DRKATEGGPVGLTKKQGLLAS

ENWTLGQNDRTGKTGLVPWH

CLYTIHTVTKHSDSCCTAVPTL

LEASSGCIFMSYKKHITLTPKSA

DSNKRPSTLGSQFKQSLDQLMK

ILTNCQPYFIRCIKPNEYKKPLG

FSDSFML1KLIRIDKVQYDSFSYI

EQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, O: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14691 45059 14777 2091 MKPDDNSTQNEGGQSFEERHE

TLQRVKFRGGPKTAPGRKLIAF

LGQMNSGTSGGQRVPGEEELM

AGGATCLPNTEAHQPIRMKNL

HTPAFRLCPLTLQDNEADAFW

HQAFVDWGMPTGKKPQTLGLT

YKTTHDLSMQNS/EGGADSPAS

VALRPSAA/APPVPASPQMLPLE

LVILGW/PLDKCIPAQWSKEG

QTNSYTYNPEPQMYAPSST/AS

YFEAPGGAQ\MVGITMDV/GGS

PIVSSAGAYLIHGG/MDSTRHSL

AHTSRSSPARSFRSNSKAPSSRK

FCC*LPTLSSKTL/SLFSKNLLRK

LPLGKHSPDSVQWPWIYGLLV

AGSESLASLLFPKASSSGETLGF

ATGQLAGESRLPSLLAFILVPID

VAWGKEQLVTQTTVYRVQGS

GQHLNKAWQEPALVNICGMGE

KVDVQVGLCQHRAHLDGWNS

SRAASVWPGETLTHHQDQCQA

NLPPGIETSI LGTKG ARYPSPQE

QGGGRVWLERLDPRG/AVSGT

DL*CLPQSDVPPGRA*SGGTGD

KS I STHDKSGRGNSKYHY/YGI R

LKPDSPLNRLQED/TQYMAMR

QQPMHQKPRWCRAELGGAGSP

L\GMEDVSHVFPEFPAPD/LGSF

LLQDGVTLHDVKAL/QLVYRR

HC/EDW/MNLQFHYIEKLWLS

FWN/SKASSSDGPTSLPASDEDP

EGAVLP/KDKLISLCQCDPILRW

14692 45060 14778 94 3006 RTRSLTRKAMAEHAPRRCCLG

WDFSTQQVKWAVDAELNVFY

EESVHFDRDLPEFGHVLDVHG

VHVHKDGLTVTSPVLMWVQA

LDIILEKMKASGFEFSQVLALSG

AGQQHGSIYWKAGAQQALTSL

SPDLRLHQQLQDCFSISDCPVW

MDSSTTAQCRQLEAAVGGAQA

LSCLTGSRAYEFNLVCDRKHLK

DTTQSVFMAGLLVGTLMFGPL

CDRIGRKATILAQLLLFTLIGLA

TAFVPSFELYMALRFA\GL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14771 45139 14857 1402 3004 TEPKTKTT*LSA*MQKGPLTKF

NNPSC*KLLIN/IVLEVLARAIRQ

EKEIKGIQVGKEEVKLSLFADD

MIVYLENPIVSAQNLLKLISNFS

KVSGYKINVQKSQAFLYTNNR

QTESQI MSELPFTI ASKRIK YLG I

QLTRDVKDLFKENYKPLLNEIK

EDTNKWKNILCSWVGRINIVK

MAILPKVIYRFNAIPIKLPMPFFT

ELEETTLKFIWNQKRARIAKAIL

SQKKKAGGITLPDFKLYYKATV

TKTAWYWYQNTDIEQWNRTEP

SEIMLHIYNYLIFDQPEKNKQW

GKDSLFNKWC WEN WLAICRKL

KLDPFLTPYTKINSRWIKDLNV

RPKTIKTLEENLG ITIQDISMGK

DFMSKTPKAKATKAKIDKWDL

IKLKSFCTAKETTI RVNRQPTK

WEKIFATYSSDKGLISRIYNELK

QIYKIKTNNPIEKWVKDMNRHF

SKEDIYAAKKHMKKCSSSLAIR

EMQIKTTMRYHLTAVRMAIIKK

SGNNSLIVGASMDTSLLSGPIPY

DIQHFDRFGSVTVRRGCAIEFY

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14774 45142 14860 5019 5574 RETRGEVKNSKNQSTSAPPKDC

SSLADPKKIQTTIREYYKHLYPN

KLENQEEMDKFLDTYTLPRLN

QEEVESLNRPITGSEIVAIINSLP

TKKSPGPDGFTAEFYQRYKEEL

VPFLLKLFQSIEKEGILPNSFYE

ASIILIPKLGRDTTKKENFRPISV

MNIDVKILNKILANRIQQHIKKL

IHHDQVGFIPGMQGWFNIHKSI

NVIQHINRTKDKNHMIISIHAEK

AFDKIQQHFMLKTLNKLGIDGT

YLKIIRAIYDKPTANIILNGQKL

EAFPLKIGTRQGCPLSPLLFNIV

LEVLARAIRQEKEIKGIQLGKEV

VKLSLFADDMIVYLENPIVSAQ

NLLKLISNFGKVSGYKINVQKS

QAFLYTNNRQTESQIMSELPFTI

ASKRIKYLGIQLTRDVKDLFKE

NYKPLLNEIKEDTNKWKNIPCS

WVGRINIVKMAVLPKLPMTFFT

ELEK\TTLKFIWNQKRARIAKSI

LSQKNKAGGITLPDFKLYYKAT

ATKTAWYWYQNRDLDQWNRT

EPSEITPHIYNYLIFDKPDKNKQ

WGKDSLFNKWCWENWLAICR

KLKLDPFLTPYTKINSRWIKDL

NIRPKTIKTLEENLGITIQDIGMG

KDFMSKTPKAMATKAKIDKW

DLIKQESFCTAKETTIRVNRQPT

KWEKIFATYSSDKGLISRIYSEL

KQIYKKKTNNPIKKWAKDMNR

HFSKEDIYAAKKHMKKCPSSLA

14775 45143 14861 1895 6140

14776 45144 14862 2875 MKAEIKVFFETNENKDTTYQNL

WDTFKAVCRGKFIALNAHKRK

QERSKIDTLTSQLKELEKQEQT

HSKASRRQEITKIRAELKEIQTQ

KTLQKINESRSWFFERINKIDRS

LARLIKKKREKNQIDTIKNDKG

DITTDPTEIQTTIREYYKHLYAN

KLENLEEMDKFLDTYTLPRLNQ

EEVESLNRPITGAEIVAIINSLPT

KKSPGPDGFTAEFYQSWAETQP

KKENFRPISLMNIDAKILNKILA

KRIQQHIK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

14905 45273 14992 473 2385 HSFLSFIVLMYLTMDLTRSQKH

GWASSPSHGTSPWPVRLRTSLA

KPCKWQVSLCWWLSASPGSSF

SLVRSSLLIIVPHAESVSRRPSLL

SRVGLFPARY*HRVWQRSPSPQ

TRDHLIKRNPSQDV*RRQQPRG

TRVSNλKCSLHTSALGIGRQPSC

DATL*GQQGLP/VK*KRQQPAP/

MSQQQTGAALEVLARAIRQEK

EIKGIQLGKEEVKLSLFADDMI

VYLENPTVSAQNLLKLISNFSK

VSG YKIN VQKSQAFL YTNNRQ

TESQIMSELPFTIASKRITYLGIQ

LTRDAKDLFKEΝYKPLLKEIKE

DTNKWKNIPCSWVGRINIVKM

A I LPKEPG WARSLVFGARGLQG

QGRCGQSRGGGGSCLGGGGST

EΝWQHREPSARKTGSTEΝRRH

REPAAPRTGSTEΝQHREPAAPR

TGTEΝRNREPSARKTGSTEΝRR

HREPAAPRTGSTEΝQHREPAAP

RTGTENRHQEPAAPRTGGTENR

QHREPAAPRTGTENRQHREPAP

RTGSTENRQHREPAPRTGSTEN

RQHRESAAPRTGSTENRHQEPA

APRTGTENRHREPSAPRTVGTE

NRRHRELVAPRTGGTENRPREP

PAGTRPRHTPMRGGSEGALFH

QRRFLEPTPDREQLEGIRYPPVA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15164 45532 15254 2423 MNGKNKT YQEPTVCQALHW

TLARIGKEEPRRGQRGEGLLCS

RERQPRGLSSPGTAAPAAPAAP

TPPALPGHRTRSGSPEGPEPILR

RGGSADAPGRVKTWVNRPAAF

VGKCLGDGSADTACDQAMKG

QRGSNRKRKTSHSLTFPTSSDM

HAGGLSAAHPCAHSRAPPPASP

SPYKGSLGTRTDGLTDSRADSA

ASGARALGVDGQPQPSPPRRAP

PRPVGADGSSRGPQPGRRRVER

RGPATQPGDSRALPEPRGVPAV

HPAGSGSEWERPPPAAPSPEHR

DKMLPGLRRLLQASARRPQPFP

EAARWVWSPCFSSGTLCPSFQS

ERPLLPFQGASFPGTTLHQRLCP

VAALHGSGKGQKWQQSHCYA

AAVMEEPPAPGRSSESLQGPLS

WAGGAPASACLLLMLLALPLA

APSCPMLCTCYSSPPTVSCQAN

NFSSVPLSLPPSTQRLFLQNNLI

RTLGARHLWVQPAHPVALLQQ

PLHHLPGHFPPL\QALEELDLGD

NRHLRSLEPDTFQGLERLQSLH

LYRCQLSSLPGNIFRGLVSLQYL

YLQENSLLHLQDDLFADLANLE

PTSFLHGNRLRLLTEHVFRGLG

SLDRLLLHGNRLQGVHRAAFR

GLSRLTILYLFNNSLASLPGEAL

ADLPSLEFLRLNANPWACDCR

ARPLWAWFQRARVSSSDVTCA

TPPERQGRDLRALREADFQACP

15165 45533 B 15255 47 482

15166 45534 A 15256 636 MRDPNTKRSRGFGFVTCATVE

EVDAAMNARPCKWGRTVEPK

RAVSREDSQRPEDTEELHLRDY

FEQYGKIEVIEIMTDQGSGKKR

GFAFVTFDNHDSMDKTVIQKY

HTVNGHNCEARKALSKQEMAR

ASSSQRGRSGSGNFGGGRGGGF

GGNDNFGRGGNFSGHGGFGGS

HGGGGYGG/SGDGYNGFGNDG

GGGSYNDFVNYNNQSSHFGPM

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15341 45709 15431 129 444 WGGPGRQPDGGRVPGRCGPRR

PATWESPAACRPRPQSRHHSFE

*GGSRSGSSHKRPCPSSPAVLRA

RDQWLHTSFEATEGDSSHEDR

STPLARRCLCSHRSGEA

15342 45710 15432 2446 METSLMVQVCGGRDCNALLPG

NLCSQPTQVLPLEVDGDDGPG

GLPLNAAPPSSVPPVPPSEALPP

PACPSAPAPWRSIISRLFGTSPA

AEAAHPPPGGALDFGALRTSSC

LSQSHGHIPGGPGLGLGAVRVP

VPSEEDPASLFTEPVPAAEAPAT

VQSVEDFVANDRLDRSFLEDM

TPARDEKKVGAKAAQQDSDTG

RASRAPEQQIPHGGH WRGH SRS

YERFRPPDMVSAGPGPSDGEAL

GGNPIVAGFQDDVDLEDQPRGS

PPPPAGPVPSQDITLSSEEEAEV

ADPPKGPAPAPQQCSEPETKWS

SIPASKPQRGTAPMTAAASPWP

GGASVHTGLEKCSSTRPPAEIEP

GKGEQASSSESDPEGPIAAQML

SFVMDDPDFESEASDTQCRAVR

RVLPAQRAENAYGSAFQPGAL

KPECRPTLKGGPGPVPSKAGKK

TEATSPRPTGGASPLAHGATVG

AAWGLGMASWPIGSSLAPTRA

RTREPRLQRRVGSELPGDPCSG

SGASCRQVCARGRATSVRLPAL

ESLWPLSSDGSAAAREGLEGPR

LRQAAAPGGPGPPLPPLSRPPSP

ARRMRGGAAVAGRGAAAPLE

GRVRLGVGFLAETAVRAGAGA

LAAADAPPGSRTPRARPLVAAG

SGAAGGRCPVPSRRQREAPSPL

GGAGVDLQLECLTSEKAGVGA

ATGGVLEALARAIRQKKEIEEIQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15406 45774 15496 1605 WQLPH PPAAPS ARQI LRACQLS

SVTAVAQSCLYGKQLC/GLTTG

NIAGAGLLFFGGGIGGTILYAK

WASHFRERVEKTIPYSDKLFEV

VLGSAPYNVPLPKKSTQSGPLK

ISSVSEVTKEFKQPASQLQKQK

GDTPASATAGDTVLVPGVQHE

ESLKTDHPAIDEGKPTPALSEEA

SSSSIRERPCEEIAACLAQEEKQ

EQVKTESLAKSFEDALRQTANV

TLQAIAAQNTVVQAVNAHSNIL

KAAMDNSEIEGKKKSAKWHTV

QGALKEHRKAVDEAANALLKA

KEEVQAAQFESKLVSQYHELV

GQAQDDFKRQLDSITPEVLPGW

KGMSVSDPADKLSTDDLNSLIA

RAHRHIDQLNRELAEQKATEK

QHITLALEKQTLEEKVQEQELK

YEFEQNLSEKLSEQELQFHHLS

QEQVHNFTLDINTAYARLRGIE

HAVQSHAVAEEEARKAYQLW

LSVEALKYSMKTSSAEMPAVPL

GSAVEAIKANCSDNEFTKALAT

AIPPESLTHGVYSEETLRVRFYA

VQKLARRVAMID

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15407 45775 15497 89 2490 PKCCFFCLLSGETAAAQSCLCG

KWLRPLRPCRRYSTSGSSGLT

TGKIAGAGLLFVGGGIGGTILY

AKWDSHFRESVEKTIPYSDKLF

EMVLGPAAYNVPLPKKSIQSGP

L* I SS VSEVM\KESNRPASQ\LQK

QK\GDTPASATAPTEAAQIISAA

GDTLSVPAPAVQPEESLKTDHP

EIGEGKPTPALSEEASSSSIRERP

PEEVAARLAQQEKQEQVKIESL

AKSLEDALRQTASVTLQAIAAQ

NAAVQAVNAHSNILKAAMDNS

EIAGEKKSAQWRTVEGALKER

RKAVDEAADALLKAK*LLMDF

NKEELEKMKSVIENAKKKEVA

GAKPHITAAEGKLHNMIVDLD

NWKKVQAAQSEAKWSQYH

ELWQARDDFKRELDSITPEVL

PGWKGMSVSDLADKLSTDDLN

SLIAHAHRRIDQLNRELAEQKA

TEKQHITLAL\EKQKL\EEKRAF\

DSAVAKAFRNIHRKLKYRA*TG

QKR*KEVRDAME\NEMRTQLR

RQAAAHTDHLRDVLRVQEQEL

KSEFEQNLSEKLSEQELQFRRLS

QEQVDNFTΛLDINTAYARLRG I E

QAVQSHAVAEEEARKAHQLW

LSVEALKYSMKTSSAETTSMPL

GSAV\EAI\KANCSDNEFTQALT

AAIP\PESLTRGWTVKRPLGAR

F\YAVQKL\ARRVAMIDETRNSL

YQYFLSYLQSLLLFPPQQLKPPP

15408 45776 15498 1212 MPKKRQALVEFEDVLGACNAV

NYAADNQIYIAGHPAFVNYSTS

QKISRPGDSDDSRSVNSVLLFTI

LNPIYSITTPTRLNVFKNDQDT

WDYTNPNLSGQGDPGSNPNKR

QRQPPLLGDHPAEYGGPHGGY

HSHYHDEGYGPPPPHYEGRRM

GPPVGEYGPHADSPVIMVYGL

DQSKMNCDRVFNVFCLYGNVE

KVKISLKKQSPGGRPMGEEWL\

DGYAVDRAITHLNNNFMFGQK

LNV/CVGAQAREGSRGTGERK

GGEWGPAEEHSEA E VLTHTEM

GCGSVSKQPAIMPGQSYGLEDG

SCSYKDFSESRNNRFSTPEQAA

KNRIQHPSNVLHFFNAPLEVTE

ENFFEICDELGVKRPSSVKVFSG

KSERSSSGLLEWESKSDALETL

GFLNHYQMKNPSΓNLVT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15459 45827 15549 1214 MEEEIAALVIDNGSGMCKAGF

AGDDAPRAVFPSIVGRPRHQGV

MVGMGQKDSYVGDEAQSKRG

ILTLKYPIEHGIVTNWDDMEKI

WHHTFYNELRVAPEEHPVLLTE

APLNPKANREKMTQIMFETFNT

PAMYVAIQAVLSLYASGRTTGI

VMDSGDGVTHTVPIYEG\YALP

HAILRLDLAGRDLTDYLMKILT

ERGYSFTTTAEREIVRDIKEKLC

YVALDFEQE\MATAA\SSSSLEK

SYELPDSPRSSTNWQLSGFRLPL

RHSFQPSFLG\MESCG\IHETTF\

ΝSIMK\CDVDIRKDLY\AΝTVLS

GRTPPCTLGIADRMQKEITALA

PSTMKIKIIAPPERKYSVWIGGF

HPWAWLSHLSSKMWVQQARS

MTESGPLHSSTANGFLGGLLTL

VAFTPFLWTKP

15460 45828 15550 2355 MKQITFAPRNHLLTNTNTWTPD

SQWLVFDMRTSGASFTGETIER

VNIPTGYVEKPNKQCRHSVTRY

GHGGHSDHTPSLTVATVATQIT

PRHSGHGSHCDRNLSLATATA

ATLITPHHLLWPRWPLGSHSVT

WCGHGGHSDHTPSPTTATAVT

RITSRHPLRPQQSLGSHPVTHYS

HGSHSDCIPVTRYAHGGHSDHT

PSLAMATAATQMALCHSLWPR

QPLGYLVNKIRRKRCTDGVSPS

GKAPVFDTGIPWFESRYPSHLL

RVSGSPPGYWGIAKRHQILNVS

NMFGKFKTNLLGYRQAVRHRI

LIPAFRGSNPRTPANLFKTLTLIS

NMRALENDFFNSPPRKTVQFG

GTVTEVLLKYKTAIEKRLEKLA

VDPHRDRAQMLKVENVQQAW

QQWTNKLPPARREDEDVKEIR

WMIEELRVSYFAQQLGKNSRA

ESML WSFHKA A I EAARTNIIQA

QTRVEAAQATERRIAADIDDSE

LKAPRDGRVQYRVAKPGEVLA

AGGRVLNMVDLSDVYMTFFLP

TEQAGTLKLGG E ARLILDA APD

LRIPATISFVASVAQFTPKTVET

SDERLKLMFRVKARIPPELLQQ

HLEYVKTGLPGVAWSFLYSINQ

TICLRLDSIEAKLQALEATCKSL

EEKLDLVTNKQHSPIQVPMVA

GSPLRTTQMCNKVR/CVNP*AT

WPPPVPQPTTQQYQGLDAGA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15556 45924 15646 2002 MLESAGNQDIEDVDIVLRQIQV

KNRSTTEVGQNGNLQVEVSYT

QAHIAPRPLASQGTWPHFVSSA

PQPCFQVQNHSKYQNLYYSGFI

RETEPISKGDVGEWLSAGKGES

SAMFASEQEISKDEQGTPVLGS

FYWEVDSPRKESSQAWAPGQE

WI KLERDTTEEKMFEQLKPIEP

VQKTLPWVGEVAATLQEAMK

RDCWREARVKKKPVTFEDVAV

NFTQEEWDCLDASQRVLYQDV

MSETFKNLTSVEGKKKELREQ

HPSLRDEGTSDDKVFLACRGA

GQCPLSAPAGTMDRTRVLQAS

QAGPP/FFFATTVGKCFSRRSYL

YSHQFVHNPKLTNSCSQCGKLF

RSPKSLSYHRRMHLGERPFCCT

LCDKTYCDASGLSRHRRVHLG

YRPHSCSVCGKSFRDQSELKRH

QKIHQNQEPVDGNQECTLRIPG

TQAEFQTPIARSQRSIQGLLDVN

HAPVARSQEPIFRTEGPMAQNQ

ASVLKNQAPVTRTQAPITGTLC

QDARSNSHPVKPSRLNVFCCPH

CSLTFSKKSYLSRHQKAHLTEP

PNYCFHCSKSFSSFSRLVRHQQ

THWKQKSYLCPICDLSFGEKEG

LMDHWRGYKGKDLCQSSHHK

CRVILGQWLGFSHDVPTMAGE

EWKHGGDQSPPRIHTPRRRGLR

EKACKGDKTKEAVSILKHK

15557 45925 15647 1048 MPSLAELFEGSSKAFGAAASQL

NFPVASGEMLKFKYGVLRNPLH

AVAAEPIASRTSRLNLFFQGKPP

FMTQQQMSPLSREGILDALFVL

FEECSQPALMKIKHVSNFVRKY

SDTIAELQELQPSAKDFEVRSLV

GCGHFAEVQWREKATGDIYA

MKVMKKKALLAQEQVSFFEEE

RNILSRSTSPWIPQLQYAFQDK

NHLYLVMEYQPGGDLLSLLNR

YEDQLDENLIQFYLAELILAVH

SVHLMGYVHRDIKPENILVDRT

GHIKLVDFGSAAKMNSNKMVN

AKLPIGTPDYMAPEVLTVMNG

DGKGTYGLDCDWWSVGVIAY

EMIYGRSPFAEGTSARTFNNIM

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15659 46027 15750 2319 MRIDGAQELTLALPFASGVACR

DVKPGPRRRPLRYRCFQKPSNR

LGSASLGAGFWAGRRDAKSGH

DDDPSGALFSVTMDRDLEQAL

DRAENIIEIAQQRPPRRRYSPRA

GKTLQEKLYDIYVEECGKEPED

PQELRSN VNLLEKL V RRESLPC

LLVNLYPGNQGYSVMLQREDG

SFAETIRLPYEERALLDYLDAEE

LPPALGDVLDKASVNIFHSGCV

IVEVRDYRQSSNMQPPGYQSRH

ILLRPTMQTLAPEVKTMTRDGE

KWSQEDKFPLESQLILATAEPL

CLDPSVAVACTANRLLYNKQK

MNTDPMEQCLQRYSWPSVKPQ

QEQSDCPPPPELRVSTSGQKEE

RKVGQPCELNITKAGSCVDTW

KGRPCDLAVPSEVDVEKLAKG

YQSVTAADPQLPVWPAQEVED

PFRHAWEAGCQAWDTKPNIMQ

SFNDPLLCGKIRPRKKARQKSQ

KSPWQPFPDDHSAWLRPGSETD

AGRAVSQAQESVQSKVKGPGK

MSHSSSGPASVSQLSSWKTPEQ

PDPVWVQSSVSGKGEKHPPPRT

QLPSSSGKISSGNSFPPQQAGSP

LKRPFPAAAPAVAAAAPAPAPA

PAAAPALAAAAVAAAAGGAAP

SHSQKPSVPLIKASRRRPAAGRP

TRFVKIAPAIQVRTGSTGL/IGH

QRGGPSPGSPGISGSGLQSSGGP

LPDARPGSSAGCPAPLCLG\QQP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15694 46062 A 15785 610 2986 QTERNSININRNGHQHQNPICRS

PSSKTKGSIKPQRSGRNQSRKA

ENSKDQRTSSPTKDCSSSPATE

QRWMENDFDELTEV/VLQKPG

RDTT\KQKEKFRPISLMNIDVKI

LNKILANRIQQHIKKLIHHDQV

GFISGMQGWFNICKSINVIHHIN

RTNDKNHMIISIDAEKAFDKIQ

QPFMLKTLKKLGIDGTYLKIIRA

IYDKSTASIILNGQKLEAFPLKD

RTRQGCPLSPLLFNIALEVLARA

IRQEKDIKCIQLGKEKVRLSLFA

EDMIVYLENPIVSAPNLFKLISN

FSKVSGYKINVQKSQVFLYINN

RQRESQIMNEFPFTIARRRIKYL

GIQLTRDVKDLFKENYKPLLKE

IKEDTNKWKNMPCSWIGRINIM

KMAILAKVIYRFΝAIPIKLPMTF

FTELEK\TTLKCI*ΝQKRAHIAK

PILSQKNKAGGITLPDFKLHYK

AAVTKTAWYWYQNRDIDQRN

RTEPTEIMLHIYNHLIFDKPDKN

KKWGNDSLFNKWCWENWLAI

CRKLKRDPFLTPYTKINSRWIE

DLNIRPETIKTLEENLGNTIQDIA

MGKDFMSKTPKAMATKAKIDK

WDLIKLKNFCTAKETTIRVNRQ

PTEWEKIFAIYSSDKGIISRIYNE

LKQIYKKK\NNPIKKWAKDINR

HFSKEDIQAASKHVKKHSTSRIF

MQIKTTLGYHLTPVRMATIKKS

KNNRCWCGCGEKGTLIHCW/M

15695 46063 15786 906 MVNQKRYHIPGGTAEISGTIKK

LKNAGWIPTTSPLNSPIWPVQ

KTDGSWRMTMDYHKLNQWT

PIAVAVPYVVALLEQINTFSCT

WYAAIDLANTFFSFSVHKA/HK

K*FAFSRQGQQYTFTVHP\YDN

YSPFERQLLACYWASVETEHLT

MGYQVTIQLELPIMNWVLSDPS

SHKLGHAKQHSIIKWKWYIRD

RARAGPEGTARIHRSRNQGVEV

EVAPLTITPSDPLARFLLPVPTIL

HSAGLEVLVPEGGTLPLGDTTT

IPFNWKLRLPPGHFRLLLPLNQ

QAKKGVTVFAGVIEAIKMK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15899 46267 15990 875 MRMEAGEAAPPAGAGGRAAG

GWGKWVRLNVGGTVFLTTRQ

TLCREQKSFLSRLCQGEELQSD

RDETGAYLIDRDPTYFGPILNFL

RHGKLVLDKDMAEEGVLEEAE

FYNIGPLIRIIKDRMEEKDYTVT

Q\VPPKHVYRVL\QCQEEELTQ

MVSTMSDGWRFEQLVNIGSSY

NYGSEDQAEFLCWSKELHSTP

NGLSSESSRKTKSTEEQLEEQQ

QQEEE V EE VE VEQ VQ VE ADAQ

EKGSRPHPLRPEAELAVRASPR

PLARPQSCHPCCYKPEEPGCEA

PDHLQGLGVPI

15900 46268 15991 2448 MRRGETRSRRPPQCWAFAHW

SRSSRRGEFFSFDRWKKHRSEV

RESAQVPTTKREPVLFQHKINIK

IVIALVDILFALGLGNLVCVSPV

QLFSVQTDSRATGDQRLPSWT

AQRYGTRTLGPDGFTERCPYGP

SPESLLCSALPWLRDLGMPVAE

APQVAGGQGDGGDGEEAEPEG

MFKACEDSKRKARGYLRLVPL

FVLLALLVLASAGLEMLSDPGS

RSYGSGLLPAWAKCPKAPHQR

SLIPPDYAPGVNHPPPQERCSM

GLRTQGTLGRHRVLSAQQVAF

SVSLLMAKIAFAKQKSDDIIPDF

KLFMVTLVHRPNRLSARVLTM

VPVLPAPCPMLLPLLEGYKAEV

MVSQVYSGSLRVLNRHFSQDL

TRRESSAFRSETAKAQKMLKEL

ITSTRLGTYYNSSSVYSFGEGPL

TCFFWFILQIPEHRRLMLSPEW

QALLVEELLSTVNSSAAVPYRA

EYEVDPEGLVILGQYCEWKPPG

RRMQTPRPAMRMEAGEAAPPA

GAGGRAAGGWGKWVRLNVG

GTVFLTTRQTLCREQKSFLSRL

CQGEELQSDRDETGAYLIDRDP

TYFGPILNFLRHGKLVLDKDMA

EEGSQVWTVTSGGWGDRNAV

LTGMGRALSLFLWLIQYLKFCL

VRAWVLEEAEFYNIGPLIRIIKD

RMEEKDYTVTQVPPKHVYRVL

QCQEEELTQMVSTMSDGWRFE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

15984 46352 16075 2111 MNTPLQSAHTHLTLVEFIAYLV

SDSPFPAASTLSLPTCNFDPCPT

KLGAGTMPPAAAGGQRRPHAA

PPAAYPHRNKVRAAEARTSRA

VRREYEAGDEASGRRGRGGRM

KSVQNARADRGMWVRERRAV

VRGQENTWVFAAAASPESDFL

QIVLRDIAREMVPEYKSDLQPR

TQMDAKKPRKCDLTPFLVLKA

RKKQKFTSAKHLWVQRKGKG

VEDHADWQGQIWVGVEGKSA

EGQGLNLTGAFNRSPENKVSPQ

GPALNALEIDSSYLDPQALALP

QGWQGLLFPPLLGTELVGSKLS

VQIQKPPSNIKNSRMTQVFHKN

TSVTSLPFVDTKGKKNTVSFPHI

SKKVLLKSSLLYQVSADGLDPE

KAGERPGFSPKPVLERPRIVGKS

TVAAEEENQAHNQMPASELKA

SEIPFHPSIKTQDPKAEEKSPKK

QKVTLTAAEALKLFKNQLSPYE

QSEILGYλPELWFLGLEAKKLDT

APEKFSKTSFDDEHGFYLKVLH

DHIAYRYEVLETIGKGSFGQVA

KCLDHKNNELVALKIIRNKKRF

HQQALMELKILEALRKKDKDN

TYNWHMKDFFYFRNHFCITFE

LLGINLYELMKNNNFQGFSLSI

VRRFTLSVLKCLQMLSVEKIIH

CDLKPEΝIVLYQKGQASVKVID

FGSSCYEHQKGHLPSRLRSAVT

TTSMILΝKVLRFSEPKLPHLQFE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

16390 46758 16487 2388 QGRLVAKPPRPARSTAADSSTP

RDMLGLRPPLLALVGLLSLGCV

LSQECTKFKVSSCRECIESGPGC

TWCQKLNFTGPGDPDSIRCDTR

PQLLMRGC A ADDI MDPTSL AET

QEDHNGGQKQLSPQKVTLYLR

PGQAAAFNVTFRRAKGYPIDLY

YLMDLSYSMLDDLRNVKKLGG

DLLRALΝEITESGRIGFGSFVDK

TVLPFVΝTHPDKLRΝPCPΝKEK

ECQPPFAFRHVLKLTΝNSΝQFQ

TEVGKQLISGΝLDAPEGGLDA

MMQ VA ACPEEIG WRΝ VTRLL V

FATDDGFHFAGDGKLGAILTPΝ

DGRCHLEDΝLYKRSΝEFDYPS

VGQLA\HKLAEΝΝIQPIFAVTSR

M VKTYEKLTEI IPKS A VGELSE

DSSNWHLIKNAYNK\LSSRVFL

DHNALP\DTLKVTYDSFCSNGV

THRNQ\PRGDC\DGVQINVPITF

QVKVTATECIQEQSFVIRALGFT

DIVTVQVLPQCECRCRDQSRDR

SLCHGKGFLECGICRCDTGYIG

KNCECQTQGRSSQELEGSCRKD

NNSIICSGLGDCVCGQCLCHTS

DVPGKLIYGQYCECDTINCERY

NGQVCGGPGRGLCFCGKCRCH

PGFEGSACQCERTTEGCLNPRR

VECSGRGRCRCNVCECHSGYQ

LPLCQECPGCPSPCGKYISCAEC

LKFEKGPFGKNCSAACPGLQLS

NNPVKGRTCKERDSEGCWVAY

16391 46759 A 16488 353 1205

16392 46760 16489 11 440 FRALTEGDTQLNWNIVSFPVAE

ELSHHENLVSFLETVNQPHHQN

VSVPSNNVHAPYSSDKEHMCT

WYFDDCMSIHQCKISC\ESMG

SHPΝIRWVSLMACCECIGPECID

YGSKTVKCMNCMF* RRQMQT

KAT**ΝΝRYKKLKK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

17049 47417 17154 999 3009 ADSGCKL/PSSC*HVLCA/WVTY

MVMAAILHKLDQLDASRGRAI

PFCGQRGRFKYEILVKTGWGR

GSGTTAHVGIMLYGVDSRSGH

RHLDGDRAFHRNSLDIFRIATP

HSLGSVWKIRVWHDNKGLSPA

WFLQHVIVRDLQTARSAFFLVN

DWLSVETEANGGLVEKEVLAA

SDAALLRFRRLLVAELQRGFFD

KHIWLSIWDRPPRSRFTRIQRAT

CCVLLICLFLGANAVWYGAVG

DSAYSTGHVSRLSPLSVDTVAV

GLVSSVWYPVYLAILFLFRMS

RSKVAGSPSPTPAGQQVLDIDS

CLDSSVLDSSFLTFSGLHAEVRT

LLGVLGWAGGPAALAQLGLKT

LCTSQQAFVGQMKSDLFLDDS

KSLVCWPSGEGTLSWPDLLSDP

SIVGSNLRQLARGQAGHGLGPE

EDGFSLASPYSPAKSFSASDEDL

IQQVLAEGVSSPAPTQDTHMET

DLLSSLCAEVHTALPLHCSCLQ

DSVQWHAVQGLPAFCRGDPVT

QE AQETA RPAAQNL VLIPLHA A

PHQAVAEIDALYDVYLDVIDK

WGTDDMLFLGDFNADCSYVR

AQDWAAIRLRSSEVFKWLIPDS

ADTTVGNSDCAYDRIVACGAR

LRRSLKPQSATVHDFQEEFGLD

QTQASGPWGGAGLGSPPPGRT

QAAGRALAISDHFPVEVTLKFH

17050 47418 17155 242 363 TKRQENGRKKQDRTPTEQQLR VK*KSRSTKKRRKQSRSES

17051 47419 B 17156 12879

17052 47420 17157 596 NLLFPVRSERGPHRPTPLSWLW

LRPCELNKLAAGGLAAGSSRA

GALYLLIYIPRRPARAAPLCPAA

ATGAPGASAGSASPASARPPGL

ARAAPGPLRGRRPRSPRTPFCV/

WLGVSLLLSVYQHYFAEPFESFQ

VCCRHCGILCLTIRVHFPCLSAN

PFHFSQLHLGPRPGKACHSVGL

QIYNSQAHSHPSQQERQLFC

17053 47421 17158 235 FFFVLYNLFLFVITSIPLQKVSIL TQRQL VAEEN VKCCTVVPEPQ* * *LSNYPIFVEMGFCHVGPGWSR TPTPKSVSR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno>vn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

17421 47789 17527 1578 MAKKEQLLSAAPSKTNAEGQEI

PSGVYTTRALGFKHKTGQPFGQ

TPSYPQEFILYTNDTWNASKTE

PFTPLERGLKPGSQESSGWHLV

GTPLGRSFQRKEQAAIFAVLQP

PLVIPRQTGSGVDLQQTPTDLQ

KRVLTVRRKTNSININKKDDHA

KTTSKGHQQQRPKVDKSTKMR

KNQCKKATNSKNQNVSSPPKD

HNSSTAKEQNWMENEFDKLTE

VGFRSSQFDQVEERISDIEDKLN

EIKHEDKI REKRMKKKEQSLQE

IWEYVKRPNLRLIGVPESDGEN

GTKLENTLQDTIQENFPNLARQ

ANIQIQEIQRTPQRYSSRRATPR

HII/E*IHQG*NEGKTVKGSQRE

K*GQEIPSGVYTTRALGFKHKT

GQPFGQTPSYPQEFILYTNDTW

NASKTEPFTPLERGLKPGSQESS

GWHLVGTPLGRSFQRKEQAAIF

AVLQPPLVIPRQTGSGVDLQQT

PTDLQKRVLTVRRKTNSININK

KDDHAKTTSKGHQQQRPKVDK

STKMRKNQCKKATNSKNQNVS

SPPKDHNSSTAKEQNWMENEF

DKLTEVGFRSSQFDQ VEERI SDI

EDKLNEIKHEDKIREKRMKKKE

QSLQEIWEYVKRPNLRLIGVPE

SDGENGTKLENTLQDTIQENFP

NLARQANIQIQEIQRTPQRYSSR

RATPRHIIGRFTKVEMKEKRLR

AVREKSRVTHKGKLIRLTADLS

17422 47790 17528 738 1323 ATGGHSNQRQRS*KLSKKFRR

MYN*NNQYREVLKGADGAEN

QGSRTTETLCM*RMRQSLQFVD

SDLVRHQRKHSGEKPYECCEC

GKAFRGSSELIRHRRIHTGEKPY

ECGEYKSYECIACGKAFGRSST

LIENQRIHTGEKPYECNECGKSF

NQSSALTQHQRIHTGEKPYECS

ECRKTFRHRSGLMQHQRTHTR

17423 47791 17529 656 MAGKPEYDKTISTSIVLNALNA

LGVSAEASGRNDLWKTVEGD

RKVSGSAYRETKDRGFHHGTL

LLNADLSRLANYLNPDKKKLA

AKGITSVRSRVTNLTELLPGITH

EQVCEAITEAFFAHYGERVEAE

IISPNKTPDLPNFAETFARQSSW

EWNFGQAPAFSHLLDERFTWG

GVELHFDV/GKRPYHPRPGVYR

QPQPRAAGSPRRTTARLPFLSL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

17635 48003 17741 2561 MKAEIKTFFETNKNKDTTYQNL

WDTFKA VCRGKFIALNAHKRK

QERSKIDTLTSQLKELEKQEQT

YSKASRRQEITKIRAELKEIETQ

KTLQKINESRSWFFEKINKIDRP

LTRLIKKKREKNQIDSIKNDKG

DITTDPTEIQTTIREYYKHLYAN

KLENLEEMDKFLDTYTLPRLNQ

EEVESLNRPITGSEIEAIINSLPT

KKSPGPDGFTAEFYQRYKEELV

PFLLKLFQSIEKEGILPNSFYEAS

IILITKPGRHTTKKNFRPISLMNI

GAKILNKILANRIQQHIKKLIHH

DQVGFIPGMQG WFNIRKSINVI

QHINITNDKNHMIISIDAENAFD

KIQQRFMLKTLNKLGIDGMYL

KIIRAIYDKPTATQNLLKLIGN F

SKVSGYKINVQKSQAFLYTNNS

QTESQIMTELPFTIASKRIKYLGI

QLTRDVKDLFKENYKPLLSEIK

EDTKKGKNIPCSWVGRINIMK

MDILPKVIYTFNAIPIKLPMTFFT

EVEKTTLKFICNQKRARIAKSFL

SQKNKAGGITPPDFKLYYKATV

TKTACYWYQNRDIDQWNRTEP

SEIMQHIYNYLIFDKPDKNKQW

GKDSLFNKWCWENWLAICRKL

KLDSFLTPYTKINSRWIKDLNIR

PKTIKTLEENLGSIIQDIGMGKD

FMSKTPKAMATKAIIDEWDLIK

LKSFCTAKETTMRVNRQPTEW

EKIFATYSSDIGLISRIYNELKQI

17636 48004 17742 5042 MTGSNSHITILTLNINGLNSAIK

RHRLASWIKSQDPSVCCIQETH

LMCRDTHRLKIKGWRKIYQAN

GKQKKAGVAILVSDKTDFKPT

KIKRDKEGHYIMVKGSIQQEEL

TILNIYAPNTGAPRFIKQVLSDL

QRDLDSHTLIMGDFNTPLSILDR

STRQKVΝKDTQELΝSALHQAD

LIDIYRTLHPKSTEYTFFSAPHH

TYSKIDHIVGSKALLSKCKRTEI

ITΝYLSDHSAIKLELRIKΝLTQS

RSTTWKLΝΝL

17637 48005 17743 101 471 MLSRILASRΝRMRFAVEWRA

VRE/RVGΝDFIIIYRLSMLDLVE

DGGTFAETVELAQAVEAAGATI

INTGIGWHEARIPTIATPVPRGA

FSWVTRKLKGHVSLPLVTTΝRI

ΝDPQVADDILSSTH

17638 48006 17744 161 ill

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

18261 48629 18368 2810 MKQTVYIASPESQQIHVWNLN

HEGALTLTQVVDVPGQVQPMV

VSPDKRYLYVGVRPEFRVLAY

RIAPDDGALTFAAESALPGSPT

HISTDHQGQFVFVGSYNAGNVS

VTRLEDGLPVGWHWDGLDR

LARQLIKNLATLKAGNARWN

SNAMSFLAQKGTPHNIVFVDPP

FRRGLLEETINLLEDNGWLADE

ALIYVESEVENGLPTVPANWSL

HREKVAAFAGAEPYHYLNHTL

GFPRVGLRRELKKAQDSYW

18262 48630 A 18369 2279 2563 MNFGASLNSPTPRSYLSLGGEK

KAPVWEHTLGVPSRRPAAGKL

KKAPERYWGGEHPPVKKWLG

G*ARKCRPRPWETL*KSHLRRR

PSLGPWAGGL

18263 48631 18370 481 1020

18264 48632 18371 998 MNENFGTQICVNNRLSFTDCSG

YVTRYDHDRFGQVTAVHREEG

LSQYRAYDSRGQLIAVKDTQG

HETRYEYNAAGDLTTVIAPDGS

RNGTQYDAWGKAICTTQGGLT

RSMEYDAAGRVIRLTSENGSHT

TFRYDVLDRLIQETGFDGRTQR

YHHDLTGKLIRSEDEGLVTHW

HYDEADRLTHRTVNGETAERW

QYDERGWLTDISHISERHRVTV

HYGYDSKGRLASEHLTVHHPQ

TOELLWQHETRLAYKRTGLAN

RCIPDTCPPVNAYLGTACCQHE

ICDTPWLSYRDPFTGKSWLSGR

YELHKRIYGITAKERKDVDVW

HPDVRFFELYDENNELRGSFYL

DLYARENKRGGAWMDDCVGQ

MRKADGSLQKPVAYLTCNFNR

PVNGKPALFTHDEVITLFHEFG

HGLHHMLTRIETAGVSGISGVP

WDAVELPSQFMENWCWEPEA

LAFISGHYETGEPLPKELLDKM

LAAKNYQAALFILRQLEFGLFD

FRLHAEFRPDQGAKILETLAEIK

KLVAWPSPSWGRFPHAFSHIF

AGGYAAGYYSYLWADVLAAD

AFSRFEEEGIFNRETGQSFLDNI

LSRGGSEEPMDLFKRFRGREPQ

L*HTWELPRPFHREILAFRPL*I

TQAYLRHHR*RA*RC*CLASGC

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

18609 48977 18718 2107 IDMIFTPGPPSTPKHKKSQKGSA

FTFPSQQSPRNEPYVARPSTSEI

EDQSMMGKFVKVERQVQDMG

KKLDFLVDMHMQHMERLQVQ

VTEYYPTKGTSSPAEAEKKEDN

RYSDLKTIICNYSETGPPEPPYSF

HQVTIDKVSPYGFFAHDPVNLP

RGGPSSGKVQATPPSSATTYVE

RPTVLPILTLLDSRVSCHSQADL

QGPYSDRISPRQRRSITRDSDTP

LSLMSVNHEELERSPSGFSISQD

RDDYVFGPNGGSSWMREKRYL

AEGETDTDTDPFTPSGSMPLSST

GDGISDSTVPLFLSSEILQKQVG

QSITSMLGFLSRGPSMKLCMGL

ACVLSLWNTVSGIKGEAKKEK

GMTFLPTTDSKKFFSLLSVTSYS

SFAFHKFSVAVYNISNLKTVDP

AKFPTRYCYCLNNRTNDLSDFT

ALLVDIIGNSTSYLTEIFKSTSIL

SVNQSNESDCIFICVMTGKSGR

NLSDFWEIEEKYPIINYTFTSGL

SGVLALLLTQSLFGGLFTRTRM

KFGAVTRIGGPPLGNQSPSSCSL

LHEKDPPTTSGPQTDQPKKHLT

NFKSAARPTFLGQGQVPLNPFS

FTLS/EQVLLS*AARTPQSLISTP

QPLISVPQSLISVPQPLLYFSGG

QEPPPPPLLCVSSLFSRLASFTM

GAFTHGTQTPSPTKATAPRYPQ

TGDLSAEWPFTAGEEPVLVPRP

18610 48978 18719 828 1063 RHSQAAED*HCPIALE/VPQTIID AELRVTLTVEGYSLPPGCLRGL MLSVSGFSRSTVQAVSGSTVLG SGGQWFSCASV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno>vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

18795 49163 18904 2074 ERSRPVALRAAVPRMNPSTPSY

PTASLYVGDLHPDVTEAMLYE

KFSPAGPILSIRICRDLITSGSSN

YAYVNFQHTKDAEHALDTMNF

DVIKGKPVRIMWSQRDPSLRKS

GVGNIFVKNLDKSINNKALYDT

VSAFGNTLSCKWCDENGSKG

YGFVHFETHVEAVAERAIEKMNG

MLVLNDRKVFVGRFKSRKEREA

ELGARAKEFTVNVYIKNFGEDM

DVDGRLKVDLFGKFVGPALKCEK

LMTDESGKSKGFGFVSVFERHE

DAQKAVDEMNGKELNGKQIY

VGRAQKKVVERQTELKRKFEQ

MKQDRITRYQGVNLVYVKNLD

DGVIDDEVRLRKEFSPFGTIQLVP

KVMDGGLVAAKGLGFVCFSSP

EVEATKAVTEMNFVRIVATEPLVY

VALAVQRKEERQAHLTNQYYG

RGMVASVTEAVPNPVUQPLPGQ

APPFRFTFMGRFSHRFRNRAVAY

YPVPSQIAQTKTKFLRWTGQGA

RTVHPFVQNMPGCYPAQLAPRPP

I*GTMVRPASSQVVPRVVMPTQRV

VANTSNTDKWVPRSCSLQAAA

AYVLVRPAPFPQYKYAAGVRNS

VQQHLVNAQPQVTMQQPCCSMV

PRVQGTLWTCLPMVGHLPPPSR

SKSQMLG WNGLFPS YSKPMHP

YSLLVKSLGVMLLEIDNSELVLH

MLVESPVESLPF* RVDEA V AGTTS

PPQAKRGLAQKAG*QVPTGVP

18796 49164 18905 988 MAEDGEEAEFHFAALYISGQW

PRLRADTDLQRLGSSAMAPSRK

FFVGGNVWKMNGRVKRRLGELI

GTLNAAKVPADTEWCAPPTA

YIDFVARQKVLDPKIAVAAQNCY

KIVTNVG A FTGEISPGVMIKDCGQ

PWWLGHSERRHVFVGESDELIV

GQKVAVHALAEGLVGVIRLHLG

RS*DERGSLGITVEKWFEVQTKV

IRR*T*KDWKQ/VWLGLMSPV

WGLWLLARLATPQQAVQEVHR

RSSRGWLVKSNVSVDAVASEPPV

TIYGVGSVVTGATLQRSLAKPSP

DVDGLPLWGGASLQARNSWDI

IQCHNNEPPSHLSLPLRCQAQG

LKQTQKPK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

18853 49221 18962 143 2159 LTHSSTWLGRSCNHDRRQMGS

KVMSYWAGRGTCAQETPIYT

TIRYLEDKEQYGGSLGVDSVLA

RLFSGASVLFISGPPFSSYLSGVP

PGHPMEDSMVDMVDMSPLVRPQ

NYLFGCELKVADKDYHFKVDVN

DENEVHQLSLRVTVNLGGLVAK

G*VAHLLKAEAIEFTEASPNLK

VTTWATVLKMVSVPAQRVFPLG

GLLKITPTRWVLKGLKVWVQG

PVHISGTAL* * L WEGRCQSPEDE

EVEEDVNRVLFMKPKGRGLKH

MFGDLVCSWKLAAIETQSSSSE

EIVPSPPSPPPLPRIYKPCFVCQD

KSSGYHYGVSACEGCKGFFRRS

IQKNMVYTCHRDKNCIINKVTR

NRCQYCRLQKCFEVGMSKESV

RNDRNKKKKEVPKPECSESYTL

TPEVGELIEKVRKAHQETFPAL

CQLGKYTTNNSSEQRVSLDIDL

WDKFSELSTKCIIKTVEFAKQLP

GFTTLTIADQITLLKAACLDILIL

RICTRYTPEQDTMTFSDGLTLN

RTQMHNAGFGPLTDLVFAFAN

QLLPLEMDDAETGLLSAICLICG

DRQDLEQPDRVDMLQEPLLEA

LKVYVRKRRPSRPHMFPKMLM

KITDLRSISAKGAERVITLKMEI

PGSMPPLIQEMLENSEGLDTLS

GQPGGGGRDGGGLAPPPGSCSP

SLSPSSNRSSPATHSP

18854 49222 18963 748 1075 ILPTSLFFLFCFVFFVCF*DRVLL

LSPGVWSAVARSWLYCNLSLRG

FKGFSCLSLLSNWDYRCTPLRS

ANFVFL/CRDRVSPCWPTSVSNS

*PQVVIHPPWPPKVLGITRV

18855 49223 18964 674 GRRRLLRDAEGPEETVRLWPA

ARAAMDAAEVEFLAEKELVTII

PNFSLDKIYLIGGDLGPFNPGVLP

VEVPLWL/ARLNLKQRQKVCRL

LPPEWMDVEKLEKMRDHEVRK

EETFVTPMPKPFTTWELTVKLLVL

NHAVSDNIPKGRTEFRDPGSRVF

WGHSY*AKFRVFGVDSFVVRQQ

EAHAKLD*LGPWMGDQQPAVT

FLTQAVLNPHVTNSRTNPPSPLE

STSVLRTS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19199 49567 19308 2597 MAMFMLLAAALLSTFLTNDVA

LYTWPLTITLKRLCEIPYNRLII

FEGAGSQRWFATDANWQPAK

YSYLGTFWSFVCRIYCPNGTAG

WRNDADAPAPVLAMQYHTGV

QTPEWKPRLVWSCLGLYIVFLT

ALEFKQELWGLVIVAAGFALL

ARRWLSVDWTLLLVFMAMFI

DVHLLTQLPALQGVLGNVISNV

PSTILLLNYVPPSLLLVWAVNV

GGFGFLTCRHARIAAPADLKDG

LAVHEKRETRSLTEKTGKMLLP

KLGVGSRECGGNVKEVGIRAIE

EFG PYKINGDKEI MRRMDDLLQ

GFDAQHRMKLPAQPTSLATKS

ARRVRYPLFCPSIFNGFFEEFIFH

RFLAEQALEFFNLLHGGSKFRG

RNNLFSGGDSSRKNQRSTRTHC

HHPSPKIYSASAKEPWVLATNL

PVEIRTPKQLVNIYSKRMQIEET

FRDLKSPAYGLGLRHSRTSSSE

RFDIMLLIALMLQLTCWLAGV

HAQKQGWDKHFQANTVRNRN

CKMATLKEKLIAPVAEEEATVP

NNKITVVGVGQVGMACAISILG

KSRAMEHTTAGAPYTPRQQTC

QCNMMSLADELALVDVLEDKL

KGEMMDLQHGSLFLQTPKIVA

DKDYSVTANSKIVWTAGVRQ

QEGESRLNLVQRNVNVFKFIIP

QIVKYSPDCIIVIWSNPRDIVLTY

GTWKLSGLPKHRVIGSGCNLDS

19200 49568 19309 435 777 RWLATHYLTVKLSLLPNLAVT CQPKREQNITSNESTDC*VIVTS TKSDSLYTVGMLALSVRAIRCP CRLVDWADIPEQKQLMVLRAS VALHG RSVTL YEKAFPAFRAM FKRSS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19304 49672 19417 2481 MRSGDLKFGKSAAWPSGQKEK

LVFRGKIEEGLEYLHKKKPSAN

SQDNGKEASKAFHGPLQQPLLS

QALGPDREEWFPGQAPWPHCC

VHPQDTAGCIPWPAPAMAQR

CTGTAWVTASEVAPSLDCFHIV

LSQQVYRIHRPTSSLHPQYGKA

TRHTTPAVSMRAAAGAEPCKA

TGADWPKTLGAQPSHPCTMDV

GQGFKKDDSGAALAPMAALM

GWAGIECLWLFHTEGVNCWP

WDLGEKNGLLGQPRGPAAVCS

LRTLLPASQQPQLLLRPWLKDA

QVQLGSLLQRVQAIGLGGFYIV

LSQFIDPSKASYPPWVKNSRHS

TAAQPMRAAAGAEHCKATGA

ELPKALGAQPSCPCVLDVGQGF

KKNDFGAVGLNNWPAGFWNV

MGTCKSRLCFVLLSGKKSSFRV

EVLTQCLDSHTLETYQFYNREV

AFEDVLESSQTGLWQKPQTDR

LTKRGRGEATRNLRGLVPSMP

RSLLPSTAQPTAWKCQRGPSPY

THQDMALIPSPTARCLSPAKEP

KQEEVGEKSLLPDPTLPLTDPR

LTGSTEQAHAEGLAALMSALR

VSHLQGRGGWTLVDSQLGVI

AVSSTQFNKGPSYRLLADVQN

RLLPKYDSQKEAELRSWIKGFT

GLSI RPDFQKGLKDGIILCTLVN

KLQPGSVPKINVASV*NWH*LEN

LSNFLKAMVSYGM/NPVDLFEA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

19331 49699 19444 2274 MLKPLMGGGAHRRAAAGARK

WDGTAIIASTSGLEVLWVTTSR

SKTVESVGLAKPGQHNDARMN

LAIALTAARYGAATANYMEW

SLLKKTDPQTGKVRVSGARCK

DVLTGQEFDVRAKCVINATGPF

TDSVRKMDDKDAAAICQPSAG

VHIVMPGYYSPESMGLLDPATS

DGRVIFFLPWQKMTIAGTTDTP

TDVTHHPIPSEEDINFILNEVRN

YLSCDVEVRRGDVLAAWSGIR

PLVTDPKSADTQSISRNHWDIS

ESGLITIAGGKWTTYRSMAEDT

INAAVKTHNLKAGPSRTVGLFL

QGGKDWSPTLYIRLVQDYGLE

SEVAQHLAATYGDKAFEVAKM

ASVTGKRWPIVGVRLVSEFPYI

EAEVKYGIKEYAC/DCCGYDFT

SYSPGLS/EMSRQQRKPYPGLL

N*/CGRELNWDDYKKQEQLET

ARKFLYYEMGYKSRSEQLTDR

SEISLLPSDIDRYKRRCHKFDAD

QRGFMTWEVQRVLESINVQM

DENTLHEILNEVDLNKNGQVEL

NEFLQLMSAIQKG RVSGSRL Al

LMKTAEENLDRRVPIPVDRSCG

GLYFCVRNWWVLGLTDFKNE

AADPSGVKLQTFTVSVTARKGS

VDPKNSGAQLASPSGSRTGAA

GGAACQSRALRLHSSALGWSM

GLGAVEHGAVLIGEARAAQEP

MEGVGGSGMAGCRSQVLPRG

19332 49700 19445 439 1542

19333 49701 19446 418 CLSLPPTPWAPVRPEPPRR/CAT

PCSTAPSPIDHPRAEECERTVQD

WRAAPPAAPVRDPLETGKIDQE

IHKYNTPGFTGCLSRVQFNQIAP

LKAALRQTNASAHVHIQGELV

ESΝCGASPLTLSPMSSATDPWH

LDHLDS

19334 49702 19447 1 1 1 215 GTCWELE*RKGKPIFWGEIKAS CRΝLHKLQGAKC

19335 49703 19448 740 959 DLYPHHLSWQSRΝAARKRKS* RGQRPIPAIS*GRVSQKQQQΝVΝ TSTPSHCPRLPYECRPLLHGAQS HRPPKG

19336 49704 19449 260 508

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19404 49772 19517 2293 MARSEAAAAGPGPGPPGLAAR

ERRGGRGCVRGCERASVRVWS

VALRRARRAPARPYVARCRRV

RRPARVAIGCGGVSSPAGVSGC

ARVSPERPPLRLCVWALSRAHG

GAVCRAGPGPDSLKRGLTSHPP

AFPLHHGSRTLLLGPLSPPPAAL

PFLLLLWAGHLVAS/ACPGRCIC

QNV/SPTLTMLCAKTGLLFVPP/

SI DRRWELRLTDNFVRRHFAN

MTSLV/QLTLSRNTIGQVAAGA

F/VDLRALRALHLDSNRLAGC/

GGDQLRGLGNLRHLI/VGNNQI

RRVESAAFD/DLLSTVEDLDLS

YNNLEA/LPWEAVGQMVNLNT

LT/LDHNLIDHIAEGTFVQLQSW

AVRAQAAHPLTVSFGGNPLHCN

CE/LLWLRRLTREDDLETCASP

N/NLTDRYFWSIPEEESCTRCQR

FCG*ASLVAAELTSNSVLIRW/S

TQRPVPGIRMYQVQYN/SSVDD

SLVYRKYSLSTYMNPTRVMIPST

SQTFLVNDLAAGRAYDLCVLVA

VYDDGATALPATRWGCVQFT

TAGDPAPCRPLRAHFLGGTMII

AIGGVIVASVLVFIVLLMIRYKV

YGDGDSRRVKGSRSLPRVSHV

CSQTOGAGTGAA/AGPGPAGPG

PLRGAARGGVP/WLPPPSPSRPR

PWRPR/LASAEPEVVLGRSLGG

SATSLCLLPSEETSGEESRAAVG

PRRSRSGALEPPTSAPPTLALVP

19405 49773 B 19518 97 255

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19449 49817 19562 2518 AAGEWPQRPRAAVAAAGAAA

RQRLPGSRQVAAGAPQPAGGG

DPSQRVPPGAEILIKVQVYVSGE

LVPLARASVDVFGNRTLLAAG

TTDSEGVATLPLSYRLGTWVLV

TAARPGFLT SVPWRVDKLPL

YASVSLYLLPERPATLILYEDLV

HILLGSPGARSQPLVQFQRRAA

RLPVSSTYSQLWASLTPASTQQ

EMRAFPCLPGH*GVSSSGNGSW

LELMPLTAVSVHLLTGNGTEVP

LSGPIHLSLPVPSETRALTVGTSI

PAWRFDPKSGLWVRNGTGVIR

KEGRQLYWTFVSPQLGYWVA

AMASPTAGLVTITSGIQDIGTYH

TIFLLTILAALALLVLILLCLLIY

YCRRRCLKPRQQHRKLQLSGPS

DGNKRDQATSMSQLHLICGGP

LEPAPSGDPEAPPPGPLH SAFSS

SRDLASSRDDFFRTKPRSASRPV

AAEPSGARGGESAGLKGARSA

EGPGGLEPGLEEH RRGPSG AAA

FLHEPPSPPPPFDHYLGHKGAA

EGKTPDFLLSQSVDQLARPPSL

GQAGQLIFCGSIDHLKDNVYRN

VMPTLVIPAHYVRLGGEAGAA

GVGDEPAPPEGTAPGPARAFPQ

PDPQRPQMPGHSGPGGEGGGG

GGEGWGAGRAAPVSGSVTIPV

LFNESTMAQLNGELQALTEKK

LLELGVKPHPRAWFVSLDGRS

NSQVRHSYIDLQAGGGARSTD

19450 49818 19563 206 1 126 LESGSHIYAFSHESLLLHVASAS

V*TSFSDFATSVCHSPLHCQLH

HALIPHGKGECSSVVSGIVATGF

GATGFLGRCWNHLGRVGSQIP

QAIAQVSKEAEVGKFIHVAHLN

VN IKSSSRYLRKKA VGEKA VR

DTFPEAIIVKLLDIFGREDRFLN

YFANMCWFGAIPLVSLGWKAV

KQPVYWDVSKGIVNAVKDPD

ANGKTFAFVGPNRYLLFDLVK

YIFAVAHSKGWVARDFEISPFE

SWTTRDKVERIHITDMTLSHLP

SLEDLGIQATPLELKAIEVLRLH

HTYCWLSAEIEDVKLAKTVNI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19463 49831 A 19578 144 722 KKGLNHHHVEQNNTRPRPRSG

PQRATSNVVFAMFDVQSQIQEFK

EAFNMIDPDQDGFHRPGKICND

MLASLGVKNPT*WSILDAMMNE

VAPGPPSNFTPWFPHHGFGEEV*

MATRS*KMVIRKCPLTCFE*KK

PLGTIVGEDYLVRELLTTHGGIGF

TDEEVDELYREAPI**KRGISITS

EFTRI LKVHG AKDKDD

19464 49832 19579 429 VACLREHKQRCERATRSLLREL

LQVRARVQLQGSELRQLQQEA

RPAAQAPEKEAPEFSGLQNQM

QALDKRLVEVREALTRLRRRQ

VQQEAERRGAEQE/DRPQTGQA

DRLAAAGGAGPGGGLRRPAEE

PRGQQPEGGPGGGQN

19465 49833 19580 2454 RFPAGVAPRRAMANVSKKVSW

SGRDRDDEEAAPLLRRTARPGG

GTPLLNGAGPGAARQSPRSALF

RVGHVMSSVKLDDELLEPVDMD

PPHPFPKEIPHNEKLLSLKYESL

DYDNSENQLFLEEERRTNHTAF

RTVEIKRWVICALIGILTGLVAC

FIDIWENLAGLKYRVIKGNIDK

FTEKGGLSFSLLLWATLNAAFV

LVGSVIVAFIEPVAAGSGIPQIK

CFLNGVKIPHWRLKTLVIKVS

GVILSWGGLAVGKEGPMIHSG

SVIAAGISQGRSSSLKRDFKIFE

YLRRDTEKRDFVSAGAAAGVS

AAFGAPVGGVLFSLEEGASFW

NQFLTWRIFFASMISTFTLNFVL

SIYHGNMWDLSSPGLINFGRFD

SEKMAYTIHEIPVFIAMGWGG

VLGAVFNALNYWLTMFRIRYI

HRPCLQVIEAVLVAAVTATVAF

VLIYSSRDCQPLQGGSMSYPLQ

LFCADG E YNSM A AAFFNTPEKS

WSLFHDPPGSYNPLTLGLFTL

VYFFLACWTYGLTVSAGVFIPS

LLIGAAWGRLFGISLSYLTGAAI

WADPGKYALMGAAAQLGGIV

RMTLSLTV I MMEATSN VTYGFP

IMLVLMTAKIVGDVFIEGLYDM

HIQLQSVPFLHWEAPVTSHSLT

AREVMSTPVTCLRRREKVGVIV

DVLSDTASNHNGFPWEHADD

TQPARLQGLILRSQLIVLLKHK

19466 49834 B 19581 508 4413

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, V=possible nucleotide insertion) sequence

19509 49877 19624 4994 7008 QWQQKPKLTNDNLKFIWNQKR

DRIAKTILSQKNKAGGITLPDFK

LYYKATVTKTAWYWYQNRHI

DQWNRTEPSETI PHIYNHLNFD

KPDKNKKWGKDSLFNKWCWE

NWLAICRKLKLDPFLTPYTKIN

SRWIKHLNVRPKTIKILEENLGN

TIQDIGMGKDFMTKTPKAIATK

PVN*QMGSNILNGQKLEAFPLKT

GTRQGCPLSPLLFNIVLEVLAR

AIRQEKEIKGIQLGKEEVKLSLF

ADDMIVYLENPIVSAQNLLKLIS

NFSKVSGYKINVQKSQAFLYTN

NRQTESQI MSELPFTI ASKRIKY

LGIQLTRDVKDLFKENYKPLLK

EIKEDTNKWKNMPCSWVGRINI

VKMAILPKVIYRFNAIPIKLPMA

FFTELEKTTLKFIWΝQKRARIA

KSILSQKΝKAGGITLPΝFELYY

KATVTKTAWYWYQΝRYIDQW

ΝRTEPSEITPHIYΝYLIFDKPGK

NKQWGKDSLFNKWCWENWLA

ICRKLQLDPFLTPYTKINSRWIK

DLNVRPKTIKTLEEDLGITIQDI

GMGKDFMSKTPKAMATKDKID

KWDLIKLKSFCTAKETTIRVNR

QPTKWEKIFATYSFDKGLISRIY

NELQQIYKKKTNNPIKKWAKD

MNRHFSKEDIYAAKKHMKKYS

SSLAIREMQIKTTMRYHLTPVR

MATIKNSGNNRQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19510 49878 19625 764 GSSEKRKFKTGNQKLSMEVEK

NQQMRSLSLYQQRVEGSKCAV

RRKGGSPKPKAFLAAAEKFLN

VPVMRSASHEQLVLTGDPNKT

LPGSKSRLSGTDSPRACSTFPIW

ATKIVTEMQVQLFAACRVQLIK

HPRPSAARTAMEVLESGEQGV

LQWDRKLSELSEPGDGEALMY

HTACQGHEEQVWEEEALQLGL

RSGILLNHWKRQLVGGAGILRS

AQLHSPYHHWQMISLVSPSPAV

MAVMENDDICMVLCVKVMDE

PNHILDAISEHQIPSLEDQWFSE

CALWTSKAYENLVERHILGPHC

RPTELETLGISEDDIDHNPYLDF

PGVAGLGSRRNVKERGWLSEM

KKEGDIFMKIQG*AICPTSGPAE

GLPPPTPVPHVPDRPCGT*GP/PP

SPGSDSSVPACGPTAARPAPRSP

APPWRCGPRWAEDVLLTGLCK

QQIAEPAFRLQFWWPI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19511 49879 A 19626 1430 MNGTAEGQHPWVHSTFNGEPQ

SLSSSVRVKNQGPRDQAELGFQ

GNGSTVPAAQARTIARARGSGS

GGGDALQGGGAGAGPGATKR

TARLLARGLRRAALRPDGRGV

LGAGAGSSQRRGGGRRKMETH

ISCLFPELLAMIFGYLDVRDKG

RAAQVCTAWRDAAYHKSVWR

GVEAKLHLRRANPSLFPSLQAR

GIRRVQILSLRRSLSYVIQGMAN

IESLNLSGCYNLTDNGLGHAFV

QEIGSLRALNLSLCKQITDSSLG

RIAQYLKGLEVLELGGCSN1TN

TGLLLIAWGLQRLKSLNLRSCR

HLSDVGIGHLAGMTRSAAEGLP

GPGAAHATGLPEAHRSFSKAHL

PRADGPEAPQPQLLWGNLGRW

PPAPVAHGQPAHAQPCAPCDNI

SDTGIMHLAMGSLRLSGLDVSF

CDKVGDQSLAYIAQGLDGLKS

LSLCS/RRGLRRAALRPDGRGV

LGAGAGSSQRRGGGRRKMETH

ISCLFPELLAMIFGYLDVRDKG

RAAQVCTAWRDAAYHKSVWR

GVEAKLHLRRANPSLFPSLQAR

GIRRVQILSLRRSLSYVIQGMAN

IESLNLSGCYNLTDNGLGHAF/R

AGDRLPARSQPEPLQADH*QQP

GPHSPVPQGP/ARCWSWEVAAT

SPTLAFCSSPGVCSASRALTSAA

AATFRMWVDRAPGRHDAQRGG

GVLPGPGAAHATGLPEAHRSFS

19512 49880 19627 293 1520 TTMDGSHSAALKLQQLPPTSSS

SAVSEASFSYKENLIGALLAIFG

HLWSIALNLQKYCHIRLAGSK

DPRAYFKTKTWWLGLFLMLLG

ELGVFASYAFAPLSLIVPLSAVS

VIASAIIGIIFIKEKWKPKDFLRR

YVLSFVGCGLAVRGVTYLLVTF

APNSHEKMTGENVTRHLVSWP

FLLYMLVEIILFCLLLYFYKEKN

ANNIWILLLVALLGSMTWTV

KAVAGMLVLSIQGΝLQLDYPIF

YVMFVCMVATAVYQAAFLSQ

ASQMYDSSLIASVGYILSTTIAIT

AGAIFYLDFIGEDVLHICMFAL

GCLIAFLGVFLITRΝRKKPIPFEP

YISMDAMPGMQΝMHDKGMTV

QPELKASFSYGALEΝNDΝISEIY

APATLPVMQEEHG SRS ASG VPY

RVLEHTKKE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19544 49912 19659 2707 MPGPHPASASCPPRLFTPRRRAF

CPLRICAPLAAAAFCPPRFLPHT

RRRAFLLLCRRGFLPPPCLGGG

L A AAFFPH PPLPFLRPHRRGFLP

HRRRGFLLPPRLGFLPAAAFYPP

PPRVFARRGFVPPSPPRLFARRA

FCHTPPAAAFSPSAAAAFCPTA

DTAFCTLAALAFCRRGFLPPRC

RGFLPLRHRRSFLPHRRRGFLPT

AAFCHRG FLLATAF YPPRLFAP

RCHGFLPPCRSDFFAAAAFCPR

RRGFLPLSPPLFAPAAVAFCPRH

RGFLLPRLFAPVTAAFCHRDFL

PPPPRIFVPAATALRAGAADSA

ASSTGVLARAALRGPCGLHRV

ALPVEAMGEKKEGGGGGDAA

ATEGGTGAAASRALQQCGQLQ

KLIVIFIGSLCGLCTKCAVSNDL

TQQEIQTPEPAKPAKPASQTRQ

PSQPSHPASQASQTSQPAKQPA

SQASQPAKPAKPPSQPSQPSHR

ASQASQATQPERPASQPASEPS

QPSLPASQASQDRQPAKPAKPD

SH PRQPSQP YQPSQPASQASQA

SQPAKPSRQPSQPRQPSQLASQ

ASQSTQPLKPAKSPVQQSQPSQ

PASPDSQASQASQATQPAKPAK

PPSQAAQPAKPAKPPSQPACQP

PSQRAKPAKPARQPSQPSQSSPP

ASQPSQACQPSQPGSQASQASQ

AAKPGMPAKPARQPSQPSQPAS

QARHASQAIQPAKPAG*PSQTS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last A ino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19545 4991 : 19660 1223 2286 RQCFKATEQPPAIHHPSSQPSRQ

PSSQPP1YPSPICGRKSGIQPKFQ

LNG*MVNG*MDEVSRERHEWP

CNYQVRPKAGEKQPGAEANRE

TRPEGGTP/RGERGRQGPATRR

QKSTPEAGPSDLEKQIARQEAP

AGTDEIERQQARPH*AP*KIPVE

WVNGEWLNGRMPGDPHEWQC

NYQPAIQPAIQPANQLSIHNLW

TQFRHSTKIPVEWVNGEWLNG

RMPGKHHEWQCNYQPAIQPAI

QPANQLSIHNLWTQFRHSTKIP

VEWVNGEWLNGRMPEDHHEW

QCNYQPAIQPAIQPASQLSIHN

MWTQFRHSGQIPVEWVNGSRL

HGRQQGIFMHGNATSSHSPSIQ

PAIQPAIQPANQLSIHNLWTQFR

HSTKIPVEWVNGEWLNGRMQR

NIMNGN ATI SHSPSIQPAIQPAIQ

PVNHLSIHNLWTQFRHSTKIPV

EWVNGEWLNGRMPGKNHEW

QCNYQPAIQPAIQPANQLSIHNL

WTQFRHSTKIPVEWVNGEWLN

GRMPGDHHEWQCNYQIAPML

QSNRTAASHSPSIQPAIQAAIQS

ATHLSIPNLWTQVRHSTKIPVE

WVNGEWLNGRMPGRDMNGH

ATIRYGPKPEKNNRAPRQTEKQ

GQKGAHQRREGKARAGNEETE

KYSRSRAIRPRKTDSASRSSRGH

RRNRKAASAATLGPIEDTNQNK

LHVRDTGLEVKAISIQGPGTLM

19546 49914 19661 39 599 GASPNQGQNRPHARQRAPPQ/G

/PPGEPERRAPLPSGHGEPCRHR

PPPFPQPP/AGTQKPLLQGPGGG

*PAENAPTAALGSPAPPRGCQA

APPPRSGAG RPDLPTLAGPRPAP

AVPPPSAAPPPPPSGAPSR/PAAG

RQRLSGVSSGPSLGWW*VGRG

RGLPAFAQIAGHQVGPRRRRTP

AGRKPRSPAGPR

19547 49915 19662 39 599 GASPNQGQNRPHARQRAPPQ/G

/PPGEPERRAPLPSG HGEPCRHR

PPPFPQPP/AGTQKPLLQGPGGG

*PAENAPTAALGSPAPPRGCQA

APPPRSGAGRPDLPTLAGPRPAP

AVPPPSAAPPPPPSGAPSR/PAAG

RQRLSGVSSGPSLGWW*VGRG

RGLPAFAQIAGHQVGPRRRRTP

AGRKPRSPAGPR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19617 49985 19732 92 2049 LTALPPAVSPGGHSSSSSSRTIS

GIT*ELQR/LLQAWPGPWQED

VADAEECAGRCGPLMDCRAFH

YNVSSHGCQLLPWTQHSPHTR

LRHSGRCDLFQEKGEWGYMPT

LRNGLEENFCRNPDGDPGGPW

CHTTDPAVRFQSCGIKSCRVAA

CVWCNGEEYRGAVDRTESGRE

CQRWDLQHPHQHPFEPGKFLD

QGLDDNYCRNPDGSERPWCYT

TDPQIEREFCDLPRCGSEAQPRQ

EATSVSCFRGKGEGYRGTANTT

TAGVPCQRWDAQIPHQHRFTPE

KYACKDLRENFCRNPDGSEAP

WCFTLRPGMRVGFCYQIRRCT

DDVRPQDCYHGAGEQYRGTVS

KTRKGVQCQR/WSLE/TG*DYP

ATTSLPLPPRFTFTSEPHAQLEE

N FC/RDPDGDSHGP WC YTMDP

RTPFDYCALRRCDQVQFEKCG

KRVDRLDQRCSKLRVAGGHPG

NSPWTVSLRNWQGQHFCGGSL

VKEQWILTARQCFSSCHMPLTG

YEVWLGTLFQNPQHGEPGLQR

VPVAKMLCGPSGSQLVLLKLE

RYVDNLGGWTKCEIAGRGETK

GTGNDTVLNVALLNVISNQEC

NIKHRGHVRESEMCTEGLLAPV

GACEGDYGGPLACFTHNCWVL

KGIRIPNRVCARSRWPAVFTRV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19618 49986 19733 2296 HSAGQRSPSNDFQVLRGTELQH

LLHAWPGPWQEDVADAEECA

GRCGPLLLSRAFFIYNVSSHGCQ

LLPWTQHSPHSRLWHSGRCDLF

QEKGEWGYMPTLRNGLEENFC

RNPDGDPGGPWCHTTDPAVRF

QSCGIKSCRVAACVWCNGEEY

RGAVDRTESGRECQRWDLQHP

HQHPFEPG KFLDQGLDDN YCR

NPDGSERPWCYTTDPQIEREFC

DLPRCGSEAQPRQEATSVSCFR

GKG EG YRGTANTTTAG VPCQR

WDAQIPHQHRFTPEKYAC/KVR

WAGGRALGRAAAGETGGG*SR

A*GWRLAG*G*VERLLRDLREN

FCWNLDGSEAPWCFTLRPGTR

VGFCYQIRRCTDDVRPQDCYH

GAGEQYRGVTVVSKTRKGVQCQ

RWSAETPHKLQ*VPGAPGPAR

ALTLGRHALMSGTRAWKWLR

LSLPRFRSRSRLGSRLTSEPHAQ

LEENFC/RDPDGDSHGPWCYTM

DPRTPFDYCA LRRCADDQPPSIL

DPPPDQVQFEKCGKRVDRLDQ

RRSKLRVAGGHPGNSPWTVSL

RNR*GTTACLPQRGAEWSSVV

MPLGAGNLSLPPEVLARRWQV

*HLSQESVPCPNSPLL*VQGQHF

CGGSLVKEQWILTARQCFSSVCE

PPLCLGTQSHPTFPFPQAS*QVS

LGATD*ESQMT*QSFSPSHMPL

TGYEVWLGTLFQNPQHGEPGL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19619 49987 19734 727 3012 PAPTHAHSAGQRSPLNDFQVLR

GTELQHLLHAWPGPWQEDVA

DAEECAGRCGPLMDCRAFHYN

VSSHGCQLLPWTQHSPHTRLRR

SGRCDLFQKKDYVRTCIMNNG

VGYRGTMATTVGGLPCQAWS

HKFPNDHKYTPTLRNGLEENFC

RNPDGDPGGPWCYTTDPAVRF

QSCGIKSCREAACVWCNGEEY

RGAVDRTESGRECQRWDLQHP

HQHPFEPG KFLDQGLDDNYCR

NPDGSERPWCYTTDPQIEREFC

DLPRCGSEAQPRQEATTVSCFR

GKGEGYRGTANTTTAGVPCQR

WDAQIPHQHRFTPEKYACKDL

RENFCRNPDGSEAPWCFTLRPG

MRAAFCYQIRRCTDDVRPQDC

YHG AG EQYRGTVSKTRKG VQC

QRWSAETPHKPQFTFTSEPHAQ

LEENFCRNPDGDSHGPWCYTM

DPRTPFDYCALRRCADDQPPSIL

DPPVDQVQFEKCGKRVDRLDQR

CSKLRVAGGHPGNSPWTVSLR

NWQGQHFVCGGSLVKEQWILTV

ARVQCFSSVCHMPLVTGY*GMVG

ATFFQNPQHGEPSLVQRVQ*AK

MLCGPSGSQLVVLLKLERSVTL

N/HRVWALIILPVPEWYWPPGTV

KCEIAGWGETVKGTGVNDTVVLN

VALLNVISNVQECNIKHRGRVRE

SEMVCTEGVLLAPVGACESDYG

GPVLACFTVHNCWVVLEGIIIPNVR

19620 49988 19735 66 234 WCSAWHSWLPHSPSGPAASYP PAACRSAPQWPDP*R*CPRTHR RRSPWRAPWHCP

19621 49989 19736 500 GRGGGGVRRCARPAPGRPPAA

ARRRGDQRGGRLGRVHVPGKTF

CCGICGRGFGRRETLKRHERIH

TGEKPHQCPVCGKRFRESFHLS

KHHWHTRERPYKCELCGKVF

GYPQSLTRHRQVHRLQLPCAL

AGAAGLPSTQGTPGACGPGAS

GTSAGPTDGLSYACSD

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19634 50002 19749 1725 MELKTKARELREECRSLRSRCD

QLEERPNLRLIGVPESDGENGT

KLENTLQDI1QENFPNLAKQVN

VQIQEIQRTPQRYSLRRATPRHII

VRFTKVEMKEKMLRAAREKGR

VTLKGKPIRLTADLSAETLQAR

REWGPIFNILKEKNFQPRISYPA

KLSFISEGEIKSFTDKQMLRDFV

TTRPALQELLKEALNMERNNRS

WFFEKINKIDRPLARVIKKKRE

KNQIDAIKNDKEDITTNPTEIQTI

IREYYKHLYPNKLENLEEMDTF

LDTYTFPRLNQEEVESLNTSITG

SEIVAIIS/NSIPTKKSPGPDGSTA

EFYQVMLEVLARAIRQEKEIKGI

QLGKEEVKLSLFADDMIVYLEN

PIVSAQNLLKLISNFSKVSGYKI

NVQKSQAFLYTNNRQTESQIMS

ELPFTIASKRIKCLGIQLTRDVK

DLFKENYKPLLKEIKEDTNKW

KNIPCSWVGRINIVKMAILPKVI

YRFΝAIPIKLPMTFFTDLEKTTL

ΝFIWΝQKRARITKSILSQKΝKA

GGITLPDFKLYYTATVTKTAW

YWYQΝ RWYWYQΝRDIDQWΝ

RTEPSEITPHVYΝYLIF

SEQ ID SEQ ID NO- Met SEQ ID NO: Nucleotide Nucleotide location of last Ammo acid sequence ( X=Unknown, NO- of peptide hod in USSN location of first codon for last ammo acid *=Stop codon, /=possιble nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possιble nucleotide insertion) sequence

19635 50003 19750 1719 MHNTDGNRFLSHWGYRQALSI

SKPASASLHPSSKTKPLGTQSKT

WAKRNREHGKKERSSSPAME

QSWMENDFDELREEGFRRSNY

SELREDIQTKGKEVENFEKNLE

ECITRITNTEKCLKELMELKTK

ARELREECRSLRSRCDQLEERR

KQERSKIDTLTSQLKELEKQEQ

THSKAGRRQEITKIRAELKEIET

QKTLQKINESRSWFFERINKIDR

PLARLIKKKREKNQIDTIKNDK

GDITTDPTEIQTTIREYYKHLYA

NKLENLEEMDTFLDTYTLPRLN

QEEVESLNRPITGSEIVAIINSLP

TKKSPGPDGFTAEFYQRYKEEL

HINRAKDKNHMIISIDAEKAFD

KIQQPFMLKTLNKLVLEVLARA

IRQEKEIKGIQLGKEEVKLSLFA

DDMIVYLENPIVSAQNLLKLLS

NFSKVSGYKINVQKSQAFLYTN

NRQTESQIMSELPFTIASKRIKY

LG IQLTRDVKHLFKEN YKPLLK

EIKEDTNKWKNIPCSWVVGRINI

VKMAILPKVIYRFNAVPIKLPM

TFFTELEKTTLKFIWNQKRACIA

KSILSQKNKAGGITLP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkπovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19636 50004 19751 2133 WRRI YQANGK* KNK/QKKAG V

VILVSDKTDFKPTKIKRDKEGH

YIMVKGSIQQEELTVLNIYAPN

TGAPRFMKQVLRDLQRDLDPH

TTIMGDFNTPLSTLDRSARQKV

NKDIQELNSALHQADLINIYRIL

HPKSTEYTFISAPHRTYSKIDHI

VGRKALLRK YKRTEI ITDCLSD

HSAIKLELRIKKLTQNSSTTWK

LNNLLLNDYWIHNKTKAEIKM

CFETSENKDTTYQNLWDTCKA

VCREKFIALNAHKRKQERSKID

TLTSQLKE/LEKQEQTHSKASRR

KSRRNG * I PGHIHPPKTKPGRI*

VPE*TNNRV*N*GNN**LTNQK

KFRTRRIHSQILPEHSAGSSGQG

NQAGERNKGYSIRKRGSQIVPV

CR*HDCIFRKPHHLSPKSP*AVK

QLQQSLRIQNQRAKITSSPIHQ*

QTNREPNHE*TFIHNCFKENKIP

RNPTYKGCEGPIQGELQTTAQQ

NKRGHKQMEEHSMLMDRKNQ

YHENG HS AQGNL* IQCHPHQAT

NDFLHRIGKNYFKVHMEPKKSP

HCQVNPKPKEQSWRHHAT*LQ

TI LQG YSNQNSM VLVPKQTYRP

MEKNRGLRNNTTHLRPSSL*QT

*QKQEMGKGFPI**MVLGKLAS

HM*KAETGSLPYTLYKN*FKM

D*RLKC*T*NHKNLRRKPRQYH

SGHRHEQGLYV*NTKSNGNKS

QN*QMGSN*TKELLHSKRNYH

19637 50005 19752 1314

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkπown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19696 50064 19811 50 2237 RSLKAFICSILSMDKQSRDPPVK

MQGSITTPGSIALAQAQAQAQV

PAKAPLAGQVSTMVTTSTTTTV

AKTVTVTRPTGVSFKKDVPPSI

NTTNIDTLLVATDQTERIVEPPE

NIQEKIAFIFNNLSQSNMTQKEE

LVNNTELVQSYRQQIGNWNQ

ANLQLFWNMYNSRRDLDINRP

GTVPNAKTLRCPVMLWGDNA

PAEDGVVECNSKLDPTTTTFLK

MADSGGLPQVTQPGKLTEAFK

YFLQGMGYMPSASMTRLARSR

TASLTSASSVDGSRPQACTHSE

SSEGLGQLNLKFEIEVLCKNLA

LDINELKPGNLLKDKDRLKNLD

EQLSAPKKDVKQPEELPPITTTT

TSTTPATNSTCTATVPPQPQYS

YHDINVYSLAGLVPHITLNPTA

HPQLKQCVRQAIERAVQELVHP

WDRSIKIAMTTCEQIVRKDFA

LDSEESRMR1AAHHMMRNLTA

GMAM1TC/RE/PLLMSISTNLKN

SFASALRTASPLQREMMDQAA

AQ AQDNCFLL/CKVGGVDPK

QLAVYEEFARNVPGFLPTNDLS

QPTGFLAQPMKQAWATDDVA

QIYDKCITELEQHLHAIPPTLAM

NPQAQALRSLLEVWLSRNSRD

AIAALGLLQKSMENGLNYMAV

AFAMQLVKILLVDERSVAHVT

EADLFHTIETLMRINAHSRGNA

PEGMDITTRQKVNKKREGFND

19697 50065 19812 3777 KNPEFNKMVLNETYRNIKVLLT

SDKAAANFSDRSLLKNLGHWL

GMITLAKNKPILHTDLDVKSLL

LEAYVKGQQELLYWPFVAKV

LESSIRSWFRPPNPWTMAIMN

VLAELHQEHDLKLNLKFEIEVL

CKNLALDINELKPGNLLKDKDR

LKNLDEQLSAPKKDVKQPEELP

PITTTTTSTTPATNTTCTATVPP

QPQYSYHDIΝVYSLAGLAPHIT

LΝPTIPLFQAHPQLKQCVRQAIE

RAVQELVHPWDR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod n USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19837 50205 19953 644 1795 RPSKSQTMLNSLSTALIISKIYFL

PHT*HIYFLLPGSFCYTHSLLSLP

QLPLFL/CLDLNAASHIIPDTTPD

PHDCISLIHLTFTFPQISFFPVSHP

DHTWFIDGSSTRPNVTTHQQRQ

AML*YLPHLSLRLPLCLPPLPLS

KPN*LP*LKPINSPYNSPILPVQK

PDKS YRLVQDLRLINQI VLPI HP

WPNPYTLLSSIPSSTTHYSMLD

LKDAFFTIPLHPSSQPLFAFTWT

DPDTHQSQQLTWAVLPQGFRD

SPHYFSQALSHDLLSFHPSASHL

IQYIDDLLLCSPSFESSQQDTLL

LLQCLFSKGYRVSPSKAQISSPS

VTYLGIILHKNTHALPADRWPS

CLRAAAAAALILVEALKITNYA

QLTLYSSHNFQNLFSSSHLTHIL

SAPRLLLLYSLFVESPTITIVPGL

DLNAASHIIPDTTPDPHDCISLIH

LTFTFPQISFFPVSHPDHTWFID

GSSTRPNHHSPAKAGYAIVSST

SIIEATALPPSTTSQQAELVTLT

QALTLAKGLRINIYTDSKYAFHI

LQHHAVIWAERGFLTTQGSSIIN

ASLIKTLLKTTLLPKEAGVIHCK

GHQKASDPIALGNAYADKVAR

QAASSPTSVPHSQFFSFASVTPT

YSPTETSTYQSLPTQGKWFLDQ

GKYLLPASQAHSILSSFHNLFH

VGYKPLDRLLEPLISFPSWKSIL

KEITSQCSICYSTTPQGLFRPPPF

PTHQARGFAPAQDWQIDFTHM

19838 50206 19954 52 641 RPSKSQTMLNSLSTALIISKIYFL

PHT*HIYFLLPGSFCYTHSLLSLP

QLPLFL/CLDLNAASHIIPDTTPD

PHDCISLIHLTFTFPQISFFPVSHP

DHTWFIDGSSTRPNVTTHQQRQ

AML*YLPHLSLRLPLCLPPLPLS

KPN*LP*LKPSLLQKDYASISILI

LNMPFIFCSTMQSYGLKEVSSL

HKGPPSLMPL

19839 50207 19955 380 TTPDPHDCISLIHLTFTPFPHISFF RVPHPYHIWFIDGSSTRPNVATH QQRQAML*YLPHLSLRLLLCPP PLPLSKPN*LP*LKPSLLQKDYA SIFILTLNMPFISCTTMQEVSSLH KGPLSLIPL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19883 50251 19999 3210 MVKGSIQQEELTILNIYAPNTG

ALRFIKQVLRDLQRDLDSHTIIM

GDFHTPLSTLDRSTRQKVNKDI

QELNSALHQEDLIDIYRTLHPKS

TEYTFFSAPHHTYSKIDHIVGSK

ALLSKCKRTEIITNCLSDHSAIK

LELRIKNLTQNRSTTWKLNNLL

LNDYWVHNEMKAEIKMFFETN

ENKDTTYQNLWDTFKAVCRGK

FIALNAHKRKQERSKIDTLTSQL

KELEKQEQTHSKASRRQEITKIR

AELKEIETQ

19884 50252 20000 2052 MGDFNTPLSTLDRSMRQKVNK

DTQELNSALHQADLIDIYRTLH

PKSTEYTFFSAPHHTYSKIDHIV

GSKALLSKCKRTEIITNYLSDHS

AIKLELRIKN LTQNRSTTWKLN

NLLLNDYWVHNEMKAEIKMFF

ETNENKDKTYQNLWDAFNAV

CRGKFVALNAHKRKQEGSKID

TLTSQLKELEKQEQTHSKASRR

QEITKVRAELKEIETQKTLQKIN

ESRSVARLIKKKREKNQI/DAIKN

DKRDITIDPTEIQTTIREYYKHL

Y ANKLEN LEEMDKFLDTYTLP

RLNQEEVESLNRPITGSEIVAIIN

SLPTKKSPGPEGFTAEFYQRYK

EELVPFLLKLFQSTEKEGILPNS

FYEASIILIPKPGRDTTKKENFRP

ISLMNIDAKILNKILAKRIQQHI

QKLIHHDQVGFIPGMQGWFNIC

KSINVIQHINRTKDKNHMIISID

AEKVFDKIQQRFMLKTLNKLV

LEVLARAVRQEKKIKGIQLGKE

ELKLSLFADDMIVYLENPIVSA

QNLLKLISNFSKVSEYKINVQKS

QAFLYTNNRQTESQIMSELPFTI

ASKRIKYLGIQLTRDVKDLFKE

ΝYKPLLKEIKEDVΝKWKΝIPCS

WVGRIΝIVKMAILPKVIYRFΝAI

PIKLPMTSFTELEKTTFKFI WΝ H

KGARIAKSILSQKNKAGGITLPD

FKLYYKATVTKTAWY SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19885 50253 20001 2314 MDKFLDTYTLPRLNQEEVESLN

RSITGSEIVAILNSLPTKKSPGPD

GFTAEFYQRYKEELVPFLLKLF

QSIEKEGILPNSFYEASIILIPKPG

RDTSKKENFRPIPLMNIDAKILN

KILAKRIQQHIKKLIHHDQVGFI

PGMQGWFNIRKSINVIQHTNRA

KDKNHMIISIDAEKAFDKIQQLF

MLKTLNKLGIDGMYLKIRRAIY

DKPTANIILNGQKLEAFPLKTGT

RQGCPLSPLLFNIVLEVLARAIR

QEKEIKGIQLGKEEVKLSLFAD

DMIVYLENPIVSAQNLLKLISNF

SKVSGYKINVQKSQAFLYTNNR

QTESQIMSELPFTLASKRIKYLG

IQLTRDVKDLFKENYKPLLNEI

KEDTNKWKNIPCSWVGRINIVK

MAILPKVIYRLNAIPIKLPMPFF

TELEKTTLKFIWNQKRARVAKS

ILSQKNKAGGITLPDFKLYYKAI

VTKTAWYWYQNRDIDQWNRT

EPSEITPHINNYLIFDKPDKNKQ

WGKDSLFNKWCWENGLAICRK

LKLDPFLTPYTKINSRWIKDLN

VRPKTRKTLEENLGITIQDIGMG

KDFMSKTPKAMATKDKIDKW

DLIKLKSFCTAKETTIRVNRQPT

KWEKIFATYSSDKGLISRIYNEL

KQI YKKKTNNPI KK WAKDMΝR

HFSKEDIYAAKKHMKKCSSSLA

IREMQIKTTMRYHLTPVRMAII

KKSGΝNVRLFTVAKTWIQPKCA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19886 50254 20002 2685 MGDFNTPLSTLDRSTRQKVNK

DTQELNSAPHQADLIDIYRTLH

PKSTEYTFFSAPHHTYSKTDHIL

GSKALLSECKRTEIITNYLSDDS

AIKLELRIKNLTQNRSTTWKLN

NLLLDDYWVHNEMKAEIKMFF

ETNENKDTTYQNLWDAFKAVC

RGKFVALNAHKRKQGRSKIDT

LTSQLKELEKQEQTHSKASRRQ

EITKIRAELKEIETQKTVQKINES

RSWFFERINKIDRQLARLIKKKR

EKΝLIDAIKΝDKGDITTDPTEIQ

TTI RE YYKHL YAΝKLEΝLEEM

DKFLDTYTLPRLΝQEEVESLΝR

PITGSEIVAIIΝSLTTKKSPGPDG

FTAEFYQRAIRQEKEIKGIQLGK

EEVKLSLFADDMIVYLENPIVS

AQKLISNFSKVSGYKINVQKSQ

AFLYTNNRQTESQIMSELPFTIA

SKRIKYLGIQLTRDVKDLFKEN

YKPLLKEIKEDTNKWKNIPCSW

VGRINIVKMAILPKVIYRFNAIPI

KLPMTFFTELKKTTLNFIWNQK

VRAHIAKS/VLSQKNKAGGITLP

DFKLYYKATVTKTAWYWYQN

RDTDQWNRTEPSEIMPRIYNYL

IFDKPEKNKQWGKDSLFNKWC

WKNWLAICRKLKLDPFLTPYT

KINSRWIKDLNIRPKTIKTLEEN

LGITIQDIGMGKDFMSKTPKAM

ATKAKIDKWDLIKLKSFCTAKE

TTNRVNRQPTKWEKIFATYSSD

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19906 50274 20022 5316 MVKGSIHQEELTILNIYAPNTG

APRFIKQVLSDLQRDLDFHTLI

MGDFNTPLSTMDRSTRQKVNK

DIQELNSALHQADLIDIYRTLHP

KSTEYTFYSAPHHTYSKIDHILG

SKALPSKCKRTDI ITN YLSDHS A

IKLELRIKNLTQNHSTTWKLNN

LLLNDYWVHNEMKAEIKMFFE

TNENKDTTYENLWDAFKAVCR

GKFIALNAHKRKQERSKIDTLT

SQLKELEKQEQTHSKASRRQEI

TKIRAEQINKIDR

19907 50275 20023 2712 WRKI YQ ANGKQKKAG VA I L VS

DKTDFKPTKIKRDKEGHYIMVK

GSIQQEELTILNIYAPNTGAPTFI

QQVLSDLQRDLDSHTLIIGDFN

TPLSTSDRSTRQKVNKDTQELN

SALHQADLIDIYRTLHPKSTEYT

FFSAPHHTYSKIDHILG SKALLS

KCKRTEIITNYLSDHSAIKLELM

IKNLTQNHSTIWKLNNLLLNDY

WVHKEMKAEIKMFFETOENKD

TTYQNLWDTFKAVCRGKFIAL

NAHKRKQERSKIDTLTSQLKEL

EKQEQTLSKASRRQEITKIRAEL

KEIETQKTLQKINESRSRFFERIN

KIDR*VTLARVIKKKGEKΝQIDTI

KNDKGDITTDPTEIQTTIRESYK

HLYANKLENLEEMDKFLDTYT

LPRLNQEEVESLNRPITGSEIVAI

VNSLPTKKSPGPDGFTAEFYQR

YKEELVPFLLKLLQSIEKEGILP

HSFYEASIILIPKPGRDTTKKVEN

FRPISLMNIDAKILNKILANQIQ

QHIKKLIHHDQVGFIPGMQGWF

NTCKSINVIQHINRTKDKNHMII

SIDAEKAFDKIQQPFMLKTLNK

LVLEVLARAIRQEKEIKGIQLGK

EEVKLSLFADDMIVDLENPIVS

AQNLLKLISNFSKVSGYKINVQ

KSQAFLYNNNRQTESQIMSELA

FTIASKRIKYLGIQLTRDVKDLF

NENYKPLLNEIQEDTNKWKNIP

CSWVGRINIVKMAILPKVIYRF SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19908 50276 A 20024 4461 MVASRSSRVGVFYGGQNSVDG

VSRRSDGSLNELCLYRPPTGAY

LAYDTLDVLPSGQFTVNTPPID

VNGKSLLALLWEHTSLLTSMG

GGRWAMQPLGQLGQLEHLGD

RRDQVLDRSGRSRRLDAAQHL

RHRPDRRPQGMVGVLTNQKEP

RTRWIHSRILPEVQGGTGTVPSE

TIPIDRKEGILPNLFDEASIILIPK

RGRDTTKKENFRPISLMNIDAKI

LNKILANRNQQHIKKLIHHDQV

GFIPGMQGWFNICK

19909 50277 B 20025 1183 4247

19910 50278 20026 2671 MVKGSIQQEELTILNIYAPNTG

APRFIKQVLSDLQRDLDSHTLI

MGDFNTPLSTLDRSTRQKVNK

DTQELNSALHQADLIDINRTLH

PKSTEYTFFSAPHHTYSKIDHIV

GSKALLSKCKRTEIITNYLSDHS

AIKL ELRIKNLTQSRSTP WKLN

NLLLNDYWVHNEMKAEIKMFF

ETNKNKDTTYQNLWDAFKAV

CRGKFIALNAYKRKQERSKIDT

LTSQLKELEKQEQTHSKASRRQ

EITKIRAELKEIETQKTLQKINES

RSWFFERINKIDRPLARLIKKKR

EKNQIDTIKNDKGDITTDPTEIQ

TTIREYYKHLYANKLENLEEM

DTFLDTYTLPRLNQEEVESLNR

PITGSEIVAIINSLPTKKSPGPDG

FTAEFY/PESYL*QTHSQYHTEW

AKTGSIPFENWHKTGMPSLTAP

1QHSVGSSGQGNQAGEGNKGY

SIRKRGSQIVPVCR*HDCLSRKP

HRLSPKSP*ADKQLQQSLRIQN

QCTKITSILIHQKQTNREPTHE*

TPIHNCFKENKIPRNPTYKGCEG

PLQGELQTTAQRNKRGHKQME

EHSMLMGRKNQYRENGHTAQ

GNLQIQCHPLQATODFLHRIGK

NYFKVHMEPKKSPHRQVNPKP

KEQSWRHHTT*LQTILQGYSNQ

NSVMVLVPKQRYRSMEQNRAL

RNNAAYLHYSDVLV*QT*EKQA

WGKGIPVIYKMVALVGKLASVPM*

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19928 50296 20044 2269 MSPDIPQVSPEVGLYPVANHSSI

WPTCHSLSEEDTEAQRNHELD

TVKALREDAQVLKIPNQSPKDT

LVTALQLAQKGTKAAAIRLGA

KVGQKQSRQAKSSPALWPGL

LSFPRARFFEWQSPGLPNTAAM

ENGTGPYGEERPREVQETTVTE

GAAKIAFPSANEVFYNPVQEFN

RDLTCAVITEFARIQLGAKGIQI

KVPGEKDTQKVWDLSEQEEE

KVELKESENLASGDQPRTAAV

GEICEEGLHVLEGLAASGLRSIR

FALEVPGLRSWANDASTRAV

DLIRRNVQLNDVAHLVQPSQA

DARMLMYQHQRVSERFDVIDL

DPYGSPATFLDAAVQAVSEGG

LLCVTCTDMAVLAGNSGETCY

SKYGAMALKSRACHEMALRIV

LHSLDLRANCYQRFWPLLSIS

ADFYVRVFVRVFTGQAKVKAS

ASKQALVFQCVGCGAFHLQRL

G KASG VPSGRAKFS AACGPPVT

PECEHCGQRHQLGGPMWAEPI

HDLDFVGRVLEAVSANPGRFH

TSERIRGVLSVITEELPDVPLYY

TLDQLSSTIHCNTPSLLQLRSAL

LHADFRVSLSHACKNAVKTDA

PASALWDIMRCWEKECPVKRE

RLSETSPAFRIVLSVEPRLQANFT

VIREDVANPSSRQRGLKRFQAVNP

EAVNWGPRPRSRPVGGKAADEA

MEERVRRLLQNKRKEPPEDVVA

19929 50297 20045 1578 2356 PLRRWACNHKLRQNAHQLSSTI

HCNTPSLLQLRVSALLHADFRVV

SLSHACKVNAVKTDAPASALWV

DIMRCWEKECPVKRERLSETSP

AFRILSVEPRLQANFTVIREDANP

SSRQRGLKRFQANPEANWGPR

PRARP/GVSGGKVGVGLSQGKK

G*RADGVPPTPSPSHRGKAADE

AMEERRRLLQNKRKEPPVEDVA

QRAARLKTFPCKRFKEGTCQRG

DQCCYSHSPPTPRVSADAAPDC

PETSNQTPPGPGAAAGPGID

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19937 50305 20053 2322 MAEGKGEAGTFFTGQQDRLLF

VFFIITIWGLFRCSVFSSSSSSSS

LSSSSSSSSSSSLSSSFLHLFFIFIF

VFFVFIFFVFIFVFVFAFFFIFFVF

VVFFVFFFFVLLVEILMRPTISIR

GQKLKISDEMSKDCLSILYNTC

VCTEGVTKRLAEKNDFVIFLFT

LMTSKKTFLQTATLIEDILGVK

KEMIRLDEVPNLSSLVSNFDQQ

QLANFCRILAVTISEMDTGNDD

KHTLLAKNAQQKKSLSLGPSA

AEINQAALLSIPGFVERLCKLAT

RKVSESTGTASFLQELEEWYT

WLDNALVLDALMRVANEESEH

NQASIVFPPPGASEENGVLAHTS

ARTVQLPQSMKIMHEIMYKLEV

LYVLCVLLMGRQRNQVHRMIA

EFKLIPVGVLNNLFDKLIWRKHS

ASALVLHGHNHYVCDCSPDITLV

KIQFLRLLQSFSDHHENKYLLL

NNQELNELSAISLKANIPEVEAV

LNTDRSLVCDGKRGLLTRLLQ

VMKKEPAESSFRFWQARAVEE

FPSRGTTSYADQMFLLKRVGLL

EHILYCIVDSVECKSRDVLQSYF

DLVLGELVMKFNVDAFKRFNKYI

NTDAKFQVFLKVQIVNSSLVDSN

MLVRCVTLSLDRFENQVDMKV

AEVLSECRLLAYISQVVPTQMSF

LFRLINIIHVQTLTQENVSCLNTV

SLVILMLVARRKERLPLVYLRLLV

QRVMEHSKKYPGLLVLNNFHNL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19938 50306 20054 237 2033 TSPTPLPLPATMPKTISVRVTTM

DAELVEFAIQPNTTGKQLFDQV

VKTIWLEGKFGFFGLQNQDTVK

GFSTVWLKLNRKVD*PRNVRKE

VSPLLFKVFRAKFYPVEDVSEELIQ

DITQRLFVFLQVKEGILNDDIYCP

VPETAVLLASYAVQSKYGDFNK

EVHKSGYLAGDKLLPQRVLEQ

HKLNRDVQWEERIQVWVHEEHR

GML/RGEDAVLEISERLLQDLE

MYGVNYFSIVKNKKGSELWLG

VDALGLNIYEQNDRLTPKIGFP

WVSEIRNISFNDKKFVVIKPIDKK

APDFVFYAPRLRINKRILALCM

GNHELYMRRRKPDTIEVQQMK

AQAREEKHQKQMERAMLENE

RKKREMAEKEKEKIEREKEEL

MERLKQIEEQTKKAQQELVEEQ

TPRAPGTLSQERKRAQSEAEKL

AKERQEAEEAKEALLQASRDQ

KKTQEQLALEMA ELTARISQLE

MARQKKESEAVEWQQKAQMV

QEDLEKTRAELKTAMSTPHVA

EPAENEQDEQDENGAEASVADL

RA* SVMAKDRSEEERTTEVAEKN

ERVQKHLKALTSELANARDES

KKTANDMIHAENMRLGRDKY

KTLRQIRQGNTKQRIDEFESM

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

19980 50348 20096 1982 QRDNLEAEAVAPCTAAARAVA

PDLLRLCSVRPSRSAPEDRQQP

CLFSHSEAGTAFIQTQQLHAAV

MADTF/LWEHMCRLVDIDSPPIT

ARNTGVIICVTIGPGLPDQVETLK

EDD*SLGMKCGSVLNFSSWEL

HGVTMRETIQGMWRTANGKA

FAFLTPFLLPGPLAVGFRTLKGP

EIPNWGSSKGNGTVAEVGA*RK

GATLKFTLVDNAYMVEKCVDENI

LVWLDYKNICKVVVEVGVSKIYV

DDGLISLQGKQKVGADFVLVTEV

ENGGSLGIVMKGVNLPVGAAVD

FACLCRRKDIQDLKFGVVEVQDV

DMVFVASFIPQSILMFHEVRKVL

GVEKGKDHQGLSSKIRESMRGF

RRFDVEILVEASDGI/LWVARG*F

*ALRIPAEKVVFVLAQKMIDLDRF

NRAVGKPVVICATQMLESMIKKP

RPTRAVEGSDVVANVAVLDWKPT

CIMLSWEKQPKGDYPLVEAVVR

MQHLV1AREARWLPSYHVLQLFV

EELRPPGAQLTSDPTEATAVGVA

VEASFKCCVSGAIIVVLTKSGKVC

SPRLARYRPRAPIIAVTRNSPGK

LVRAHLVYRGIFPGVVCQGPDSR

RAWA*DIGVLRVKLCHGMFGK

ARGFFQERGDWHCA*PEWRP

WLPAPPNNMRWPCCRDGPRG

PSSSRPCSHPFFPKPIPFRPSNGL

VELHSGAVNVATG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

20109 50477 20225 1970 MWKGFTILDSFKNISDSWEDVR

ISTLTGVWKKLIVTLMDDLEEF

KTSVEEITLTQRKLFFVMESPV

GPISPPQPPSVSAWNKPLTSFGS

APSSEGAKNGQESGLEIGTDTIQ

FGAPASNGNENEWPVLSEKSA

DKIPEPKEQRQKQPRAGPIKAQ

KLPDLSPVDNKVEHKPGPIGKER

SLKNRKVKDAQQVEPEGQEKP

SPATVRSTDPVTTKETKAVSEM

STEIGTMISVSSAEYGTNAKESV

TDYTTPSSSLPNTVATNNTKME

DTLVNNMESARKAWENSPNVR

EKGSPVTSTAPPIATGVSSSASG

PSTANYNSFSSASMPQIPVASVT

PTASLSGAGTYTTSSLSTKSTTT

SDPPNICKVKPQQLQTSSLPSAS

HFSQLSCMPSLIAQQQQNPQVY

VSQSAA/ATLTTACLS*WSTAQI

PAFYMDTSHLFNTQHARLAPPS

LAQQQGFQPGLSVRSQPAFMQS

SLSQPSWLSGTAIHNFPTVQH

QEL AKAQSGL AFQQTSNTQPI PI

LYEHQLGQASGLGGSQLIDTHL

LQVTVPLPASQLSLPNFGSTGQ

PLIALPQTLQPPLQHTTPQAQA

QSLSRPAQVSQPFRGLIPAGTQ

HSMIATTGKMSEMELKAFGSGI

DIKPGTPPIAGRSTTPTSSPVSGL

LLQVRTASPAK

20110 50478 20226 260 8485 VSTEMSEKSGQSTKAKDGKKY

ATLSVLFNTSKGKSLETQKTTVA

ARHGLQSLGKVGISRVRMPPPC*

PPKFLKPE*QRANDPNVNIVPK

DGTGWASKQEQHEEEKVTPEVP

PAVQPKPGVAAPPEVAPAPKSW

ASNKQGGQGDGIQVNSQFQQE

FPSLQAAVDQEKKVEKETNDDN

YGP*PSLRPPNVACWRDGGKA

AGSPSSSDQDEKLPGQDESTAG

TSEQNDILKVVEKRIACGPPQA

KLNGQQAALASQYR

20111 50479 A 20227 330 485 RQGDRVSLCCLGRS*TPGLK*F SHLDLLNCWDYRCETVHLAEI AQVSEKQI

20112 50480 20228 1 189 1413

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno>vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

20148 50516 20264 2519 MAPSSRSGAGNTSTPGGCARAR

APPGNAGVHSGTQTGAVRDTA

FISPSSPGLFLSSEPPQPGQRAGF

LQPSCCGAYYLYPWLRERQSSI

LWSGGAAAPQRKSGPLGRSDQ

PPPSPHWGGFQKRCRHRIAQL

FAVGALVCCLVLLHLSAMISAS

RAAAARLVGAAASRGPTVAAR

HQDSWVNGLSHEAFRLVSRRDY

VASVEAIKGAWGIVDLGTTNSCV

AVMEGNQAKVVLENAEGAKTT

PSWAFTADGERLGGMPAKRQ

AVTNPNNTFYATKRLIGRRYDD

PEVQKDIKΝVPFKIVRASΝGDA

WVEAHGKLYSPSQIGAFVLMK

MKETAEΝ YLG HTAKΝ A VITVP

AYFΝDSQRQATKDAGQISGLΝ

VLRVIΝEPTAAALAYGLDKSED

KVIAVYDLGGGTFDISILEIQKG

VFEVKSTNGDTFLGGEDFDQAL

LRHIVKEFKRETGVDLTKDΝM

ALQRVREAAEKAKCELSSSVQT

DIΝLPYLTMDSSGPKHLΝMKLT

RAQFEGIVTDLIRRTIAPCQKA

MQDAEVSKSDIGEVILVGGMT

RMPKVQQTVQDLFGRAPSKAV

ΝPDEAVAIGAAIQGGVLAGDV

TDVLLLDVTPLSLGIETVHGAVF

SKLIΝRKTNIPTKKSQVFSTAAD

GQTQVEIKVCQGEREMAGDΝK

LLGQFTLIGIPPAPRGVPQIEVTF

DIDAΝGIVHVSAKDKGTGREQ

20149 50517 A 20265 168 LERERRKRSRKELLΝFYAWQH

RESKMEHLR/QLRKKFEEDKQR

IELLRAQRKFRPY

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

20207 50575 20323 270 2945 NTSSFKLSPTTGPPGRYLTTTGA

RIWNRLARYLVSEGSGLGAIEV

MGTQDPGNMGTGVPASEQISC

AKEDPQVYCPEETGGTKDVQV

TDCKSPEDSRPPKETDCCNPED

SGQLMVSYEGKAMGYQVPPFG

WRICLAHEFTEKRKPFQANNVS

LSYMIKHIGMGLRYLQWRDRK

THVEKKTPFIDMNKSVPPIQSYF

VVPLGGLRGGTSTRGWRGQFCR

WQLNPGMYQHRTV1ADQFTVC

LRVREGQTVYQQVLSLVERPSVL

RSWNWGLCGYFAFYHALYPRA

WTVYQLPGQNVTLTCRQITPIL

PHDYQDSSLPVGVFVWDVENE

GDE ALDVSIM FSMRN/GTG W W

RRCPRGFVGMSPSVWSVGVQT

VRGLLLHSSNPSKPLHDGLWLA

RSSRAATTVNPH/CTAFDPGVRT

GAAVVWQDLLQDGQLDSPTGQ

RTPTQKGVGIAGAVCVSSKLRP

RGQCRLEFSLAWDMPRIMFGA

KGQVHYRRYTRVFGAGVGDAP

PALSHYALCRYAEWEERISAW

QSPVVLDDRSLPAWYKSALFNE

LYFLADGGTVWLEVLEDSLPEE

VRAETSVTSAPTLRDYRRFG*LE

GQEYVRMYNTYDVHFYASFALI

MLWPKLELSLQYDMALATLRE

DLTRRRYLMSGVMGTCEKEGT

FIPHDIGGPRWMEPWASAFNAY

VLIHDTADWVKDLΝLKFVACRFI

20208 50576 20324 123 359

20209 50577 20325 259 KPVGEKDTWSGMRTTGQLRPA HGVRLKAΝKDSLYKPILRQKK HFNSLHIPKALQKALPFKΝKPK TQAKAGKVPKDRRR*TVSΝITV

20210 50578 20326 297 585

20211 50579 20327 182 374 PDFRI A AT* V VLDLDKSIKI VKK LKLTGFPYKIFKNTSFIKACISIY SHIYKSPYCLRKGMKYL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

20249 50617 A 20365 160 2810 GLRVPLSPSSPRSRLRSGPLRLP

GADSGSGPKAVCSPPFIVAPTG

RGYCGDHESSFGAMEEPGATP

QPYLGLLLEELRRWAALPEG

MRPDSN L YGFP WEL VIC A A V V

GFFAVLFFLWRSFRSVRSRLYV

GREKKLALMLSGLIEEKSKLLE

KFSLVQKEYEGYEVESSLKDAS

FEKEATEAQSLEATCEKLNRSN

SELEDEILCLEKELKEEKSKHSE

QDELMADISKRIQSLEDESKSL

KSQVAEAKMTFQIFPMNEERLK

IAIKDALNENSQLQESQKQLLQ

EAEVWKEQVSELNKQKVTFED

SKVHAEQVLNDKESHIKTLTER

LLKMKDWAAMLGEDITDDDN

LELEMNSESENGAYLDNPPKG

ALKKLIHAAKLNASLKTLEGER

NQIYIQLSEVDKTKEELTEHIKN

LQTEQASLQSENTHFENENQKL

QQKLKVMTELYQENEMKLHR

KLTVEENYRLEKEEKLSKVDEK

ISHATEELETYRKRAKDLEEEL

ERTIHSYQGQIISHEKKAHDNW

LAARNAERNLNDLRKENAHNR

QKLTETELKFELVLEEDPYALDV

PNTAFGREHSPYGPSPLGWPSS

ETRAFLSPPTLLEGPLTLSPLLP

GGGGRGSRGPGNPLDHQITNER

GESSCDRLTDPHRALSDTGFLS

PPWDQDRRMMFPPPGQSYPDS

ALPPQRQDRFCSNSGRLSGPAE

20250 50618 20366 131 461

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

20251 50619 20367 1761 MARGYGATVSLVLLGLGLALA

VIVLAWLSRHQAPCGPQAFAH

AAVAADSKVCSDIGRVAILQQQ

GSPVDAS1AALVCTSVVNPQSM

GLGGGVIFTIYNVTTGKVEVIN

ARETVPASHAPSLLDQCAQALP

LGTGAQWIGVPGELRGYAEAH

RRHGRLPWAQLFQPTIALLRGG

HVEAPVLSRFLHNSILRPSLQAS

TLRQLFFNGTEPLRPQDPLPWP

ALATTLETVATEGVEVFYTGRL

GQMLVEDIAKEGSQLTLQDLA

KFQPE VVDA LEVPLGD YTL YSP

PPPAGGAILSFILNVLRGFNFST

ESMARPEGRVNVYHHLVETLK

FARGQRWRLGDPRSHPKLQNA

SRDLLGETLAQLIRQQIDGRGD

HQLSHYSLAEAWGHGTGTSHV

SVLGEDGSAVAATSTIVNTPFGA

MVYVSPRTGIILNNELLDLCERC

PRGSGTTPSTVSGDRVGGAPGR

CWPPVPGEPSPSSMEPSILΓNKA

QGSNLVIGCAGGELIISAVAQAI

MSKLWLGFDLRAAIAAPILHVN

ΝKGCVEYEPΝFSQEVQRGLQD

RGQNQTQRPFFLNWQAVSQE

GACVYAVSDLRKSGEAAGY

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

20285 50653 20402 190 2189 AFCPAGTRSAPCPRPRTMTMTL

HTKASGMALLHQIQGNELEPLN

RPQLKIPLERPLGEVYLDSSKPA

VYNYPEGAAYEFNAAAAANA

QVYGQTGLPYGPGSEAAAFGS

NGLGGFPPLNSVSPSPLMLLHPP

PQLSPFLQPHGQQVPYYLENEP

SGYTVREAGPPAFYRPNSDNRR

QGGRERLASTNDKGSMAMESA

KETRYCAVCNDYASGYHYGV

WSCEGCKAFFKRSIQELPTLC*I

GWYWYQNRDIDQWNRTEPSEI

I PHI YN HLIFDKRDKNKK WGKD

SLFNK*CWENWLAICRKLKLD

HFLTPYTKINSRWIKDLNVRTK

TIKTLEENLGNTIQDIGMGKDF

MSKTPKA MATKAKI DKWDLIK

LKSFCSLLGYLKTENTAKETTIR

LNRQPTEWEKIFAIYSSDKGLIS

RIYKELKQIYKKK/GNPINKWV

KDMNRHFSKEDIYAANRHMKK

CSSSLAIREMQIKTTMRYHLTP

VRMVIIRKSGNDRCWRGCGEIG

TLLHCWWDCKLVQPLWKTVW

RFLRDLQLEIPFDPAIPLLGIYPK

DYKSCCYKDTCTRMFIAALFTI

AKT WNQPKYPTTIG *IKKM WH I

YTMEYYAAIKKDEFI/SLVGTW

MKLETIILSKLTQEQKTKHHMF

SFITGSRTMRTHGCREGNITHW

GLLRDSVNMVTQAH

20286 50654 20403 907 RVPAMATSSFALPRILGAGARA

PSRWLGFLGKATPRPARPSRRT

LGSATALMIRESEDSTDFNDKIL

ΝEPLKHSDFFΝVKELFSVRSLF

DARVHLGHKAGCRHRFMEPYI

FGSRLVDHDIIDLVEQTATHLQLA

LΝFTAHMAYRKGIILFISRΝRQF

SYLIEΝMARDCGEVYAHTRYFM

GGMLTNARLLYGPTVRLPDLVII

FLHTLΝNIFEPHVAVRDAAKM

ΝIPTVGIVDTNCΝPCLITYPVPG

ΝDDSPLAVHLYCRLFQTAITRA

KEKRQQVEALYRLQGQKEPGD

QGPAHPPGADMSHSL

20287 50655 B 20404 70 1477

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

20315 50683 20432 1791 MPGARTSSSGASENHRARGQG

GGPQGVGRMAEGKAGGAAGL

FAKQVQKKFSRAQEKVLQKLG

KAVETKDERFEQSANNFYQQQ

AEGHKLYKDLKNFLSAVKVMH

ESSKRVSETLQEIYSSEWDGHE

ELKAIVWNNDLLWEDYEEKLV

ADQAVRTMEIYVAQFSEIKEVRI

AKRGRKLVDYDSARHHLEAVQ

NAKKKDEAKTAKAEEEFNKAQ

TVFEDLNQELLEELPILYNSRIG

CYVTIFQNISNLRDVFYREMSK

LNHNLYEVMSKLEKQHSNKVF

WKGLSSSSRRSLVISPPVRTAT

VSSPLTSPTSPSTLSLKSESESVS

ATEDLAPDAAQGEDNSEIKELL

EEEEIEKEGSEASSSEEDEPLPA

CNGPAQAQPSPTTERAKVSQEE

VLPSSTTPSPGGALSPSGQLSSS

ATE V VLRTRT ASEG SEVRPKKT

ASIQRTSAPPRRPPPPRATASPRP

CSGNIPSSPTASGGGSAVTSPRAS

LGTGTASPRTSLEIV* PNPEVPPEK

PVRTPEAKENENIHNQNPEELC

TSPTLMTSQVASEPGEAKKME

DKEKDNKLISADSSEGQDQLQV

SMVPENNNLTAPEPQEEVSTSE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

20324 50692 20441 582 2595 PPPPVRRRDPGPAVRPAGAMA

KKSAENGIYSVSGDEKKGPLIA

PGPDGAPAKGDGPVGLGTPGG

RLA VPPRVETWTRQM DFI MSC V

GFAVGLGVNVWRFPYLCYKNG

GGVFLIPYVLIALVGGIPIFFLEIS

LGQFMKAGSINVWNICPLFKGL

GYASMVIVFYCNTYYIMVLAW

GFYYLVKSFVTSTLPWATCGNY/

TWKHSPTCVEIFVRHEDCVANAS

LANLTCDQLANRVRSPVVIEFWE

NKVLKLSGGLEVVPGALNWEVV

TLGLLACWVLVYFCVWKGVK

STGKVIVYFTA/THYPYVVLWL

LVRGVLLPGALDGIIYYLKPDW

SKLGSPQVWIDAGTQIFFSYAIG

LGALTVLGSYNRFNNNCYKDA

IILALINSGTSFFAGFWFSILGF

MAAEQGVHISKVAESGPGLAFI

AYPRAVTLMPVAPIVWAALFFF

MLLLLGLDSQFVGVEGFITGLL

DLLPASYYFRFQREISVALCCA

LCFVIDLFMGVTDGGMYVFQLF

DYYSASGTTLLWQAVFWECW

VAWVYGADRFMDDIACMIGY

RPCPWMKRVCWSFFTPLVCVMGI

FILNWYYEPLVYKQN/TYVYP

WWGEVAMGVWPFALSVSMLFVP

LVHLLGLPSLRAKGHPWLKRW

QHVLTVQPIWGLHPL/EELPRFRD

ADVQGTLTHP*TPVSESSKWVV

20325 50693 A 20442 363 MGKRGLILLIEACIAIAQPLQRW

FWPPRAGMPVTYD/HSNSAAG

SPPV*NARLCSPGEKVLCRSQT

GNFPHTPQEQAVPSAWNALPV

QP* SH/GPSPML VPCRCVCPMET

RVQGSASPGGQG

20326 50694 20443 747 1389 LGAVQLCPPPCRPCHRAALPGG

LFPPPRPPHSPQAGPLHPQWTQ*

PGSVGSPTQLSPEASRPQWPPT

AVGSPRAGVHPGHGQA*SADISS

AKQWTQVGPAGQGGSKFGKT

KVPWQSGPLGWDPGARAGQG

VG*ETRGPSLQLAWSDGEGV/P

GWRGSYRGHRRGP*PPAPWPW

SGGHPGSPMEWPCPGTELQMR

NRAGSRDLHSLGRAPPAATAPS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

20869 51237 20988 2577 MPPNRHRMRGETTLWNPGCDH

AGIATQVWEKKLWREQGLSR

HQLGREAFLQEVWKWKEEKG

DRIYHQLKVKLGSSLDWDRACF

TMDPKLSVAAVTEAFVGLHEKG

IIYRSTAFVΝWPCTLΝSAISDIE

VDKKELTGRTLLSVPGYKEKV

EFGVLVSFVAYKVVQGSD*/DDE

EVWAΝKLGSKTVMLGDVAVA

VPPPKDTRVYQHLVKGKNVIHPVF

LSRSLSPLSSDEFVDMDFVGTGA

VKDHPPRHDQNDYEVGQRHGL

EAISIMDSRGAVPIKCASAFPGPA

AGLRPGKRCWWR*RNRGLFRG

IEDNPMWPLCNRSKDWEPLL

RPQWYVRCGEMAQAASAAVT

RGDLRILPEAHQRTWHAWMD

NIREWCISRQLWWGHRIPAYFV

TVSDPAVPPGESEDLSVFYPGT

LLETGHDILFFWVARMVMLGL

KLTGRLPFREVYLPCPSCENAH

GRKVMSKSLGNVIDPLDVHL/Y

GISLQGLHNQLLNSNLDPSEVE

KAKEGQKADFPAGVPECGTDA

LRFGLCAYMSQGS*K*TWNVN

RIMG * RQFCNKL WKCTKF ALR

GLGKGFVPSVDTSNSAGHESLA

DR* IRNLLTE AVRLSNQGFQA Y

DFPAVTTAQYSFWLYELCDVY

LECLKPVLNGVDQV/AQAECAR

QTLYTLPWTLGLRLLSPFMPFV

TEELFQRLPRRMPQAPPSLCVT

20870 51238 A 20989 4083 SQRGEHVGAGCRGGDLRELGS

PGEPPTVSARSTPPPGPLGGSQP

RPAPGCEVDSPAQSDHLPPVFP

LRSDLLITMSTLYVSPHPDAFPS

LRALIAARYGEAGEGPGWGGA

HPRICLQPPPTSRTSFPPPRLPAL

EQGPGGLWVWGATAVAQLLW

PAGLGGPGGSRAAVLVQQWVS

YADTELIPAACGATLPALGLRS

SAQDPQAVLGALGRALSPLEE

WLRLHTYLAGEAPTLADLAAV

TALLLPFRYVLDPPAR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21025 51393 21 151 1536 MGGGEQGTLRTAENQGLQVCP

GEAGSSLGFSGNTPTNGLPARG

DQTSYRDFWSGPQFPDTSLRTA

APGAREQCGTHGGEGSTLEGSR

PDVPQDLFSPTLGFYGSTYPELE

QGMLGGH*G/PAENQGLQVCP

GEAGSSLGFSGNTPTNGLPARG

DQTSYRDFWSGPQFPDTSLRTA

APGAREQCGTHGGEGSTLEGSR

PDVPQDLFSPTLGFYGSTYPELE

QGMLGGHVEASREYQMLSHV

GΝPDYPHALATEQATSPSTESG

SAGFKGVALAMLSKITMCVRIG

ILVFQQDQGSMCKAFSTTGMG

LVTYLLTCRAWSRLQCGASYR

AHDVΝVLPGCSGPAALLLGDW

FSLHSSDAVLPAQGQGMLSQG

EADACITLPHLFPSREWFLLGL

EAGGLIPGAEGPPEDMGLVRGP

PAVAAGPPPRWLSPEFCLLQYS

EEEGCKEPLWLKVEAEVSTLYR

FMPTGFTRGPFΝIEHREWGΝTT

ATWTRMISΝHΝKHSQRGRKMT

ARLPCGGAPHFSDRTDDKWRR

SSLLTRSGCQTERLLTSQTEPLP

AGGSPHFSΝGETGQRRSSPPQR

GCDRPQALLTSKTEQQRKSASH

ISYDERPGKDAPHFLDGMVAG

KRRSSLSRLGSQA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21070 51438 21197 2466 MLSRLFRMHGLFVASHPWEVI

VGTVTLTICMMSMNMFTGIAG

LFTIFSSFVFSTWIHFLDKELTG

LNEALPFFLLLIDLSRASTLAKF

ALSSNSQDEVRENIARGMAILG

PTFTLDALVECLVIGVGTMSGV

RQLEIMCCFGCMSVLANYFVF

MTFFPACVSLVLELSRESREGR

PIWQLSHFARVLEEEENKPNPV

TQRVKMIMSLGLVLVHAHSRW

IADPSPQNSTADTSKVSLGLDE

NVSKRIEPSVSLWQFYLSKMIS

MDIEQVITLSLALLLAVKYIFFE

QTETESTLSLKNPITSPWTQKK

VPDNCCRREPMLVRNNQKCDS

VEEETGINRERKVEVIKPLVAET

DTPNRATFVVGNSSLLDTSSVL

VTQEPEIELPREPRPNEECLQIL

GNAEKGAKFLSDAEIIQLVNAK

HIPAYKLETLMETHERGVSIRR

QLLSKKLSEPSSVLQYLPYRGYV

NYSL W* WG ACCEN VIGYMPIP

VGVAGPLCLDEKEFQVPMATT

EGCLVASTNRGCRAIGLGGGAS

SRVLADGMTRGPWRLPRACD

SAEVKAWLETSEGFAVIKEAFD

STSRFARLQKLHTSIAGRNLYIR

FQSRSGDAMGMNMISKGTEKA

LSKLHEYFP*NCRF*AVVSGNYC

TDKKPAAINWIEGRGKSWCET

VI PAKV VREVLKTTTEAMIEVN

INKNLVGSAMAGSIGGYNAHA

21071 51439 21 198 236 3022 GEGSFRSATALTGARLSVGAGV

RWPLVRSGGSKDSVATMLSRL

FVRMHGLFVASHPWEVILGTVT

LTICMMSMNMFTGNNKICGWN

YECPKFEEDVLSSDIIILTITRCIA

ILYIYFQFQNLRQLGSKYILGIA

GLFTIFSSFVFSTWIHFLDKELT

GLNEALPFFLLLIDLSVRASTLA

KFALSSNSQDEVRENIARGMAI

LGPTFTLDALVECLVIGVGTMS

GVRQLEIMCCFGCMSVLANYF

VFMTFFPAC

21072 51440 A 21199 450 CKSRGSNLRVHFKNTRETAQAI

KGMHIRTATKYLKDVTLQKQC

VPFRRYNGGVGRCAQAKQWG

WTQGRWPKKSAEFVLVIEHIQV

NKAPKMRRRTYRAHGRINPYM

SSPCHIEMILTEKEQIVPKPEEEV

AQKKKISQKKLKKQKLMARE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21094 51462 A 21221 2157 MGFPLRPSPAHLSSGRQQFPAK

EERLLLSLTQESQSEEIDCNDKD

LFKAVDAALKKYNSQNQSNNQ

FVLYRITEATKTVGSDTFYSFK

YEIKEGDCPVQSGKTWQDCEY

KDAAKAATGECTATVGKRSST

KFSVATQTCQITPGGWFILWHC

PGGKLTISDYPNSSRVLHCTQC

VQGLNRRTRRHKTCPPLQAAS

QIEERIGFEGRPGLESFRAPCLL

ASPFPCLEKGAEGPWTAQYDC

LGCVHPISTQSPDLEPILRHGIQ

YFNNNTQHSSLFMLNEVKRAQ

RQAAP/GREFSSMDTFEGYEGA

EDMEKLAGPFPVG*QSRNLFLQ

IRFPGEERKHPGRKRRTR*GSN

GDRQHQEGACWGVHAG*LLR

GRRLVSRRGRGARGPPPRRAAL

PAVAPAPRLQSARIPERGDGDD

GVRRWGHREAIGS*GQS/LS/CN

GIIILIKEERLPCPFHCISLMKRPP

GFSPFRSSRIGEIKEETTVSPPHT

SMAPAQDEERDSGKEQGHTRR

HDWGHEKQRKHNLGHGHKHE

RDQGHGHQRGHGLGHGHEQQ

HGLGHGHKFKLDDDLEHQGGH

VLDHGHKHKHGHGHGKHKNK

GKKNGKHNGWKTEHLASSSED

STTPSAQTQEKTEGPTPIPSLAK

PGVTVTFSDFQDSDLIATMMPPI

SPAPIQSDDDWIPDIQIDPNGLSF

NPISDFPDTTSPKCPGRPWKSVS

21095 51463 21222 207 424 HHINCVLLYLQSHLRSVCEYQGV RPPKAGAEPASEVREVSLTN W A ESSTPRHIAPTTSASNLEMEGQE ERWDRI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21100 51468 21227 846 3269 GFMEVLRDP1KKNSSESKPAQS

GFSRGNSPLSCPESVEASPAVNE

KSVYSTHNYGTTQRHGCRGLP

YADHNYGAPPPPTPPASPPVQTI

IPRSDLNGLPSPVEERCGDSPNS

EGETVPTWCPCGLSQDGFLLNC

DKCRGMSRGKVIRLHRRKQDN

ISGGDSSATESWDEELSPSTVLY

TATQHTPTSITLTVRRTKPKKR

KKSPEKGRAAPKTKKIKAFREG

SRKSLRMKNSPSEAQNLDENTT

EGWENRIRLWTDQYEEAFTNQ

YSADVQNALEQHLHSSKEFVG

KPTILDTINKTELACNNTVIGSQ

MQLQLGRVTRVQKHRKILRAA

RDLALDTLIIEYRGKVMLRQQF

EVNGHFFKKVPYPVFVLFLLQNL

NGVEMCVDARTFGNDARFIRR

SCTPNAEVRHMIADGMIHLCIY

AVSAITKDAEVT1AFDYEYSNC

NYKVDCACHKGNRNCPIQKRN

S*CYRTATPTTSSKPTHHWSRD

*T*KSVRRKELEMEQQNEASEEN

NDQQSQEVPEKVTVSSDHEEV

DNPEEKPEEEKEEVIDDQENLA

HSRRTREDRKVEAIMHAFENLE

KRKKRRDQPLEQSNSDVEITTT

TSETPVGEETKTEAPESEVSNSV

SNVTIPSTPQSVGVNTRRSSQA

GDIAAEKLVPKPPPAKPSRPRPK

SRISRYRTSSAQRLKRQKQANA

QQAELSQAALEEGGSNSLVTPT

21101 51469 21228 197 CRPPSPRPVRAARPARPQASFSR

EPPPRRMAP*SKRRRQSARGPV

RPSRVWARIKAKPYSCCCQL

21102 51470 21229 488 GSYDINRQDTFQKDRQRVGPSG

ASQKTEGFLLRLLYSGLIIAHCS

LEILGRNDPPASASKVAETTDS

GSLSLANT*PPTPR/VTSQTANA

TSQAAPALPLGSVPGRRAADPR

PLLAWAPAPPGPGTSRNTHPAP

DGLDMLVPIGDGVLGGNCFRN

QCKSVSTS

21103 51471 21230 124 293

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21126 51494 21253 2775 QALARRAVQAEKMAPPSTREP

RVLSATSATKSDGEMVLPGFPD

ADSFVKFALGSWAVTKASGG

LPQFGDEYDFYVRSFPGVFQAFC

ETQGDR/LCFQCMSRVMQVPM

GCVRSNVI KDRSKVVTELEDKFVD

LLVVDANVDVILERVGILLDEAS

GVNKNQQPVLPAGLQVPKTW

VSSWNRKAAEYGKKAKSETFRL

LHAKNIIRPQLKFREKIDNSNTP

FLPKIFHSNPMVQVKPLPQALSK

ERRERPQDRPE

21 127 51495 21254 2668 QALARRAVQAEKMAPPSTREP

RVLSATSATKSDGEMVLPGFPD

ADSFVKFALGSWAVTKASGG

LPQFGDEYDFYRSFPGFQAFCE

TQGDRLLQCMSRVMQYHGCRS

NIKDRSKVTELEDKFDLLVDAN

DVILERVGILLDEASGVNKNQQ

PVLPAGLQVPKTWSSWNRKA

AEYGKKAKSETFRLLHAKNIIR

PQLKFREKIDNSNTPFLPKIFIKP

NAQKPLPQALSKERRERPQDRP

EDLDVPPALADFIHQQRTQQVE

QDMFA H PYQ YELNHFTPADA V

LQKPQPQL YRPI EETPCHFISSL

DELVELNEKLLNCQEFAVDLEH

HSYRSFLGLTCLMQISTRTEDFII

DTLELRSDMYILNESLTDPAIVK

VFHGADSDIEWLQKDFGLYW

NMFDTHQAARLLNLGRHSLDH

LLKLYCNVDSNKQYQLADWRI

RPLPEEMLSYARDDTHYLLYIY

DKMRLEMWERGNGQPVQLQV

VWQRSRDICLKKFIKPIFTDESY

LELYRKQKKHLNTQQLTAFQL

LFAWRDKTARREDESYGYVLP

NHMMLKIAEELPKEPQGIIACC

NPVPPLVRQQINEMHLLIQQAR

EMPLLKSEVAAGVKKSGPLPSA

ERLENVLFGPHDCSHAPPDGYP

11 PTSGS VPVQKQASLFPDEKED

NLLGTTCLIATAVITLFNEPSAE

DSKKGPLTVAQKKAQNIMESFE

21128 51496 21255 98 286 HARPRHGPRLRCEVGLRCAPG YAGASARPTCECGDTRYCPQDP NQT* SRPVPII AHRYCLTG

21129 51497 21256 1020 1280

21130 51498 21257 153 3804

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vπ, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

21 174 51542 21301 1 16 1559 PRTARPSCAHARTVRAVATRRR

RVHFRDLSAAPSGLSVLRPRPT

EPVRVDCPESANPPVRARPDSP

DPRMFELLAASDARINGPFCAP

RVLLAPLLGAFVTVSKIVSKIAL

SPK* SRRSHLLRRNGSQ WVVKV

HVELKEHNGVHITGIDVWAPKSD

RICH CLGADRNCLMVWSVQKVD

GVWKPNPG*FLRNLIGGGNFL*

KWVPPRRTKFGCGGSGARLISV

CYFESENDWWVSKHIKKPIRST

VLSLDWHPNNVLLAAGSCDFK

CRVFSAYIKEVDEKPASTPWGS

KMPFGQVLMSEFGGVSGTGVGW

VHGVSFSVASGVDRLGWGSATD

STVVSVA*CLQKWQVSTLKTVE

FLAAP*WSFVSREPASGLPAH

DCVCPMLFNYG*PRAALTFRLP

KLDIPKVQSIQRNMSAHGNAFG

NMVDKRATTEDVRNTALVETLHV

QNSITQVLYLLRWDKQDVCRKF

CTVTGIVDGEPWTIWDFQDPRSL

PSQGLRIM

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Ammo acid sequence ( X=Uπknown,

NO: of peptide hod in USSN location of first codon for last ammo acid *=Stop codon, /=possιble nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possιble nucleotide insertion) sequence

21290 51658 21418 1584 TQKNTAVRAHRLWGREKISRK

EGAGPTPQESRRIGARSGALMT

RKGRGMQEVEELSETGKWKQ

HRVGEALRVWLVWAGSLG/D

RRGLVLGRRGYYGAVPAVEMP

ARALLPRRMGHRTLASTPALW

ASIPCPRSELRLDLVLPSGQSFR

WREQSPAHWSGVLADQVWTL

TQTEEQLHCTVYRGDKSQASRP

TPDELEAVRKYFQLDVTLAQL

YHHWGSVDSHFQEVAQKFQG

VRLLRQDPIECLFSFICSSNNNIA

RITGMVERLCQAFGPRLIQLDD

VTYHGFPSLQALAGPEVEAHLR

KLGLGYRARYVSASARAILEEQ

GGLAWLQQLRESSYEEAHKAL

CILPGVGTKVADCICLMALDKP

Q A VPVDVHM WH I AQRD YS WH

PTTSQAKGPSPQTOKELGNFFR

SLWGPYAGWAQAGLLGNAFD

GHQLLRPLIFCQDHLREGPPIGR

GDSQGEELEPQLPSSLSSIPYGF

CDHCWTKDVDDPPLVTHPSPG

SRDGHMTQAWPVKWSPLATV

IGHVMQASLLAL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21291 51659 21419 837 2785 WTRMLFAVSCNDGECQNSNVI

LFCDMCNLAVHQECYGVPYIPE

GQWLCRRCLQSPSRAVDCALC

PNKGGAFKQTDDGRWAHWC

ALWIPEVCFANTVFLEPIDSIEHI

PPARWKLTCYICKQRGSGACIQ

CHKANCYTAFHVTCAQQAGLY

MKMEPVRETGANGTSFSVRKT

AYCDIHTPPGSARRLPALSHSE

GEEDEDEEEDEGKGWSSEKVK

KAKAKSRIKMKKARKILAEKR

AAAPWSVPCIPPHRLSKITNRL

TIQRKSQFMQRLHSYWTLKRQ

SRNGVPLLRRLQTHLQSQRNCD

Q VGRDSEDKN WALKEQLKS W

QRLRHDLERARLLVELIRKREK

LKRETIKVQQIAMEMQLTPFLIL

LRKTLEQLQEKDTGNIFSEPVPL

SEVPDYLDHIKKPMDFFTMKQ

NLEAYRYLNFDDFEEDFNLIVS

NCLKYNAKDTIFYRAAVRLRE

QGGAWRQARRQAEKMGIDFE

TGMHIPHSLAGDEATHHTEDA

AEEERLVLLENQKHLPVEEQLK

LLLERLDEVNASKQSVGRSRRA

KMIKKEMTALRRKLAHQRETG

RDGPERHGPSSRGSLTPHPAAC

DKDGQTDSAAEESSSQETSKGL

GPNMSSTPAHEVGVGEPQFCSP

KRTRRQ/HGPPKRPGRPPKNRES

QMTPSHGGSPVGPP/RAPHHEFP

ASAQAG*EPQFCSPKRTRRQLD

21292 51660 A 21420 2625 MENKITGYTTVDISQWHRKEHF

EAFQSVAQCTYNQTVQLDITAF

LKTVKKNKHKFYPAFIHILARL

MNAHPEFRMAMKDGELVIWD

SVHPCYTVFHEQTETFSSLWSE

YHDDFRQFLHIYSQDVACYGE

NLAYFPKGFIENMFFVSANPWV

SFTSFDLNVANMDNFFAPVFTM

GKYYTQGDKVLMPLAIQRDSE

DKNWALKEQLKSWQRLRHDL

ERARLLVELIRKREKLKRETIKV

QQIAMEMQLTPFLILLRK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21302 51670 21430 1660 AGVLASHPNSTDVHIINLSLTFH

GQELLSDTKLELNSGRRYGLIG

LNGIGKSMLLSAIGKREVPIPEH

IDIYHLTREMPPSDKTPLHCVM

EVDTERAMLEKEAERLAHEDA

ECEKLMELYERLEELDADKAE

MRASRILHGLGFTPAMQRKKL

KDFSGGWRMRVALARALFIRPF

MLLLDEPTNHLDLDACVWLEE

ELKTFKRILVLVSHSQDFLNGV

CTNIIHMHNKKLKYYTGNYDQ

YVKTRLELEENQMKRFHWEQD

QIAHMKNYIARFGHGSAKLAR

QAQSKEKTLQKMMASGLTERV

VSDKTLSFYFPPCGKIPPPVIMV

QNVSFKYTKDGPCIYNNLEFGI

DLDTRVALVGPNGAGKSTLLK

LLTGELLPTDGMIRKHSHVKIG

RYHQH LQEQLDLDLSPLEYMM

KCYPEIKEKEEMRKIVIGRYGLT

GVKQQVSPIRNLSDGQKCRVCL

AWLAWQNPHMLFLDEPTNHL

DIETIDALADAINEFEGGMMLV

SHDFRLIQQVAQEIWVCEKQTI

TKWPGVDILVAYKEHLKSKLVDV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21351 51719 21479 2421 QAGAMASGSVAECLQQETTCP

VCLQYFAEPMMLDCGHNICCA

CLARCWGTAETNVSCPQCRETF

PQRHMRPΝRHLAΝVTQLVKQL

RTERPSGPGGEMGVCEKHREPL

KLYCEEDQMPICWCDRSREHR

GHSVLPLEEAVEGFKEQIQΝQL

DHLKRVTRLKFTDFLAQGEQA

RAELLSLTHMEREKIVWEFEQL

YHSLKEHEYRLLARLEELDLAI

YΝSIΝGAITQFSCΝISHLSSLIAQ

LEEKHQQPTRELLQDIGDTLSK

AERIVRIPEPWITPPDLQEKIHIFA

PKCLFLTESLKQFTEKMQSDME

KIQELREAQLYSGGSIVGGHEP

GEPRGIKAGYGTCΝCFPEEEKC

FCEPEDIQDPLCDELCRTVIAAA

VLFSFVVSVLLSAFCIHCYHKF

AHKPPISSAEMTFRRPAQAFPVS

YSSSGARRPSLDSMEΝQVSVDA

FKILEDPKWEFPRKΝLVLGKTL

GEGEFGKWKATAFHLKGRAG

YTTVAVKMLKEΝASPSELRDL

LSEFΝVLKQVΝHPHVIKLYGAC

SQDGPLLLIVEYAKYGSLRGFL

RESRKVGPGYLGSGGSRΝSSSL

DHPDERALTMGDLISFAWQISQ

GMQYLAEMKLVHRDLAARΝIL

VAEGRKMKI SDFGLSRDVYEE

DPYVKRSQGRXPVKWMAIESLF

DHIYTTQSDVWSFGVLLWEIVT

LGGΝPYPGIPPERLFΝLLKTGH

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21358 51726 21486 2589 MSPVTLWVRTSSRGEDRCGMC

TPGRDTGFAP1SGMCSKYRSCTI

NEDTGLGLAFTMPMSLDTKHIP

NFGKVHGYIMRHHKNEDTIPW

RRNTKKEEARGTQPLEADDQN

PGWEDGKPGSLENEGRRSHRG

NPAPDMPQPPKEDLFI LPDEYK

SCLRHKRSLLRSHRNEELNVET

LVWDKKMMQNHGHENITTY

VLTILNMERILKKTSFTIIHPSA

MERCPVLNLQIRDSLWNHCFSL

ATTVHRFHPVGRHALKKMYKL

PSAYINVSITKYTQRFALTYISC

VFHRNAAFVAVPGEGRCCAGV

DVPAPMSLRSPGPHWPQEHGA

LWISCTVRGMASCLGQLCRVS

MRVRANIGKVQKPRLRISNGK

GLHTQSELSGSAYLEKGWRGA

APGLDSRNEKGTEGARDSGTPG

RQSQTLQRGPPGPVPGSSKIAPQ

TLTRQGSMTASRKLVLLLPEFC

ERTGEQSGQLYPPSPLLVEWV

MPAGTSSTVDPLLPELCRRWER

QALSLCRLYRQRTSVSIKALCD

HTETRSVALSTCQGLECNSSPA

RKQNWMENEFEELTEVGFRKS

VITKFSKLKEHILTHRKEAKNLE

KRLDEWLTRITSVEKSLNDLME

LKTTVRKVLHEAYTSFNSRFDQ

VEERILVIEHQINEIKQEDKVRE

KRVKRNEQSLQEIWDCVKRPN

LCLIGVPESDGENGTKLENTVLQ

21359 51727 A 21487 260 1292 RLCAFNKRMTFQFNFTIEDHLE

NELTPIRDGALTLDSSKELSVSE

SQKGEERDRKCSAEQFDLPQD

HLWEHKSMENAAPSQDTDSPL

SAASSSRNLEPHGKQPSLRAAK

EHAMPKDLKKMLENKVIETLP

GFQHVKLSVVKTILLKENFPGE

NIVSKSFSSHSDLITGVYEGGLK

IWECTFDLLAYFTKAKVKFAG

KKVLDLGCGSGLLGITAFKGGS

KEIHFQDYNSMVIDEVTVLPNV

VANSTLEDEENDVNEPDVKRC

RKPKVTQLYKCRFFSGEWSEFC

KLVLSSEKLFVKYDLIVLTSETIY

NPDYYSNLHQTFLRLLSKNGRV

LLASKAHVQRNSLSRL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21390 51758 21518 1321 VKSRAALLGPGA/LSPLEVSRRR

PWTERRLGSVRGDRLRERSRPA

VNRTPRMSRVPSGAPRGTPSRR

WWMMKCWDHQPLG*IPAPHV

GPLAG/IRKREWSDESEEEPEKE

LAPEPEETWVVEMLCGLKMKL

KQQRVSSILPEHHKDFNSQLAP

GVNPSPPHRSFCWKRKMEWW

DQSEESLEEEPRKVLAPEPEEIW

VAEMLCGLKMKLKRRRVSLVL

PEHHEAFNRLLEDPVIKRFLAW

DKDLRVSDKYLLAMVIAYFSR

AGFPS WQ YQRIHFFL A L YLAND

MEEDDEDSKQNIFHFLYRKNRS

RIPLLRKRWFQLGHSMNPRARK

NRSRIPLLRKRRFQLYRSTNPRA

RKΝRSRIPLLCKRRFQLYRSMΝ

SRARKΝRSQIVLFQKRRFHFFCS

MSCRAWVSPEELEEΝTGPRGD

VDFQQELYSΝAΝGRHQAGGEE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21396 51764 A 21524 727 2953 HVSGYDDVPLGTLSLDIWPPAL

FSWSFAAFFFTPPIEAVLKSFSC

LLVWYIGMAQPKQERVARARH

QRSETARHQRSETA/KTPTLGN

RQTPTLGNRQTPRLGIHARPRR

RATTSLLTLLRAFGKKTQS/STE

PAKAIKPIDRKSVHQICSGQWL

SLSTAVKKIVENSLDAGATNID

LKLKDYGMDLIEVSGΝGCGVE

EEΝFKGLTLKHHTSKIQEFADL

TRVETFGFRGEALSSLCALSDV

TISTCHVSAKVGTRLVFDHDGK

IIQKTPYPHPRGTTVSVKQLFST

LPVRHKEFQRΝIKKAQR/PQAR/

CYRCS*PΝVSPGPGMAAASTLS

A*PRSQSSYFISCKA/EDNAICPI

AEQKAEGKFSSRYRNHDSAEN

RRDGSMTRPRTDWTLKRACTE

KRRPQHASSFEWRGHSLCWDR

EQRDAETLKMLLDSGLSVQKK

TKDRTETRFGEMGQILGKIMMS

HQPQPQEEQSPQRSTSGYPLQE

WDDEVSGPSAPGVDPSPPRRS

LGWKRKRECLDESDDEPEKEL

APEPEETWVAETLCGLKMKAK

RRRVSLVLPEYYEAFNRLLEDP

VIKRLLAWDKDLRVSDKIPSEP

TILGASPKTLPPASRICIRPSNTP

PPRNFHMSTVTPMLSYLANDM

EEDDEAPKQNIFYFLYEETRSHI

PLLRELWFQLCRYMNPRARKN

CSQIALFRKYRFHFFCSMRCRA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

21445 51813 A 21573 59 2384 PRPGSRSGLCRRAGERGAVRAG

GMSRRTRCEDLDELHYQDTDS

DVPEQRDSKCKVKWTHEEDEQ

LRALVRQFGQQDWKFLASHFP

NRTDQQCQYRWLRVLNPDLVK

GPWTKEEDQKVIELVKKYGTK

QWTLIAKHLKGRLGKQCRERW

HNHLNPEVNKSCWTEEEDRIIC

EAHKVLGNRWAEIAKMLPGRT

DNAGKNHWNFTIQK/RKGDTG

GFLREYKD* KPP V YLPLVELEDK

DGLQSAQPTEGQRSLLTNWPSV

PPTIKEEENVSEEELAAATTSKE

QEPIGTDLDAVRVTPVEPLEEFPVK

REDQEGSPPETD/SLPYKWWE

AVNLLIPAWSVSLYEALDLIGSV

DPDAWCDLSRFDLPEEPSIEDSI

NNSVLVQLQASVHQQQILPPRQP

SAVLVPSVTEYRLDGHTISDLSR

SSRGELIPISPSTEVGGVSGIGTPP

SVLKRQRKRRVALSPVTENSTS

LSFLDSCNSLTPKSTPVKTLPFS

PSQFLNFWNKVQDTLELESPLA

DYPPQVCSQKVWTTPLHRVDK

TPLHQKHAVAFVTPDQKYSMD

NTPHTVPTPFKNALEKYGPLKPL

PQTPHLVEEDLKEVLRSEAGIELI

IEDDIRPEKQKRKPGLRRSPIKK

VRKSLALDIVDEDVKLMMSTL

PKSLSCRTTAPSNVSSTVLTLSGIK

EDNSLVLNQGLLAGPSPRKAAC

VPEGPESHFHGQLAPYVPVPGK

21446 51814 21574 190 889 SLPRRLESPGRLAMAARGVIAP

VGES/LCRYAEVPCSPSAKRPDA

DVDQQRLVRSLIAVGQGVAAL

AFAGVRYALVRIWKPLEVQVITET

AKGRFQTPRFSSY* * GG/FLNI I *

LRREAVGLILGVSPVSAGKAKIRT

VAHRVRVMILESPQIKGGSPYVA

AKINEAKDVLLETTTKRLMLKD

HTEGKKNEGTSKKKKSPAKYS

KTWSFLIFYMGFDHSLIFRPLSC

ITNKMLIVLLFIIF

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21458 51826 21586 929 MDPSIYFLPSKREGHLQAYIRDS

VPEDPLILIFFSASSDQRPWLKA

PHLPALRGFRGGGAGGGAQSR

TTEDYVAWAKGNSPTSPSPRSR

GGCSAKLSGPRRPPRRPGRLFN

MAASANSVSRAWRTESPEGLE

SLHSTSLSAISVSRPEGGAELSD

TADTMGFGDLKSPAGLQWPTI

TWRTRATSRGMCHHKQMWQY

LKPCPAHRLPTCVMPYV/GYNH

IKSYEKEKASLPGVKKALGKYG

PADVEDTTGSGATDSKDDDDID

LFGSDDEEESEEAKRLRE/DTSC

TI*IKESQKTCTCCQVFHLTRCE

21459 51827 21587 2405 MALRWRSVRAVLCSLHVACE

KVGMQIPRFCYHERLSVAGNC

RMCLVEIEKAPKDQSMMFGND

RSRFLEGKRAVEDKNIGPLVKT

IMTRCIQCTRCIRFASEIAGVDD

LGTTGRGNDMQVGTYIEKMFM

SELSGNIIDICPVGALTSKPYAFT

ARPWETRKTESIDVMDAVGSNI

WSTRTGEVMRILPRMHEDINE

EWISDKTRFAYDGLKRQRLTEP

MVRNEKGLLTYTSWEDALSRV

AGMPPALALQSAEIAASARPPP

RLGSEEPLCLAAHRLGCEEPLC

LAASLESEERLCPAAIPPGNLRY

VFISSAKTDKYSKLAPVEWVTV

EKVPENVEVTLELGNRQSRDR

VSRIPGNAIVIWFTGFKWKKTV

TTLWFLNLAIADFIFLLFLPLYIS

YVAMNFHWPFGIWLCKANSFT

AQLNMFASVFFLT/GDQPGPLY

PLDPSCLISSASNPQELSDCHYI

HLAFGFSNWRSCPVLPGHCGV

Q*SYSLL*QFSEA*S*PHFDQAP

CSDLGEIYHWLSLPFANNEYLL

LVSHLQGEEAKHPDLQ*AFLDN

SGCGCGLCGLLDSLSPV* HLG A

HHSPQ*LFPPCDAGWNPPLHWF

GIPQ*LLEPHPLCPN**EVPSSLP

VLSC*DTQVHTVGSQLFWVQVL

KEAKKPMVVLGSSALQRNDGA

AILAAVSSIAQKIRMTSGVTGD

WKVMNILHRIASQVAALDLGY SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21460 51828 21588 2065 MLRIPVRKALVGLSKSPKGCVR

TTATAASNLVIRVFVDGQSLMVV

EPGTTVLQACEVRIGMQIPRFCY

HERLSVAGNCRMCLVEIEKAPK

DQSMMFGNDRSRFLEGKRAVE

DKNIGPLVKTIMTRCIQCTRCIR

FASEIAGVDDLGTTGRGNDMQ

VGTYIEKMFMSELSGNIIDICPV

G ALTSKPY A FTARP WETRKTES

IDVMDAVGSNIWSTRTGEVM

RILPRMHEDINEEWISDKTRFA

YDGLKRQRLTEPMVRNEKGLL

TYTSWEDALSRVAGMLQSFQG

KDVAAIAGGLVDAEALVALKD

LLNRVDSDTLCTEEVFPVTAGA

GTDLRSNYLLNTTIAGWEEAD

WLLVGTNPRFVEAPLF*C*EFR

KSWVLHNDVLKVALIRAVPVDLV

TYTYDHLGVDSPKILQVDIASGK/

SHPFSQVLKEAKKPMVWLGSS

ALQRNDGAAILAAVSSIAQKIVR

MTSGVTGDWKVMNILHRIASQ

VAVLVDLGYKPGVEAIRKNPPK

VLFLLGADGGCITRQDLPKDCF

IIYVQGHHGDVGAPIADVILPGA

AYTEKSATYVNTEGRAQQTKV

AVTPPGLAREDWKIIRALSEIAG

MTLPYDTLDQVRNRLEEVSPNL

VRYDDIEGANYFQQANELSKL

VNQQLLADPLVPPQLTIKDFYM

TGEVTEINEALAENPGLVNKSR

YEDGWLIKMTLSNPS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkπown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21514 51882 21642 2230 MMRTSGGTRDNESSSDDERER

ENRLSDEKSNEYANLVGGERY

EPDEENPMLGFRGAGRYVSDSF

LRLCSSLEIVKARETVALIQGLK

HVDLLADDTALRALIPQRADRFP

MNAVRSTLKEEEKLVNSSDWG

YVDAQAFARWRPEYGYFAKQA

GFTVKTSASLAALWQWNQIG

GKERYFFGNILWQTRALMDRAI

GHKLAKGRPEREYLQTGDAVD

SWKVIWEPEKQLTLLFGMKAP

GLGRLCFSLEDKGDYRTIDVRA

FWHPHGNRAEREKPRFQPYSRR

KSFIGQNMLLPMSIMPPVFRRVI

CPLGVARLGKFRDPVYLVCVFT

RQIFRYYTSGDEFLQINTTGGED

IDDIDDIKLFVYEESYGISKESH

WREAINAKAMGAMTLNWQEK

RWQRFFNSEEPGNIEPVYMLEK

VENQNHAKWEVHNFTMGYQR

QVTEDTYEYLLLNWGVPVPD

NIHPMTKDEAGVWSWRTPILK

GNLYEYFFNVDGVRSIDTGTA

MTNPQRQVNSSMILVPGSYLDT

RSVAHGDLIAITYHSNALQSER

QMYVWTPPGYTGMGEPLPVLY

FYHGFGDTGRSAIDQGRIPQIM

DNLLAEGKIKPMLWIPDTETD

AKGIIPEDFVPQERRKVFYPLNA

KAADRELMNDIIPLISKRFNVR

KDADGRALAGLSQGGYQALVS

GMNHLESFGWLATFSGVTTTT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21559 51927 21687 2339 MSGGQTEKQAQLIRDFQPDMI

MVTPSYCLNLIEELERQLGGDA

SGCSLRVGVFGAEPWTQAMRK

EIERRLGITALDIYGLSEVMGPG

VAMECLETTDGPTIWEDHFYPE

IVNPHDGTPLADGEHGELLFTT

LTKEALPVIRYRTRDLTRLLPGT

ARTMRRMDRISGRSDDMLVLR

RRHLCRPSACQLCRPPSLPATD

RVLELFAQSGAQWLVILGDVL

NHGPRNALPEGYAPAKVAERL

NEVAHKVIAVRGNCDSEVDQM

LLHFPITAPWQQVLLEKQRLFL

THGHLFGPENLPALNQNDVLV

YGHTHLPVAEQRGEIFHFNPGS

VSIPKGGNPASYGMLDNDVLS

VIALNDQSIIAQVAINPAPEKEG

FLIMEQRRLASTEWVDIVNEEN

EVIAQASREQMRAQCLRHRAT

YIWHDGMGKILVQRRTETKDF

LPGICATSKVRKLLCKSAALLP

VSELLLVLLTPVFVGSAVIGKL

GAFAIHIDGITVKRRLVRNTVL

QFCGRSRQPLEYVSAGDTGPVL

RALKRMMAMRHYMRSQTVKG

VTDTRAIDEVALSVAQVEEMY

RYLAIANYEDRFVIPTSHREMA

GDAFAERNGCGFTFGDGCHGS

DSKFNLFNSSRIDAINITEILKVI

GLLMEYPDELLWECKEDALALI

RRDAPMLTDFTHNLLNAPLLD

KQAEWCEVFDRGRTTSLLLFEH

21560 51928 21688 391 631

21561 51929 21689 2779 3348 LMQLHNGLPVAGLRQFCQQLV

IQRLYFFTTATAHQCTRHMCHR

HRSLLTAHRQMALCFQYVDDL

HHAFADVLINNACYPLLMGEQ

GVFIYNGTQQLLHWVIIDSRQD

HGFGGL*KSRIVCERRRL*SQH

GQFVFRHHVPDHRIDIAFNNAL

*TLVIREISSVPASVGVGIDFPGG

AATWAGPVVIKPGQS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21782 52150 21910 52 1719 IGQWDVDTCFTRIHLVFVNFD

NDTGSIHVLNDTTTFSYRSYTG

VNGNSTFHTSTNQRLISAQSRN

GLTLHVRTHQCTVGVIVFQERD

QGRTDGYHLLGGYVHWNLV

AAEQAGFAFATASYQVFYEVA

FFIQVGVRLGDNWAFFDSRQV

VNFVSYNTVGHFTIRSLKEAVF

VSLCVHGQRVDQTDVRTFRGF

DWTDATWSRVYVSNFEACTF

TGQTAWAECGDTTFVRNLRQR

WLVHKLRQLAGTEELFHCCG

SQDPQQPWGWNLRVNPLAQTT

GHAHE AQRKQ WH KGNEEADD

PEPERAFTPGFVQFETERFRPPV

GHPCEAAEDHAADDHVMEVR

NQEQAVMQNEVRARYGQQHA

SHPAHREGDDKTDGPQHRRME

HDAALIHGEQPVEDLHPGRDG

DNHCGDTKEGVYVRARTHRKE

WQPNDERQHGDTDGCPYQRG

ITKQTFTREGCRNFGEHTENRQ

DQDVNFRVAPGPNQVDVHHH

VATHIVGKEMGAQIAIQGQHAT

YRQNGKDL*SNRGVASGNPQC

RHRAHRRATDCQTVIKQPVFFG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21865 21993 145 1929 VSGVIEIADGSRRRKAAALTES

DYRVLVGELDDEQMAALSRLG

NDYRPTSAYERGQRYASRLQN

EFAGNISALADAECDNLKTCHT

SHGSVMAETAVINHKKRKNSP

RIVQSNDLTEAAYSLSRDQKRM

LYLFVDQIRKSDGTLQEHDGIC

EIHVAKYAEIFGLTSAEASKDIR

QALKSFAGKEWFYRPEEDAG

DEKGYESFPWFIK/RPSRGLYSV

HINPYLIPFFIGVLQNRFTQFRLS

ETKEITNPYAM RLYESLCQYRK

PDGSGIVSLKIDWIIERYQLPQS

YQRMPDFRRRFLQGFCRFRNH

HQTGFSPAGANQRGPLAATLSG

PGGEGQSAVARLTGEKKNHPG

AQYANRLSPRVGRFINAAGTTG

FPTWKAGSERNAINDDVTYAIK

PTCWPGLDIIPSCLALHRIETEL

MGKFDEGKLPTDPHLMLRLAIE

TVAHDYDVIVIDSAPNLGIGTIN

WCAADVLIVPTPAELFDYTSA

LQFFDMLRDLLKNVDLKGNSN

GSQSPWMEEQIRDAWGSMVLK

NWRETDEVGKGQIRMRTVFE

QAIDQRSSTGAWRNALSIWEPE

CNEISIGVSLDQDGGSNSVLRK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno>vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

21880 52248 22008 1894 EGEDRGLPRTMGAALGTGTRL

APWPGRACGALPRWTPTAPAQ

GCHSKPGPARPVPLKKRGYDV

TRNPHLNKGMAFTLEERLQLGI

HGLIPPCFLSQDVQLLRIMRYY

ERQQSDLDKYIILMTLQDRNEK

LFYRVLTSDVEKFMPIVYTPTV

GLACQHYGLTFRRPRGLFITIHD

KGHLATMLNSWPEDNIKAVW

TDGERILGLGDLGCYGMGIPVG

KLALYTACGGVNPQQCLPVLL

DVGTNNEELLRDPLVYIGLKHQ

RVHGKAYDDLLDEFMQAVTD

KFGINCVLIVQFEDFANANAFRLL

NKYRNKYCMFNDDIQGTASVA

VAGILAALRITNNKLSNHVFVF

QGAGEAAMGVIAHLLVMALEVK

EGVPKAVEATRKIWVMVDFVKGL

IVKGRSHLNHEKEMFAQDVHPE

SNSLDEWRLVKPTAIIGVAAIA

EAVFTEQI LRNM ASFVRRAPI IF A

LSNPPRKAECTAVEKCYRVTEG

PRGFFASGKSFLRSVDL/ESMGK

TFIPGGRGNNA*RVPRGWQLG

VHSPGGDPGH I PVDEIFLPDSRA

KLPQEVSEQHLVSQGRLYPVPLS

TVIRDVSLRIAI KVLDY A YKHNL

WSYYPEPKDKEAFCKIPGSYTP

DYDSFYT/VDSYIWAQGKAMN

21881 52249 22009 322 567

21882 52250 22010 338 603

21883 52251 22011 127 417

21884 52252 22012 253 424

21885 52253 22013 124 1235 YLCLLPKGQGDRALSRTSQWP

QMSQSQACGGSEQIPGIDIQLN

RKYHTTRKLSTTKRFPTACWR

KKVGAFTKIIEAMGFTGPLKYS

KWEDLRLRALRIVY*LCGRKLD

FEGFFSKVCSVMPDTFNSWFLINP

YFHVWMCLVRMKQEGRSGKY

MCRIIVHFMWEDVQQRGRVM

GVNPYILKKNMILMTNHFYAVA

ILGYDEGILSDDHGLAAALWK

NLLVNVRKCEDPRHLELLVEYVR

KQIQYLDSVMNGEDLLLTGEVS

WRPLVEKNPQSILKPHSPTYND

RGTFDGLGPPHGPPAGFRGTSR

EEKCLVGPRTPARKWPELDLLN

KHLSKYLAPICVEFPLSVPQESD

LLGYRAWENPLALPGCPSSLRG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21890 52258 A 22018 1806 MRGNTAGGPGDEKPDSTHPPW

EGTLQEAQEMKKWRFMWTS

GGPDPQHWRGSGLYGQLVAQ

MLHIDVAQVYMDSWWPRCST

LAWLRFIWTAGGPDAPHWLRS

GLGGQLVAWMLHVGVAQVYV

DSWWPSCSASMWLSFMEHKQ

CLTLGYEVALFLQHFLSRAFVL

VWVPRKEKAQVLRQGLSLTFR

ENPGVCVMSSYRPWLITAAAD

MQPSKPGGTGSYCSYWSPTDN

TPRLAAACTWNLGSSHGSAPG

VRTFIEAGFSPPFLAPKALALTL

SDSDSRWGPNPVYAQPQP/PEP

AWGPNPV*GQPQPRNRPGVPEP

CVCSTPTAEPPWGPNPVSTPTA

EPAWGPNPVYA/PTPTAEPPWG

PNPV*GQPQP/REPAWGPNPVY

GQPQPRNRPGSVPPQGNLYCSA

ALGATDPSQSWHQCSQNLLPA

DKGAKREAPW/PRPPSGEVDHQ

VWHLHGWPLPTTAPPLLQGVW

RVEQTPASHHRQPRPRQSSPST

KAPPVITVNQGPASHHRQPRPR

QSSPSTKAPPVITVNQGPASHH

RQPRPRQSSPST/TGPASHHRQP

RPRQSSPSTKAPPVITVNQGPAS

HHRQPRPRQSSPSTKAPPVITVN

QGPASHHRQPRPRQSSPSTKAP

PVITVNQGPASHHRQPRPRQSSP

STKAPPVITVNQGPASHHRQPR

PRQSSTLTKAPPVITVNQSPASH

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21920 52288 22048 357 1579 QRRPRPFPSQGISMTECFLPPTSS

PSEHRRVEHGSGLTRTPSSEEIS

PTKFPGLYRTGEPSPPHDILHEP

S*SNGLMDEKDHGKKKGNFKK

KEKRTEGYAAFQEDSSGDEAE

KLMPRFEEAYGRTTETEKVQEF

QRLLKELPEGNYLLISLFWHM

DHVITKELEAKMNIQNIYIWSP

TVQISNLVLYVFFTHVQELFGN

WLKQVTKTRRWSNVATMPTL

PETQAGFKEEIRIQELLLNCLHQ

DLQGGIKDLSEEERLWEEKEIL

TKQEELLGMEQFLRRQIASEKE

EIECLRAETAEIQSHQQQGLSET

EEYSSESESEDEEELQIILEDLQR

QNEELEIKNNHLNQAIHEESEA

VIEPRMQPWLLQLQPDRAKQQ

AQEDEEPEWRGGAMQTPKNGI

21921 52289 22049 182 2212 VTEKTSSLPSQGISMTECFLPPT

SSPSEHRRVVEHG/SAGLTPGPPA

SEEIQPLPKFPGLYVRTGEPPHPP

P*HPSHEPSLM*CPDDEKDHGK

KKGKFKKKEKRTEGYAAFQED

SSGDEAESPSKMKRVSKGIHVFK

KPSFSKKVREKDFKIKEKPKEEK

HKΕEKHKEEKHKEKKSKDLTVA

ADVVKQWKEKXKXKKPIQEPE

VPQIDVPNLKPIFGIPLADAVER

TMMYDGIRLPAVFRECIDYVEK

YGMKCEGIYRVSGIKSKVDELK

AAYDREESTNLEDYEPNTVASL

LKQYLRDLPENLLTKELMPRFE

EACGRTTETEKVQEFQRLLKEL

PECNYLLISWLIVHMDHVIAKE

LETKMNIQNISIVLSPTVQISNR

VLYVFFTHVQELFGNWLKQV

MKPLRWSNMATMPTLPETQAG

IKEEIRRQEFLLNCLHRDLQGGI

KDLSKEERLWEVQRILTALKRK

LREAKRQECETKIAQEIASLSKE

DVSKEEMNENEEVIN1LLAQEN

EILTEQEELLAMEQFLRRQIASE

KEEIERLRAEIAEIQSRQQHGRS

ETEEYSSESESESEDEEELQIILE

DLQRQNEELEIKNNHLNQAIHE

EREAIIELRVQLRLLQMQRAKA

EQQAQEDEEPEWRGGAVQPPR

DGVLEPKAAKEQPKAGKEPAK

21922 52290 B 22050 34 322

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21954 52322 22082 233 2096 RREDEGNKTSWIHPSPWWLIF

RFFSLFFFKQPLFTMNKLYIGNL

SENAAPSVDLVKSIFKDAKIPVSG

PFLVKTGYAFVDCPVDESWAVLR

AIKAFSGKIELHGKPIEVEHSVP

KRQRIRKLQIRNIPPHLQWEVL

DSLLVQYGVVESCEQVNTDSET

AWNVTYSSKDQARQALDK/L

LDKLNGFQLENFTLKVAYIPDE

MATQQNPFLQPRGRRGLGQRG

SVSRQGSPGSVSKQKPCDSPLRL

LVPTQFVGAIIGKEGATIRNITK

QTQSKIDVHRKENAGAAEKSIT

I PSTPEGTSA ACKSILEIMHKEA

QDIKFTEEIPLKILAFTNNFVGRLI

GKEGRNLKKIEQDTDTKITISPL

QELTLYNPERTITVKGNVETCA

KAEEEIMKKIRESYENDIASMN

LQAHLIPGLNLNALGLFPPTSG

MPPPTSGPPSAMTPPSPQSEQSE

SETVHLFIPALSVRALISKQGQH

IKQLSRFAGASSKIAPVEAPDAK

VRMVMIAGSPEARFKAQGRIY

GKIKEENFVSPKEEVKLEAHIR

VPSFAAGRVIGKGGKTWNELQ

NLSSAEVWPRDQTPDENDQV

WKITGHFYACQVVAQRKI*EFL

TQVRQHQQQKALQSGPPQSRR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmiπo acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possib!e nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21968 52336 22096 20 2482 RVCSSSASTASQAVMADAWEE

IRRLAADFQRAQFAEATQRLSE

RNCIEIVNRL1AQKQLEWHTL

DGKEYITPAQISKEMRDELHVR

GGRVNIVDLQQVINVDLIHIEN

RIGDIIKSEKHVQLVLGQLVIDEN

YLVDRVGQEVNDKLQESGQVTI

SELCKTYDLPGNFLTQALTQRL

AIIIIGHIDLDNRG V I FTEAFVAR

HRARIRGLFSAITRPTAVNSLIS

KYGFQEQLLYSVLDELVNSGRL

RGTWGGRQDKAVFVPDIYSR

TQSTWVDSFFRQNGYLEFDALS

RLGIPDAVSYIKKRYKTTQLLFL

KAACVGQGLVDQVEASVEEAI

SSGTWVDIAPLLPTSLSVEDAAI

LLQQVMRAFSKQASTWFSDT

VWSEKFVINDCTELFRELMHQ

KAEKEMKNNPVHLITEEDLKQI

STLESVSTSKKDKKDERRRKAT

EGSGSMRGGGGGNAREYKIKK

VKKKG RKDDDSDDESQSSHTG

KKKPEISFMFQDEIEDFLRKHIQ

DAPEEFISELAEYLIKPLNKTYL

EWRSVFMSSTTSASGTGRKRT

IKDLQEVEVSNLYNNIRLFGKRG

WKFFVADDTQGWLLPKHLLEV

QCVLISLNLIVFNFVLGFGILMDG

Q*DDPGRPFTSVELRKEIVLSKLS

EETKVALTKLHNSLNEKSIEDFI

FCVLDSAAEACDIMVKRGDKKR

ERQILFQHRQALAEQLKVTEDP

21969 52337 22097 711 VLSLFDGIATGYLVLKELGIKV

GKYVASEVCEESIAVGTVKHEG

NIKYVNDVRNITKKNIEEWGPF

DLVIGGSPCNDLSNVNPARKGL

YEGTGRLFFEFYHLLNYSRPKE

GDDRPFFWMFENWAMKVGD

KRDISRFLECNPVMIDAIKVSAA

HRARYFWGNLPGMNRPVIASK

NDKLELQDCLEYNRIAVRIFGFP

VHYTDVSNMGRGARQKLLGRS

WSVPVIRHLFAPLKDYFAC SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

21970 52338 22098 406 2885 GRGILVNGACSDQSSDSPPILEA

IRTPEIRGGWAVGTGWSGADI

VSGHCRQWSLLSLFQGSGTLSL

AFITWAFRETRTRSESPAVSSHT

SSQSTCGQHST*HT*HARGRQG

RNHVDESPVEFPATRVGSPDAQ

TPARSL*LGDMPHSLTIDLTDDT

EDTHGTPQSSSTPYARLAQDSQ

QGGMESPQVEADSGDGDSSEY

QVDGREGLLPRV/I*GP*TRGKTS

YAMWSWKATSKRQAMSGMR

WVQWFGDGKFSEVSPGKGKGF

CRPEAVPACLPLNKLVSYRKA

MYHALEVTWDEGMRAKP*EQ

G*SKRPTELEDQLKPMLEWAH

GGFKPTGIEGLKPNNTQPGGNE

SPWQHPLPLLVGPLLGRVRLKT

NCYNNGKDRGDEDQSRGDCW

VPGIMGQMGGGRCRSGIDVIPL

TPWLGL*ACLVCQTCRVSPPTT

ALDLPPLASSΝSPLLPCEGRELL

LCSΝTSCCR*ALGPVGWMWVG

PQGSYVPAV*EPWSCYMCLPQ

RCHGVLRRRKDWNVRLQAFFT

SDTGLEYVSHRLPPLPPQIPGAQ

GVGKLWFDGIATGEFGEHLETL

LSCHNRVARESEESIAVGTVKH

EGNIKYVNDVRNITKKNVRAV

CTLRASSLPVFFPSPPHPNPARK

GLYGEHPSLWQSLESLCHLTTG

PGAGNK/RGLGWRFQMNPALS

SFLSTVGVQRDISRFLEVRESGD

21971 52339 22099 729 896

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Uπkno>vn, NO: of peptide hod n USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22078 52446 22206 1894 QSLADLLQSQPSITLTSQIWPSP

A*GFWSWGNLSVTTPSKVPATP

TRTIAATPIQTLPQSQTAPKRID

TPSLEEPSDLEELEQFAKTFKQR

RIILGFTVQGDAGLAMVKLYGN

DFSPTTIFRFEALNLSFKNMCKL

KPLLEKWLNDAENLSSDSSLSS

PSALNSPGIEGLSRRRKKRTSIE

TNIRVALEKSFLENQKPTSEEIT

MIADQLNMEKEVIRVWFCNRR

QKEKRINPPSSGGTSSSPIKAIFP

SPTSLVATTPSLVTSSAATTLTV

SPVLPLTSAAVTNLSVTASTSEA

SSASETSTTQTTSTPLSSPLGTSQ

VMVTASGLQTAAAAALQGAA

QLPANASLAAMAAAAGLNPSL

MAPSQFAAGGALLSLNPGTLSG

ALSPALMSNSTLATIQALASGG

SLPITSLDATGNLVFANAGGAP

NIVTAPLFLNPQNLSLLTSNPPG

GFTIEISNNNSTMVMTGMRIQIG

TQAIERAPSYIEIFGRTMQLNLS

RSRWFDFPFTREEALQADKKLN

LFTVRKFQNIRHTLFKCENKNT

FQQCLLLEQDSSCGTGFCSMTT

YPVMLLSSEQPVQSLSVRQCVI

LLDAAAVISGGMGAVCLLLTH

LCPLCYAGLLSEITDPESFVKDL

LYSVP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22092 52460 22220 1908 MKY IQDFQREKQEFERNLARFR

EDHPDLIQNAKKSDIPEKPKTPQ

QLWYTHEKKVYLKVRPDATTK

EVKDSLGKQWSQLSDKKRLK

WIHKALEQRKEYEEIMRDYIQK

HPELNISEEGITKSTLTKAERQL

KDKFDGRPTKPPPNSYSLYCAE

LMANMKDVPSTERMVLCSQQ

WKLLSQKEKDAYHKKCDQKK

KDYEVELLRFLESLPEEEQQRV

LGEEKMLNINKKQATSPASKKP

AQEGGKGGSEKPKRPVSAMFIF

SEEKRRQLQEERPELSESELTRL

LARMWNDLSEKKKAKYKARE

AALKAQSERKPGGEREERGKLP

ESPKRAEEIWQQSVIGDYLARF

KNDRVKALKAM EMTWNNME

KKEKLMWIKKAAEDQKRYERE

LSEMRAPPAATNSSKKMKFQG

EPKKPPMNGYQKFSQELLSNGE

LNHLPLKERMVEIGSRWQRISQ

SQKEHYKKLAEEQQKQYKVHL

DLWVKSLSPQDRAAYKEYISN

KRKSMTKLRGPNPKSSRTTLQS

KSESEEDDEEDEDDEDEDEEEE

DDENGDSSEDGGDSSESSSEDE

SEDGD/EGGADRAQWEGRGVL

PGGPPGDSTSFLTPQNEEDDED

EDDDEDDDEDEDNESEGSSSSS

SSSGDSSDSDSN

22093 52461 22221 129 2365

22094 52462 22222 2730 PSLRFAISGFVWRLAAPASAAA

ELRLDCSARRAPRCPRPALPSTR

SAEGAVLCAFRREEQQAAATA

AAAAAAATAAAAAAPAPPPRP

EEEPLPPREGAAAVPGRAGEGA

ATQSQGGSRWSGKPGGRAAPA

RPRRWLDSWRMNGEADCPTDL

EMAAPKGQDRWSQEDMLTLLE

CMKNNLPSNDSSKFKTTESHM

DWEKVAFKDFSGDMCKLKWV

EISNEVRKFRTLTELILDAQV*HF

KNPYKGVKKLKKHPDFPK

22095 52463 22223 446 RPSPPTSSM/PGLWGYSRPCSSG

VPASALQA*SPAFSPASQRPPTT

SWWEVP*EEGRAVPVWEGRIRA

VGPAPAS*PSDLPAWSCRSWR£

TRGVSPAEDAMLLRAVEPLEGC

QRPLLDSEPP/SPARTSAPAASA

SPPAPGGPPCLARPLPR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkπown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22105 52473 22233 2027 EESDCLTEYEEDAGPDCSRDEG

GSPEGASPSTASEMDVSLHFVL

WGCLHVYQRMIDKAEDVCLFV

AQPGELVGQLAVLTGEPLIFTL

RAQRDCTFLRISKSDFYEYDSP

KLECGWHSEDPNPWTSPSTGL

NPLFLELCRHMVFQRLGQGDY

VFRPGQPDASIYWQDGLLELC

LPGPDGKECVVKEWPGDSVN

SLLSILDVITGHQHPQRTVSARA

ARDSTVLRLPVEAFSAVFTKSA

RTITGCVWRYVRASASYCPYLP

PLCDPKDGHLLVDGCYVNNVP

GSLWRYVRASMTVRRATCPRCA

TPRTGTYSWMAATSTICQASGR

PHHPHTQAPPAPHTRTRRTSPA

AWVPKRSSPLTWGARMRRTSA

PTGTACPAGGCCGSG*IPGLTR*

RFQTWLKSSPAWPTCPVCGS*R

LSSPAPTASTCARPSTASRPWTL

GSSTRSILRTTRRMSTAVTTTAT

PAPIITPST*GTNGTGCAPQIRPA

EPSPGARTSWNPSLSATFAPEEF

VASP*LDVPICRMGQCCSLPGG

ATLP*GPCGPQCMPGNWPPER

TAARYRQTTAYQTPACPTPPRG

QRPT/CVPTVSSLQAGLQGGPRS

DFDMAYERGRISVSLQEEASGG

SLAAPAREPREQPAGACEYSYC

EDESATGGCPFGPYQGRQTSSIF

EAAKQELAKLMRIE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

221 i : 52481 22241 2232 MQDTEKDDNNNDEYDNYDEL

VAKSLLNLGKIAEDAAYRARTE

SEMNSNTSNSLEDDSDKNENLG

RKSELSLDLDSDWRETVDSLK

LLAQGHGWLSENMNDRNYA

DSMSQQDSRNMNYVMLGKPM

NNGLMEKMVEESDEEVCLSSL

ECLRNQCFDLARKLSETNPQER

NPQQNMNIRQHVRPEEDFPGRT

PDRΝYSDMLΝLMRLEEQLSPRS

RVFASCAKEDGCHERDDDTTS

VΝSDRSEEVFDMTKGΝLTLLE

KAIALETERAKAMREKMAMEA

GRRDΝMRSYEDQSPRQLPGED

RKPKSSDSHVKKPYYGKDPSRT

EKKESKCPTPGCDGTGHVTGL

YPHHRSLSGCPHKDRVPPEILA

MHESVLKCPTPGCTGRGHVΝS

NRNSHRRDIQVFNLQKQEMIDR

LESLSGCPIAAAEKLAKAQEKH

QSCDVSKSSQASDRVLRPMCFV

KQLEIPQYGYRNNVPTTTPRSN

LAKELEKYSKTSFEYNSYDNHT

YGKRAIAPKVQTRDISPKGYDD

ANGYCKDPSPSSSSTSSYAPSSS

SNLSCGGGSSASSTCSKSSFDYT

HDMEAAHMAATAILNLSTRCR

EMPQNLSTKPQDLCATRNPDM

EVDENGTLDLSMNKQRPRDSC

CPILTPLEPMSPQQQAVMNNRC

FQLGEGDCWDLPVDYTKMKPR

VRIDEDESKDITPEDLDPFQEALE

22114 52482 22242 727 4372 LWACVLPGVTLPPFLGEKTSCK

MEVDTEEKRHRTRSKGVRVPV

EPAIQELFSCPTPGCDGSGHVSG

KYARHRSVYGCPLAKKRKTQD

KQPQEPAPKRKPFAVKADSSSV

DECDDSDGTEDMDEKEEDEGE

EYSEDNDEPGDEDEEDEEGDRE

EEEEIEEEDEDDDEDGEDVEDE

EEEEEEEEEEEEEEENEDHQMN

CHNTRIMQDTDVLDDNNNDEY

DNYDELVAKSLLNLGKIAEDA

AYRARTESEMNSNTSNS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22150 52518 22278 1871 MEDNLISINKIKILLAVSDGEIDE

TFSLKQLMFNSVPVQNEDGSFN

FEGVKAEFRPGTQTQEYIKGME

DSSSEVTVNREVTTDNPYTISVT

NKTLSAIRIKMFMPRVAYELKVT

VIKMAFELSTRCSKRLM/DGSFE

TVLTDVIEGKTMSGYDRSRRV

NLPNFNNQVIFRWRKTPDSND

SNWDAIQVRSYAEVIDAKFRY

PLTGLLFVEFDSKMFPNQLPTISV

IRKRWKIVNVPSNYDPESRTYN

GNWDGTFKKAWTNNPAWVLY

DLMINQRYGLDQKELGISVDK

WALYEAAQYCDQMWLTAKA

ARNLATFVT/CIIQSQTDAYKW

VRDICSIFRGMSFWNGESISVIID

RPREPAYIFTNDNWNGDFSYTV

SQ ARRACTRRAT* CLMMSKTCI

NRTLSQYSI/V/EGHSTVRVNNVT

SITAIGVAHVEARPTDCGRWILK

TNLRSTTVNFATGLEGMIPTIGD

WAISDNFWSSNLTMNLSGRLQ

EVSGSQIFLPFRVDARAGDFNIV

NKPDAKPVKRTISSVSADGKTI

EINIGFGFPVKPNTVFAIDRTDL

ALQQYWTKIDKGDDDEEFTVS

KSRRWSTILISTMKLITGLTSTT

DRQASLSQIR/CPKPENVKVCPQS

RESSRG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22151 52519 22279 5307 5305 CRSSQNTQETSPDRALLVNLRP

SQGPLLALWVPAEGVGGKGHC

LPPRSFFRMDNQLVPAVSDGEI

DETFSLKQLMFNSVPVQNEDGS

FN FEG VKAEFRPGTQTQEYIKG

MEDSSSEVTVNREVTTDNPYTI

SVTNKTLSAIRIKMFMPRVAYEL

KVTVIKMAFELSTRCSKRLM/D

GSFETVLTDVIEGKTMSGYDRS

RRVNLPNFNNQVIFRWRKTPD

SNDSNWDAIQVRSYAEVIDAK

FRYPLTGLLFVEFDSKMFPNQL

PTI SI RKRWKI VN VPSNYDPESR

TYNGNWDGTFKKAWTNNPAW

VLYDLMINQRYGLDQKELGISV

DKWALYEAAQYCDQMWLTA

KAARNLATFVT/CIIQSQTDAYK

WRDICSIFRGMSFWNGESISVII

DRPREPAYIFTNDNWNGDFSY

TVSQARRACTRRAT*CLMMSKT

CINRTLSQYSI/V/EGHSTVRVNN

VTSITAIGVAHVEA/KANRRGRW

ILKTNLRSTTVNFATGLEGMIPT

IGDWAISDNFWSSNLTMNLSG

RLLEVSGSQIFLPFRVDARAGD

FIIVNKPDGKPVKRTISSVSADG

KTIEINIGFGFPVKPNTVFAIDRT

DLALQQYWTKIDKGDDDEEF

TVSKSRRWSTILISTMKLITGLTS

TTDRQASLSQIR/CPKPENVKVCP

QSRESSRG

22152 52520 22280 412 PAAVA*VKTEPETPGPSCLSQE

GQTAVVKTEESSELGNYVIKIDH

LETIQQLLTAWKKIPLITAKVW

QRAMTMRKVLQEILEKNPRFH

HLTPLKTKHIAHWCRCHGYTPP

DPESLRNDGDSIEDVLTQIDSEP

22153 52521 22281 513 IFACWGKQAWPACCNSLRGQA

VKGNQLLPVSLVKRKTTLAPNT

QTASPRALADSLMQLARQVSR

LE/QRAKREPENEEEVDILSLSE

PVKINIKKEQEEKQEEVKFYLPP

TPGSEFIGDVTQKRLEEVDSTFG

DDLVQGFSGGISRRYGEKPGVQ

DLEVEPDSVTEMLQFYD

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22205 52573 22333 8875 EDGSLLQEVGIICLARGPGCGPE

TPLYSPATGLALQLQGPAAMG

ALWSWWILWAGATLLWVGKSG

EDWISGPTTVFSQPGLTQEASV

DLKNTGREEFLTAFLQNYQLA

YSKAYPRLLISSLSESPASVSILS

QADNTSKKVTVRPGESVMVNI

SAKAEMIGSKIFQHAWIHSDY

AISVQALNAKPDTAELTLLRPIQ

ALGTEYFVLTPPGTSARNVKEF

AWAGAAGASVSVTLKGSVTF

NGKFYPAGDVLRVT

22206 52574 22334 2214 ISATDGPLAPCHGLVPPAQYFQ

GCLLDACQVQGHPGGLCPAVA

TYVAACQAAGAQLGEWRRPDF

CPLQCPAHSHYELCGDSCPVSC

PSLSAPEGCESACREGCVCDAG

FVLSGDTCVPVGQCGCLHDGR

YYPLGEVFYPGPECERRCECGP

GGHVTCQEGAACGPHEECRLE

DGVQACHATGCGRCLANGGIH

YITLDGRVYDLHGSCSYVLAQ

VCHPKPGDEDFSIVLEKNAAGD

LQRLLVTVAGQWSLAQGQQV

TVDGEAVALPVAVGRVRVTAE

GRNMVLQTTKGLRLLFDGDAH

LLMSIPSPFRGRLCGLCGNFNG

NWSDDFVLPNGSAASSVETFG

AAWRAPGSSKGCGEGCGPQGC

PVCLAEETAPYESNEACGQLRN

PQGPFATCQAVLSPSEYFRQCV

YDLCAQKGDKAFLCRSLAAYT

AACQAAGVAVKPWRTDSFCPL

HCPAHSHYSICTRTCQGSCAAL

SGLTGCTTRCFEGCECDDRFLL

SQGVCIPVQDCGCTHNGRYLPV

NSSLLTSDCSERCSCSSSSGLTC

QVAAGCPVPGVRVCEVKAEARVN

CWVATRGLVCVLSVGVANLVTTF

DGARGATTSPGVYELSSRCPGL

QNTI P WYRV VAEVQICHGKTE

AVGQVHIFFQDGMVTLTPNKG

VWVNGLRVDLPAEKLASVSVS

RTPDGSLLVRQKAGVQVWLGA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22269 52637 22397 2382 QTEMTIEGLQPTVEYVVSVYAQ

NPSGESQPLVQTAVTNIDRPKG

LAFTDVDVDSIKIAWESPQGQV

SRYRVTYSSPEDGIHELFPAPDG

EEDTAELQGLRPGSEYTVSWA

LHDDMESQPLIGTQSTAIPAPTD

LKFTQVTPTSLSAQWTPPNVQL

TGYRVRVTPKEKTGPMKEFNLA

PDSSSVWSGLMVATKYEVSV

YALKDTLTSRPAQGWTTLEN

VSPPRRARVTDATETTITISWRT

KTETITGFQVDAVPANGQTPIQ

RTIKPDVRSYTITGLQPGTDYKI

YLYTLNDNARSSPWIDASTAI

DAPSNLRFLATTPNSLLVSWQP

PRARITGYIIKYEKPGSPPREW

PRPRPGVTEATITGLEPGTEYTI

YVIALKNNQKSEPLIGRKKTDE

LPQLVTLPHPNLHGPEILDVPST

VQKTPFVTHPGYDTGNGIQLPG

TSGQQPSVGQQMIFEEHGFRRT

TPPTTATPIRHRPRPYPPNVGEEI

QIGHIPREDVDYHLYPHGPGLN

PNASTGQEALSQTTISWAPFQD

TSEYIISCHPVGTDEEPLQFRVP

GTSVTSATLTGLTRGATYNIIVE

ALKDQQRHKVREEWTVGNSV

NEGLNQPTDDSCFDPYTVSHYA

VGDEWERMSESGFKLLCQCLG

FGSGHFRCDSSRWCHDNGVNY

KIGEKWDRQGENGQMMSCTCL

GNGKGEFKCDPHEATCYDDGK

22270 52638 22398 48 7500 GATMACCAAQGEERVTPCASG

KRGPAATTSLVLWIPSVPPPVPF

PTLWPPPSWRRQPPGGIRRDFS

RRLRREANLVATCLPVRASLPH

RLNMLKGPGPGLLLLAVLCLG

TAVPSTGASKSKRQAQQMVQP

QSPVAVSQSKPGCYDNGKHYQ

INQQWERTYLGNVLVCTCYGG

SRGFNCESKPEAEETCFDKYTG

NTYRVGDTYERPKDSMIWDCT

CIGAGRGRISCTIANRCHEGGQS

YKIGDTWRRPH ETGG YM

22271 52639 22399 403 NSTNKRRGFCFITFKEVEMEKKY

HΝVGLSKCEIKVAMSKEQYQQ

QQQWGSRGGFAGRARGRGGG

PSQΝWΝQGYSΝYWΝQGYGΝY

GYΝSQGYGGYGGYDYTGYNΝ

YYGYGDYSΝQQSGYGKVSRRG

GHQΝSYKPY

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Uπknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22372 52740 22500 90 2166 SQHFGRLRRVDYLRTSKMQTSS

SRSVHLSEWQKNYFAITSGICT

GPKADAYRAQILRIQYAWANS

EISQVCATKLFKKYAEKYSAIID

SDNVESGLNNYAENILTLAGSQ

QTDSDKWQSGLSINNVFKMSS

VQKMMQAGKKFKDSLLEPALA

SWIHKEATVFDLPKFSVCGSS

QESDSLPNSAHDRDRTQDFPES

NRLKLLQNAQPPMVTOTARTC

PTFSAPVGESATAKFHVTPLFG

NVKKENHSSAKENIGLNVFLSN

QSCFPAACENPQRKSFYGSGTI

DALSNPILNKACSKTEDNGPKE

DSSLPTFKTA EQLWVDQQKK

YHQPQRASGSSYGGVKKSLGA

SRSRGILGKFVPPIPKQDGGEQN

GGMQCKPYGAGPTEPAHPVDE

RLKNLEPKMIELIMNEIMDHGP

PVNWEDIAGVEFAKATIKEIW

WPMLRPDIFTGLRGPPKGILLFG

PPGTGKTLIGKCIASQSGATFFSI

SASSLTSKWVGEGEKMVRALF

AVARCQQPAVIFIDEIDSLLSQR

GDGEHESSRRIKTEFLVQLDGA

TTSSEDRILVVGATNRPQEIDEA

ARRRLVKRLYIPLPEASARKQI

VINLMSKEQCCLSEEEIEQIVQQ

SDAFSGADMTQLCREASLGPIS

AV/SQTADIATITPDQVRPIAYID

FENAFITVRPIVSPKDL*LYENW

22373 52741 22501 523 FFFFFPAFKMSKRGVRGWVPSG

CRKFPDFPLGLPVVGTL*SNWCL

TNTVGAQKTLYIVISREGGIKGTG

LTRLPRLPGVGVDMVMAHSSRK

ANPELQKKGYIPAVWIRQRKVI

TVGKRWRCFFIFEDVNAGVIGDV

NKGVEMKGFAITGVPRAKECAD

LWPRDCIQMLGSIAWFSQYIL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22397 52765 22525 474 2527 SASPLGPYLLPSGAPERGSPGKE

HPEERWTAPPSSSQSAEVLGE

LVLDGTAPSAHHDIPALSPLLPE

EARPKHALPPKKKLPSLKQVNS

ARKQLRPKATSAATVQRAGSQ

PASQGLDLLSSSTEKPGPPGDPD

PIVASEEASEVPLWLDRKESAV

PTTPAPLQISPFTSQPYVAHTLP

QRPEPGEPGPDMAQEAPQEDTS

PMALMDKGENELTGSASEESQ

ETTTSTIITTTVITTEQAPGMQPP

TPMGEGPPIVKHTWILDKCNVA

TLQST*ALGPNEGYIDSSDYPLL

PLNNFLECTYNVTVYTGYGVE

LQVTPGEYPDGELLSIRGVDGP

TLTVLANQTLL V EGQVIRSPTN

TISVYFRTFQDDGLGTFQLHYQ

GRVRPRLFPRRPDSGDVTVMDL

HSGGVAHFHCHLGYELQGAK

MLTCINASKPHWSSQEPICSGM

LQPQPHNATIGRVLSPSYPENT

NGSQFCIWTIEAPEGQKLHLHF

ERLLLHDKDR*SSEGPQTNKSA

LLYDSLQTESVPFEGLLSEGNTI

RIEFTSDQARAASTFNIRFEGEG

PWELYEPYIQNGNFTTSDPTYNI

GTIVEFTCDPGHSLEQGPAIIECI

NVRDPYWNDTEPLCRGERIHN

ASAVAGVVLSPNWPEPYVEGE

DCIWKIHVGEEKRIFLDIQ/FVS

V*NGSVFSQEKVRPTPEWW

22398 52766 22526 131 3125 LVSFLLFQDALPEGDASPLGPY

LLPSGAPERGSPGKEHPEERW

TAPPSSSQSAEVLGELVLDGTA

PSAHHDIPALSPLLPEEARPKHA

LPPKKKLPSLKQVNSARKQLRP

KATSAATVQRAGSQPASQGLD

LLSSSTEKPGPPGDPDPIVASEE

ASEVPLWLDRKESAVPTTPAPL

QISPFTSQPYVAHTLPQRPEPGE

PGPDMAQEAPQEDTSPMALMD

KGENELTGSASEESQETTTSTIIT

TTVITTEQAP

22399 52767 22527 161 352

22400 52768 22528 368 LGSTHASVRINILSVDVLYFIFY

RRDDNKDIDSEKEAAMEAEIKA

ARERAIVPLEARMKQFKDMLL

ERGVRKQSLGEIFLFCISNINMS

C*KVKSKVSAFSTWEKELHKIV

FDPRYLLLNLI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22502 52870 22630 276 1905 LFLYSSHGQYGCPSCSATDGW

RNGKSTAGHQRYLCSHCRKTW

QLQFTYTASQPAGQ*RTAIATVI

CCNNCQRRHTNSRCHTDNCRR

ADSASSHATSGSSSRGCAGSGR

CGASSTRRCLGPVCCFRGSKRS

WRRQHEGHKDCRKLVFFTNFSFI

HRMDNTAVPPVQLLTGWCVTA

KAPPDISAISALTAVKHGNCSSL

TPLLNPPG SDVI VC AEMDEQ W

GYVGAKSRQRWLFYAYDSLRK

TWAHVFGERTMATLGRLMSL

LSPFDWIWMTDGWPLYESRL

KGKLHVISKRYTQRIERHNLNL

RQHLARLGRKSLSFSKSVELHD

KQQGLDAALIDAPLAVDAQTP

LSELLSHVGQAPCAVPWDED

QQYVGIISKGMLLRALDREGGV

RVPVIYPKRFRTTDVCMPLSLG

TCIREIEAEFPDPIFRRSWYICE

FINTNGAMGIIVNKPLENLKIEGI

LEKLKITPEPRDESIRLDKPVML

GGPLAEDRGFILHTPASNFASSI

RISDNTVMTTSRDVLETLGTDK

QPSDVLVALGYASWEKGQLEQ

EILDNAWLTAPADLNILFKTPIA

DRWREAAKLIGVDILTMPAQD

GTPDWNIIERLLKEWQPDEIIVG

LPLNMDGTEQPLTARARKFAN

RIHGRFGVEVKLHDERLSTVEA

RSGLFEQGGYRALNKGKVDSA

SAVIILESYFEQGY

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possib!e nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22503 52871 22631 399 2337 PEVQGLQQAGAAARRPGVGLA

APRWCEGRLRGSGLQSRLCPG

ASV*ATDGVVRNGKSTAGHQR

YLCSHCRKTWQLQFTYTASQP

AGQ*REKEEKEEVEEEEEEEKK

KRRREGEKEEKEEKEKEKKKK

F KKKKXKKKKKKKKd<-KKKK

KKKKKKKQLSLVTVMSQQCQL

WRNEARTTGACLPSPTVSAAAP

PIVSTTVTAFAAATLAKGDLRS

RASSKQVPLLWLVWVWPHPG

WFVKAGSVALGSSPGCVLELL

CKLLTGWCVTAKAPPDISAISA

LTAVKHGNCSSLTPLLNPPGSD

VIVCAEMDEQWGYVGAKSRQ

RWLFYAYDSLRKTWAHVFGE

RTM ATLG RLMSLLSPFDWI W

MTDGWPLYESRLKGKLHTQER

KARSKQQKDADTAPPIQVGTQ

TPQTVHAARDTRQASPRASKIS

QHRQADGDKRQTRH A E AQAT

RTHTGRRKTIKETATQQAYADE

QTRRTARTHRRTARHTAAHTH

RTRVAARQTTEKDNEQSDTQPP

TQKTPSATATAHTPRRTETTTNI

VQARHTSARERNHTRQHQATR

RETTTNAHTNTPHYHAEHTQSR

SQQQTTSTERPTTDSSTTINNNN

HTPRTVRDERRMTQHKHPSRA

STTTNRTTTTGAYQHTQRDTRD

TRRDTHEDTTTQQPHTTTPTAN

EAAYTAHTTKTDDHRHTADDT

22504 52872 22632 103 313 ATAGCPSCSATEGWRNGKST AGHQRYLCSPCRKTWQLQFTY TASQP/GARIMGVGLNTVLRHL KNSGRSR

22505 52873 A 22633 620 832

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

22512 52880 22640 747 MIIIDPRYTDTGAGREDEWIPIR

PGTDAALVNGLAYVMITENLV

DQAFLDKYCVGYDEKTLPASA

PKNGHYKAYILATD/GWRTAK

STAGHQRYLCSHCRKTWQLQF

TYTASQPAGQ* R YTDTGAGRE

DEWIPIRPGTDAALVNGLAYV

MITENLVDQAFLDKYCVGYDE

KTLPASAPKNGHYKAYILATDG

WCVPPKAPPDISAISALTAVKH

GNCSSLTPLLNPPGSDVIVCAE

MDEQWGYVGAKSRQRWLFYA

YDSLRKTWAHVFGERTMATL

GRLMSLLSPFDWIWMTDGWP

LYESRLKGKLHVISKRYTQRIE

RHNLNLRQHLARLGRKSLSFSK

SVELHDKVIGHYLNIKHYQ

22513 52881 22641 1722 2463 NPRLAGSEGSCPSCSATDGWR

NGKSTAGHQRYLCSHCRKTWQ

LQFTYTASQPAGQ*RKLTPGCL

FVALKGERFDAHDFADQAKAG

GAGALLVSRPLDIDLPQLIVKD

TRLAFGELAAWVRQQVPARW

ALTGSSGKTSVKEMTAAILSQC

GNTLYTAGNLNNDIGVPMTLL

RLTPEYDYAVIELGANHQGEIA

WTVTHPPRFVTKQWLCFLPDG

LLLFAEARFVIWQMQPAVMAV

DVAAFAHLFNQQQYQRFTGRP

PDSSKLPWKITCNGECVTFHW

WLLGVAVRISRLLPVRVMTAL

EGNYNGTEGISALPFNGIILAHS

NESEWVTFRNNKNNEAFLDRV

YIVKVPYCLRISEEIKIYEKLLN

HIFECWQHFLNNPESLQCYIWA

ANADFREARQVIFKTFFTVGVE

EELGIRQTRTODFLVTGDNLLRI

FRFDVGNEDKVRQQFAWRIH

REVFLVTFHGVNQRFSRHREEF

LFEFCVSVTANLTRCFFGIGFNL

RLTFFVIGDDFPTLTQNFRILIGV

IDGEFRLAHKAVAANHAIGLNA

QNGCRNDFVAHAAGSRALAAD

GRSLEHAPTVETWAGPLCESG

DVFTQQEGGNVETRALPEVKA

AVPPVQLLTGWCVTAKALPDIS

AISALTAVKHGNCSSLTPLLNPP

GSDVIVCAEMDEQWGYVGAKS

RQRWLFYAYDRLRKTWAHRL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22517 52885 22645 1479 1793 TRY RSCPSCS ATDG V V RNGKST

AGHQRYLCSHCRKTWQLQFTY

TASQPAGQ*RRNACQYRTPAV

VASRQKRWHGDLGMIGSRDV

MLFISDSVGAKELDLIIPRLEDK

SIALLAMTGKPTSPLGLAAKAV

LDISVEREACPMHLAPTSSTVN

TLMMGDALAMAVMQARGFNE

EDFARSHPAGALGARLLNKVH

HLMRRDDAIPQVALTASVMDA

MLELSRTGLGLVAVCDAQQQV

QGVFTDGDLRRWLVGGGALTT

PVNEAMTVGGTTLQSQSRAIDA

KEILMKRKITAAPWDENGKLT

GAIKLQDFYQGRGLFNPSIPRVS

TADAGLANRARRNWVGSSWK

QVGQIILQGGPQNAEKSGQRYT

VSHDRHRDAERQRVKSGLPRY

AECSTYPSCPVALDLAFASHGI

HMHAPGEALRMLVTAMDKAA

DARTKLARLLATKGITHEIQIPD

ISTKEKAQQPIGLNMEQIKPEKQ

DFIKPVIPQAGKHNGVNMSVLR

SLLTAGVLASGLLWSLNGITAT

PAAQASDDRYEVTQQRNPDAA

CLDCHKPDTEAVPPVQLLTGW

CVTAKAPPDISAISALTAVKHG

NCSSLTPLLNPPGSDVIVCAELD

EQWGYVGAKSRQRWLFYAYA

QSPRTTRCCARIRLHALWRRW

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vπ, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possib!e nucleotide insertion) sequence

22551 52919 A 22679 2210 MEQKGEFKNDTLI YEFFH I VAK

PHPLPIKSSTYTTFQSARVTRFF

LDAEKECRCQEGQVEAALIAM

GGTCQGTQRLSTAGESESATH

MREPAVQCRRDSQCVSVLAGR

RRFFQGAASPLHPASVALTQLH

VRWASTATIGQVSGFPGKIRVS

PTTNLGDSDYIFTASHWGLGHY

GPAVHVHSQGGIDERGSNDSG

RLYVTNPCGNVPSWTPNIDRLA

EDGVKLTQHISAASLCTPSRAA

FLTGRYPVRSGMVSSIGYRVLQ

WTGASGGLPTNETTFAKILKEK

GYATGLIGKWHLGLNCESASD

HCHHPLHHGFDHFYGMPFSLM

GDCARWELSEKRVNLEQKLNF

LFQVLALVALTLVAGKLTHLIP

VSWMPVIWSALSAVLLLASSYF

VGALIVHADCFLMRNHTITEQP

MCFQRTTPLILQEVASFLKRNK

HGPFLLFVSFLHVHIPLITMENF

LGKSLHGLYGDNVEEMDWMV

GRILDTLDVEGLSNSTLIYFTSD

HGGSLENQLGNTQ YGG WNGI Y

KGGKGMGGWEGGIRVPGIFRW

PGVLPAGRVIGEPTSLMDVFPT

WRLAGGE VPQDRVI DGQDLL

PLLLGTAQHSDHEFLMHVYCER

VLHAARWHQRDRGTMWKVHF

VTPVFQPEGAGACYGRKVCPCF

GEKWHHDPPLLFDLSRDPSET

HILTPASEPVFYQVMERVQQAV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22557 52925 22685 53 1966 VGQPRGLRTLEKLTASVAGGA

ANFFGDIERDLGPRDTSRGIRG

GNLGDRGCSSAEMAYASWQR

WSPVE WA RWM WTA VTSSG DS

SLLVLQGDSGKRSSDSEEAFET

PESTTPVKAPPAPPPPPPEV I PEP

EVSTQPPPEEPGWGSETVPVPD

GPRSDSVEGSPFRTQAHSFSGVF

DEDQPIASTGTDILDFDNIELVD

TFQTLEPRASDAKNQEGKVNT

RRKSTDSVPISKSTLSRSLSLQA

SDFDGASSSGNPEAVALAPDAY

STESAKRWPPASGGGRVQNSP

PVGRKTLPLTTAPEAGEVTPSD

SGGQEDSPAKGLSVRLEFDYSE

DKSSWDNQQENPPPTKKIGKKP

VAKMPLRRPKMKKTPEKLDNT

PASPPRSPAEPNDIPIAKGTYTF

DIDKWDDPNFNPFSSTSKMQES

PKLPQQSYNFDPDTCDESVDPF

KTSSKTPSSPSKSPASFEIPASA

MEANAWDGDGLNKPAKKKKT

PLKTMVEDVMSVCSLFDTFRV

KKSPKRSPLSDPPSQDPTPAATP

ETPPVISAWHATDEEKLAVTN

QKWTCMTVDLEADKQDYPQPS

DLSTFVNETKFSSPTEELDYRNF

YEIEYM EKIGSSLPQDDDAPKK

QALYLMFDTSQESPVKSSTVR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22558 52926 22686 662 2927 HLRRKRNLPRREGLSPALLEET

PLEPAVGPKAACPLDSESAEGV

VPPASGGKRCLFTTAPEAGEVT

PSDSGGQEDSPAKGLSVRLEFD

YSEDKSSWDNQQENPPPTKKIG

KKPVAKMPLRRPKMKKTPEKL

DNTPASPPRSPAEPNDIPIAKGT

YTFDIDKWDDPNFNPFSSTSKM

QESPKLPQQSYNFDPDTCDESV

DPFKTSSKTPSSPSKSPASFEIPA

SAMEANGVDGDGLNKPAKKK

KTPLKTDTFRVKKSPKRSPLSD

PPSQDPTPAATPETPPVISAWH

ATDEEKLAVTNQKWTCMTVD

LEADKQDYPQPSDLSTFVNETK

FSSPTEELDYRNSYEIEYMEKIG

SSLPQDDDAPKKQALYLMFDT

SQESPVKSSPVRMSESPTPCSGSV

SFEETGSPLRNTAAVKNQVHPVP

TRDWAP*PRSSHLAGCQRKSSQ

E/VELGGPWGLGHPFQEGDLKF

TASPRGSFASADALLSRLAHPV

FSL/CGALDYLVEPNFRQKRNPP

LFAQKLQREAVVHPTDVSIVSKT

ALYSRIRTTEVEKPAGLLFQQP

DLVDSALQIARAEIIVTKEREVSE

WKDKYEESRVREVMEMRKIVLA

EYEKTIAQMIEDEQREKSVSVHQ

TVQQLVLEKEQAVLADLNSVEK

VSLADLFRRYEKMKEVLESFRK

NEEVLKRCAQEYLSRVKKEEQ

RYQAVLKVHAVEEKLDRANAEVI

22559 52927 22687 374 1268 AETNMVWYDWMRPSHAQLHS

DYMQPLTEAKAKSKNKVRGV

QQLIQRLRLIKSPAEIERMQIAG

KLTSQAFIETMFTSKAPVEEAFL

YAKFEFECRARGADILAYPPW

AGGNRSNTLHYVKNNQLIKDG

EMVLLDGGCESSCYVSDITRTW

PVNGRFTAPQAELYEAVLEIQR

DCLALCFPGTSLENIYSMMLTLI

GQKLKDLGIMKNTQGK*CL/RR

LLE/QYCPHHVGHYLGMDVHD

TPDMPRSLPLQPGMVITIEPG I YI

PEDDKDAPEKFRGLGVRIEDDV

WTQDSPLILSADCP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Uπkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22590 52958 A 22718 2240 MRSDPDTSVNEIETKLSALLGS

ETTGEILFDLLCANGPEWNRFV

TLEMKYGRIMLDTAKIIDEQDV

PTHILSKLTFTLRNHPEGWMK

NFEVLQPLQNSLSGLPLWVSER

ILQQINQLTHYEPVIGIMGKTGA

GKSSLCNALFAGEVSPVSDVAA

CTRDPLRFRLQIGEHFMTIVDLP

GVGESGVRDTEYAALYREQLP

RLDLILWLIKADDRALATDEHF

YRQVIGEAYRHKMLFVISQSDK

AEPTSGGNILSTEQKQNISRKIC

LLHELFQPVHPVCAVSVRLHPV

VALLQQFRTDDERTHRYHYDS

QHRLVDYTRTQYEEPLVESRYL

YDPLGRRVAKRVWRRERDLTG

WMSLSRKPQVTWYGWDGDRL

TTIQN DRSRIQTIYQPGSFTPLIR

VETATGELAKTQRRSLADALQ

QSGGEDGGSVVFPPVLVQMLD

RLESEILADRVSEESRRWLASC

GLTVEQMQNQMDPVTEGTTAW

Y/AEYDEWGNLLNEENPHQLQ

QLIRLPGQQYDEESGLYYNRHR

YYDPLQGRYITQDPIGLKGGW

NFYQYPLNPISDIDPLGLSMWE

VARQMNAIASKLPEGFHIGINFS

ASHIISPTFVDECLNFRDSFTRR

DLNLVLEVTERDLLNVDESLVQ

RLNILHENGFVIALDDFGTGYS

GLSYLHDLHIDYIKIDHSFVGRV

NADPESTRILDCVLDLARKLSIS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=ρossible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22706 53074 22834 1889 ACRRRAGTWTPPRPRGSGSRA

MAGNCGARGALSAHTLLFDLP

PALLGELCAVLDSCDGALGWR

GLAERLSSSWLDVRHIEKYVDQ

GKSGTRELLWSWAQKNKTIGD

LLQVLQEMGHRRAIHLITNYGA

VLSPSEKSYQEGGFPNILFKETA

NVTVDNVLIPEHNEKGVLLKSS

ISFQNIIEVGTRNFHKDFLIGERG

E/IFGGYQEGKIQTLTYAVKLFK

QEKKMQCKKHWKRFLSELEVL

LLFHHPNILELAAYFTETVEKFC

LIYPYMRNGTLFDRLQCVGDT

APLPWHIRIGILIGISKTIHYLHN

VQPCSVICGSISSANILLVDDQFH

PKLTDFSMAHFRSPVLEHQSCCI

NMPSSVSRKHLWYVMPEEYIRQ

GKLSIKTDVYSFGIVIMEVLTGC

RWLDDPKHIQLRDLLRELMEK

RGLDSCLSFLDKKVPPCPRN FS

AKLFCLAGRCAATRAKLRPSM

DEVV*RALESTQASLYFVAGDPP

TSLKALRGPVSPLFVLEKVTVSIPV

VEDDEVKPNNNLLPS**KALRMK

RWPQKVTPFVECSQPVEVWFLSLE

QKAREARENEEACNMPSSSVCE

ESWFPKYVIVPSVQDLRPL*GK*K

I LSSQAVSGHSCVRTKPVESSCSS

KFSWDEYEQYKKE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkπo n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22717 53085 22845 2355 MVGSRRISGVIPLPFTRRAGIFS

DPRANMQPLWAPVPPATFVPTS

LPPVPTARPPTSASCHCQQVPC

AGLEVALPGNRTICWLSLWPS

WQLDEDAQSPALESSSIRQFPT

APRSGYPGTLCPSFLFGPRPRTC

EYHSKPVLCAPSSRASPSSATTL

STRTLWGPGAGSHPFGVHNTR

LSPDLCPGKIVLRALKESGAGM

PEQHKDPRVQENPDDQRTVPE

VTGDARSAFWPLRDNGGPSPFV

PRPGPLQTDLHAQSSEIRYNHTS

QTSWTSSSTKRNAISSSYSSTGG

LPGLKQRRGPASSRCQLTLSYS

KTVSEDRPQAVSLGHTRCEKG

ADTAPGQTIAPTASRPHINTSLH

VEDKAISDCRPSRPSHTLSSLAT

GASGGPPVSKAPTMDAQQDRP

KSQDCLGLVAPLASAAEVPAT

APVSGKKHRPPGPLFSSSDPLPA

NSSHSRDSAQVTSMIPAPFTAA

SRDAGMRRTRSAPAAAAAAPP

PSTLNPTSGSLLNVEWMEAPHIS

WPQPQLQHVPRGQ/NVRYNQR

SQTSRTRS/CPQTKCQLQLPQLY

GRPPGSKAEEGVPASSHCQLALS

SSNTVSEDGPQAVSSGHRCENK

AGTAPGQTLAPRGGSPRSQASR

PHINTALHVEDKAISDCRPSRPS

HTLSSLATGASGGPPVSKAPTM

DAQQDRPKSQDSLGLLAPLASA

AEVPSTAPVSGKKHRPPGPLFSS

22718 53086 22846 1200 M PEQDKDPRVQENPDDQRRVP

EVTGDARSAFRPLRDNGGLS/PP

FVPGPGPLQTDLHTQRVLGYRV

TVEDLDREKEAAFQRINSALQV

EDKAISDCRLSRPSHTLSSLATG

TSGLPAVSKAPSMDAQQERHK

SQDCLGLLAPLAPAAEVPSTAP

MSGKKHRPPG PLFSSSDPLPATS

SHSQDSAQVTSLIPAPFPAASM

DAGMRRTSPGTSAPAAAAAPPP

STLNPTLGSLLEWIEALHISGPQ

PQLQQVPRGQNQRSQTSRTSSC

PKRK/CHLQLLQLYGRPPGTKA

EEGVPASSHCQLTLSSSNTVSED

GPQAVSSGHTHCEKTADTAPG

QTLAPRGGFPRSQASRPCRHKF

PLLPRRRGEPLMLPPPLELGYR

VTAEDLDREKEVAFQRIKSALQ

VEDKAI SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \-possible nucleotide insertion) sequence

22719 53087 A 22847 1762 YHSKPVLCAPSSRASPSSATTLS

TRTLWGPGAGSHPFGVHNTRL

SPDLCPGKIVLRALKESGAGMP

EQHKDPRVQENPDDQRTVPE V

TGDARSAFWPLRDNGGPSPFVP

RPGPLQTDLHAQSSEIRYNHTS

QTS WTSSSTKRN A I SSS YSSTGG

LPGLKQRRGPASSRCQLTLSYS

KTVSEDRPQAVSLGHTRCEKG

ADTAPGQTIAPTASRPHINTSLH

VEDKAISDCRPSRPSHTLSSLAT

GASGGPPVSKAPTMDAQQDRP

KSQDCLGLVAPLASAAEVPAT

APVSGKKHRPPGPLFSSSDPLPA

NSSHSRDSAQVTSM I PAPFTA A

SRDAGMRRTRSAPAAAAAAPP

PSTLNPTSGSLLNVEWMEAPHIS

WPQPQLQHVPRGQ/NVRYNQR

SQTSRTRS/CPQTKCQLQLPQLY

GRPPGSKAEEGVPASSHCQLALS

SSNTVSEDGPQAVSSGHRCENK

AGTAPGQTLAPRGGSPRSQASR

PHINTALHVEDKAISDCRPSRPS

HTLSSLATGASGGPPVSKAPTM

DAQQDRPKSQDSLGLLAPLASA

AEVPSTAPVSGKKHRPPGPLFSS

SDPLPATSYHSRDTAQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22720 53088 A 22848 292 2052 GSVAWSPFSPSPSSLCLWDLPV

APTLWGPGAGSHPFGVHNTRL

SPDLCPGKIVLRALKESGAGMP

EQDKDLRVQENPDDQRRVPEV

TGDARSA/FLAPAGQWSPLSLC

AQSRASADIPPCPEVRNQI*PDIP

DHLDELMHQPKCHLQLLQLCG

RLAGAKVEEGASGAKEQGRDA

* AGQGTPESQQN PDDQRTVPEV

TGDARSTVRPLRDSGGLSPFVP

RPGPLQTDLHAQSSEIRYNQTS

QTSWTSSSTKRNAISSSYSSTGG

LLGLKQRRGPASSRCQLTLSYS

KTVSEDRPQAVSSGHTRCEKA

ADTAPGQTLAPRGGSPRSQGSR

PRRRKIALLPHR*GELQVEDKAI

LDCRPSWPSHTLSSLATGASGE

PPVSKAPTMDAQQDRPKSQDC

LGLVAPLASAAEIPSTAPVSGK

KHRPPGPLFSSSDPLPATSSHSR

DSAQVTSLIPAAFTAASMDVG

MRRTRPGTSAPAAAAAAPPPST

LNPTSGSLLNVEWMEALHISGPQ

PQLQQVPRGQ/NVRYNQRSQTS

RTRS/CPQTKCQLELPQLYGRPP

GTKGCRHEKNVLCSKLFEGFGF

IFVGFFFFAYMGILQLLII

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vπ, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

22972 53340 A 23105 122 2437 RLELKLPLWTMRFTEMELLGH

LSIFKITGKQKQLTRTAPGPSGQ

LRSNQTTGNSLEPSGQPRSSQTT

GNSLEPSGQPRSSQTTGNSLEPS

GQPRSSQTTGNSLEPSGQPRSSQ

TTGNSLEPSGQPRSSQTTGNSLE

PSGQPRSSQTTGDSLEPSGQLRS

NQTTGDSVQPNNREQPGTVRS

APLQPNNREQPGTVRSAPLQPN

NRGQRPTKQQGTTWNRQVSSA

PTKQQGTARVPSGQPRSNQTTG

NSLEPSSQLRSNQTTGDSVQPN

NREQPGTVRSAPLQPNNRGQRP

TKQQGTARVPSGQPCSΝQTTGΝ

SLEPSSQLRSΝQTTGDSVQPΝN

REQPGTIRSAPLQPΝNRGQRWD

RQVSSAPTKQGTALGPSGVSSAP

TKQQGTALEPSSQLRSΝQTTGΝ

SLEPSGQPRSΝQTTGΝSREPSSQ

LCSΝQTIGΝSQDRQVSSAP/IQT

TGΝSQDRQVSPAPTKQQGTAG

ΝRQVSST/PIQTGΝSVQPΝNREQ

PGTVSGAM/VWVATPVKGPAR

VETSAHKVSAAGLPKKKT/QPG

VTGGAPRLTLΝTVLPKHSRTPS

RHEAGSTQALYHΝGQAQYALS

FPHEAAPMAAFYWTGIEVTTA

LTLEEAPCTVEITTALTLEEPPC

TVFWΝKTERΝTRTLVQDKGSΝ

TKGFVQTATCCFRADCKASRPS

PHPPSPHREWTSDLRHKQVSKF

PGAHRLPGHPELPIQEAWDRGE

22973 53341 23106 605 813 LFVFIΝFREΝPALLRWVAYARVTI

ΝVYPVΝFRPTPKΝSLMGALCGF

GPLIFIYYIIKTERVSIQTRCLVF

22974 53342 23108 273 936 AYSΝKVPSWΝQKAVPSPTKPAG

TLIFDFPAVKTVRΝKFVFFINYP

VSGYTEDLKKFLKPYTLEEQKΝ

LTVCPDGALFEQKGPVYVACQ

SPISLLQACRGMΝDLDFGYSQR

ΝPCILVKMΝRIIGLKSEGVPRID

CVSKΝEDIPΝVAVYPHΝGIIDL

KYFPYYGEKLHVGYLQPLVAV

QVSFAPΝDTGKEVTVECKIDGS

AΝLKSQDDRDKFLGRVMFKIT

22975 53343 23109 104 478 ETEVGGLVEASMSHΝCTTALQ

PGQHSQKEΝLQΝKPIPGREKY*

VSIEFELIYFP/YYCQVGYLQPL

VAVQVSFAPΝΝTGKEVTVECKI

VDGSAΝLKSQVDDRDKFLGVRV

MFQΝHSTVHSMSRVSSTE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod n USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23184 53552 23318 3366 WRKIYQANGKQKKAGVAILVS

DKTDFKPTKIKRDKEGHYIMVK

GSIQQEELTILNIYAPNTGAPTFI

QQVLSDLQRDLDSHTLIIGDFN

TPLSTSDRSTRQKVNKDTQELN

S ALHQA DLIDI YRTLHPKSTE YT

FFSAPHHTYSKIDHILGSKALLS

KCKRTEIITNYLSDHSAIKLELM

IKNLTQNHSTIWKLNNLLLNDY

WVHKEMKAEIKMFFETNENKD

TTVYQNL WDTFKA VCRGKFIAL

NAHKRKVQER

23185 53553 23319 2611 MGDFNTPLSTLDRSTRQKANK

DTQELNSALHQVDLIDIYRTLH

PKSTEYTFFSAPHHTYSTTDHIL

GSKALLSKCRRTEIITNYLSDHS

AIKLELRIKNLTQNRSTTWKLN

NLLLNDYGVHNEMKAEIKMFF

ETNENKDTTYQNL WDTFKA VC

RGKFIALNAHKRKQERSKIDTL

TSQLKELEKQEQTHSKASRRQE

ITKΪRAELKEIETQKTLQKVINES

RSWFFERINKIDRPLARLIKKKR

EKNQIDAIKNDKGDITTDPTEIQ

TTIREYYKHLY ANKLENLEEM

DKFLHTYTLPRLNQEEVESLNR

PITGSEIVAIINSLPTKKSPGPDG

FTAEFDQRYKEELVPFLLKLFQ

SIEKEGILPNSFYEASIILIRKPGR

DTTKKENFRPISLMNTDAKILN

KILAKRIQQHIKKLIHHDQVGFI

PGMQGWFNIHKSINVIQHINRA

KDKNHMIISIDAEKAFDKIQQPF

MLKTLSKLGIDGTYFKIIRAIYD

KPTANIILNGQKLEAFPLKTGTR

QGCPLSPLLFN I VLE VLA RAIRQ

EKEIKLISNFSKVSGYKINVQKS

QAFLYTNNRQTESQIMSQLPFTI

ASKRIKYLGIQLTRDVKDLFKE

NYKPLLKEIKEDTNKWKNIPCS

WVGRJNIMKMAILPKVIYRFNA

IPIKLPMTFFTELEKTTFKFIWN

QKRARITKSILSQKNKAGGITLP

DFKLYYKATVTKTAWYWYQN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23196 53564 23330 2372 TTNCLSDHSAIKLELRIKKLTEN

HTTTWKLNNLLLNDYWVDNE

MKAEIKMFFEINEKKVDTTSQNL

WDTFKA VCRGKLIALNAHKRK

QERSKIDTLTSQLKKVLEKQEQR

NSKASRKQEITKIRAELKE1ETQ

KKTLQKINESRSWFFEKINKIDG

PLARLIKKKREKNQVDAIKNDK

GDI ITDPTEMQTTIREY YKYLY

ANKLENLEEMDKFLNTYTLQR

LNQEGIESLNRPITGSEIEAIΓNSL

PTKKSPGPDGFTAKFYQRYKEE

LVYPEPRSESECLSNIREFLRGC

GASLRLESIREDRNGRSQKTVH

TEGDMNMN I KKI VKQ AT VLTF

TTALLAGGATQAFAKENNQKA

YKETYGVSHITRHDMLQIPKQQ

QNEKYQVPQFDQSTIKNIESAK

GLDVWDSWPLQNADGTVAEY

NGYHWFALAGSPKDADDTSI

YMFYQKVGDNSIDSWKNAGR

VFKDSDKFDANDPILKDQTQE

WSGSATFTSDGKIRLFYTDYSG

KHYGKQSLTTAQVNVSKSDDT

LKINGVEDHKTIFDGDGKTYQN

VQQFIDEGN YTSGDNHTLRDPH

YVEDKGHKYLVFEANTGTENG

YQGEESLFNKAYYGGGTNFFR

KESQKLQQSAKKRDAELANGA

LGIIELNNDYTLKKVMKPLITSN

TVTDEIERANVFKMNGKWYLF

TDSRGSKMTIDGINSNDIYMLG

23197 53565 23331 2987 APRFIKQVLSDLQRDLDSHTIIM

GDFNTPLSTLDRSTRQKVHKDT

QELNSALHQADLIDIYRTLHPK

STEYTCFSAPHHTYSKIDHIVGS

KALLSKCKRSEIITNCLSDHSAI

KLELRIKKLTQΝRSTTWKLΝNL

LLΝDYWVHΝEMKAEIRMFFET

NENKDTTYQNLWDTFKAVCRG

KFIALNAHKRKQERSKIDTLTS

QLKELEKQEQTHSKASRRQEIT

KIRAELKEIETQKTLVQKINEVSR

SWFFVERTNK

23198 53566 A 23332 339 701 PDKEGNEIWVDMYTVKPSGWT

VRTFDKPRKRFIAFFIAGILFRAI

KNHFLPRETLQCLPYILTGFRRG

QSEYFSIFSNMDLADTVMFL*G

A I RFSDL VN EQIQHTFLIPGETIC

RLSEVV

23199 53567 A 23333 190 502 SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23200 53568 23334 4472 8032 KKSGNNRLMRVHGKKRFLWQ

KQGVCEVEIQAQRESARDGTD

REDAESPHAEVTVPRGTRTEILT

LWASRDRPASACGVTVPKGST

THPGGMDRVCGVDTAVLHWM

KQVQGISNLEVETGPRRRDMD

EAGSRHSQQTNIGTENQTPHVL

THKWQLNRNSACDKLHKPHSV

PGGVAAGDVGGKTISNPGVCAI

EYQVDGSPHIWEDVNKGVYIEE

DRAPLMERSSSPAMEQSWMEN

DFDELREEGFRRSNYSELRED

23201 53569 23335 2374 MVSISDLVICPPRJdPKVLGLQGP

PGLDSISDPSAGAGFLDWGEIG

MPGPGRAGHQALCKCDCQCLE

KTTTKAPGKMPKSTRSGPVRV

RLADGPNRCAGRLECGMPDAG

EQCVMTTGTSGRHCGLLGTGL

WKGYTDLTIIPPGPGTPPQERTC

QGDYHSGGTWTHSPLETTRRP

GSSSPAIRRLPAQMLLLPARPPH

PRSSSPEAMDPPPPKAPPFPKAE

GPSSTPSSAAGPRPPRLGRHLLI

DAN/G V YPYTYTVQLEEEPRG P

PQREAPPGEPGPRKGYSCPECA

RVFASPLRLQSHRVSHSDLKPF

TCGACGKAFKRSSHLSRHRATH

RARAGPPHTCPLCPRRFQDAAE

LAQHSWGTPRGPLLAAACNCE

VARGRLESPGPERLLHGYGGRE

EEGG WGRA AGGLDRVEG FISS

KAHHYLLIDTQGVPYTVLVTRS

HRGSQGPVGLQARKVLQLPRV

LKGLRVHVHLQRHSITHSEVPQ

DFAGSLDSFQTPGESLRLVFRA

LDTTQSSRISKAEPCLKEEPLSL

GDLPYMHTTLCFCRKRRASPGP

GTLQRGALAWPDWASPRALPV

PSLSSTTRSPAAPLFAVPLSGRT

TQAMA FDG IIFQGQSQRSAGLT

TTSRFLACQRPLRLCAWWASRS

PRCTLRRPVGLRPGVHPRPRLV

YRDLKPENVMASGQPRDRPQP

WFAWPPRPTRFCGGCWTLTPK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possib!e nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23255 53623 A 23389 1986 MGIGEGPTTSEGCRESVEYSHQ

KSELPLSGDSQVPGPIGCNCDP

QGSVSSQCDAAGQCQCKAQVE

GLTCSHCRPHHFHLSASNPDGC

LPCFCMGITQQCASSAYTRHLIS

THFAP/GDFQ/GFA/LVNPQRNS

RLTGEFTVEPVPEGAQLSFGNF

AQLGHESFYWQLPETYQGDKG

EAYFARMRRAHQNRTSLSEEQ

LRAAVTAGRIPEPPEGRDWAQR

ASQFSLSYEGFSLLPGSLYYWQ

LPRAFLGDKVAAYGGKLRYTL

SYTAGPQGSPLSDPDVQITGNNI

MLVASQPALQGPERRSYEIMFR

EEFWRRPDGQPATREHLLMAL

ADLDELLIRATFSSVPLAASISA

VSLEVAQPGPSNRPRALEVEEC

RCPPGYIGLSCQDCAPGYTRTG

SGLYLGHCELCECNGHSDLCHP

ETGACSQCQHNAAGEFCELCA

PGYYGDATAGTPEDCQPCACP

LTNPENMFSRTCESLGAGGYRC

TACEPGYTGQYCEQCGPGYVG

NPSVQGGQCLPESSELHFPSVQ

PSDAGVYICTCRNLHQSNTSRA

ELLVTEAPSKPITVTVEEQRSQS

VRPGADVTFICTAKSKSPAYTL

VWTRLHNGKLPTRAMDFNGIL

TIRNVQLSDAGTYVCTGSNMF

AMDQGTATLHVQGSAEAGERS

MYSISVLLKYTS

23256 53624 23390 13319 PASGRLRAARSGRRGASERESG

AGRAMGWRAPGALLLALLLH

GRLLAVTHGLRAYDGLSLPEDI

ETVTASQMRWTHSYLSDDEYM

LADSISGDDLGSGDLGSGDFQM

VYFRALVNFTRSIEYSPQLEDA

GSREFREVSEAWDTLESEYLKI

PGDQWSWFIKELDGWVFVE

LDVGSEGNADGAQIQEMLLRVI

SSGSVASYVTSPQGFQFRRLGT

VPQFPRACTEAEFACHSYNECV

ALEYRCDRRPDCRDMS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid -Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23354 53722 23489 990 EKMNTADQARVGPADDGPAPS

GEEEGEGGGEAGGKEPAADAA

PGPSAAFRLMVTRREPAVKLQ

YAVSGLEPLAWSEDHRVSVST

ARSIAVLELICDVHNPGQDLVIH

RTSVPAPLNSCLLKVGSKTEVA

ECKEKFAASKDPTVSQTFMLDR

VFNPEGKALPPMRGFKYTSWSP

MGCDANGRCLLAALTMDNRL

TIQANLNRLQWVQLVDLTEIYG

ERLYETSYRLSKNEAPEGNLGD

FAEFQRRHSMQTP VRME WSG I

CTTQQVKHNNESRDVGSVLLA

VLFENGNIAVWQFQLPFVGKES

ISSCNTIESGITSPSVLFWWEYE

HNNRKMSGLIVGSAFGPIKILPV

NLKAVKGYFTLRQPVILWKEM

DQLPVHSIKCVPLYHPYQKCSC

SLWAARGSYVFWRLLLISKAG

LNLHNSHVTGLHSLPIVSMTAD

KQNGTVYTCSSDGKVRQVIPIF

TDVALKFEHQLIKLSDVFGSVR

THGIAVKPCGAYLAIITTEGMIN

GLHPVNKNYQVQFVTLKTFEE

AAAQLLESSVQNLFKQVDLIDL

VRWKILKDKHIPQFLQEALEKK

IESSGVTYFWRFKLFLLRILYQS

MQKTPSEALWKPTHEDSKILLV

DSPGVMGNADDEQQEEGTSSKQ

WKQGLQERSKEGDVEEPTDVD

SLPTTGVDAGVGREPMGRRNSW

GNSKGKIRSCWEMRLTREHMK

23355 53723 23490 1218 1446 RCTDSQWRSPTPLHLAAQACSL ETTVCLLCSKADYTLSEKRGW MPIHFAAFYDNVCIIIALCRKDP SLLEAEATAE

23356 53724 23491 632 NMAKTYDYLFKLLLIGDSGVG

KTCVLVFRFSEVDAFNSTFIFTIRI

DFKIRTIELDGKRIKLQIWDTAG

QERFRTITTAYYRGAMGIMLVY

DITNEKSFDNIRNWIRNTEEHAS

ADVEKMILGNKCDVNDKRQVS

KGS/GENKLALDYGIKFMETSA

KANINVENAFFTLARDI KAKMD

KKLDGNSPVQGSNQGVKITPDQ

QKRSSFFRCVLL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23375 53743 23510 2094 2619 ASPASPAPCSGIPRT*SPYPSPSR TQVAPRARGPAIHAHPGP/RGCT ALPRQGPPTPGSARAPPRIPAHR APTSPTLNFCLASSRQSMPPAPR PPPVPATNPVTPGCGRPPPTLGC RNPQTLRPPPGLPSPALLRRPLP PPARVGMPPHQPPLPTTPACWR PVDWARAEGAGRAVC

23376 53744 2351 1 5050 3317 PARTSPSASGPP**DLISALWTPS QPRAPTRQSLNSLSSSAPSSSTIG PSPSPPAPGPAPPLPWLPPSPSSL PRLSQVSRRPHSH LHPQ

23377 53745 23512 862 2954 AEHTLLVCFLNTSLTTTSTHVES

FGGQLRGSQIGHPRRPNKMPYA

WSIPQDPPLKPERDPGGPLGVS

LSLPVNQYGESEEPMGDDDYD

EYSKELNQYRRSKDSRGRGLSR

GRGRGSRGRGKGMGRGRGRG

GSRGGMNKGGMNDDEDFYDE

DMGDGGGGSYRSRDHDKPHQ

QSDKKGKVICKYFVEGRCTWL

YHTTGNCINGDDCMFSHDPLTE

ETRELLDKVEMTGSSVFDYIHP

GDHSEVLEQLGLRTPTPGPPTPP

SVSSSSSSSSSLADTPEIEASLTK

VPPSSLVQERSFFVRMKSTLTK

RGLHVKASGYKVIHVTGRLRA

HALGLVALGHTLPPAPLAELPL

HGHMIVFRLSLGLTILACESRVS

DHMDLGPSELVGRSCYQFVHG

QDATRIRQSHVDCETHLHPPSL

PTTPQTRASHSLVPGSPSSGLPT

VPPAAPTAPGTPFSIGRAARRLS

DASGLLDKGQVMTGYYRWLQ

RAGGFV WLQS VATV AG SGKSP

GEHHVLWVSHVLSQAEGGQTP

LDAFQLPASVACEEASSPGPEPT

EPEPPTEGKQAAPAENEAPQTQ

GKRIKVEPGPRETKGSEDSGDE

DPSSHPATPRPEFTSVIRAGVLK

QDPVRPWGLAPPGDPPPTLLHA

GFLPPWRGLCTPGTIRYGPAEL

GLVYPHLQRLGPGVPALPEAFYP

PLGLPYPGPAGTRLPRKGD

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknowπ, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23398 53766 A 23533 2094 RPLDVGGPAAGTPGVLSRPCPS

TAALAPKPFCAAPRPQPDAPAC

AGATGGSCADFDSGVDFVRRR

SSGLWGPQPPLFPVKNYTEMFQ

DPVAFKDVAVNFTQEEWALLD

ISQKNLYREVMLDTFWNLTSIG

KKWKDQNIEYEYQNPRRNFRS

VTEEKVNEIKEDSHCGETFTPV

PDDRLΝFQKKKASPEVKSCDSF

VCGEVGLGΝSSFΝMΝIRGDIGH

KAYEYQEYGPKPCKCQQPKKA

FRYRPSFRTQERDHTGEKPYAL

LKΝDGKKPLFYHSSIQRHMW

HSGDGPYKCKFCGKAFHWLSL

YLIHERTHTGEKPYECKQCGKS

FSYSATHRIHERTHIGEKPYECQ

ECGKAFHSPRSCHRHERSHMGE

KAYQCKECGKAFMCPRYVRRH

ERTHSRKKLYECKQCGKALSSL

TSFQTHIRVMHSGERPYECKTCG

KGFYSAKSFQRHEKTHSGEKPY

KCKQCGKAFTRSGSFRYHERTH

TGEKPYECKQCGKAHERTHTG

EKPYECKLYGKALSRLISFRRH

MRMHTGERPHKCKICGKAFVSS

PSSFQRHERSHTGEKPYKCKQC

GKAFTCFHFVFQYHERTHTGEK

PDGCKQCGKAFRSAKYIRIHGR

THTGEKPYECKQCGKAFHWVS

SFHRHERTHAGEKPYECKHCG

KAFTCSIYIRIHERIHTGEKPYQ

CKECGKAFIRSSYCRKHERTHTI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possiblc nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23544 53912 23679 1216 LGNKRAGLRRADGEAPSALPY

CYFLQKDAEAPWLSKPAYDSA

ECRHHAAEALRVAWCLEAASL

SHRPGPRSGLSVSSLRPTRKMA

TTFLAHEKIWFDKFKYDDAERR

FYEQMNGPVAGASRQENGAVT

VILRDIARARENIHKSLAGSSGPV

GASVSGTSGDHGELWRIASLEV

ENQSLRGWQELQQAISKLEAR

LNVLGKELRLAHRGTAPQTQH

VSPMRVQVEPPVAKKPATPAEDD

EDDDIDVLVGRDNEVEEDKEAA

QLVREERVLRVHYAEKKAQESLP

LGGQVPPSLLDVKVPWDDESDM

AQLEACVRSIQ/LGTGRSWGAS

QMVAVGYGVIRKLQIQCWEDD

KVGTDLLEEEITKFEEARARSV

DIASFSTRSEALKCVYVAHVRE

GPCTRSKDLRPAKKKKKK

23545 53913 A 23680 2066 MAAALRAPTQVSAASSRPPLPS

PPETEGRVKGFLQPGPHCPAQC

LCSGDDGSNEDLEQKREVIFPR

PHEAPVAEHRQQTVGLRELVAI

PKRKEETTAIVQVFVAFEDVAI

YFSQEEWELLDEMQRLLYRDV

MLENFAVMASLGCWCGAVDE

GTPSAESVSVEELSQGRTPKAD

TSTDKSHPCEICTPVLRDILQMI

ELHASPCGQKLYLGGASRDFW

MSSNLHQLQKLDNGEKLFKVD

GDQASFMMNCRFHVSGKPFTF

GEVGRDFSATSGLLQHQVTPTI

ERPHSRIRHLRVPTGRKPLKYT

ESRKSFREKSVFIQHQRADSGE

RPYKCSECGKSFSQSSGFLRHR

KAHGRTRTHECSECGVKSFSRK

THLTQHQRVHTGERPYDCSEC

GKSFRQVSVLIQHQRVHTGERP

YECSECGKSFSHSTNLYRHRSA

HTSTRPYECSECGKSFSHSTNLF

RHWRVHTGVRPYECSECGKAF

SCNIYLIHHQRFHTGERPYVCSE

CGKSFGQKSVLIQHQRVHTGER

PYECSECGKVFSQSSGLFRHRR

AHTKTKPYECSECEKSFSCKTD

LIRJTQTVHTGERPYECSVCGKS

FIRKTHLIRHQTVHTNERPYEC

DECGKSYSQSSALLQHRRVHT

GERPYECRECGKSFTRKNHLIQ

HKTVHTGERPYECSECGKSFSQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23867 54235 24005 2502 MEARVERAVQKRQVLFLCVFL

GMSWAGAEPLRYFVAEETERG

TFLTNLAKDLGLGVGELRARG

TRIVSDQNMQILLLSSLTGDLLL

NEKLDREELCGPREPCVLPFQL

LLEKPFQIFRAELWVRDINDHA

SVFLDREISLKILESTTPGAAFLL

ESAQDSDVGTNSLSNYTISPNA

YFHINVHDSGEGNIYPELVLNQ

VLDREEIPEFSLTLTALDGGSPP

RSGTALVRILVLDVNDNAPDFV

RSLYKVQVPENSPVGSMWSV

SARDLDTGSNGEIAYAFSYATE

RILKTFQΓNPTSGSLHLKAQLDY

EAIQTYTLTIQAKDGGGLSGKC

TVWDVTDINDNRPELLLSSLT

SPIAENSPETVVAVFRIRDRDSG

NNGKTVCSIQDDLPFILKPSVEN

FYTLVTEKPLDRERNTEYNITIT

VTDLGTPRLKTEHNITVLVSDV

NDNAPAFTQTSYTLFVRENNSP

ALPIGSVSATDRDSGTNAQVIY

SLLPSQDPHLPLASLVSINADNG

HLFALSPWTTMPLRAFEFRNNS

PALHIGSVSTAETNIQVTYSLLP

PRNPHLPLASLVSINTDNGHLF

ALRSLDYEALQEFEFRVGASDR

GSTALSSEALVRVLVLDANDSS

LFVLFPLQNGSAPCTELMPRAVA

AEPGYLVTKNAWLS*QLLKAT

EPGLFGVWAHN/GTDRLLSERD

TAKHRLMVLVKDNGEPPRSAT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

23983 54351 24121 2204 IDMIFTPGPPSTPKHKKSQKGSA

FTFPSQQSPRNEPYVARPSTSEI

EDQSMMGKFVKVERQVQDMG

KKLDFLVDMHMQHMERLQVQ

VTEYYPTKGTSSPAEAEKKEDN

RYSDLKTIICNYSETGPPEPPYSF

HQVTIDKVSPYGFFAHDPVNLP

RGGPSSGKVQATPPSSATTYVE

RPTVLPILTLLDSRVSCHSQADL

QGPYSDRISPRQRRSITRDSDTP

LSLMSVNHEELERSPSGFSISQD

RDDYVFGPNGGSSWMREKRYL

AEGETDTDTDPFTPSGSMPLSST

GDGISDSTVPLFLSSEILQKQVG

QSITSMLGFLSRGPSMKLCMGL

ACVLSLWNTVSGIKGEAKKEK

GMTFLPTTDSKKFFSLLSVTSYS

SFAFHKFSVAVYNISNLKTVDP

AKFPTRYCYCLNNRTNDLSDFT

ALLVDIIGNSTSYLTEIFKSTSIL

SVNQSNESDCIFICVMTGKSGR

NLSDFWEIEEKYPIINYTFTSGL

SGVLALLLTQSLFGGLFTRTRM

KFGAVTRIGVDLPWEINP/LSSCS

LLHEKDPPTTSGPQTDQPKKHL

TNFKSAARPTFLGQGQVPLNPF

SFTLSGKSCFPRRQEPPNRLFPH

PNLLSLCPNPLFLCPNPFSTFLE

GKNHHPHPFSVSQVFSLGLPPS

LWEHSPMAHRLRVQPRQQPPDI

HKQVISLQSGHSLLVKSQSWSQ

DPIKFQLPHHHKNTASVCINPSV

23984 54352 24122 2102 2529 ETTMSFIFSLLYPFRMHLSFLIVS

PALRSISRRALAAFPRGRSLDLQ

PAMPEPPTPS/CGLLCVPSVPPMS

AAPCSKVPQSHLFAFMSCNTAK

VCSFTAEASETTSPPGGTNNSR

RATLRAVTLTRRSATLTRRSAA

SHRSSTV

23985 54353 24123 299 567 TAMLLTQSLFGGLFTQTRMKF GAVTQIVADLPWEINPLSSCSLL HEKDPPTSSGPQTDQPKEHLTN FKSGETKEMHFIRGPKTPAPVM

23986 54354 24124 684 822 KVKRQSYSQNTFYYPICSRH*IK LQKLNSGPQTPQQDLINLAIKV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24243 54611 24381 2208 MLLVSASVNAMSISGQAGKEY

TNIGVGFGTETTGLALSGNWTH

NDDDGDVAGVGLGLNLPLGPL

MATVGGKGVYTNPNYGDEGY

AAAVGGGLQWKIGNSFRLFGE

Y Y YSPDSLSSG IQS YEEANAG A

RYTIC VQVF V V VMLI RNQLFTP

VNTAIDGFATN YAI MPA YA VG

EGVATHGLQFELMRTTGGNTQ

HVFHHPLPLFAMWRYAAEMFP

YQQMCQFVRYHFFNKSFTVFQ

QQNGIEANFIAFQPGRSGGGSA

LGRNVFGFRYQPQCQQDKQYV

QSRIHPEGVGVTQRVEHGQERC

ANDHVQSSGTELMQEGVMSAS

LKNQQGFSLPEVMLAMVLMV

MIVTALSGFQRTLMNSLASRNQ

YQQLWRHGWQQTQLRAISPPA

N WQSGAA MLRV YHSN RLD VL

EALMEFIVERERLDDPFEPEMIL

VQSTGMAQWLQMTLSQKFGIA

ANIDFPLPASFIWDMFVRVLPEI

PKESAFNKQSMSWKLMTLLPQ

LLEREDFTLLRHYLTDDSDKRK

LFQLSSKAADLFDQYLVYRPD

WL AQ WETGHL VEG LGEAQA W

QAPLWKALVEYTHQLGQPRW

HRANLYQRFIETLESATTCPPG

YLRASLYAAIQHALASVREHTT

LWIAHRLSTIVDADTILVLHRG

QAVEQGTHQQLLAAQGRYWQ

MYQLQLAGEELAASKGHAELY

24244 54612 24382 729 DCSPLIDHCDADTILVLHRGQA

VEQGTHQQLLAAQGRYWQMY

QLQLAGEELAASVQPLPNSDRR

GSMKLVTVIIKPFKLEDVREAL

SSIGIQGLTVTEVKGFGRQKGH

AELYRGAEYSVNFLPKAAYTG

KIGDG/KIFV AELQRVIRIRTGEA

DEAALYLWHTATERDGPFRNF

TAGAFRASLPHPARHGRRPILA

APFMPVNPSRLPPRRRHLASGR

SLRFNCCTAGDETCSARSGERR

24245 54613 24383 683 1 161 RTGHCH/SAFSFSTVLTSCSLSRF

SFLAHRLQYLLRVAEPLPNSDR

RGSMKLVTVIIKPFKLEDVREA

LSSIGIQGLTVTEVKGFGRQKG

HAELYRGAEYSVNFLPKVKIDV

AIADDQLDEVIDIVSKAAYTGKI

GDGKIFVAELQRVIRIRTGEADE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24385 54753 A 24523 891 3240 RYRKSPGSWR/CMSCILTSWITT

MFPI*RLGQWC*NPCVTMAL/L

API DVHLMVKPVDRI VPDFAAA

GASIITFHPEASEHVDRTLQLIK

ENGCKAGLVFNPATPLSYLDY

VMDKLDVILLMSVNPGFGGQS

FIPQTLDKLREVRRRIDESGFDI

RLEVDGGVKVNNIGEIAAAGA

DMFVAGSAIFDQPDYKKVIDE

MRSELAKFEDIRGVAFDLDGTL

VDSAPGLAAAVDMALYALELP

VAGEERVITWIGNGADVLMER

ALTWARQERATQRKTMGKPPV

DDDIPAEEQVRILRKLFDRYYG

EVAEEGTFLFPHVADTLGALQA

KGLPLGL VTN KPTPFVAPLLEA

LDIAKYFSWIGGDDVQNKKPH

PDPLLLVAERMGIAPQQMLFVG

DSRNDIQAAKAAGLDAQARRK

NAGYYYYLRLAKRQMRAGVA

EALRDDLLAAKLNVKLVNAGD

YKFKQI ASEKLLl V VTSTQG EGE

PPEEAVALHKFLFSKKAPKLEN

TAFAVFSLGDSSYEFFCQSGKD

FDSKLAELGGERLLDRVDADV

EYQAAASEWRARWDALKSRA

PVAAPSQSVATGAVNEIHTSPY

SKDAPLVAWRLPNVEGRARAG

GASSFLADRVEEEGEVRVFIEH

NDNFRLPANPETPVIMIGPGTGI

APFRAFMQQRAADEAPGKNWL

FFGNPHFTEDFLYQVEWQRYV

24386 54754 24524 950 2124 MSLISSVIAATWLHVKSYRLSC

GFYACQSLVLVS/IFPTLSCLFA

AEQLLIWSASAFITKVLLVPLIM

TYAARNIPQNIPEKALFGPAMM

ALLAALIVLLCAFWQPVKLPM

ATGLKPALAVALGHFLLGLLCI

VSQRNILRQIFGYCLMENGSHL

VLALLAWRAPELVEIGIATDAIF

AVIVMVLLARKIWRTHGTLDL

TPLLFSLLCFACRKRRLSATRTV

TVLHSLG ITLLLIL AL WVVQTA

ADAGEIFAAGLWLHIDGLGGLF

LAILGVIGFLTGIYSIGYMRHEV

AHGELSPVTLCDYYGFFHLFLF

TMLLWTSNNLIVMWAAIEAT

TLSSAFLVGIYGQRSSLEAAWK

YIIICTVRVAFGLFGTVLVYANA

ASVMPQAEMAIFWSE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24463 54831 24601 190 MTDFRESDTMSLFDKKHLVSP

ADALPGRNTPMPVATLHAVNG

HSMTNVPDGMEIAIFAMGCFW

GVERLFWQLPGVYSTAAGYTG

GYTPNPTYREVCSGDTGHAEA

VRIVYDPSVISYEQLLRKYRCV

AVALLGYFKCKPILLNPSYKSM

QDDLAFIARFHFKDLKFRRFSL

KADQKSRIYERVLSIAGVNSWK

DKQHQPRLVEHLLVCAESWVA

PRALFDAAIEYLAHQKIAIPAYL

VAFLVLGPLVLSLIPSQMLPSLT

WSSITYSIWIVEAGYQYHSRLR

RFGRVEVNEQIEYLIHNPIRTRA

RAVNFVDNNNRLQAPRILRQDS

WWITRPLPGLTWAIIGSPGILPQ

WKSARVMKQAVAYLEPFIEA

SKEQGKTNGKMVIATVKGDVH

DIGKNIVGWLQCNNYEIVDLG

VMVPAEKILR*KLGGTPRTL*R

SNRVPGPPEDRHSCLFGCV/YW

FLVP*CCLSSLRRCCRR*RGQAS

RIQ*LLSSKLAISTIL/GLRRFGR

VEVNEQIEYLIHNPIR/IARQGG

QLC**QQSASGPTDITAGFMVD

HQTFTGADVGDNRVARNPATG

GQIGARHETGGGLPRTVY*SQQ

RAGQNQRQDGDRHREGRRPRH

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24496 54864 A 24634 1926 MATAKANQEIQEWLGKYGTAR

VKLNVDKDFSLKDSSLEMLYPI

YDTPTNMLFTQGAIHRTDDRTQ

SNIGFGWRHFSGNDWMAAVIT

FIDHDLSRSHTRIGVGAEYWRD

YLKLSANGYIRASGWKKSPDIE

DYQERPANGWDIRAEGYLPAW

PQLGASLMYEQYYGDEVGLFG

KDKRQKDPHAISAEHSPEFRSE

ALKLVNASVLLPQPVNSACMN

HNSTTGAVNSKISRRLLNVNW

RCLPRLHVSNASWQNGMKSWL

SSKRPRHTSEAPEMKYVFIEKH

QAEFSIKAMCRVLRVARSGWY

TWCQRRTRINIAWRRADGSRT

SFVYTSYLAKVNEEWKNNVGT

GSTVKWPIGLGGKGNDGIAAF

VQRLPGAIGYVEYAYAKQNNL

AYTKLISA*NEVCLY*KTSG*V

QHQSNVPR/RSGWPAAAGIRGV

SGGQG*TLL*YAAQMAPELPSS

TPATWRK*TKSGKTTLV/HGST

VKWPIGLGGKGNDG1AAFVQR

LPGAIGYVEYAYAKQNNLAYT

KLISADGKPVSPTEENFANAAK

GADWSKTFAQDLTOQKGEDA

WPITSTTFILIHKDQKKPEQGTE

VLKFFDWAYKTGAKQANDLD

YASLPDSWEQVRAAWKTNIK

DSSVNFDMANVFFRVTPGNFL

VNREASHQRRVFAVRAGVDFI

YRASSDGLRRCRDRRTRFKRFN

24497 54865 24635 1387 1639 ESKPLNLGRGSGFLLTRALSAQ PLWQSPDQHLTPQAGLRSRL*A QRQA*QKTASRW*PKPLWAL VKATSEDISVVL* ESACQC

24498 54866 24636 1570 2516 IEVAMSIWKNNIHWVGQRDW

EVRDFHGTEYKTLRGSSYNSYF

IREEKNVLIDTVDHKFSREFVQ

NLRNEIDLADIDYIVINHAEEDH

AGALTELMAQIPDTPIYCTANAI

DSINGHHHHPEWNFNWKTGD

TLDIGNGKQLIFVETPMLHWPD

SMMTYLTGDAVLFNYDAFGQH

YCDEHLFNDEVDQTELFEQCQ

RYYANILTPFSRLVTPKITEILGF

NLPVDMIATSHGWWRDNPTQ

IVELYLKWAADYQEDRITIFYD

TMVNNTPMMADAIAQGIAVETG

PRLAGENFNVVARNDKHEDPDL

LSFRSERGA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Uπknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24509 54877 24647 194 2481 GMFRMNLMEPLTQCINAGHEM

TKAIAIAQFNDDSPEARKITRR

WRIGEAADLVGVSSQAIRDAEK

AGRLPHPDMEIRGRVEQRVGY

TIEQINHMRDVFGTRLRRAEDV

FPPVIGVAAHKGGVYKTSVSVH

LAQDLALKGLRVLLVEGNDPQ

GTASMYHGWVPDLHIHAEDTL

LPFYLGEKDDVTYAIKPTCWPG

LDHPSCLALHRIETELMGKFDE

GKLPTDPHLMLRLAIETVAHDY

DVIVIVDSAPNLGIGTINWCAA

DVLIVPTPAELFDYTSALQFFD

MLRDLLKNVDLKGFEPDVRILL

TKYSNSNGSQSPWMEEQIRDA

WGSMVVIKNVVRETNEVGKAA

PMVDSLIARVGVMARGNAITLP

VCGRDVKFTLEVLRGDSVEKTS

RVWSGNERDQELLTEDALDDLI

PSFLLTGQQTPAFGRRVSGVIEI

ADGSRRRKAAALTESDYRVLV

GELDDEQMAALSRLGNDYRPT

SAYERGQRYASRLQNEFAGNIS

ALADAENISRKIITRCINTAKLP

KSWALFSHPGELSARSGDALQ

KAFTDKEELLKQQASNLHEQK

KAGVIFEAEEVITLLTSVLKTSS

ASRTSLSSRHQFAPGATVLYKG

DKMVLNLDSPQSFSPGAGDHA

NSPQSSSPSTGVHINSPQLSSLS

AGVHTISPQSSNPSVGVTALSHP

DLVWVFTLTAHSRPVLVWVFT

24510 54878 24648 1361 1694

2451 1 54879 24649 3852 MKLMETLNHCINAGHEMTKAV

AIAQFNDDSPEARKITRRWRIG

EAADLVGVSSQAIRDAEKAGR

LPHPDMEIRGRVEQRVGYTIEQI

NHMRDVFGTRLRRAEDVFPPVI

GVAAHKGGVYKTSVSVHRAQ

DLALKGLRVLLVEGNAPQGTA

SVYHGWVPDLHIHAEAALLPF

YLGEKDDVTYAIKPTCWPGLDI

IPSCLALPRIEPELMGK/FDEGRS

FMPGPP/HHHPLGRSSQ*QVSNS

LDRAAKGN*KPLCHC

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24595 54963 24733 815 MRVGRKAVGAIWWSSKQELFQ

QLFLRTELEDIGPGIVKRELGRE

GSKDTGSSDDWEQLPDWKTKR

VGNERDQELLIEDALDDLIPSFL

LTGQQTPAFGRRVSGVIEIADG

SRRRKAAALTESDYRVLVGEL

DDEQMAALSRLGNDYRPTSAY

ERGQRYASRLQNEFAGNISALA

DAENISRKIITRCINTAKLPKSV

VALFSHPGELSARSGDALQKAF

TDKEELLKQQASNLHEQKKAG

VIFEAEEVITLLTSVLKTVQSKN

LSHFTWICHAETAVINHKKRKN

SPRIVQSNDLTEAAYSLSRDQK

RMLYLFVDQIRKSDGTLQEHD

GICEIHVAKYAEIFGLTSAEASK

DIRQALKSFAGKEWFYRPEED

AGDEKGYESFPWFIKHWVTISP

QTSAYERGQRYASRCKNEFAG

NISALADAENISRKIITRCINTAK

LPKSWALFSHPGELSARSGDA

LQKAFTDKEELLKQQASN LHE

QKKAGVIFEAEEVITLLTSVLKT

SSASRTSLSSRHQFAPGATVLY

KGDKMVLNLDRSRVPTECKRK

LRPF* SGQRTDTAY VFDPGRDY

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24596 54964 24734 1249 DF A DFGTTIKQDFRLLGQTS V D

RLLQLSQGQAVKGNQLLPVSL

VKRKTTLAPNTQTASPRALADS

LMQLARQVSRLESGQLAISGRI

LFLPMLNSINKLAAPSQPCTEPF

FRRDPTLHPKSEVRLPPKVTTIT

VISNPILITPQEKSVAQCTYNQT

VQLDITAFLKTVKKNKHKFYPA

FIHILARLMNAHPEFRMAMKD

GELVIWDSVHPCYTVFHEQTET

FSSLWSEYHDDFRQFLHIYSQD

VACYGENLAYFPKGFIENMFFV

SANPWVSFTSFDLNVANMDNF

FAPVFTMGKYYTQGDKVLMPL

AIQI RKSDGTLQEHDG ICEIH VA

KYAEIFGLTSAEASKDIRQALKS

FAGKEWFYRPEEDAGDEKGY

ESFPWFIKRAHSPSRGLYSVHIN

PYLIPFFIGLQNRFTQFRLSETKE

ITNPYAMRLYESLCQYRKPDGS

GIVSLPIDWIIERYQLPQSYQRM

PDFRRRFLQVCVNEINSRTPMR

LSYIEKKKGRQTTHIIRISDGTL

QEHDGICEIHVAKYAEIFGLTSA

EASKDIRQALKSFAGKEWFYR

PEEDAGDERGYESFPWFIKRAH

SPSRGLYSVHINPYLIPFFIGLQN

RFTQFRLSETKEITNPYAMRLY

ESLCQYHLCGTLRNSRFCEI H V

AKYAEIFGLTSAEASKDIRQAL

KSFAGKEWFYRPE/VGCRR*K

RL*IFSLVYQTCAQSIQRALQCT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24602 54970 24740 398 MVDSLIARVGVMARGNAITLP

VCG RD VKFTLQ VLRGDS VEKT

SRVPPGNERDQEMLTEDALDD

LIPSFLLTGQQTPAFGRRVSGVI

HTADGSRRRKAAALTEKFCIVD

NPPGEIRKRACLFIPTHALNLNR

FEDICYAHQLPDGGLLSARVGV

MARGNPILSPVCGRNVKFTLKV

LRGDSVENPSRVWSGNERAQE

LLTEHALDDLTLSFLLTGQQTP

AFGRRVSGVIEIADGSRRRKAA

ALTESDYRVLVGELDDEQMAA

LSRLGNDYRPTSPYERGQRYAS

RLQNEFAGNISALADAENISRKI

ITRCINTAKLPKSWALFSHPGE

LSARSGNERDQELLTEDALDDL

IPSFLLTGQQTPAFGRRVSGVIH

TADG SRRRKAA/DTYRKIL YR* *

PPGGD*KKSVPFYSNTCAQSQP

24603 54971 24741 1450 3699 RN PLQI PKQQQNEKYQVPQFDQ

STIKNIESAKGLDVWDSWPLQN

ADGTVAEYNGYHWFALAGSP

KDADDTSIYMFYQKVGDNSIDS

WKNAGRVFKDSDKFDANDPIL

KDQTQEWSGSATFTSDGKIRLF

YTDYSGKHYGKQSLTTAQIFQ

MITVFITSLCNTTSSHICLHISWV

TTMHGAMPHPGHIPTAPASLPA

KVKGSGKVCWLAFPLSELTPPS

ALQVNVSKSDDTLKINGVEDH

KTIFDGDGKTYQNVQHFIDEGN

YTCGDNHTLRDPHYVEDKGHK

YLVFEANTGTENGYQGEESLFN

KAYYGGGTNFFRKESQKLQQS

AKKRDAELAΝGALGIIELΝNDY

TLKKVMKPLITSΝTVTDEIERA

ΝVFKMΝGKWYLFTDSRGSKM

TIDVPQAKSTΝWITSYMTΝRG

FFEPEGSKGSITAAVMAKGLSV

ASGΝSTPERRRATAΝEΝVQPRA

IRDAEKAGRLPHPDMEIRGRVE

QRVGYTIEQIΝHMRDVFGTRLR

RAEDVFPPVIGVAAHKGGVYK

TSVSVHLAQDLALKGLRVLLV

EGΝDPQGTASMYHGWVPDLHI

HAEDTLLPFYLGEKDDVTYAIK

PTCWPGLDIIPSCLALHRIETEL

MRKFDEGΝLPTDPHLMLRLAIE

TVAHDYDVI VIDS APΝLG IGTIN

WCAADVLIVPTPAEQLDISVSS

RQFFDVILRDLLKΝVDLKGFEPD SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Uπknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblι- nucleotide insertion) sequence

24604 54972 24742 3899 MVDSLIAPVGVMARGNAITLPV

RATNVKFTLEELRGDSVEKTSR

VWSEKKDRGGQEAEVSGEGSS

QTKSLQKRQHSNGSDFTARGF

HTGQALVRSKGTYWNPTGLGL

SHGTEDPNLIGEELDAGEWDK

NTRKELAVLNVRRDFADFGTTI

KQDFRLLGQTSVDRLLQLSQG

QAVKGNQLLPVSLVKRKTTLA

PNTQTASPRALADSLMQLARQ

VSRLESGQFWVFEGGLRVLVR

ERVTTPKGTVASMYQGWVVPD

24605 54973 24743 268 2617 RMFRMKLMETLVSQCINAGHE

MTKAIAIAQFNDDSPEARKITR

RWRIGEAADLVGVSSQAIRDAE

KAGRLPHPDMEISGRVVKHGVG

YTIEQIYLVTRDVFGTRLPRAEDV

VFPPVIGVAAHKGGVYKTSVSV

HLAQDLALKGLRVLLVEGNDP

QGTASMYHGWVPDLHIHAEDT

LLPFYLGEKDDVTYAIKPTCWP

GVLDIIPSCLALHRIETELMGKFD

EGKLPTDPHLMLRLAIETVAHD

YDVIVIDSAPNLGIGTINWCAA

DVLIVPTPAELFDYTSALQFFD

MLRDLLKTVDLKGFEPDVRILL

TKYSNSNGSQSPWMEEQIRDA

WGSMVLKNVVRETDEVGKGQI

RMRTVFEQAIDQRSSTDTSLSTP

AAPMVDSLIARVGVMARGNAI

TLPVCGRDVKFTLEVLRGDSVE

KTSRVWSGNERDQELLTEDAL

DDLIPSFLLTGQQTPAFGRRVSG

VIEIADGSRRRKAAALTESDYR

VLVGELDDEQMAALSRLGNDY

RPTSAYERGQRYASRLQNEFAG

NISALADAENISRKIITRCINTAK

LPKSWALFSHPGELSARSGDA

LQKAFTDKEELLKQQASNLHE

QKKAGV IFEAEE VITLLTS VLKT

SSASRTSLSSRHQFAPGATVLY

KGDKMALNLDRSRVPAYIIRSY

IRCGRKGFASAGVGGCRGWLN

YAASEQIVLRVHHMRCEIPHRC

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24793 55161 24931 2249 MLPDIARFLPRLANDQIEEFTW

YVNHFTYSNAIKIFCYQMFLAS

TQARASGAPLQRLFRAIGGNA

WERPFRMVFCSAAFSEESSPFR

ETNYEPQLFLGFATDYRFAGW

TLRDVEMGYNHDSNGRSDPTS

RSWNRLYTRLMAENGNWLVE

VKPWYWGNTDDNPDITKYM

GYYQLKIGYHLGDAVLSAKGQ

YNWNTGYGGAELGLSYPITKH

VRLYTQVYSGYGESLIDYNFNQ

TRVGVGAIGVNVAQAEVLNLE

SGAKQVLQETFGYQQFRPGQE

EIIDTVLSGRDCLWMPTGGGK

SLCYQIPALLLNGLTVWSPLNS

LKEKSANPFEFTFAAFAHAFHW

VIQAIGMINTPA DGSTHKQART

SWLPYSSLPVLSVSTQDEKAKK

KMRFMQRSKDSLAKWLSAILP

WI VGL VGLFAVTVIRD YG RAS

EADRQALLEKGNVLIRALESGS

RVGMGMRMHHVQQQALLEEM

AGQPGVLWFAVTDAQGIIILHS

DPDKVGRALYSPDEMQKLKPE

ENSRWRLLGKTETTPALEVYRL

FQPMSAPWRHGMHNMPRCNG

KAVPQVDAQQAIFIAVDASDLV

ATQSGEKRNTLIILYALATVLL

ASVLSFFWYRRYLRSRQLLQDE

MKRKEKLVALGHLAA/GVAHE

IRNPLSSIKGLAKYFAERAPAGG

EAHQLAQHVQIRRFHAHHPAS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24824 55192 24962 128 2574 QWWMAMVAKWIDIWW

GVEMIRVKVVAIWEVWVEV

VWMVAWWW****WW*/DMG

EARWWWEYGVWEVEPEIILNA

PQQYLLAGIGDTLAKWYEAW

LAPQPETLPLTVRLGINNAQAIR

DVLLNSSEQALSDQQNQQLTQS

FCDWDAIIAGGGMVGGLGDR

FTRVAAAHAVHNGLTVLPQTE

KFLHGTKVAYGILVQSALLGQ

DDVLAQLTGAYQRFHLPTTLA

ELEVDINNQAEIDKVIAHTLRPV

ESIHYLPVTLTPDTLRAAFKKYS

QSCFVIRLGGDFIHQLAEΝHIVI

FVΝΝHΝGTRCQTFQWAISΝCH

TVSLQKFSVRKFLSDLFAIGGR

RGVRPPTEAPGHQKSDΝQAHV

SVSFDGLDLVFFWΝQWAGW

FCFDLFSRKRGRFSVWRΝKGFG

RYCQRLAΝFRDRQAFQLLΝQIH

FTRCKQVDΝGGTEFKATHFLAF

QQCHRTWFPGRPAIKTRVERL

DRYRΝRMEKSΝGQAΝLRVHG

GTWEKLVLQLDSAGMVΝRVSS

VGAPLREPIPTEGKGAKEDTWG

NLSSNDPLLEAFGGQFGIAISMH

QTLATRGGKRNARPTTRPRFHR

GTNPRGIAPHIGTANARYSTGH

CPVALPFGLRGPPLARENVATA

TKGH ESASRETEW A VAKLTSR

VLLICDATHALPIQVLRN DIRVI

AAGNGCTDDLQLEHLPANTDIR

24825 55193 24963 117 335 PGLAPATRRSTPGRFNADAGAD * RRAAGTGAGRAKRRGVGIHR CLADPFLADCRNAGLRGAALC GTAAASGK

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24887 55255 25025 2209 MIGEIRDGETAEIAIKAAQTGHL

VLSTLHTNSTCETLVRLQQMG

VARWMLSSALTLVIAQRLVRK

LCPHCRRQQGEPIHIPDNVWPSP

LPHWQAPGCVHCYHGFYGRTA

LFEVLPITPVIRQLISANTDVESL

ETHARQAGMRTLFENGCLAVE

QGLTTFEELIRVLGMPHGDGAA

MDREENELGVSCIAVPVFDIHG

RVPYAVSISLSTSRLKQLYAGLP

VWCDGSRFFAQKARAIKCKQW

GYVGAKSRQRWLFYAYDRLRK

TWAHVFGERTMATLGRLMSL

LSPFDWIWMTDGWPLYESRL

KGKLHVISKRYTQRIERYNLNL

RQHLARLGRKSLSFSKSVELHD

KAAGGVPVLVRELLKAGLLHE

DVNTVAGFGLSRYTLEPWLNN

GELDWREGAEKSLDSNVIASFE

QPFSHHGGTKVLSGNLGRAVM

KTSAVPVENQVIEAPAVVFESQ

HDVMPAFEAGLLDRDCWWR

HQGPKANGMPELHKLMPPLGV

LLDRCFKIALVTDGRLSGASGK

VPSAIHVTPEAYDGGLLAKVRD

GDIIRVNGQTGELTLLVDEAEL

AAREPHISELSAFTFGTGRGYSA

AFGVKCPFRKRALSDPCYAMR

EVADFLINKGVDGLFYLGTGGE

FSQMNTAQRMALAEEAVTIVD

GRVPVLIGVGSPSTDEAVKLAQ

HAQA YGADGI V A IN PY Y WKV A

24888 55256 25026 3395 MSELPFTIASKRIKYLGIQLTRD

VKDLFKENYKPLLKEIKEDTNK

WKYIPCSWLGRINIVKMAILAK

VIYRFΝAIPIKLPMTFFKELEKT

TLKFIWΝQKGAASRSΝPEPKΝK

LEDHITΝSTIYRLSTKSCSVSGL

KQTLLAESEALTSYSHRVFSAW

DFGLCGDVHVRLRQRIILYELK

GQVPALLLDDGTLLTEGVAIM

QYLADSVPDRQLLAPVΝSISRY

KTIEWLΝYIATELHKELKFSFH

WSTTSHKGLGM

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24926 55294 25064 1368 2451 PAHAAPGGGC/VRSLACRFLWN

MRVTGKSYSTLRRVLSAIWNW

RMMRCALTRALVAFRVR/SSVP

LAAVLAIYARENGAGTMFEPE

AAYDEDTSIMNDEEASADNET

VMSVIDGDKPDHDDDTHPDDE

PPQPPRGGRPGLRGLTLRWFSV

AAQRSDILDAVTLSLKVAALAT

LIALVLGTLAAAALWRRDFFG

KNAISLLLLLPIALPGIVTGLALL

TAFKTINLEPGFFTIWGHATFC

WWFNNVIARFRRTSWSLVEA

SMDLGAΝGWQTFRYWLPΝLS

SALLAGGMLAFALSFDEIIVTTF

TAGHERTLPLWLLΝQLGRPRD

VPVTNWALLVMLVTTLPILGA

WWLTAKATYLEKLKV

24927 55295 A 25065 2072 MSEQLTDQVLVERVQKGDQKA

FNLLWRYQHKVASLVSRYVP

SGDVPDWQEAFIKAYRELTPR

RPYLLRAFYEWLLDΝQLTPHL

WDVTLPGVQVPMEYARDGQI

VLΝIAPRAVGΝLELAΝDEVRFΝ

ARFGGIPRQVSVPLAAVLAIYA

REΝGAGTMFEPEAAYDEDTSI

MΝDEEASADΝETVMSVIDGDK

PDHDDDTHPDDEPPQPPRGGRP

ALRWΝVIVAIIFTTKPTAMGIA

VRFTTAKGETPAIPDVTTTTAVI

GETARASWAKCIGIIITTAVPIV

VKPFAΝISPATTSVPRFFGLPAS

SSHTLIGAIIGIGLTNALLTGSSV

MDALΝLREVTKIFSSLIVSPIVG

LVIAGGLIFLLRRYWSGTKKRD

RIHRIPEDRKKKKGKRKPPFWT

RIALIVSAAGVAFSHGAΝDGQK

GIGLVMLVLVG1APAGFVVΝM

ΝASGYEITRTRDAVTNFAARES

EASVIRHSΝRFIETIΝGGRRCSR

GITLTLHKLRVSAQPLLVAVLΝR

LEQKKPVGLRYDPQAQSLVCLP

TQTRTGWΝLΝGFEVGFRPCVR

LMIYGRSLEAQATASLAAATG

YDSH1FDLFPASASAQIDTDTAV

ILLCHDLΝRELPVLQAAREAKP

F YLG ALG S YRTHTLRLQKLHEL

G WSVRQETTQIRAPVGIFPKARD

AHTLALSVLAEVASVRLHQEE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmiπo acid sequence ( X=Unkno\vn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24954 55322 25092 338 2388 CVQEPLITVSWRLFAIPAGMKF

SLFLRCLFCFHLAARYLVLLCQ

LH SQGIKVLDFTGVQSGPSCTQ

MLA WFGAD VIKIERPG VG DVT

RHQLRDIPDIDALYFTMLNSNK

RSIELNTKTAEGKEVMEKLIRE

ADILVENFHPGAIDHMGFTWEH

IQEINPRLIFGSIKGFDECSPYVN

VKAYENVAQAAGGAASTTGF

WDGPPLVSAAALGDSNTGMHL

LIGLLA ALLHRELNMTV A El VE

REEWAGFRARETAALEAVTAP

STVIATGGGIILTEFNRHFMQNN

GIWYLCAPVSVLEDFRQRTME

VLRLAFLSSGILEFFTSLSIALVA

VYFGFSYLGELDFGHYDTGVTL

AAGFLALILAPEFFQPLRDLGTF

YHAKAQAVGAADSLKTFMETP

LAHPQRGEAELASTDPVTIEAE

ELFITSPEGKTLAGPLΝFTLPAG

QRAVLVGRSGSGSRYCPYIΝHR

ΝVRLGPIVTDVPWEΝSGDKSLP

EATAQVISSGSGATKVEDGLGD

LΝKPVSΝQΝLVTGIDTPVYΝAP

SAGSAPFGVLADΝMRYPILHKL

KDRLΝQTWYQ1RIGDRLAYISA

LDAQPDΝGLSVLTYHHILRDEE

ΝTRFRHTSTTTSVRAFNΝQMA

WLRDRGYATLSMVQLEGYVK

ΝKIΝLPARAWITFDDGLKSVS

RYAYPVLKQYGMKATAFIVTT

24955 55323 25093 1810 2399 STFRΝSDDEPYIVRPVAVAWRD

YVPQPARNGLSΝFTGΝLEEPAV

MVΝYFLQGDPYQGMVHFTRFF

HQHPSGLS*WVAGΝIFQILCAΝ

QPVRKRTRDNVQLLHSRGQRG

VFRCSRRVLTGLVDRFGRTQTF

HREAAGEFSGEITGVTDGAWR

HFRLVLTTQAQRAEEARQQAIS

GGTEPSAFPDTLPVDTEYVMNF

24956 55324 25094 577 MPVSTAVATVIKTKQVEFQLQ

VGVPLYFRLRANPIKTILDNQK

RLDSKGNIKRCRVPLIKEAEQIA

WLQRKLGNAARVEDVHPISER

PQYFSGDGKSGKIQTVCFEVIG

CREEPDAEECHGDREQRRVFIR

EDGFF VTKDL YPNRRAVG 11 STT

AVISPSQPPIIAPRVAQSSEPRSA

AHALARAIRQSTTV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24974 55342 251 12 1087 3289 RLRSCGAQKNTFCNAAAGCRW

RTTLSKMGGLLIAADLQDPVQ

DMEMWQFHPTGIAC/AGVLVT

E/GCRGEGGYLLNKHGERFMER

YAPNAKDLAGRDWARSIMIEI

REGRGCDGPWGPHAKLKLDHL

GKEVLESRLPGILELSRTFAHVD

PVKEPIPVIPTCHYMMGGIPTKV

TGQALTVNEKGEDVWPGLFA

VGEIACVSVHGANRLGGNSLL

DLWFGSARQVLHLQESIAEQG

ALRDASESDVEASLDRLNRWN

NNRNGEDPVAIRKALQECMQH

NFSVFREGDAMAKGLEQLKVI

RERLKNARLDATSSEFNTQRVE

CLELHNLMETAYATAVYATFR

TERRGAHSRVFDFPDRDDENWL

CHSLYLPESESMTRRSDYTLEA

DEGRDMMLLDALIQLKEKDPS

LSFRRSCREGVCGSDGLNMNG

KNGLACITPISALNQPGKKIVIR

PLPGLPVIRDLWDMGQFYAQ

YEKIKPYLLNNGQNPPAREHLQ

MPEQREKLDGLYECILCACCST

SCPSFWWNPDKFIGPGSLLAGY

RSGLIAGIPKCSARYLSGEKRSV

AWQQIAAEIGISIDAQFNESLKG

ISRDESLRRILQHGGKEGDFNSQ

ERAQLAYRKΝLLYVHSLRELT

VΝAVLPGIRSLLADLRAQQISV

GLASVSLΝAPTILAALELREFFT

FCADASQLKΝSKPGPGIFLAGC

24975 55343 251 13 47 630 VGWETSFAQIRSRFLRIRFCRAY

SSTLFVSAAΝPTT*G/QMVF*CG

NGAQHKNILLLYRSIHGGFHFQ

RGHHINTFNKRWRR* *NRT* YQ

RDVRATTGSGGGDRKTHLAGA

VIRDITHRIERFTRRAGGNHNV

QMFQWDGRKCATAISTVLDM

FGDHFGRQKIASCQRWLAKTIR

TVQQPICKNIVRKPGCHSLA

24976 55344 251 14 731 829

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

24993 55361 25131 473 1765 KAWLMTGIVRHWKGRAVPPA

EQLLEHLGNGKSFDSVAQAWD

AAMADAKAEDTVLWGVEAFRI

NAAVAKDDTQIHTHMCYCEFT

DIMDSIAALDADVITIETSRSDM

ELLESFEEFDYPNEIGPGVYDIH

SPNVPSVEWIEALLKKAAKRIP

AERLWVNPDCGLKTRGWPETR

AALANMVQAAQNLRRGARAG

CAADFAASARLAVGEALTNIA

ATQIGDIKRIKLSANWMAAAG

HPGEDAGLYEAVKAVGEELCP

ALGLTIPVGKDSMSMKTRWQE

GNEEREMTSPLSLVISAFARVE

DVRHTITPQLSTEDNALLLIDLG

KGNNALGATALAQVYRQLGD

KPADVRDVAQLKGFYDAIQAL

VAQRKLLAYHDRSDGGLLVTL

AEMAVLSSLGQGGYFGHMII/D

SGQYPGKSKTGQSTPDVAAQA

RQSWIP

24994 55362 25132 602 2563 WTTLTLVLTAVGSVLLLLFLV

MKARMHAFLALMWSMGAGL

FSGMPLDKIAATMEKGMGGTL

GFLAVWALGAMFGEILHETG

AVDQIAVKMLKSFGHSRAHYA

IG L AGL VC ALPLFFEVAI VLLIS

VAFSMARHTGTNLVKLVIPLFA

GVAAAAAFLVPGPAPMLLASQ

MNADFGWMILIGLCAAIPGMII

AGPLWGNFISRYVELHIPDDISE

PHLGEGKM PSFGFSLSLILLPL V

LVGLKTIAARFVPEGSTAYEWF

EFIGHPFTAILVACLVAIYGLAM

RQGMPKDKVMEICGHALVQPA

GIILLVIGAGGVFKQVLVDSGV

GPALGEALTGMGLPIAITCFVL

AAAVRIIQGSATVACLTAVGLV

MPVIEQLNYSKRRGFTGRVEEN

FGVCKGPSKYHSQHDAINRQG

REASDAHGTLENLPLPLVPQPN

AATALAALRASGLEVSENAIRD

G I ASAILPGRFQI VSESPRVIFDV

AHNPHAAEYLTGRMKALPKNG

RVLAVIGMLHDKDIAGTLAWL

KSWDDWYCAPLEGPRGATAE

QLLEHLGNGKSFDSVAQAWDA

AMADAKAEDTVLVCGSFHTVA

HVMEVIDARRSGGKLCQMHVN

VQDKIDEEINQVHICLCLVLVIV

SGCKYVGYSLKCSEHYYSLVR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25039 55407 25177 2635 MNKSGKYLVWTVLSIMGAFAL

GYIALNRGEQINALWIWASVC

IYLIAYRFYGLYIAKNVLAVDP

TRMTPAVRHNDGLDYVPTDKK

VLFGHHFAAIAGAGPLVGPVLA

AQMGYLPGMIWLLAGWLAG

AVQDFMVLFVSTRRDGRSLGE

LVKEEMGPTAGVIALVACFMI

MVIILAVLAMIVVKALTHSPWG

TYTVAFTIPLALFMGIYLRYLRP

GRIGEVSVIGLVFLIFAIISGGWV

AESPTWAPYFDFTGVQLTWML

RLINRSIMMDFSLTEEQELLLAS

IRELITTNFPEEYFRTCDQNGTY

PREFMRALADNGISMLGVPEEF

GGIPADYVTQMLALMEVSKCG

APAFLITOGQCIHSMRRFGSAE

QLRKTAESTLETGDPAYALALT

EPGAGSDNNSATTTYTRKNGK

VYINGQKTFITGAKEYPYMLVL

ARDPQPKDPKKAFTLWWVDSS

KPGIKINPLHKIGWHMLSTCEV

YLDNV*TSVWRTCACPALRRA

TQRYRRQSRAGNLRTSGEAIRR

DMEWTSLRSEVDWEKGDTIKQC

ISAATSCVYGVTGEGILEGGDA

QILREPLPGTKLGLLNWPVFDA

LESRSTRERDGKPGGEICGETA

NILIRGPENRPLRRDPPGKP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25089 55457 25227 1886 HRLNITAENDCRRLHCSLRDLS

SLLQAVGRLAEYFIGDVFAARF

NDALTWERLVKVTLYGSQIKL

YNIETAVPSVLKPDLIDVHAQS

LAGGCRLSAHWLAQYCSEIHR

QNTQQFVTLISTTMDAITPLIST

KVQDKLLLSACHLLVSLATTVR

PVFLISIPAVQKVFNRITDASAL

RLVDKAQVLVCRALSNILLLPW

PNLPENEQQWPVRSINHASLISA

LSRDYRNLKVPSAGAPQRKMPL

DDTKLIIHQTLQRLRKILWENIS

GVESTKSSTDFAYQFGCRESVVQ

VSLGLFPAFVIHQSDVTDEMLSF

FLTLFRGLRVQMGVPFTEQIIQT

FLNMFTREQLAESILHEGSTGC

RWEKFLKILQVWQEPGQVFK

PFLPSIIALCMEQVYPIIAERPSP

DVKAELFELLFRTLHHNWRYFF

KSTVLASVQRGIAVEEQMENEP

QFSAIMQAFGQSFLQPD1HLFK

QNLFVYLVETLNTKQKLVYHKKVI

FRVTAMVLFQFVNVLLQVVLVVH

KSHDLLVQEVEIGHRHSYNMASV

DFVDGFFAAFLPEFLVTSCVDGVV

DANQKSVLGRNFVKMDRLCPCL

PGPAPHSPRMCTGWSTTCGLLT

DSGNDSLAPWGLWKLLGPCLL

PGGTRDFLLVAT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25090 55458 A 25228 689 3053 VDCRMS/FSYIEKFTDFLRLFVS

VHLRRIESYSQFPWEFLTLLFK

YTFHQPTHEGYFSCLDIWTLFL

DYLTSKIKSRLGDKEAVLNRYE

DALVLLLTEVLNRIQFRYNQAQ

VLEELVDDETLDDDQQTEWQRY

LRHSLEWAKVMELLPTHAFST

LFP VLQDN LVE V YLGLQQFI VTS

GSGHRLNITAENDCRRLHCSLR

DLSSLLQAVGRLAEYFIGDVFA

ARVFN DALTV VERL VKVTLYGS

QIKLYNIETAVPSVLKPDLIDVH

AQSLAALQAYSHWLAQYCSEV

HRQNTQQFVTLISTTMDAITPLI

STKVQDKLLLSACHLLVSLATT

VRPVFLISIPAVQKVFNRITDAS

ALRLVDKAQVLVCRALSNILLL

PWPNLPENEQQWPVRSINHASL

ISALSRDYRNLKPSAVAPQRKM

PLDDTKLIIHQTLSVLEDIVENIS

GESTKSRQICYQSLQESVQVSL

ALFPAFIHQSDVTDEMLSFFLTL

FRGLRVQMGVPFTEQIIQTFLN

MFTREQLAESILHEGSTGCRW

EKFLKILQWVQEPGQVFKPFL

PSIIALCMEQVYPIIAERPSPDVK

AELFELLFRTLHHNWRYFFKST

VLASVQRGIAEEQMENEPQFSA

IMQAFGQSFLQPDIHLFKQNLF

YLETLNTKQKLYHKKIFRTAML

FQFVNVLLQVLVHKSHDLLQE

EIGIAIYNMASVDFDGFFAAFLP

25091 55459 25229 853 MISVANEIAEAGFDPQGRTSED

LLDLAESRVFKIAESRANKDEG

PKNIADVLDATVARIEQLFQQP

HDGVTGVNTGYDDLNKKTAG

LQPSDLIIVAARPSMGKTTFAM

TLVENAGRVMLQDKPVVLIFSLE

MPSEQIMMRSLASLSRVDQTKI

RTGQLDDEDWARISGTMGILLE

KRNIYIDDSSGLTPTEVRSRARR

IVAREHGGIGLIMIDYLPLMRVP

ALFDNRTLEIAEISRSLKALAKE

LNVPWALSHLNRSLEQRAEER

PGNSDLGESGSIEQDADLIL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25138 55506 A 25276 652 2689 KFSVGYAVQNFNATVSTKQFQ

VFSEQNTSSYFAEPQLDVNYYQ

NDWHFVTTRDDMPEATRVHL

EPTINLPLSNNWGSINTEAKLLA

THYQQTNLDWYNSRNTTKLDE

SVNRVMPQFKVDGRMVFERD

MEMLAPGYTQTLEPRAQYLYV

PYRDQSDIYNYDSSLLQSDYSG

LFRDRTYGGLDRIASANQVTTG

VTSRIYDDAAVERFNISVGQIY

YFTESRTGDDNITWENDDKTGS

L V WAGDTY WRI SERWGLRGGI

QYDTRLDNVATSNSSIEYRRDE

DRLVQLNYRYASPEYIQATLPN

VNHHITMEHLHMKTRTQQIEEL

QKEWTQPRWEGITVRPYSAEDV

VKLRGSVNPECTLAQLGAAKM

WRLLHGESKKGYINSLGALTG

GQALQQAKAGIEAVYLSGWQV

AADANLAASMYPDQSLYPANS

VPAWERINNTFRRADQIQWSA

GIEPGDPRYVDYFLPIVADAEA

GFGGVLNAFELMKAMIEAGAA

AVHFEDQLASVKKMRHMGRT

ASDQPWLAYAPYADLVWCEPP

PPDLELARRFAQAIHAKYPGKL

LAYNCSPSFNWQKNLDDKTIAS

FQQQLSDMGYKFQFITVLAGIHS

MWFNMFDLANAYAQGEGMK

HYVEKVQQPEFAAAKDGYTFV

SHQQEVGTGYFDKVTTIIQGGT

SSVTALTGSTEESQF

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25226 55594 25364 2701 TFFLPAGEILPPRLEPQITLPVGS

RRIISIAVTDLPEPESPHLRSGLG

WASLCCFMVICKFFPAAEGLIL

AAVCDSRGSRYWCNGNRRYG

YASDLLVRCGATVMFSEVTEV

RDAIHLLTPRAVNEEVGKRLLE

EMEWYDNYLNMGKTDRSANP

SPGNKKGGLGKRGSSKALWLP

LLQIQARKQVGLRVYTVACVL

RTGTWYDRNGPDWRVPGQLN

MGNPAPETGRYRLAHPATPHD

PRTTPDHPSHIKPHAPTNQQPDT

LTPTHHHHTDTRDPSPPPPRTRT

PRQSTHTTPPHPTTTTRHTDIHP

PTHTNPPPPTRVLTRQLH HTNRI

IPHRTHTTTCRRNHHNQMNTTT

PPPPHTPQITHRHHNTTLREQTQ

KHRQHIHGTQHHTTRKPPTPTT

RQYNTSIVGTIGGGVMVERKVIE

ESLQALQERKPRLFHGRMARN

GADAVGSDCGGAMSVFISVHG

MRPRL VLIG AG HVN RAIAQS A A

LLGFDIAVADIYRESLNPELFPP

STTLLHAESFGAAVEALDIRPD

NFVLIATNNQDREALDKLIEQPI

AWLGLLASRRKVQLFLRQLRE

KGVAEEHIARLHAPVGYNIGAE

TPQEIAIRVLAEILQVKNNAPGG

LMMKPSHPSGHQMVVIRGAGD

IASGVALRLYHAGFNVIMLEVE

KPTVIRCTVAFAQAVFDGEMT

VEGVTARLATSSAEAMKLTER

SEQ ID SEQ ID NO: Met SEQ ID NO- Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno>vn, NO: of peptide hod in USSN location of first codon for last ammo acid *=Stop codon, /=possιble nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possιble nucleotide insertion) sequence

25261 55629 25399 174 2238 LRSGDLPWEINPLSSCSLLHEKD

PPTTSGPQTVTSPRNISPISNPRQR

RHILSMDPKLRRRSWTWVGSLP

LVFNHCRDASLIIHPGFRGVRPR

RDVCLGPSPLATITDAELYVTL

TVEGKSIPFLIDTEATHSTLPSFK

GPVALASIHVQNVQ1KRDKEGH

YIMVKGSIQQEELTILNMYAPN

TGAPRFIKQVLNDLQRDLDSHT

IIMGDFNTPLSTLDRSTRQKVN

KDIQDLNSALHQADLIDIYRTL

HTKSTECTFFSAPHRTYSKIDHI

VGSKALLSKCKRTEIIINCLSDH

SAIKLELRIKKLTQNHSTTWKL

NNLLLNDYWVHKEMKAEIKM

FFEΓNENKNTTYQNLWDTFKAV

CRGKFIALNAYKRKQERSKIDT

LTSQLEELEKQEQTRSKASRRE

EITKIRAELKEIETQKTLQKINES

RSWFFEKINKIDILLARLIKKKR

EKNQIDA I KNDKGDI ATDPTEIQ

TTIREYYKHLCPNKLENLEEMD

KFLDTYTLPRLNQEEDESLNRPI

TGSEIVAIINSLPTKKSPGPDGFT

AKFYQRYKEELVPFLQKYKEEL

VPFLLKLFQSIEKEGILPNSFSEA

SHLIPKPGRDTTKKENFRPISLM

NIDAKILNKILANQIQQHIKKLI

HHDQVGFIPGMQGWFNIRKSIN

VIQHINRTKDKNHMIISIDAEKA

FDKIQQPSC

25262 55630 25400 267 EKDPLTTSGPQTVTSPRNISPISN LRLFAFTWTDPDTHQAQQITW AVLPQGFTDSPRYFSQAQISSLS VTYLSIILIKTHVLSLPIMSD

25263 55631 25401 167 408 LGSRTFPWEINPPSSCSLLREKD PPTTSGPQTVTRPRNISPISNLVS GLFLLSSPTSLTIPQPLSSFNLDD TLQSLPSLNF

25264 55632 A 25402 142 441 LRLGDLPWEINPLSSCSLLCEKD

PPTTSGPVPRNISPISNPVSGLFLL

SSPTCLTIPQPLSPFNLGATLQSL

PSLNFNSFHFLVETKETRFIRGP

KTPAP

25265 55633 25403 79 381 LGSGDLPWEINPLSSCSLLREKE PPTTSGPQTVTRPRNISPISNPELA TLAGNLATGPRNARSPGFLLSH VLSVWDPTENQTVQLTWQPLP QPLELWPKAL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod n USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25290 55658 A 25428 557 MARSLGVLVALPFPLPVGFNAE

EAHNIVKEFSPGKSHPRESLSQQ

RETLVQAGAFHWFGWRGKEK

LKPKFNTFGRLPNEMLEQWLSP

TNQCVDGV/LKGGEDVYNHNNI

NQWTASIVEQSLVTHLVKLGKA

YKYIVTCAVVQKSAYGFHTASS

CFWDTTSDGTCTVRL/WENRT

MNVCIVNVFCHCLFVL

25291 55659 25429 178 2270 VRRLFCVQTGGSPVGRGSLHHL

WLVFSHVLSLLCSPCLLAPGM

WGFHDRDLVLRKALYTMMRT

GAEREALKRRWRWQQTQQNK

ESGLVYTEEEWEREWTELLKL

ASSEPRTHFSKNGGTGGGHLPP

EGKPLHGCSSLLRSGKGGHVK

AEPSRLQQSQAKPPLTSQIRALH

FPIPSQINEKPGAGHWSAKLHFP

YWQLGEAGEEEGSSPPDIMRCL

LTCLSVPSTAVIPLTDSEHKLLP

LHFAVDPGKDWΕWGKDDNDN

ARLAHLILSLEAKLNLLHSYMN

VTWIRIPSETRAPLAQPESPTAS

AGEDVQSLADSLDSDRDSVCS

NSNSNNGKNGKDKEKEKQRKE

KDKTRADSVANKLGSFSKTLGI

KLKKNMGGLGGLVHGKMGRA

NSANGKNGDSAERGKEKKAKS

RKGSKEESGASASTSPSEKTTPS

PTDKAAGASPAEKGGGPRGDA

WKYSTDVKLSLNILRAAMQGE

RKFIFAGLLLTSHRHQFHEEMIG

YYLTSAQERFSAEQEQRRRDA

ATAAAAAAVPPPPPRP/ERPPRRP

ETEGVPVPERASPGPPTQLVLK

LKERPSPGPAAGRAARAAAGG

TA/CPGGRRAACERQRTSAWPQ

PPGASAPERHPRAGVGRAGRG

VRAGRGGAAAVRHVPAAEPLA

WAELQPGARRRPAHRQHGRV

AGARGARGPTGRGGDRGGGRA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25304 55672 A 25443 2355 MDHPGFREFCWKPHEVLKDLP

LGSYSYCSPPSSLMTYFFPTERG

GKIYYDGMGQDLADIRGSLEL

AMTHPEFYWYVDEGLSADNLK

SSLLRSEILFGAPLPNYYSVDDR

WEEQRAKFQSFWTYVAMLAK

QSTSKVQVLYGGTDLFDYEVR

RTFNNDMLLAFISSSCIAALVYI

LTSCSVFLSFFGIASIGLSCLVAL

FLYHWFGIQYLGILNGVAAFV

IVGIGVDDVFVFINTYRQATHL

EDPQLRMIHTVQTAGKATFFTS

LTTAAAYAANVFSQIPAVHDFG

LFMSLIVSCCWLAVLVTMPAA

LGLWSLYLAPLESSCQTSCHQN

CSRKTSLHFPGDVFAAPEQVGG

SPAQGPIPYLDDDIPLLEVEEEP

VSLELGDVSLVSVSPEGLQPAS

NTGSRGHLIVQLQELLHHWVL

WSAVKSRWVIVGLFVSILILSLV

FASRLRVSASRAPLLFRPDTNIQ

VLLDLKYNLSAEGISCITCSGLF

QEKPHSLQNNIRTSLEKKRRGS

GVPWASRPEATLQDFPGTVYIS

KVKSQGHPAVYRLSLNASLPAP

WQAVSPGDGEVPSFQVYRAPF

GNFTKKLTACMSTVGLLQAAS

PSRKWMLTTLACDAKRGWKF

DFSFYVATKEQQHTRKLYFAQS

HKPPFHGRVCMAPPGCLLSSSP

DGPTKGFFFVPSEKVPKARLSA

TFGFNPCVNTGCGKPAVRPLVD

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25305 55673 25444 1737 MLYAAECLRNVMKLQVIPSAL

NEALQAQSTWSDLGLASHALS

STWCLHGESAAWSQPAWECG

QPRDQLQTHSEAWLCALVATF

SQELEQFAVTGAQISDRQGHAV

CTAPPRGRPSTLMTNLVCASSA

DECGGGKTETQTAGGRLQGAE

TRSRGQLTRLITRTQAAEPRWF

LQLLKRSANRSRALTRPFSGLSS

DGARRLRLSFVSAVSSADTKPT

VPVSSDSSGRDGCGETRAEAGP

GGPHVAQPQRVAPPAAAARDF

RKPRGLNRQNVSP/PGPGEQGP

G/PRPQKPAGRAPVPEPQGEPGL

GLFPRVGRPPRSFPGSPADPAAS

VSHTQGPSPDTGLPGTCQNRLP

NPAAVDEQTCTRGSLNCRLSRS

PRVSERRG PEGTPGRRPAAPPQ

CAGTRGLSPRADLGAAIRTPRA

PYRPHGQGRPSRHNCDSVSSQG

WPPHSCWWKTTSNGMPWKAS

FCSRTAQPANQNTGNHERGLRS

VAMFGDRASREATPALSLCESQ

GCFEDEKEVFSPEPHVETSDEPL

PICSGPGDGWGDPIARPGRGNN

LSPGTSAWEVPRWIRVTGEDW

LSTGPAECVFINDLTT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno>vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25396 55764 25537 2204 IDMIFTPGPPSTPKHKKSQKGSA

FTFPSQQSPRNEPYVARPSTSEI

EDQSMMGKFVKVERQVQDMG

KKLDFLVDMHMQHMERLQVQ

VTEYYPTKGTSSPAEAEKKEDN

RYSDLKTIICNYSETGPPEPPYSF

HQVTIDKVSPYGFFAHDPVNLP

RGGPSSGKVQATPPSSATTYVE

RPTVLPILTLLDSRVSCHSQADL

QGPYSDRISPRQRRSITRDSDTP

LSLMSVNHEELERSPSGFSISQD

RDDYVFGPNGGSSWMREKRYL

AEGETDTDTDPFTPSGSMPLSST

GDGISDSTVPLFLSSEILQKQVG

QSITSMLGFLSRGPSMKLCMGL

AC VLSL WNTVSG I KGEAKKEK

GMTFLPTTDSKKFFSLLSVTSYS

SFAFHKFSVAVYNISNLKTVDP

AKFPTRYCYCLNNRTNDLSDFT

ALLVDIIGNSTSYLTEIFKSTSIL

SVNQSNESDCIFICVMTGKSGR

NLSDFWEIEEKYPIINYTFTSGL

SGVLALLLTQSLFGGLFTRTRM

KFGAVTRIGVDLPWEINP/LSSCS

LLHEKDPPTTSGPQTDQPKKHL

TNFKSAARPTFLGQGQVPLNPF

SFTLSGKSCFPRRQEPPNRLFPH

PNLLSLCPNPLFLCPNPFSTFLE

GKNHHPHPFSVSQVFSLGLPPS

LWEHSPMAHRLRVQPRQQPPDI

HKQVISLQSGHSLLVKSQSWSQ

DPIKFQLPHHHKNTASVCINPSV

25397 55765 25538 110 542 TALLLTQSLFGGLFTRTRMKFG AMTRIGVDLPWEINPLSSCSLLC EKHPPTTSGPQTDQPKKHLTNF KSETKETCFIHEPKTLAPVTDW EGSLPLVFNHCRDGLSDHSATF QGCQTMQGCLPWSFTLSGKSR FSGEGASCSLPG

25398 55766 25539 781 MPLQPLATPFTSPGSPSVAQVT

TNTGEPGFAQQEYAETPQTTAR

PPHPHPALRALQASVHQTPRLG

DCLGSSESATALHGSGEPNKLA

PPGRPTERGGLFKCSVPLRTVR

GCRAGLRGTETVPSSLQRQPAG

DVGWINNKSTTALDRTPTDTQ

RTRRPRPPKQKQRGRALKERPR

DSDSAREGPLKAVAGLFGGLFT

RTCMKFGAVTRIGVDLPWEΓNPL

SSCSLLH EKDPPTTSGPQTDQPK

KHLTNFKSDLLSLATED

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25413 55781 25554 84 2804 PRGSWRCRRDLKCRPLSHSDA

DWDDLWDQFDERRYLNAKKW

RVGDDPYKPVCFSTSGRVSGSP

AIRAIPDTRHLRKKATSNSLSRQ

QLASPLPRSSYCGVTPGPIAIGP

LWTSGSLRTPNHIDTVFAPGLP

QPWFHLNYLRAMPSLSSAPKCT

LLVYCTDLPPTSIIITFHNEARST

LLRTIRRPPAVSTSQMAMTAAA

LTPAPLRTYSVHLSCRAHQLVP

MPQRKKYDETWVREHTKHSKl

SLFPSCRLHFSCLSRRRMAVGS

GKFQVMGDLGEPFLRVRWLRI

WTLGPDFHGSALNSVLNRVTPT

HLIREIILVDDFSNDPDDCKQLI

KLPKVKCLRNNERQGLVRSRIR

GADIAQGTTLTFLDSHCEVNRD

WLQPLLHRVKEDYTRWCPVI

DIINLDTFTYIESASELRGGFDW

SLHFQWEQLSPEQKARRLDPTE

PIRTPIIAGGLFVIDKAWFDYLG

KYDMDMDIWGGENFEMMTVQ

VLQPRRSEALICTWKVHHLTRE

STALLIALVQAPFTGPQAKKLQ

QSPCPAMLAPEYAPEASVLVCT

VSLLTYTTLQSEISFRVWMCGG

SLEIVPCSRVGHVFRKKHPYVF

PDGNANTYIKNTKRTAEVWMD

EYKQYYYAARPFALERPFGNV

ESRLDLRKNLRCQSFKWYLENI

YPELRYPSYLLELWLAESRGPQ

LAWSGEETDNDQLDEGFYVYQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmiπo acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25575 55943 25716 924 MFAIISYSSLAAVLLTATLTAAG

IISFPVALCLVIGANLGSGLLAM

LNNSAANAAARRVALGSLLFK

LVGSLIILPFVHLLAETMGKLSL

PKAELVI Y FH VF YNLVRCL VML

PF VDPM A RFCKTIIRDEPELDTQ

LRPKHLDVSALDTPTLALANAA

RETCALATPWTDDGRKYAYSA

ASGGRRSATKVMVWTDGESH

DGSMLKAVIDQCNHDNILRFGI

AVLGYLNRNALDTKNLIKEIKA

IASIPTERYFFNVSDEAALLEKA

GTLGEQIFSIEDMDLGDEVYTV

GRPHPMIDPTLRNQLIADLGAK

PQVRVLLLDVVIGFGATADPAA

SLVSAWQKACAARLDNQPLYA

IATVTGTERDPQCRSQQIATLED

AGIAWSSLPEATLLAAALIHPL

SPAAQQHTPSLLENVAVINIGLR

SFALELQSASKPVVHYQWSPV

AGQGKWLANPELLEADADAEY

AAVIDIDLADIKEPILCAPNDPD

DARPLSAVQGEKIDEVFIGSCM

TWGHFRAAGKLLDAHKGQLPT

RLWVAPPTRMDAAQLTEEGYY

S VFGKSG ARVSS IPCA VPCV WA

RVADGATVVSTSTRNFPNRLGT

GANVFLASAELAAVAALIGKLP

TPEEYQTYVAQVDKTAVDTYR

YLNFNQLSQYTEKADGLLKPRF

RPWQRKILDTLATYHEQHRDEP

GPGRERLRRMALPMEDEALVL

25576 55944 25717 417 MG VLNN WLSEEESLWIQSRIHL

RALRYYSNWRQYFAGYTFGRQ

YWQSPEDDHLPLLREFLARYER

PMKNCWKILDIEETTDVDIIRRA

YLALLPSFHPETDPQDFKQLRQ

AYEEALRIAQSPAKSVWQPEEY

EV AEHEI LLAFRALLASDSERFL

PSAWQRFIQQLNYCSMEEIDEL

RWSLCTIAMNTAHLSFECWLL

AERLRWLQEENTGEIDEEELGS

FLYAIAKGNVFNFQTILHLPVA

RRPDICTQHNDQSRCEGYQILS

DKRGHQHGGGITALYQCGNAD

PRAKGERLFFDAPA*CASSARV

CVLSLAGASKKSRSPFARGSAL

PHWYRAVMPPPCW SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25577 55945 25718 1680 2058 YRAYAPAFLPLSPSCPPLWRHC

GSGRGENRRRDSSAHGPYAPRR

QPDMPAHRQS*SFV/PASCSAC

MDEPHKRLTVTAGTECGTSASS

AALRAILKPCSSVCSSFFLLLLL

PPPPPSSSSSSFFFLF

25578 55946 25719 1 1 15 3549 NPDRLLQLNLILETSK*QQMGD

TRKKRS/NLTVAPIISPLKRYEQ

HTELSRHINVVNLGDRNRRQQL

ILDQGKSSQRNIYLSHVAQKIPG

RATYALSHSVDMITIQLGTLLR

CAPPHRRRYAGRFFCRSAGNFL

NVQGFDAVLVAVKHDLLLCLT

IAPSLIVCTRLRSPWCGALRRCS

TDGRSDLASSGVMFSIDTESAL

TRWCLSLPHGALGKIIAEGLLS

VIASKASAIVTTVAWPVTRRSS

LVNWHSGGSGLWRCNRTDERD

QQASQGTTRMGRTQRNYSPTR

QAIHKTGSPTMATTSNTEQPPH

EKPNTLTQHPRNPDRTIHPKAT

HNELTQDTPQRDAKQNGEKTQ

RKKNCLSELNDAEDQAERFQD

RLMLKLQVTTKPCSMTRLRDC

AGIWSAANRWSGIGIDRMIMLF

TNSHTIATLFSSRRCAHRNKFH

LMNEAVRRLLRSSFRKSVLRRD

ASFHDNQRVHSLQLLKERKKSL

IHGRICAAKASLFQTRRYRWQK

APLFSAQFRGRNRAVTHNRWV

TTTTAIERTRARGLRPNSGRGF

HSSPAWQLRHRKCRRCARRYH

TVYWIKRRRSVARASTWSGRI

TSRRGENRRRDSSAIAHMLHAA

KQTCLRIAVMIIRAASCSACMD

EPPSDLTVTAGTDAGLAPAGYA

LNERRDLLHALTKSTALRTAHR

GPNRTGWLNRRIVRFVMTALF

25579 55947 25720 606 1562

25580 55948 25721 688 762

25581 55949 25722 492 737 SLPSGATLPPPALLLASAPDTA* WRCRER*YHLPAYAALSPAVA HRASLYSTLPSSVPWRRQCAGF RARRSPEQAWAYPAR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25588 55956 25729 2376 MAEVEEKKQRIFRKFTYRGVD

LGQLLDMSFEQLRQLYGARQL

RRLNHGLWRNAEAQAAFAAE

APMLGQEGGADHREAGSGEDA

PAGYDHPSQDGGQQGGRLQRQ

DLQPGGDQAGDDRPRPGRVLH

HLQAQRGKKPM/ISTVTFGQ*P

DPPLRAGQRL*RC/RLLIYGRGK

CWALSGNP/RSGKTTLLKSISAR

LTPQQGEIHYENRSLYAMSEAD

RRRLLRTEWGWHQHPLDGLR

RQVSAGGNIGERLMATGARHY

GDIRATAQKWLEEVEIPANRID

DLPTTFLRATHTVKMFSIPGYSS

PGQLLDPETNINIGTSYLQYVY

QQFGNNRIFSSAAYNAGPGRVA

TAIVLTLYIIYMVGFFATSGELT

YEVWIGFFASAFTKVFTLLALF

SILIHAWIGMWQVLTDYVKPLA

LRLMLQLVIWALWYVIYGFV

WWGMRAALQISQSGQTCALL

SKVFPTRSHTVSAQGGITVALG

NTHEDNWEWHMYDTVKGSDY

IDAGRKRQEEGDWNSGVGDPS

DAGDRKHQLKAAQLRPEAIKQ

RRIANRLKRRTQFPRHLKGFVN

TLKPIHGGCSVGTKCPQMASLP

EGLHHPVKLVFLGKPGCLLTDR

PLKGPNTAKPVAVDLNASATAI

TSYSLYGGSMILLFLASTLYHAI

PHQRAKMWLKKFDHCAIYLLI

AGTYTPFLLVGLDSPLARG LMI

25589 55957 25730 219 652 SASWREAICLSRCRLPRSATAR

GAGRGGCGLADRRASRQGKNL

EAESAQEQNGHQHRIHESQHPC

QGGAPVSHHQAAVRLRESQIQ

GAAEKR* PTGD VI H PGQPVSGG

/LK*YPSIPTCLLTTRTASLLKPP

GVRTSVCWQQLPR

25590 55958 25731 1902 2100 RKFFSSSSGRS*PVRCSKL*SSID

A*PLERIKRSRSYQVGSVGLCL

RKSFHSTSAISAMPIGAPG

25591 55959 25732 3223 3669

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno\vn,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25658 56026 25799 2392 MEMVAASKMRKSQDRMAASR

PYAETMRKVIGHLAHGNLEYK

HPYLEDRDVKRVGYLWSTDR

GLCGGLNINLFKKLLAEMKTW

TDKGVQCDLAMIGSKGVSFFNS

VGGNVVAQVTGMGDNPSLSEL

IGPVKVMLQAYDEGRLDKLYI

VSNKFINTMSQVPTISQLLPLPA

SDDDDLKHKSWDYLYEPDPKA

LLEQCSCMLRSPAWGITSTDTT

RARTDLACPIWLLLDPYPKLMG

NAPKALASVDKRGVPVNTILVS

ALVTALCVLINYLAPESAFGLL

MALWSALVINWAMISLAHMK

FRRAKQEQGVVTRFPALLYPLG

NWICLLFMAAVLVIMLMTPGM

AISVYLIPPLQTNTFNSTTIAMA

DYQMESLSAEINFAAAKLARA

CADEWTARTPEKPRYVAGVLG

PTNRTASISPDVNDPAFRNITFD

GLVAAYRESTKALVEGGADLIL

IETVFDTLNAKAAVFAVKTEFE

ALGVELPIMISGTITDASGRTLS

GQTTEAFYNSLRHAEALTFGLN

CALGPDELRQYVQELSRIAECY

VTAHPNAGLPNAFGEYDLDAD

TMAKQIREWAQAGFLNIVRGC

CGTTPQHIAEMSPGRKRLTRAE

SSSVPSTLPGKAWLEHALPLIAE

QL/QGRRSAVFIPFVAGVTQTWD

DYTAKTAAVLAPLGVSVTGIHS

WDPVAAIENAEIVIVGGGNTF

25659 56027 25800 412 1115 LAGEVMDLLLLSNSTLPGKAW

LEHALPLIAEQLQGRRSAVFIPF

AGVTQTWDDYTAKTVAVLAPL

GISVTGIHSVVDPVAAIENAEIVI

VGGGNTFQLLKQCRERG LLAPI

TDWKRGALYIGWSAGANLAC

PTIRTTNDMPIVDPQGFDALNLF

PLQINPHFTNALPEGHKGDPRL

FRVIRELLWAPELTIIGLPEGNW

ITVSKGHATLGGPNTTYVFKAG

EEAVPLEAGHRF

25660 56028 25801 360 MDHAIAGIAVQFRGGNLLRFK

AFQQRVKYRMCQAERA INRLF

NIAVKRLTGNRLDDKSKQHIIDI

AVDIPKWSDHLHIIRRKHHDPT

QDSGTHLPAVADDGFRTSVRN

RSA*HIRYLTRC*KALNRNKLPP

RN*TAIPAMA

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25704 56072 25845 489 2797 TRRRRRTMIALIQRVTRASVTV

EGEVTGEIGAGLLVLLGVEKDD

DEQKANRLCERVLGYRIFSDAE

GKMNLNVHQAAGSVLWSQFT

LAADTERGMRPSFSKGMSQLP

GLSRETRESIAMYHLRVPQTEE

ELERYYQFRWEMLRKPLHQPK

GSERDAWDAMAHHQMWDEQ

GNLVAVGRLYFNADNEASIRFM

AVHPDVQDKGLGTLMAMTLES

VAPYFSGSETGMMTLNRYRLR

HMAKQGNRSAKRVEKLLRKPD

RLISLVLIGNNLVNILASALGTI

VGMRLYGDAGVAIATGVLTFV

VLVFAEVLPKTIAALYPEKVAY

PSSFLLAPLQILMMPLVWLLNA

ITRMLMRMMGIKTDIVDMLLS

VLDLEKM/TVDDIMLPRSEIIGI

DINDDWKSIL/R/QLSHSPHGAIV

LYRDSLDDAISMLRVREAWRL

MSEKKEFTKETMLRAADEIYFV

PEGTPLSTQLVKFQRNKKKVGL

WNEYGDIQGLVTVEDILEEIV

GDFTTSMSPTLAEEVTPQNDGS

VIIDGTAN VREINKA FN WHLPE

DDARTVNGVILEALEEIPVAGT

RVRIGEYDIDILDKLSFCFRYSN

HRRTNRTTIQRITFLHNAQYVT

WRNVIRFHHCDGLMHIRVQWD

VSFGDHFNAKLTHNIQHRLQRQ

LNAFNHRRFIIRVSFISHFQRTIQ

AINHRQQFVDEFLQREFVGFFNI

25705 56073 25846 87 199 QPASVQTAGAGCRL*LHQRQW RECLVLDSKRRGDGVL

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possiblc nucleotide insertion) sequence

25710 56078 25851 2730 2893 WPVGERLAPGDYPV TGQLCT AAGD/EWRR*KVRRHQPLWRG FPNRRYMAWRSA

2571 1 56079 25852 750 929 SFHPAGRRYLYRHSSRSGNITN

GCCRLWSAFCRLRTATTVPPAR

P*QLRPDRSRAQCPV

25712 56080 25853 2427 CRQHHRWHSGSTAVYRRVLITS

KCWNVFIRTKTWTVSILTTSW

CASARRVCVPAPRAVSSRCLSV

TTLIPSASTPW*LAHRISLAAR*

AF WFNCRIPAGIDNVKVLERI H

PDKDVDGFHPYNVGRLCQRAP

RLRPCTPRGIVTLLERYNIDTFG

LNAWIGASNIVGRPMSMELLL

AGCTTTVTHRFTKNLRHHVEN

ADLLIVAVGKPGFIPGDWIKEG

AIVIDVGINRLENGKWGDWF

EDAAKRASYITPVPGGVGPMT

VATLIETRYRQGKMFDGSSIGG

WKGINESDMVLMPDASTAVID

PFFADSTLIIRCDILEPGTLQGYD

RDPRSIAKRAEDYLRSTGIADT

VLFGPEPEFFLFDDIRFGSSISGS

HVAIDDIEGAWNSSTQYEGGN

KGHRPAVKGGYFPVPPVDSAQ

DIRSEMCLVMEQMGLWEAHH

HEVATAGQNEVATRFNTMTKK

ADEIQIYKYVVHNVAHRFGKT

ATFMPKPMFGDNGSGSPPSQPQ

SQPTPPEILLQALLSAGCFYAVY

YVTYKTRLRKRVADVPRRPLFT

MNRVETNLTWVILMGIALVSV

GIFFMHNGFLLFRLNSYSQIFSS

EVSGVALKRFFYFFIPAMLWY

FLRQDSKAWLFFLVSTVAFGLL

TYMIVGGTRANIIIAFAIFLFIGII

RGWISLWMLAAAGVLGIVGMF

WLALKRYGMNVSGDEAFYTFL

25713 56081 25854 502 885

25714 56082 25855 233 738 SNSCKRTKIISDVTSVFHAIFPAI

KITAPNSPRLRVNDSATPLTSAG

ESSGSTTLQKLCQRVAPSVSAA

SSYSGPNLFQHRLHGTHPKRNA

GKGHSHRNPQPCIGDFDIKLRQ

PFTVKTLYVKEKGQR*GGDRV

LPAQRVNPSAHQAACGLGSDS

GLGSTPSADRKRR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25739 56107 25880 2613 QRKPTSSRKGLSARMMSGLTG

TITTVSTGWCTTRGHNMKSRW

SKVAIFTTR/SGRRVAKRVWRR

ERDLTGWMSLSRKPQVTWYG

WDGDRLTTIQNDRSRIQTIYQP

GSFTPLIRVETATAVRRRRRWQ

WGIPAGTVQMLDRLESEILADR

VSEESRRWLASCGLTVEQMKK

TSIHASIVRHKLLTAEQALKLLG

EMFVYHMPFNRALGMELERYE

KEFAQLAFKNQPMMVGNWAQ

SILHGGVIASALDVAAGLVCVG

STLTRHETISEDELRQRLSRMGT

IDLRVDYLRPGRGERFTATSSLL

RAGNK VA VARVELHNEEQL Y I

ASATATYMSKSMFLAVATILIS

KSSLSRLRRPSTIVCGIPISSISAN

ITPGRSLRSSSSTSKTLCTQFAV

QFLSKLLYAEGFVHVHRQNRH

LERRDSVRPYDASFVWLLNRR

SYHTRYPDTVATHRQDLVTAIF

TLYGGFQCFGVLGTQLEDVTNF

DTTFDQQPTLAIRAWIASHHVT

DICNFRGSDIAIPVDAEWFTID

VSTSSEITHRRNVDLFPDQLTVT

RSQTFTAYERLSTALTVAQVCG

VQRLCNYYSARLTPLPGPDSTR

ESNHRLAQITQYARQLASSPSII

DNRSRQHLNDVGLTAWDCVIIS

QIIGFIGFQARTIATFQAYLGHP

VRWLPGLEIQNYADASLFADES

LRWRSSYEVEKLPEEHTKSSTA

25740 56108 25881 71 3478 CCLSSHPSTTATALRSLSPVRK

WPKISALIPWEWAMCSLLSHGL

MLSGRSLVAWCWTVLVQNAS

TSGRSLSGRCLPCCKASSISLVD

SALSFLLFTLRFLVGLAEAPSFP

GNSRIVAAWFPARKGTGIINEVIS

PVLANTALEGLGGSGDALCTQC

EAEGFRHITYYLDRPDVLARFT

TKIIADKIKYPFLLSNGNRVAQG

ELENGRHWVQWQDPFPKPCYL

FALVAGDFDVLRDTFTTRSGRE

VALELYVDRGN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25752 56120 25893 888 892 TVDLDACTKGVLTFTTALLAG

GANQAFAKENTKKAYKETYGV

SHITRHDMLQIFKQQQNEKYQV

PQFDQSTIKNIESAKGLDVWDS

WPLQNADGTVAEYNGYHWF

ALAGSPKDADDTSIYMFYQKV

GDNSIDSWKNAGRVFKDSDKF

DANDPILKDQTQEWSGSATFTS

DGKIRLFYTDYSGKHYGKQSLT

TAQVNVSKSDDTLKINGVEDH

KTIFDGDGKTYQNVQQFIDEGN

YTSGDNHTLRDPHYV/EDKGH

KYLVFEANTGTENGYQGEESLF

NKAYYGGGTNFFRKESQKLQQ

SAKKRDAELANGALGIIELNND

YTLKKVMKPLITSNTVTDEIER

ANVFKMNGKWYLFTDSRGSK

MTIDDLWKFELENDDLEYLVE

ENSKQKTIQDVIWLFLTAYTHI

RGATQAFAKENNQKAYKETYG

VSHITRHDMLQIPKQQQNEKYQ

VPQFDQSTIKNIESAKGLDVWD

SWPLQNADGTVAEYNGYHWF

ALAGSPKDADDTSIYMFYQKV

GDNSIDSWKNAGRVFKDSDKF

DANDPILKDQTQEWSGSATFTS

DGKIRLFYTDYSGKHYGKQSLT

TAQVNVSKSDDTLKINGVEDH

KTIFDGDGKTYQNVQQFIDEGN

YTPGDNHTLRDPHYVKTKAMR

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25870 56238 26011 1854 CGGTLARACDGCLNGEFAA LI

TGPVHKGVΓNDAGI/PFTGHTEF

FEERSQAKK/VVMMLATEELRV

ALATT/HLPLRDIADAITPALL/H

QPKYLDNADAVLAMY/HDQGL

PVLKYQGFGRGV/NITLGLPFIR

TSVGHG/TALELAGRGQ/ADVG

SFIRPYSAIK*L*NAGASVRWLS

ERRICRAITGPVHKGVINDAGIP

LPVIPSFSKSVRRRKRCDDAGD

RRTSRGAGNDALPLRDIADAIT

PALLHNRNILITPTPCWRCTRSG

SSRAKIPGLRARCDITLGLPFIRT

SVGHGQPLNWRDVANRCWQF

YTPLFCHQMIVKPMHNRIPRAT

YRGAVKSAIGLGCCCLKASATR

CAYRWRRSGRRDQSRFRYFEIA

GIRSRGINFIACPTCSRRNLMLS

VRLTRWSNAWRYHHSDGRFD

YRLRGECPGEALVSTLGVTGG

NKKAASMKMGAQRPSGQQDM

IDQLEARIRAKASQRTKRVELT

FSRLKNNNVEKQDTALFALYQ

RRLRCVRKVRRYVMAAVSAGC

GGGVCAVSAYMPLNRLPNAQE

ANNEYTSFENCIKCTVCTTACR

VTLRNNDPKLPYLVKAGLKMK

RVTRSPRRYCAAASATHRFNDE

RAGKVQGMPDINKLPADRETC

STLTCARSRQNQTNPYPANRAA

NAYQWLATKALEKVSMKSP

WQHKVSSPAAVRHLPSITQRRT

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknown,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25871 56239 26012 1504 MG I V ASASVQAAEIYNKDGNK

LDVYGKVKAMHYMSDNASKD

GDQSYIRFGFKGETQINDQLTG

YGRWEAEFAAWTDMFPEFGG

DSSAQTDNFMTKRASGLATYR

KTTSSAYRWPELNLQYHRCTS

AARAMLLSGRPVMQINERTAV

RRQMTVYLRVERIHEIDPLVSL

SHSMSVIPIDVERPIAAAPCTPG

LWRTKTPLRVPSTYPLRLPGRA

RWCHRTFRLHLCKDWVFMFS

GLLIILVPLIVGYLIPLRQQAAL

KVINQLLSWMVYLILFFMGISL

AFLDNPRPYLADSVPDRQLLAP

VNSISRYKTIEWLNYIATELHK

GFTPLFRPDTPEEYKPTVRAHSE

KKLQYVNEALKDEHWICGQRF

TIADAYLFTVLRWAYAVKLNL

EGLEHIAAFMQRMAERPEVQD

ALSAEGLKGSRHLSAGARRLIL

GIIVTFSLILALICVTQPFNPLAQ

FIFLMLLWGVALIVRRMPGRFS

ALMLIVLSLTVSCRYIWWRYTS

TLNWDDPVSLVCGLILLFAETY

A WI VLVLG YFQV V WPLNRQPV

PLPKDMSLWPSVDIFVPTYNED

LNVTPDELKQVLDVAAALKAL

RAENISTKVFNSGLGISVFRDNS

TRTRFSYASALNLLGLAQQDLD

EGKSQIAHGETVRETANMISFC

ADAIGIRDDMYLGAGNAYMRE

VGAALDDGYKQASGFSEPAMR

25872 56240 26013 2903 3024

25873 56241 26014 123 335

25874 56242 26015 2634 2787

25875 56243 26016 1477 2485 NPEQLMVKTQRWITPGEPAGI

GPDLWQLAQREWPVELWCA

DATLLTNRAAMLGLPLTLRPYS

PNSPAQPQTAGTLTLLPVALRA

PVTAGQLAVENGHYWETLAR

ACDGCLNGEFAALITGPGVHKG

VINDAGIPFTGHTEFFEERSQAK

KWMMLATEELRVGLATTHLP

VRDI ADAITPALLHEG I AILHHD

LRTKFGIGEPRILWGGLNPHAG

EGVGPMGTEEIDTIIPVLNELRA

QGMKLNGPLPADTLFQPKYLD

NADAVRPMYHDQGLPVLKYQ

GFGRGVNITLGLPFIRTSVDRGT

ALELAGRGKVADVGSFITALNL

AIKMIVNTQ

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

25896 56264 A 26037 1162 3478 LVRFGLLPLAYSARCFSARSED

RPKDECETCCIKYPNGRNVLSQ

EIHQVFVLNGIQSMSGYVYNLG

NELASMQGLVDWRLSPQGSS

AREAFSHSLDLARLAEKRGYH

RY WLAEHHNMTG I ASA ATS VLI

GYLAANTTTLHLGSGGVMLPN

HSPLVIAEQFGTLNTLYPGRIDL

GLGRAPGSDQRTMMALRRHM

SGDIDNFPRDVAELVDWFDAR

DPILEPTHNGRRLCSTVRHPRM

GYTPGVEPTTGPLGQGLANAV

GLAIAERTLAAQFNQPDHEIVD

HFTYVFMGDGCLMEEGWFTD

DTAKRFEAYHWHVIHEIDGHD

PQAVKEAILE AQS VKDKPSLI IC

RTVIGFGSPNKAGKEEAHGAPL

GEEEVALARQKLGWHHPPFEIP

KEIYHAWDAREKGEKAQQSW

NEKFAAYKKAHPQLAEEFTVRR

MSGGLPKDWEKTTQKYINELQ

ANPAKIATRKASQNTLNAYGP

MLPELLGGSADLAPSNLTIWKG

SVSLKEDPAGNYIHYGVREFG

MTAIANGIAHHGGFVPYTATFL

MFVEYARNAARMAALMKARQ

IMVYTHDSIGLGEDGPTHQAVE

QLASLRLTPNFSTWRPCDQVEA

AVGWKLAVERHNGPTALILSR

QNLAQVERTPDQVKEIARGGY

VLKDSGGKPDIILIATGSEIEITL

QAAEKLAGEGRNVRWSVLASS

25897 56265 26038 1032 MΝKSPKTRDIQEEELEVLLEEE

A AGGDEDREKEIL I ERIQSIKEE

KQKGLGLAAGWTADVSSRRPG

ASQLPPPPTHPIPQYRGWGPPD

QHLLSTLWTNVGSYKSGSFLQL

GGWCMNLDMDLΝSEESRWLF

RRHWDTGGIKPHERKRAVAHL

TLSEREEIRAGLSAKMSIRAIAT

ALΝRSPSTISREVQRΝRGRRYY

KAVDANNRANRMAKRPKPCLL

DQNLPLRKLVLEKLEMKWSPE

QISGWLRRTKPRQKTLRISPETI

YKTLYFRSREALNHLNIQVHLA

RSH WL WPG ERYVNRNGERGPV

TLWTG/TPISDGSRTSVKRALGQ

WGEHLSRRNAFFPLCATW

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

26086 56454 26233 152 2099 GNRLLWSFIAFSKNSTHFKGIF

AMRIILLGAPGAGKGTQAQFIM

EKYGIPQISTGDMLRAAVKSGS

ELGKQAKDIMDAGKLVVTDELV

IALVKERIAQEDCRNGFLLDGF

PRTIPQADAMKEAGINGHYVLE

FDVPDELIVDRIVGRRVHAPSG

RVYHVKFNPPKVEGKDDVTGE

ELTTRKDDQEETVRKRLVEYH

QMTAPLIGYYSKEAEAGNTKY

AKVDGTKPQIYRGSLYVSDQIG

HTIVNPDGWCDCGRYGCLET

VASLSALKKQARVWLKSQPVS

TQLDPEKLTTAQLIAAWQSGEP

WITSWVDRSANAIGLSLYNFLN

ILNINQIWLYGRSCAFGENWLN

TIIRQTGFNPFDRDEGPSVKATQ

IGFGQLSRAQQGVDLGNMIITS

GQIPVNPKTGEVPADVAAQAR

QSLDNVKAIVEAAGLKVGDIV

KTTVFVKDLNDFAPVNATYEA

FFTEHNATFPARSCVEVARLPK

DVKIEIEAIAMLYTGYHYNDAP

SAVRYPRGNASGVELTPLEKLP

IGKGIVKRRGEKLAILNFGTLM

PEAAKVAESLNATLVDMRFVK

PLDEALILEMAASHEALVTVEE

NAIMGGAGSGVNEVLMAHRKP

VPVLNIGLPDFFIPQGTQEEMRA

ELGLDAAGMEAKIKAWLA

26087 56455 26234 935 1020

26088 56456 26235 145 373

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

26089 56457 26236 530 1865 RGNKRLDLMFKQSHASMYIKQ

PEQLDYQLNLKEVITAVFISMV

VLNISPTLY/PDKPSPKDKYVAY

AINIPDYELAADVYNINVTSPSG

QQETFKILINLEHLRQTLERKSL

TAVQKSQCEIITPKKPGEAILHA

FNATYQQIRENMSEFARCHYG

Y1QIPPVTTFRADGPETPEEEKG

YWFHAYQPEDLCTIHNPMGDL

QDFIALVKDAKKFGVIDIIPDYTF

NFMGIGGSGKNDLDYPSADIRA

KISKDIEDPVTKERKQIHPEDIH

LTAKDFEASKDNISKDEWENLH

ALKEKRLNGMPKTTPKSDQVI

MLQNQYVREMRKYGVRGLRY

DAAKHSKHEQIERSITPPLKNY

NERVHNTNLFNPKYHKKAVM

ΝYMEYLVTCQLDEQQMSSLLY

ERDDLSAIDFSLLMKTIKAFSFG

GDLQTLASKPGSTISSIPSERRILI

26090 56458 26237 14 2031 LIVLS*QHG/DLRQΝRSGAEHFG

LQRLMLHASQLSLTHPFTGEPL

TIHAGLDDTWMQALSQFGWRG

LLPENERVEFSAPSGQDGDPTL

GLIKEVACELSGMMRRSQPWE

EAEESIPDRGESLLEVSGTPNAG

WGAEGLAEREALLLCCCCGPM

GPDPLGLGSPGSVRGRSRLIHH

AISGEALWEVTSEGLDMAAAR

QFAIEKGAPALRAMTFIERAAM

LKAVAKHLLSEKERFYALSAQT

GATRADSWVDIEGGIGTLFTYA

SLGSRELPDDTLWPEDELIPLSK

EGGFAARHLLTSKSGVAVHINA

FNFPCWGMLEKLAPTWSGRNA

SHHQTSYRDGPLTQAMEFEDK

AQQRDVETARHFTFFRII AN ED

KKTGFPRFQTIVITASHKTIDRT

RYTYGAWRCYRPLLTVEEYRA

TGSLITQPKFPPHKSSEVHRVPR

NQGRFVAVNSTLPTEPATVAPV

RNGNASRDTAKTQTAERPSTTR

PARQQAVIEPKKPQATVKTEPK

PVAQTPKRTEPAAPVASTKAPA

ATSTPAPKETATTAPVQTASPA

QTTATPAAGAKTAGNVGSLKS

APSSHYTLQLSSSSNYDNLNGW

AKKENLKNYWYETTRNGQP

WYVLVSGVYASKEEAKKAVST

LPADVQAKNPWAKPLRQRHRD

LRGDERRDDRRSEYFNRQVIS

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmiπo acid sequence ( X=Unknown, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

261 1 1 56479 26258 1616 5678 PLAKTGRQREQLAGLAK/AHPS

LTLHQDPVYVTRADAPVAGKV

ALLSGGGTEHEPMHCGYIGQG

MLSGACPGEIFTSPTPDKIFECA

MQVDGGEG VLLI I KN YTGDILN

FETATELLHDSGVKVTTWIDD

DVAVKDSLYTAGRRGVANTVL lEKLVGAAAERGDSLDACAELG

RKLNNQG HSIGI ALGACTVRS A

GKPSFTLADNEMEFGVGIHAIL

KGDIPEAEAILASIKPAGWSRA

DWLPNQFQALRKSFIPERPVP

VMVTRLFELPVQISLGVYSLER

PANPQPIAYLVLQPRRKANNQN

ASTSAIIRATIGEPISCSVPSRGC

EGGISVAETVPAMIIAIGITISEG

LDARYRHVNSEHDPSDRQAKF

EWRYFGNLGKTVNDWRKNNK

ADIKEDGNRRCRHTNQPHCRIE

AVEYDDGRLCPLHGAHRGQSS

DGELVKPTVKTQSLAVHYSIGK

LRHRPNHGAVYYQRLRSGMGL

MNAFDSQTEDSSPAIGRNLRSR

L ARKKLSEM VEEELEQM I RRRE

FGEGEQLPSERELMAFFNVGRL

RAGSVKTQRSGANKQRRTRCV

SRPSADTIIGELSGMAKDFLSHP

GGIAHFEQLRLFFESSLVRYAA

EHATDSRDPRYRPKFYSISRSVP

VSDNITLQQLLLSLNDQPARCK

PSARCRLHGSHTSRYECNHRHG

261 12 56480 26259 185 775 IPEIFSGETHLKVSTLSKPTFSISS

LIRCTTRFSSQLSLGIATMSHRK

RVISALKSLSRLSANSLVFANQ

VERSSLTNLGCTRCSG*SLFWQ

RPALR*PFGLCPTVALTYLIVSP

EW*KAVSVKCWRNRRLTLMTS

PICTNSGTLTTAPVDRVAQVTF

QSPECLQHMRLTIALRYFRVAL

SRRLLVYASVCFTFSG

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

26204 56572 A 26351 2212 MKRSRCRDRPQPPPPDRREDGV

QRAAELSQSLPPRRRAPPGRQR

LEERTGPAGPEGKEQPPALASQ

SAEIAASARLPPRLGRLLGFQK

ACRCWSLNPHILMALLRSLVPP

DKKHPQVWRGRPPLHLAPNVG

LFSRVKVRSSWIEDKSMRDSR

RGLSQRRRRRKKKKRGSSSKK

KKRRKKRKKKKRKKRKRRKN

RKKKKKRKNKRKKKRKKEEK

KEEEEERRKKEEEDEEGRGRGR

RKRKRKKRKKRRSRKKKETAA

AAAAGERLGKWWPGECPVEC

VAYFLRRRLQQRLHPARQLLL

QGMAGYLSESDFVMVEEGFST

RDLLKELTLGASQATTDEVAAF

FVADLGAIVRKHFCFLKCLPRV

RPFYAVKCNSSPGVLKVLAQL

GLGFSCANKAEMELVQHIGIPA

SKIICANPCKQIVSQIKYAAKHGI

QLLSFDNEMELAKWKSHPSA

NFHIGSGCPDPQAYAQSIANAR

LVFEMGTELGHKMHVLDLGGG

FPGTEGAKVRFEEIASVINSALV

DLYFPEGCGVDIFAELGVRYYV

TSAFTVAVSIIAKKEVLLDQPGR

EEENGSTSKTIVYHLDEGVYGIF

NSVLFDNICPTPILQKSSTKSLR

TTIGEAFERLHRLLRERQKAML

EELEADTARTLTDIEQKVQRYS

QQLRKVQEGAQILQERLAETDR

HTFLAGVASLSERLKGKIHETN

26205 56573 26352 860 MKKEDAFLKAFYIVHGKWNCV

KGSLTRTPCCCTNCLAGGIWC

MRVQI FQLENKVLPGFP WACR

VDLYGQIGFDAAAQCLSLSVSK

AEPLVKKAPPELREQLARKTLS

SDNLKYLFDNKDIMKVKQSKK

KKEHSFRKNNGCIKIIAFSDHAE

DFRKLGCEVLGISVDSQFTHLA

WINNPQREGDLGPLNIPLLAEV

ASGLSEDYAVLKTDAGIAYRG

RFISDGKGVL/SQITVNDLPVGR

SVDEALRLVQAFQYAEEHAEV

CPAGWKPGTDTIKLNVGDSKE

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

26236 56604 A 26383 2237 NRRKFSVSIGFYTVMDAQYKII

TKTAHLITKESPQEEGKEMFAT

MSKLKEQLTKVRK*FNALLYES

QQLLIPLEELEKQMTSFYDSLG

KINEIITVLEREAQSSALFKQKH

QVRTILFKWCNSSQKMTLCLVL

GSMISMLSTAKITIAGYKSEVEV

SVSHHCI*NCKKTLTLIEKGSQS

VQKFVTLSNVLKHFDQTRLQR

QIADIHVAFQVICSPC*DWKKH

VETNSRLMKKFEESRAELEKVL

RIAQEGLEEKGDPEELLRRHTV

SPPFRDQRVLNAFLKACDELTD

ILPEQEQQGLQEAVRKLHKQW

KVSQDRTAYHLLHLKIDVEKN

RFLASVEECRTELDRETKLMPQ

EGSEKIIKEHRVRLPHHSPHHLC

EKRLQLIEELCVKLPVRDPVRD

TPGTCHVTLKELRAAIDSTYRK

LMEDPDKWKDYTSR*PQNGLW

ISTNETQLKGIKGEAIDTANHGE

VKRAVEVSSGSLSKRGETLSWL

KSRLKVLTEVSSENEAQKQGDE

LAKLSSSFKALVTLLSEVQHLL

THFGDCVQYKEIVKNSLEELIS

GSKEVQEQAEKILDTENLFEAQ

QLLLHHQVKMPLSSAKKRDVQ

QQIAQAQQGEGGLPDRGHEEL

RKLESTLDGLERSRERQERRIQ

VGAGS*ERFETNKETWRYLFQ

TGSSHERFLSFSSLESLSSELEQT

KVYYGSLESIAVQAENLVKEAS

26237 56605 26384 390 GTSLFDEEGAKIVKDLMSKAEK

NGVKITLPVDFVTADDFDENAK

TGQATVASGIPAGWMGLDCG/P

ESSKKYAEAVTRAKQIVWNGP

VGVFEWEAFARGTKALMDEV

VKATSRGCITIIGKRSYTKLIPI

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /^possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

26365 56733 26512 161 2150 YLDAEKMGQKASQQLALKDSK

EVPWCEWSEAIVHAAQKLKE

YLGFEYPPSKLCPAANTLNEIFL

IHFITFCQEKGVDEWLTTTKMT

KHQAFLFGADWIWTFWGSNKQ

IKLQLAVQTLQMSSPPPVESKP

CDLSNPESRVEESSWKKSRFDK

LEEFCNLIGEDCLGLFIIFGMPG

KPKDIRGWLDSVKSQMVRSH

LPGGKAVAQFVLETEDCVFIKE

LLRNCLSKKDGLREGGASPGSL

RLAAPGPPLTLNAACPLRLAVL

AAMAAAALPAWLSLQSRARTL

RAFSTAVYSATPVPTPSLRVDD

LHLTEIVGMLDSVLTPEDSSGK

YRFISGEVLCRITGCFTGVRVEA

KDLFGGCCSNPNEVMVTWIKVI

VEKEVWLYLRYILKALPPRTEK

MAVDQDWPSVYPVAAPFKPSA

VPLPVRMGYPVKKGVPMAKEG

NLELLKIPNFLHLTPVAIKKHCE

ALKDFCTEWPAALDSDEKCEK

HFPIEIDSTDYVSSGPSVRNPRA

RVWLRVKLSSLNLDDHAKKK

LIKLVGERYCKTTDVLTIKTDR

CPLRRQNYDYAVYLLTVLYHE

SWEYWKEWGKK*D*SRHGKSI

YGENSSSERKYPGKRFSR*KLL

RKNMGN*LKKSSLGTKEIEEYK

KSWSLKNEEENENSISQYKES

26366 56734 26513 i 186 PASTMSIRVTQKSYKVSTSGPW

FFSSCSYLSGPSAHISSLSFSRAG

SSSFQGGLGRGYGGASGMEVIT

AVMVNQSLLSPFIDKVQFLEQQ

NKMLENKWSLLQQQKMAQSN

LDNMFESYINNLRWQLETLGR

KKLKLEAELGNMQGLVEDFKN

KYEDEINKYTEMENEFVLIKKD

VDEAYMNKVELEYRLEGPTDEI

NFLRKLYEQEIRELQSQILDMS

WLSMDNSHSLDMDSIIAEVKV

QYEEIANRSWAEAERMYQN*Y

AKLSQLEAALQRAKQDMALQL

HEYQELMNFKLAQDIVITTYRK

LLESEGSWLESGMQSMSIHMK

TTSGYAGSLSSAYGGLTSPSLS

YSLGSSFGSGAGSSSFSHTSSTR

AAWKKIEAQNGKLVSKSSDV

26367 56735 B 26514 361 1215

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n,

NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

27535 57903 A 27701 2231 MGKKQSRKTGNSKKQSASPPP

KERSSTPATEQSWSENDFDELR

EEGFRRSNYSKLQEEIQTKGKE

VKHFEKNLDECITRITNREKCL

KELMELKAKARELREECRSLRS

QCDQVEERTVLARLIKKKREKN

QIDAIKIDKGDITTNPTETQTTIR

EYYKHLYTNKLENLEEMDKFL

DTYTLPRLNQDDVESLNRPITG

SEIEAINHSLPTKKSPGPDRFTA

KFYQSLPSSCDYGHAPAHPDVF

RVSSFWWVRGLAGSGVKLQTF

AVSVTALKAARLELFIPPDSGA

QLASPSGSLTRTGGGAACQSHA

VCPHSSAFGWSMGLGAMEQG

AALIGEARASREPMEEVGGSG

MAACRSQALPRGQLRPSEKSRA

APEHSSSPAMEQSWMENDFDE

LREEGFRRSNYSELREDIQTKG

KEVENFEKNLEECITRITNTEKC

LKELMELKTKARELREECRSLR

SRCDQLEERVSAMEDEMNEMK

QEGKFREKRIKRNEQSLQEIWD

YVKRPNLHLIGVPESDGENGTK

LENTLQDIIQENFPNLARQANIQ

IQEIQRTPQTYSSRRATPRHIIVR

FTKVEMKEKMLRAAREKGDSV

ERSFSNKAELLFQLHGHQRESL

SKKEAQVWRDKGLYFRKGLLD

QAQSWSRQVASILGAQIQVEGS

PEQRLENVELAGGHLNTLKAIP

MVAVAGGISFKCGAVLLLGAA

27536 57904 27702 596 1593 KPRLENYVKNAEASGANAINW

KKGY/LVMEDEMNEMKQEGKF

REKRLKRNEQSLQEIWDYVKR

PNLRLIGVPESDGENGTKLENT

LQDIIQENFPNLARQATVHIREI

QRTPQRFSLRRSTPRHIVRFSKV

ETKEKMLRAAREKEIQTTIREY

YKHLYTTKLENLEEMEKFLDT

YTLPRLNQKEVESMKRPITSSEI

EAVINILPIKRSPGPDGLTATFY

QRYKEELERSSSPATEQSWMEN

DFDELREEGFRRSNYSELREDIQ

TKVKEVENFEKNLEECITRITNT

EKCLKELMELKTKARELREECR

SLRSRCDQLEERVSAMEDEMN

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

28135 58503 28305 189 1890 MKMASSLAFLLLNFHVSLLLV

QLLTPCSAQFSVLGPSGPILAM

VGEDADLPCHLFPTMSAETME

LKWVSSSLRQWNVYADGKEV

EDRQSAPYRGRTSILRDGITAG

KAALRIHNVTASDSGKYLCYFQ

DGDFYEKALVELKVAALGSΝL

HVEVKGYEDGGIHLECRSTGW

YPQPQIQWSΝAKGEΝIPAVEAP

WADGVGLYEVAASVIMRGGS

GEGVSCIIRΝSLLGLEKTASISIA

DPFFRSAQPWIAALAGTLPILLL

LLAGASYFLWRQQKEITALSSEI

ESEQEMKEMGYAATEREISLRE

RKKIQYLTPDVILYPDMAΝAIL

LVSEDQRSVQRAEEPHDLPDΝP

ERFEWRYCVLGCESFMSERHY

WEVEVGDRKEWHIGVCSKΝVE

RKKVWVKMTPEΝGYWTMGLT

DGΝKYRALTEPRTOLKLPEPPR

KVGVILDYETGHISFYΝATDGS

HIYTFLHASSSEPLYPVFRILTLE

PTALTVCPIPK/GREFPRFPTLVP

DHSLEIPLTPGLANESGEPQAEV

TSLLLPAQPGAKGLTLHNSQSE

PYSYRHTLKHFTDIHSIIP

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Amino acid sequence ( X=Unknovvn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

29139 59507 29314 2104 STLAQQWQAGDS1WSRPAIRVF

ATYAKWDEKWGYDYTGNADN

NANFGKAVPADFNGGSFGRGD

SDEWTFGAQMEIWCSYLLALR

QCQADIHSAGCICHGWLVND

QCLPPVKCWGRCGAKSPFCAIT

FRVRWTIRKSTKCCANRAYKR

NITVGRIRRLRRIRQPLPDATLC

VLSGLQTEHNRRWPNSVCHFSP

DSTFYNDLSGRMKNVRLMFNG

IHRDNGFSKRPTDLNYTRKPLV

LAFQTAWFITVRVEIVGFRGINR

LSLMLEQNNVLIGENAWGKSS

LLDALTLLLSPESDLYHFERDD

FWFPPGDINGREHHLHI1LTFRE

SLPGRHRVRRYRPLEACWTPCT

DG YHRI FYRLEGES AEDGS VMT

LRSFLDKDGHPIECRG PIKAR

HLVVRLMPVVLVRLRECPVLMRR

IRVNGTVPNVPNVEVTARQLDF

LARGGQARYRLMRRRASNEQR

SWRYLDIINRMIERPETRYTREI

GFTSTMDLIYGLPKQTPESFAF

TLKRVAELNPDRLSVFNYAHLP

TIFAAQRKIKDADLPSPQQKLDI

LQETIAFLTQSGYQFIGMDHFA

RPDDELAVAQREGVLHRNFQG

YTTQGDTDLLGMGVSAISMIGD

CYAQNQKELKQYYQQVDEQG

NALWRGIALTRDDCIRRDVIKS

LICNFRLDYAPIKKQGDLHFAD

YFAEDLKLLAPLAKDGLGDVD

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno n, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

30126 60494 30309 153 2031 RRNYQRQQKKRGSEGAGRPDR

RSRISAAYSPRSEFNNAAVTEH

Y*NRF*T/LVPRSR/HANADTVT

REAVNQVIALLDSGALRVAEKI

DGLPTNQMQASRRAKEEEVHL

TGQPSRVQSPPRRCEEKQYMVL

MIVSGRSGSGKSVALRALEDM

GFYCVDΝLPWLLPDLARTLA

DREISAAVSIDVRΝMPESPEIFE

QAMSNLPDAFSPQLLFLDADRN

TLIRRYSDTRRLHPLSSKNLSLE

SAIDKESDLLEPLHGFPDYDTV

GFSCKRRIDYVCRIKHSRRIRQV

VLLNFAKSGAFSTTRGTDDKTR

RSLLVTLVRIFCVRVIFAYDIRD

GIHVRIIQINSKSGKVGSKHNSG

YSAAKFGGVGLTQSLALDLAE

YGITVHSLM LGNLLKSPMFQSL

LPQYATKLG I KPDQ VEQ Y YIDK

VPFKRGCDYQDVLNMLLFYAS

PKAWLAPDSRSMSPAVSGRFK

PRVWAIALDDQQRIVDTLFMK

GLTVFARPQKIPAITGRHSGATL

QKQGKCSVEELAQYFDTTGTT

MRKDLVILEHAGTVIRTSGGW

PDSPPHTRRDPRRFSMAFPWFD

NIRSAEFHHVTTLLAEIPRQQND

IHRPAHAAAAPKVETRSGDETN

RRWΝRPAQHLFA

30127 60495 30310 720 872 EKVPVSIGPGGMQELPMQSPDR RSAGKPGPASRAGR*TGGGAFS TKRDYR

30128 60496 50311 1967 2452 SRRCSASIΝQRPRPGHEKMVSV

RIAPASΝVPTCRPITVTTGSIALR

SA WTI ITRMRVSPLARAVRM* S

SPSTSSIEERVIRTMTASGIVPST

MAGKIIWATASIKLPSSPQMAV

SISIKPVΝGLESSRΝTISLTRPET

GVRFQCTETSMISIMPHQKIGIE

30129 60497 30312 1912 3960

30130 60498 30313 250 LIRKVST*SVLMKAFLRIA*KDC ERLGLKCFWSGSEKGCPLVΝT ΝAFGGHCEHHQWVSSVSRVRV SQSAGGCPLFΝILLΝTV

30131 60499 30314 300 SVFSH*AKKIWKGVSQRALGQ

ΝSRGSGSGCQASWTIRFPVGFH

TDGTRLRRΝPGMQAFLGPVAR

FLALEARSLDCAFSSSLLFKRKL

SGRWGRASRGTKL

TC980/l0Sfl/13d Z.90S/.0/Ϊ0 OΛV

SEQ ID SEQ ID NO: Met SEQ ID NO: Nucleotide Nucleotide location of last Λmino acid sequence ( X=Unkno\vn, NO: of peptide hod in USSN location of first codon for last amino acid *=Stop codon, /=possible nucleotide sequence 09/540,217 codon for peptide of peptide sequence deletion, \=possible nucleotide insertion) sequence

30366 60734 30551 711 MAEIQHKTIRPLLEGRDLLAAV

KTGSGKTLAVLIPAIELWKLKF

MPRNGTGVLILSPTRQLAMQTF

GVLKELMTHHVHTYGLIIGGSN

RSAEAQKLANGINIIWTPGRLL

DHTQNTPGFMYKNLQVEDLAR

ISPKKEPLYVGVDEDKANATVD

GLEQGH F VCPSEKRYLLLFTFL

KKNQKKKLMVFFSACMSVKYP

YGLLKYIDL/PVLAIHGKQKQN

KHTTTFF*YCNADSGTLL

30367 60735 A ,0552 661 987 VTFYSSEHSNPCHKNLRKARRK DTKRIILKW*HTLV*GRDI*N*NI I ITRNTRYSLLCP WATKKLKAC FISQK*KRDVIERNSAQCLQPKS IYTLVR*VQILKSTKILL

30368 60736 30553 188 2188 KFQGASNLTLSETQNGDVSEET

MGSRKVKKSKQKPMNVGLSET

QNGGMSQEAVGNIKVTKSPQK

STVLTNGEAAMQSSNSESKGK

MKKKRKMVNDAEPDTKKAKT

ENKGKSEEESAETTKETENNVE

KPDNDEDESEVPSLPLGLTGAF

EDTSFASLCNLVNENTLKAIKE

MGFTNMTEIQHKSIRPLLEGRD

LLAAAKTGSGKTLAFLIPAVELI

VVKLRFMPRNGTGVLILSPVTRE

LAMQTFGVLKELMTHHVHTYG

LIMGGSNRSAEAQKLGNGINIIV

ATPGRLLDHMQNTPGFMYKNL

QCLVIDEADRILDVGFEEELKQI

IKLLPTRRQTMLFSATQTRKVE

DLARISLKKEPLYVGVDDDKA

NATVDGLEQGYVVVCPSEKRFL

LLFTFLKKNRKKKLMVFFSSCM

SVKYHYELLNYIDLPVLAIHGK

QKQNKRTTVTFFQFCNADSGVTL

LCTVDVVAARGLDIPEVDWIVQY

DPPDDPKEYIVHRVG* EQPEGLN

GEEGHALASFLRPRKDLGFFFR

LL*KHSKGFPLSGIWTFSW/SLK

ISDIQFSAWRNWIGKVITFLHKS

AVQEAYKSYITEPMDSPFL*NRS

FNVVNNLNLASGLLCQFGFKVVP

PFVDLNVNSNEGKQKKRGGGG

GFGLPRKTQEKLEKSVKIFTH*

ARKSSGQAGQFSH

Claims

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-30368, a mature protein coding portion of SEQ ID NO: 1-30368, an active domain of SEQ ID NO: 1-30368, and complementary sequences thereof.

2. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide hybridizes to the polynucleotide of claim 1 under stringent hybridization conditions.

3. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide has greater than about 90% sequence identity with the polynucleotide of claim 1.

4. The polynucleotide of claim 1 wherein said polynucleotide is DNA.

5. An isolated polynucleotide of claim 1 wherein said polynucleotide comprises the complementary sequences.

6. A vector comprising the polynucleotide of claim 1.

7. An expression vector comprising the polynucleotide of claim 1.

8. A host cell genetically engineered to comprise the polynucleotide of claim 1.

9. A host cell genetically engineered to comprise the polynucleotide of claim 1 operatively associated with a regulatory sequence that modulates expression of the polynucleotide in the host cell.

10. An isolated polypeptide, wherein the polypeptide is selected from the group consisting of:

(a) a polypeptide encoded by any one of the polynucleotides of claim 1 ; and (b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions with any one of SEQ ID NO: 1 -30368.

1 1. A composition comprising the polypeptide of claim 10 and a carrier.

12. An antibody directed against the polypeptide of claim 10.

5871

13. A method for detecting the polynucleotide of claim 1 in a sample, comprising: a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.

14. A method for detecting the polynucleotide of claim 1 in a sample, comprising: a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions;

b) amplifying a product comprising at least a portion of the polynucleotide of claim 1 ; and c) detecting said product and thereby the polynucleotide of claim 1 in the sample.

15. The method of claim 14, wherein the polynucleotide is an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.

16. A method for detecting the polypeptide of claim 10 in a sample, comprising: a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.

17. A method for identifying a compound that binds to the polypeptide of claim 10, comprising: a) contacting the compound with the polypeptide of claim 10 under conditions sufficient to form a polypeptide/compound complex; and b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

18. A method for identifying a compound that binds to the polypeptide of claim 10, comprising: a) contacting the compound with the polypeptide of claim 10, in a cell, under conditions sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

19. A method of producing the polypeptide of claim 10, comprising, a) culturing a host cell comprising a polynucleotide sequence selected from the group consisting of a polynucleotide sequence of SEQ ID NO: 1 -30368, a mature protein coding portion of SEQ ID NO: 1-30368, an active domain of SEQ ID NO: 1-30368, complementary sequences thereof and a polynucleotide sequence hybridizing under stringent conditions to SEQ ID NO: 1-30368, under conditions sufficient to express the polypeptide in said cell; and b) isolating the polypeptide from the cell culture or cells of step (a).

20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 30369-60736, the mature protein portion thereof, or the active domain thereof.

21 The polypeptide of claim 20 wherein the polypeptide is provided on a polypeptide array.

22. A collection of polynucleotides, wherein the collection comprises the sequence information of at least one of SEQ ID NO: 1-30368.

23. The collection of claim 22, wherein the collection is provided on a nucleic acid array.

24. The collection of claim 23, wherein the array detects full-matches to any one of the polynucleotides in the collection.

25. The collection of claim 23, wherein the array detects mismatches to any one of the polynucleotides in the collection.

26. The collection of claim 22, wherein the collection is provided in a computer-readable format.

27. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.

28 A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising an antibody that specifically binds to a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.